Drug_ID drug_Name TTD_ID TTD_ID_old Highest_status disease_represent icd_represent PubChem_CID np_or_at Synonymous Drug_Type InChI InChIKey Canonical_SMILES Formula CAS_Number CHEBI HERB_id SymMap_id TCMSP_id DrugBank_id Genomics DR2770 Arsenite D0X8KC D0X8KC Investigative Prostate cancer ICD-11: 2C82 . Anticancer Treatment . . . . . . . . . . . . . DR9750 BRD4770 D0LA0P D0LA0P Investigative Pancreatic cancer ICD-11: 2C10 CID: 72193870 Anticancer Treatment "BRD4770; 1374601-40-7; Methyl 2-benzamido-1-(3-phenylpropyl)-1H-benzo[d]imidazole-5-carboxylate; BRD 4770; BRD-4770; methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate; C25H23N3O3; GTPL7016; AOB3886; CHEMBL3970748; SCHEMBL16569005; EX-A692; CHEBI:131143; BDBM225263; BCP10433; 2282AH; MFCD23143627; NSC777671; s7591; ZINC95099914; AKOS026750266; BRD 4770;BRD-4770; CCG-268804; CS-3446; NSC-777671; SB19344; NCGC00351780-01; NCGC00351780-04; AS-16771; DA-35008; HY-16705; BRD4770, >=98% (HPLC); FT-0733814; A14401; J-690148; BRD-K72264770-001-01-6; Q27075478; methyl 2-benzamido-1-(3-phenylpropyl)-1H-1,3-benzodiazole-5-carboxylate; Methyl-2-(benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylate; 2-(Benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylic acid methyl ester" Small molecule "1S/C25H23N3O3/c1-31-24(30)20-14-15-22-21(17-20)26-25(27-23(29)19-12-6-3-7-13-19)28(22)16-8-11-18-9-4-2-5-10-18/h2-7,9-10,12-15,17H,8,11,16H2,1H3,(H,26,27,29)" UCGWYCMPZXDHNR-UHFFFAOYSA-N COC(=O)C1=CC2=C(C=C1)N(C(=N2)NC(=O)C3=CC=CC=C3)CCCC4=CC=CC=C4 C25H23N3O3 . CHEBI:131143 . . . . . DR5742 Caffeic acid phenethyl ester D06YGF D06YGF Investigative Ovarian cancer ICD-11: 2C73 CID: 5281787 Anticancer Treatment "Caffeic acid phenethyl ester; Phenethyl caffeate; 104594-70-9; CAPE; Phenylethyl caffeate; phenethyl 3-(3,4-dihydroxyphenyl)acrylate; Capeee; 115610-29-2; caffeic acid phenylethyl ester; PHENETHYL CAFFEATE (CAPE); UNII-G960R9S5SK; 2-phenylethyl caffeate; 2-phenylethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; CHEBI:8062; CHEMBL319244; G960R9S5SK; (E)-phenethyl 3-(3,4-dihydroxyphenyl)acrylate; MFCD00866470; 100981-80-4; 2-Phenylethyl (2e)-3-(3,4-Dihydroxyphenyl)prop-2-Enoate; 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)acrylate; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, 2-phenylethyl ester; SMR000326751; SR-01000075785; 2-phenylethyl 3-(3,4-dihydroxyphenyl)prop-2-enoate; caffeic-acid-phenethyl-ester; phenethyl 3,4-dihydroxycinnamate; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid 2-phenylethyl ester; QAP; 2-phenylethyl 3-(3,4-dihydroxyphenyl)-2-propenoate; Caffeic Acid Phenethyl Ester, Synthetic; Phenethyl (E)-caffeate; caffeic acidphenethylester; caffeic acid phenethylester; caffeic acid phenylethylester; Lopac0_000269; BSPBio_001560; BSPBio_003586; MLS000859889; MLS002207297; SPECTRUM1502209; phenethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; ZINC1083; CHEBI:93478; DTXSID80861176; FR102; HMS1361N22; HMS1791N22; HMS1989N22; HMS2233J04; HMS3260F20; HMS3402N22; HMS3413D22; HMS3649C16; HMS3677D22; Phenylethyl 3,4-dihydroxycinnamate; Caffeic acid beta-phenylethyl ester; Trans-Caffeic Acid Phenethyl Ester; BCP27877; Caffeic acid phenethyl ester(CAPE); EBD26363; HY-N0274; Tox21_500269; BDBM50029207; Caffeic acid phenethyl ester (CAPE); CCG-39542; s7414; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, 2-phenylethyl ester, (E)-; AKOS015888207; AC-8896; LP00269; SDCCGSBI-0050257.P002; IDI1_034030; QTL1_000016; NCGC00093727-01; NCGC00093727-02; NCGC00093727-03; NCGC00093727-04; NCGC00093727-05; NCGC00093727-06; NCGC00093727-07; NCGC00093727-08; NCGC00093727-09; NCGC00093727-16; NCGC00260954-01; AS-14021; I793; LS-14562; CS-0008774; EU-0100269; SW219156-1; B-6327; C 8221; C10484; 3,4-Dihydroxy-trans-cinnamic acid phenethyl ester; SR-01000075785-1; SR-01000075785-6; SR-01000075785-9; BRD-K84709232-001-02-6; BRD-K96188950-001-02-9; BRD-K96188950-001-04-5; Caffeic acid phenethyl ester, >=97% (HPLC), powder; Q15410860; 3-(3,4-Dihydroxy-phenyl)-acrylic acid phenethyl ester; Methanone, 1,1'-(1,2-cyclopropanediyl)bis[1-phenyl-; (E)-3-(3,4-Dihydroxy-phenyl)-acrylic acid phenethyl ester" Small molecule "1S/C17H16O4/c18-15-8-6-14(12-16(15)19)7-9-17(20)21-11-10-13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2/b9-7+" SWUARLUWKZWEBQ-VQHVLOKHSA-N C1=CC=C(C=C1)CCOC(=O)C=CC2=CC(=C(C=C2)O)O C17H16O4 CAS 115610-29-2 CHEBI:8062 . . . . . DR3524 Lithium chloride D07WXT D07WXT Investigative Multiple myeloma ICD-11: 2A83 CID: 433294 Anticancer Treatment "LITHIUM CHLORIDE; 7447-41-8; Lithium chloride (LiCl); Lithiumchloride; LiCl; chlorolithium; chlorure de lithium; MFCD00011078; Lithium Cholride; UNII-G4962QA067; CHEBI:48607; CHEMBL69710; Chlorku litu; NSC327172; G4962QA067; Lithiumchlorid; Lithium Chloride, Anhydrous; Lithium chloride, ultra dry; Chlorku litu [Polish]; Lithium chloride, 99%, extra pure; Luthium chloride; ClLi; Lithium chloride, 99+%, ACS reagent; Chlorure de lithium [French]; CCRIS 5924; Lithium chloride, 99%, for molecular biology; HSDB 4281; Lithium chloride, 99%, for analysis, anhydrous; Lithium chloride solution; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; Lithium Chloride (2.3% in Tetrahydrofuran, ca. 0.5mol/L); lithim chloride; lithii chloridum; lithium;chloride; Lithium chloride, anhydrous, chunks, 99.99% trace metals basis; cloruro de litio; Lithium Chloride Salt; Lopac-L-4408; Lithium chloride (powder); MolMap_000071; WLN: LI G; EC 231-212-3; LithiumChlorideGr(Anhydrous); Lithium chloride, ACS grade; Lopac0_000604; Lithium chloride battery grade; Lithium chloride 1 M solution; Lithium chloride, ACS reagent; DTXSID2025509; Lithium chloride, 3-5% in THF; HMS3261J10; Tox21_500604; ANW-36491; BDBM50494542; AKOS015902822; AKOS015950647; AKOS024438070; Lithium chloride, 1M aqueous solution; CCG-204693; lithium chloride, gamma irradiated, 8m; LP00604; NSC-327172; SDCCGSBI-0050586.P002; Lithium chloride, ACS reagent, >=99%; Lithium chloride, ReagentPlus(R), 99%; NCGC00015607-01; NCGC00015607-02; NCGC00015607-03; NCGC00015607-04; NCGC00015607-07; NCGC00093980-01; NCGC00093980-02; NCGC00261289-01; AK323906; BP-13612; Lithium chloride, 200mM aqueous solution; SY002997; Lithium chloride solution, 1 M in ethanol; Lithium chloride solution, 2 M in ethanol; Lithium chloride, Vetec(TM) reagent grade; EU-0100604; FT-0627896; L0204; L0222; Lithium chloride, Trace metals grade 99.9%; W8215; L 4408; Lithium chloride, SAJ first grade, >=98.0%; Lithium chloride, for molecular biology, >=99%; Lithium chloride, SAJ special grade, >=99.0%; A838146; Lithium chloride, BioXtra, >=99.0% (titration); Q422930; SR-01000076252; SR-01000076252-1; Electrolyte solution, nonaqueous, 2 M LiCl in ethanol; Lithium chloride solution, 1 M in glacial acetic acid; Lithium chloride, powder, >=99.99% trace metals basis; Z1741960146; Electrolyte solution, nonaqueous, LiCl in ethanol (saturated); Lithium chloride solution, 0.5 M in anhydrous tetrahydrofuran; Lithium chloride solution, 8 M, for molecular biology, >=99%; Lithium chloride, puriss. p.a., anhydrous, >=99.0% (AT); Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone; Lithium chloride, anhydrous, beads, -10 mesh, >=99.9% trace metals basis; Lithium chloride, anhydrous, beads, -10 mesh, 99.998% trace metals basis; Lithium chloride, puriss. p.a., ACS reagent, anhydrous, >=99.0% (AT); Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), 99%; Lithium chloride, BioUltra, for molecular biology, anhydrous, >=99.0% (AT); Lithium atomic spectroscopy standard concentrate 1.00 g Li, 1.00 g/L, for 1 l standard solution, analytical standard; Lithium standard solution, suitable for atomic absorption spectrometry, 1 mg/mL Li, 1000 ppm Li" Small molecule 1S/ClH.Li/h1H;/q;+1/p-1 KWGKDLIKAYFUFQ-UHFFFAOYSA-M [Li+].[Cl-] ClLi CAS 7447-41-8 CHEBI:48607 . . . DB16607 . DR6224 Sodium orthovanadate D0C6RO D0C6RO Investigative Acute lymphoblastic leukemia ICD-11: 2B33 CID: 61671 Anticancer Treatment "Sodium orthovanadate; 13721-39-6; Trisodium vanadate; Sodium pervanadate; Sodium o-vanadate; Sodium vanadate (ortho); Trisodium tetraoxovanadate; Sodium vanadium oxide (Na3VO4); Sodium tetraoxovanadate(3-); Vanadic acid, trisodium salt; TRISODIUM ORTHOVANADATE; Vanadic acid (H3VO4), sodium salt; UNII-7845MV6C8V; trisodium trioxido(oxo)vanadium; trisodium;trioxido(oxo)vanadium; 7845MV6C8V; MFCD00003511; Sodium orthovanadate, 99%; CCRIS 9063; EINECS 237-287-9; NSC 79534; Vanadyl; Vanadate (VO43-), trisodium, (T-4)-; AI3-52157; Vanadate(VO4(3-)), trisodium; sodiumorthovanadate; Sodium Ortho Vanadate; Sodium vanadate(V) (Na3VO4) (6CI); Na3VO4; Vanadate (VO43-), trisodium, (beta-4)-; 3Na.O4V; sodium tetraoxidovanadate(V); sodium tetraoxidovanadate(3-); DTXSID2037269; CHEBI:35607; vanadate (VO4(3-)), trisodium; AKOS004910370; CCG-266460; Sodium orthovanadate, >=90% (titration); FT-0688138; X5030; Sodium orthovanadate, 100mM aqueous solution; Vanadic acid (H3VO4), trisodium salt (8CI); Sodium orthovanadate, 99.98% trace metals basis; J-006982; Q2156566" Small molecule 1S/3Na.4O.V/q3*+1;;3*-1; IHIXIJGXTJIKRB-UHFFFAOYSA-N [O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+] Na3O4V CAS 13721-39-6 CHEBI:35607 . . . . . DR5051 SP600125 D02PVB D02PVB Investigative Chronic kidney disease ICD-11: GB61 CID: 8515 Anticancer Treatment "129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra[1,9-cd]pyrazol-6(2H)-one; SP-600125; Anthra-1,9-pyrazol-6-none; JNK Inhibitor II; 2H-Dibenzo[cd,g]indazol-6-one; C.I. 70300; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; NSC 75890; UNII-1TW30Y2766; NSC-75890; CHEMBL7064; MLS002693964; 2h-dibenzo(cd,g)indazol-6-one; CHEBI:90695; 1TW30Y2766; NCGC00015958-03; SAPK Inhibitor II; 1pmv; SMR000015440; SR-01000075840; NSC75890; EINECS 204-955-6; BRN 0746890; 2zmd; Kinome_3844; Tocris-1496; BiomolKI_000068; Lopac-S-5567; BiomolKI2_000072; cid_8515; DSSTox_CID_20525; DSSTox_RID_79502; CBiol_002049; DSSTox_GSID_40525; Lopac0_000473; BMK1-G8; BSPBio_001066; ChemBiol10705 Compound 4; KBioGR_000406; KBioSS_000406; cc-622; JMC517015 Compound 2; MLS002153267; MLS006011577; SCHEMBL170980; anthra[1,9-cd]pyrazol-6-one; GTPL5273; CHEMBL1725279; DTXSID2040525; SCHEMBL15583517; BCBcMAP01_000053; BDBM16018; dibenz[cd,g]indazol-6(2h)-one; KBio2_000406; KBio2_002974; KBio2_005542; KBio3_000771; KBio3_000772; Bio1_000335; Bio1_000824; Bio1_001313; Bio2_000373; Bio2_000853; HMS1362F07; HMS1667K13; HMS1792F07; HMS1990F07; HMS2250C03; HMS3229I16; HMS3261O08; HMS3267P06; HMS3295M01; HMS3403F07; HMS3412F05; HMS3654P10; HMS3676F05; HMS3747M19; ALBB-024051; AMY31086; Anthra[1,9cd]pyrazol-6(2H)-one; BCP05457; EX-A1998; Tox21_110267; Tox21_500473; Anthra[1-9-cd]pyrazol-6(2H)-one; ANW-68872; BDBM50024294; BDBM50433916; CCG-47500; Dibenzo[cd,g]indazol-6(2H)-one #; HSCI1_000136; MFCD00022289; NSC755773; s1460; SBB000595; ZINC96298875; AKOS000115584; Anthra[1,9-cd]pyrazol-6(2H)-one;; Anthrapyrazolone; 1,9-Pyrazoloanthrone; CCG-100672; CS-0196; DB01782; LP00473; MCULE-7820194475; NSC-755773; SDCCGSBI-0050458.P003; VA10299; 1,6-dihydrodibenzo[cd,g]indazol-6-one; 2,6-dihydrodibenzo[cd,g]indazol-6-one; IDI1_002128; QTL1_000077; SMP2_000240; NCGC00015958-01; NCGC00015958-02; NCGC00015958-04; NCGC00015958-05; NCGC00015958-06; NCGC00015958-07; NCGC00015958-08; NCGC00015958-22; NCGC00025186-01; NCGC00025186-02; NCGC00025186-03; NCGC00025186-04; NCGC00025186-05; NCGC00261158-01; WLN: T C6665 1A P IV OMNJ; 14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one; AC-32051; AK-57219; AS-14374; CAS-129-56-6; HY-12041; JNK Inhibitor II - CAS 129-56-6; K914; SMR002530644; ST018684; DB-041928; EU-0100473; FT-0607068; SW218106-2; EN300-02083; Anthra[1,9-cd]pyrazol-6(2H)-one & Z-100; K00068; S 5567; SP600125, >=98% (HPLC); AB00075935-01; SP 600125 & Z-100; 129S566; Q4545713; SR-01000075840-1; SR-01000075840-2; SR-01000075840-4; SR-01000075840-6; SR-01000637108-1; W-108360; BRD-K01567962-001-04-0; BRD-K01567962-001-06-5; BRD-K01567962-001-08-1; BRD-K01567962-001-22-2; Z56785477; F1414-1245; 120093-15-4; 14,15-diazatetracyclo[7.6.1.0;{2,7}.0;{13,16}]hexadeca-1(15),2(7),3,5,9(16),10,12-heptaen-8-one" Small molecule "1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)" ACPOUJIDANTYHO-UHFFFAOYSA-N C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O C14H8N2O CAS 129-56-6 CHEBI:90695 . . . DB01782 . DR4508 Edetic acid D00KEP D00KEP Phase 3 Diabetes mellitus ICD-11: 5A10 CID: 6049 Anticancer Treatment "EDTA; Edetic acid; Ethylenediaminetetraacetic acid; 60-00-4; Edathamil; Endrate; Versene; Havidote; Sequestrol; Titriplex; EDTA acid; Cheelox; Sequestric acid; Warkeelate acid; Gluma cleanser; Sequestrene aa; Komplexon ii; Quastal Special; Tetrine acid; Versene acid; Metaquest A; Trilon bw; Complexon II; Hamp-ene acid; Titriplex II; Cheelox BF acid; Trilon BS; Celon A; Chelest 3A; Questex 4H; Celon ATH; Chemcolox 340; Universne acid; Vinkeil 100; Dissolvine E; Nullapon B acid; Nullapon bf acid; Perma kleer 50 acid; Nervanaid B acid; Clewat TAA; (Ethylenedinitrilo)tetraacetic acid; EDTA (chelating agent); Versenate; Ethylenedinitrilotetraacetic acid; Calcium disodium versenate; Acidum edeticum; Acide edetique; Acido edetico; Caswell No. 438; Disodium EDTA; Chelaton 3; ICRF 185; Acetic acid, (ethylenedinitrilo)tetra-; Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-; Cheladrate; SEQ 100; Edetate calcium; Ethylenebisiminodiacetic acid; YD 30; Acide edetique [INN-French]; Acido edetico [INN-Spanish]; Acidum edeticum [INN-Latin]; CCRIS 946; Edetate; ETHYLENEDIAMINE TETRAACETIC ACID; HSDB 809; Acide ethylenediaminetetracetique; Ethylenediamine-N,N,N',N'-tetraacetic acid; UNII-9G34HU7RV0; MFCD00003541; EPA Pesticide Chemical Code 039101; Edta disodium; Disodium edetate; Disodium versene; Endrate disodium; Kyselina ethylendiamintetraoctova; Sodium versenate; Edetic acid disodium salt; Ethylenediaminetetraacetate; Kyselina ethylendiamintetraoctova [Czech]; Acide ethylenediaminetetracetique [French]; Metaquest B; ethylene diamine tetraacetic acid; Kiresuto B; Chelaplex III; Complexon III; Diso-Tate; Titriplex III; 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid; 3,6-Diazaoctanedioic acid, 3,6-bis(carboxymethyl)-; AI3-17181; Chelaton III; Versene NA; Triplex III; Disodium versenate; Edathamil disodium; Trilon BD; Versene Na2; Disodium sequestrene; Disodium tetracemate; EDTA disodium salt; F 1 (complexon); EDTA, ion(4-); CHEMBL858; Sequestrene sodium 2; Acetic acid, 2,2',2'',2'''-(1,2-ethanediyldinitrilo)tetrakis-; N,N'-1,2-Ethanediylbis(N-(carboxymethyl)glycine); Glycine, N,N'-1,2-ethanediylbis(N-(carboxymethyl)-; {[-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-CARBOXYMETHYL-AMINO}-ACETIC ACID; Disodium salt of EDTA; 9G34HU7RV0; Perma Kleer Di Crystals; Calcium disodium versenate (TN); ethylene-diamine tetraacetic acid; 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid; CHEBI:42191; 2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid; 4-04-00-02449 (Beilstein Handbook Reference); N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine); Ethylenediaminetetraacetic acid disodium salt; Edetate calcium disodium (USP); Sequestrene Na2; Trilon B; Selekton B2; Disodium ethylenediaminetetraacetate; (ethylenedinitrilo)tetraacetic acid, ion(4-); ETHYLENEDIAMINETETRAACETIC ACID-D16; Perma kleer 50 crystals disodium salt; Disodium (ethylenedinitrilo)tetraacetate; Disodium ethylenediaminetetraacetic acid; SODIUM ETHYLENEDIAMINETETRAACETATE; CBC 50152966; DR-16133; Ethylenediaminetetraacetate, disodium salt; Disodium diacid ethylenediaminetetraacetate; D'E.d.t.a. disodique; Disodium (ethylenedinitrilo)tetraacetic acid; Ethylenediamine-N,N,N',N'-tetraacetic Acid-13C4; 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate; Disodium dihydrogen ethylenediaminetetraacetate; Ethylenediaminetetraacetic acid, disodium salt; Disodium dihydrogen(ethylenedinitrilo)tetraacetate; 139-33-3; NSC2760; CaEDTA; Ethylenediaminetetraacetic acid, 99%, pure; 203805-96-3; C10H16N2O8; N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycine]; NCGC00159485-02; 6381-92-6; EINECS 200-449-4; BRN 1716295; disodium-edta; Edetic acid [INN:BAN:NF]; Ethylenebis(iminodiacetic acid); (Ethylenedinitrilo)tetraacetic acid, disodium salt; 2-[2-(bis(carboxymethyl)amino)ethyl-(carboxymethyl)amino]acetic acid; Tricon bw; ([2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino)-acetic acid; {[2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid; Calcium Disodium Edetate (JAN); Techrun DO; Zonon AO; EDTA, free acid; EDTA, free base; EDTA ACS grade; ACETIC ACID, (ETHYLENEDINITRILO)TETRA-, DISODIUM SALT; Versene acid (TN); Acroma DH 700; Spectrum_001018; ACMC-209mhe; Edetic acid (NF/INN); 53632-26-1; Spectrum2_000003; Spectrum3_000412; Spectrum4_000531; Spectrum5_000955; Edetic acid [BAN:INN]; DSSTox_CID_2977; EC 200-449-4; DSSTox_RID_76814; DSSTox_GSID_22977; ethylenediaminetetracetic acid; BSPBio_001964; Diaminoethanetetra-acetic acid; Ethylenediamineteraacetic Acid; KBioGR_001161; KBioSS_001498; ethylenediaminetetraacetic-acid; MLS001249457; BIDD:ER0565; DivK1c_000777; ethylenediamine tetracetic acid; SPBio_000005; ethylenediamine-tetraacetic acid; DTXSID6022977; EDTA, 500 mM Solution, pH 8.0, ULTROL Grade; KBio1_000777; KBio2_001498; KBio2_004066; KBio2_006634; KBio3_001184; EBD3431; (Ethylenedintrilo)tetraacetic acid; ethylen-ediamine tetra-acetic acid; NINDS_000777; STR08855; Tox21_202736; ANW-33408; BDBM50330325; s6350; SBB008807; STK386291; ZINC19364242; AKOS001574475; Glycine, (N,N'-1,2-ethanediylbis(N-(carboxymethyl)-, labeled with carbon-14; (ethane-1,2-diyldinitrilo)tetraacetate; DB00974; MCULE-1868494404; CAS-60-00-4; IDI1_000777; NCGC00159485-03; NCGC00159485-04; NCGC00260284-01; 688-55-1; AC-10615; AK109916; SMR000058776; ST072179; SBI-0051360.P003; DB-084840; DS-003836; B7197; E0084; Ethylenediaminetetraacetic acid, 2Na (EDTA); Ethylenediaminetetraacetic acid, LR, >=98%; FT-0626319; FT-0668253; FT-0668254; C00284; D00052; Ethylenediaminetetraacetic acid, p.a., 98.0%; ETHYLENEDIAMINETETRAACETIC ACID-D4 (CAR; AB00053468_03; Ethylenediaminetetraacetic acid solution, 0.02 N; Ethylenediaminetetraacetic acid, >=98.0% (KT); A832566; N,N'-1,2-Ethanediylbis[N-(carboxymethyl)]glycine; Q408032; SR-01000883946; Ethylenediaminetetraacetic acid, Cell Culture Reagent; J-610078; SR-01000883946-1; 37C3C5E7-D921-445F-82D6-FEBF1AE5AEF5; Ethylenediaminetetraacetic acid, 99.5%, ACS reagent; Ethylenediaminetetraacetic acid, Electrophoresis Grade; Z2688689169; Ethylenediaminetetraacetic acid, BioUltra, >=99.0% (KT); Ethylenediaminetetraacetic acid, 0.5M aq. solution, pH 8.0; Ethylenediaminetetraacetic acid, 99.995% trace metals basis; Ethylenediaminetetraacetic acid, SAJ special grade, >=99.0%; Ethylenediaminetetraacetic acid, Vetec(TM) reagent grade, 98%; [{2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino]acetic acid; 2,2',2'',2'''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid; Edetic acid, United States Pharmacopeia (USP) Reference Standard; Edetic acid; EDTA; (Ethylenedinitrilo)tetraacetic acid; Edathamil; Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder; Ethylenediaminetetraacetic acid, purified grade, >=98.5%, powder; 2,2'',2'''',2''''''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid; Ethylenediaminetetraacetic acid, 0.5M aqueous solution, pH 8.0, autoclaved; Ethylenediaminetetraacetic acid, BioUltra, anhydrous, >=99% (titration); Glycine, N,N'-1, {2-ethanediylbis[N-(carboxymethyl)-,} disodium salt; {[2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid(EDTA); 2-[2-[bis(2-hydroxy-2-oxoethyl)amino]ethyl-(2-hydroxy-2-oxoethyl)amino]ethanoic acid; Ethylenediaminetetraacetic acid, anhydrous, free-flowing, Redi-Dri(TM), >=98%; 124949-23-1; 470462-56-7; Ethylenediamine-N,N,N inverted exclamation mark ,N inverted exclamation mark -tetraacetic Acid-13C4 (; A-labels); Ethylenediaminetetraacetic acid solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture; Ethylenediaminetetraacetic acid solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O; Ethylenediaminetetraacetic acid, anhydrous, crystalline, BioReagent, suitable for cell culture; Ethylenediaminetetraacetic acid, anhydrous, free-flowing, powder, Redi-Dri(TM), ACS reagent, 99.4-100.6%" Small molecule "1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)" KCXVZYZYPLLWCC-UHFFFAOYSA-N C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O C10H16N2O8 CAS 60-00-4 CHEBI:42191 . . . DB00974 . DR5752 Androgen D0SP7S D0SP7S Investigative Diminished ovarian reserve ICD-11: 5A80 CID: 5995 Anticancer Treatment "testosterone propionate; 57-85-2; Agovirin; Androlon; Androteston; Aquaviron; Hormoteston; Enarmon; Bio-testiculina; Androtest P; Androsteston; Sterandryl; Testonique; Andronate; Masenate; Orchiol; Orchistin; Pantestin; Propiokan; Solvotest; Synandrol; Synerone; Telipex; Testaform; Testodet; Testodrin; Testogen; Testolets; Testormol; Testosid; Testoxyl; Testrex; Tostrin; Uniteston; Nasdol; Vulvan; Enarmon-oil; Neo-Hombreol; Okasa-Mascul; Andrusol-P; Oreton propionate; Recthormone testosterone; NSC 9166; Testosteron propionate; 17beta-(Propionyloxy)androst-4-en-3-one; Testosterone-17-propionate; Homandren (amps); Androgen; UNII-WI93Z9138A; CHEMBL1170; CHEBI:9466; (17beta)-3-oxoandrost-4-en-17-yl propanoate; (17beta)-3-oxoandrost-4-en-17-yl propionate; Testosterone-17.beta.-propionate; WI93Z9138A; NSC-9166; Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17b)-; [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] propanoate; NCGC00016254-01; 17-propionyl-17beta-hydroxyandrost-4-en-3-one; DSSTox_CID_16515; DSSTox_RID_79286; DSSTox_GSID_36515; Orchisterone; Testosteroni propionas; CAS-57-85-2; CCRIS 575; Testoviron (ampule); testosteron-17-propionat; Testosterone-17beta propionate; Testosterone-17beta-propionate; Testosterone-17-beta-propionate; EINECS 200-351-1; Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17.beta.)-; AI3-26378; 17beta-Hydroxyandrost-4-en-3-one propionate; 17beta-Hydroxy-4-androsten-3-one 17-propionate; Testosterone propionate [USP:JAN]; Androst-4-en-3-one, 17beta-hydroxy-, propionate; delta(sup 4)-Androstene-17-beta-propionate-3-one; Prestwick_432; 17beta-Hydroxyandrost-4-en-3-one-17beta-propionate; Testex (TN); 17.beta.-(Propionyloxy)androst-4-en-3-one; Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17beta)-; .DELTA.4-androstene-17.beta.-propionate-3-one; 17.beta.-hydroxyandrost-4-en-3-one, propionate; 3-Oxoandrost-4-en-17-yl propionate, (17.beta.)-; Prestwick0_000401; Prestwick1_000401; Prestwick2_000401; Prestwick3_000401; Androst-4-en-3-one, 17.beta.-hydroxy-, propionate; 17-(1-Oxopropoxy)androst-4-en-3-one, (17.beta.)-; Testosterone propionate ciii; SCHEMBL4044; BSPBio_000322; MLS002153796; Testosterone propionate, solid; SPBio_002261; BPBio1_000356; GTPL7100; Testosterone-17.beta.propionate; DTXSID9036515; Testosterone propionate [Androgenic (anabolic) steroids]; NSC9166; HMS1569A04; HMS2096A04; HMS2272K06; HMS3713A04; Testosterone propionate (Agovirin); ZINC490791; HY-B1269; Tox21_110330; Tox21_302270; BBL029912; BDBM50215709; LMST02020076; MFCD00003653; NRB-03689; STK801834; Testosterone propionate (JP17/USP); AKOS005622513; AKOS015842719; Tox21_110330_1; CCG-220401; CS-4905; DB01420; MCULE-8627319345; NCGC00179602-01; NCGC00179602-03; NCGC00179602-06; NCGC00255481-01; AC-12172; AC-33160; SMR000058348; VS-09499; BCP0726000215; C08158; D00959; 003T653; Testosterone Propionate 1.0 mg/ml in Acetonitrile; Testosterone propionate, tested according to Ph.Eur.; W-105436; BRD-K90553655-001-03-6; Q10354588; WLN: L E5 B666 OV MUTJ A E FO52 -B&AEF; Androst-4-en-3-one, 17-(1-oxopropoxy)-(17.beta.)-; Testosterone propionate, British Pharmacopoeia (BP) Reference Standard; Testosterone propionate, European Pharmacopoeia (EP) Reference Standard; Testosterone propionate, United States Pharmacopeia (USP) Reference Standard; (1S,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl propanoate; Propionic acid (8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester; Propionic acid 10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester; Propionic acid 10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester(Testosterone Propionate); Testosterone propionate for system suitability, European Pharmacopoeia (EP) Reference Standard" Small molecule "1S/C22H32O3/c1-4-20(24)25-19-8-7-17-16-6-5-14-13-15(23)9-11-21(14,2)18(16)10-12-22(17,19)3/h13,16-19H,4-12H2,1-3H3/t16-,17-,18-,19-,21-,22-/m0/s1" PDMMFKSKQVNJMI-BLQWBTBKSA-N CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C C22H32O3 CAS 57-85-2 CHEBI:9466 . . . . . DR3743 Sucrose D08TCV D08TCV Phase 4 Pain ICD-11: MG30-MG3Z CID: 5988 Anticancer Treatment "sucrose; 57-50-1; saccharose; Cane sugar; Table sugar; White sugar; D-Sucrose; sugar; Rohrzucker; Saccharum; Granulated sugar; Amerfand; Amerfond; Microse; Beet sugar; Rock candy; Confectioner's sugar; Sucrose, dust; Sucrose, pure; D(+)-Saccharose; sacarosa; D-(+)-Sucrose; Sucraloxum [INN-Latin]; beta-D-Fructofuranosyl alpha-D-glucopyranoside; beta-D-Fructofuranosyl-alpha-D-glucopyranoside; D-(+)-Saccharose; CCRIS 2120; HSDB 500; Sacharose; alpha-D-Glucopyranosyl beta-D-fructofuranoside; CHEBI:17992; D-Saccharose; AI3-09085; (alpha-D-Glucosido)-beta-D-fructofuranoside; D(+)-Sucrose; alpha-D-Glucopyranoside, beta-D-fructofuranosyl; Fructofuranoside, alpha-D-glucopyranosyl, beta-D; Glucopyranoside, beta-D-fructofuranosyl, alpha-D; UNII-C151H8M554; MFCD00006626; alpha-D-Glucopyranoside, beta-D-fructofuranosyl-; NCI-C56597; 1-alpha-D-glucopyranosyl-2-beta-D-fructofuranoside; C151H8M554; beta-D-Fruf-(2<->1)-alpha-D-Glcp; NCGC00164248-01; DSSTox_CID_1288; NSC 406942; DSSTox_RID_76060; DSSTox_GSID_21288; D(+)-Sucrose, ACS reagent; Sucraloxum; Sucrose [USAN:JAN]; (+)-Sucrose; CAS-57-50-1; (2R,3R,4S,5S,6R)-2-(((2S,3S,4S,5R)-3,4-Dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; (2R,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol; D(+)-Sucrose, 99.7%, for biochemistry; FICOLL; Sucrose [JAN:NF]; EINECS 200-334-9; GLC-(1-2)FRU; Sucrose,ultrapure; D(+)-Sucrose, 99+%, for biochemistry, DNAse, RNAse and protease free; Compressible sugar; NSC-406942; Sucrose, purified; Sucrose, AR; Sucrose, LR; Sucrose, ultrapure; Sucrose, USP; Sucrose ACS grade; Sucrose (TN); Sugar spheres (NF); Sugar,(S); Sucrose, ACS reagent; Sucrose, reagent grade; 1af6; Sucrose (JP17/NF); Glc(alpha1->2beta)Fru; Sucrose Biochemical grade; Sucrose, SAJ first grade; Sugar, compressible (NF); bmse000119; bmse000804; bmse000918; Epitope ID:153236; Sucrose, >=99.5%; Sucrose, JIS special grade; White soft sugar (JP17); Sucrose, analytical standard; Sucrose, cell culture tested; Sugar, confectioner's (NF); 1-alpha-D-glucopyranosyl-2-beta-D-fructofranoside; 25702-74-3; Sucrose, p.a., ACS reagent; CHEMBL253582; GTPL5411; DTXSID2021288; CHEBI:65313; Sucrose, 1.2M aqueous solution; Sucrose, Molecular Biology Grade; GNE-410; Sucrose, >=99.5% (GC); S-67F; alpha-D-Glc-(1-2)-beta-D-Fru; 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol; HY-B1779; ZINC4217475; Tox21_112093; Tox21_201397; Tox21_300410; 5903AE; BDBM50108105; s3598; Sucrose, for electrophoresis, >99%; AKOS024306988; alpha-D-Glc-(1-->2)-beta-D-Fru; DB02772; MCULE-5933491732; Sucrose, BioXtra, >=99.5% (GC); a-D-Glucopyranosyl A-D-fructofuranoside; b -D-Fructofuranosyl a-D-glucopyranoside; NCGC00164248-02; NCGC00164248-03; NCGC00164248-05; NCGC00254237-01; NCGC00258948-01; 92004-84-7; Sucrose, meets USP testing specifications; Sucrose, Vetec(TM) reagent grade, 99%; D-Saccharose 1000 microg/mL in Methanol; alpha-D-Glucopyranosylbeta-D-fructofuranoside; CS-0013810; S0111; ST50308554; Sucrose, Grade I, plant cell culture tested; Sucrose, Grade II, plant cell culture tested; C00089; D00025; Sucrose, for molecular biology, >=99.5% (GC); Sucrose; ?-D-Fructofuranosyl ?-D-glucopyranoside; SR-01000883983; Sucrose, NIST(R) SRM(R) 17f, optical rotation; J-519846; Q4027534; SR-01000883983-1; Sucrose, for microbiology, ACS reagent, >=99.0%; alpha-D-glucopyranosyl-(1->2)-beta-D-fructofuranoside; Sucrose, British Pharmacopoeia (BP) Reference Standard; Sucrose, European Pharmacopoeia (EP) Reference Standard; Sucrose, Vetec(TM) reagent grade, RNase and DNase free; Z1601554751; alpha-D-Glucopyranoside, beta-D-fructofuranosyl, homopolymer; Sucrose, analytical standard, for enzymatic assay kit SCA20; UNII-YUH1C99228 component CZMRCDWAGMRECN-UGDNZRGBSA-N; Sucrose, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent; Sucrose, BioUltra, for molecular biology, >=99.5% (HPLC); Sucrose, United States Pharmacopeia (USP) Reference Standard; Carbon isotopes in sucrose, NIST(R) RM 8542, IAEA-CH-6 sucrose; Compressible sugar, United States Pharmacopeia (USP) Reference Standard; Sucrose, puriss., meets analytical specification of Ph. Eur., BP, NF; WURCS=2.0/2,2,1/[ha122h-2b_2-5][a2122h-1a_1-5]/1-2/a2-b1; (2R,3R,4S,5S,6R)-2-((2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-ylhydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-((2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; 2-[(2S,3S,4S,5R)-2,5-bis(hydroxymethyl)-3,4-dihydroxyoxolan-2-yloxy](4S,5S,2R, 3R,6R)-6-(hydroxymethyl)-2H-3,4,5,6-tetrahydropyran-3,4,5-triol; 8027-47-2; 8030-20-4; 85456-51-5; 86101-30-6; 87430-66-8; Sucrose, BioReagent, suitable for cell culture, suitable for insect cell culture, >=99.5% (GC); Sucrose, Low Endotoxin, PharmaGrade, USP/NF, Ph Eur, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production." Small molecule "1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1" CZMRCDWAGMRECN-UGDNZRGBSA-N C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)CO)O)O)O)O C12H22O11 CAS 57-50-1 CHEBI:17992 . . . DB02772 . DR2744 Deprenyl D0Y8AN D0Y8AN Phase 4 Parkinson's disease ICD-11: 8A00 CID: 5195 Anticancer Treatment "Deprenyl; Deprenil; 2323-36-6; PHENETHYLAMINE, N,alpha-DIMETHYL-N-2-PROPYNYL-; CHEBI:50217; methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine; (+-)-Deprenyl; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; dl-Deprenyl; UNII-DPF682Q08V; Selegiline D5; DPF682Q08V; N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride; (+/-)-Deprenyl; (.+/-.)-Deprenyl; N,alpha-Dimethyl-N-2-propynylphenethylamine; 1,N-Dimethyl-N-propargyl-2-phenylethylamine; N,alpha-Dimethyl-N-2-propynylbenzeneethanamine; CHEMBL8663; SCHEMBL74753; cid_92913; BDBM39862; DTXSID60860142; HMS2089B08; MCULE-3188554308; NCGC00015624-03; NCGC00016708-02; NCGC00162273-01; SBI-0206908.P001; FT-0665904; N,.alpha.-Dimethyl-N-2-propynylphenethylamine; AB00489975_10; DEP_188.1433_10.1; Phenethylamine, N,.alpha.-dimethyl-N-2-propynyl-; Q402633; Benzeneethanamine, N,.alpha.-dimethyl-N-2-propynyl-; BRD-A28545468-003-10-9; N-methyl-N-(1-methyl-2-phenylethyl)prop-2-yn-1-amine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl- (9CI); N-Methyl-N-(1-methyl-2-phenylethyl)-2-propyn-1-amine #; methyl-(1-methyl-2-phenyl-ethyl)-propargyl-amine;hydrochloride; N-methyl-1-phenyl-N-prop-2-ynyl-2-propanamine;hydrochloride; N-methyl-1-phenyl-N-prop-2-ynyl-propan-2-amine;hydrochloride; METHYL-(1-METHYL-2-PHENYL-ETHYL)-PROP-2-YNYL-AMINE HYDROCHLORIDE" Small molecule "1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3" MEZLKOACVSPNER-UHFFFAOYSA-N CC(CC1=CC=CC=C1)N(C)CC#C C13H17N CAS 2323-36-6 CHEBI:50217 . . . . . DR8223 AG1478 D0ZH1U D0ZH1U Investigative Diabetic retinopathy ICD-11: 9B71 CID: 2051 Anticancer Treatment "AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG1478; AG 1478; Tyrphostin AG-1478; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; AG-1478 (Tyrphostin AG-1478); tyrphostin AG1478; SUH0SEZ9HY; UNII-SUH0SEZ9HY; AG-1478 hydrochloride; CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; Tyrphostin AG-1478;NSC 693255; BRD6408; BRD-6408; SR-01000076156; NSC693255; PubChem22408; Tocris-1276; tyrphostin-AG-1478; AG-1478 free base; BiomolKI_000018; Maybridge1_004001; Lopac-T-4182; BiomolKI2_000028; DSSTox_CID_30044; CBiol_002058; DSSTox_GSID_51447; Lopac0_001127; Oprea1_653581; SCHEMBL93838; BSPBio_001390; KBioGR_000110; KBioSS_000110; cc-598; MLS006012026; PD153035 Analog 31; BDBM3532; GTPL4862; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; DTXSID0051447; BCBcMAP01_000035; HMS552N19; KBio2_000110; KBio2_002678; KBio2_005246; KBio3_000219; KBio3_000220; AOB2928; Bio1_000344; Bio1_000833; Bio1_001322; Bio2_000110; Bio2_000590; HMS1361F12; HMS1791F12; HMS1989F12; HMS3229O03; HMS3263B15; HMS3656B19; HMS3672E11; ZINC116937; BCP07988; BCP15152; EX-A1236; Tyrphostin AG 1478, >=98%; Tox21_303781; Tox21_501127; BBL101047; CCG-52663; MFCD00270914; s2728; STL554841; AKOS002350880; AG-1478 - Tyrphostin AG-1478; AG-1478/AG1478; CS-1606; LP01127; MCULE-8403703571; SB19361; SDCCGSBI-0051095.P003; VZ27727; IDI1_033860; NCGC00016017-01; NCGC00016017-02; NCGC00016017-03; NCGC00016017-04; NCGC00016017-05; NCGC00016017-06; NCGC00016017-07; NCGC00016017-08; NCGC00016017-09; NCGC00016017-20; NCGC00025093-01; NCGC00025093-02; NCGC00025093-03; NCGC00025093-04; NCGC00025093-05; NCGC00261812-01; NCGC00357072-01; AC-32828; AK-63142; GK 03499; HY-13524; NCI60_033425; SMR001456495; DB-026463; CAS-175178-82-2; EU-0101127; FT-0643504; FT-0643682; SW219714-1; EC-000.2540; 6,7-dimethoxy-4-(3'-chloroanilino)quinazoline; A24890; S-7703; T 4182; 11N-812; InSolution AG 1478 - CAS 175178-82-2; CU-00000000399-1; J-011074; J-519544; SR-01000076156-1; SR-01000076156-4; SR-01000076156-7; (3-Chlorophenyl)(6,7-dimethoxyquinazolin-4-yl)amine; AG 1478 - CAS 175178-82-2; BRD-K68336408-001-02-6; BRD-K68336408-003-02-2; Q27074338; COC1=C(OC)C=C2C(NC3=CC(Cl)=CC=C3)=NC=NC2=C1; 0TO" Small molecule "1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)" GFNNBHLJANVSQV-UHFFFAOYSA-N COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC C16H14ClN3O2 CAS 153436-53-4 CHEBI:75404 . . . . . DR9353 BMS-228987 . . Investigative Breast cancer ICD-11: 2C60 CID: 88045546 Anticancer Treatment SCHEMBL6816325; BMS-228987 Small molecule "1S/C27H30O2/c1-26(2,3)16-14-21-15-17-27(4,5)24-13-10-20(18-23(21)24)7-6-19-8-11-22(12-9-19)25(28)29/h6-16,18H,17H2,1-5H3,(H,28,29)/b7-6+,16-14+" JCIUGJPHCGNCKU-DBSWOVOKSA-N CC1(CC=C(C2=C1C=CC(=C2)C=CC3=CC=C(C=C3)C(=O)O)C=CC(C)(C)C)C C27H30O2 . . . . . . . DR2625 BMS-231974 . . Investigative Breast cancer ICD-11: 2C60 CID: 10092292 Anticancer Treatment "SCHEMBL6813836; SCHEMBL6813842; BMS-231974; 4-[(E)-2-[8-(3,3-dimethylbut-1-ynyl)-5,5,7-trimethyl-6H-naphthalen-2-yl]ethenyl]benzoic Acid" Small molecule "1S/C28H30O2/c1-19-18-28(5,6)25-14-11-21(17-24(25)23(19)15-16-27(2,3)4)8-7-20-9-12-22(13-10-20)26(29)30/h7-14,17H,18H2,1-6H3,(H,29,30)/b8-7+" DQRQOOAPWNLJRO-BQYQJAHWSA-N CC1=C(C2=C(C=CC(=C2)C=CC3=CC=C(C=C3)C(=O)O)C(C1)(C)C)C#CC(C)(C)C C28H30O2 . . . . . . . DR1130 PD184352 D0B9BU D0B9BU Investigative Chronic lymphocytic leukaemia ICD-11: 2A82 CID: 6918454 Anticancer Treatment "212631-79-3; CI-1040; PD184352; PD 184352; PD-184352; 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD184352 (CI-1040); CI 1040; CI1040; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD-18435; UNII-R3K9Y00J04; C.I. 1040; CHEMBL105442; R3K9Y00J04; MFCD02683961; NCGC00189074-01; CI-1040 (PD184352); DSSTox_CID_28871; DSSTox_RID_83140; DSSTox_GSID_48945; C17H14ClF2IN2O2; CAS-212631-79-3; PD 184,352; cc-384; MLS006010176; SCHEMBL570330; PD 184352, Free Base; GTPL5676; QCR-25; DTXSID8048945; CHEBI:91353; SYN1031; HMS3244G05; HMS3244G06; HMS3244H05; HMS3265I07; HMS3265I08; HMS3265J07; HMS3265J08; HMS3654I05; AOB87195; BCP01791; EX-A2202; ZINC1489691; Tox21_113363; ABP000919; BDBM50132260; NSC765695; s1020; 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide; AKOS022184333; Tox21_113363_1; CCG-269529; CS-0058; DB12429; NSC-765695; SB19417; 2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-(CYCLOPROPYLMETHOXY)-3,4-DIFLUOROBENZAMIDE; NCGC00189074-03; NCGC00189074-05; AC-25483; AS-19373; HY-50295; SMR004701284; CI-1040,PD184352; PD 184352CI-1040; AB0033705; DB-014962; CI-1040; PD184352; FT-0673543; SW219604-1; X7396; EC-000.2331; PD 184352(CI-1040); PD184352 - CI-1040; A25744; PD184352, >=98% (HPLC); S-7729; CI-1040/CI1040,PD184352; 631C793; US8575391, 341; J-505572; BRD-K05104363-001-01-9; Q27076005; 4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; 2-(2-Chloro4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-[(2-Chloro-4-iodophenyl)amino]-N-cyclopropylmethoxy)-3,4-difluorobenzamide; Benzamide, 2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluoro-; CI-1040; ; ; 2-(2-Chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide" Small molecule "1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)" GFMMXOIFOQCCGU-UHFFFAOYSA-N C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl C17H14ClF2IN2O2 CAS 212631-79-3 CHEBI:91353 . . . . . DR7504 GW9662 D00ACX D00ACX Investigative Breast cancer ICD-11: 2C60 CID: 644213 Anticancer Treatment "GW9662; 22978-25-2; 2-Chloro-5-nitro-N-phenylbenzamide; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; benzamide, 2-chloro-5-nitro-N-phenyl-; UNII-UM18UZV2YD; MFCD01215270; UM18UZV2YD; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro- N -phenylbenzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Benzamide,2-chloro-5-nitro-N-phenyl-; Tocris-1508; Spectrum5_001989; Lopac-M-6191; DSSTox_CID_20723; DSSTox_RID_79570; DSSTox_GSID_40723; Lopac0_000798; BSPBio_001021; KBioGR_000361; KBioSS_000361; SCHEMBL420231; CHEMBL375270; cid_644213; GTPL3442; DTXSID8040723; BCBcMAP01_000086; BDBM55936; KBio2_000361; KBio2_002929; KBio2_005497; KBio3_000701; KBio3_000702; ZINC39173; EX-A595; Bio2_000341; Bio2_000821; HMS1362C03; HMS1792C03; HMS1990C03; HMS2235C11; HMS3262O18; HMS3267P20; HMS3372P17; HMS3403C03; HMS3412F15; HMS3649C18; HMS3651L10; HMS3676F15; AOB31774; BCP06354; 2-Chloro-5-nitrobenzanilide, 97%; METHYL15-METHYLHEPTADECANOATE; Tox21_301993; Tox21_500798; s2915; SBB006523; STL260137; AKOS000155195; CCG-204882; CS-1102; DB07863; LP00798; MCULE-8174475490; SDCCGSBI-0050775.P002; 2-chloranyl-5-nitro-N-phenyl-benzamide; IDI1_002096; Benzanilide, 2-chloro-5-nitro- (8CI); NCGC00015688-01; NCGC00015688-02; NCGC00015688-03; NCGC00015688-04; NCGC00015688-05; NCGC00015688-06; NCGC00015688-07; NCGC00015688-08; NCGC00015688-09; NCGC00015688-21; NCGC00025193-01; NCGC00025193-02; NCGC00025193-03; NCGC00025193-04; NCGC00025193-05; NCGC00025193-06; NCGC00025193-07; NCGC00255683-01; NCGC00261483-01; AC-31443; AK173264; AS-14069; GW9662, >98% (HPLC); HY-16578; ST055753; SY040458; AB0109180; CAS-22978-25-2; EU-0100798; FT-0664839; SW203813-2; Z6199; EC-000.2405; A11984; Benzamide, 2-chloro-5-nitro-N-phenyl- (9CI); C15627; J90030; M 6191; S-7731; J-014928; SR-01000075999-1; SR-01000075999-3; SR-01000075999-6; SR-01000075999-9; BRD-K93258693-001-02-5; BRD-K93258693-001-05-8; Q27077962; Z27782632" Small molecule "1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)" DNTSIBUQMRRYIU-UHFFFAOYSA-N C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl C13H9ClN2O3 CAS 22978-25-2 CHEBI:79993 . . . . . DR1229 PP242 D0H2CM D0H2CM Investigative Colon cancer ICD-11: 2B90 CID: 135565635 Anticancer Treatment TORKinib Small molecule "1S/C16H16N6O/c1-8(2)22-16-13(15(17)18-7-19-16)14(21-22)12-6-9-5-10(23)3-4-11(9)20-12/h3-8,20,23H,1-2H3,(H2,17,18,19)" MFAQYJIYDMLAIM-UHFFFAOYSA-N CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N C16H16N6O CAS 1092351-67-1 . . . . . . DR5291 4-hydroxy-tamoxifen D0B4VV D0B4VV Phase 2 Cyclic Mastalgia ICD-11: GB23 CID: 5284643 Anticancer Treatment 4'-hydroxytamoxifen; 82413-23-8; 4-Hydroxy-tamoxifen; (Z)-4'-hydroxytamoxifen; CHEMBL10041; trans-Hydroxytamoxifen; 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol; 4-HT; 4-{(1Z)-1-[{4-[2-(dimethylamino)ethoxy]phenyl}(phenyl)methylene]propyl}phenol; 4Hydroxy Tamoxifen; NCGC00091028-01; GTPL2817; SCHEMBL2165503; DTXSID00873019; ZINC8602413; BDBM50180684; NCGC00091028-02; Q27073761; 4 inverted exclamation mark -Hydroxy Tamoxifen (contains up to 10% E isomer); 4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-1-phenylbut-1-en-2-yl] phenol; 4HT Small molecule "1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-" DODQJNMQWMSYGS-QPLCGJKRSA-N CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=C(C=C3)O C26H29NO2 CAS 82413-23-8 . . . . . . DR6961 T0901317 D0B5FC D0B5FC Investigative Lung cancer ICD-11: 2C25 CID: 447912 Anticancer Treatment "293754-55-9; T 0901317; TO-901317; TO901317; UNII-A07663A39I; T-0901317; CHEMBL62136; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide; A07663A39I; N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE; N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]benzenesulfonamide; T-1317" Small molecule "1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2" SGIWFELWJPNFDH-UHFFFAOYSA-N C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O C17H12F9NO3S CAS 293754-55-9 . . . . . T0901317 DR6385 Nutlin-3 D01QKK D01QKK Investigative Lung cancer ICD-11: 2C25 CID: 216345 Anticancer Treatment "nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one; 548472-68-0; 890090-75-2" Small molecule "1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)" BDUHCSBCVGXTJM-UHFFFAOYSA-N CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl C30H30Cl2N4O4 CAS 548472-68-0 . . . . . Nutlin-3 DR2806 Bacillus Calmette-Guerin D0KO9R D0KO9R Phase 3 Bladder cancer ICD-11: 2C94 CID: 6451 Anticancer Treatment "Bromocresol green; 76-60-8; BROMCRESOL GREEN; bromo cresol green; 3,3-Bis(3,5-dibromo-4-hydroxy-2-methylphenyl)-3H-benzo[c][1,2]oxathiole 1,1-dioxide; Tetrabromo-m-cresolphthalein sulfone; 3',3'',5',5''-Tetrabromo-m-cresolsulfonephthalein; Bromocresol blue; NSC 7817; UNII-8YGN0Y942M; EINECS 200-972-8; BRN 0372527; CHEMBL145704; 8YGN0Y942M; Bromocresol Green, ACS reagent; NSC7817; FRPHFZCDPYBUAU-UHFFFAOYSA-N; MFCD00005874; o-Toluenesulfonic acid, alpha-hydroxy-, gamma-sultone; BROMOCRESOL GREEN, ACS; Phenol, 4,4'-(3H-2,1-benzox" Small molecule "1S/C21H14Br4O5S/c1-9-12(7-14(22)19(26)17(9)24)21(13-8-15(23)20(27)18(25)10(13)2)11-5-3-4-6-16(11)31(28,29)30-21/h3-8,26-27H,1-2H3" FRPHFZCDPYBUAU-UHFFFAOYSA-N CC1=C(C(=C(C=C1C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C(=C4C)Br)O)Br)Br)O)Br C21H14Br4O5S CAS 76-60-8 . . . . . . DR5065 Alpha PD-L1 antibody . . Investigative Osteosarcoma ICD-11: 2B51 . Anticancer Treatment . Antibody . . . . . . . . . . . DR0684 X-ray irradiation . . Phase 3 Scaphoid Fracture ICD-11: NC53 . Anticancer Treatment . Radiotherapy . . . . . . . . . . . DR0767 Vasostatin . . Phase 4 Pancreatic endocrine tumor ICD-11: 2E92 . Anticancer Treatment . . . . . . . . . . . . . DR1850 Ultraviolet A irradiation . . Phase 2 Systemic sclerosis ICD-11: 4A42 . Anticancer Treatment . Radiotherapy . . . . . . . . . . . DR6642 Thymic stromal lymphopoietin . . Investigative Colon cancer ICD-11: 2B90 . Anticancer Treatment . . . . . . . . . . . . . DR6255 Synthetic lipid A . . Investigative Vaccination ICD-11: N.A. . Anticancer Treatment . . . . . . . . . . . . . DR4171 Stilbenoids . . Investigative Influenza ICD-11: 1E30 . Anticancer Treatment . . . . . . . . . . . . . DR8652 SG611-VSTM1 . . Investigative Acute lymphoblastic leukemia ICD-11: 2B33 . Anticancer Treatment . Gene therapy . . . . . . . . . . . DR1364 SG611-PDCD5 . . Investigative Acute lymphoblastic leukemia ICD-11: 2B33 . Anticancer Treatment . Gene therapy . . . . . . . . . . . DR1512 Sclerotherapy . . Phase 1 Parotid hemangiomas ICD-11: 2E81 . Anticancer Treatment . . . . . . . . . . . . . DR7409 Rituximab D09EXD D09EXD Approved Malignant haematopoietic neoplasm ICD-11: 2B33 . Anticancer Treatment . Antibody . . . . . . . . . DB00073 . DR6676 Rifaximin alpha . . Phase 4 Hepatic fibrosis/cirrhosis ICD-11: DB93 . Anticancer Treatment . . . . . . . . . . . DB01220 . DR8666 Reorafenib . . Investigative Colorectal cancer ICD-11: 2B91 . Anticancer Treatment . . . . . . . . . . . DB08896 . DR2147 Recombinant tissue plasminogen activator . . Phase 4 Pulmonary thromboembolism ICD-11: BB00 . Anticancer Treatment . . . . . . . . . . . . . DR5410 Recombinant mutant human TRAIL . . Investigative Colorectal cancer ICD-11: 2B91 . Anticancer Treatment . . . . . . . . . . . . . DR8799 Radiation . . Phase 2 Breast cancer ICD-11: 2C60 . Anticancer Treatment . . . . . . . . . . . . . DR5708 PNC-27 D00GNN D00GNN Investigative Solid tumour/cancer ICD-11: 2A00-2F9Z . Anticancer Treatment . . . . . . . . . . . . . DR3085 PKRI . . Investigative Alzheimer disease ICD-11: 8A20 . Anticancer Treatment dsRNA-dependent protein kinase inhibitor . . . . . . . . . . . . DR9458 Physiotherapy . . Phase 2 Oral cavity carcinoma ICD-11: 2E60 . Anticancer Treatment . . . . . . . . . . . . . DR1194 Octyl disulfamate . . Investigative Breast cancer ICD-11: 2C60 . Anticancer Treatment . . . . . . . . . . . . . DR6085 NL-101 . . Investigative Anaplastic large cell lymphoma ICD-11: 2A90 . Anticancer Treatment . . . . . . . . . . . . . DR5673 Nanoliposomal C6-ceramide . . Investigative Hepatocellular carcinoma ICD-11: 2C12 . Anticancer Treatment . . . . . . . . . . . . . DR8145 N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine . . Investigative Lung cancer ICD-11: 2C25 . Anticancer Treatment . . . . . . . . . . . . . DR1391 "N, N-dimethyl-D-erythro-sphingosine" . . Investigative Colon cancer ICD-11: 2B90 . Anticancer Treatment . . . . . . . . . . . . . DR1235 Monodesbutyl benflumetol . . Investigative Malaria ICD-11: 1F40 . Anticancer Treatment . . . . . . . . . . . . . DR5679 Methioninase . . Investigative Breast cancer ICD-11: 2C60 . Anticancer Treatment . . . . . . . . . . . . . DR7247 Lopinavi . . Phase 4 Human immunodeficiency virus disease ICD-11: 1C62 . Anticancer Treatment . . . . . . . . . . . DB01601 . DR8712 C1632 . . Investigative Lip/oral cavity/pharynx neoplasm ICD-11: 2B6E . Anticancer Treatment . . . . . . . . . . . . . DR5040 KML001 . . Phase 1 Lung cancer ICD-11: 2C25 . Anticancer Treatment . . . . . . . . . . . . . DR6157 Ionizing radiation . . Phase 3 Renal Insufficiency ICD-11: GB6Z . Anticancer Treatment . Radiotherapy . . . . . . . . . . . DR5269 Hypothermia . . Phase 2 Cerebral ischaemia ICD-11: 8B1Z . Anticancer Treatment . . . . . . . . . . . . . DR1442 Growth factor . . Phase 3 Diminished ovarian reserve ICD-11: 5A80 . Anticancer Treatment . Protein . . . . . . . . . . . DR0167 GC-SF . . Approved Acute myelogenous leukemia ICD-11: 2A41 . Anticancer Treatment . Protein . . . . . . . . . . . DR8626 GM-CSF . . Approved Acute myelogenous leukemia ICD-11: 2A41 . Anticancer Treatment . Protein . . . . . . . . . DB15845 . DR6409 Glyoxalase I . . Phase 2 Glucose intolerance ICD-11: 5C61 . Anticancer Treatment . . . . . . . . . . . . . DR5586 Gamma-ray irradiation . . Phase 3 Brain metastases ICD-11: 2D50 . Anticancer Treatment . Radiotherapy . . . . . . . . . . . DR5773 Fernblock . . Investigative Photoaging ICD-11: EJ20 . Anticancer Treatment . . . . . . . . . . . . . DR2520 Dextran sulfate sodium . . Phase 1 Human immunodeficiency virus disease ICD-11: 1C62 . Anticancer Treatment . . . . . . . . . . . . . DR9147 DC/Dribble vaccine . . Phase 1 Lung cancer ICD-11: 2C25 . Anticancer Treatment . Vaccine . . . . . . . . . . . DR3388 Daratumumab D0RV4P D0RV4P Approved Multiple myeloma ICD-11: 2A83 . Anticancer Treatment . Antibody . . . . . . . . . DB09331 . DR9409 Cytidine-5'-diphosp-bocholine . . Phase 4 Substance abuse ICD-11: 6C40 . Anticancer Treatment . . . . . . . . . . . . . DR9842 Chloramphenicol D0X6IU D0X6IU Approved Bacterial infection ICD-11: 1A00-1C4Z . Anticancer Treatment . . . . . . . . . . . DB00446 . DR8792 Cell differential agent-II . . Investigative Acute lymphoblastic leukemia ICD-11: 2B33 . Anticancer Treatment . . . . . . . . . . . . . DR6904 Canstatin . . Investigative Hepatocellular carcinoma ICD-11: 2C12 . Anticancer Treatment . . . . . . . . . . . . . DR1920 BS21 . . Investigative Obesity ICD-11: 5B81 . Anticancer Treatment . . . . . . . . . . . DB14669 . DR7340 Brentuximab vedotin D03TIS D03TIS Approved Hodgkin lymphoma ICD-11: 2B30 . Anticancer Treatment . Antibody . . . . . . . . . DB08870 . DR3226 Bis-chloroethylnitrosourea . . Investigative Brain cancer ICD-11: 2A00 . Anticancer Treatment . . . . . . . . . . . . . DR5858 Bcl-2 siRNA . . Investigative Pancreatic cancer ICD-11: 2C10 . Anticancer Treatment . Small interfering RNA . . . . . . . . . . . DR1784 Anti-CD8 (53.6.72) antibody . . Phase 2 Solid tumour/cancer ICD-11: 2A00-2F9Z . Anticancer Treatment . Antibody . . . . . . . . . . . DR9844 Anti-CD4 (GK1.5) antibody . . Phase 2 Melanoma ICD-11: 2C30 . Anticancer Treatment . Antibody . . . . . . . . . . . DR1274 Angiotensin-II converting enzyme inhibitor . . Phase 4 Brain infarction ICD-11: 8B25 . Anticancer Treatment . . . . . . . . . . . . . DR4283 5-LOX shRNA . . Investigative Prostate cancer ICD-11: 2C82 . Anticancer Treatment . Small hairpin RNA . . . . . . . . . . . DR6066 Tanespimycin D0SC2J D0SC2J Phase 2 Breast cancer ICD-11: 2C60-2C65 CID: 6505803 Anticancer Treatment "Tanespimycin; 17-AAG; 75747-14-7; 17-(Allylamino)-17-demethoxygeldanamycin; 17-(Allylamino)geldanamycin; NSC-330507; 17-Allylaminogeldanamycin; KOS-953; 17-Demethoxy-17-allylamino geldanamycin; UNII-4GY0AVT3L4; Cp 127374; NSC 330507; 17AAG; CHEBI:64153; 17-AAG (Tanespimycin); BMS-722782; 4GY0AVT3L4; MFCD04973892; NCGC00163424-01; 17-N-allylamino-17-demethoxygeldanamycin; 17-demethoxy-17-(2-propenylamino)geldanamycin; Geldanamycin, 17-demethoxy-17-(2-propenylamino)-; NSC330507; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; Tanespimycin [USAN:INN]; tanespimycina; tanespimycine; tanespimycinum; CCRIS 9401; 17-Demethoxy-17-allylaminogeldanamycin; C31H43N3O8; Tanespimycin (USAN); Geldanamycin, 17-(Allylamino)-17-demethoxy-; DSSTox_CID_26352; DSSTox_RID_81555; DSSTox_GSID_46352; BSPBio_001434; SCHEMBL2604976; DTXSID5046352; SCHEMBL13037468; SCHEMBL16226295; CHEBI:94756; CNF-101; CNF1010; HMS1361H16; HMS1791H16; HMS1989H16; HMS3402H16; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(allylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; CNF-1010; EX-A4668; NSC-330507D; Tox21_112054; BDBM50008057; s1141; AKOS024456643; ZINC100014666; BCP9000064; CCG-208039; CS-0161; DB05134; NSC-704057; IDI1_033904; NCGC00163424-02; NCGC00163424-04; NCGC00163424-05; NCGC00163424-06; NCGC00163424-07; HY-10211; Geldanamycin, des-O-methyl-17-allylamino-; CAS-75747-14-7; CP-127374; Geldanamycin, 17-allylamino-17-demethoxy-; X7553; D06650; W-5317; 747A147; Geldanamycin,17-demethoxy-17-(2-propenylamino)-; J-504153; BRD-K81473043-001-03-9; BRD-K81473043-001-08-8; 17-(Allylamino)-17-demethoxygeldanamycin, >=98% (HPLC), solid; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-Hydroxy-8,14-dimethoxy-4,10,12,16- tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo(16.3.1)docosa- 1(21),4,6,10,18-penten-9-yl carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-(allylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate; 17-AAG; ; ; 17-(Allylamino)-17-demethoxy-geldanamycin; ; ; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate" Small molecule "1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1" AYUNIORJHRXIBJ-TXHRRWQRSA-N CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC C31H43N3O8 CAS 75747-14-7 CHEBI:64153 . . . DB05134 . DR9368 Folfox . . Approved Colorectal cancer ICD-11: 2B91 CID: 135659064 Anticancer Treatment Folfox protocol; Folfox regimen; FOLFOX-4 protocol; FOLFOX-6 protocol; FOLFOX-7 protocol; Folfox; FOLFOX-4; FOLFOX-6; FOLFOX-7; C410216000; Fluorouracil regimen with leucovorin calcium and oxaliplatin Small molecule "1S/C20H23N7O7.C8H14.C4H3FN2O2.C2H2O4.Pt/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;1-7-5-3-4-6-8(7)2;5-2-1-6-4(9)7-3(2)8;3-1(4)2(5)6;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);7-8H,1-6H2;1H,(H2,6,7,8,9);(H,3,4)(H,5,6);/q;-2;;;+2/t12?,13-;7-,8-;;;/m01.../s1" YXTKHLHCVFUPPT-YYFJYKOTSA-N [CH2-]C1CCCCC1[CH2-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)O)O.[Pt+2] C34H42FN9O13Pt . . . . . . . DR5605 Polyinosinic acid-polycytidylic acid D0AY7O D0AY7O Investigative Middle East Respiratory Syndrome ICD-11: 1D64 CID: 135618150 Anticancer Treatment "Polyinosinic acid-polycytidylic acid; Poly(rI).poly(rC); 24939-03-5; Poly C poly I; Poly I:poly C; Poly(I).poly(C); Poly(rI).(rC); PI:C; Poly(I).poly(C) complex; Polyinosinate:polycytidylate; Poly IC; Polycytidylic-polyinosinic acid; Polyinosinic-polycytidylic acid; Polyinosinate-polycytidylate complex; Polyinosinic acid:polycytidylic acid; Polyinosinic-polycytidylic acid complex; Polyriboinosinic-polyribocytidylic acid; NSC-120949; Polyriboinosinic: polyribocytidylic acid; Poly(cytidylic acid)-poly(inosinic acid); Polyinosinic:polycytidylic acid; Polyinosinic acid:polycytidylic acid complex; Polyriboinosinic-polyribocytidylic acid complex; Polyribocytidylic acid-polyriboinosinic acid complex; Polyriboinosinic acid-polyribocytidylic acid complex; Poly(I:C) (VAN); NSC 123233; UNII-3R630IWW5I; UNII-O84C90HH2L; Poly(I).poly(C); Poly(I).poly(C) complex; Polyinosinic:polycytidylic acid copolymer; 3R630IWW5I; O84C90HH2L; DTXSID90947819; AKOS025402393; AC-8822; Q7226506; 5'-aInosinic acid, homopolymer, complex with 5'-acytidylic acid homopolymer (1:1); 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI); 5'-Inosinic acid, polymers, complex with 5'-cytidylic acid polymers (1:1) (8CI); [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate" Small molecule "1S/C10H13N4O8P.C9H14N3O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,10-;4-,6-,7-,8-/m11/s1" ACEVNMQDUCOKHT-ZLOOHWKQSA-N C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O C19H27N7O16P2 . . . . . . . DR8475 Pemetrexed D0Y4GO D0Y4GO Approved Pleural mesothelioma ICD-11: 2C26 CID: 135410875 Anticancer Treatment "Pemetrexed; 137281-23-3; Pemetrexed disodium; Alimta; LY231514; UNII-04Q9AIZ7NO; Pemetrexed acid; CHEBI:63616; 04Q9AIZ7NO; LY-231514; (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; C20H21N5O6; 137281-23-3 (free acid); LY 231514; NSC-698037; LY-2315; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; Alimta (TN); (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid; (4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamic acid; (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; LYA; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; Pemetrexed [INN:BAN]; HSDB 7316; 1juj; Pemetrexed (TN); N-(4-[2-(2-amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-Glutamic Acid; Pemetrexed (INN); Alimta (TN) (Lilly); SCHEMBL7968; US9422297, Pemetrexed; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; CHEMBL225072; DTXSID2048329; Premetrexed [Common mis-spelling]; ZINC1540998; BDBM50027656; CP0119; NSC698037; s5971; AKOS015896253; AKOS016842348; AC-1701; CS-1297; DB00642; NCGC00166414-11; NCGC00167517-01; NCGC00242485-01; AS-30680; HY-10820; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-; DB-024764; P2288; A12668; D07472; S-4927; 41413-EP2270012A1; 41413-EP2270013A1; 41413-EP2305681A1; 41413-EP2311838A1; 41421-EP2270012A1; 41421-EP2270013A1; 41421-EP2305681A1; 41421-EP2311838A1; 89077-EP2270012A1; 89077-EP2270013A1; 89077-EP2305681A1; AB01273937-01; 281P233; Q415220; J-502393; L-Glutamic acid,3-d]pyrimidin-5-yl]ethyl]benzoyl]-; 1006872-74-7; N-({4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl}carbonyl)-L-glutamic acid; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimi-din-5-yl)ethyl]benzoyl]l-glutamic acid; N-[4-[2-[2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]glutamic acid" Small molecule "1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1" WBXPDJSOTKVWSJ-ZDUSSCGKSA-N C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O C20H21N5O6 CAS 137281-23-3 CHEBI:63616 . . . DB00642 . DR3046 Raltitrexed D01KKQ D01KKQ Approved Rectum cancer ICD-11: 2B92 CID: 135400182 Anticancer Treatment "Raltitrexed; Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ICI D1694; UNII-FCB9EGG971; D1694; CHEBI:5847; C21H22N4O6S; Raltitrexed (Tomudex); ZD-16; FCB9EGG971; ZD 1694; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_CID_26482; DSSTox_RID_81653; DSSTox_GSID_46482; (S)-2-(5-(Methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)-methyl)amino)thiophene-2-carboxamido)pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; (2S)-2-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; D16; Tomudex (TN); D 1694; CAS-112887-68-0; Raltitrexed (JAN/USAN/INN); (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 1hvy; 2kce; 2tsr; ZN-D1694; KS-5069; ZD1694; Raltitrexed; SCHEMBL7438; MLS001424225; MLS006010125; N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid; Raltitrexed [USAN:INN:BAN]; GTPL7403; DTXSID0046482; BDBM18795; QCR-125; 1i00; HMS2052I03; HMS3715P08; AMY42113; ZINC3832372; Tox21_112237; BDBM50027655; MFCD00864168; NSC639186; s1192; AKOS015894877; AKOS015994729; Tox21_112237_1; CCG-101075; CCG-221273; DB00293; NC00325; NCGC00263534-02; HY-10821; L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-; L-Glutamic acid, N-[[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-; NCI60_013008; SMR000469217; SMR002529608; BCP0726000267; SW197705-2; C11372; D01064; S-7682; AB00698356-05; 134189-EP2275102A1; 134189-EP2292233A2; 887R680; SR-01000763351; J-524216; SR-01000763351-3; BRD-K89839824-001-01-2; Q15304877; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; N-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)carbonyl]-L-glutamic acid; N-[[5-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid" Small molecule "1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1" IVTVGDXNLFLDRM-HNNXBMFYSA-N CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1 C21H22N4O6S CAS 112887-68-0 CHEBI:5847 . . . DB00293 . DR2461 Ganciclovir D05ARP D05ARP Approved Virus infection ICD-11: 1A24-1D9Z CID: 135398740 Anticancer Treatment "ganciclovir; 82410-32-0; Cytovene; Gancyclovir; Vitrasert; Zirgan; RS-21592; Ganciclovirum; Cymevene; BW-759U; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; Virgan; BW 759U; 2'-NDG; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; UNII-P9G3CKZ4P5; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; MFCD00870588; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; GA2; CHEBI:465284; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; Hydroxyacyclovir; P9G3CKZ4P5; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; MLS000028481; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; Ganciclovir, 98%; NCGC00015471-02; HHEMG; SMR000058324; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one; Biolf 62; Ganciclovirum [Latin]; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; CAS-82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; DSSTox_CID_21032; DSSTox_RID_79613; DSSTox_GSID_41032; 2'-Nor-2'-deoxyguanosine; BIOLF-62; 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine; Citovirax; Cymevan; Cymeven; BW-B 759U; 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol; DRG-0018; 2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1,9-dihydro-6H-purin-6-one; Vitrasert (TN); BW 759; Cytovene (TN); CCRIS 9212; HSDB 6512; SR-01000075894; GCV & MSL; Ganciclovir (JAN/USP/INN); 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-1H-purin-6-one; Ganciclovir,(S); 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; BW-795; MB3795; Prestwick_1068; ST-605; Zirgan (TN); 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; GCV & 1110U81; Ganciclovir [USAN:USP:INN:BAN:JAN]; Opera_ID_284; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; Prestwick0_000839; Prestwick1_000839; Prestwick2_000839; Prestwick3_000839; Lopac-G-2536; CHEMBL182; EC 627-054-3; G 2536; SCHEMBL3033; Lopac0_000539; BSPBio_000797; MLS001077349; BIDD:GT0783; SPBio_002718; BPBio1_000877; ZINC1505; DTXSID8041032; methyl)-1H-purin-6(9H)-one; SCHEMBL14491348; BDBM85707; HMS1570H19; HMS2090K08; HMS2097H19; HMS2235C21; HMS3259B13; HMS3261L19; HMS3371H01; HMS3604L19; HMS3655M18; HMS3714H19; Pharmakon1600-01502362; ACT03317; BCP12705; NSC_3454; Tox21_110160; Tox21_500539; ANW-47031; BBL029078; BDBM50237614; NSC759656; PDSP1_000816; PDSP2_000803; s1878; SBB066292; STK801910; STL514515; 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-3H-purin-6-one; AKOS004119898; AKOS026749928; AKOS037492029; Tox21_110160_1; Valganciclovir hydrochloride impurity a; AC-8069; CCG-204629; CS-2014; DB01004; Ganciclovir, >=99% (HPLC), powder; KS-1065; LP00539; MCULE-9512761592; NC00647; NE60398; NSC 759656; NSC-759656; SDCCGSBI-0050522.P002; 2-Amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6H-purin-6-one; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-6,9-dihydro-1H-purin-6-one; SMP2_000038; NCGC00015471-01; NCGC00015471-03; NCGC00015471-04; NCGC00015471-05; NCGC00015471-06; NCGC00015471-08; NCGC00015471-16; NCGC00093928-01; NCGC00093928-02; NCGC00168567-01; NCGC00188980-01; NCGC00261224-01; 9-(1,3-dihydroxy-2propoxymethyl)guanine; AK-76645; HY-13637; SY027981; 9-(1,3-dihydroxy-2-propoxymethyl)guanine; AB0012496; CAS_82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy); 9-(1,3-dihydroxy-2-propoxymethyl)-guanine; EU-0100539; FT-0611007; FT-0668948; G0315; SW197135-3; EN300-49857; A11645; C07019; D00333; J10127; 40034-EP2377510A1; Ganciclovir 100 microg/mL in Acetonitrile:Water; 410G320; 9-[[(1,3-Dihydroxy-2-propyl)oxy]methyl]guanine; A840322; Ganciclovir, Antibiotic for Culture Media Use Only; Q417640; SR-01000721941; Q-201148; SR-01000075894-1; SR-01000075894-4; SR-01000721941-3; Z1259084907; Ganciclovir, European Pharmacopoeia (EP) Reference Standard; 2-[(2-amino-6-hydroxy-9H-purin-9-yl)methoxy]propane-1,3-diol; 2-azanyl-9-[1,3-bis(oxidanyl)propan-2-yloxymethyl]-3H-purin-6-one; Ganciclovir, United States Pharmacopeia (USP) Reference Standard; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}hydropurin-6-one; Ganciclovir, Pharmaceutical Secondary Standard; Certified Reference Material; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-1,9-dihydro-6H-purin-6-one; Ganciclovir, 1.0 mg/mL (1% 1M HCl in Methanol), certified reference material; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody" Small molecule "1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)" IRSCQMHQWWYFCW-UHFFFAOYSA-N C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N C9H13N5O4 CAS 82410-32-0 CHEBI:465284 . . . DB01004 . DR3806 Rifampicin D0G3DL D0G3DL Approved HIV-infected patients with tuberculosis ICD-11: 1B10-1B1Z CID: 135398735 Anticancer Treatment "Rifampicin; rifampin; Rifadin; Rimactane; Rimactan; Rifamycin AMP; 13292-46-1; Rifaldazine; Rifaprodin; Riforal; Tubocin; Rifa; Rifampicinum; Archidyn; Rifoldin; Rifoldine; Rimactizid; Rifagen; Rimazid; Rifampicin SV; L-5103 Lepetit; R/AMP; Arficin; Benemicin; Doloresum; Eremfat; Fenampicin; Rifadine; Rifaldazin; Rifamor; Rifinah; Rifobac; Rimactazid; Sinerdol; Arzide; Rifcin; Rifam; Dione 21-acetate; Rifampicine [French]; Rifampicina; Rifampicinum [INN-Latin]; Ba 41166/E; Rifampicina [INN-Spanish]; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; CCRIS 551; Rifadin I.V.; HSDB 3181; C43H58N4O12; UNII-VJT6J7R4TR; BA-41166E; NSC113926; VJT6J7R4TR; NSC-113926; Rifampicine; Abrifam; Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-; RFP; CHEBI:28077; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; L-5103; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-; Rifomycin SV, 8-(N-(4-methyl-1-piperazinyl)formidoyl)-; Rifaldin; DSSTox_CID_1244; DSSTox_RID_76035; DSSTox_GSID_21244; RIF; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate; CAS-13292-46-1; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; rifamcin; [1,11,13]trienimino)naphto[2,1-b]furan-21-yl acetate; Rifomycin sv, 8-[N-(4-Methyl-1-piperazinyl)formidoyl]-; Rifamsolin; Rifampicin [INN:BAN:JAN]; Famcin; MFCD00151389; Rimactane (TN); NCGC00094777-01; AZT + Rifampin; Rifampin (USP); (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[[(4-methylpiperazin-1-yl)imino]methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acet; (2S,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; [pentahydroxy-methoxy-heptamethyl-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-dioxo-[?]yl] acetate; Rifampicin & EEP; Prestwick_833; EINECS 236-312-0; R-Cin; Rifadin (TN); NSC 113926; Piperine & Rifampicin; Rifampicin & Propolis; Reserpine & Rifampicin; Rifampin [USAN:USP]; Prestwick2_000525; Prestwick3_000525; Spectrum5_002018; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; Rifampicin (JP17/INN); SCHEMBL23490; BSPBio_000509; L-5103-LEPETIT; 8CI); BPBio1_000561; CHEMBL374478; DTXSID6021244; HMS1569J11; HMS2089F12; HMS2096J11; HMS3713J11; DRG-0109; Rifampicin, >=97.0% (HPLC); Rifampicin, powder, gamma-irradiated; Tox21_111329; Tox21_201385; Tox21_300550; Ba 41166; BDBM50370232; GR-306; NIH-10782; AKOS015951372; Rifampicin - CAS 13292-46-1; Rifampicin, >=97% (HPLC), powder; Tox21_111329_1; BA 411661E; CCG-208267; DB01045; NCGC00022678-03; NCGC00022678-04; NCGC00022678-05; NCGC00022678-06; NCGC00179536-02; NCGC00254537-01; NCGC00258936-01; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione 21-acetate; M880; ST057531; C06688; D00211; J10110; Rifampicin, VETRANAL(TM), analytical standard; AB00383022_07; 292R461; SR-05000002118; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; SR-05000002118-3; WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; Rifampicin, European Pharmacopoeia (EP) Reference Standard; Rifampin, United States Pharmacopeia (USP) Reference Standard; Rifampin, Pharmaceutical Secondary Standard; Certified Reference Material; 4,7>.0<5,28>]triaconta-1(28),2,4,9,1 9,21,25(29),26-octaen-13-yl acetate; Rifampicin, plant cell culture tested, BioReagent, >=97% (HPLC), crystalline; yl]-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ac; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11- methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino] methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1 (28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; 2,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; 2,7-(epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(E)-[(4-methyl-1-piperazinyl)imino]meth; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate (; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate (8CI); 26-[(1E)-2-(4-methylpiperazinyl)-2-azavinyl](7S,11S,13S,17S,18S,12R,14R,15R,16 R)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-d ioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-beta)furan-1,11(2H)-dione 21-acetate; 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; Rifampicin in combination with actinonin, BB-3497, hydroxylamine hydrochloride, and 1,10-phenanthroline; RMP; Stereoisomer of 5,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-he@ptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate" Small molecule "1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1" JQXXHWHPUNPDRT-WLSIYKJHSA-N CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C C43H58N4O12 CAS 13292-46-1 CHEBI:28077 . . . DB01045 . DR0067 3-methyladenine . . Investigative Cardiac injury ICD-11: NB31 CID: 135398661 Anticancer Treatment "3-methyladenine; 5142-23-4; 3-Methyl-3H-purin-6-amine; 6-Amino-3-methylpurine; 3-MA; 3-Methyl-3H-adenine; 3H-Purin-6-amine, 3-methyl-; NSC 66389; n3-methyladenine; ADENINE, 3-METHYL-; MFCD00010531; CHEBI:38635; UNII-DR88TV7SNU; DR88TV7SNU; 3-METHYL-3H-PURIN-6-YLAMINE; 3-Methyladenine autophagy inhibitor; 3-Methyladenine, 90+%; 3-MA nucleobase; 3-Methyladenine (3-MA); 3MA; 60192-57-6; N(3)-methyladenine; 3-methylpurin-6-amine; EINECS 225-908-6; BRN 0146087; 3-methyl-7H-purin-6-imine; 3mea; 3-methyl-Adenine; 3-Methyladenine?; NSC66389; 1p7m; 4ai5; Autophagy Inhibitor, 3-MA; NCIOpen2_000270; SCHEMBL48369; 5-26-17-00151 (Beilstein Handbook Reference); MLS006010995; SCHEMBL254058; CHEMBL292268; 3-methyl-3-hydropurin-6-imine; CHEMBL4303725; SCHEMBL15764619; 3-Methyl-3H-purin-6-amine #; AOB2548; DTXSID80199406; EX-A130; 3-methyl-3-hydropurine-6-ylamine; Bio1_000422; Bio1_000911; Bio1_001400; HMS3656P04; ZINC403086; 3-Methyl-7H-purine-6(3H)-imine; ACN-C001131; AMY11868; BCP02452; 3-Methyladenine, autophagy inhibitor; ABP000334; ANW-54285; BDBM50488841; NSC-66389; QC-518; s2767; SBB086626; AKOS003382321; AKOS006228458; ZINC100003619; ACN-001131; CCG-206388; CS-5207; DB04104; MCULE-5086156902; NSC 66389 (3-MA); VZ27096; NCGC00345447-02; AC-28818; AK-94088; AS-19224; HY-19312; SMR002530641; SY026559; AB0007938; DB-051961; A7582; FT-0635560; FT-0671432; M2518; ST50298916; SW220216-1; X5709; 3-methyl-3H-purin-6-amine (ACD/Name 4.0); C00913; Q-9331; 3-methyl-3H-purin-6-ylamine (ACD/Name 4.0); J-640198; J-800199; W-202935; BRD-K81647657-001-01-9; Q27094948" Small molecule "1S/C6H7N5/c1-11-3-10-5(7)4-6(11)9-2-8-4/h2-3,7H,1H3,(H,8,9)" ZPBYVFQJHWLTFB-UHFFFAOYSA-N CN1C=NC(=N)C2=C1N=CN2 C6H7N5 CAS 5142-23-4 CHEBI:38635 . . . DB04104 . DR8289 Acyclovir D0B5MP D0B5MP Approved Virus infection ICD-11: 1A24-1D9Z CID: 135398513 Anticancer Treatment "acyclovir; Aciclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; Sitavig; 9-(2-Hydroxyethoxy)methylguanine; 9-HYROXYETHOXYMETHYLGUANINE; W-248-U; Acyclovir-side chain-2-3H; 9-((2-Hydroxyethoxy)methyl)guanine; UNII-X4HES1O11F; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; Acyclovir-d4; NSC 645011; CHEBI:2453; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; Acyclovir (Aciclovir); 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-; Zovirax (TN); MFCD00057880; 9-[(2-Hydroxyethoxy)-methyl]guanine; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; X4HES1O11F; MLS000069633; 141294-79-3; Activir; 9-(2-Hydroxyethoxymethyl)guanine; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-; 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one; NSC645011; NSC-645011; AC2; 2-amino-9-((2-hydroxyethoxy)methyl)-3H-purin-6(9H)-one; Acycloguanosine, 98%; NCGC00015061-02; Aciclovirum [Latin]; Aciclovier; Hascovir; SMR000058225; Genvir; Maynar; Zyclir; 2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one; CAS-59277-89-3; 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-; DSSTox_CID_2556; DSSTox_RID_76626; Aciclovirum [INN-Latin]; DSSTox_GSID_22556; 2-amino-9-[(2-hydroxyethoxy)methyl]hydropurin-6-one; Acicloftal; Cargosil; Viropump; AcycloFoam; 2-amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin-6-one; Acic; BW-248U; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; Acyclo-V; Acyclovir Lauriad; DRG-0008; Acyclovir (USP); BW 248U; CCRIS 1953; 1185179-33-2; HSDB 6511; SR-01000075540; Acyclovir [USAN:USP]; EINECS 261-685-1; ACV & Pluronic F-68; Acyclovir & Pluronic F-68; Cyclovir; Poviral; Sitavir; 2-amino-9-((2-hydroxyethoxy)methyl)-3,9-dihydro-6H-purin-6-one; Prestwick_6; ACYCLOVIR-SIDECHAIN-2-3H; 1pwy; Aciclovir [INN]; BW-248-U; Sitavig (TN); PubChem9572; Spectrum_001739; Opera_ID_1674; Prestwick0_000086; Prestwick1_000086; Prestwick2_000086; Prestwick3_000086; Spectrum2_001563; Spectrum3_001874; Spectrum4_000225; Spectrum5_001093; Lopac-A-4669; Aciclovir (JP17/INN); CHEMBL184; A 4669; Acycloguanosine (Acyclovir); SCHEMBL3175; Lopac0_000037; BSPBio_000012; BSPBio_003348; KBioGR_000889; KBioSS_002219; ARONIS27002; BIDD:GT0646; DivK1c_000185; SPECTRUM1503603; SPBio_001466; SPBio_001951; BPBio1_000014; GTPL4829; SCHEMBL9828560; 9(2-hydroxyethoxymethyl)guanine; DTXSID1022556; HMS500J07; KBio1_000185; KBio2_002219; KBio2_004787; KBio2_007355; KBio3_002850; NINDS_000185; HMS1568A14; HMS1922E08; HMS2090G09; HMS2095A14; HMS2234K21; HMS3259N10; HMS3260G15; HMS3269M15; HMS3372K02; HMS3413D21; HMS3655C14; HMS3677D21; HMS3712A14; Pharmakon1600-01503603; BCP11036; EBD48195; ZINC1530555; 9-(2-hydroxyethoxy methyl) guanine; Tox21_110075; Tox21_500037; 59277-89-3 (free); 69657-51-8 (Na salt); ANW-43941; BBL009642; BDBM50021776; BDBM50103518; CCG-39909; NSC758477; NSC780378; s1807; SBB063281; STK796771; STL257059; STL301862; AKOS000656213; AKOS015995680; AKOS022135433; Tox21_110075_1; AC-8068; CS-1353; DB00787; KS-1027; LP00037; MCULE-2703274259; NC00717; NSC-758477; NSC-780378; SDCCGSBI-0050026.P003; IDI1_000185; SMP1_000007; NCGC00015061-01; NCGC00015061-03; NCGC00015061-04; NCGC00015061-05; NCGC00015061-06; NCGC00015061-07; NCGC00015061-08; NCGC00015061-09; NCGC00015061-10; NCGC00015061-12; NCGC00015061-13; NCGC00015061-28; NCGC00022426-03; NCGC00093555-01; NCGC00093555-02; NCGC00093555-03; NCGC00093555-04; NCGC00167756-01; NCGC00167756-02; NCGC00260722-01; NCGC00381719-03; AK-24687; HY-17422; ST024744; SY051130; Acycloguanosine, >=99% (HPLC), powder; AB0012294; AB0068584; Aciclovir 1.0 mg/ml in Dimethyl Sulfoxide; AM20100442; EU-0100037; FT-0621607; FT-0657847; SW196324-3; 6383-EP2270005A1; 6383-EP2305243A1; 6383-EP2305640A2; 6383-EP2305808A1; 6383-EP2314582A1; 6383-EP2314585A1; C06810; D00222; J10243; M-1904; 32284-EP2281815A1; 32284-EP2301933A1; 32284-EP2311827A1; 277A893; A832236; Q147101; Q-200591; SR-01000075540-1; SR-01000075540-3; SR-01000075540-5; 2-amino-9-[(2-hydroxyethoxy)methyl]-9H-purin-6-ol; 2-azanyl-9-(2-hydroxyethyloxymethyl)-3H-purin-6-one; BRD-K32318651-001-17-9; Aciclovir, British Pharmacopoeia (BP) Reference Standard; F2173-0946; Aciclovir, European Pharmacopoeia (EP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one; Acyclovir, United States Pharmacopeia (USP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one (ACV); 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one #; 2-amino-9-[(1,1,2,2-tetradeuterio-2-hydroxyethoxy)methyl]-1H-purin-6-one; ACV; Acycloguanosine; Acyclovir; NSC 645011; NSC-645011; NSC645011; Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material; Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard; Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard; Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard" Small molecule "1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)" MKUXAQIIEYXACX-UHFFFAOYSA-N C1=NC2=C(N1COCCO)N=C(NC2=O)N C8H11N5O3 CAS 59277-89-3 CHEBI:2453 . . . DB00787 . DR1922 Proanthocyanidins . . Phase 2 Atherosclerosis ICD-11: BD40 CID: 122173182 Anticancer Treatment ZINC584567037; N1697 Small molecule "1S/C30H26O13/c31-14-7-19(35)16-11-25(28(41-23(16)9-14)12-1-3-17(33)20(36)5-12)43-30(13-2-4-18(34)21(37)6-13)29(40)27(39)26-22(38)8-15(32)10-24(26)42-30/h1-10,25,27-29,31-40H,11H2/t25-,27+,28+,29-,30+/m1/s1" HGVVOUNEGQIPMS-JOFXVPDFSA-N C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC4(C(C(C5=C(C=C(C=C5O4)O)O)O)O)C6=CC(=C(C=C6)O)O C30H26O13 . . . . . . . DR3679 Sucralfate D06ULU D06ULU Approved Acne vulgaris ICD-11: ED80 CID: 121494085 Anticancer Treatment "Sucralfato; Ulcerban; Ulcogant; Ulsanic; Sucralfatum; Ulcerlmin; Ulcar; Sucralfatum [INN-Latin]; Sucralfato [INN-Spanish]; OGA-6J; UNII-XX73205DH5; HSDB 3926; XX73205DH5; EINECS 259-018-4; OS 202; DB00364; Sucralfate [USAN:USP:INN:BAN:JAN]; Aluminum, hexadeca-mu-hydroxytetracosahydroxy(mu8-(1,3,4,6-tetra-O-sulfo-beta-D-fructofuranosyl alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca-; Sucrose hydrogen sulfate basic aluminium salt; Sucrose octakis(hydrogen sulfate) aluminum complex; 1,2,3,3',4,4',6,6'-Octa-O-sulfo-beta-D-fructofuranosyl-alpha-D-glucopyranosid aluminium hydroxid-hydrat-salz; alpha-D-Glucopyranoside, beta-D-fructofuranosyl-, octakis(hydrogen sulfate), aluminum complex; Hexadeca-mu-hydroxytetracosahydroxy[mu8-[1,3,4,6-tetra-O-sulfo-beta-Dfructofuranosyl-alpha-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum; Hexadeca-U-hydroxytetracosahydroxy-(U8-(1,3,4,6-tetra-O-sulfo-beta-D-fructofuranosyl-alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-))) hexadecaaluminum" Small molecule "1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1" YZPQNHUVIVIUCT-JTJNLBSYSA-F C(C1C(C(C(C(O1)OC2(C(C(C(O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al] C12H54Al9O55S8 CAS 54182-58-0 . . . . DB00364 . DR1867 Thearubigin . . Investigative Acute lung injury ICD-11: NB32 CID: 100945367 Anticancer Treatment Thearubigin Small molecule "1S/C43H34O22/c44-17-7-23(46)21-11-32(64-42(60)15-3-25(48)36(55)26(49)4-15)39(62-30(21)9-17)14-1-19(35(41(58)59)38(57)29(52)2-14)20(13-34(53)54)40-33(12-22-24(47)8-18(45)10-31(22)63-40)65-43(61)16-5-27(50)37(56)28(51)6-16/h1-10,20,32-33,39-40,44-51,55-56H,11-13H2,(H,52,57)(H,53,54)(H,58,59)/t20?,32-,33-,39-,40-/m1/s1" FNRFUGUISXPIKU-HYMCCRAQSA-N C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=O)C(=C(C(=C3)C(CC(=O)O)C4C(CC5=C(C=C(C=C5O4)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O)C(=O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O C43H34O22 . . . . . . . DR4199 Alpelisib D0W7HE D0W7HE Approved Breast cancer ICD-11: 2C60-2C65 CID: 56649450 Anticancer Treatment "alpelisib; 1217486-61-7; BYL-719; BYL719; NVP-BYL719; Piqray; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; UNII-08W5N2C97Q; BYL 719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; C19H22F3N5O2S; (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (2s)-N~1~-{4-Methyl-5-[2-(1,1,1-Trifluoro-2-Methylpropan-2-Yl)pyridin-4-Yl]-1,3-Thiazol-2-Yl}pyrrolidine-1,2-Dicarboxamide; (S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.; 1,2-Pyrrolidinedicarboxamide, N1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl)-2-thiazolyl)-, (2S)-; 1,2-PYRROLIDINEDICARBOXAMIDE, N1-[4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYLETHYL)-4-PYRIDINYL]-2-THIAZOLYL]-, (2S)-; 4jps; Piqray (TN); Alpelisib [USAN:INN]; QCR-1; Alpelisib (JAN/USAN/INN); cc-697; GTPL7955; SCHEMBL1911869; CHEBI:93752; DTXSID70153355; EX-A405; BYL 719; BYL719; AOB87192; NVP-BYL719 (BYL719); 2294AH; BDBM50436459; MFCD22417085; NSC765974; NSC800065; s2814; ZINC68198368; AKOS022186315; CCG-269139; CS-0663; DB12015; NSC-765974; NSC-800065; SB16575; NCGC00346717-03; NCGC00346717-06; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidine; (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl)thiazol-2-yl)amide; 1217486-47-9; AS-16349; HY-15244; AB0094905; SW220128-1; cas:1217486-61-7;BYL-719; D11011; W-5917; J-004627; Q27074391; 1LT; BYL-719; ; ; (2S)-1-N-[4-Methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide" Small molecule "1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1" STUWGJZDJHPWGZ-LBPRGKRZSA-N CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F C19H22F3N5O2S CAS 1217486-61-7 CHEBI:93752 . . . DB12015 . DR6317 Eravacycline D0LZ7E D0LZ7E Approved Infectious gastroenteritis/colitis ICD-11: 1A40 CID: 54726192 Anticancer Treatment "ERAVACYCLINE; TP-434; Xerava; 1207283-85-9; UNII-07896928ZC; CHEMBL1951095; 07896928ZC; (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; Eravacycline [USAN:INN]; TP434; YQM; TP434;Eravacycline; Eravacycline (USAN); CHEMBL4597183; SCHEMBL10040430; GTPL10805; EX-A751; MFCD28978145; ZINC200151468; CS-7564; DB12329; compound 17j [PMID: 2148514]; HY-16980; D10369; J-690064; Q15410941; 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline; (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboxamide; (4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 1-Pyrrolidineacetamide, N-((5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl)-; 7-[6-(2-Hydroxy-2-propanyl)-3-pyridinyl]-1-(4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one; N-[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide" Small molecule "1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1" AKLMFDDQCHURPW-ISIOAQNYSA-N CN(C)C1C2CC3CC4=C(C=C(C(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F C27H31FN4O8 CAS 1207283-85-9 . . . . DB12329 . DR0641 Minocycline D08LTU D08LTU Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 54675783 Anticancer Treatment "minocycline; 10118-90-8; Minocyclin; Minociclina; Minocyn; Dynacin; Minocin; Minomycin; CL 59806; MINO; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; UNII-FYY3R43WGO; CHEBI:50694; FYY3R43WGO; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; Tri-minocycline; Minocyclinum; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-; Minocyclinum [INN-Latin]; NCGC00183044-01; Borymycin; Minociclina [INN-Spanish]; MIY; minociclinum; Minocline; Minoz; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; HSDB 3130; NSC-141993; Minocin (Hydrochloride); Vectrin (Hydrochloride); Minocycline (USAN/INN); BRN 3077644; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minocycline [USAN:INN:BAN]; SR-05000001675; (minocycline); (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2- CARBOXAMIDE; (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; NSC141993; Spectrum_000967; Prestwick0_000315; Prestwick1_000315; Prestwick2_000315; Spectrum2_001047; Spectrum3_000508; Spectrum4_000062; Spectrum5_001293; SCHEMBL4042; CHEMBL1434; DSSTox_CID_25033; DSSTox_RID_80650; DSSTox_GSID_45033; SCHEMBL24315; BSPBio_002035; KBioGR_000583; KBioSS_001447; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-; cc-666; ls-007; CHEMBL69484; DivK1c_000450; SPBio_000974; SPBio_002529; DTXSID1045033; SCHEMBL16681149; BCBcMAP01_000027; GTPL10831; KBio1_000450; KBio2_001447; KBio2_004015; KBio2_006583; KBio3_001535; NINDS_000450; HMS2090D03; KUC106429N; KSC-12-231B; ZINC4019704; Tox21_113643; BDBM50103599; LMPK07000002; ZINC14879992; AKOS015969674; ZINC100409820; BCP9000928; CL59806; DB01017; IDI1_000450; SMP1_000191; NCGC00178854-01; NCGC00178854-02; NCGC00188954-01; AC-30184; CL-59806; SBI-0051449.P003; CAS-10118-90-8; AM20090714; 1371-EP2269978A2; 1371-EP2269985A2; 1371-EP2269991A2; 1371-EP2272832A1; 1371-EP2284150A2; 1371-EP2284151A2; 1371-EP2284152A2; 1371-EP2284153A2; 1371-EP2284155A2; 1371-EP2284156A2; 1371-EP2284164A2; 1371-EP2287140A2; 1371-EP2287148A2; 1371-EP2287150A2; 1371-EP2289871A1; 1371-EP2292590A2; 1371-EP2292612A2; 1371-EP2295402A2; 1371-EP2295419A2; 1371-EP2295426A1; 1371-EP2295427A1; 1371-EP2298732A1; 1371-EP2301534A1; 1371-EP2301912A2; 1371-EP2301913A1; 1371-EP2301914A1; 1371-EP2301916A2; 1371-EP2305637A2; 1371-EP2308832A1; 1371-EP2308863A1; 1371-EP2311451A1; 1371-EP2311796A1; 1371-EP2311797A1; 1371-EP2311798A1; 1371-EP2311799A1; 1371-EP2316450A1; 18M908; C07225; D05045; AB00053501-03; AB00053501_04; AB00053501_05; Q415336; J-500789; SR-05000001675-3; (2E,4S,4aR,5aS,12aR)-2-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3 ,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-" Small molecule "1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1" FFTVPQUHLQBXQZ-KVUCHLLUSA-N CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C C23H27N3O7 CAS 10118-90-8 CHEBI:50694 . . . DB01017 . DR4920 Tetracycline D08NQZ D08NQZ Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 54675776 Anticancer Treatment "tetracycline; 60-54-8; Tetracyclinum; Achromycin; Tetracyclin; Deschlorobiomycin; Sumycin; Abramycin; Tsiklomitsin; Achromycin V; Liquamycin; Panmycin; Tetracyn; Tetrazyklin; Ambramycin; Hostacyclin; Omegamycin; Tetradecin; Tetraverine; Tsiklomistsin; Vetacyclinum; Tetrafil; Tetracycline base; Cefracycline; Criseociclina; Abricycline; Agromicina; Ambramicina; Biocycline; Ciclibion; Copharlan; Democracin; Lexacycline; Limecycline; Mericycline; Micycline; Orlycycline; Polycycline; Polyotic; Purocyclina; Roviciclina; Solvocin; Tetrabon; Tetracycl; Amycin; Veracin; SK-Tetracycline; Tetracycline II; Tetra-Co; UNII-F8VB5M810T; Cyclomycin; Sustamycin; Sumycin syrup; Tetracycline I; Bio-tetra; (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; CHEBI:27902; Piracaps (base); Centet (base); Polycycline (VAN); 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-; Cefracycline suspension; Liquamycin (Veterinary); Polycycline (antibiotic); F8VB5M810T; (4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; Tetraciclina; Tetracycline (internal use); Supramycin; Vetquamycin-324 (free base); MFCD00151232; 60-54-8 (FREE BASE); NSC-108579; E701; Achromycin (naphthacene derivative); NSC 108579; T-125; HSDB 3188; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide; Tetracyclinum [INN-Latin]; Tetraciclina [INN-Spanish]; (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide; Sumycin (TN); 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha))-; 6416-04-2 (3H2O); Economycin; Vetquamycin; Brodspec; Tetracycline (JAN/USP/INN); CCRIS 9483; SR-01000000212; NSC108579; Tetrabid Organon; Ala-Tet; Tetracycline [USP:INN:BAN:JAN]; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-; EINECS 200-481-9; Spectrum_001034; Tetracycline, EP grade; Prestwick0_000140; Prestwick1_000140; Prestwick2_000140; Prestwick3_000140; Spectrum2_001329; Spectrum3_000565; Spectrum4_000352; Spectrum5_001112; DSSTox_CID_3645; EC 200-481-9; SCHEMBL3098; DSSTox_RID_77127; DSSTox_GSID_23645; BSPBio_000220; BSPBio_001950; KBioGR_000783; KBioSS_001514; BIDD:GT0653; DivK1c_000827; SCHEMBL537050; SPBio_001457; SPBio_002159; BPBio1_000242; SCHEMBL2116649; SCHEMBL2116661; DTXSID7023645; SCHEMBL21271987; GTPL10927; KBio1_000827; KBio2_001514; KBio2_004082; KBio2_006650; KBio3_001450; NINDS_000827; HMS2090B04; Tetracycline, >=98.0% (NT); HY-A0107; RKL10088; Tetracycline, >=88.0% (HPLC); Tox21_300150; BDBM50237605; s4490; ZINC84441937; AKOS024277860; AKOS026749977; ZINC100303069; ZINC102229720; CS-8188; DB00759; MCULE-3752961261; CAS-60-54-8; IDI1_000827; NCGC00017323-03; NCGC00017323-04; NCGC00017323-05; NCGC00017323-07; NCGC00017323-15; NCGC00142507-02; NCGC00254063-01; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,1 0,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; ST019403; SBI-0051530.P003; 1369-EP2269978A2; 1369-EP2269985A2; 1369-EP2269991A2; 1369-EP2270008A1; 1369-EP2275420A1; 1369-EP2284150A2; 1369-EP2284151A2; 1369-EP2284152A2; 1369-EP2284153A2; 1369-EP2284155A2; 1369-EP2284156A2; 1369-EP2284164A2; 1369-EP2287140A2; 1369-EP2287148A2; 1369-EP2287150A2; 1369-EP2289871A1; 1369-EP2289891A2; 1369-EP2292088A1; 1369-EP2292590A2; 1369-EP2292612A2; 1369-EP2292617A1; 1369-EP2295402A2; 1369-EP2295419A2; 1369-EP2298732A1; 1369-EP2301534A1; 1369-EP2301912A2; 1369-EP2301913A1; 1369-EP2301914A1; 1369-EP2301916A2; 1369-EP2305637A2; 1369-EP2305640A2; 1369-EP2305662A1; 1369-EP2307027A1; 1369-EP2308832A1; 1369-EP2308863A1; 1369-EP2308883A1; 1369-EP2311451A1; 1369-EP2311796A1; 1369-EP2311797A1; 1369-EP2311798A1; 1369-EP2311799A1; 1369-EP2311822A1; 1369-EP2314583A1; 1369-EP2316450A1; 1369-EP2371797A1; 1369-EP2371798A1; 1369-EP2371800A1; 1369-EP2371804A1; C06570; D00201; AB00053550-04; AB00053550_05; AB00053550_06; Q193045; SR-01000000212-3; Z2144222809; (4S,4aS,5aS,6S,12aS)-2-[Amino(hydroxy)methylene]-4beta-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-6alpha,10,12,12abeta-tetrahydroxy-6-methylnaphthacene-1,3,11-trione; (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide; (4S,6S,12aS,4aS,5aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,1 1-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide" Small molecule "1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1" NWXMGUDVXFXRIG-WESIUVDSSA-N CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O C22H24N2O8 CAS 60-54-8 CHEBI:27902 . . . DB00759 . DR7091 Doxycycline D0S0LZ D0S0LZ Approved Periodontal disease ICD-11: DA0C CID: 54671203 Anticancer Treatment "doxycycline; Vibramycin; 564-25-0; Doxytetracycline; Doxiciclina; Doxycyclinum; Doxycycline (anhydrous); Monodox; Oracea; Vibra-tabs; Doxycycline hyclate; 6alpha-Deoxy-5-oxytetracycline; 5-Hydroxy-alpha-6-deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; Doxycyclin; alpha-6-Deoxy-5-hydroxytetracycline; BMY-28689; Doxycycline anhydrous; Liviatin; DOXY; Doxy-Caps; Vibravenos; UNII-334895S862; Deoxymykoin; Dossiciclina; Azudoxat; Doxitard; Doxivetin; Doxycen; Doxychel; Investin; Ronaxan; CHEBI:50845; Spanor; Doxy-Puren; alpha-Doxycycline; Doxy-Tabs; alpha-6-Deoxyoxytetracycline; MMV000011; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-; Supracyclin; Doxysol; Jenacyclin; 6-Deoxyoxytetracycline; Dossiciclina [DCIT]; Doxiciclina [Italian]; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; GS-3065; Doxycyclinum [INN-Latin]; Doxycycline (internal use); Doxiciclina [INN-Spanish]; 334895S862; BU-3839T; 4-Epidoxycycline; Zenavod; DOXCYCLINE ANHYDROUS; Oxytetracycline, 6-deoxy-; Doxycycline (TN); Doxychel (TN); (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-; Vivox (*Hyclate); Doxycycline (INN); DMSC (*Fosfatex); NSC633557; HSDB 3071; Monodox (*monohydrate); BMY28689; BU 3839T; EINECS 209-271-1; BMY 28689; Vibramycin (*monohydrate); GS-3065 (*monohydrate); Doxirobe; Doxycycline [USAN:INN:BAN]; SR-01000075844; Anhydrous doxycycline; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-; AB08 (*Fosfatex); Spectrum_000807; 24390-14-5; Spectrum2_000143; Spectrum3_000408; Spectrum4_000527; Spectrum5_000947; UPCMLD-DP021; CHEMBL1433; Lopac0_000405; SCHEMBL40930; SCHEMBL66828; BSPBio_001936; KBioGR_001133; KBioSS_001287; BIDD:GT0146; DivK1c_000345; SPBio_000246; CHEMBL436921; GTPL6464; SCHEMBL1176275; 4-Epioxytetracycline, 6-deoxy-; DTXSID0037653; SCHEMBL17826665; SCHEMBL19270298; SCHEMBL21753474; UPCMLD-DP021:001; BCBcMAP01_000024; KBio1_000345; KBio2_001287; KBio2_003855; KBio2_006423; KBio3_001156; DTXSID80992212; NINDS_000345; HMS2090E06; DOXYTETRACYCLINE; DOXYCYCLINE; HY-N0565; LMPK07000001; s5159; ZINC16052277; AKOS015900372; ZINC100056779; ZINC100302137; ZINC100611210; ZINC109562088; CCG-204498; DB00254; MCULE-4368118692; SDCCGSBI-0050391.P005; IDI1_000345; SMP1_000107; NCGC00161602-01; NCGC00161602-03; NCGC00161602-04; NCGC00161602-05; NCGC00161602-14; NCGC00188979-01; (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 2-Naphthacenecarboxamide, 4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo-; AS-13499; I455; SBI-0050391.P004; CS-0009105; 1368-EP2269978A2; 1368-EP2269985A2; 1368-EP2269991A2; 1368-EP2284150A2; 1368-EP2284151A2; 1368-EP2284152A2; 1368-EP2284153A2; 1368-EP2284155A2; 1368-EP2284156A2; 1368-EP2284164A2; 1368-EP2287140A2; 1368-EP2287148A2; 1368-EP2287150A2; 1368-EP2289871A1; 1368-EP2295402A2; 1368-EP2295419A2; 1368-EP2298732A1; 1368-EP2301534A1; 1368-EP2301912A2; 1368-EP2301913A1; 1368-EP2301914A1; 1368-EP2301916A2; 1368-EP2305637A2; 1368-EP2305640A2; 1368-EP2308863A1; 1368-EP2311451A1; 1368-EP2311796A1; 1368-EP2311797A1; 1368-EP2311798A1; 1368-EP2311799A1; 1368-EP2316450A1; C06973; D07876; AB00053465-03; AB00053465_04; AB00053465_05; 564D250; Doxycycline, Antibiotic for Culture Media Use Only; Q422442; SR-01000075844-7; W-105517; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 4-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid; 7164-70-7" Small molecule "1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1" SGKRLCUYIXIAHR-AKNGSSGZSA-N CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O C22H24N2O8 CAS 564-25-0 CHEBI:50845 . . . DB00254 . DR3757 Torin 2 D2B7WM D2B7WM Investigative Mature T-cell lymphoma ICD-11: 2A90 CID: 51358113 Anticancer Treatment "Torin 2; 1223001-51-1; Torin2; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE" Small molecule "1S/C24H15F3N4O/c25-24(26,27)17-2-1-3-18(11-17)31-22(32)9-6-16-13-29-20-7-4-14(10-19(20)23(16)31)15-5-8-21(28)30-12-15/h1-13H,(H2,28,30)" GUXXEUUYCAYESJ-UHFFFAOYSA-N C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F C24H15F3N4O CAS 1223001-51-1 CHEBI:90682 . . . . . DR7865 Birinapant D0E8NP D0E8NP Phase 2 Lymphoma ICD-11: 2A80-2A86 CID: 49836020 Anticancer Treatment "Birinapant; 1260251-31-7; Birinapant (TL32711); TL32711; TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide; (2s,2's)-N,N'-[(6,6'-Difluoro-1h,1'h-2,2'-Biindole-3,3'-Diyl)bis{methanediyl[(2r,4s)-4-Hydroxypyrrolidine-2,1-Diyl][(2s)-1-Oxobutane-1,2-Diyl]}]bis[2-(Methylamino)propanamide]; Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-, (2S,2'S)-; Birinapant [USAN:INN]; Birinapant di-HCl; Birinapant (USAN/INN); MLS006011237; GTPL7432; TL32711 2HCl; CHEMBL3039522; SCHEMBL10049847; DTXSID30155057; EX-A258; TL-32711 2HCl; C42H56F2N8O6; AOB87396; 2269AH; ABP001107; BDBM50071920; MFCD25976869; NSC767128; NSC816007; s7015; ZINC96941868; AKOS030526366; CCG-270498; CS-1719; DB11782; NSC-767128; NSC-816007; SB16522; AC-32868; AS-17035; HY-16591; SMR004702997; SW220103-1; A12738; D10417; Z-3165; Q27075298; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanam; (2S,2'S)-N,N'-((2S,2'S)-((3S,3'S,5R,5'R)-5,5'-((6,6'-difluoro-1H,1'H-[2,2'-biindole]-3,3'-diyl)bis(methylene))bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-2,1-diyl))bis(2-(methylamino)propanamide); (2S,2'S)-N,N'-((2S,2'S)-1,1'-((3S,3'S,5R,5'R)-5,5'-(6,6'-difluoro-1H,1'H-2,2'-biindole-3,3'-diyl)bis(methylene)bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-2,1-diyl))bis(2-(methylamino)propanamide); (2S,2'S)-N,N'-[(6,6'-difluoro-1H,1'H-2,2'-biindole-3,3'-diyl)bis{methanediyl[(2R,4S)-4-hydroxypyrrolidine-2,1-diyl][(2S)-1-oxobutane-1,2-diyl]}]bis[2-(methylamino)propanamide] (non-preferred name); GT6" Small molecule "1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1" PKWRMUKBEYJEIX-DXXQBUJASA-N CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC C42H56F2N8O6 CAS 1260251-31-7 . . . . DB11782 . DR6231 Gilteritinib D04KZY D04KZY Approved Acute myeloid leukaemia ICD-11: 2A60 CID: 49803313 Anticancer Treatment "Gilteritinib; 1254053-43-4; ASP2215; ASP-2215; Xospata; UNII-66D92MGC8M; ASP 2215; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 66D92MGC8M; Gilteritinib HCl; 1254053-43-4 (free base); 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-; 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-; 6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide.; 6-ethyl-3-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; Gilteritinib [USAN:INN]; Gilteritinib (ASP2215); gilteritinibum; C6F; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; CHEMBL3301622; CHEBI:145372; BDBM144315; C29H44N8O3; BCP28756; EX-A2775; 3694AH; MFCD28144685; NSC787846; NSC787854; NSC788454; NSC800106; s7754; ZINC113476229; CCG-270016; CS-3885; DB12141; NSC-787846; NSC-787854; NSC-788454; NSC-800106; SB16988; NCGC00481652-01; NCGC00481652-02; AC-29030; AS-35199; HY-12432; QC-11768; DB-108103; A14411; D10709; US8969336, 547; US8969336, 577; Q27077802; 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazine-1-yl)piperidino]anilino]-5-[(tetrahydro-2H-pyran-4-yl)amino]pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide" Small molecule "1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)" GYQYAJJFPNQOOW-UHFFFAOYSA-N CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5 C29H44N8O3 CAS 1254053-43-4 CHEBI:145372 . . . DB12141 . DR1750 MK2206 . . Phase 2 Nasopharyngeal cancer ICD-11: 2B6B CID: 46930998 Anticancer Treatment "1032350-13-2; MK-2206 dihydrochloride; MK-2206 2HCl; MK2206; MK-2206 HCl salt; UNII-Q34I3E28IO; MK 2206; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride; 8-[4-(1-AMINOCYCLOBUTYL)PHENYL]-9-PHENYL-1,2,4-TRIAZOLO[3,4-F][1,6]NAPHTHYRIDIN-3(2H)-ONE DIHYDROCHLORIDE; Q34I3E28IO; C25H21N5O; MK 2206 2HCl; AHU377 calcium salt; PubChem22473; 1032349-77-1; MK 2206 dihydrochloride; C25H21N5O.HCl; cc-295; C25H21N5O.2HCl; SCHEMBL17100521; EX-A259; SYN1162; AOB87741; ABP000407; MFCD14584463; s1078; AKOS015966903; CCG-264809; MK-2206/MK2206; PB19401; 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-, hydrochloride (1:2); 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochl; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride; AC-28437; AK172013; AS-16298; FT-0672430; SW202557-3; X7427; Z1978; W-5580; J-000912; J-519356; Q27286944; (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester; 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt; 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H,3H-[1,2,4]triazolo[3,4-f]1,6-naphthyridin-3-one hydrochloride" Small molecule "1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H" HWUHTJIKQZZBRA-UHFFFAOYSA-N C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl C25H23Cl2N5O CAS 1032350-13-2 . . . . . . DR4035 Exenatide D00YVF D00YVF Approved Type 2 diabetes mellitus ICD-11: 5A11 CID: 45588096 Anticancer Treatment "Exenatide; Exendin-4; 141758-74-9; Exenatide free base; UNII-9P1872D4OL; AC 2993; Exendin 4; Byetta; Bydureon; 9P1872D4OL; 141758-74-9 (free base); Bydureon Pen; ITCA 650; HSDB 7789; Exenatide [USAN:INN:BAN:JAN]; PT302; AC 2993A; DA 3091; Exenatide; Exendin-4; LY 2148568; SCHEMBL14634818; AKOS015994651; HS-2012; Y-100006; Exendin 3 (Heloderma horridum), 2-glycine-3-L-glutamic acid-" Small molecule "1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1" HTQBXNHDCUEHJF-XWLPCZSASA-N CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N C184H282N50O60S CAS 141758-74-9 . . . . DB01276 . DR4313 Ertugliflozin D0Q3VE D0Q3VE Approved Type 2 diabetes mellitus ICD-11: 5A11 CID: 44814423 Anticancer Treatment "Ertugliflozin; 1210344-57-2; PF-04971729; Steglatro; PF04971729; UNII-6C282481IP; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; CHEMBL1770248; 1210344-57-2 (free base); 6C282481IP; (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; PF 04971729; Ertugliflozin [USAN:INN]; (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; MK-8835; Tube108; Ertugliflozin (USAN/INN); PF 04971729-00; PF-04971729-00; cc-212; SCHEMBL181047; GTPL8376; PF-04971729;Ertugliflozin; DTXSID40153120; EX-A407; AMY32613; ABP000359; BDBM50342885; MFCD21609259; s5413; ZINC68197809; AKOS025404928; CCG-269087; CS-0976; DB11827; SB11082; 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; AC-29007; AS-35204; beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-; HY-15461; Y0303; D10313; W-5850; J-504029; PF-04971729/PF04971729/; Q27077223; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,5S)-1-(Hydroxymethyl)-5-[3-(4-ethoxybenzyl)-4-chlorophenyl]-6,8-dioxabicyclo[3.2.1]octane-2beta,3alpha,4beta-triol" Small molecule "1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1" MCIACXAZCBVDEE-CUUWFGFTSA-N CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl C22H25ClO7 CAS 1210344-57-2 . . . . DB11827 . DR8583 Glasdegib D0S5LO D0S5LO Approved Chronic myelomonocytic leukaemia ICD-11: 2A40 CID: 25166913 Anticancer Treatment "Glasdegib; 1095173-27-5; PF-04449913; PF 04449913; Glasdegib (PF-04449913); Daurismo; 1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea; UNII-K673DMO5H9; 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea; K673DMO5H9; CHEMBL2043437; C21H22N6O; PF-913; 1095173-27-5 (free base); PF-4449913; Glasdegib [USAN:INN]; glasdegibum; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; SCHEMBL2068480; Glasdegib(PF-04449913); EX-A858; CHEBI:145428; AMY38164; 2640AH; BDBM50385635; MFCD25976839; NSC775772; ZINC68251434; CCG-268350; DB11978; NSC-775772; SB16679; NCGC00378600-02; BS-14357; HY-16391; QC-11459; S7160; D10636; Z-3230; J-690029; Q27077810; N-[(2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)urea; N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-N'-(4-cyanophenyl)urea; 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea(PF-04449913); 4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)-benzonitrile" Small molecule "1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1" SFNSLLSYNZWZQG-VQIMIIECSA-N CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N C21H22N6O CAS 1095173-27-5 CHEBI:145428 . . . DB11978 . DR9639 Daclatasvir D09SGV D09SGV Approved Hepatitis virus infection ICD-11: 1E51 CID: 25154714 Anticancer Treatment "Daclatasvir; 1009119-64-5; BMS-790052; Daklinza; Daclatasvir (BMS-790052); EBP 883; Daclatasvir dihydrochloride; BMS 790052; 1214735-16-6; CHEBI:82977; BMS790052; UNII-LI2427F9CI; C40H50N8O6; Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dica; 1009119-65-6; LI2427F9CI; Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate; MLS006011140; EBP883; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; GTPL11266; EBP-883; EX-A410; AMY36655; AOB87747; dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate; 3503AH; ABP000738; BDBM50387084; MFCD17129086; s1482; ZINC68204830; ACN-050889; CA10002; CCG-270425; CS-0588; DB09102; SB20303; NCGC00346533-09; AC-28958; AS-75298; BMS 790052; EBP 883; HY-10466; SMR004702917; SW219754-1; X7549; D10065; Q-4025; J-520204; Q5207712; methyl [(2s)-1-{(2s)-2-[4-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1h-imidazol-4-yl}-4-biphenylyl)-1h-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate; methyl [(2S)-1-{(2S)-2-[4-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; methyl N-[(2S)-1-[(2S)-2-[5-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; methyl-N-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl] pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1himidazol-2-yl]pyrrolidin-1-yl]3-methyl-1-oxobutan-2-yl]carbamate" Small molecule "1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1" FKRSSPOQAMALKA-CUPIEXAXSA-N CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC C40H50N8O6 CAS 1009119-64-5 CHEBI:82977 . . . DB09102 . DR8662 PFK15 D0A8AL D0A8AL Investigative Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 25142799 Anticancer Treatment PFK-015; 4382-63-2; PFK15; 1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one; CHEMBL3105836; (E)-1-pyridin-4-yl-3-quinolin-2-ylprop-2-en-1-one; 1-(4-Pyridinyl)-3-(2-quinolinyl)-2-propen-1-one; PFK 15; PFK015; SCHEMBL2702934; SCHEMBL16534534; AOB4632; SYN5216; BCP10875; EX-A4218; 2649AH; BDBM50445946; s7289; AKOS025287166; ZINC103235314; ACN-050165; CCG-267056; NCGC00386328-09; AC-28651; AS-16574; HY-12204; SW219876-1; A14287; (E)-1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one; 2314451-67-5 Small molecule 1S/C17H12N2O/c20-17(14-9-11-18-12-10-14)8-7-15-6-5-13-3-1-2-4-16(13)19-15/h1-12H/b8-7+ UJJUKZPBUMCSJZ-BQYQJAHWSA-N C1=CC=C2C(=C1)C=CC(=N2)C=CC(=O)C3=CC=NC=C3 C17H12N2O . . . . . . . DR5354 Triptorelin D03QRS D03QRS Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 25074470 Anticancer Treatment "TRIPTORELIN; 57773-63-4; Triptoreline; Decapeptyl; (D-Trp6)-GnRH; Triptorelina; Triptorelinum; Trelstar; Triptodur; Diphereline; (6-D-Tryptophan)luteinizing hormone-releasing hormone; CL 118532; CL-118532; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2; AY-25650; Luteinizing hormone-releasing factor (pig), 6-D-tryptophan; CL 118,532; CHEBI:63633; Pamorelin; Trelstar depot; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; Trelstar LA; Arvekap; Diferelin; Luteinizing hormone-releasing factor (swine), 6-D-tryptophan-; UNII-08AN7WA2G0; 08AN7WA2G0; D-Tryptophan-LH-RH; Wy 42462; Triptoreline [INN-French]; Triptorelinum [INN-Latin]; Triptorelina [INN-Spanish]; AY 25650; Salvacyl; Trellasar; Moapar; Triptorelin [USAN:INN:BAN]; Decapeptyl SR; Pamorelin LA; UNII-9081Y98W2V; Triptorelin (swine); BIM 21003; Wy 42422; Wy-42462; D-Trp6-LHRH; Debio-8206; Triptorelin (USAN/INN); (D-Trp6)-LH-RH; GTPL1177; SCHEMBL5079698; CHEMBL1201334; SCHEMBL22289009; HMS2090C17; EX-A3857; BIM-21003; AKOS030213249; 9081Y98W2V; CS-5745; DB06825; NCGC00167301-01; NCGC00167301-02; AK552887; AS-71149; BN-52014; HY-12551; 73T634; D06247; [D-Trp6]-LH-RH, >=97% (HPLC), powder; AB01275488-01; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-GlyNH2; Q1992452; (S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6,15-bis((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide" Small molecule "1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1" VXKHXGOKWPXYNA-PGBVPBMZSA-N CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8 C64H82N18O13 CAS 57773-63-4 CHEBI:63633 . . . DB06825 . DR9224 BI-D1870 D02VBF D02VBF Preclinical Mature B-cell leukaemia ICD-11: 2A82 CID: 25023738 Anticancer Treatment "BI-D1870; 501437-28-1; 2-((3,5-difluoro-4-hydroxyphenyl)amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; 2-(3,5-difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7H-pteridin-6-one; C19H23F2N5O2; 2-((3,5-difluoro-4-hydroxyphenyl)amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one.; 2-(3,5-difluoro-4-hydroxyphenylamino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; 2-[(3,5-DIFLUORO-4-HYDROXYPHENYL)AMINO]-7,8-DIHYDRO-5,7-DIMETHYL-8-(3-METHYLBUTYL)-6(5H)-PTERIDINONE; cc-687; CHEMBL573107; GTPL8038; SCHEMBL13881333; BDBM25017; BID1870; DTXSID40648506; SYN1020; BCPP000343; HMS3244C11; HMS3244C12; HMS3244D11; HMS3651D17; HMS3674C15; BCP01977; EX-A2471; ABP000282; BI-D-1870; MFCD11223662; NSC747342; s2843; AKOS015918879; BCP9000401; CCG-268540; CS-1243; NSC-747342; SB19282; AC-32826; AK-37190; AS-16192; HY-10510; AB0007926; DB-071116; FT-0720677; SW219252-1; X5923; W-5481; 437D281; J-505744; Q27075243; 2-(3,5-Difluoro-4-hydroxy-phenylamino)-5,7-dimethyl-8-(3-methyl-butyl)-7,8-dihydro-5H-pteridin-6-one; 2-(3,5-Difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7,8-dihydropteridin-6(5H)-one; 2-(3,5-difluoro-4-hydroxyphenylamino)-8-isopentyl-5,7-dimethyl-7,8-dihydropyrido[2,3-d]pyrimidin-6(5H)-one; 2-[(3,5-difluoro-4-hydroxyphenyl)amino]-5,7-dimethyl-8-(3-methylbutyl)-5,6,7,8-tetrahydropteridin-6-one; 2-[(3,5-Difluoro-4-hydroxyphenyl)amino]-5,7-dimethyl-8-(3-methylbutyl)-7,8-dihydropteridin-6(5H)-one; 2-[(3,5-difluoro-4-hydroxyphenyl)amino]-7,8-dihydro-5,7-dimethyl-8-(3-methylbutyl)-6(5h)-pteridone" Small molecule "1S/C19H23F2N5O2/c1-10(2)5-6-26-11(3)18(28)25(4)15-9-22-19(24-17(15)26)23-12-7-13(20)16(27)14(21)8-12/h7-11,27H,5-6H2,1-4H3,(H,22,23,24)" DTEKTGDVSARYDS-UHFFFAOYSA-N CC1C(=O)N(C2=CN=C(N=C2N1CCC(C)C)NC3=CC(=C(C(=C3)F)O)F)C C19H23F2N5O2 CAS 501437-28-1 . . . . . . DR5892 GSK2041706 . . Investigative Type 2 diabetes mellitus ICD-11: 5A11 CID: 24964226 Anticancer Treatment "GPR119 agonist; 1037779-47-7; SCHEMBL2370813; ZINC95929383; 5-[4-[(2R)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole" Small molecule "1S/C21H30FN3O4S/c1-14(2)20-23-21(29-24-20)25-10-7-16(8-11-25)15(3)9-12-28-17-5-6-19(18(22)13-17)30(4,26)27/h5-6,13-16H,7-12H2,1-4H3/t15-/m1/s1" AJJISMLYIMQAKP-OAHLLOKOSA-N CC(C)C1=NOC(=N1)N2CCC(CC2)C(C)CCOC3=CC(=C(C=C3)S(=O)(=O)C)F C21H30FN3O4S . . . . . . . DR0459 Albiflorin . . Investigative Chronic obstructive pulmonary disease ICD-11: CA22 CID: 24868421 Anticancer Treatment "Albiflorin; 39011-90-0; Alibiflorin; Q63399047; 7-Oxatricyclo[4.3.0.03,9]nonan-8-one,9-[(benzoyloxy)methyl]-1-(b-D-glucopyranosyloxy)-4-hydroxy-6-methyl-,(1R,3R,4R,6S)-; CHEBI:132793; HY-N0037; MFCD29477681; ZINC38143679; AKOS032948342; CS-3643; NCGC00169374-01; NCGC00169374-02; AS-75074; C17457; BRD-K76724902-001-01-6; [(1R,3R,4R,6S,9S)-1-(beta-D-glucopyranosyloxy)-4-hydroxy-6-methyl-8-oxo-7-oxatricyclo[4.3.0.0(3,9)]nonan-9-yl]methyl benzoate; [(1R,3R,4R,6S,9S)-4-hydroxy-6-methyl-8-oxo-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7-oxatricyclo[4.3.0.03,9]nonan-9-yl]methyl benzoate; [(1R,3R,4R,6S,9S)-4-HYDROXY-6-METHYL-8-OXO-1-{[(2S,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL]OXY}-7-OXATRICYCLO[4.3.0.0(3),?]NONAN-9-YL]METHYL BENZOATE" Small molecule "1S/C23H28O11/c1-21-8-13(25)12-7-23(21,33-19-17(28)16(27)15(26)14(9-24)32-19)22(12,20(30)34-21)10-31-18(29)11-5-3-2-4-6-11/h2-6,12-17,19,24-28H,7-10H2,1H3/t12-,13+,14+,15+,16-,17+,19-,21-,22-,23-/m0/s1" QQUHMASGPODSIW-ICECTASOSA-N CC12CC(C3CC1(C3(C(=O)O2)COC(=O)C4=CC=CC=C4)OC5C(C(C(C(O5)CO)O)O)O)O C23H28O11 CAS 39011-90-0 CHEBI:132793 . . . . . DR6756 Olaparib D0J9HW D0J9HW Approved Ovarian cancer ICD-11: 2C73 CID: 23725625 Anticancer Treatment "Olaparib; 763113-22-0; AZD2281; Lynparza; KU-0059436; AZD 2281; AZD-2281; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; Olaparib (AZD2281, Ku-0059436); 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; UNII-WOH1JD9AR8; KU-59436; AZD2281(olaparib); MFCD13185161; WOH1JD9AR8; Olaparib (AZD-2281); 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one; C24H23FN4O3; CHEBI:83766; AZ2281; 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; 937799-91-2; KU59436; 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one; 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one; OLAPARIB cpd; Olaparib [USAN:INN]; Acylpiperazine analogue, 47; Olaparibum; AZD221; Lynparza (TN); 09L; 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one; PubChem19148; KU 59436; Olaparib (AZD2281); Olaparib - AZD2281; cc-16; AZD-2281 (Olaparib); Olaparib (JAN/USAN/INN); MLS006010185; SCHEMBL426568; CHEMBL521686; GTPL7519; BDBM27566; AOB1085; DTXSID60917988; EX-A002; BCPP000360; HMS3295I09; HMS3426C03; HMS3654G13; HMS3746K07; HMS3870H03; AMY10295; BCP01872; ABP000423; ANW-43329; NSC747856; NSC753686; s1060; ZINC40430143; AKOS005145764; AC-7939; ACN-032229; AZ-2281; BCP9000363; CCG-264799; CS-0075; DB09074; EX-7210; KEYLYNK-010 COMPONENT OLAPARIB; NSC 747856; NSC-747856; NSC-753686; QC-2660; SB14617; SS-4573; AZD2281,Olaparib, KU-0059436; NCGC00238451-01; NCGC00238451-02; NCGC00238451-09; NCGC00238451-11; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; AK-40514; HY-10162; Olaparib (AZD2281, KU0059436); SMR004701291; SY040527; OLAPARIB COMPONENT OF KEYLYNK-010; AB0009952; Olaparib(AZD2281,KuDOSKU-0059436); A9666; BB 0260909; FT-0651458; KU 0059436; SW218142-2; EC-000.2324; D09730; S-3781; S-7836; Z-3275; AZD2281(olaparib)/AZD-2281/KU0059436; J-503540; Q7083106; BRD-K02113016-001-08-9; BRD-K02113016-001-09-7; AZD 2281; ; ; KU 0059436; ; ; KU 59436; 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine; 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-; [4-(Cyclopropanecarbonyl)piperazin-1-yl]{2-fluoro-5-[(4-hydroxyphthalazin-1-yl)methyl]phenyl}methanone; 1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-; 1021843-02-6; 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one; 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one" Small molecule "1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)" FDLYAMZZIXQODN-UHFFFAOYSA-N C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F C24H23FN4O3 CAS 763113-22-0 CHEBI:83766 . . . DB09074 . DR7648 Sodium ferulate . . Investigative Influenza ICD-11: 1E30 CID: 23669636 Anticancer Treatment "Sodium ferulate; 24276-84-4; Sodium ferulic; Sodium 3-(4-hydroxy-3-methoxyphenyl)acrylate; Ferulic acid (sodium); ferulic acid sodium salt; UNII-OIS7F1IRQK; OIS7F1IRQK; Sodium 3-methoxy-4-hydroxycinnamate; Monosodium 4-hydroxy-3-methoxycinnamate; Monosodium 3-(4-hydroxy-3-methoxyphenyl)-2-propenoate; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid monosodium salt; sodium (E)-3-(4-hydroxy-3-methoxyphenyl)acrylate; sodium;(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate; ferulic acid sodium; MFCD00075727; Ferulicacidsodiumsalt; C10H9O4.Na; Cinnamic acid, 4-hydroxy-3-methoxy-, monosodium salt; CHEMBL4594451; FEMA NO. 3812; HY-N0060A; DTXSID80894080; CHEBI:114954; BCP05695; s4740; AKOS015890674; AC-7966; ACN-035276; CCG-266691; CS-5275; AS-12205; K-6527; Q3092716; W-200547; sodium (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate; sodium (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate; 151109-65-8" Small molecule "1S/C10H10O4.Na/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13;/h2-6,11H,1H3,(H,12,13);/q;+1/p-1/b5-3+;" NCTHNHPAQAVBEB-WGCWOXMQSA-M COC1=C(C=CC(=C1)C=CC(=O)[O-])O.[Na+] C10H9NaO4 CAS 24276-84-4 CHEBI:114954 . . . . . DR8812 Lcotinib . . Investigative Pulmonary hypertension ICD-11: BB01 CID: 22024915 Anticancer Treatment "Icotinib; 610798-31-7; Conmana; BPI-2009; N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine; UNII-9G6U5L461Q; CHEMBL2087361; 9G6U5L461Q; N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine; Lcotinib; BPI2009; Icotinib(Lcotinib); icotinib,BPI-2009H; GTPL7641; SCHEMBL5843603; DTXSID20209952; EX-A306; HMS3651F12; 4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline; BCP21716; 2468AH; BDBM50391089; HY-15164A; MFCD22124501; NSC800770; s2922; ZINC43207566; AKOS030231301; CCG-264757; DB11737; NSC-800770; SB16602; NCGC00386224-06; AC-32044; AK547890; AS-55948; DA-33567; N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine; FT-0701617; SW219698-1; D11251; Z-3130; Q16868421; (1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-; (3-Ethynyl-phenyl)(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diazacyclododeca[b]naphthalen-4-yl)-amine; N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.0^{14,19]icosa-1(12),13,15,17,19-pentaen-18-amine" Small molecule "1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)" QQLKULDARVNMAL-UHFFFAOYSA-N C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4 C22H21N3O4 CAS 610798-31-7 . . . . . . DR5502 BIIB021 D05HWN D05HWN Phase 2 Breast cancer ICD-11: 2C60-2C65 CID: 16736529 Anticancer Treatment "BIIB021; 848695-25-0; 6-chloro-9-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-9H-purin-2-amine; BIIB-021; CNF2024; BIIB 021; UNII-851B9FQ7Q0; CNF-2024; 6-Chloro-9-[(4-Methoxy-3,5-Dimethylpyridin-2-Yl)methyl]-9h-Purin-2-Amine; CHEMBL467399; CHEBI:90687; 851B9FQ7Q0; 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine; CNF 2024; 848695-25-0 (free base); (6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9h-purin-2-yl)amine; [6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-yl]amine; 6-chloro-9-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)-9h-purin-2-amine; 6-chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine; 6-Chloro-9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-9h-purin-2-amine; 94M; 3qdd; BIIB021, Free Base; cc-544; MLS006011080; GTPL9258; SCHEMBL1791028; BIIB021,CNF2024; BIIB021/CNF2024; BDBM20800; AOB4502; EX-A681; QCR-185; BIIB021(CNF2024); BIIB021; CNF2024; BCPP000335; HMS3654G16; BCP02111; 2-amino-6-halopurine analogue, 20; ABP000837; ANW-70835; MFCD15528939; NSC773265; s1175; ZINC14974583; 9H-purin-2-amine, 6-chloro-9-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)-; AKOS015969048; BCP9000411; CCG-264848; CS-0168; DB12359; NSC-773265; SB16641; NCGC00247877-01; AC-32860; AK104952; AS-55914; HY-10212; SMR004702868; AB0008087; FT-0696777; SW220186-1; X7555; W-5597; J-518605; BRD-K51967704-001-01-0; Q27075249" Small molecule "1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)" QULDDKSCVCJTPV-UHFFFAOYSA-N CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N C14H15ClN6O CAS 848695-25-0 CHEBI:90687 . . . DB12359 . DR1806 Ivacaftor D0W7WC D0W7WC Approved Cystic fibrosis ICD-11: CA25 CID: 16220172 Anticancer Treatment "Ivacaftor; 873054-44-5; VX-770; Kalydeco; Ivacaftor (VX-770); N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; VX 770; VX770; UNII-1Y740ILL1Z; N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; CHEBI:66901; 1Y740ILL1Z; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide; 3-Quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-; 3-Quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-; Kalydeco (TN); Ivacaftor [USAN:INN]; ivacaftorum; Ivacaftor D18; Tube715; Ivacaftor (USAN/INN); VX-770 - Ivacaftor; cc-231; MLS006011119; SCHEMBL351373; GTPL4342; QUI135; VX-770, Ivacaftor, Kalydeco; CHEMBL2010601; DTXSID00236281; EX-A441; QCR-155; BCPP000199; HMS3654E10; HMS3744K05; AOB31714; BCP19794; ABP000259; BDBM50032693; MFCD17171361; s1144; VX-770/VX770; ZINC52509463; AKOS015994762; AKOS032950001; BCP9000799; CCG-268562; CS-0497; DB08820; EX-7211; LE-0002; SB16815; N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; NCGC00242480-01; NCGC00242480-03; 1413431-05-6; AC-28324; AK170457; HY-13017; SMR004702900; AB0008116; FT-0696681; SW219620-1; X7565; EC-000.2478; A25626; D09916; W-5681; AB01565806_02; Q6095693; CTP-656; CTP-656; CTP-656; d9-ivacaftor;VX-561; Cystic Fibrosis Transmembrane Conductance Regulator Potentiator; N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; N-(5-Hydroxy-2,4-bis(2-methyl-2-propanyl)phenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide; 1134822-00-6; Kalydeco; ; ; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; VX7" Small molecule "1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)" PURKAOJPTOLRMP-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C C24H28N2O3 CAS 873054-44-5 CHEBI:66901 . . . DB08820 . DR8071 Liraglutide D03GOI D03GOI Approved Type 2 diabetes mellitus ICD-11: 5A11 CID: 16134956 Anticancer Treatment Liraglutide; victoza; Liraglutidum; Liraglutida; NN2211; 204656-20-2; NN-2211; NN 2211; CHEMBL4084119; Saxenda; Liraglutidum [INN-Latin]; Liraglutida [INN-Spanish]; HSDB 8205; Liraglutide [USAN:INN:BAN:JAN]; GTPL1133; CHEBI:71193; EX-A2418; BDBM50240819; AKOS037435224; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide; AS-56276; A16115; Arg34Lys26-(N-epsilon-(gamma-Glu(N-alpha-hexadecanoyl)))-GLP-1(7-37); N(sup 26)-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide Small molecule "1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1" YSDQQAXHVYUZIW-QCIJIYAXSA-N CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O C172H265N43O51 CAS 204656-20-2 CHEBI:71193 . . . DB06655 . DR7735 Insulin D05ELO D05ELO Approved Acute diabete complication ICD-11: 5A2Y CID: 16131098 Anticancer Treatment 12584-58-6; DTXSID60154957; 8A-L-threonine-10A-L-isoleucine-Insulin Small molecule "1S/C256H381N65O76S6/c1-29-131(23)205(313-193(337)104-258)251(391)317-204(130(21)22)247(387)288-159(75-82-200(347)348)217(357)282-156(71-78-189(262)333)221(361)308-183-116-401-402-117-184-242(382)305-178(111-323)239(379)294-162(88-123(7)8)224(364)295-168(95-140-53-61-146(327)62-54-140)227(367)283-154(69-76-187(260)331)218(358)290-161(87-122(5)6)222(362)285-158(74-81-199(345)346)220(360)302-174(101-190(263)334)234(374)298-170(97-142-57-65-148(329)66-58-142)230(370)309-182(241(381)304-176(255(396)397)103-192(265)336)115-400-399-114-181(213(353)272-107-194(338)278-153(72-79-197(341)342)216(356)281-151(51-42-84-270-256(266)267)211(351)271-108-195(339)279-166(93-138-46-36-32-37-47-138)226(366)297-167(94-139-48-38-33-39-49-139)229(369)299-171(98-143-59-67-149(330)68-60-143)237(377)320-208(136(28)326)253(393)321-85-43-52-186(321)245(385)286-152(50-40-41-83-257)214(354)277-134(26)254(394)395)311-249(389)203(129(19)20)316-235(375)164(90-125(11)12)292-228(368)169(96-141-55-63-147(328)64-56-141)296-223(363)160(86-121(3)4)289-209(349)133(25)276-215(355)157(73-80-198(343)344)287-246(386)202(128(17)18)315-236(376)165(91-126(13)14)293-232(372)173(100-145-106-269-120-275-145)301-238(378)177(110-322)280-196(340)109-273-212(352)180(113-398-403-118-185(310-243(183)383)244(384)319-207(135(27)325)252(392)306-179(112-324)240(380)318-206(132(24)30-2)250(390)312-184)307-225(365)163(89-124(9)10)291-231(371)172(99-144-105-268-119-274-144)300-219(359)155(70-77-188(261)332)284-233(373)175(102-191(264)335)303-248(388)201(127(15)16)314-210(350)150(259)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-208,322-330H,29-30,40-43,50-52,69-104,107-118,257-259H2,1-28H3,(H2,260,331)(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H,268,274)(H,269,275)(H,271,351)(H,272,353)(H,273,352)(H,276,355)(H,277,354)(H,278,338)(H,279,339)(H,280,340)(H,281,356)(H,282,357)(H,283,367)(H,284,373)(H,285,362)(H,286,385)(H,287,386)(H,288,387)(H,289,349)(H,290,358)(H,291,371)(H,292,368)(H,293,372)(H,294,379)(H,295,364)(H,296,363)(H,297,366)(H,298,374)(H,299,369)(H,300,359)(H,301,378)(H,302,360)(H,303,388)(H,304,381)(H,305,382)(H,306,392)(H,307,365)(H,308,361)(H,309,370)(H,310,383)(H,311,389)(H,312,390)(H,313,337)(H,314,350)(H,315,376)(H,316,375)(H,317,391)(H,318,380)(H,319,384)(H,320,377)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,394,395)(H,396,397)(H4,266,267,270)/t131-,132-,133-,134-,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1" NOESYZHRGYRDHS-ZYCCASTOSA-N CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN=CN2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN C256H381N65O76S6 CAS 12584-58-6 . . . . DB00030 . DR9857 Bivalirudin D09HVL D09HVL Approved Thrombocytopenia ICD-11: 3B64 CID: 16129704 Anticancer Treatment "Bivalirudin; 128270-60-0; Angiomax; BG-8967; Bivalirudin Trifluoroacetate; BG8967; Hirulog; UNII-TN9BEX005G; CHEBI:59173; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-; Angiox; bivalirudina; bivalirudine; bivalirudinum; BG 8967; Bivalirudin [USAN:INN:BAN]; C98H138N24O33; HS-2004; SCHEMBL25739; GTPL6470; Bivalirudin trifluoroacetate salt; CHEMBL2103749; DTXSID00155847; Bivalirudin;0.9% Sodium Chloride; 1191386-55-6; EBD32115; BDBM50248103; MFCD08692016; AKOS015994644; DB00006; 70B600; 270B600; J-005587; Q4919218; (R,R)-2,6-Bis(4,5-dihydro-4-phenyl-2-oxazolyl)pyridine; (R,R)-2,6-Bis(4-phenyl-2-oxazolinyl)pyridine; (+)-2,6-Bis[(4R)-4-phenyl-2-oxazolin-2-yl]pyridine" Small molecule "1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1" OIRCOABEOLEUMC-GEJPAHFPSA-N CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C5CCCN5C(=O)C(CC6=CC=CC=C6)N C98H138N24O33 CAS 128270-60-0 CHEBI:59173 . . . DB00006 . DR3065 Macitentan D0S7JH D0S7JH Approved Cardiovascular disease ICD-11: BA00-BE2Z CID: 16004692 Anticancer Treatment "Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; UNII-Z9K9Y9WMVL; ACT064992; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; Z9K9Y9WMVL; CHEBI:76607; Actelion-1; 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'- propylsulfamide; Macitentan [USAN:INN]; macitentanum; zlchem 5; Opsumit (TN); Macitentan (JAN/USAN); (non-labelled)Macitentan-d7; MLS006011174; C19H20Br2N6O4S; GTPL7352; SCHEMBL1445625; CHEMBL2103873; DTXSID50196063; EX-A544; ZLA0005; HMS3653N06; HMS3747E09; cas:441798-33-0;Macitentan; AOB87765; BCP05309; ABP001066; BDBM50395626; MFCD17167076; s8051; ZINC43202140; AKOS024463406; ACN-034475; AM81244; CCG-270155; CS-0686; DB08932; SB14841; Macitentan (Actelion-1,ACT-064992); NCGC00346456-01; NCGC00346456-05; AC-30102; AK162704; AS-74590; HY-14184; n-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-n'-propylaminosulfonamide; QC-10426; SMR004702943; AB0007893; DB-070519; FT-0696675; SW219473-1; X6162; A11492; ACT 064992; ACT-064992; D10135; S-7749; Q6724151; {[5-(4-BROMOPHENYL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]SULFAMOYL}(PROPYL)AMINE; N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-N'-propylsulfamide; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; n-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-n'-propyl-sulfamide; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'-propylsulfuric diamide; Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl-" Small molecule "1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)" JGCMEBMXRHSZKX-UHFFFAOYSA-N CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br C19H20Br2N6O4S CAS 441798-33-0 CHEBI:76607 . . . DB08932 . DR3103 Gemigliptin D0ZD3C D0ZD3C Phase 3 Acute diabete complication ICD-11: 5A2Y CID: 11953153 Anticancer Treatment "Gemigliptin; 911637-19-9; UNII-5DHU18M5D6; LC15-0444; 5DHU18M5D6; 911637-19-9 (free base); (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; LC-15-0444; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; DB12412; PB11419; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4-bis(trifluoromethyl)pyrido(3,4-d)pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoro-; HY-14892; Pyrido(3,4-d)pyrimidine, 7-((3S)-3-amino-4-(5,5-difluoro-2-oxo-1-piperidinyl)-1-oxobutyl)-5,6,7,8-tetrahydro-2,4-bis(trifluoromethyl)-; LC-150444; CS-0003618; D10502; Q5530612; 1-((2S)-2-Amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6H)-yl)-4-oxobutyl-5,5-difluoropiperidin-2-one; 1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one" Small molecule "1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1" ZWPRRQZNBDYKLH-VIFPVBQESA-N C1CC(CN(C1=O)CC(CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F C18H19F8N5O2 CAS 911637-19-9 CHEBI:134731 . . . DB12412 . DR0234 Empagliflozin D06ALD D06ALD Approved Diabetes mellitus ICD-11: 5A10 CID: 11949646 Anticancer Treatment "Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; Empagliflozin (BI 10773); BI-10773; BI10773; UNII-HDC1R2M35U; HDC1R2M35U; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; CHEBI:82720; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol; Empagliflozin [USAN:INN]; MFCD22566222; Jardiance (TN); (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; Tube106; (S)-Empagliflozin D4; BI-10773;Empagliflozin; Empagliflozin (BI10773); C23H27ClO7; SCHEMBL899986; GTPL4754; CHEMBL2107830; Empagliflozin (JAN/USAN/INN); AMY1858; EX-A414; BDBM150162; BBL104150; CE0108; s8022; STL557964; US8980829, EMPAGLIFLOZIN; ZINC36520252; AKOS024464680; CCG-269242; CS-0940; DB09038; DS-9824; PB23119; VA10802; AC-27643; HY-15409; SW219120-1; X5927; C22194; D10459; Q-4526; Q5373824; Empagliflozin (BI-10773;BI 10773;BI10773); (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-" Small molecule "1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1" OBWASQILIWPZMG-QZMOQZSNSA-N C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl C23H27ClO7 CAS 864070-44-0 CHEBI:82720 . . . DB09038 . DR8750 Trametinib D04XVN D04XVN Approved Melanoma ICD-11: 2C30 CID: 11707110 Anticancer Treatment "Trametinib; 871700-17-3; GSK1120212; Mekinist; GSK-1120212; JTP 74057; JTP-74057; GSK 1120212; Trametinib (GSK1120212); N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide; GSK212; UNII-33E86K87QN; TMT212; CHEBI:75998; TMT-212; 33E86K87QN; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; Trametinib [USAN:INN]; trametinibum; JTP74057; N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)acetamide; N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl}phenyl)acetamide; QOM; Trametinib (USAN); Trametinib (GSK1120212JTP 74057); cc-37; SCHEMBL170938; C26H23FIN5O4; GTPL6495; QCR-39; GSK1120212 (Trametinib); CHEMBL2103875; EX-A022; BCPP000218; DTXSID901007381; HMS3295I05; HMS3656J11; AOB87707; BCP02307; ABP000312; BDBM50531540; MFCD17215075; NSC758246; NSC800956; RW4149; s2673; ZINC43100709; AKOS015850628; AM90271; CCG-264976; CS-0060; DB08911; EX-5957; NSC-758246; NSC-800956; SB16553; NCGC00263180-01; NCGC00263180-07; NCGC00263180-14; AC-25891; AK174783; AS-19382; HY-10999; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; AB0008115; FT-0688438; SW218089-2; X7454; A11029; A25168; D10175; GSK1120212 - JTP-74057; S-7800; GSK-1120212/GSK1120212/; GSK1120212,JTP-74057, GSK212; SR-01000941589; A1-01871; J-523325; Q7833138; SR-01000941589-1; BRD-K12343256-001-01-4; Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)-; Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-; N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; N-[3-[3-Cyclopropyl-5-[(2-Fluoro-4-Iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe nyl]acetamide; N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide; N-{3-[3-Cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}ethanimidic acid; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide" Small molecule "1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)" LIRYPHYGHXZJBZ-UHFFFAOYSA-N CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 C26H23FIN5O4 CAS 871700-17-3 CHEBI:75998 . . . DB08911 . DR2875 Hydrocinchonine . . Investigative Uterine Sarcoma ICD-11: 2B5F CID: 11630759 Anticancer Treatment "Hydrocinchonine; 485-65-4; Dihydrocinchonine; (1S)-((2R,4S,5R)-5-Ethylquinuclidin-2-yl)(quinolin-4-yl)methanol; UNII-ZPF9J31NM8; (+)-hydrocinchonine; TCMDC-125880; ZPF9J31NM8; (9S)-10,11-Dihydrocinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol; EINECS 207-621-8; (+)-Dihydrocinchonine; SCHEMBL192607; CHEMBL548921; DTXSID30878431; CHEBI:174145; 6625AB; ZINC13826669; AC-30195; (+)-Dihydrocinchonine, analytical standard; Q27295839; Hydrocinchonine, >=95.0% (sum of enantiomers, HPLC); (S)-((2R,4S,5R)-5-ethylquinuclidin-2-yl)(quinolin-4-yl)methanol" Small molecule "1S/C19H24N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h3-7,9,13-14,18-19,22H,2,8,10-12H2,1H3/t13-,14-,18+,19-/m0/s1" WFJNHVWTKZUUTR-QAMTZSDWSA-N CCC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O C19H24N2O CAS 485-65-4 CHEBI:174145 . . . . . DR2569 Crizotinib D03ZBT D03ZBT Approved Lung cancer ICD-11: 2C25 CID: 11626560 Anticancer Treatment "Crizotinib; 877399-52-5; Xalkori; PF-02341066; (R)-crizotinib; PF-2341066; PF 2341066; Crizotinib (PF-02341066); 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine; PF 02341066; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; UNII-53AH36668S; PF2341066; CHEMBL601719; Crizotinib (PF-2341066); CHEBI:64310; 877399-52-5 (free base); 53AH36668S; 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine; 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine; (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; Xalkori (TN); C21H22Cl2FN5O; Crizotinib [USAN:INN]; crizotinibum; VGH; PubChem19322; PF02341066; SCHEMBL93829; PF-2341066,Crizotinib; cc-190; Crizotinib (JAN/USAN/INN); PF-2341066(Crizotinib); GTPL4903; QCR-32; Crizotinib, >=98% (HPLC); PF-2341066 (Crizotinib); PF-2341066 - Crizotinib; AOB2688; EX-A096; SYN1139; PF-02341066 (Crizotinib); BCPP000116; DTXSID701009329; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; AMY10313; ABP000131; ANW-47749; BDBM50306682; MFCD12407409; NSC749005; NSC749769; NSC800080; ZINC35902489; AKOS015901233; AKOS015995207; CCG-264803; DB08865; GS-6178; NSC 756645; NSC-749005; NSC-749769; NSC-800080; PB11015; NCGC00250400-01; NCGC00250400-02; NCGC00250400-09; NCGC00250400-12; 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-; HY-50878; AB0027203; BB 0261738; SW202555-3; W9013; D09731; Q-3209; 399P525; J-510370; Q5186964; BRD-K78431006-001-01-1; BRD-K78431006-001-03-7; 877399-52-5, 877399-53-6 (acetate); 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine; 3-(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy-5-1-(4-piperidinyl)-1H-pyrazol-4-yl-2-Pyridinamine; 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine" Small molecule "1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1" KTEIFNKAUNYNJU-GFCCVEGCSA-N CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N C21H22Cl2FN5O CAS 877399-52-5 CHEBI:64310 . . . DB08865 . DR0019 Pemafibrate D04QIE D04QIE Approved Hyperlipidemia ICD-11: 5C80 CID: 11526038 Anticancer Treatment "Pemafibrate; 848259-27-8; UNII-17VGG92R23; (R)-2-(3-((benzo[d]oxazol-2-yl(3-(4-methoxyphenoxy)propyl)amino)methyl)phenoxy)butanoic acid; CHEMBL247951; (R)-K-13675; 17VGG92R23; K-13675, (R)-; 848259-27-8 (free acid); CAS#848259-27-8; (2~{R})-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid; (2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid; Pemafibrate [INN]; Parmodia (TN); P7F; Pemafibrate (JAN); (R)-K 13675; SCHEMBL2766188; DTXSID00233891; BCP20864; EX-A1919; BDBM50214899; CS-6084; DB15212; SB19229; HY-17618; D10711; Q27251943; K-877; (R)-K 13675; CS-2768; K-877; K877; K 877; (R)-K 13675; (R)-K13675; (R)K-13675; (R)-2-[3-[N-(benzoxazol-2-yl)-N-(3-(4-methoxyphenoxy)propyl)aminomethyl]phenoxy]butyric acid" Small molecule "1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1" ZHKNLJLMDFQVHJ-RUZDIDTESA-N CCC(C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3 C28H30N2O6 CAS 848259-27-8 . . . . DB15212 . DR5364 Alogliptin D0NJ5H D0NJ5H Approved Type 2 diabetes mellitus ICD-11: 5A11 CID: 11450633 Anticancer Treatment "Alogliptin; 850649-61-5; UNII-JHC049LO86; Alogliptin (SYR-322); (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; JHC049LO86; CHEBI:72323; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; alogliptina; vipidia; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile; Alogliptin [INN]; alogliptine; alogliptinum; SYR322; HSDB 8203; SCHEMBL121028; CHEMBL376359; GTPL6319; BDBM16285; HY-A0023A; DTXSID90234130; AMY22119; Alogliptin pound SYR-322 pound(c); MFCD09833196; s2868; s5365; ZINC14961096; AKOS025149226; CCG-267914; CCG-267915; CS-1617; DB06203; SB20301; 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile; AC-26300; AS-19582; SW219186-1; Y1123; Q-4517; Q4734170; BRD-K83003151-057-02-4; 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile" Small molecule "1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1" ZSBOMTDTBDDKMP-OAHLLOKOSA-N CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N C18H21N5O2 CAS 850649-61-5 CHEBI:72323 . . . DB06203 . DR4815 PX-478 D06ZVO D06ZVO Phase 1 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 11234794 Anticancer Treatment "PX-478; 685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; PX-478 HCl; CHEMBL4061538; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide dihydrochloride; T23U22X160; L-Phenylalanine, 4-[bis(2-chloroethyl)oxidoaMino]-, (Hydrochloride) (1; 685898-44-6 (HCl); PX-478 dihydrochloride; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; Melphalan N-Oxide Impurity HCl; C13H18Cl2N2O3.2ClH; SCHEMBL18548830; DTXSID00218688; 4-[(2S)-2-amino-2-carboxyethyl]-N,N-bis(2-chloroethyl)benzeneamine oxide;dihydrochloride; EX-A4655; 2675AH; BDBM50231387; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; CCG-268582; CS-5164; DB06082; HY-10231; A14319; Z-3209; Q27289565; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride" Small molecule "1S/C13H18Cl2N2O3.2ClH/c14-5-7-17(20,8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19;;/h1-4,12H,5-9,16H2,(H,18,19);2*1H/t12-;;/m0../s1" GIGCDIVNDFQKRA-LTCKWSDVSA-N C1=CC(=CC=C1CC(C(=O)O)N)[N+](CCCl)(CCCl)[O-].Cl.Cl C13H20Cl4N2O3 CAS 685898-44-6 . . . . DB06082 . DR3220 Volasertib D00BYM D00BYM Phase 3 Acute myeloid leukaemia ICD-11: 2A60 CID: 10461508 Anticancer Treatment "Volasertib; 755038-65-4; BI 6727; Volasertib (BI 6727); BI6727 (Volasertib); BI-6727; UNII-6EM57086EA; BI6727; 6EM57086EA; N-((1s,4S)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide; N-(Trans-4-(4-(cyclopropylMethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-Methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)aMino)-3-MethoxybenzaMide; N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI 6727 (Volasertib); BI6727 (Volasertib)/; cc-629; MLS006011195; SCHEMBL738946; GTPL7947; SCHEMBL2169101; SCHEMBL9888052; CHEMBL1233528; CHEMBL4284151; SCHEMBL21916558; BCPP000341; C34H50N8O3; AOB87138; BCP02405; EX-A1364; ABP000330; BDBM50402023; MFCD20926414; NSC757149; NSC800965; s2235; ZINC39716290; AKOS030257530; ZINC100071772; ZINC248087828; BCP9000403; CCG-264952; CS-0274; DB12062; NSC-757149; NSC-800965; PB19742; NCGC00263087-01; NCGC00263087-02; NCGC00263087-03; NCGC00263087-12; NCGC00263087-15; NCGC00485964-01; AC-32844; AS-16996; HY-12137; SMR004702964; SW218140-2; X7437; D10182; Q-4502; SR-03000003275; Q7939986; SR-03000003275-1; Benzamide, N-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-; N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide; n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide; n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide" Small molecule "1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1" SXNJFOWDRLKDSF-XKHVUIRMSA-N CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C C34H50N8O3 CAS 755038-65-4 . . . . DB12062 . DR7260 VE-465 . . Investigative Hepatocellular carcinoma ICD-11: 2C12 CID: 10343860 Anticancer Treatment CHEMBL484609; VE-465; 639089-73-9; N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-propanamide; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide; SCHEMBL1080455; SCHEMBL12430853; BDBM50277639; 135408-EP2292614A1; N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)propionamide; N-{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulfanyl]-phenyl}-propionamide Small molecule "1S/C22H28N8OS/c1-4-21(31)23-16-5-7-17(8-6-16)32-22-25-18(24-19-13-15(2)27-28-19)14-20(26-22)30-11-9-29(3)10-12-30/h5-8,13-14H,4,9-12H2,1-3H3,(H,23,31)(H2,24,25,26,27,28)" LCQYMDMUCJFFKN-UHFFFAOYSA-N CCC(=O)NC1=CC=C(C=C1)SC2=NC(=CC(=N2)N3CCN(CC3)C)NC4=NNC(=C4)C C22H28N8OS . . . . . . . DR2477 Napabucasin D01IGZ D01IGZ Phase 3 Pancreatic cancer ICD-11: 2C10 CID: 10331844 Anticancer Treatment "Napabucasin; 83280-65-3; BBI608; 2-acetylnaphtho[2,3-b]furan-4,9-dione; 2-Acetylfuro-1,4-naphthoquinone; BBI-608; 2-acetylbenzo[f][1]benzofuran-4,9-dione; UNII-Z1HHM49K7O; BBI 608; 2-Acetylfuranonaphthoquinone; Z1HHM49K7O; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; Napabucasin [USAN:INN]; FNQ; Napabucasin; BBI608; Napabucasin (BBI608); CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; GTPL11358; AMY27812; BCP07628; EX-A1314; BDBM50366597; MFCD28155270; NSC788900; s7977; ZINC13306865; AKOS027470201; ACN-053294; CCG-266871; CS-1747; DB12155; NSC-788900; AC-32935; AK547981; AS-60519; HY-13919; 2-Acetyl-naphtho[2,3-b]furan-4,9-dione; A13474; D10717; Q27294876" Small molecule "1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3" DPHUWDIXHNQOSY-UHFFFAOYSA-N CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O C14H8O4 CAS 83280-65-3 . . . . DB12155 . DR2172 Afatinib D05UFG D05UFG Approved Lung cancer ICD-11: 2C25 CID: 10184653 Anticancer Treatment "Afatinib; 439081-18-2; 850140-72-6; BIBW2992; Tovok; Tomtovok; BIBW 2992; BIBW-2992; Afatinib (BIBW2992); (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; Afatinib free base; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide; UNII-41UD74L59M; C24H25ClFN5O3; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; CHEMBL1173655; CHEBI:61390; 41UD74L59M; 850140-72-6 (free base); S1011; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide.; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; Afatinib [USAN:INN]; afatinibum; MFCD12407405; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl)-amide; (E)-4-Dimethylamino-but-2-enoic acid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl]-amide; 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-; Afatinib, Free Base; BIBW2992,Afatinib; PubChem22403; Afatinib (USAN/INN); BIBW2992 - Afatinib; Tovok; ; ; BIBW 2992; (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide; cc-109; MLS006010000; GTPL5667; CHEBI:94698; DTXSID20893451; EX-A065; QCR-169; BCPP000338; AOB87785; BCP01779; ZINC3976838; BIBW2992/Tovok,BIBW-2992; 3123AC; ABP000859; BDBM50322823; NSC750691; NSC799327; Afatinib(cis-trans isomerismtautomers); AKOS015850681; AKOS015904219; AKOS025149636; BCP9000407; CCG-264776; DB08916; EX-8656; NSC-750691; NSC-799327; PB28439; NCGC00185000-01; (2e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-2-butenamide; AC-26079; AC-27018; AM808098; DS-14172; SMR004701084; AB0033685; SW219248-1; X7366; A15572; D09724; Q-3651; AB01565886_02; 081B182; SR-01000941576; J-500781; J-502300; Q4688818; SR-01000941576-1; BRD-K66175015-001-01-7; (2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-[[(3S)-oxolane-3-yl]oxy]quinazoline-6-yl]-4-(dimethylamino)-2-buteneamide; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6yl)-amide; (R,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3''S'')-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide" Small molecule "1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1" ULXXDDBFHOBEHA-CWDCEQMOSA-N CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4 C24H25ClFN5O3 CAS 850140-72-6 CHEBI:61390 . . . DB08916 . DR6609 Selumetinib D0T5DP D0T5DP Phase 3 Melanoma ICD-11: 2C30 CID: 10127622 Anticancer Treatment "Selumetinib; 606143-52-6; AZD6244; AZD 6244; ARRY-142886; 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE; AZD-6244; Selumetinib (AZD6244); ARRY 142886; AZD6244 (Selumetinib); ARRY-886; UNII-6UH91I579U; 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benzo[d]iMidazole-6-carboxaMide; CHEMBL1614701; CHEBI:90227; 6UH91I579U; NCGC00189073-01; NCGC00189073-02; C17H15BrClFN4O3; DSSTox_CID_28870; DSSTox_RID_83139; DSSTox_GSID_48944; 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; AZD 6244;5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; CAS-606143-52-6; ARRY142886; AZD6244(Selumetinib); Selumetinib [USAN:INN]; selumetinibum; Koselugo; 1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 3EW; PubChem21092; AZD 6244 Selumetinib; Selumetinib (USAN/INN); AZD-6244(Selumetinib); AZD6244 - Selumetinib; AZD 6244 (Selumetinib); SCHEMBL155456; GTPL5665; QCR-91; Selumetinib, ARRY-142886; DTXSID3048944; EX-A020; SYN1016; BCPP000367; CC-49; HMS3244G03; HMS3244G04; HMS3244H03; HMS3265K01; HMS3265K02; HMS3265L01; HMS3265L02; HMS3654O03; NSC 741O78; AOB87732; BCP01739; Tox21_113362; ABP000918; ANW-45526; BDBM50355497; MFCD11977472; NSC741078; NSC800882; s1008; ZINC31773258; ARRY142886/AZD6244; AKOS015904255; Tox21_113362_1; ACN-031539; BCP9000354; CCG-264774; CS-0059; DB11689; EX-8621; NSC-741078; NSC-800882; SB14707; NCGC00189073-07; AC-25059; AK-40782; AM808016; AZD6244,Selumetinib, ARRY-142886; BC004624; HY-50706; AZD6244 (Selumetinib,ARRY-142886); AB0007973; FT-0674552; SW202561-3; X2640; D09666; S-7764; 143A526; Q-101405; Q7448840; BRD-K57080016-001-01-9; 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy -ethoxy)-amide; 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxyethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-N-(2-hydroxyethoxy)-3,7-dimethyl-3H-benzo[d]imidazole-5-carboxamide; 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide" Small molecule "1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)" CYOHGALHFOKKQC-UHFFFAOYSA-N CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO C17H15BrClFN4O3 CAS 606143-52-6 CHEBI:90227 . . . DB11689 . DR8004 Sorbitan trioleate . . Investigative Brain cancer ICD-11: 2A00 CID: 9920343 Anticancer Treatment "Sorbitan, tri-(9Z)-9-octadecenoate; UNII-QE6F49RPJ1; QE6F49RPJ1; Glycomul TO; Liposorb TO; Protachem STO; Sorbitani trioleas; Sorbitan, trioleate; Crill 5; Trioleate de sorbitan; Emasol 430; Rheodol SP 030; Trioleato de sorbitano; Emsorb 2503; Ionet S 85; Nissan nonion OP 85; Anhydrosorbitol trioleate; Nissan nonion OP 85R; Anhydro-D-glucitol trioleate; Sorbitan, tri-9-octadecenoate; OP 85R; CHEMBL3989778; Sorbitani trioleas [INN-Latin]; TE 33; EINECS 247-569-3; Trioleate de sorbitan [INN-French]; Trioleato de sorbitano [INN-Spanish]; Sorbitan trioleate [USAN:INN:BAN:NF]; Sorbitan, tris(9-octadecenoate), (Z)-; AI3-03902; EC 247-569-3; Sorbitan, esters, tri-9-octadecenoate, (Z,Z,Z)-; Sorbitan, tri-9-octadecenoate, (Z,Z,Z)- (9CI); Q27287216; UNII-MDL271E3GR component PRXRUNOAOLTIEF-ADSICKODSA-N; Sorbitan trioleate. (Compound usually contains also associated fatty acids.); [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate" Small molecule "1S/C60H108O8/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-56(62)65-53-55(67-57(63)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2)60-59(54(61)52-66-60)68-58(64)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3/h25-30,54-55,59-61H,4-24,31-53H2,1-3H3/b28-25-,29-26-,30-27-/t54-,55+,59+,60+/m0/s1" PRXRUNOAOLTIEF-ADSICKODSA-N CCCCCCCCC=CCCCCCCCC(=O)OCC(C1C(C(CO1)O)OC(=O)CCCCCCCC=CCCCCCCCC)OC(=O)CCCCCCCC=CCCCCCCCC C60H108O8 CAS 26266-58-0 . . . . . . DR8995 Dapagliflozin D01TNW D01TNW Approved Type 2 diabetes mellitus ICD-11: 5A11 CID: 9887712 Anticancer Treatment "Dapagliflozin; 461432-26-8; BMS-512148; Forxiga; Farxiga; BMS 512148; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; UNII-1ULL0QJ8UC; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; 1ULL0QJ8UC; CHEMBL429910; CHEBI:85078; Dapagliflozin [USAN:INN]; BMS512148; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Forxiga (TN); CHEMBL3125458; (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-; (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol; 960404-48-2; Dagagflozin; (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; BMS5121458; C-aryl glucoside, 6; PubChem22435; Tube101; Dapagliflozin (USAN/INN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; cc-205; SCHEMBL157820; GLU006; GTPL4594; BDBM20880; DTXSID20905104; EX-A005; BCPP000265; AMY18541; AOB87300; ZINC3819138; BDBM50448923; CD0219; MFCD13182359; s1548; AKOS005145763; BCP9000583; BL-0052; CCG-229917; CS-0781; DB06292; EX-7214; PB11055; NCGC00250402-09; AC-24699; HY-10450; A25150; C22193; D08897; Q-3845; 432D268; Q409898; J-500392; BRD-K58160573-001-01-3; BRD-K58160573-001-05-4; 1-[3-(beta-D-Glucopyranosyl)-6-chlorobenzyl]-4-ethoxybenzene; (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;BMS-512148; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol" Small molecule "1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1" JVHXJTBJCFBINQ-ADAARDCZSA-N CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl C21H25ClO6 CAS 461432-26-8 CHEBI:85078 . . . DB06292 . DR2074 PR-104A . . Investigative Hepatocellular carcinoma ICD-11: 2C12 CID: 9848786 Anticancer Treatment "PR-104A; 680199-06-8; PR 104A; SN 27858; UNII-397986RF9L; 397986RF9L; 2-((2-Bromoethyl)(2-((2-hydroxyethyl)carbamoyl)-4,6-dinitrophenyl)amino)ethyl methanesulfonate; 2-[N-(2-bromoethyl)-2-(2-hydroxyethylcarbamoyl)-4,6-dinitroanilino]ethyl methanesulfonate; 2-((2-bromoethyl)-2-{[(2-hydroxyethyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate; SCHEMBL366334; CHEMBL4438907; 3,5-Dinitrobenzamide nitrogen mustard; AKOS025147034; J-505203; 2-((2-Bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-N-(2-hydroxyethyl)-3,5-dinitrobenzamide; 2-(N-(2-Bromoethyl)-2-(((2-hydroxyethyl)amino)carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-N-(2-hydroxyethyl)-3,5-dinitro-" Small molecule "1S/C14H19BrN4O9S/c1-29(26,27)28-7-5-17(4-2-15)13-11(14(21)16-3-6-20)8-10(18(22)23)9-12(13)19(24)25/h8-9,20H,2-7H2,1H3,(H,16,21)" AZICEEZSDKZDHX-UHFFFAOYSA-N CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(=O)NCCO C14H19BrN4O9S CAS 680199-06-8 . . . . . . DR4332 Chlorhexidine D0V4GY D0V4GY Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 9552079 Anticancer Treatment "chlorhexidine; 55-56-1; Rotersept; Fimeil; Hexadol; Soretol; Chlorhexidin; Chlorhexidinum; Chlorohexidine; Nolvasan; Cloresidina [DCIT]; Chlorhexidin [Czech]; Chlorhexidinum [INN-Latin]; Clorhexidina [INN-Spanish]; Hibistat; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; UNII-R4KO0DY52L; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; Exidine; Tubulicid; 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-; Sterilon; CHEMBL790; R4KO0DY52L; MLS001332388; CHEBI:3614; Cloresidina; Clorhexidina; 56-95-1; Biguanide, 1,1'-hexamethylenebis(5-(p-chlorophenyl)-; Chlorhexidine, 98%; CAS-55-56-1; NCGC00016246-03; SMR000857146; Sterido; Savlon babycare; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; DSSTox_CID_13314; DSSTox_RID_79062; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; DSSTox_GSID_33314; Chlorhexidine [INN:BAN]; Chlorhexidine dihydrochloride; MLS001304094; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine; 1-(4-chlorophenyl)-3-[N-[6-[[N-[N-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]amino]hexyl]carbamimidoyl]guanidine; N-(4-chlorophenyl)-1-3-(6-{N-[3-(4-chlorophenyl)carbamimidamidomethanimidoyl]amino}hexyl)carbamimidamidomethanimidamide; CCRIS 9230; Chlorhexidine (INN); C22H30Cl2N10; HSDB 7196; Merfen-incolore (TN); SR-01000799135; Nolvasan (*Diacetate*); 1,1'-Hexamethylenebis(5-[p-chlorophenyl]biguanide); SMR000718621; EINECS 200-238-7; Lisium (*Dihydrochloride*); BRN 2826432; 1,6-Di(N-p-chlorophenyldiguanido)hexane; Dentisept [veterinary] (TN); 1,6-Bis(N5-[p-chlorophenyl]-N1-biguanido)hexane; Prestwick_53; Chlorhexidine (1); Hibidil (Salt/Mix); Hibisol (Salt/Mix); Chlorhexidine diacetate salt hydrate; Hibitane (Salt/Mix); Hibiscrub (Salt/Mix); Hibispray (Salt/Mix); NSC526936; Spectrum_000237; Savloclens (Salt/Mix); Prestwick0_000143; Prestwick1_000143; Prestwick2_000143; Prestwick3_000143; Spectrum2_000135; Spectrum3_000339; Spectrum4_000277; Spectrum5_001322; chlorhexidine diacetate salt; EC 200-238-7; SCHEMBL3984; Chlorhexidine, >=99.5%; BSPBio_000246; BSPBio_001977; KBioGR_000774; KBioSS_000717; 4-12-00-01201 (Beilstein Handbook Reference); MLS001332387; MLS002154209; DivK1c_000761; SPBio_000210; SPBio_002185; BPBio1_000272; DTXSID2033314; BDBM51937; BDBM64773; cid_9552079; KBio1_000761; KBio2_000717; KBio2_003285; KBio2_005853; KBio3_001197; 2,4,11,13-Tetraazatetradecanediimidamide, N1,N14-bis(4-chlorophenyl)-3,12-diimino-; cid_12303047; NINDS_000761; REGID_for_CID_9552079; BDBM152706; HMS1568M08; HMS2095M08; HMS2233B16; HMS3712M08; HY-B1248; Tox21_110325; Tox21_201404; Tox21_303445; BDBM50170723; s5397; SBB057564; STK089248; AKOS005394319; Tox21_110325_1; CCG-220143; CS-4958; DB00878; EBD2224760; MCULE-4644073142; 2,4,11,13-Tetraazatetradecanediimidamide, N,N'-bis(4-chlorophenyl)-3,12-diimino-; IDI1_000761; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide; QTL1_000020; NCGC00016246-01; NCGC00016246-02; NCGC00016246-04; NCGC00016246-05; NCGC00016246-06; NCGC00016246-07; NCGC00016246-09; NCGC00016246-13; NCGC00091025-01; NCGC00091025-02; NCGC00091025-04; NCGC00247766-01; NCGC00257242-01; NCGC00258955-01; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine; AS-12648; Chlorhexidine, purum, >=99.0% (HPLC); SBI-0051301.P003; AB00053427; C06902; D07668; AB00053427-24; AB00053427-28; AB00053427_29; 009C673; Q-200828; SR-01000799135-5; 1,1''-Hexamethylene bis(5-(p-chlorophenyl)biguanide); BRD-K52256627-300-03-3; BRD-K52256627-300-05-8; SR-01000799135-10; SR-01000799135-11; Chlorhexidine, European Pharmacopoeia (EP) Reference Standard; 1,1'-(Hexane-1,6-diyl)bis[5-(4-chlorophenyl)biguanide] diacetate; Chlorhexidine, United States Pharmacopeia (USP) Reference Standard; Chlorhexidine, Pharmaceutical Secondary Standard; Certified Reference Material; N'',N''''''''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N''-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine;hydrochloride; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;hydrochloride; (1E)-2-[6-[[azanyl-[(E)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine; (1E)-2-[6-[[azanyl-[(E)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine;hydrochloride; {[(4-chlorophenyl)amino]iminomethyl}{[(6-{[({[(4-chlorophenyl)amino]iminomethy l}amino)iminomethyl]amino}hexyl)amino]iminomethyl}amine; 2-[amino-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine; 2-[amino-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine;hydrochloride" Small molecule "1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)" GHXZTYHSJHQHIJ-UHFFFAOYSA-N C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl C22H30Cl2N10 CAS 55-56-1 CHEBI:3614 . . . DB00878 . DR0366 Belinostat D0XT6W D0XT6W Phase 2 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 6918638 Anticancer Treatment "Belinostat; 414864-00-9; PXD101; Belinostat (PXD101); 866323-14-0; Beleodaq; PXD-101; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; NSC726630; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; PXD 101; UNII-F4H96P17NZ; PX-105684; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; 2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-; F4H96P17NZ; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; CHEBI:61076; PX 105684; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide.; E-Belinostat; Belinostat [USAN:INN]; N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide; PX105684; 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-; Belinostat Ph3; Beleodaq (TN); PubChem22405; Belinostat - PXD101; Belinostat (USAN/INN); Belinostat (PXD101); N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide; cc-489; MLS006011091; CHEMBL408513; GTPL7496; BDBM25150; CHEBI:94531; AMY1792; DTXSID60194378; EX-A180; QCR-181; (E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid; BCPP000351; AOB87787; BCP01741; ZINC3818726; Belinostat,PXD101, PX105684; Belinostat/PXD101,PX105684/; ABP000140; MFCD08064035; NSC758774; s1085; AKOS025401741; BCP9000386; CCG-208758; DB05015; LS41098; NSC-726630; NSC-758774; SB16466; NCGC00263155-02; NCGC00263155-05; AC-25046; AS-17068; SMR004702879; AB0007889; SW219445-1; EC-000.2286; A25012; D08870; W-5363; J-523584; Q4882925; BRD-K17743125-001-01-9; N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide; (E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; 5OG" Small molecule "1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+" NCNRHFGMJRPRSK-MDZDMXLPSA-N C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO C15H14N2O4S CAS 866323-14-0 CHEBI:61076 . . . DB05015 . DR7128 Dutasteride D0A9YA D0A9YA Approved Prostate hyperplasia ICD-11: GA90 CID: 6918296 Anticancer Treatment "Dutasteride; Avodart; 164656-23-9; GG-745; GI 198745; GI-198745; UNII-O0J6XJN02I; C27H30F6N2O2; O0J6XJN02I; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; CHEMBL1200969; Avolve; CHEBI:521033; Dutasteride, 99%; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(2,5-Bis(trifluoromethyl)phenyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide; 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; GG 745; Duagen; Avodart (TN); GI198745; Avidart; Dutasteride [USAN:INN:BAN]; NCGC00164571-01; 1H-Indeno(5,4-f)quinoline-7-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; GI-198745X; SCHEMBL5903; DSSTox_CID_26452; DSSTox_RID_81626; DSSTox_GSID_46452; Dutasteride (JAN/USP/INN); GTPL7457; DTXSID8046452; Dutasteride, >=98% (HPLC); AOB5568; BCPP000248; BCP02344; EX-A1952; ZINC3932831; Tox21_112199; BDBM50340481; MFCD00937869; NSC740477; s1202; AKOS015920136; AKOS015924431; BCP9000630; CCG-269904; CS-1542; DB01126; GS-3565; MCULE-1602474627; NSC 740477; NSC 759880; NSC-740477; N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; HY-13613; CAS-164656-23-9; B-2151; D03820; J10036; AB01274774-01; AB01274774_02; 656D239; Q424760; Q-201052; BRD-K30373883-001-02-8; Z1563146168; Dutasteride, European Pharmacopoeia (EP) Reference Standard; Dutasteride, United States Pharmacopeia (USP) Reference Standard; Dutasteride for system suitability, European Pharmacopoeia (EP) Reference Standard; (5.alpha.,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride;Avodart;; (5alpha,17beta)-N-{2,5-bis(trifluoromethyl)-phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide" Small molecule "1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1" JWJOTENAMICLJG-QWBYCMEYSA-N CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C C27H30F6N2O2 CAS 164656-23-9 CHEBI:521033 . . . DB01126 . DR9647 Temsirolimus D0ES1Q D0ES1Q Approved Renal cell carcinoma ICD-11: 2C90 CID: 6918289 Anticancer Treatment "Temsirolimus; CCI-779; Torisel; 162635-04-3; UNII-624KN6GM2T; 624KN6GM2T; CHEMBL1201182; 42-[3-Hydroxy-2-methylpropanoate; MFCD00934421; NCGC00167518-01; Cci 779; Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]; Temsirolimus (CCI-779, NSC 683864); CHEBI:79699; Temserolimus; NSC-683864; Temsirolimus - Torisel; Rapamycin 42-(2,2-bis(hydroxymethyl)propionate); Temsirolimus(CCI-779); DSSTox_CID_20945; DSSTox_RID_79605; DSSTox_GSID_40945; SCHEMBL18792; 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin; WAY-CCI 779; GTPL5892; DTXSID2040945; HSDB 7931; Temsirolimus, >=98% (HPLC); C56H87NO16; AOB87306; Temsirolimus [USAN:INN:BAN:JAN]; Tox21_112515; BDBM50343413; s1044; AKOS025142069; AM84554; CCG-264790; CS-0129; NCGC00167518-02; NCGC00167518-05; NCGC00167518-09; HY-50910; CAS-162635-04-3; T3574; AB01274736-01; AB01274736_02; 635T043; SR-01000898799; J-009958; Q7699074; SR-01000898799-3; BRD-K08177763-001-02-6; 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin; Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)" Small molecule "1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1" CBPNZQVSJQDFBE-FUXHJELOSA-N CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC C56H87NO16 CAS 162635-04-3 CHEBI:79699 . . . DB06287 . DR6644 6-benzylthioinosine . . Investigative Acute myeloid leukemia ICD-11: 2A60 CID: 6477178 Anticancer Treatment "6-Benzylthioinosine; CHEMBL60662; (2R,3R,4S,5R)-2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; SCHEMBL7617372; BDBM50240561; ZINC13560348; Purine, 6-benzylthio-9-beta-D-ribofuranosyl-; (2R,3R,4S,5R)-2-(6-Benzylsulfanyl-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; (2R,3R,4S,5R)-2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5R)-2-(6-(benzylthio)-9H-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol; (2R,3R,4S,5R)-2-(6-(benzylthio)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol" Small molecule "1S/C17H18N4O4S/c22-6-11-13(23)14(24)17(25-11)21-9-20-12-15(21)18-8-19-16(12)26-7-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,22-24H,6-7H2/t11-,13-,14-,17-/m1/s1" OMJRXFOHHLLDFR-LSCFUAHRSA-N C1=CC=C(C=C1)CSC2=NC=NC3=C2N=CN3C4C(C(C(O4)CO)O)O C17H18N4O4S . . . . . . . DR7612 Everolimus D0K3QS D0K3QS Approved Renal cell carcinoma ICD-11: 2C90 CID: 6442177 Anticancer Treatment "001, RAD; 40-O-(2-hydroxyethyl)-rapamycin; 40-O-(2-Hydroxyethyl)rapamycin; Afinitor; Certican; Everolimus; RAD; RAD 001; RAD, SDZ; RAD001; SDZ RAD; SDZ-RAD; Zortress; 42-O-(2-Hydroxyethyl)rapamycin; 159351-69-6; Votubia; Afinitor Disperz; CHEBI:68478; RAD-001; UNII-9HW64Q8G6G; 9HW64Q8G6G; NCGC00167512-01; Rapamycin, 42-O-(2-hydroxyethyl)-; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; everolimusum; NSC733504; Everolimus solution; Everolimus (INN); SDZRAD; XIENCE V; PubChem20048; Everolimus - RAD001; SCHEMBL4378; DSSTox_CID_20599; DSSTox_RID_79508; NVP-RAD001; DSSTox_GSID_40599; Everolimus [USAN:INN:BAN]; NVP-RAD-001; Everolimus, analytical standard; GTPL5889; RAD-001C; CHEMBL1908360; DTXSID0040599; HSDB 8255; RAD 666; RAD-666; Everolimus; RAD001; SDZ-RAD; C53H83NO14; 42-O-(2-Hydroxyethyl)-rapamycin; EX-A2057; Tox21_112510; BDBM50088378; AKOS015850977; ZINC169677008; CS-0064; DB01590; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; AS-16971; AT-22180; HY-10218; CAS-159351-69-6; V2036; Everolimus solution, 1.0 mg/ml in acetonitrile; 351E696; Q421052; Q-101413; BRD-K13514097-001-01-2; BRD-K13514097-001-05-3; dihydroxy-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxy-cyclohexyl]-1-methyl-ethyl]-dimethoxy-hexamethyl-[?]pentone; Everolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material" Small molecule "1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1" HKVAMNSJSFKALM-GKUWKFKPSA-N CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC C53H83NO14 CAS 159351-69-6 CHEBI:68478 . . . DB01590 . DR2568 Germacrone . . Investigative Idiopathic pulmonary fibrosis ICD-11: CB03 CID: 6436348 Anticancer Treatment "Germacrone; 6902-91-6; (3E,7E)-3,7-Dimethyl-10-(propan-2-ylidene)cyclodeca-3,7-dienone; Germacron; (3E,7E)-3,7-dimethyl-10-propan-2-ylidenecyclodeca-3,7-dien-1-one; Germacrone,(S); Germacrol (obsol;); Germacrone, analytical standard; SCHEMBL2551615; SCHEMBL14215872; CHEBI:80830; HY-N0440; MFCD00210050; s9311; ZINC31308583; AKOS016009673; CCG-266711; CS-0008961; G0519; N1500; V0249; (E,E)-Germacra-3,7(11),9-trien-6-one; C16966; 902G916; Q-100776; Q15410959; trans,trans-3,7-dimethyl-10-isopropylidene-3,7-cyclodecadien-1-one" Small molecule "1S/C15H22O/c1-11(2)14-9-8-12(3)6-5-7-13(4)10-15(14)16/h7-8H,5-6,9-10H2,1-4H3/b12-8+,13-7+" CAULGCQHVOVVRN-SWZPTJTJSA-N CC1=CCC(=C(C)C)C(=O)CC(=CCC1)C C15H22O CAS 6902-91-6 CHEBI:80830 . . . . . DR9419 Nystatin D08XAC D08XAC Approved Fungal infection ICD-11: 1F29-1F2F CID: 6433272 Anticancer Treatment "nystatin; Stamycin; Nilstat; Mycostatin; Biofanal; Diastatin; Moronal; Nystex; Nystatin A1; 1400-61-9; Nistatin; Nyotran; Nystavescent; Myconystatin; Mykostatyna; Nystatinum; Terrastatin; Herniocid; Mykinac; Nystatyna; Nyamyc; Nystan; Nystop; Candio-hermal; Candex Lotion; Zydin E; Mycostatin 20; Nystatin (Fungicidin); Barstatin 100; Mycostatin Pastilles; Nystatyna [Polish]; Moronal (antibiotic); Caswell No. 607B; Nystatin LF (liposome); Nystatine [INN-French]; Nystatinum [INN-Latin]; Nistatina [INN-Spanish]; Nystatin A; HSDB 3138; Nystatin A1, A2, A3 complex; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; EINECS 215-749-0; EPA Pesticide Chemical Code 202800; NSC 150817; AI3-26526; AV & NYS; Nystatin + Aloe Vera Extract; SCHEMBL284974; Nystatin [USP:INN:BAN:JAN]; CHEBI:473992; (Liposomal Nystatin)Nyotrantrade mark; AKOS016339654; DB00646; KS-1373; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid" Small molecule "1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1" VQOXZBDYSJBXMA-RKEBNKJGSA-N CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O C47H75NO17 CAS 1400-61-9 CHEBI:473992 . . . DB00646 . DR1288 Cefotaxime D0D1HA D0D1HA Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 5742673 Anticancer Treatment "cefotaxime; Cephotaxime; 63527-52-6; Cefotaxime acid; E-cefotaxime; UNII-N2GI8B1GK7; Cefotaximum; Cefotaxima; CHEBI:204928; N2GI8B1GK7; 60846-21-1; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Omnatax; Taxim; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Cefotaxima [INN-Spanish]; Cefotaxima acid; 4kot; (6R,7R)-3-(acetoxymethyl)-7-((E)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-3-(Acetyloxymethyl)-7-[[(2z)-2-(2-Amino-1,3-Thiazol-4-Yl)-2-Methoxyimino-Ethanoyl]amino]-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]oct-2-Ene-2-Carboxylic Acid; (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-; Cefotaxime (INN); EINECS 264-299-1; Cefotaxim Hikma (TN); RU 24662; Prestwick2_000139; Prestwick3_000139; Claforan (*Sodium salt*); CHEMBL1730; Lopac0_000278; BSPBio_000218; BPBio1_000240; SCHEMBL3731931; DTXSID6022761; HY-A0088A; HMS2090M11; (6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; ZINC3830437; AC-217; BDBM50482777; MFCD00864971; s4720; AKOS015951267; DB00493; SDCCGSBI-0050266.P002; (6R,7R)-3-(Acetoxymethyl)-7-(()-2-(2-amino-4-thiazolyl)-2-methoxyiminoglyoxylamino)-8-oco-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; 3-(Acetyloxymethyl)-7-(((2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; AS-12690; clo[4.2.0]oct-2-ene-2-carboxylic acid; CS-0013515; C06885; D07647; J90010; 527C526; BRD-K78364995-236-03-5; Q27262497; Di- poundg-chlorotetrakis[2,4-dimethyl-6-(2-quinolinyl-KN)phenyl-KC]di-iridium; (6R)-3-(Acetoxymethyl)-7alpha-[[(2-amino-4-thiazolyl)[(E)-methoxyimino]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]octa-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-8-oxo-5-thia-1-azabicy; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-8-oxo-5-thia-1-azabicy clo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 1056874-43-1; 3-(Acetoxymethyl)-7beta-[(2-amino-4-thiazolyl)(methoxyimino)acetylamino]cepham-3-ene-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-" Small molecule "1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1" GPRBEKHLDVQUJE-QSWIMTSFSA-N CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O C16H17N5O7S2 CAS 63527-52-6 CHEBI:204928 . . . DB00493 . DR8240 Ceftazidime D0PH5Z D0PH5Z Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 5481173 Anticancer Treatment "ceftazidime; Tazidime; 72558-82-8; Fortaz; Pentacef; Tazicef; Ceptaz; ceftazidima; ceftazidimum; Ceftazidime anhydrous; GR 20263; CHEBI:3508; LY 139381; Ceftazidime (INN); Fortaz (TN); GR-20263; LY-139381; CAZ; (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (contains ca. 10% Na2CO3); C22H22N6O7S2; Ceftazidime (TN); Ceptaz (TN); SCHEMBL36849; BIDD:GT0734; CHEMBL44354; DTXSID5022770; J01DD07; HMS2090M13; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; HY-B0593; BDBM50420259; AKOS015951273; CCG-269983; DB00438; NCGC00179584-05; CEFTAZIDIME (ARGININE FORMULATION); AB00513848; C06889; D07654; AB00513848-02; Cefprozil, Antibiotic for Culture Media Use Only; Q-200811; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate" Small molecule "1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1" ORFOPKXBNMVMKC-DWVKKRMSSA-N CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-] C22H22N6O7S2 CAS 72558-82-8 CHEBI:3508 . . . DB00438 . DR9753 Ceftriaxone D07ACT D07ACT Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 5479530 Anticancer Treatment "ceftriaxone; Biotrakson; Rocephin; 73384-59-5; Ceftriazone; Rocefin; Ceftriaxonum [INN-Latin]; Ceftriaxona [INN-Spanish]; Ceftriaxona; Ceftriaxonum; Rocephine; CEFTRIAXONE SODIUM; Rocephalin; CHEBI:29007; UNII-75J73V1629; CHEMBL161; CTRX; 75J73V1629; Ceftriaxone and Dextrose in Duplex Container; 74578-69-1; Ro 139904; Rophex; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; DRG-0071; Ceftriaxone (TN); Ceftriaxone (INN); C18H18N8O7S3; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; EINECS 277-405-6; Ceftriaxone [USAN:INN:JAN]; SCHEMBL23354; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R-(6alpha,7beta(Z)))-; 78384-59-5; DTXSID0022773; (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; HY-B0712; ZINC8584434; BDBM50049707; BDBM50103601; AKOS015960618; AC-1592; DB01212; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; AS-56320; K250; C06683; D07659; Cefatriaxone, Antibiotic for Culture Media Use Only; W-104454; (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2-(Z)-(O-; (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R,7R)-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, (6R,7R)-; 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (Ceftriaxone); 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid(Ceftriaxone)" Small molecule "1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1" VAAUVRVFOQPIGI-SPQHTLEESA-N CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O C18H18N8O7S3 CAS 73384-59-5 CHEBI:29007 . . . DB01212 . DR3804 Cefuroxime D0Y2IE D0Y2IE Approved Acute bronchitis ICD-11: CA42 CID: 5479529 Anticancer Treatment "cefuroxime; Cephuroxime; Cefuroxim; Cefuroximo; 55268-75-2; Cefuroximum; Zinacef Danmark; Zinacef; Sharox; Cefuroximum [INN-Latin]; Cefuroximo [INN-Spanish]; UNII-O1R9FJ93ED; O1R9FJ93ED; CHEBI:3515; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Biofuroksym; Cefuril; Kefurox; Q63409033; (6r,7r)-3-[(Carbamoyloxy)methyl]-7-{[(2z)-2-(Furan-2-Yl)-2-(Methoxyimino)acetyl]amino}-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]oct-2-Ene-2-Carboxylic Acid; Cefuroxime [USAN:INN:BAN]; C16H16N4O8S; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; EINECS 259-560-1; BRN 5783190; Cefuroximine; Cefuroxime [USAN:BAN:INN]; 4kov; Cefuroxime (TN); Cefuroxime (USAN/INN); Prestwick3_000720; CHEMBL1436; BSPBio_000939; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-; BIDD:GT0619; BPBio1_001033; SCHEMBL1821942; HY-B1256A; ZINC3830485; BDBM50422689; MFCD00864889; AKOS015962849; AC-4539; DB01112; KS-5162; P802; AB0010602; CS-0013520; EN300-53016; C06894; Cefuroxime, VETRANAL(TM), analytical standard; D00262; 268C752; A830563; Cefuroxime, Antibiotic for Culture Media Use Only; W-105575; BRD-K02733959-236-02-8; BRD-K02733959-236-07-7; (6R,7R)-3-((Carbamoyloxy)methyl)-7-((Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(aminocarbonyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyimino-ethanoyl]amino]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furanyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furyl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic Acid; 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid; KEF; KOV" Small molecule "1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1" JFPVXVDWJQMJEE-IZRZKJBUSA-N CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O C16H16N4O8S CAS 55268-75-2 CHEBI:3515 . . . DB01112 . DR6220 S-farnesylthiosalicylic acid D00KTV D00KTV Phase 2 Lung cancer ICD-11: 2C25 CID: 5469318 Anticancer Treatment "Salirasib; 162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; Benzoic acid, 2-[[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]-; 2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)benzoic acid; Salirasib [USAN:INN]; Farnesylthiosalicyclic acid; Salirasib; FTS; S-trans,trans-farnesylthiosalicylic acid; Salirasib (INN/USAN); Lopac-F-8175; Lopac0_000517; MLS006010835; GTPL6281; Salirasib, >=98% (HPLC); AMY39921; BCP27978; EX-A1170; ONO-7056; trans,trans-Farnesylthiobenzoic acid; ZINC1650377; 2030AH; BDBM50034278; KD-032; MFCD00467723; NSC685986; NSC755771; s7684; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; AKOS024458453; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; CCG-204607; CS-0681; DB12681; NSC-685986; NSC-755771; NCGC00015448-01; NCGC00015448-02; NCGC00015448-03; NCGC00015448-11; NCGC00093912-01; NCGC00093912-02; AS-73028; HY-14754; SMR004701762; EU-0100517; D08995; F 8175; W-5109; Farnesylthiosalicylic acid, >98% (HPLC), solid; SR-01000075885; J-009946; SR-01000075885-1; Q27088685; 2-[(3,7,11-Trimethyl-2,6,10-dodecatrienyl)thio]benzoic acid; 2-((2E,6E)-3,7,11-Trimethyl-dodeca-2,6,10-trienylsulfanyl)-benzoic acid; 2-{[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl}benzoic acid; 166445-40-5" Small molecule "1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+" WUILNKCFCLNXOK-CFBAGHHKSA-N CC(=CCCC(=CCCC(=CCSC1=CC=CC=C1C(=O)O)C)C)C C22H30O2S CAS 162520-00-5 . . . . . . DR8137 Cotylenin A . . Investigative Acute myeloid leukemia ICD-11: 2A60 CID: 5458687 Anticancer Treatment "COTYLENIN A; UNII-O6G9S48JRX; O6G9S48JRX; 12708-37-1; NSC319518; NSC 319518; Dicyclopenta(a,d)cyclooctene-1,5-diol, 1,2,3,3a,4,5,6,8,9,9a-decahydro-1-(methoxymethyl)-4-methyl-7-(1-methylethyl)-6-(((2S,3S,4aS,5R,7S,8R,8aR)-tetrahydro-8-hydroxy-5-(methoxymethyl)-3-methyl-3-((2S)-oxiranyl)-7H-2,4a-epoxy-5H-pyrano(3,4-b)-1,4-dioxin-7-yl)oxy)-, (1R,3aS,4R,5R,6R,9aR)-" Small molecule "1S/C33H50O11/c1-16(2)18-8-10-30(4)12-20-19(9-11-32(20,36)15-38-7)17(3)24(34)26(23(18)30)41-28-25(35)27-33(22(40-28)13-37-6)43-29(42-27)31(5,44-33)21-14-39-21/h12,16-17,19,21-22,24-29,34-36H,8-11,13-15H2,1-7H3/b20-12+/t17-,19+,21?,22?,24-,25?,26-,27?,28-,29?,30-,31+,32+,33+/m1/s1" SMQRKTIIIYTOTN-BQPZYPMMSA-N CC1C2CCC(C2=CC3(CCC(=C3C(C1O)OC4C(C5C6(C(O4)COC)OC(O5)C(O6)(C)C7CO7)O)C(C)C)C)(COC)O C33H50O11 CAS 12708-37-1 . . . . . . DR3693 Lisinopril D07HGR D07HGR Approved Hypertension ICD-11: BA00-BA04 CID: 5362119 Anticancer Treatment "lisinopril; Prinivil; Zestril; 76547-98-3; Linopril; Lysinopril; 83915-83-7; Acercomp; Inhibril; Lisipril; Noperten; Presiten; Sinopril; Tensopril; Acerbon; Carace; Vivatec; Coric; Lisinopril anhydrous; Lisinopril dihydrate; Alapril; Inopril; Lisinal; Lisoril; Lispril; Novatec; Sinopryl; Cipral; Linvas; Lipril; Loril; Prinil; Tensyn; Tersif; Lisinoprilum; Longes; Hipril; UNII-7Q3P4BS2FD; MK-521; Lisinopril (INN); [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE; Lisinopril (Zestril); C21H31N3O5; N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; Zestril (TN); 7Q3P4BS2FD; CHEBI:43755; Lisinopril [INN]; Qbrelis; (S)-1-((S)-6-Amino-2-(((S)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylic acid; LPR; (S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; Nanopril; Lisinoprilum [Latin]; (S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline; MFCD01698825; CHEMBL1237; Lizinopril; Diroton; Lisitec; Lisopril; Listril; Lizonoton; Optimon; Prinvil; Skopryl; Vitopril; Amicor; Doneka; Irumed; Laaven; MLS002154258; MK 521; MK 522; (2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid; SMR000544473; CCRIS 3568; SMR001233519; EINECS 278-488-1; BRN 4276619; lysinopryl; (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; HSDB 6852; (S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; 77726-95-5; (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate; 1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; L-Proline, N2-((1S)-1-carboxy-3-phenylpropyl)-L-lysyl-; Spectrum_000497; 1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline; Prestwick0_000301; Prestwick1_000301; Prestwick2_000301; Prestwick3_000301; Spectrum2_001456; Spectrum3_000941; Spectrum4_001040; Spectrum5_000995; SCHEMBL15680; BSPBio_000262; KBioGR_001599; KBioSS_000977; (2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; MLS001306436; MLS001306481; BIDD:GT0755; DivK1c_001037; SPECTRUM1501217; SPBio_001351; SPBio_002481; BPBio1_000290; GTPL6360; ICI-209K; DTXSID6040537; BDBM66979; HMS503O15; KBio1_001037; KBio2_000977; KBio2_003545; KBio2_006113; KBio3_002002; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-; N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; N~2~-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; cid_22887897; NINDS_001037; HMS1921B14; HMS2090O14; HMS2092L21; HMS2850N20; Pharmakon1600-01501217; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-; ZINC3812863; 1835AH; 2517AH; BDBM50367879; CCG-39190; DL-434; KM1776; NSC751176; NSC758151; s2076; AKOS015836369; AKOS015894970; L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-; AB04852; BCP9000856; DB00722; MCULE-7813362088; NSC-751176; NSC-758151; IDI1_001037; NCGC00179623-01; HY-18206; SBI-0051692.P002; L0220; A11876; D08131; 54256-EP2270011A1; 54256-EP2272834A1; 54256-EP2277879A1; 54256-EP2287165A2; 54256-EP2287166A2; 54256-EP2292228A1; 54256-EP2292620A2; 54256-EP2298742A1; 54256-EP2298776A1; 54256-EP2298779A1; 54256-EP2301923A1; 54256-EP2301929A1; 54256-EP2301931A1; 54256-EP2301935A1; 54256-EP2305648A1; 54256-EP2305674A1; 54256-EP2308562A2; AB00052250-13; AB00052250_14; AB00052250_15; 547L983; A838743; Q412208; SR-05000001786; SR-05000001786-1; BRD-K67966701-335-03-5; Z2786051707; N-[N2 (1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; N-[N2 -(1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; (S)-1-[N2-(1-Carboxy-3-phenylpropyl)-lysyl-proline dihydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]proline;hydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid;hydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate; (2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate; (S)-1-((S)-6-amino-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid" Small molecule "1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1" RLAWWYSOJDYHDC-BZSNNMDCSA-N C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O C21H31N3O5 CAS 76547-98-3 CHEBI:43755 . . . DB00722 . DR7548 Bleomycin D06UVD D06UVD Approved Hodgkin lymphoma ICD-11: 2B30 CID: 5360373 Anticancer Treatment bleomycin; Bleocin; Bleomicin; bleomycin a2; Bleomycine [INN-French]; Bleomycinum [INN-Latin]; Bleomicina [INN-Spanish]; Bleomycins; 11056-06-7; Bleomycin sulfate; Bleomicina; Bleomycine; Bleomycinum; Bleomycin [INN]; CCRIS 2754; HSDB 3208; NDC 0015-3010; Bleomycin [INN:BAN]; BLM; NSC 125066; SCHEMBL21090952; LMPK14000006; DB00290 Small molecule "1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1" OYVAGSVQBOHSSS-WXFSZRTFSA-O CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O C55H84N17O21S3+ CAS 11056-06-7 . . . . DB00290 . DR7470 Combretastatin A-4 phosphate D07JVO D07JVO Phase 2 Rheumatoid arthritis ICD-11: FA20 CID: 5351387 Anticancer Treatment "Fosbretabulin; Combretastatin A-4 phosphate; (Z)-2-Methoxy-5-(3,4,5-trimethoxystyryl)phenyl dihydrogen phosphate; 222030-63-9; Fosbretabulin disodium; UNII-I5590ES2QZ; Fosbretabulin free acid; combretastatin A4 phosphate; CA4DP; I5590ES2QZ; CA 4DP; 222030-63-9 (free acid); Phenol, 2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, dihydrogen phosphate; Fosbretabulin [INN]; Phosbretabulin; [2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate; SCHEMBL66079; GTPL8857; CHEMBL1206232; ZINC1543513; 2-Methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl phosphate; DB12577; Z-3247; Q5150956" Small molecule "1S/C18H21O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H2,19,20,21)/b6-5-" WDOGQTQEKVLZIJ-WAYWQWQTSA-N COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O C18H21O8P CAS 222030-63-9 . . . . DB12577 . DR6421 Fluvoxamine D03HFG D03HFG Approved Depression ICD-11: 6A70-6A71 CID: 5324346 Anticancer Treatment "fluvoxamine; 54739-18-3; Fluvoxaminum; Fluvoxamina; (Z)-Fluvoxamine; UNII-O4L1XPO44W; Fluvoxaminum [INN-Latin]; Fluvoxamina [INN-Spanish]; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; CHEMBL814; O4L1XPO44W; CHEBI:5138; Fluvoxamine [INN:BAN]; (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; DSSTox_CID_24002; DSSTox_RID_80097; DSSTox_GSID_44002; (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)-pentan-1-one O-(2-aminoethyl) oxime; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-; Fluvoxamine (INN); CAS-54739-18-3; C15H21F3N2O2; N06AB08; (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime; NCGC00018193-06; FVX; Prestwick2_000995; Prestwick3_000995; Lopac0_000495; SCHEMBL33983; BSPBio_001089; BIDD:GT0609; BPBio1_001199; DTXSID2044002; 2-[(Z)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; HY-B0103; Tox21_110837; BDBM50028091; ZINC12466082; AKOS016003882; Tox21_110837_1; AC-1679; CCG-204586; CS-1840; DB00176; SDCCGSBI-0050479.P002; 2-[({(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; NCGC00018193-04; NCGC00018193-05; NCGC00018193-07; NCGC00018193-08; NCGC00018193-11; NCGC00018193-21; NCGC00021870-04; NCGC00021870-05; AS-15332; O893; AB0016707; AB00514702; 39F183; C07571; D07984; AB00513735_05; AB00513735_06; A830353; BRD-K53517854-050-03-2; Q27259474; (E)-5-Methoxy-4'-(trifluormethyl)valerophenon-O-(2-aminoethyl)oxim; (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; 5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-aminoethyl)oxime; 1-Pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-,O-(2-aminoethyl)oxime, (1E)-" Small molecule "1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+" CJOFXWAVKWHTFT-XSFVSMFZSA-N COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F C15H21F3N2O2 CAS 54739-18-3 CHEBI:5138 . . . DB00176 . DR7358 Vinorelbine D01HTL D01HTL Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 5311497 Anticancer Treatment "vinorelbine; 71486-22-1; Navelbine; Vinorelbinum; Exelbine; Vinorelbina; Nor-5'-anhydrovinblastine; UNII-Q6C979R91Y; Vinorelbinum [Latin]; Vinorelbina [Spanish]; Navelbine base; CHEBI:480999; KW-2307; Q6C979R91Y; Navelbine (TN); Eunades; Vinorelbine [INN:BAN]; KW 2307 base; methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate; methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Vinorelbine (INN); Vinorelbine(Navelbine); SR-05000001504; HSDB 7665; ANX-530; SDP-012; C45H54N4O8; Vinorelbine(Navelbine)/; 5'-Noranhydrovinblastine; NVB; SCHEMBL4765; cc-469; C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-; CHEMBL553025; GTPL7105; DTXSID8040640; HMS2090E13; ABP000672; ZINC85536958; AKOS024457606; AT-7140; CCG-208616; DB00361; NSC 760087; NCGC00165966-03; K210; methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; FT-0657343; D08680; AB01275493-01; AB01566877_01; 486V221; SR-05000001504-1; SR-05000001504-2; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12beta,19alpha)-; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-" Small molecule "1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1" GBABOYUKABKIAF-IELIFDKJSA-N CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC C45H54N4O8 CAS 71486-22-1 CHEBI:480999 . . . DB00361 . DR3991 Levetiracetam D0E1XL D0E1XL Approved Chronic pain ICD-11: MG30 CID: 5284583 Anticancer Treatment "Levetiracetam; 102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; ucb L059; UCB-L 059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L059; Levetiracetamum; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; MFCD03265610; UCB-22059; Levetiracetamum [INN-Latin]; CHEBI:6437; Levetiracetam In Sodium Chloride; UCB 22059; 44YRR34555; Levroxa; (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide; (S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE; matever; Leviteracetam; Levipil; Torleva; Elepsia XR; (S)-Levetiracetam; SMR000466303; Keppra (TN); Levesam 500; Etiracetam levo-isomer; SR-01000759400; Levetiracetame; E Keppra; HSDB 7528; N03AX14; Levetiracetam [USAN:USP:INN:BAN]; E keppra (TN); Levetiracetam solution; (S)-2-(2-Oxo-1-pyrrolidinyl)butyramide; L-059; 2(S)-(2-OXOPYRROLIDIN-1-YL)BUTYRAMIDE; CHEMBL1286; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-; MLS000759403; MLS001424069; MLS006010215; BIDD:GT0242; SCHEMBL118843; GTPL6826; Levetiracetam (JAN/USP/INN); DTXSID9023207; AGB-101; Levetiracetam, >=98% (HPLC); Levetiracetam, analytical standard; HMS2051D07; HMS2089L20; HMS2235I18; HMS3262H11; HMS3713P16; HMS3884O11; Pharmakon1600-01502265; ACT02712; ALBB-027275; BCP11856; HY-B0106; ZINC1547851; Tox21_500835; ANW-41693; BDBM50422542; NSC760119; s1356; STL388027; Levetiracetam 1.0 mg/ml in Methanol; AKOS015841981; AB13957; AC-1479; CCG-100928; CS-1854; DB01202; KS-1176; LP00835; LS41261; MCULE-5120797917; NC00178; NSC 760119; NSC-760119; SDCCGSBI-0633760.P001; (2S)-(2-Oxopyrrolidin-1-yl)butyramide; NCGC00186028-01; NCGC00186028-13; NCGC00261520-01; (S)-2-(2-oxopyrrolidin-1-yl)butyramide; (s)-2-(2-oxopyrrolidin-1-yl) butyramide; (2S)-2-(2-oxo-1-pyrrolidinyl)butanamide; AB0012613; AM20070676; L0234; SW197558-3; C07841; D00709; M-2814; AB00639945-06; AB00639945_07; AB00639945_08; 767L282; A800616; (2S)-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide; Q-201292; SR-01000759400-4; SR-01000759400-5; (ALPHAS)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE; UNII-230447L0GL component HPHUVLMMVZITSG-LURJTMIESA-N; Levetiracetam, European Pharmacopoeia (EP) Reference Standard; (??S)???-??-???Ethyl-???2-???oxo-1-???pyrrolidineacetamide; Levetiracetam, United States Pharmacopeia (USP) Reference Standard; (-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide; Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1" HPHUVLMMVZITSG-LURJTMIESA-N CCC(C(=O)N)N1CCCC1=O C8H14N2O2 CAS 102767-28-2 CHEBI:6437 . . . DB01202 . DR0619 Paricalcitol D0N1TP D0N1TP Approved Hyper-parathyroidism ICD-11: 5A51 CID: 5281104 Anticancer Treatment "Paricalcitol; 131918-61-1; Zemplar; 19-Nor-1alpha,25-dihydroxyvitamin D2; Compound 49510; UNII-6702D36OG5; Compound-49510; CHEBI:7931; 6702D36OG5; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; NCGC00182706-01; Paracalcin; 19-Nor-1,25-(OH)2D2; Zemplar (TN); 19-Nor-1-alpha,25-dihydroxyvitamin D2; HSDB 7360; Paricalcitol [USAN:USP:INN]; ABT-358; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; Paricalcitol solution; PubChem18825; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; SCHEMBL3655; DSSTox_CID_28566; DSSTox_RID_82838; DSSTox_GSID_48640; BIDD:GT0330; Paricalcitol (JAN/USP/INN); GTPL2791; CHEMBL1200622; DTXSID4048640; AMY2878; BDBM233195; (1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol; ACT07192; EX-A4434; 19-Nor-1,25-dihydroxyvitamin D2; Tox21_112987; LMST04030163; s6681; ZINC13911941; AKOS005145562; AC-1198; BCP9001050; CS-0705; DB00910; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-; HY-50919; CAS-131918-61-1; C08127; D00930; W-5365; 918P611; Q155746; (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-" Small molecule "1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1" BPKAHTKRCLCHEA-UBFJEZKGSA-N CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C C27H44O3 CAS 131918-61-1 CHEBI:7931 . . . DB00910 . DR5683 Montelukast D00QET D00QET Approved Asthma ICD-11: CA23 CID: 5281040 Anticancer Treatment "montelukast; 158966-92-8; Singulair; UNII-MHM278SD3E; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; CHEMBL787; MHM278SD3E; CHEBI:50730; Cyclopropaneacetic acid, 1-((((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-; Montelukast [INN:BAN]; (R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid; 142522-28-9; Aerokast; Brondilat (TN); 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid; 2-[1-({[(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetic acid; Montelukast (INN); SR-01000763441; HSDB 7582; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; cc-91; SCHEMBL4486; SCHEMBL4487; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; BIDD:GT0394; GTPL3340; DTXSID9023334; CHEBI:94710; HMS2089D07; HMS3715N13; HMS3886L03; ACT04773; ZINC3831151; BDBM50052024; HY-13315A; AKOS025310659; CCG-221186; DB00471; SB19081; NCGC00188977-01; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid; Cyclopropaneacetic acid, 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, (R-(E))-; CS-0002595; S5783; 5306-EP2270008A1; 5306-EP2276739A1; 5306-EP2280006A1; 5306-EP2281813A1; 5306-EP2281815A1; 5306-EP2281819A1; 5306-EP2284166A1; 5306-EP2287154A1; 5306-EP2288595A2; 5306-EP2292617A1; 5306-EP2292619A1; 5306-EP2295409A1; 5306-EP2298415A1; 5306-EP2301933A1; 5306-EP2305640A2; 5306-EP2305659A1; 5306-EP2308562A2; 5306-EP2311818A1; 5306-EP2311827A1; 5306-EP2314590A1; C07482; D08229; AB01275454-01; 522M289; Q417767; SR-01000763441-3; SR-01000763441-5; BRD-K99673372-001-01-9; 1-[[[(R)-3-[2-(1-Hydroxy-1-methylethyl)phenyl]-1-[3-[2-(7-chloroquinoline-2-yl)ethenyl]phenyl]propyl]thio]methyl]cyclopropane-1-acetic acid; 1124196-02-6; r-(e)-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid" Small molecule "1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1" UCHDWCPVSPXUMX-TZIWLTJVSA-N CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O C35H36ClNO3S CAS 158966-92-8 CHEBI:50730 . . . DB00471 . DR5598 Amphotericin B D02DWM D02DWM Approved Fungal infection ICD-11: 1F29-1F2F CID: 5280965 Anticancer Treatment "amphotericin b; 1397-89-3; Amphotericine B; Amphotericin; Fungizone; Amfotericina B; Amphotericinum B; AMPH-B; Liposomal Amphotericin B; Amphotericin-B; Ambisome; Fungilin; Abelcet; Ampho-Moronal; UNII-7XU7A7DROE; Amphotec; MFCD00877763; 7XU7A7DROE; NCGC00090808-01; Abelecet; Halizon; DSSTox_CID_2601; DSSTox_RID_76653; DSSTox_GSID_22601; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; Amphotericin B trihydrate; C47H73NO17; Amphortericin B; Anfotericine B; Amphotericin b deoxycholate; IAB; NSC 527017; Fungisome; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; CCRIS 5963; HSDB 3008; Amphotericin B [USP:INN:JAN]; Fungizone (TN); Amphotec (TN); (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; AmBisome (TN); Amp B; CAS-1397-89-3; EINECS 215-742-2; NS 718; BRN 0078342; AI3-26528; Prestwick3_000410; Amphotericin B solubilized; SCHEMBL17973; BSPBio_000340; 5-18-10-00525 (Beilstein Handbook Reference); BIDD:GT0351; BPBio1_000374; NKTR-024; Amphotericin B and cinnamon oil; DTXSID9022601; HMS2096A22; HMS3713A22; Amphotericin B (JP17/USP/INN); HY-B0221; Amphotericin B, Streptomyces nodosus; Tox21_111027; Tox21_202484; Amphotericin B from Streptomyces sp.; BRL-49594; LMPK06000002; s1636; AKOS024464746; ZINC253387843; CCG-220410; DB00681; NCGC00260033-01; (1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; 14,39-Dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,2 7,29,31-heptaene-36-carboxylic acid, 33-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-(1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E, 25E-27E,29E,31E,33R*,35S*,36R*,37S*))-; AB00513832; C06573; D00203; J10140; AB00513832_02; 397A893; Q412223; 1397-89-3, C47H73NO17; Amphotericin B from Streptomyces sp., ~80% (HPLC), powder; Amphotericin B from Streptomyces sp., BioReagent, suitable for cell culture, ~80% (HPLC); Amphotericin B solubilized, powder, gamma-irradiated, BioXtra, suitable for cell culture; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-Amino-3,6-dideoxy-?-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-he; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-hept; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-; 23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; Amphotericin B from Streptomyces sp., Vetec(TM) reagent grade, BioReagent, suitable for cell culture, ~80%; Amphotericin B solution, 250 mug/mL in deionized water, sterile-filtered, BioReagent, suitable for cell culture" Small molecule "1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1" APKFDSVGJQXUKY-INPOYWNPSA-N CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O C47H73NO17 CAS 1397-89-3 . . . . DB00681 . DR4377 Rasagiline D06OMW D06OMW Approved Parkinsonism ICD-11: 8A00 CID: 3052776 Anticancer Treatment "rasagiline; 136236-51-6; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; Azilect; (R)-N-2-Propynyl-1-indanamine; (R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine; 1-Indanamine, N-2-propynyl-, (R)-; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; UNII-003N66TS6T; TV-1030; Azilect (TN); RAS; CHEMBL887; (1R)-N-propargylindan-1-amine; CHEBI:63620; 003N66TS6T; (R)-Indan-1-yl-prop-2-ynyl-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-; (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; Rasagiline [USAN:INN]; MFCD00866571; HSDB 7699; (1R)-N-prop-2-ynylindan-1-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R); TV 1030; PubChem23269; Rasagiline (USAN/INN); SCHEMBL74699; cc-221; MLS006012042; N-propargyl-1-(R)aminoindan; GTPL6641; IND057; SCHEMBL2029054; DTXSID3041112; BDBM10989; HMS3264K12; HMS3715L12; HMS3886N03; Pharmakon1600-01502333; AC-723; ANW-49399; HY-14605A; NSC759639; NSC789038; s5795; ZINC19875504; AKOS006271452; AKOS015837675; AM84542; CCG-213034; DB01367; FS-3130; MCULE-4385913742; NSC 759639; NSC-759639; NSC-789038; SMR002533187; (1R)-N-(prop-2-yn-1-yl)indan-1-amine; AB0035569; DB-001111; A2916; X9941; D08469; S-3541; AB01562963_01; AB01562963_02; Q420685; SR-00000006359; SR-00000006359-3; 1204184-69-9" Small molecule "1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1" RUOKEQAAGRXIBM-GFCCVEGCSA-N C#CCNC1CCC2=CC=CC=C12 C12H13N CAS 136236-51-6 CHEBI:63620 . . . DB01367 . DR1489 Clomiphene citrate D0I5WB D0I5WB Approved Female infertility ICD-11: GA31 CID: 3033832 Anticancer Treatment "Clomifene citrate; CLOMIPHENE CITRATE; 50-41-9; Zuclomiphene citrate; Clomid; Clomiphene A citrate; cis-Clomiphene citrate; Clomiphene citrate salt; Milophene; Serophene; Chloramiphene; Omifin; Clomifene citrate (Serophene); UNII-UY5X264QZV; Clostilbegyt; RMI 16289; Clomivid; Clomphid; Dyneric; Genozym; Ikaclomin; 2-(4-(2-Chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate; Zuclomiphene (citrate); MFCD00058322; NSC 35770; 7619-53-6; UY5X264QZV; 50-41-9 (CITRATE); MRL 41; Zuclomid; RMI 16312; (Z)-2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate; (Z)-Clomiphene citrate; Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-,2-hydroxy-1,2,3-propanetricarboxylate (1:1); MER-41; MRL-41; NSC 151466; NSC-35770; Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, citrate (1:1); CAS-50-41-9; Clomiphene citrate, cis-; Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, citrate (1:1), (Z)-; MLS001332629; MLS002207099; ARONIS23854; SCHEMBL223472; SPECTRUM1500196; SGCUT00109; CHEMBL1213137; HMS501H04; HY-B1617A; HMS1920O19; HMS2091G06; HMS2232D12; Pharmakon1600-01500196; AMY33425; BCP03057; to_000032; CCG-39553; NSC151466; NSC756698; s2561; SBB080555; AKOS005111131; BCP9000541; DS-6814; NSC-151466; NSC-756698; SB17214; NCGC00017008-01; NCGC00017008-02; NCGC00017008-03; NCGC00094626-01; NCGC00094626-02; NCGC00164385-01; AC-19685; AC-32011; Ethanamine, 2-(4-((1Z)-2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1); BCP0726000214; AB0006636; 2-[4-(2-Chloro-1,2-diphenylvinyl)phenoxy; CS-0111663; SW196898-3; C08161; Triethylamine,2-diphenylvinyl)phenoxy]-, citrate; SR-05000001591; SR-05000001591-1; Q27291328; Triethylamine,2-diphenylvinyl)phenoxy]-, citrate (1:1); UNII-1B8447E7YI component PYTMYKVIJXPNBD-OQKDUQJOSA-N; Triethylamine,2-diphenylvinyl)phenoxy]-, citrate (1:1), (Z)-; (2)2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine citrate (1:1); 2-(4-[2-Chloro-1,2-Diphenylethenyl]Phenoxy)-N,N-Diethylethanamine Citrate salt; (2-(4-[(Z)-2-CHLORO-1,2-DIPHENYLETHENYL]PHENOXY)ETHYL)DIETHYLAMINE, 2-HYDROXYPROPANE-1,2,3-TRICARBOXYLIC ACID; {2-[4-((1Z)-2-chloro-1,2-diphenylvinyl)phenoxy]ethyl}diethylamine, 2-hydroxypr opane-1,2,3-tricarboxylic acid; {2-[4-(2-Chloro-1,2-diphenylvinyl)phenoxy]ethyl}diethylamine 2-hydroxypropane-1,2,3-tricarboxylic acid salt; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt); Ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI); Ethanamine,2-diphenylethenyl)phenoxy]-N,N-diethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1); Ethanamine,2-diphenylethenyl)phenoxy]-N,N-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)" Small molecule "1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;" PYTMYKVIJXPNBD-OQKDUQJOSA-N CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O C32H36ClNO8 CAS 7619-53-6 . . . . DB00882 . DR0615 Benfotiamine . . Phase 4 Substance abuse ICD-11: 6C40 CID: 3032771 Anticancer Treatment "benfotiamine; Benphothiamine; Benzoylthiamine monophosphate; 22457-89-2; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; Benzoylthiamine O-monophosphate; Benfotamine; Benfotiamina; Benfotiaminum; 22457-89-2 (free acid); N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; S-Benzoylthiamine-O-monophosphate; C19H23N4O6PS; (3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; SR-01000872627; CHEBI:41039; MFCD00057343; Prestwick_68; Biotamin (TN); PubChem17412; Prestwick2_000654; Prestwick3_000654; Benfotiamine (JAN/INN); BSPBio_000687; SCHEMBL188070; BPBio1_000757; CHEMBL4303665; SCHEMBL19184708; HMS1570C09; HMS2097C09; HMS3714C09; ZINC2015559; STL453586; AKOS015920320; AC-8280; CCG-220654; DB11748; NCGC00179477-01; H493; ST056187; AB0013076; 57B892; A15020; D01255; SR-01000872627-1; SR-01000872627-2; 137-74-6; S-[(2Z)-2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR" Small molecule "1S/C19H23N4O6PS/c1-13(23(12-24)11-16-10-21-14(2)22-18(16)20)17(8-9-29-30(26,27)28)31-19(25)15-6-4-3-5-7-15/h3-7,10,12H,8-9,11H2,1-2H3,(H2,20,21,22)(H2,26,27,28)/b17-13-" BTNNPSLJPBRMLZ-LGMDPLHJSA-N CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOP(=O)(O)O)SC(=O)C2=CC=CC=C2)C C19H23N4O6PS CAS 22457-89-2 CHEBI:41039 . . . DB11748 . DR6719 Lincomycin D0Q0EX D0Q0EX Approved Gram-positive bacterial infection ICD-11: 1B74-1G40 CID: 3000540 Anticancer Treatment "lincomycin; 154-21-2; Cillimycin; Lincomycinum; Lincomicina; Lincomycin A; Lincomycin hydrochloride; UNII-BOD072YW0F; CHEMBL1447; Lincolnensin; Lincomycine; Jiemycin; Lincocin; Lincomycin (USAN/INN); BOD072YW0F; U 10,149A; CHEBI:6472; Frademicina; (2S,4R)-N-((1R,2R)-2-hydroxy-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; U-10149; Methyl 6,8-dideoxy-6-trans-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-D-erythro-alpha-D-galacto-octopyranoside; U-10,149; LCM; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; methyl 6,8-dideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-D-erythro-alpha-D-galacto-octopyranoside; Lincomycin, (2S-cis)-Isomer; Lincomycine [French]; C18H34N2O6S; NSC-70731; AC1MHD7X; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; Lincomicina [INN-Spanish]; Bactramycin; Lincorex; Lincomycin [USAN:INN:BAN]; HSDB 3109; L-Mycin; Lincomycin,(S); 3QB; EINECS 205-824-6; NSC70731; BRN 0707677; SCHEMBL4010; D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-; DTXSID3023215; GTPL10941; HMS2089A13; ZINC3982483; BDBM50335522; AKOS015951392; CCG-208231; DB01627; MCULE-4676929559; NE39438; SMP1_000178; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; D-erythro-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-; Methyl 6,8-dideoxy-6-(1-methyl-4-propyl-2-pyrrolidinecarboxamido)-1-thio-D-erythro-D-galacto-octopyranoside (alpha-form); 54L212; C06812; D00223; AB01275426-01; Lincomycin, Antibiotic for Culture Media Use Only; Q423428; W-109518; BRD-K49384696-003-01-9; Z1665194511; (2S,4R)-N-((1R,2R)-2-hydroxy-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; (2S,4R)-N-((1S)-2-hydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; 1-Methyl-4-propyl-pyrrolidine-2-carboxylic acid [2-hydroxy-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; D-Erythro-.alpha.-D-gluco-octopyranoside, methyl 6,8-dideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-((((2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-; Methyl (5r)-5-[(1r,2r)-2-Hydroxy-1-{[(4r)-1-Methyl-4-Propyl-L-Prolyl]amino}propyl]-1-Thio-Beta-L-Arabinopyranoside; methyl 6,8-dideoxy-6-({[(2S,4R)-1-methyl-4-propylpyrrolidin-2-yl]carbonyl}amino)-1-thio-D-erythro-alpha-D-galacto-octopyranoside" Small molecule "1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1" OJMMVQQUTAEWLP-KIDUDLJLSA-N CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)O C18H34N2O6S CAS 154-21-2 CHEBI:6472 . . . DB01627 . DR0456 Scopolamine D0B7YT D0B7YT Approved Addictive disorder ICD-11: 6C50-6C5Z CID: 3000322 Anticancer Treatment "scopolamine; Hyoscine; (-)-Hyoscine; 51-34-3; Scopine (-)-tropate; l-Scopolamine; Scopine tropate; 6,7-Epoxytropine tropate; Transderm-Scop; (-)-Scopolamine; Hyosol; Atrochin; Atroquin; Isopto Hyoscine; Epoxytropine tropate; Scopolamine hydrobromide; 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate; UNII-DL48G20X8X; Beldavrin; Scopamin; CHEMBL3084722; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; Skopolamin; Hyosceine; Scop; DL48G20X8X; Tropic acid, ester with scopine; CHEBI:16794; LSM-4015; Isoscopil; Tranaxine; (1S,3S,5R,6R,7S)-6,7-epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate; Hysco; Hyoscine bromide; Scopace; Transderm scop; Scopolamine HCl; Boro-Scopol; Scopolaminium bromide; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); Scopolammonium bromide; l-Hyoscine hydrobromide; (1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (S)-3-hydroxy-2-phenylpropanoate; SEE; (-)-Scopolamine bromide; l-Scopolamine-hydrobromide; SCOPOLAMINE BROMIDE; (-)-Hyoscine hydrobromide; Scopoderm; (+)-Scopolamine; levo-duboisine; (+)-Hyoscine; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0(2,4)]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate; [(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate; Hyoscyine hydrobromide; Atroscine Hydrobromide; Hydroscine hydrobromide; hydrobromicum, Scopolaminum; Tropane alkaloid; HSDB 4074; EINECS 200-090-3; NSC61806; S-(-)-Tropate; Prestwick3_000877; EC 200-090-3; 6beta,7beta-Epoxy-3alpha-tropanyl S-(-)-tropate; SCHEMBL16226; BSPBio_000953; GTPL330; 6beta,7beta-Epoxy-1alpha,5alpha-tropan-3alpha-ol; BPBio1_001049; CHEMBL569713; CHEMBL1906925; DTXSID6023573; SCHEMBL22393238; CHEBI:93572; HMS2090N13; HMS3886L22; HY-N0296; AC-968; BDBM50263508; CS0019; s9326; ZINC13118910; AKOS025402477; Tropic acid, 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(sup 2,4))non-7-yl ester; ZINC100037020; ZINC101147375; CCG-267504; CS-6609; DB00747; 3-Oxa-9-azatricyclo(3.3.1.0(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); SMP1_000270; NCGC00024357-04; NCGC00024357-05; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate; AB00429689; AB00429689-30; AB00429689-31; AB00429689_32; Q337188; (methyl[?]yl) (2S)-3-hydroxy-2-phenyl-propanoate; BRD-K89923877-003-02-4; Q27165268; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2R)-3-hydroxy-2-phenylpropanoate; (1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate; [7(S)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)]-.alpha.-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo-[3.3.1.0^2,4]non-7-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (1alpha,2beta,4beta,5alpha,7beta)-9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester, (alphaS)-; Benzeneacetic acid, alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))-" Small molecule "1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1" STECJAGHUSJQJN-USLFZFAMSA-N CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4 C17H21NO4 CAS 114-49-8 CHEBI:16794 . . . DB00747 . DR7720 HLM006474 . . Investigative Melanoma ICD-11: 2C30 CID: 2895500 Anticancer Treatment "HLM006474; 353519-63-8; 7-[(4-ethoxy-3-methylphenyl)(2-pyridinylamino)methyl]-2-methyl-8-quinolinol; 7-[(4-ethoxy-3-methylphenyl)-(pyridin-2-ylamino)methyl]-2-methylquinolin-8-ol; 7-[(4-ethoxy-3-methylphenyl)(pyridin-2-ylamino)methyl]-2-methylquinolin-8-ol; Oprea1_498948; SCHEMBL9963974; CHEMBL4571419; BCP34559; EX-A3531; 3384AH; CCG-21518; s8963; STK509159; AKOS000357958; AKOS022004575; CS-3180; HLM 006474; MCULE-1162226397; NCGC00387261-01; HY-16667; EU-0079871; HLM006474, >=98% (HPLC); HLM-006474; HLM 006474; SR-01000502837; SR-01000502837-1" Small molecule "1S/C25H25N3O2/c1-4-30-21-13-11-19(15-16(21)2)23(28-22-7-5-6-14-26-22)20-12-10-18-9-8-17(3)27-24(18)25(20)29/h5-15,23,29H,4H2,1-3H3,(H,26,28)" CYNZBLNMIJNBSF-UHFFFAOYSA-N CCOC1=C(C=C(C=C1)C(C2=C(C3=C(C=CC(=N3)C)C=C2)O)NC4=CC=CC=N4)C C25H25N3O2 . . . . . . . DR3320 Caspofungin D00ZCN D00ZCN Approved Fungal infection ICD-11: 1F29-1F2F CID: 2826718 Anticancer Treatment "Caspofungin; Cancidas; L-743,872; CHEBI:474180; MK-991; Cancidas (TN); L-743872; MK-0991; Caspofungin (INN); CHEMBL499808; SCHEMBL6726364; N-[(2-aminoethylamino)-[(1R)-3-amino-1-hydroxy-propyl]-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-trihydroxy-[(1R)-1-hydroxyethyl]-hexaoxo-[?]yl]-10,12-dimethyl-tetradecanamide; BDBM50478215; NSC754342; NSC-754342; D07626; Q420875; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-(threo-3-hydroxy-L-ornithine)-; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)" Small molecule "1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1" JYIKNQVWKBUSNH-OGZDCFRISA-N CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O C52H88N10O15 CAS 162808-62-0 CHEBI:474180 . . . DB00520 . DR9260 Ethionamide D0P0HB D0P0HB Approved HIV-infected patients with tuberculosis ICD-11: 1B10-1B1Z CID: 2761171 Anticancer Treatment "ethionamide; 536-33-4; 2-ethylpyridine-4-carbothioamide; Ethioniamide; Ethyonomide; Amidazine; Ethinamide; Etionamid; Etioniamid; Thioamide; Trecator; Ethylisothiamide; 2-Ethylthioisonicotinamide; Trecator-SC; 4-Pyridinecarbothioamide, 2-ethyl-; Amidazin; Ethimide; Etiocidan; Etionizin; Etionizina; Etionizine; Fatoliamid; Iridocin; Iridozin; Isotiamida; Itiocide; Nicotion; Rigenicid; Sertinon; Thianide; Thioniden; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; Aetina; Aetiva; Ethina; Etimid; Etionid; Isothin; Nizotin; Teberus; Thianid; Tianid; Atina; Bayer 5312; Ethionamid prothionamid; Iridocin Bayer; Nisotin; Thiomid; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; Etionamide [DCIT]; Ethionamidum; Etionamida; Etionamide; Tiomid; 2-Ethylisothionicotinamide; 2-Ethylisonicotinothioamide; Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 1314 TH; 2-Ethylisonicotinic acid thioamide; TH 1314; 2-ethyl-4-thiopyridylamide; NCI-C01694; UNII-OAY8ORS3CQ; 1314-Th; F.I. 58-30; 1314TH; 2-Ethyl-4-thioamidylpyridine; Isonicotinamide, 2-ethylthio-; OAY8ORS3CQ; Aethionamidum; Tio-Mid; MLS000069764; CHEBI:4885; .alpha.-Ethylisothionicotinamide; .alpha.-Ethylthioisonicotinamide; .alpha.-Ethylisonicotinoylthioamide; Trecator SC; NSC255115; NSC-255115; 1314 TN; .alpha.-Ethylisonicotinic acid thioamide; Ethina (VAN); NCGC00016497-05; CAS-536-33-4; SMR000058716; DSSTox_CID_577; DSSTox_RID_75669; DSSTox_GSID_20577; alpha-Ethylisothionicotinamide; alpha-Ethylthioisonicotinamide; alpha-Ethylisonicotinoylthioamide; 2-Ethylisonicotinic thioamide; alpha-Ethylisonicotinic acid thioamide; CCRIS 287; amino(2-ethyl(4-pyridyl))methane-1-thione; HSDB 7473; Bayer5312; SR-01000759219; EINECS 208-628-9; NSC 255115; BRN 0116474; Thiodine; Trecator (TN); Prestwick_842; Isonicotinimidic acid, 2-ethylthio-; MFCD00057361; Ethionamide [USAN:USP:INN:BAN:JAN]; PubChem15920; Spectrum_001082; CPD001370750; Opera_ID_632; Prestwick0_000526; Prestwick1_000526; Prestwick2_000526; Prestwick3_000526; Spectrum2_000994; Spectrum3_000428; Spectrum4_000547; Spectrum5_000979; 2-Ethylisonicotinothiamide; 2-Ethylisonicotinthioamide; E0695; CHEMBL1441; SCHEMBL27007; BSPBio_000511; BSPBio_002016; KBioGR_001213; KBioSS_001562; 5-22-02-00360 (Beilstein Handbook Reference); MLS001074114; MLS002454402; DivK1c_000145; SPECTRUM1500292; WLN: T6NJ B2 DYZUS; SPBio_001087; SPBio_002432; BPBio1_000563; Ethionamide (JP17/USP/INN); DTXSID0020577; AEOCXXJPGCBFJA-UHFFFAOYSA-; HMS500H07; KBio1_000145; KBio2_001562; KBio2_004130; KBio2_006698; KBio3_001236; .alpha.-Ethyl-thioisonicotinamide; Isonicotinamide, 2-ethyl, thio-; NINDS_000145; HMS1569J13; HMS1920M22; HMS2091F03; HMS2096J13; HMS2231F10; HMS2233J11; HMS3259K17; HMS3370I18; HMS3371D12; HMS3655M10; HMS3713J13; Pharmakon1600-01500292; BCP29626; HY-B0276; ZINC3872520; Tox21_110458; Tox21_202409; Tox21_302769; ANW-42028; CCG-40212; NSC757028; s1777; SBB055548; AKOS006220662; Tox21_110458_1; DB00609; FS-1770; MCULE-1322319906; NC00508; NSC-757028; IDI1_000145; NCGC00016497-01; NCGC00016497-02; NCGC00016497-03; NCGC00016497-04; NCGC00016497-06; NCGC00016497-08; NCGC00016497-09; NCGC00091074-01; NCGC00091074-02; NCGC00091074-03; NCGC00091074-04; NCGC00256600-01; NCGC00259958-01; AC-13715; AK163496; M381; SMR001370750; SBI-0051377.P003; AB0015183; DB-049945; AB00051990; ST50949989; SW196973-3; C07665; D00591; 33010-EP2286812A1; 33010-EP2287165A2; 33010-EP2287166A2; 33010-EP2292620A2; 33010-EP2297130A1; 33010-EP2301536A1; 33010-EP2301538A1; 33010-EP2305675A1; 33010-EP2305695A2; 33010-EP2305696A2; 33010-EP2305697A2; 33010-EP2305698A2; 33010-EP2305808A1; 33010-EP2308833A2; 33010-EP2308852A1; 33010-EP2308874A1; 33010-EP2311455A1; 33010-EP2311815A1; 73833-EP2308926A1; 73833-EP2309564A1; AB00051990-09; AB00051990_10; AB00051990_11; A829694; Q414767; SR-01000759219-2; SR-01000759219-5; W-105719; BRD-K33710385-001-05-4; BRD-K51207550-001-09-9; Ethionamide, European Pharmacopoeia (EP) Reference Standard; Ethionamide, United States Pharmacopeia (USP) Reference Standard; Ethionamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Trecator;2-Ethylthioisonicotinamide;Ethinamide; Ethioniamide; Trecator SC; Trecator-SC" Small molecule "1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)" AEOCXXJPGCBFJA-UHFFFAOYSA-N CCC1=NC=CC(=C1)C(=S)N C8H10N2S CAS 536-33-4 CHEBI:4885 . . . DB00609 . DR8398 Flunarizine D05CEU D05CEU Approved Migraine ICD-11: 8A80 CID: 941361 Anticancer Treatment "flunarizine; 52468-60-7; Sibelium; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; Flunarizinum [INN-Latin]; Flunarizina [INN-Spanish]; UNII-R7PLA2DM0J; Flunarizinum; (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; R7PLA2DM0J; 40218-96-0; CHEMBL30008; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; Flunarizina; 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (E)-; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-, (E)-; Flunarizine [INN:BAN]; DSSTox_CID_25616; DSSTox_RID_81005; DSSTox_GSID_45616; Narzine; 4-((2E)-3-phenylprop-2-enyl)-1-[bis(4-fluorophenyl)methyl]piperazine; Sibelium (TN); Flunarizine (INN); CAS-52468-60-7; EINECS 257-937-5; Flunarazine; Flunarizine2HCl; NCGC00018102-06; EINECS 254-842-0; Prestwick2_000312; Prestwick3_000312; Spectrum5_001570; Lopac0_000527; SCHEMBL43440; SCHEMBL43441; BSPBio_000304; BSPBio_001341; BSPBio_003096; BPBio1_000336; DTXSID6045616; BCBcMAP01_000120; CHEBI:92209; cid_6365505; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-cinnamyl]piperazine; CHEBI:135652; HMS1361D03; HMS1791D03; HMS1989D03; HMS2089H21; Tox21_110825; BDBM50017702; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-; STL477617; ZINC19360739; 1-[Bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]piperazine; AKOS015960783; Tox21_110825_1; AC-1283; CCG-204617; DB04841; SDCCGSBI-0050510.P004; IDI1_000043; IDI1_033811; NCGC00018102-04; NCGC00018102-05; NCGC00018102-07; NCGC00018102-08; NCGC00018102-09; NCGC00018102-10; NCGC00018102-12; NCGC00018102-24; NCGC00024308-04; NCGC00024308-05; NCGC00024308-06; NCGC00024308-07; ST024768; SBI-0050510.P003; D07971; AB00053586-15; AB00053586_16; AB00053586_17; 118378-EP2270011A1; 118378-EP2275420A1; 118378-EP2280008A2; 118378-EP2298764A1; 118378-EP2298765A1; Q416237; 1-[bis-(4-Fluorophenyl)methyl]-4-cinnamylpiperazine; BRD-K12184470-300-01-8; BRD-K29582677-001-02-7; BRD-K29582677-300-05-6; BRD-K29582677-300-06-4; 1-[Bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine; 1-[Bis-(4-fluoro-phenyl)-methyl]-4-((E)-3-phenyl-allyl)-piperazine; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]-; 1-[Bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine(Flunarizine)" Small molecule "1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+" SMANXXCATUTDDT-QPJJXVBHSA-N C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F C26H26F2N2 CAS 52468-60-7 CHEBI:92209 . . . DB04841 . DR8796 Azoles D0S1HI D0S1HI Investigative Trypanosomiasis ICD-11: 1D51-1F53 CID: 699591 Anticancer Treatment "5-(4-fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole; 421581-70-6; Azoles; ACMC-209jo2; Cambridge id 6767136; ZINC78448; DTXSID90351417; ANW-29760; MFCD03142768; STK140413; AKOS001657153; MCULE-6698398368; V5884; B-3616; SR-01000496544; SR-01000496544-1" Small molecule 1S/C14H8FN3O3/c15-11-6-4-9(5-7-11)14-16-13(17-21-14)10-2-1-3-12(8-10)18(19)20/h1-8H PHSKMUVSVYQIRN-UHFFFAOYSA-N C1=CC(=CC(=C1)[N+](=O)[O-])C2=NOC(=N2)C3=CC=C(C=C3)F C14H8FN3O3 CAS 421581-70-6 . . . . . . DR3098 6-mercaptopurine D09UZO D09UZO Approved Mature B-cell lymphoma ICD-11: 2A85 CID: 667490 Anticancer Treatment "6-Mercaptopurine; mercaptopurine; 50-44-2; Purinethol; Mercapurin; 6-Thiopurine; Leukerin; Leupurin; Mercaleukin; 6-Thioxopurine; Puri-Nethol; Ismipur; 7H-purine-6-thiol; Mern; 6-Thiohypoxanthine; 6-Mercaptopurin; 6-Purinethiol; Purimethol; Purinethiol; 6-MP; 1,9-dihydro-6H-purine-6-thione; Purine-6-thiol; 3H-Purine-6-thiol; 6 MP; Mercaleukim; 9H-Purine-6-thiol; 1,7-Dihydro-6H-purine-6-thione; Hypoxanthine, thio-; Mercaptopurine (6-MP); 3,7-dihydropurine-6-thione; 6H-Purine-6-thione, 1,7-dihydro-; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Merkaptopuryna; Xaluprine; 6-Merkaptopurin; Purine, 6-mercapto-; 9H-Purine-6(1H)-thione; Mercaptopurine anhydrous; Purine-6(1H)-thione; NCI-C04886; 7-Mercapto-1,3,4,6-tetrazaindene; 1H-Purine, 6-mercapto-; NSC 755; U-4748; NSC-755; UNII-PKK6MUZ20G; Mercaptopurine;6-MP; NSC755; 3,7-dihydro-6H-purine-6-thione; Purinethol (TN); PKK6MUZ20G; 1,9-dihydropurine-6-thione; 1H-purine-6(7H)-thione.; CHEBI:2208; 157930-13-7; Mercaptopurine (VAN); DSSTox_CID_810; Mercaptopurin [German]; Merkaptopuryna [Polish]; 6-Merkaptopurin [Czech]; DSSTox_RID_75801; DSSTox_GSID_20810; Mercaptopurine (anhydrous); 157930-14-8; Mercaptopurinum [INN-Latin]; Mercaptopurina [INN-Spanish]; Purixan; thiohypoxanthine; Purine-6-thiol, monohydrate; CAS-50-44-2; SMR000544948; Mercaptopurine, 6-; CCRIS 2761; Mercaptopurine (INN); HSDB 3235; SR-05000001925; 1194-62-3; EINECS 200-037-4; NCIMech_000025; 9H-Purin-6-yl hydrosulfide; a thiopurine; Mercaptopurine;; Mercaptopurine [USAN:USP:INN]; PubChem9680; Spectrum_000921; ACMC-1AUNA; Spectrum2_000060; Spectrum3_000491; Spectrum4_000857; Spectrum5_000950; M0063; H-Purine-6(1H)-thione; Azathioprine EP Impurity B; SCHEMBL3893; CHEMBL1425; BSPBio_001981; KBioGR_001493; KBioGR_002363; KBioSS_001401; KBioSS_002366; AG-670/31547064; MLS001066623; MLS001304020; MLS001304953; MLS006011869; ARONIS27054; DivK1c_000493; SPECTRUM1500387; SPBio_000219; GTPL7226; SCHEMBL2790086; 7H-Purin-6-yl hydrosulfide #; DTXSID0020810; SCHEMBL12683725; CHEBI:50667; CHEBI:94796; HMS501I15; KBio1_000493; KBio2_001401; KBio2_002363; KBio2_003969; KBio2_004931; KBio2_006537; KBio2_007499; KBio3_001481; KBio3_002842; 7-Mercapto-1,4,6-tetrazaindene; cMAP_000033; NINDS_000493; 6,7-dihydro-3H-purine-6-thione; HMS1920L07; HMS2091B20; HMS2236L06; HMS3259N03; HMS3369M05; HMS3651G07; HMS3713N10; HMS3747A17; HMS3872N13; Pharmakon1600-01500387; ACT11542; EBD16256; ZINC4658290; [S]C1=NC=NC2=C1NC=N2; Tox21_111158; Tox21_202591; 6450AJ; ANW-30999; ANW-57555; BBL033743; BDBM50423778; CCG-35344; CCG-39915; EBD540779; MFCD00233552; NSC759614; s1305; SBB037953; STK727062; STL257085; 6-Mercaptopurine, analytical standard; WLN: T56 BM DN FN HNJ ISH; AKOS000170222; AKOS000275858; AKOS005224624; AKOS008901311; AKOS016903205; Tox21_111158_1; AM81386; CCG-266232; CS-1499; DB01033; LS20858; MCULE-4811219863; NC00613; NSC-759614; IDI1_000493; NCGC00091641-02; NCGC00091641-03; NCGC00091641-04; NCGC00094717-01; NCGC00094717-02; NCGC00094717-03; NCGC00094717-05; NCGC00094717-06; NCGC00188973-01; NCGC00188973-02; NCGC00260139-01; AC-11464; AS-13109; H348; HY-13677; NCI60_041653; SMR004703503; ST086505; ST086506; SBI-0051437.P004; AB0013000; AB0119973; DB-026398; BB 0241023; FT-0621175; SW199090-2; EN300-61517; 1766-EP2270008A1; 1766-EP2272827A1; 1766-EP2272832A1; 1766-EP2277876A1; 1766-EP2292614A1; 1766-EP2292617A1; 1766-EP2295409A1; 1766-EP2295426A1; 1766-EP2295427A1; 1766-EP2298768A1; 1766-EP2298778A1; 1766-EP2308833A2; 1766-EP2308855A1; 1766-EP2308861A1; 1766-EP2314590A1; 1766-EP2316834A1; 1766-EP2374454A1; 50M442; C01756; C02380; D04931; W-5114; 15150-EP2272827A1; 15150-EP2275420A1; 15150-EP2295055A2; 15150-EP2295416A2; 15150-EP2298748A2; 15150-EP2298764A1; 15150-EP2298765A1; 15150-EP2305642A2; 15150-EP2305679A1; 15150-EP2308833A2; 15150-EP2311453A1; 15150-EP2311825A1; 15150-EP2311840A1; 15150-EP2311842A2; 15150-EP2316832A1; 15150-EP2316833A1; 21414-EP2270006A1; 21414-EP2270014A1; 21414-EP2272509A1; 21414-EP2272847A1; 21414-EP2275413A1; 21414-EP2277874A1; 21414-EP2284158A1; 21414-EP2287156A1; 21414-EP2287159A1; 21414-EP2295439A1; 21414-EP2311818A1; 21414-EP2314295A1; AB00171799_05; AB00641894-03; AB00641894-04; AB00641894_05; AB00876276-13; 233D552; 462M721; 599M524; A828129; Q418529; SR-05000001925-1; SR-05000001925-2; W-105961; purine antimetabolite: inhibits nucleic acid replication; 1,9-Dihydropurine-6-thione DISCONTINUED, see M225450; Mercaptopurine; 7H-Purine-6-thiol; Azathioprine BP Impurity B; 157930-11-5" Small molecule "1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)" GLVAUDGFNGKCSF-UHFFFAOYSA-N C1=NC2=C(N1)C(=S)N=CN2 C5H4N4S CAS 50-44-2 CHEBI:2208 . . . DB01033 . DR6872 Nilotinib D00STL D00STL Approved Myeloproliferative neoplasm ICD-11: 2A20 CID: 644241 Anticancer Treatment "Nilotinib; 641571-10-0; Tasigna; AMN107; AMN 107; AMN-107; Nilotinib(AMN-107); Nilotinib (AMN-107); Nilotinib free base; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; UNII-F41401512X; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; CHEMBL255863; C28H22F3N7O; CHEBI:52172; Nilotinib-d6; 641571-10-0 (free base); MFCD09833716; NSC747599; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; F41401512X; 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; Nilotinib & its intermediates; nilotinibum; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; SMR002544680; Nilotinib [USAN:INN:BAN]; Nilotinib/; HSDB 7842; PubChem18272; 3gp0; Nilotinib (USAN/INN); EC 700-544-5; SCHEMBL7901; cc-353; MLS003915611; MLS006010160; GTPL5697; DTXSID5042663; QCR-112; SYN1057; BCPP000149; HMS3244A13; HMS3244A14; HMS3244B13; HMS3295A23; HMS3654M07; HMS3748E11; AOB87115; BCP01367; ZINC6716957; ABP000478; AC-647; ANW-41982; BDBM50237710; NSC800804; s1033; AKOS005063561; BCP9000989; CCG-264784; CS-0102; DB04868; NSC 747599; NSC-747599; NSC-800804; SB17315; NCGC00183285-01; NCGC00183285-03; NCGC00183285-04; NCGC00183285-09; NCGC00183285-15; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AK-59889; AS-16214; HY-10159; N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide; AB0007991; AM20090651; FT-0654026; SW218083-2; V0705; EC-000.2344; D08953; N-8207; S-6060; 49312-EP2270008A1; 49312-EP2292617A1; 49312-EP2305667A2; 49312-EP2311840A1; 78680-EP2305667A2; AB01273978-01; AB01273978-02; AB01273978_03; 139316-EP2270008A1; 139316-EP2292617A1; 571N100; Q412327; SR-01000931150; Q-101348; SR-01000931150-2; BRD-K81528515-001-04-7; 1353151-22-0; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI)" Small molecule "1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)" HHZIURLSWUIHRB-UHFFFAOYSA-N CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 C28H22F3N7O CAS 641571-10-0 CHEBI:52172 . . . DB04868 . DR3651 Micafungin D06TOE D06TOE Approved Candidosis ICD-11: 1F23 CID: 477468 Anticancer Treatment "Micafungin; Mycamine; 235114-32-6; UNII-R10H71BSWG; Micafungin [INN]; CHEBI:600520; R10H71BSWG; Micafungin (INN); Mycamine(TM); FK463; CHEMBL457547; SCHEMBL11893279; C56H71N9O23S; Pneumocandin A0, 1-((4R,5R)-4,5-dihydroxy-N2-(4-(5-(4-(pentyloxy)phenyl)-3-isoxazolyl)benzoyl]-L-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-L-threonine)-; BDBM50478216; DB01141; X7260; D08218; Z-3191; 114M326; J-015136; Q6827850; [5-[(1S,2S)-2-[[(1R)-3-amino-1-hydroxy-3-oxo-propyl]-tetrahydroxy-[(1R)-1-hydroxyethyl]-methyl-hexaoxo-[[4-[5-(4-pentoxyphenyl)isoxazol-3-yl]benzoyl]amino][?]yl]-1,2-dihydroxy-ethyl]-2-hydroxy-phenyl] hydrogen sulfate; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}" Small molecule "1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1" PIEUQSKUWLMALL-YABMTYFHSA-N CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O C56H71N9O23S CAS 235114-32-6 CHEBI:600520 . . . DB01141 . DR2271 Posaconazole D07ABV D07ABV Approved Aspergillosis ICD-11: 1F20 CID: 468595 Anticancer Treatment "Posaconazole; 171228-49-2; Noxafil; Sch 56592; SCH56592; SCH-56592; Posaconazole SP; Schering 56592; UNII-6TK1G07BHZ; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE; 6TK1G07BHZ; CHEMBL1397; CHEBI:64355; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; pasaconazole; Posaconazole [USAN:INN:BAN]; HSDB 7421; C37H42F2N8O4; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one; Noxafil (TN); Posaconazole solution; cc-165; SCHEMBL991747; Posaconazole (JAN/USAN/INN); DTXSID6049066; GTPL11428; AMY30591; BCP01102; ZINC3938482; BDBM50181473; CP0094; MFCD00941162; MMV688774; s1257; AKOS005145917; AC-1350; ACN-040495; CCG-270387; CS-0998; DB01263; KS-1413; PB30668; NCGC00274060-02; HY-17373; M842; Posaconazole in combination with MGCD290; AB0015409; P2477; SW219391-1; D02555; P-7020; Q-4359; AB01274762-01; AB01274762_02; Posaconazole, VETRANAL(TM), analytical standard; 228P492; Q906453; Posaconazole, Antibiotic for Culture Media Use Only; Posaconazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3R-(3alpha(1S*,2S*),5alpha))-; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-(4-(4-(4-(((3R,5R)-5-(3,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-1H-1,2,4-triazol-5(4H)-one; 4-(4-(4-(4-(((5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-(4-{4-[(R)-5-(2,4-difluoro-phenyl)-5-(4,5-dihydro-[1,2,4]triazol-1-ylmethyl)-tetrahydro-furan-3-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-((1S,2S)-1-ethyl-2-hydroxy-propyl)-2,4-dihydro-[1,2,4]triazol-3-one; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1S,2S)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-; PCZ" Small molecule "1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1" RAGOYPUPXAKGKH-XAKZXMRKSA-N CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F C37H42F2N8O4 CAS 171228-49-2 CHEBI:64355 . . . DB01263 . DR3952 MG132 . . Investigative Lung cancer ICD-11: 2C25 CID: 462382 Anticancer Treatment "MG-132; 133407-82-6; Z-Leu-leu-leu-al; MG132; MG 132; Zlllal; Z-LLL-CHO; Zlll-cho; Z-Leu-leu-leucinal; Z-Leu-Leu-Leu-H; Carbobenzoxy-leucyl-leucyl-leucinal; UNII-RF1P63GW3K; Benzyloxycarbonyl-leu-leu-leu-aldehyde; Benzyloxycarbonyl-leucyl-leucyl-leucinal; Carbobenzoxyl-leucinyl-leucinyl-leucinal-H; Cbz-Leu-Leu-Leu-H; C26H41N3O5; Benzyloxycarbonylleucyl-leucyl-leucine aldehyde; Z-Leu-Leu-Leu-aldehyde; RF1P63GW3K; Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal; CHEMBL64925; benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; Cbz-L-Leu-L-Leu-L-Leu-CHO; CHEBI:75142; MFCD00674886; Benzyl ((S)-4-methyl-1-(((S)-4-methyl-1-(((S)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)carbamate; Lll cpd; (S)-N-((Phenylmethoxy)carbonyl)-L-leucyl-N-(1-formyl-3-methylbutyl)-L-leucinamide; N-[(Benzyloxy)carbonyl]-L-Leucyl-N-[(2s)-4-Methyl-1-Oxopentan-2-Yl]-L-Leucinamide; BRD0970; BRD-0970; Z-LLL; N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide; (R)-MG132; (S)-MG132; N-[(benzyloxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide; Z-LLL-aldehyde; 1211877-36-9; Benzyl N-[(1S)-3-methyl-1-[[(1S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-pentan-2-yl]carbamoyl]butyl]carbamoyl]butyl]carbamate; Z-LLLal; Cbz-Leu-Leu-Leu-al; Cbz-Leu-Leu-Leucinal; Z-LLL-H; Z-L-leu-L-leu-L-leu-H; BSPBio_001310; carbobenzoxy-Leu-Leu-leucinal; KBioGR_000030; KBioSS_000030; cc-245; MLS006011220; Cbz-L-Leu-L-Leu-L-Leu-H; SCHEMBL160925; GTPL8616; DTXSID3042639; BCBcMAP01_000028; KBio2_000030; KBio2_002598; KBio2_005166; KBio3_000059; KBio3_000060; AOB4946; QCR-183; benzyloxycarbonyl-Leu-Leu-leucinal; Bio2_000030; Bio2_000510; HMS1361B12; HMS1791B12; HMS1989B12; HMS3402B12; AMY40914; EX-A1500; ABP000958; BDBM50069985; NSC782153; PI-102; s2619; ZINC13476439; AKOS027420457; MG132/MG-132/; ACN-047884; CCG-207860; CCG-208036; CS-0471; NSC-782153; SB19111; compound 5b [PMID: 16686537]; IDI1_033780; NCGC00161679-01; NCGC00161679-02; NCGC00161679-03; NCGC00161679-04; Z-Leu-Leu-Leu-al, >=90% (HPLC); AS-55854; HY-13259; SMR002530629; AB0033810; SW219780-1; UNM000011053701; X7579; W-5117; InSolution MG-132 - CAS 133407-82-6; n-benzyloxycarbonyl-l-leucyl-l-leucyl-l-leucinal; Q3272916; SR-01000864598-1; BRD-K60230970-001-04-3; BRD-K60230970-001-05-0; BRD-K60230970-001-06-8; BRD-K60230970-001-07-6; BRD-K60230970-001-08-4; BRD-K60230970-001-10-0; MG-132 - CAS 133407-82-6; MG-132, >/=95% by HPLC - CAS 133407-82-6; L-Leucinamide, N-((phenylmethoxy)carbonyl)-L-leucyl-N-((1S)-1-formyl-3-methylbutyl)-; L-Leucinamide, N-((phenylmethoxy)carbonyl)-L-leucyl-N-(1-formyl-3-methylbutyl)-, (S)-; L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N1-[(1S)-1-formyl-3-methylbutyl]-; N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-(1-formyl-3-methylbutyl)-(S)-L-leucinamide; (S)-4-methyl-2-(3-phenyl-propionylamino)-pentanoic acid [(S)-1-((S)-1-formyl-3-methyl-butylcarbamoyl)-3-methyl-butyl]-amide; {(S)-1-[(S)-1-((S)-1-Formyl-3-methyl-butylcarbamoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester; {1-[(S)-(S)-1-((S)-1-Formyl-3-methyl-butylcarbamoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester; {1-[1-(1-Formyl-3-methyl-butylcarbamoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester; benzyl N-[(1S)-1-[[(1S)-1-[[(1S)-1-formyl-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamate; benzyl(S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; phenylmethyl N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate" Small molecule "1S/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)/t21-,22-,23-/m0/s1" TZYWCYJVHRLUCT-VABKMULXSA-N CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 C26H41N3O5 CAS 133407-82-6 CHEBI:75142 . . . . . DR9949 Tiazofurin D0S7DV D0S7DV Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 457954 Anticancer Treatment "TIAZOFURIN; Tiazofurine; 60084-10-8; Riboxamide; 2-b-D-Ribofuranosyl-4-thiazolecarboxamide; Tiazofurinum; Tiazofurina; Tiazofurin [USAN]; TCAR; NSC-286193; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; UNII-ULJ82834RE; CI-909; Tiazofurine (INN); Tiazofurin (USAN); ULJ82834RE; CHEBI:90239; Tiazofurine [INN]; Tiazofurinum [Latin]; Tiazofurina [Spanish]; 2-(beta-D-ribofuranosyl)-4-thiazolecarboxamide; (1R)-1,4-anhydro-1-(4-carbamoyl-1,3-thiazol-2-yl)-D-ribitol; (1r)-1-[4-(Aminocarbonyl)-1,3-Thiazol-2-Yl]-1,4-Anhydro-D-Ribitol; 2-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)thiazole-4-carboxamide; BRN 1084555; Cpd-5825; 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]thiazole-4-carboxamide; 2-beta-D-Ribofuranosylthiazole-4-carboxamide; 4-Thiazolecarboxamide, 2-beta-D-ribofuranosyl-; SCHEMBL4287; DIBUTYLAMINEHYDROCHLORIDE; CHEMBL108358; DTXSID00208827; ZINC4217560; 8957AB; BDBM50368057; MFCD00866494; DB13243; BS-17271; C22196; D06130; 124722-EP2295426A1; 124722-EP2295427A1; Q7800305" Small molecule "1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1" FVRDYQYEVDDKCR-DBRKOABJSA-N C1=C(N=C(S1)C2C(C(C(O2)CO)O)O)C(=O)N C9H12N2O5S CAS 60084-10-8 CHEBI:90239 . . . DB13243 . DR4974 Ketoconazole D0B4IF D0B4IF Approved Fungal infection ICD-11: 1F29-1F2F CID: 456201 Anticancer Treatment "ketoconazole; 65277-42-1; (+)-Ketoconazole; (2R,4S)-ketoconazole; Kuric; Ketocanazole; CPD000058460; CHEMBL75; MFCD00058579; C26H28Cl2N4O4; SMR000058460; MLS000069784; MLS001146934; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine; 142128-59-4; CHEBI:48336; DSSTox_CID_9879; DSSTox_RID_78829; DSSTox_GSID_29879; 1-(4-(4-(((2R,4S)-2-((1H-IMIDAZOL-1-YL)METHYL)-2-(2,4-DICHLOROPHENYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)ETHANONE; R-41400; rac-trans-Ketoconazole; KTZ; SR-01000075626; SR-01000597381; Ketoconazole (k); Ketoconazole,(S); NCGC00016907-01; 83374-59-8; Prestwick_744; CAS-65277-42-1; Tocris-1103; Opera_ID_397; Prestwick0_000389; Prestwick1_000389; Prestwick2_000389; Prestwick3_000389; R 41,400; UPCMLD-DP138; SCHEMBL8407; Lopac0_000666; BSPBio_000577; MLS000758224; MLS001423987; MLS002207053; MLS002222255; BIDD:GT0696; US9150527, Ketoconazole; SPBio_002498; AMY917; BDBM8610; BPBio1_000635; DTXSID7029879; UPCMLD-DP138:001; BDBM60666; HY-B0105A; Ketoconazole, >=98% (HPLC); HMS1569M19; HMS2051A19; HMS2089N05; HMS2096M19; HMS2234H17; HMS3262E13; HMS3414J19; HMS3678J17; HMS3713M19; ZINC643138; BCP28528; Piperazine, (+/-)-1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel-; Ketoconazole 2.0 mg/ml in Methanol; Tox21_110676; Tox21_300267; Tox21_500666; EI-107; s1353; AKOS007930650; AB02344; CCG-100815; CS-1846; KS-1205; LP00666; MCULE-2726394491; NC00065; SDCCGSBI-0050645.P002; MRF-0000100; 24F2-1,25(OH)D3; NCGC00025000-01; NCGC00025000-02; NCGC00025000-03; NCGC00025000-04; NCGC00025000-05; NCGC00025000-06; NCGC00025000-07; NCGC00025000-08; NCGC00025000-09; NCGC00025000-10; NCGC00025000-14; NCGC00025000-16; NCGC00025000-28; NCGC00253967-01; NCGC00261351-01; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; AC-15957; cis-1-Acetyl-4-[4-[[2-(2,4-; AB0090681; Ketoconazole 100 microg/mL in Acetonitrile; EU-0100666; K0045; SW196888-4; BIM-0050645.0001; J10202; K 1003; W-2941; 277K421; Ketoconazole, Antibiotic for Culture Media Use Only; Q-201267; SR-01000075626-1; SR-01000075626-4; SR-01000597381-1; SR-01000597381-6; BRD-K29113274-001-03-6; BRD-K29113274-001-11-9; BRD-K29113274-001-21-8; Q27121163; Ketoconazole, British Pharmacopoeia (BP) Reference Standard; UNII-R9400W927I component XMAYWYJOQHXEEK-OZXSUGGESA-N; Ketoconazole, European Pharmacopoeia (EP) Reference Standard; Ketoconazole, United States Pharmacopeia (USP) Reference Standard; dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Ketoconazole, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (2R,4S)-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine; 1-(4-(4-(((2R,4S)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethan-1-one; 1-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one; cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy]phenyl]piperazine; Ethanone, 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]-; KZ; Piperazine, (+)-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-" Small molecule "1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1" XMAYWYJOQHXEEK-OZXSUGGESA-N CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl C26H28Cl2N4O4 CAS 65277-42-1 CHEBI:48336 . . . DB01026 . DR1293 Clindamycin D0R0ZL D0R0ZL Approved Acne vulgaris ICD-11: ED80 CID: 446598 Anticancer Treatment "clindamycin; 18323-44-9; Chlolincocin; Dalacine; Dalacin C; Sobelin; Cleocin; UNII-3U02EL437C; 7-Chlorolincomycin; 7-Chloro-7-deoxylincomycin; Clindamycine; Antirobe; Klimicin; ClindaDerm; 3U02EL437C; U 21251; U-21251; U-21,251; Klindan 300; 7(S)-Chloro-7-deoxylincomycin; 7-Deoxy-7(S)-chlorolincomycin; (2S,4R)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; Clindamycine [French]; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Clindamicina [INN-Spanish]; 7-CDL; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; methyl 7-chloro-6,7,8-trideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-L-threo-alpha-D-galacto-octopyranoside; Clindamicina; Clindamycinum; L-threo-a-D-galacto-Octopyranoside, methyl7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; C18H33ClN2O5S; Clindamycin [USAN:INN:BAN]; SR-05000001477; HSDB 3037; Clindamycin,(S); (2S,4R)-N-[(1S,2S)-2-chloranyl-1-[(2R,3R,4S,5R,6R)-6-methylsulfanyl-3,4,5-tris(oxidanyl)oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-2-oxanyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; EINECS 242-209-1; CLDM; NSC305832; Clindamycin (USAN/INN); SCHEMBL3154; CHEMBL1753; CLINDA & IL-12; BIDD:GT0418; Clindamycin & Interleukin 12; DTXSID2022836; GTPL10607; HMS2089A05; HMS2089N16; HY-B1455; ZINC4038341; 2327AH; CC0170; AM84752; CCG-268941; CS-11147; L-threo-.alpha.-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-; CS-0013163; 58207-19-5; C06914; D00277; AB01275425-01; AB01275425_02; 323C449; A812757; A831786; SR-05000001477-1; L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-((((2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-; L-threo-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-; methyl 7-chloro-6,7,8-trideoxy-6-({[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl}amino)-1-thio-L-threo-alpha-D-galacto-octopyranoside" Small molecule "1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1" KDLRVYVGXIQJDK-AWPVFWJPSA-N CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl C18H33ClN2O5S CAS 18323-44-9 . . . . DB01190 . DR0928 Dithiothreitol . . Investigative Cholestasis ICD-11: DC10 CID: 446094 Anticancer Treatment "Dithiothreitol; DL-1,4-Dithiothreitol; dl-Dithiothreitol; 3483-12-3; (2S,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL; 1,4-Dithiothreitol; D-1,4-Dithiothreitol; D-Dtt; 1,4-Dithiothreithol; Cleland's reagent; (2S,3S)-1,4-disulfanylbutane-2,3-diol; 27565-41-9; DTT; MFCD00004877; D-threo-1,4-Dimercapto-2,3-butanediol; threo-1,4-Dimercapto-2,3-butanediol; CHEBI:42170; (2S,3S)-1,4-bis(sulfanyl)butane-2,3-diol; cis-2,3-Dihydroxy-1,4-butanedithiol; Sputolysin; rac-Dithiothreitol; DL-1,4-Dithiothreitol, 98%, pure; DTV; DL-1,4-Dithiothreitol, 99%, for biochemistry; dithio threitol; DL-1,4-Dithiothreitol, for biochemistry, 1M solution in water; D-Dithiothreitol; WR 34678; (R*,R*)-1,4-Dimercaptobutane-2,3-diol; Reagents, Cleland's; 2,3-Butanediol, 1,4-dimercapto-, (R*,R*)-; (+/-)-Dithiothreitol; DL-Dithiothreitol, 99%; DL-Dithiothreitol, powder; DTT (threitol derivative); DTT, 1,4-Dithiothreitol; D,L-Dithiothreitol (DTT); SCHEMBL10601; CHEMBL1232392; DL-Dithiothreitol, >=99.0%; DTXSID5041017; Dithiothreitol, biochemical grade; ZINC3852211; EINECS 240-263-0; ETHYL4-NITRO-L-PHENYLALANINE; EBD485460; AKOS005259570; AKOS015855399; AT-2091; CCG-207964; DB02184; DL-Dithiothreitol, >=99.0% (RT); Threitol, 1,4-dithio- (7CI,8CI); BRN 2036371; Threitol, 1,4-dithio-, L- (8CI); threo-2,3-Dihydroxy-1,4-butanedithiol; DL-1,4-Dimercapto-2,3-dihydroxybutane; DTT, Dithiothreitol (Cleland's Reagenz); (+/-)-1,4-Dimercapto-2,3-butanediol; 35454-97-8; AS-57473; DL-Dithiothreitol solution, 1 M in H2O; B7294; X4647; 1698-EP2270001A1; 1698-EP2270004A1; 1698-EP2270008A1; 1698-EP2270014A1; 1698-EP2272516A2; 1698-EP2272827A1; 1698-EP2272972A1; 1698-EP2272973A1; 1698-EP2275102A1; 1698-EP2275412A1; 1698-EP2275413A1; 1698-EP2275414A1; 1698-EP2277867A2; 1698-EP2277872A1; 1698-EP2277876A1; 1698-EP2277881A1; 1698-EP2280003A2; 1698-EP2280011A1; 1698-EP2280012A2; 1698-EP2281563A1; 1698-EP2284178A2; 1698-EP2284179A2; 1698-EP2287155A1; 1698-EP2287156A1; 1698-EP2289893A1; 1698-EP2289894A2; 1698-EP2292593A2; 1698-EP2292614A1; 1698-EP2292617A1; 1698-EP2295406A1; 1698-EP2295410A1; 1698-EP2295412A1; 1698-EP2295413A1; 1698-EP2295432A1; 1698-EP2295550A2; 1698-EP2298305A1; 1698-EP2298743A1; 1698-EP2298744A2; 1698-EP2298772A1; 1698-EP2298779A1; 1698-EP2298783A1; 1698-EP2301928A1; 1698-EP2301939A1; 1698-EP2305250A1; 1698-EP2305682A1; 1698-EP2305687A1; 1698-EP2305808A1; 1698-EP2305825A1; 1698-EP2308839A1; 1698-EP2308855A1; 1698-EP2308877A1; 1698-EP2308879A1; 1698-EP2308880A1; 1698-EP2308883A1; 1698-EP2311807A1; 1698-EP2311814A1; 1698-EP2311818A1; 1698-EP2311825A1; 1698-EP2311829A1; 1698-EP2311837A1; 1698-EP2311842A2; 1698-EP2314576A1; 1698-EP2316459A1; 1698-EP2316835A1; DL-Dithiothreitol, BioUltra, >=99.0% (RT); DL-Dithiothreitol, for electrophoresis, >=99%; M02712; M02716; (R-(R*,R*))-1,4-Dimercaptobutane-2,3-diol; A822424; DL-Dithiothreitol, SAJ special grade, >=98.0%; DL-Dithiothreitol, Vetec(TM) reagent grade, 98%; Q414783; (+/-) Dithiothreitol molecular biology grade >99%; 2,3-BUTANEDIOL, 1,4-DIMERCAPTO-, L-threo-; DL-Dithiothreitol, BioXtra, >=99.0% (titration); 2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel- (9CI); DL-Dithiothreitol, >=98% (HPLC), >=99.0% (titration); UNII-T8ID5YZU6Y component VHJLVAABSRFDPM-QWWZWVQMSA-N; 2,3-Butanediol, 1,4-dimercapto-, (R-(R*,R*))- (9CI); DL-Dithiothreitol; Cleland inverted exclamation mark s reagent; DL-Dithiothreitol, BioUltra, for molecular biology, >=99.5% (RT); DL-Dithiothreitol solution, BioUltra, for molecular biology, ~1 M in H2O; DL-Dithiothreitol, for molecular biology, >=98% (HPLC), >=99% (titration); Cleland's Reagent DTT racemic '(+/-)-threo-1,4-Dimercapto-2,3-butanediol' C4H10O2S2 154.25 40-43 degrees 125-130 degrees /12mm >110 degrees (230 degrees F) 3483-12-3 '14,3376' 222-468-7 MFCD00004877 EK1610000 Y" Small molecule "1S/C4H10O2S2/c5-3(1-7)4(6)2-8/h3-8H,1-2H2/t3-,4-/m1/s1" VHJLVAABSRFDPM-QWWZWVQMSA-N C(C(C(CS)O)O)S C4H10O2S2 CAS 3483-12-3 CHEBI:42170 . . . DB01692 . DR1791 Tacrolimus D06OMK D06OMK Approved Transplant rejection ICD-11: NE84 CID: 445643 Anticancer Treatment "tacrolimus; Fujimycin; Prograf; 104987-11-3; Protopic; FK506; Tacrolimus anhydrous; Advagraf; Modigraf; Protopy; Fk-506; LCP-Tacro; Anhydrous Tacrolimus; tacrolimus (fk506); FK 506; FR-900506; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; UNII-Y5L2157C4J; Astagraf XL; FR 900506; (-)-FK 506; Tsukubaenolide; Prograf (TN); FR900506; CHEMBL269732; CHEBI:61049; Y5L2157C4J; K506; NCGC00163470-03; Prograft; Avagraf; Envarsus; Graceptor; Envarsus XR; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)tetrone; Tacrolimus (INN); Tacrolimus [USAN]; Tacrolimus, anhydrous; MFCD11045918; Tacrolimus (anhydrous); SR-05000001879; Tacrolimus [USAN:INN]; Hecoria; Talymus; CCRIS 7124; MFCD00869853; HSDB 8195; C44H69NO12; L 679934; FK-506/Tacrolimus; PubChem18875; FK-506 (Tacrolimus); SCHEMBL3088; DSSTox_CID_26354; DSSTox_RID_81557; DSSTox_GSID_46354; BSPBio_001279; CHEMBL66247; L-679934; GTPL6784; DTXSID5046354; CHEBI:93221; HMS503O21; HMS1792O21; HMS1990O21; HMS2093M19; HMS3403O21; Pharmakon1600-01503968; EX-A1677; Tox21_112056; ABP000474; BDBM50030448; BDBM50079777; LMPK04000003; NSC758659; s5003; AKOS005145901; ZINC169289411; AC-1182; AM81227; AT-2441; CCG-270494; CS-1507; DB00864; NSC-758659; IDI1_001040; NCGC00163470-01; NCGC00163470-02; NCGC00163470-04; NCGC00163470-05; NCGC00163470-06; NCGC00163470-07; NCGC00163470-27; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; HY-13756; Fujimycin; ; ; FK-506; ; ; FR-900506; SBI-0052894.P002; AB0012538; CAS-104987-11-3; M2258; C01375; D08556; W-1246; AB01209746-01; AB01209746_03; 581T933; Q411648; Q-201775; SR-05000001879-1; SR-05000001879-2; SR-05000001879-5; BRD-K35452788-001-02-1; BRD-K69608737-001-03-7; BRD-K69608737-001-10-2; [(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,; (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-prop-2-en-1-yl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; (E)-(1R,9S,12S,13R,14R,21S,23S,24R,25S,27R)-17-Allyl-1,14-dihydroxy-12-[(E)-2-((3R,4R)-4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-, (3S-(3R*(E(1S*,3S*,4S*)),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*))-; 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyc; 4,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-heptadecahydro-5,19-dihydroxy-3-; dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-,(3S,4R,5S,8R,12S,14S,15R,16S,18R,19R,26aS)-; lohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-; Tacrolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material" Small molecule "1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1" QJJXYPPXXYFBGM-LFZNUXCKSA-N CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC C44H69NO12 CAS 104987-11-3 CHEBI:61049 . . . DB00864 . DR5834 Docosahexaenoic acid D0Q5XX D0Q5XX Approved Hyper-lipoproteinaemia ICD-11: 5C80 CID: 445580 Anticancer Treatment "Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; all-cis-DHA; Doconexento; Doconexentum; Doxonexent; Docosahexaenoate; cis-4,7,10,13,16,19-Docosahexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; UNII-ZAD9OKH9JC; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID; 4,7,10,13,16,19-Docosahexaenoic acid, (all-Z)-; CHEMBL367149; docosahexaenoic acid(DHA); CHEBI:28125; delta4,7,10,13,16,19-Docosahexaenoic acid; 4-cis,7-cis,10-cis,13-cis,16-cis,19-cis-Docosahexaenoic acid; 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-Docosahexaenoic acid; (all-Z)-4,7,10,13,16,19-Docosahexaenoic acid; OMEGA-3 MARINE TRIGLYCERIDES; MFCD00065722; efalex; NCGC00161345-04; DOCOSAHEXAENOIC ACID (22:6 n-3); 22:6(n-3); cis-4,7,10,13,16,19-Docosahexanoic acid; 4,7,10,13,16,19-Docosahexaenoic acid; C22:6n-3,6,9,12,15,18; Monolife 50; Doconexent [INN]; Marinol D 50TG; 4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)-; SR-05000002130; Doconexentum [INN-Latin]; Doconexento [INN-Spanish]; DHA-[21,21,22,22,22-d5]; Cervonate; 1fdq; FA 22:6; Algal DHA; cis-4,7,13,16,19-docosahexaenoic acid; Omega 3 fatty acid; all-Z-Docosahexaenoate; Cervonic acid; ; ; DHA; Spectrum5_002062; Docosahexaenoic acid (6CI); DSSTox_CID_20465; DSSTox_RID_79498; DSSTox_GSID_40465; SCHEMBL19577; BSPBio_001298; Docoshexaenoic Acid (Powder); MLS004773950; BML3-B02; GTPL1051; Retriacyl (proposed trade name); DTXSID5040465; BCBcMAP01_000145; HMS1361A20; HMS1791A20; HMS1989A20; HMS3402A20; HMS3649J15; HY-B2167; ZINC4474564; Tox21_111992; BDBM50210259; LMFA01030185; AKOS015962159; AC-1010; CCG-207958; CCG-208135; CS-6261; DB03756; KL-0761; IDI1_033768; 4,7,10,13,16,19-Docosahexaenoate; NCGC00161345-01; NCGC00161345-02; NCGC00161345-03; NCGC00161345-05; NCGC00161345-07; all cis- Docosahexaenoic acid (cis-DHA); M355; SMR001881493; CAS-6217-54-5; cis-4,7,10,13,16,19-Docosahexanoate; D2226; S6454; C06429; AB01563379_01; 217D545; Q423345; SR-05000002130-1; SR-05000002130-4; BRD-K39965020-001-02-6; 4,7,10,13,16,19-Docosahexaenoic acid, (all cis)-; A320050000; cis-4,7,10,13,16,19-Docosahexaenoic acid, >=98%; z,z,z,z,z,z-docosa-4,7,10,13,16,19-hexaenoic acid; (all-Z)-4,7,10,13,16,19-Docosahexaenoic Acid, DHA; 800E8E72-BBF4-46F7-A60B-B8F2B54669C7; C22H32O2 (cis-4,7,10,13,16,19-docosahexaenoic acid); UNII-71M78END5S component MBMBGCFOFBJSGT-KUBAVDMBSA-N; UNII-96GS7P39SN component MBMBGCFOFBJSGT-KUBAVDMBSA-N; UNII-9B22238JYI component MBMBGCFOFBJSGT-KUBAVDMBSA-N; UNII-F85N2YHE4E component MBMBGCFOFBJSGT-KUBAVDMBSA-N; 4,7,10,13,16,19-Docosahexaenoic acid, (all-Z)- (8CI); cis-4,7,10,13,16,19-Docosahexaenoic acid, analytical standard; (4Z,7Z,10Z,13Z,16Z, 19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10,13,16,19-hexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19- hexaenoic acid; cis-4,7,13,16,19-Docosahexaenoic acid (stabilized with vitamine E); 4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)- (9CI); 1024594-51-1; cis-4,7,10,13,16,19-Docosahexaenoic acid, 500 mug/mL in ethanol, certified reference material" Small molecule "1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-" MBMBGCFOFBJSGT-KUBAVDMBSA-N CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O C22H32O2 CAS 6217-54-5 CHEBI:28125 . . . DB03756 . DR6829 Linezolid D07UYO D07UYO Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 441401 Anticancer Treatment "linezolid; 165800-03-3; Zyvox; (S)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide; Zyvoxid; PNU-100766; U-100766; Zyvoxam; PNU 100766; U 100766; C16H20FN3O4; UNII-ISQ9I6J12J; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; CHEMBL126; ISQ9I6J12J; N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; CHEBI:63607; Linezolid, 98%; MFCD00937825; U-100,766; Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; N-{[(5s)-3-(3-Fluoro-4-Morpholin-4-Ylphenyl)-2-Oxo-1,3-Oxazolidin-5-Yl]methyl}acetamide; ZLD; Zivoxid; Zyvoxa; Acetamide, N-(((5S)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-; N-({(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholino-phenyl)-2-oxo-oxazolidin-5-yl]methyl]acetamide; SMR000466335; Zyvox (TN); HSDB 7478; SR-01000759376; Linezolid & VRC3375; Linezoid; Linezolid (JAN/USAN/INN); Linezolid [USAN:INN:BAN]; (S)-N-[[3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; NCGC00164628-01; Linezolid (Zyvox); N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide; PNU100766; 111GE017; CPD000466335; NDA 21-130 Zyvox (linezolid tablets); SCHEMBL5027; DSSTox_CID_26489; DSSTox_RID_81660; DSSTox_GSID_46489; cc-154; MLS000759444; MLS001424075; BIDD:GT0404; Benzotriazol-2-yl-acetonitrile; cid_441401; Linezolid (PNU-100766); QCR-88; DTXSID5046489; Linezolid, >=98% (HPLC); NDA 21-131 Zyvox for injection (linezolid injection); GTPL10827; SYN3021; (R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide; HMS2051F08; HMS2089K06; HMS3260C14; HMS3713K10; NDA 21-132 Zyvox oral suspension (linzolid oral suspension); BCP05586; ZINC2008866; Tox21_112246; Tox21_500096; BDBM50116067; s1408; AKOS016340522; AM84567; BCP9000855; CCG-101009; CS-0756; DB00601; KS-1178; NC00259; Acetamide, N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (S)-; Linezolid 100 microg/mL in Acetonitrile; NCGC00260781-01; NCGC00263531-03; NCGC00263531-05; NCGC00263531-10; HY-10394; AB0012049; CAS-165800-03-3; SW197639-3; C08146; D00947; J90009; M-8338; AB00639994-06; AB00639994-08; AB00639994-09; AB00639994_10; AB00639994_11; 800L033; A810662; Q411377; Q-201308; SR-01000759376-4; SR-01000759376-5; Linezolid, United States Pharmacopeia (USP) Reference Standard; (S)-N-((3-fluoro-4-morpholinophenyl)-2-oxaoxazolidin-5-yl)methyl)acetamide; Linezolid, Pharmaceutical Secondary Standard; Certified Reference Material; (Linezolid)N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; (S)-N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; (S)-N-[ [3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-oxazolidin-5-yl]methyl]-acetamide; (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide; N-[(R)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[(S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide(linezolid); (S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-5-[(1-hydroxy-ethylamino)-methyl]-oxazolidin-2-one; N-((S)-2-oxo-3-(S)-2,3,3a,4-tetrahydro-1H-benzo[b]pyrrolo[1,2-d][1,4]oxazin-7-yl-oxazolidin-5-ylmethyl)-acetamide; N-[[(5S)-3-(3-fluoranyl-4-morpholin-4-yl-phenyl)-2-oxidanylidene-1,3-oxazolidin-5-yl]methyl]ethanamide" Small molecule "1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1" TYZROVQLWOKYKF-ZDUSSCGKSA-N CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F C16H20FN3O4 CAS 165800-03-3 CHEBI:63607 . . . DB00601 . DR8104 Cis-diamminedichloroplatinum . . Approved Ovarian cancer ICD-11: 2C73 CID: 441203 Anticancer Treatment "cis-Platin; cis-DDP; Cisplatine; Cisplatino; Cisplatinum; Lederplatin; Briplatin; Cismaplat; Neoplatin; Platamine; Platinex; Randa; trans-platin; cis-Dichlorodiammineplatinum(II); Peyrone's salt; cis-Diamminedichloroplatinum; Peyrone's chloride; trans-Platinum(II) ammonium chloride; cis-[PtCl2(NH3)2]; trans-Dichlorodiammine platinum; trans-Platinumdiammine dichloride; CHEBI:27899; CHEBI:35852; TRANS-DIAMMINEDICHLOROPLATINUM; trans-Platinum(II) diamminedichloride; trans-DDP, 8; Cisplatin, 1; Epitope ID:194799; Epitope ID:194800; BDBM92386; cis-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloroplatinum; trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloridoplatinum; AKOS025117566; DB00515; EU-0100918" Small molecule 1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+4/p-2 BSJGASKRWFKGMV-UHFFFAOYSA-L N.N.Cl[Pt+2]Cl Cl2H6N2Pt+2 CAS 15663-27-1 CHEBI:27899 . . . DB00515 . DR1137 Meropenem D0O5FY D0O5FY Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 441130 Anticancer Treatment "meropenem; 96036-03-2; Merrem; Meropenem anhydrous; Meropenemum; Antibiotic SM 7338; MERONEM; SM-7338; MEPM; 119478-56-7; UNII-YOP6PX0BAO; CHEBI:43968; Meropenemum [INN-Latin]; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem (INN); Meropenem [INN]; Meropenem Hydrate; YOP6PX0BAO; Merrem I.V.; ICI-194660; (4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4r,5s,6s)-3-{[(3s,5s)-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl}-6-[(1r)-1-Hydroxyethyl]-4-Methyl-7-Oxo-1-Azabicyclo[3.2.0]hept-2-Ene-2-Carboxylic Acid; 96036-03-2 (free); SM 7338; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; ICI 194,660; NCGC00016962-01; ICI 194660; DSSTox_CID_25526; DSSTox_RID_80930; DSSTox_GSID_45526; Meropen; (1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-YLTHIO]-6-[(R)-1-HYDROXYETHYL]-1-METHYLCARBAPEN-2-EM-3-CARBOXYLIC ACID; (4R,5S,6S)-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meronem (TN); CAS-96036-03-2; MFCD08600005; Merrem I.V. (TN); SR-01000762894; HSDB 8019; Merrem IV; Meropenem,(S); M2279; BRN 6940582; PubChem17275; Meropenem (closed form); Prestwick0_001106; Prestwick1_001106; Prestwick2_001106; Prestwick3_001106; CHEMBL127; Epitope ID:195064; SCHEMBL34442; BSPBio_001212; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; MLS001401437; BIDD:GT0851; 4-methyl-7-oxo-1-azabicyclo; SPBio_003086; BPBio1_001334; Meropenem with Sodium Carbonate; DTXSID7045526; GTPL10829; HMS1571M14; HMS2051G08; HMS2090C05; HMS2098M14; HMS3715M14; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-; AMY22192; ZINC3808779; 96036-03-2 (anhydr.); Tox21_110715; Tox21_113794; BDBM50129062; AKOS015920140; Tox21_110715_1; CCG-100850; CS-1865; DB00760; KS-5224; NC00100; [3.2.0]hept-2-ene-2-carboxylic acid; NCGC00179259-01; NCGC00179259-06; NCGC00179259-17; NCGC00253670-01; NCGC00262579-02; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid; HY-13678; SMR000469184; AB0012458; AB00514051; D08185; J10087; M05727; S-3680; AB00514051-02; AB00698370-05; pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-; 036M032; Q421670; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl); SR-01000762894-3; SR-01000762894-4; Meropenem trihydrate, Antibiotic for Culture Media Use Only; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[[(3S,5S)-5-(dimethylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(S*,5S*),4-alpha,5-beta,6-beta(R*)))-" Small molecule "1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1" DMJNNHOOLUXYBV-PQTSNVLCSA-N CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O C17H25N3O5S CAS 96036-03-2 CHEBI:43968 . . . DB00760 . DR8051 Quinidine . . Approved Supraventricular tachyarrhythmia ICD-11: BC81 CID: 441074 Anticancer Treatment "quinidine; 56-54-2; (+)-Quinidine; Conchinin; Chinidin; Pitayine; Quinidex; beta-Quinine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; Cin-Quin; Conquinine; Kinidin; Conchinine; chinidinum; quinidina; Quiniduran; Chinidine; Cinchonan-9-ol, 6'-methoxy-, (9S)-; UNII-ITX08688JL; Quinaglute; Auriquin; Quinidine sulfate; CHEBI:28593; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol; MFCD00135581; Quinicardine; CHEMBL1294; Cardioquin; Duraquin; Quinact; Quinalan; Quinatime; (1S)-(6-Methoxyquinolin-4-yl)((2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; Quinidine hydrochloride monohydrate; ITX08688JL; 6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; beta-Quinidine; (3'.alpha., 9S)-6'-Methoxycinchonan-9-ol; Quinidine, 98%, anhydrous; TCMDC-131239; NCI-C56246; (8R,9S)-6'-Methoxycinchonan-9-ol; (R)-(6-methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol; (S)-(6-methoxy-4-quinolyl)-[(2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol; (S)-[(4S,5R,7R)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol; Chinidin [German]; SMR000857275; Quinidine [BAN:NF]; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; Quinindine; CCRIS 672; HSDB 225; (S)-(6-methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; QDN; EINECS 200-279-0; Quinidine, anhydrous; PubChem7994; Prestwick3_000280; bmse000511; Epitope ID:141803; SCHEMBL15943; BSPBio_000160; MLS001335913; MLS001335914; MLS002548869; BPBio1_000176; GTPL2342; DTXSID4023549; SCHEMBL17537608; HMS2234L10; HMS3259O09; ACT09863; HY-B1751; ZINC3831405; (9S)-6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol (9S)-; BDBM50121975; RW2069; AKOS015920101; CCG-256507; CS-7812; DB00908; MCULE-7178915526; NC00478; SDCCGMLS-0066600.P001; NCGC00091231-01; NCGC00091231-02; NCGC00091231-03; AS-30538; AB00514657; 6470-EP1441224A2; 6470-EP2272835A1; 6470-EP2272844A1; 6470-EP2272972A1; 6470-EP2272973A1; 6470-EP2275411A2; 6470-EP2277872A1; 6470-EP2305655A2; 6470-EP2314576A1; 6470-EP2314585A1; M-7594; AB01562940_01; Q412496; W-109256; BRD-K59632282-052-01-5; BRD-K59632282-052-02-3; BRD-K70799801-311-02-7; Quinidine, crystallized, >=98.0% (dried material, NT); 101143-86-6" Small molecule "1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1" LOUPRKONTZGTKE-LHHVKLHASA-N COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O C20H24N2O2 CAS 56-54-2 CHEBI:28593 . . . DB00908 . DR2765 AT101 . . Phase 2 Prostate cancer ICD-11: 2C82 CID: 227456 Anticancer Treatment "Gossypol acetic acid; gossypol-Acetic acid; 12542-36-8; Gossypol acetate; Acetate gossypol; 866541-93-7; Gossypol (acetic acid); (-)-Gossypol acetic acid; GOSSYPOL-ACETIC ACID COMPLEX; AT101; 5453-04-3; (S)-Gossypol (acetic acid); NSC 19048; 1189561-66-7; Gossypol acetic acid clathrate; MLS000028630; MLS002702979; NSC19048; SMR000058743; 12542-36-8 (ACETIC ACID); acetic acid compound with (S)-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1:1); acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; (+/-)-Gossypol-acetic acid;BL 193 (acetic acid); (R)-Gossypol acetic acid; (S)-Gossypol acetic acid; NSC-19048; Gossypol acetate, (R)-; UNII-U9GNI6VT5N; Gossypol acetic acid, R-; AT-101 (acetic acid); R-(-)-gossypol acetic acid; Gossypol acetic acid, (R)-; Acetate-gossypol; Aceticacidgossypol; Gossypol xAcetate; Gossypol AcOH Salt; GOSSYPOLACETATE; AT 101 acetic acid; Opera_ID_1014; U9GNI6VT5N; SCHEMBL352576; (R)-Gossypol acetic acid salt; (S)-Gossypol acetic acid salt; CHEMBL1516388; HMS500I15; DTXSID90921593; HMS3651H13; BCP09006; BCP24040; C32H34O10; CCG-39212; CG0045; MFCD00058385; NSC727858; s2303; s2812; AKOS022188380; AT-101 (AT101); NSC-727858; NCGC00178279-01; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-(R)-5,5'-bis(1-methylethyl)-, (2R)-, compd. with acetic acid (1:1); AS-15487; HY-17510; P562; AB0017083; DB-081879; FT-0686636; FT-0768953; N2134; SW197103-3; A13578; A14795; A16323; 542G368; A800636; J-005228; (+/-)-Gossypol-acetic acid, analytical standard, crystalline complex consisting of equimolar quantities of gossypol and acetic acid, ~95%; 115038-46-5; 732279-26-4; acetic acid compound with 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthyl-8,8'-dicarbaldehyde (1:1); Acetic acid--1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1/1); acetic acid; 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-yl-2-naphthalenyl)-2,3,8-trihydroxy-6-methyl-4-propan-2-yl-1-naphthalenecarboxaldehyde; AT 101 acetic acid; AT101 acetic acid;AT-101 acetic acid; (-)-Gossypol acetic acid; (R)-Gossypol acetic acid; Gossypol acetic acid; ethanoic acid; 7-[8-methanoyl-3-methyl-1,6,7-tris(oxidanyl)-5-propan-2-yl-naphthalen-2-yl]-6-methyl-2,3,8-tris(oxidanyl)-4-propan-2-yl-naphthalene-1-carbaldehyde" Small molecule "1S/C30H30O8.C2H4O2/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36;1-2(3)4/h7-12,33-38H,1-6H3;1H3,(H,3,4)" NIOHNDKHQHVLKA-UHFFFAOYSA-N CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O.CC(=O)O C32H34O10 CAS 866541-93-7 . . . . . . DR6061 Lenalidomide D0Q5NX D0Q5NX Approved Multiple myeloma ICD-11: 2A83 CID: 216326 Anticancer Treatment "Lenalidomide; 191732-72-6; Revlimid; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; Lenalidomide (CC-5013); CDC 501; IMiD3; CC 5013; CDC-501; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Revlimid (TN); CHEBI:63791; C13H13N3O3; MFCD07772307; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; NCGC00167491-01; 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; DSSTox_CID_26664; DSSTox_RID_81806; DSSTox_GSID_46664; Revlimid (lenalidomide); 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione; CAS-191732-72-6; Lenalidomide (USAN/INN); Lenadoamide; Lenalidomide [USAN:INN:BAN]; (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; ENMD 0997; ENMD-0997; HSDB 8220; IMID-5013; CDC-5013; ALBB-015321; 1227162-34-6; PubChem19113; CHEMBL848; Revlimid (TN) (Celgene); SCHEMBL32978; MLS003899194; GTPL7331; SCHEMBL1980410; 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione; DTXSID8046664; BDBM65454; 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (3S)-; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; BCPP000186; HMS3654G07; HMS3674C05; BCP01390; HY-A0003; Revlimid, Lenalidomide, CC-5013; SYP-1512; Tox21_112492; ABP001089; AC-914; NSC747972; s1029; STK639603; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; AKOS005146276; AKOS005174869; Tox21_112492_1; ACN-034469; BCP9000847; CCG-264781; CS-0125; DB00480; KS-1207; MCULE-9771679074; NSC 747972; NSC-747972; NCGC00167491-02; NCGC00167491-03; NCGC00167491-04; AK-47482; SMR002529986; SY047646; AB0017965; AM20050439; FT-0659651; FT-0670758; FT-0670759; SW218084-2; T5245; EC-000.2340; D04687; S-4172; AB01273975-01; AB01273975-02; AB01273975_03; 732L726; Q425681; SR-01000883999; Q-101410; SR-01000883999-1; Z1741976709; 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)-2,6-piperidinedione; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one; 443912-14-9" Small molecule "1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)" GOTYRUGSSMKFNF-UHFFFAOYSA-N C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N C13H13N3O3 CAS 191732-72-6 CHEBI:63791 . . . DB00480 . DR1299 Paromomycin D04NDM D04NDM Approved Amoebiasis ICD-11: 1A36 CID: 165580 Anticancer Treatment "paromomycin; Aminosidin; catenulin; AMINOSIDINE; Neomycin E; Hydroxymycin; Zygomycin A1; Crestomycin; Paucimycin; Estomycin; Monomycin A; 7542-37-2; Paromomycine; Paromomycin I; Paramomycin Sulfate; Humatin; Paromomicina; Paromomycinum; Paucimycinum; Antibiotic 503-3; Antibiotic SF 767B; UNII-61JJC8N5ZK; Gabbromycin; Paromomycin (INN); Paromomycin [INN]; R 400; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; 61JJC8N5ZK; Amminosidin; Gabromycin; Humycin; Aminosidine I; Quintomycin C; CHEBI:7934; Antibiotic 2230D; paramomycin sulphate; R-400; Hydroxymycin sulfate; Paramomycin; Monomycin; Paromomycin (TN); Paromomycin sulfate Rx346208; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol; Aminosidine, sulfate; hATT & Paromomycin; Paromomycin [INN:BAN]; Paromomycine [INN-French]; Paromomycinum [INN-Latin]; Paromomicina [INN-Spanish]; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-hydroxy-cyclohexoxy]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-tetrahydropyran-3,4-diol; EINECS 231-423-0; BRN 0072285; Human .alpha.-1-antitrypsin & Paromomyin; SCHEMBL4072; 4-18-00-07534 (Beilstein Handbook Reference); CHEMBL370143; DTXSID8023424; ZINC60183170; AKOS030489917; DB01421; MCULE-1528618434; NCGC00166210-02; D-Streptamine, O-2-amino-2-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine; C00832; D07467; 10845-EP2301536A1; 10845-EP2301538A1; 10845-EP2311455A1; 10845-EP2316452A1; AB00639998_04; Q415625; PAROMOMYCIN I; AMMINOSIDIN; CATENULIN; CRESTOMYCIN; MONOMYCIN A; NEOMYCIN E; (2R,3S,4R,5R,6S)-5-amino-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}-2-(hydroxymethyl)oxane-3,4-diol; Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-O-beta-D-ribofuranosyl-(1-5)-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-" Small molecule "1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1" UOZODPSAJZTQNH-LSWIJEOBSA-N C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N C23H45N5O14 CAS 7542-37-2 CHEBI:7934 . . . DB01421 . DR4059 Methylseleninic acid . . Investigative Breast cancer ICD-11: 2C60 CID: 161597 Anticancer Treatment "Methaneseleninic acid; Methylselenic acid; Methylseleninic acid; 28274-57-9; methylseleninate; UNII-9900C6V162; CHEBI:77012; 9900C6V162; Methyl seleninic acid; Methaneseleninic acid, 95%; SCHEMBL772883; CHEMBL399906; DTXSID9040550; AKOS025296197; C18902; Q6823570" Small molecule "1S/CH4O2Se/c1-4(2)3/h1H3,(H,2,3)" UEQANLFPOFICBH-UHFFFAOYSA-N C[Se](=O)O CH4O2Se CAS 28274-57-9 CHEBI:77012 . . . . . DR2851 Telbivudine D0CL9S D0CL9S Approved Hepatitis virus infection ICD-11: 1E51 CID: 159269 Anticancer Treatment "Telbivudine; Epavudine; 2'-Deoxy-L-thymidine; L-Thymidine; beta-L-Thymidine; 3424-98-4; Telbivudin; Tyzeka; L-dT; L-Deoxythymidine; Sebivo; NV-02B; LDT600; beta-L-2'-Deoxythymidine; LdT; NV 02B; UNII-2OC4HKD3SF; CHEBI:63624; LDT-600; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2OC4HKD3SF; 26879-47-0; 1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-deoxy-beta-L-ribofuranosyl)-5-methyluracil; MFCD02683612; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; LLT; Tyzeka (TN); Telbivudine (USAN/INN); Telbivudine [USAN:INN:BAN]; 5-methyl-l-uridine; b-L-2'-deoxy-thymidine; SCHEMBL124279; Telbivudine (Sebivo, Tyzeka); CHEMBL374731; Epavudine;L-Thymidine;NV 02B; Thymine, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-; ZINC2159; Telbivudine, >=98% (HPLC); DTXSID30187813; AMY23971; HY-B0017; BDBM50088372; s1651; AKOS025117349; AC-5632; CCG-266887; CS-1934; DB01265; SB20806; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-Pyrimidinedione; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-b-L-erythro-pentofuranosyl)-5-methyl-; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-5-methyl-; NCGC00346560-01; NCGC00346560-06; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; AS-35209; SW220236-1; D06675; AB01274717-01; AB01274717_02; Q413621; BRD-K15976406-001-01-7; Thymine, 1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-; Z2574360267; 1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-((2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; L-thymidine; beta-L-thymidine; L-dT; 2'-deoxy-L-thymidine; 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione" Small molecule "1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1" IQFYYKKMVGJFEH-CSMHCCOUSA-N CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O C10H14N2O5 CAS 3424-98-4 CHEBI:63624 . . . DB01265 . DR8439 Naproxen D0DJ1B D0DJ1B Approved Osteoarthritis ICD-11: FA00-FA05 CID: 156391 Anticancer Treatment "NAPROXEN; 22204-53-1; (S)-Naproxen; (+)-Naproxen; Naprosyn; Equiproxen; Naproxene; Aleve; (S)-(+)-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; Laraflex; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; d-Naproxen; Naproxenum; Calosen; Naprosyne; Naproxeno; Nycopren; Bonyl; Naixan; Reuxen; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; naproxen(+); Acusprain; Anexopen; Arthrisil; Artrixen; Artroxen; Bipronyl; Clinosyn; Danaprox; Flexipen; Leniartil; Novonaprox; Anaprox; Apronax; Artagen; Atiflan; Congex; Daprox; Genoxen; Lefaine; Nafasol; Nalyxan; Napflam; Napmel; Naposin; Napren; Naprius; Veradol; Fuxen; Naxen; Naxyn; Xenar; Dysmenalgit N; Apo-Naproxen; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Floginax; (S)-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionic acid; RS-3540; Naprelan; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Dysmenalgit; Diocodal; (S)-2-(6-Methoxy-2-naphthyl)propanoic acid; Prexan; Apo-Napro-NA; d-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionsaeure; UNII-57Y76R9ATQ; (+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Proxen; CG 3117; CHEBI:7476; (2S)-2-(6-methoxy-2-naphthyl)propanoic acid; MFCD00010500; CHEMBL154; (+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Laser; 57Y76R9ATQ; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure; Naprium; Naprux; Propionic acid, 2-(6-methoxy-2-naphthyl)-, (+)-; Duk; Headlon; Napratec; Naprontag; Narocin; Naxopren; Prafena; Priaxen; Pronaxen; Rheumaflex; Saritilron; Sinartrin; Soproxen; Sutolin; Tohexen; Traumox; Flexen; Napxen; Noflam; Patxen; Rahsen; Sinton; Sutony; Velsay; Vinsen; Narma; Roxen; Anax; CAS-22204-53-1; Flanax Forte; Napren E; Naprosyn LLE; Proxen LE; Naxen F; Proxen LLE; U-Ritis; Naprosyn LLE Forte; (S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid; Naproxi 250; Naproxi 500; (alphas)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid; (S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; Naxyn 250; Naxyn 500; Equiproxen (Veterinary); Naproxene [INN-French]; Naproxenum [INN-Latin]; Naproxeno [INN-Spanish]; 26159-31-9; Xenar-CR; CCRIS 5265; HSDB 3369; EINECS 244-838-7; RS 3540; (S)-(+)-6-Methoxy-alp.-methyl-2-naphthalene acetic acid; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (S)-; Naprolag; Naprosine; Naprosy; Panoxen; Proxine; Mnpa; SR-01000075977; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (.alpha.S)-; DL Naproxen; Naprosyn (TN); Naproxen,(S); NPS; Prestwick_349; (+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]; Naproxen [USAN:USP:INN:BAN:JAN]; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]; PubChem8102; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)-; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)-; Spectrum_000977; 4or0; 4po0; (S)-(+)-Naproxene; Prestwick0_000791; Prestwick1_000791; Prestwick2_000791; Spectrum2_001043; Spectrum3_000514; Spectrum4_000069; Spectrum5_001327; (+)NAPROXEN; Naproxen2-(6-Methoxy-naphthalen-2-yl)-propionic acid; Epitope ID:139974; UPCMLD-DP001; 2-(6-Methoxy-naphthalen-2-yl)-propionic acid(Naproxen); EC 244-838-7; SCHEMBL3046; DSSTox_CID_20686; DSSTox_RID_79542; DSSTox_GSID_40686; Lopac0_000792; BSPBio_002067; KBioGR_000597; KBioSS_001457; ARONIS24306; BIDD:GT0062; DivK1c_000242; SPECTRUM1500425; Naproxen (JP17/USP/INN); SPBio_000966; SPBio_002861; GTPL5230; DTXSID4040686; UPCMLD-DP001:001; CMWTZPSULFXXJA-VIFPVBQESA-; HMS500M04; KBio1_000242; KBio2_001457; KBio2_004025; KBio2_006593; KBio3_001567; Naproxen 1.0 mg/ml in Methanol; PN400 COMPONENT NAPROXEN; NINDS_000242; HMS1920P13; HMS2089N21; HMS2091H12; HMS3649M13; HMS3886C15; Pharmakon1600-01500425; ZINC105216; ACT02593; Tox21_301953; ANW-24773; BDBM50339185; CCG-40130; NSC750183; NSC757239; AKOS005267223; AC-1363; DB00788; MCULE-2589082817; ME-0100; NSC 750183; NSC 757239; NSC-750183; NSC-757239; SDCCGSBI-0050769.P005; IDI1_000242; Naproxen 100 microg/mL in Acetonitrile; Naproxen solution 1.0 mg/ml in methanol; NCGC00016759-01; NCGC00016759-02; NCGC00016759-03; NCGC00021127-01; NCGC00161591-01; NCGC00255562-01; HY-15030; Naproxen, meets USP testing specifications; SBI-0050769.P004; AM20060551; M1021; S5177; W4580; Naproxen, VETRANAL(TM), analytical standard; (2S)-2-(6-Methoxynaphth-2-yl)propanoic acid; (S)-2-(6-methoxy-2-naphthyl)-propionic acid; 04N531; C01517; D00118; J10145; M-5280; (2S)-2-(6-methoxy(2-naphthyl))propanoic acid; AB00052049-04; AB00052049_05; (+)(S)2-(6-methoxy-2-naphthyl)-propionic acid; 2-(6-Methoxy-2-naphthyl)propanoic acid , (+)-; SR-01000003110; Q-201447; Q1215575; SR-01000003110-5; SR-01000075977-3; SR-01000075977-4; (+)-6-Methoxy-.alpha.-methyl-2-napthaleneacetic acid; BRD-K59197931-001-02-9; BRD-K59197931-001-03-7; BRD-K59197931-236-09-6; SR-01000075977-10; (+)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; (S)-(+)-2-(6-methoxy-naphthalen-2-yl)-propionic acid; (S)-6-Methoxy-.alpha.-methyl-2-naphthalene acetic acid; Naproxen, British Pharmacopoeia (BP) Reference Standard; Naproxen, European Pharmacopoeia (EP) Reference Standard; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid, 98%; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (+)-; Naproxen, United States Pharmacopeia (USP) Reference Standard; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI); Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material; Naproxen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 131991-52-1; d-Naproxen; (2S)-2-(6-Methoxynaphthalen-2-yl)propanoic acid; (S)-6-Methoxy-?-methyl-2-naphthaleneacetic Acid; d-2-(6-Methoxy-2-naphthyl)propionic Acid" Small molecule "1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1" CMWTZPSULFXXJA-VIFPVBQESA-N CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O C14H14O3 CAS 22204-53-1 CHEBI:7476 . . . DB00788 . DR6843 Bazedoxifene D0JY8T D0JY8T Approved Skeletal anomaly ICD-11: LD24 CID: 154257 Anticancer Treatment "Bazedoxifene; 198481-32-2; Conbriza; TSE-424; UNII-Q16TT9C5BK; Bazedoxifene free base; Q16TT9C5BK; 1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; CHEMBL46740; 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol; 198481-32-2 (free base); WAY 140424; Bazedoxifeno; C30H34N2O3; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol; 1H-Indol-5-ol, 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-; Bazedoxifene [INN]; Bazedoxifeno [INN-Spanish]; 1-{4-[2-(azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; 1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-; SCHEMBL41935; GTPL7355; DTXSID70173593; CHEBI:135947; HY-A0031; ZINC1895505; 3473AH; BDBM50099585; AKOS030255808; CS-0932; DB06401; SB19326; 1-[[4-[2-(AZEPAN-1-YL)ETHOXY]PHENYL]METHYL]-2-(4-HYDROXYPHENYL)-3-METHYL-INDOL-5-OL; 1-((4-(2-Hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; US8815934, No. 98; A15019; W-5320; AB01566901_01; J-012822; Q4875166" Small molecule "1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3" UCJGJABZCDBEDK-UHFFFAOYSA-N CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O C30H34N2O3 CAS 198481-32-2 CHEBI:135947 . . . DB06401 . DR7727 Ertapenem D0Q1MS D0Q1MS Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 150610 Anticancer Treatment "Ertapenem; 153832-46-3; Invanz; UNII-G32F6EID2H; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Invanz (TN); G32F6EID2H; C22H25N3O7S; CHEBI:404903; (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Ertapenem (INN); Ertapenem [INN:BAN]; HSDB 8020; (4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CHEMBL1359; SCHEMBL34454; GTPL10906; AOB6700; DTXSID50165456; ZINC3918453; AKOS015895077; AC-6814; DB00303; NCGC00387409-02; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl-4-methyl-7-oxo-, (4R,5S,6S)-; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-; D07908; 832E463; Q553220" Small molecule "1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1" JUZNIMUFDBIJCM-ANEDZVCMSA-N CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O C22H25N3O7S CAS 153832-46-3 CHEBI:404903 . . . DB00303 . DR7335 Pralatrexate D02LWU D02LWU Approved Breast cancer ICD-11: 2C60-2C65 CID: 148121 Anticancer Treatment "Pralatrexate; 146464-95-1; Folotyn; 10-Propargyl-10-deazaaminopterin; Pralatrexate(Folotyn); HSDB 7786; PDX; CHEBI:71223; N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid; 146464-95-1 (racemic); (2S)-2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioic acid; (2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid; NCGC00242596-01; (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid; (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid; N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid; L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-; N -(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid; Folotyn (TN); Pralatrexate [USAN:INN]; pralatrexato; pralatrexatum; Pralatrexate(Folotyn)/; DSSTox_CID_28504; DSSTox_RID_82776; N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-L-glutamic Acid; DSSTox_GSID_48578; SCHEMBL21633; GTPL6840; Pralatrexate (JAN/USAN/INN); CHEMBL1201746; DTXSID3048578; SCHEMBL15075302; BCPP000101; EX-A2142; Tox21_112906; 2667AH; ABP000543; BDBM50457437; MFCD00920897; NSC754230; s1497; AKOS015966891; AM84423; CCG-269517; CS-0504; DB06813; NSC 754230; NSC-754230; QC-3214; SB17353; 10-Propargyl-10-deazaaminopterin, 95%; NCGC00386226-01; AC-28388; BS-15438; HY-10446; AB0095450; CAS-146464-95-1; SW220187-1; D05589; AB00443251-02; AB00443251_04; 464P951; Q637059; SR-01000941578; J-008227; SR-01000941578-1; L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-" Small molecule "1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1" OGSBUKJUDHAQEA-WMCAAGNKSA-N C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O C23H23N7O5 CAS 146464-95-1 CHEBI:71223 . . . DB06813 . DR9657 Angiotensin-(1-7) D0MH8O D0MH8O Phase 3 Sarcoma ICD-11: 2A60-2C35 CID: 123805 Anticancer Treatment "Angiotensin (1-7); angiotensin 1-7; 51833-78-4; TXA127; Angiotensin i (1-7); Angiotensin II (1-7) heptapeptide; angiotensin-(1-7); angiotensin II (1-7); ASP-ARG-VAL-TYR-ILE-HIS-PRO; 8-Des-phe-angiotensin II; UNII-IJ3FUK8MOF; IJ3FUK8MOF; Angiotensin, Canine, Rat; CHEBI:55438; TXA-127; Ile(5)-angiotensin II (1-7); MFCD00153513; Ang-(1-7); 39386-80-6; L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline; L-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline; Angiotensin I/II (1-7); Human angiotensin-(1-7); 1-7-Human angiotensin II; Angiotensin II, des-phe(8)-; TXA 127; C41H62N12O11; AngiotensinI(1-7); Angiotensin II, des-phenylalanine(8)-; Angiotensin, canine, ra; ang 1-7; GTPL582; Ang(1-7); Angiotensin II, 5-L-isoleucine-8-de-L-phenylalanine-; GTPL5578; [Ile5]Angiotensin I (1-7); CHEMBL3545347; SCHEMBL15926158; BDBM85556; [125I]ang-(1-7); TXA127; Ang-(1-7); 3446AH; ZINC96077632; AKOS024456667; CS-3413; DB11720; Angiotensin (1-7) acetate salt hydrate; Angiotensin II, 8-de-L-phenylalanine-; NCGC00167219-01; HY-12403; C15850; [125I]angiotensin-(1-7) (human, mouse, rat); 833A784; Angiotensin I/II fragment 1-7 trifluoroacetate salt; Q27074464; H-Asp-Arg-Val-Tyr-Ile-His-Pro-OH trifluoroacetate salt; (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(3H-imidazol-4-yl)propanoyl]pyrrolidine-2-carboxylic acid; (S)-1-((6S,9S,12S,15S,18S)-18-((1H-imidazol-4-yl)methyl)-1-amino-6-((S)-2-amino-3-carboxypropanamido)-15-sec-butyl-12-(4-hydroxybenzyl)-1-imino-9-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecane)pyrrolidine-2-carboxylic acid" Small molecule "1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1" PVHLMTREZMEJCG-GDTLVBQBSA-N CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N C41H62N12O11 CAS 39386-80-6 CHEBI:55438 . . . . . DR2426 Mexidol . . Phase 3 Ischemic stroke ICD-11: 8B11 CID: 122298 Anticancer Treatment "mexidol; 127464-43-1; 2-Ethyl-6-methylpyridin-3-ol succinate; Emoxypine succinate; UNII-2R985002CT; 2-Ethyl-3-hydroxy-6-methylpyridine Succinate; 2-Ethyl-6-methyl-3-pyridinol succinate; butanedioic acid, compd. with 2-ethyl-6-methyl-3-pyridinol (1:1); 2R985002CT; 2-Ethyl-6-methyl-3-hydroxypyridine succinate; Emicidine; Mexidole; Butanedioic acid 2-ethyl-6-methyl-3-pyridinol (1:1); ACMC-20a84f; Cambridge id 5110148; SCHEMBL1010987; DTXSID30155577; BCP13396; ANW-61453; MFCD00445612; AKOS003239209; AK-41005; DS-13730; E1069; FT-0660570; X0082; 2-Ethyl-6-methyl-3-pyridinol succinate (salt); butanedioic acid;2-ethyl-6-methylpyridin-3-ol; butanedioic acid; 2-ethyl-6-methyl-3-pyridinol; butanedioic acid; 2-ethyl-6-methyl-pyridin-3-ol; 647M960; A805706; Q-100116; Q27255507" Small molecule "1S/C8H11NO.C4H6O4/c1-3-7-8(10)5-4-6(2)9-7;5-3(6)1-2-4(7)8/h4-5,10H,3H2,1-2H3;1-2H2,(H,5,6)(H,7,8)" IKMNOGHPKNFPTK-UHFFFAOYSA-N CCC1=C(C=CC(=N1)C)O.C(CC(=O)O)C(=O)O C12H17NO5 CAS 127464-43-1 . . . . . . DR1480 Parecoxib D05UWI D05UWI Phase 4 Gastrointestinal stromal tumor ICD-11: 2B5B CID: 119828 Anticancer Treatment "Parecoxib; 198470-84-7; Dynastat; SC-69124; SC 69124; CHEBI:73038; UNII-9TUW81Y3CE; N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; 9TUW81Y3CE; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide; Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-; Valus-P; Vorth-P; Parocoxib; Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-; N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide; parecoxibum; Parecoxib [USAN:INN:BAN]; Valdecoxib Impurity J; Parecoxib (USAN/INN); SCHEMBL9529; GTPL2895; CHEMBL1206690; DTXSID1044229; HMS3741C09; HMS3885L14; AMY42103; BCP07254; EX-A1993; ZINC5761797; BDBM50506744; CP0130; s4656; AKOS025401810; CCG-268299; CS-1959; DB08439; SC69124; NCGC00181773-03; NCGC00181773-05; NCGC00378576-02; Parecoxib 100 microg/mL in Acetonitrile; AC-25842; AS-72353; HY-17474; FT-0697932; Y1120; Parecoxib, VETRANAL(TM), analytical standard; D03716; Q347941; J-523329; BRD-K13800121-236-01-7; N-[4-(5-Methyl-3-phenyl-oxazol-4-yl)phenyl]sulfonylpropanamde; n-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-propanamide; n-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide; N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl}propanamide; N-[[4-(5-methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide; N-?[[4-?(5-?Methyl-?3-?phenyl-?4-?isoxazolyl)?phenyl]?sulfonyl]?propanamide; PXB" Small molecule "1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)" TZRHLKRLEZJVIJ-UHFFFAOYSA-N CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C C19H18N2O4S CAS 198470-84-7 CHEBI:73038 . . . DB08439 . DR6890 L-buthionine sulfoximine . . Phase 1 Brain cancer ICD-11: 2A00 CID: 119565 Anticancer Treatment "l-buthionine sulfoximine; L-Buthionine-sulfoximine; 83730-53-4; (2S)-2-Amino-4-(butylsulfonimidoyl)butanoic acid; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (2S)-; L-Buthionine-(S,R)-sulfoximine; BUTHIONINE SULFOXIME; (2S)-2-Amino-4-(S-butylsulfonimidoyl)butanoic Acid; MFCD00067000; NSC 326231; BRN 2367136; L-Buthionine-(S,R)-sulfoximine, 99%; l-buthionine(s,r)-sulfoximine; L-BSO; Buthionine sulfoximine, L-; L-Buthionine (SR)-sulfoximine; Buthionine-S,R-sulfoximine, L-; L-Buthionine-(S,R)-sulphoximine; NSC-381100; NCIMech_000342; BUTHIONINE-SULFOXIMINE; Lopac0_000221; SCHEMBL62034; CHEMBL261642; D,L-Buthionine-S,R-sulfoximine; CHEBI:94288; DTXSID70894150; HMS3260N03; BSO; Tox21_500221; BDBM50487312; NSC801426; s9728; 1-beta-DL-Buthionine(S,R)sulfoximine; AKOS027320570; CS-W020947; HY-106376A; LP00221; MCULE-5971306528; NSC-326231; NSC-801426; SDCCGSBI-0050209.P002; BSO (L-Buthionine-(S,R)-sulfoximine); NCGC00093690-01; NCGC00093690-02; NCGC00093690-03; NCGC00093690-11; NCGC00260906-01; AS-69850; L-Buthionine-sulfoximine, >=97% (TLC); EU-0100221; B 2515; SR-01000075712; SR-01000075712-1; BRD-A47706533-001-01-8; Q27166100; UNII-EEY8DZS103 component KJQFBVYMGADDTQ-JKYUHCHBSA-N; UNII-LW4108Q0BV component KJQFBVYMGADDTQ-JKYUHCHBSA-N; (R*,S*)-(+-)-2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; (2S)-2-AMINO-4-[BUTYL(IMINO)OXO-??-SULFANYL]BUTANOIC ACID; Butanoic acid, 2-amino-4-((R)-S-butylsulfonimidoyl)-, (2S)-rel-; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (R*,S*)-(+-)-; 97590-40-4" Small molecule "1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)/t7-,14?/m0/s1" KJQFBVYMGADDTQ-CVSPRKDYSA-N CCCCS(=N)(=O)CCC(C(=O)O)N C8H18N2O3S CAS 83730-53-4 CHEBI:94288 . . . . . DR4025 Efonidipine . . Investigative Diabetes mellitus ICD-11: 5A10 CID: 119171 Anticancer Treatment "Efonidipine; 111011-63-3; Efonidipine [INN]; Efonidipine (INN); NCGC00182046-01; NZ-105; 2-(Benzyl(phenyl)amino)ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; ( inverted exclamation markA)-2-[benzyl (phenyl) amino] ethyl 1,4-dihydro-2,6- dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethano; C34H38N3O7P; 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; DSSTox_CID_23988; DSSTox_RID_80095; DSSTox_GSID_43988; SCHEMBL49637; CHEMBL2074922; DTXSID9043988; CHEBI:146221; HMS3886A09; ACT06293; BCP14772; EX-A3998; Tox21_113418; 3603AH; AC-389; MFCD00865899; s4977; AKOS015967143; CCG-270291; CS-3623; DB09235; 2-(N-Benzylanilino)ethyl (+-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-5-phosphononicotinate, cyclic 2,2-dimethyltrimethylene ester; HY-12502; CAS-111011-63-3; FT-0748191; D07886; Q5347555; 2-(N-Benzylanilino)ethyl (- )-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-5-phosphononicotinate, cyclic 2,2-dimethyltrimethylene ester.; 2-(N-benzylanilino)ethyl 5-(5,5-dimethyl-2-oxo-1,3,2$l^{5-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2; E?-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2lambda(5)-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate" Small molecule "1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3" NSVFSAJIGAJDMR-UHFFFAOYSA-N CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5 C34H38N3O7P CAS 111011-63-3 CHEBI:146221 . . . DB09235 . DR1332 Perospirone D0F6GV D0F6GV Approved Psychotic disorder ICD-11: 6A20-6A25 CID: 115368 Anticancer Treatment "Perospirone; 150915-41-6; Lullan; UNII-N303OK87DT; N303OK87DT; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; C23H30N4O2S; 129273-38-7; cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)-1-piperazinyl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; Perospirone [INN]; (3aS,7aR)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; NCGC00164567-01; Perospirine; Lullan (Japan); SCHEMBL120579; GTPL7556; CHEMBL1472975; DTXSID2048163; CHEBI:94777; HY-B0731A; HMS3715H10; s5185; ZINC13828184; AKOS025311209; CCG-221234; DB08922; VA11509; MRF-0000147; 1H-Isoindole-1,3(2H)-dione,2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-,(3aR,7aS)-rel-; AS-14845; M813; CS-0019906; 73P387; AB00698486-07; A809087; J-008757; Q6590349; cis-N-[4-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]butyl]cyclohexane-1,2-dicarboximide; (3aR,7aS)-2-(4-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)butyl)hexahydro-1H-isoindole-1,3(2H)-dione; 1H-Isoindole-1,3(2H)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, (3aR,7aS)-rel-; 1H-Isoindole-1,3(2H)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, cis-" Small molecule "1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+" FBVFZWUMDDXLLG-HDICACEKSA-N C1CCC2C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54 C23H30N4O2S CAS 150915-41-6 CHEBI:94777 . . . DB08922 . DR9623 Tafenoquine D07TWN D07TWN Approved Malaria ICD-11: 1F41 CID: 115358 Anticancer Treatment "Tafenoquine; 106635-80-7; Etaquine; WR 238605; Tafenoquine free base; SB-252263-AAB; 106635-80-7 (free base); WR238605; 4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine; Krintafel; N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine; 1,4-Pentanediamine, N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-; SB-252263; Arakoda; Tafenoquine [USAN:INN:BAN]; 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-; N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine; Tafenoquine (USAN); (R)-N3-(2,6-Dimethoxy-4-methyl-5-(3-trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine; SCHEMBL347388; CHEMBL298470; GTPL9722; CHEBI:141487; EX-A3146; DB06608; SB16555; (RS)-N(sup 3)-(2,6-Dimethoxy-4-methyl-5-(3-trifluoro-methylphenoxy)quinolin-8-yl)pentane-1,4-diamine; HY-111529; CS-0042381; FT-0775258; D10490; Q2387553; N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]pentane-1,4-diamine; (+/-)-8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy) quinoline; (4-Amino-1-methylbutyl){2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy](8-quinolyl)}amine; N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine" Small molecule "1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3" LBHLFPGPEGDCJG-UHFFFAOYSA-N CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC C24H28F3N3O3 CAS 106635-80-7 CHEBI:141487 . . . DB06608 . DR0879 Carboxyamidotriazole D05IIP D05IIP Phase 3 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 108144 Anticancer Treatment "Carboxyamidotriazole; 99519-84-3; 5-amino-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide; CAI; L651582; L-651582; L-651,582; NSC-609974; 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide; L 651582; UNII-6ST3ZF52WB; NSC609974; MLS003373924; 6ST3ZF52WB; Carboxyamido-triazole; L-651582;CAI; SMR002048715; 1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-; 5-Amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1H-1,2,3-triazole-4-carboxamide; 4-CAI; NSC 609974; CCRIS 9404; Carboxiamidotriazol; 5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide; 5-amino-1-(4-[4-chlorobenzoyl]-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide; 5-amino-1-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide; 1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-; 5-AMINO-1-[[3,5-DICHLORO-4-(4-CHLOROBENZOYL)PHENYL]METHYL]-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE; PubChem13343; NCIStruc1_001699; NCIStruc2_001836; SCHEMBL18866; MLS006010700; CHEMBL95431; cid_108144; MERCK L651582; BDBM97191; DTXSID40244108; RFE-007; ZINC538116; CCG-37684; MFCD00866325; NCGC00014926; NCI609974; AKOS024457417; Carboxyamidotriazole, >=98% (HPLC); AC-6332; DB11960; SB17291; NCGC00014926-02; NCGC00014926-03; NCGC00098026-01; DA-38085; HY-16126; NCI60_004782; B7269; CS-0006152; FT-0740142; X7001; 519A843; SR-01000902267; Q5038072; SR-01000902267-2; 5-amino-1-[3,5-dichloro-4-(4-chlorobenzoyl)benzyl]triazole-4-carboxamide; 5-amino-1(4-[4-chlorobenzoyl]-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide; 5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)- 1,2,3-triazole-4-carboxamide; 5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)1,2,3-triazole-4-carboxamide; 5-amino-l-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)- 1,2,3-triazole-4-carboxamide; 1H-1,3-Triazole-4-carboxamide, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-; 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-4,5-dihydrotriazole-4-carboxamide; 5-amino-1-[[3,5-dichloro-4-[(4-chlorophenyl)-oxomethyl]phenyl]methyl]-4-triazolecarboxamide; 5-azanyl-1-[[3,5-bis(chloranyl)-4-(4-chlorophenyl)carbonyl-phenyl]methyl]-1,2,3-triazole-4-carboxamide" Small molecule "1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)" WNRZHQBJSXRYJK-UHFFFAOYSA-N C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl C17H12Cl3N5O2 CAS 99519-84-3 . . . . DB11960 . DR3286 FTY720 D0HI1K D0HI1K Phase 1 Psychoactive substances use disorder ICD-11: 6C4G CID: 107969 Anticancer Treatment "Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty 720; Fty-720; Fingolimod (hydrochloride); Fingolimod (FTY720) HCl; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; FTY720 free base; CHEBI:63112; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride; G926EC510T; MFCD00939512; Gilenya (TN); 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (1:1); FTY720 hydrochloride; Fingolimod-d4 Hydrochloride; 2-amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride.; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride; 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, hydrochloride; Fingolimod hydrochloride [USAN]; Fingolimod (FTY720); Imusera; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride; Fingolimod, HCl; FTY720,Fingolimod; Fin;limod hydrochloride; PubChem23815; FTY720 - Fingolimod; Fingolimod HClFTY-720; Epitope ID:156573; SCHEMBL81362; cc-329; MLS006010179; Fingolimod (FTY-720 HCl); FTY-720 HYDROCHLORIDE; CHEMBL544665; FTY-720A; Fingolimod hydrochloride FTY720; AOB7477; DTXSID00167364; EX-A960; TDI-132; 2-Amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol, HCl; BCPP000225; BCP01808; Fingolimod hydrochloride (JAN/USAN); s5002; AKOS005145784; AC-1929; AM84549; BCP9000705; CCG-265016; CS-0114; KS-1172; AK-33554; HY-12005; SMR004701287; SY057854; AB0018286; DB-014816; A8548; F1018; FT-0643569; SW219384-1; 162359-56-0 (HCl); EC-000.2314; A25158; D04187; J10426; W-5231; 359F560; SR-01000942237; Q-101363; SR-01000942237-2; Q27132395; 2-(4-octylphenethyl)-2-aminopropane-1,3-diol hydrochloride; 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride; 2-Amino-2-[2-(4-octylphenyl)-ethyl]-1,3-propanediol hydrochloride; 2-Amino-2-[2-(4-n-octylphenyl)ethyl]propane-1,3-diol Hydrochloride; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane -1,3-diol hydrochloride; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride" Small molecule "1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H" SWZTYAVBMYWFGS-UHFFFAOYSA-N CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl C19H34ClNO2 CAS 162359-56-0 CHEBI:63112 . . . DB08868 . DR0344 Imipenem D0H3TD D0H3TD Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 104838 Anticancer Treatment "imipenem; 64221-86-9; Imipemide; N-Formimidoylthienamycin; Tienamycin; Imipenem anhydrous; Imipenemum; N-formimidoyl thienamycin; imipen; MK 0787; CHEBI:471744; 74431-23-5; Imipenem, N-Formimidoyl thienamycin; UNII-Q20IM7HE75; Imipenem (INN); Primaxin; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; MK-0787; CHEMBL148; Q20IM7HE75; (5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; Imipenem [INN]; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Imipenen; DSSTox_CID_3143; DSSTox_RID_76888; DSSTox_GSID_23143; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-,(5R,6S)-; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, (5R,6S)-; Imipenemum [Latin]; CAS-64221-86-9; SR-05000000294; NCGC00016928-01; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-(2-methanimidamidoethylsulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-; Prestwick_844; EINECS 264-734-5; MK-787; MK0787; Prestwick0_000519; Prestwick1_000519; Prestwick2_000519; Prestwick3_000519; Epitope ID:120384; BSPBio_000477; cc-394; BIDD:GT0686; SPBio_002398; BPBio1_000525; SCHEMBL1649260; SCHEMBL8781920; DTXSID2023143; GTPL10821; Primaxin (imipenem + cilastatin); HMS1569H19; HMS2090A15; HMS2096H19; HMS3260H20; HMS3713H19; Pharmakon1600-01506001; BCP13012; ZINC4097225; Tox21_110689; Tox21_500279; BDBM50049708; BDBM50213266; NSC717864; NSC759901; AKOS016010844; Tox21_110689_1; CCG-220519; CCG-221583; DB01598; LP00279; NSC-717864; NSC-759901; SDCCGSBI-0633697.P001; NCGC00167958-01; NCGC00167958-02; NCGC00167958-03; NCGC00167958-05; NCGC00167958-09; NCGC00260964-01; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; AS-75130; C06665; D04515; X-2302; AB01563339_01; Recarbrio (imipenem + cilastatin + relebactam).; 847I667; Q425152; SR-05000000294-2; SR-05000000294-5; (5R,6S)-3-((2-formimidamidoethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-({2-[(E)-(aminomethylidene)amino]ethyl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-(2-formimidamidoethylthio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[(2-methanimidamidoethyl)sulfanyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2- [(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid monohydrate; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R-(5-alpha,6-alpha(R*)))-; 103730-39-8; 3-[(2-Aminoethyl)thio]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (4-nitrophenyl)methylester monohydrochloride compd. with 1-methyl-2-pyrrolidinone (1:1)" Small molecule "1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1" ZSKVGTPCRGIANV-ZXFLCMHBSA-N CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O C12H17N3O4S CAS 64221-86-9 CHEBI:471744 . . . DB01598 . DR4455 Mizoribine D0G5AG D0G5AG Approved Transplant rejection ICD-11: NE84 CID: 104762 Anticancer Treatment "mizoribine; 50924-49-7; Bredinin; HE-69; UNII-4JR41A10VP; MLS000028813; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-hydroxy-1H-imidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; SMR000058473; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide; 4JR41A10VP; Bredinine; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-beta-D-ribofuranosyl-; MFCD00057221; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide; 50524-49-7; NCGC00094087-01; Mizoribinum; Mizoribina; Mizoribine [INN:JAN]; DSSTox_CID_25777; DSSTox_RID_81119; DSSTox_GSID_45777; Mizoribinum [INN-Latin]; Mizoribina [INN-Spanish]; Bredinin (TN); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide; CAS-50924-49-7; SR-01000075989; BRN 4151713; 4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; HE 69; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; Mizoribine(Bredinin); NSC 289637; HS-0046; Mizoribine (Bredinin); Opera_ID_1558; Spectrum2_001559; Spectrum3_000739; Spectrum4_000220; Spectrum5_001671; Mizoribine (JP17/INN); M 3047; SCHEMBL7118; Lopac0_000745; BSPBio_002298; KBioGR_000859; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-b-D-ribofuranosyl-; MLS001076272; MLS006010038; DivK1c_000948; SPBio_001438; CHEMBL245019; cid_104762; Mizoribine, >=98% (TLC); DTXSID8045777; BDBM68669; CHEBI:31858; HMS502P10; KBio1_000948; KBio3_001518; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; NINDS_000948; HMS2230D04; HMS3262E12; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imida-zole-4-carboxamide; EX-A2256; ZINC3812887; Tox21_111242; Tox21_500745; CCG-39778; QC-367; s1384; AKOS015994615; Tox21_111242_1; AC-5266; BCP9000933; CS-1823; DB12617; LP00745; SDCCGSBI-0050723.P004; IDI1_000948; SMP1_000195; NCGC00094087-02; NCGC00094087-03; NCGC00094087-04; NCGC00094087-05; NCGC00261430-01; HY-17470; Q571; BCP0726000318; SBI-0050723.P003; AB0017672; EU-0100745; M2399; A10597; A16794; D01392; AB00053323_12; AB00053323_13; 924M497; J-700185; Q6884708; SR-01000075989-1; SR-01000075989-4; 1-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; 4-Carbamoyl-1-(beta-D-ribofuranosyl)-5-oxylatoimidazolium; 5-hydroxy-1-b-D-ribofuranosyl-1H-Imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-hydroxy-4-imidazolecarboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-5-oxidanyl-imidazole-4-carboxamide; Bredinin; ; ; HE-69; ; ; NSC-289637; ; ; 1-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide" Small molecule "1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1" HZQDCMWJEBCWBR-UUOKFMHZSA-N C1=NC(=C(N1C2C(C(C(O2)CO)O)O)O)C(=O)N C9H13N3O6 CAS 50924-49-7 CHEBI:31858 . . . DB12617 . DR2378 Uftoral D0Y8PT D0Y8PT Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 104747 Anticancer Treatment "Tegafur-Uracil; Ufur; Uftoral; 74578-38-4; UFT; Youfuding; Uracil-Tegafur; orzel; Tegafur - uracil mixture; Tegafur / uracil; UFT(R) drug; FT mixt. with uracil (1:4); Uracil mixt. with FT (4:1); Tegafur Mixture With With Uracil; Tegafur mixt. with uracil (1:4); Uracil mixt. with tegafur (4:1); Tegafur/uracil; Tegafur and uracil; Uftoral (TN); 1-(2-Tetrahydrofuryl)-5-fluorouracil mixt. with uracil (1:4); Uracil mixt. with 1-(2-tetrahydrofuryl)-5-fluorouracil (4:1); SCHEMBL8228; DTXSID3023635; Uracil, 5-fluoro-1-(tetrahydro-2-furyl)- mixt. with uracil (1:4); DB09327; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4(1H,3H)-pyrimidinedione; D02131; 117638-EP2270505A1; 117638-EP2295426A1; 117638-EP2295427A1; 117638-EP2298768A1; Q27098002; 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione - pyrimidine-2,4(1H,3H)-dione (1:1)" Small molecule "1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)" DHMYGZIEILLVNR-UHFFFAOYSA-N C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O C12H13FN4O5 CAS 74578-38-4 . . . . . . DR6343 Lobeline D01IVE D01IVE Phase 2 Unspecific substance use disorder ICD-11: 6C4Z CID: 101616 Anticancer Treatment "lobeline; alpha-Lobeline; (-)-Lobeline; Lobnico; Lobelin; 8,10-Diphenyllobelionol; Lobelina; Lobelinum; 90-69-7; Inflatine; UNII-D0P25S3P81; 2-(6-(2-Hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenylethanone; 2-{(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl}-1-phenylethanone; CHEMBL122270; CHEBI:48723; 2-(6-(beta-Hydroxyphenethyl)-1-methyl-2-piperidyl)acetophenone; D0P25S3P81; NCGC00024378-05; Alpha-Lobeline HCl; Lobeline [INN:BAN]; Lobelinum [INN-Latin]; Lobelina [INN-Spanish]; SR-01000075960; Lobeline A; Lobeline (INN); L0B; EINECS 202-012-3; BRN 0091533; Prestwick0_000585; Prestwick1_000585; Prestwick2_000585; Prestwick3_000585; DSSTox_CID_3219; DSSTox_RID_76929; DSSTox_GSID_23219; Lopac0_000698; BSPBio_000430; 5-21-12-00627 (Beilstein Handbook Reference); Ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))-; SCHEMBL290803; SPBio_002649; BPBio1_000474; ZINC1624; DTXSID3023219; Tox21_110900; BDBM50080818; AKOS024278800; CCG-204783; DB05137; NSC 757421; SDCCGSBI-0050676.P002; 2-((2R,6S)-6-((S)-2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl)-1-phenylethan-1-one; CAS-90-69-7; NCGC00024378-06; NCGC00024378-07; NCGC00024378-08; NCGC00024378-09; NCGC00024378-10; NCGC00024378-14; AB00489926; C07475; D02364; Q421905; SR-01000075960-5; BRD-K66206289-003-03-1; BRD-K66206289-003-09-8; UNII-73BJ3LA259 component MXYUKLILVYORSK-HBMCJLEFSA-N" Small molecule "1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1" MXYUKLILVYORSK-HBMCJLEFSA-N CN1C(CCCC1CC(=O)C2=CC=CC=C2)CC(C3=CC=CC=C3)O C22H27NO2 CAS 90-69-7 CHEBI:48723 . . . DB05137 . DR7874 Diosgenin . . Investigative Hepatocellular carcinoma ICD-11: 2C12 CID: 99474 Anticancer Treatment "DIOSGENIN; 512-04-9; Nitogenin; UNII-K49P2K8WLX; Spirost-5-en-3-ol, (3b,25R)-; (20R,25R)-Spirost-5-en-3beta-ol; K49P2K8WLX; CHEBI:4629; (25R)-spirost-5-en-3beta-diol; MFCD00016887; NSC 33396; Spirost-5-en-3-beta-ol, (25R)-; (3beta,25R)-spirost-5-en-3-ol; (25R)-Spirost-5-en-3beta-ol; SP 37; C27H42O3; (2'R,4S,5'R,6aR,6bS,8aS,8bR,9S,11aS,12aS,12bS)-5',6a,8a,9-Tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol; (25R)-14beta,17beta-spirost-5-en-3beta-ol; 3beta-Hydroxy-5-spirostene; nitrogen in; CCRIS 6803; 22alpha-Spirost-5-en-3beta-ol; Dioscorea sapogenin; Diosgenin,(S); (7S,8S,10S,13S,15S,18S,22S,3R,12R,14R,19R)-3,13,15,19-tetramethyl-11-oxaspiro[ 2H-3,4,5,6-tetrahydropyran-6,6'-pentacyclo[10.8.0.0<2,9>.0<4,8>.0<13,18>]icosa ne]-24-en-22-ol; YUV; EINECS 208-134-3; DISOGENIN; BRN 0094582; Diosgenin, >=93%; 3A-Hydroxy-5-spirostene; SCHEMBL83359; 5-19-03-00030 (Beilstein Handbook Reference); (25R)-5-Spirosten-3A-ol; CHEMBL412437; (25R)-5-Spirosten-3beta-ol; DTXSID00895074; (25R)-Spirost-5-en-3.beta-ol; HY-N0177; ZINC6857614; LMST01080037; SBB058140; AKOS015961083; ACN-034765; CS-5303; MCULE-6739922044; NCGC00386027-01; Spirost-5-en-3-ol, (3-beta,25R)-; AS-13640; ST097775; AB0090307; N1715; S2291; Spirost-5-en-3beta-ol, (25R)- (8CI); C08898; J10028; M03858; Spirost-5-en-3-ol, (3beta,25R)- (9CI); 512D049; Q-100574; Q1107734; BRD-K28690501-001-02-1; Diosgenin, European Pharmacopoeia (EP) Reference Standard; UNII-5E5W122QCR component WQLVFSAGQJTQCK-VKROHFNGSA-N; (2R,5'R)-5'-tetramethylspiro[[?]-2,2'-tetrahydropyran]ol; NCGC00386027-01_C27H42O3_Spirost-5-en-3-ol, (3beta,25R)-; (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-ol" Small molecule "1S/C27H42O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h5,16-17,19-24,28H,6-15H2,1-4H3/t16-,17+,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1" WQLVFSAGQJTQCK-VKROHFNGSA-N CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C)OC1 C27H42O3 CAS 512-04-9 CHEBI:4629 . . . . . DR0445 Clarithromycin D0Z1ZM D0Z1ZM Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 84029 Anticancer Treatment "clarithromycin; 81103-11-9; Biaxin; 6-O-Methylerythromycin; Klaricid; 6-O-Methylerythromycin a; Clarithromycine; Clathromycin; Abbott-56268; Erythromycin, 6-O-methyl-; A-56268; Macladin; Clarith; Klacid; Kofron; Veclam; Clarithromycinum; Naxy; TE-031; Biaxin XL; UNII-H1250JIK0A; Clarithromycin identity; C38H69NO13; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; Prevpac; CHEBI:3732; H1250JIK0A; Claritromicina; Abbotic; Astromen; Bicrolid; Clacine; Clambiotic; Claribid; Claricide; Claridar; Claripen; Fromilid; Heliclar; Klaciped; Mabicrol; Clacee; Clacid; Clarem; Crixan; Cyllid; Klabax; Klarid; Klarin; Maclar; Zeclar; Helas; Mavid; Adel; Biaxin filmtab; Klax; Biaxin HP; Biaxin xl filmtab; Klaricid Pediatric; CLA; Clarithromycin extended release; DRG-0099; Klaricid H.P.; CTY; SMR000466382; Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; SR-05000001992; 116836-41-0; Clarithromycin (Biaxin, Klacid); clarithromycina; Cyllind; CCRIS 8833; Klaricid XL; HSDB 8055; (14R)-14-Hydroxyclarithromycin; TE031; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy; Clarithromycin,(S); Biaxin (TN); Clarithromycin, 97%; Spectrum_000089; CPD000466382; Clarithromycin [USAN:USP:INN:BAN:JAN]; SpecPlus_000559; 6-O-methyl erythromycin; O(6)-methylerythromycin; CLA;; Spectrum2_001668; Spectrum3_001667; Spectrum4_000629; Spectrum5_001729; 6-0-methylerythromycin A; CHEMBL1741; SCHEMBL38125; BSPBio_003453; KBioGR_001218; KBioSS_000509; MLS000759516; MLS001201751; MLS001424066; BIDD:GT0200; DivK1c_006655; SPECTRUM1504231; SPBio_001855; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; DTXSID3022829; Clarithromycin & Interleukin-12; CLM & IL-12; GTPL10903; KBio1_001599; KBio2_000509; KBio2_003077; KBio2_005645; KBio3_002673; ANX-015; SDP-015; Clarithromycin (JP17/USP/INN); Clarithromycin, >=95% (HPLC); Clarithromycin, >=98% (HPLC); HMS1922H09; HMS2051G18; HMS2090O11; HMS2094M05; HMS2231A08; HMS3715J17; Pharmakon1600-01504231; EBD13493; BDBM50404044; CCG-39086; LMPK04000014; MFCD00865140; NSC758704; s2555; ZINC85534098; AKOS015894242; CS-2576; DB01211; MCULE-7168853332; NC00140; NSC 758704; NSC-758704; NCGC00178054-01; NCGC00178054-06; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; H781; HY-17508; SBI-0206716.P001; Clarithromycin 100 microg/mL in Acetonitrile; C06912; D00276; J10130; AB00053394-10; AB00053394-12; AB00053394-13; AB00053394_14; AB00053394_15; 103C119; Q118551; Q-200870; SR-05000001992-1; SR-05000001992-2; BRD-K49668410-001-07-1; BRD-K49668410-001-18-8; Clarithromycin, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, United States Pharmacopeia (USP) Reference Standard; Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard; Clarithromycin, Ready Made Solution, 50 mg/mL in DMSO, 0.2 mum filtered; Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name); (3R,4S,5S,6R,7R,9R,11S, 12R,13S,14S)-6-{[(2S,3R,4S,6R)- 4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy- 4-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1- oxacyclotetradecane-2,10-dione" Small molecule "1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1" AGOYDEPGAOXOCK-KCBOHYOISA-N CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O C38H69NO13 CAS 81103-11-9 CHEBI:3732 . . . DB01211 . DR1642 Pinostrobin . . Investigative Parkinson's disease ICD-11: 8A00 CID: 73201 Anticancer Treatment "Pinostrobin; 480-37-5; Pinostrombin; Pinocembrin-7-methylether; UNII-SZD9LZS694; SZD9LZS694; CHEMBL254613; (S)-2,3-Dihydro-5-hydroxy-7-methoxy-2-phenyl-4-benzopyrone; CHEBI:80491; (2s)-5-hydroxy-7-methoxyflavanone; 5-Hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; (2S)-5-hydroxy-7-methoxy-2-phenyl-2,3-dihydrochromen-4-one; pinocembrin-7-methyl ether; dihydrotectochrysin; (-)-pinostrobin; (2S)-pinostrobin; (2S)-5-hydroxy-7-methoxy-2-phenyl-chroman-4-one; SCHEMBL7648566; DTXSID50963979; ZINC391894; Pinostrobin, >=99.0% (TLC); HY-N2127; EINECS 207-548-1; BDBM50338968; (+/-)-5-hydroxy-7-methoxyflavanone; AKOS037515398; CCG-262304; NCGC00163610-01; 5-Hydroxy-7-methoxy-2-phenyl-chroman-4-one; CS-0018678; C16419; 480P375; SR-05000013704; SR-05000013704-1; Q27149542; 5-Hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-5-hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5-hydroxy-7-methoxy-2-phenyl-, (S)-" Small molecule "1S/C16H14O4/c1-19-11-7-12(17)16-13(18)9-14(20-15(16)8-11)10-5-3-2-4-6-10/h2-8,14,17H,9H2,1H3/t14-/m0/s1" ORJDDOBAOGKRJV-AWEZNQCLSA-N COC1=CC(=C2C(=O)CC(OC2=C1)C3=CC=CC=C3)O C16H14O4 CAS 480-37-5 CHEBI:80491 . . . . . DR4674 Voriconazole D0N3VR D0N3VR Approved Aspergillosis ICD-11: 1F20 CID: 71616 Anticancer Treatment "Voriconazole; 137234-62-9; Vfend; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; UK-109496; UK 109496; UK-109,496; UNII-JFU09I87TR; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; C16H14F3N5O; (+/-)-Voriconazole; VCZ; CHEMBL638; JFU09I87TR; CPD000466350; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; CHEBI:10023; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-; VRC; Voriconazol; DSSTox_CID_26485; DSSTox_RID_81656; DSSTox_GSID_46485; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-; Voriconazolum; Vorikonazole; Voriconazole [USAN:INN:BAN]; 188416-29-7; DRG-0301; SMR000466350; CAS-137234-62-9; Vfend (TN); VFEND I.V.; Pfizer; MFCD00905717; NCGC00164622-01; Voriconazole solution; Voriconazole, 98%; Voriconazole - Vfend; Voriconazole in combination with MGCD290; Voriconazole, (+/-)-; SCHEMBL36233; 2R,3S-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; MLS000759464; MLS001424082; MLS006010028; DTXSID5046485; Voriconazole (JP17/USP/INN); ZINC14864; AMY8903; SYN3012; Voriconazole, >=98% (HPLC); BCPP000019; DTXSID201019420; HMS2051N09; HMS3260M22; HMS3713F12; Pharmakon1600-01502346; Tox21_112241; Tox21_500150; Voriconazole 2.0 mg/ml in Methanol; AC-823; BDBM50333117; MFCD20488064; NSC759888; s1442; AKOS005145705; Tox21_112241_1; CCG-100941; CS-1227; DB00582; KS-1157; NC00191; NSC 759888; NSC-759888; SB17419; NCGC00164622-02; NCGC00164622-04; NCGC00164622-06; NCGC00260835-01; HY-76200; I992; Voriconazole related compound A RS [USP]; AB0013963; SW197571-2; C07622; D00578; J10329; W-5208; AB00639948-04; AB00639948-06; AB00639948_07; AB00639948_08; Voriconazole, VETRANAL(TM), analytical standard; 234V629; Q412236; J-006986; Z2616414875; UNII-USG4B1CD29 component BCEHBSKCWLPMDN-MGPLVRAMSA-N; Voriconazole, European Pharmacopoeia (EP) Reference Standard; Voriconazole, United States Pharmacopeia (USP) Reference Standard; (2R,3S)-2,3-bis(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; Voriconazole, Pharmaceutical Secondary Standard: Certified Reference Material; (2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol; (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-rel-" Small molecule "1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1" BCEHBSKCWLPMDN-MGPLVRAMSA-N CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O C16H14F3N5O CAS 188416-29-7 CHEBI:10023 . . . DB00582 . DR7295 Dexrazoxane D07XVN D07XVN Approved Breast cancer ICD-11: 2C60-2C65 CID: 71384 Anticancer Treatment "Dexrazoxane; 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dextrorazoxane; Dexrazoxanum; Dexrazoxano; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; ADR 529; ICRF 187; ADR-529; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; Desrazoxane; 2,6-Piperazinedione, 4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; UNII-048L81261F; NSC169780; CHEBI:50223; NSC-169780; NSC 169780; MFCD00866449; Razoxanum [INN-Latin]; Razoxana [INN-Spanish]; 048L81261F; 4-[(2S)-1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione; (S)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; DSSTox_CID_20647; DSSTox_RID_79520; DSSTox_GSID_40647; (S)-4,4'-(Propane-1,2-diyl)-bis(piperazine-2,6-dione); (+)-dexrazoxane; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; CAS-24584-09-6; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; HSDB 7319; 2,6-Piperazinedione, 4,4'-propylenedi-, (+)-; SR-01000883995; Dexrazoxane HCl (ICRF-187, ADR-529); BRN 5759131; Soluble ICRF (L-isosomer); Dexrazoxane [USAN:INN:BAN]; CCRIS 9394; NCGC00164737-01; CHEMBL1738; SCHEMBL18400; MLS006010158; BIDD:GT0068; Dexrazoxane (JAN/USAN/INN); (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; GTPL7330; DTXSID3040647; Dexrazoxane, >=95% (HPLC); AMY39004; EBD45155; HY-B0581; Tox21_112256; 2, 4,4'-propylenedi-, (+)-; ANW-44923; s5651; ZINC87515509; AKOS015896392; Tox21_112256_1; (+)-1,5-dioxopiperazin-1-yl)propane; CCG-267131; DB00380; DS-1394; MP-0159; NCGC00263544-01; NCGC00263544-02; Dexrazoxane, analytical reference material; NCI60_001367; SMR002529680; AB0011515; (S)-(+)-1,5-dioxopiperazin-1-yl)propane; D4227; D03730; J90038; AB01273932-01; AB01273932-02; AB01273932_03; 2,4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; 584D096; A817380; Q524995; 2,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; J-015579; J-520219; SR-01000883995-1; SR-01000883995-2; SR-01000883995-5; (S)-4,4'-(propane-1,2-diyl)dipiperazine-2,6-dione; BRD-K07265709-003-01-5; (S)-4,4-(Propane-1,2-diyl)bis(piperazine-2,6-dione); 4,4'-[(2S)-1,2-Propanediyl]di(2,6-piperazinedione); UNII-5AR83PR647 component BMKDZUISNHGIBY-ZETCQYMHSA-N; 4-[(2S)-2-(3,5-dioxo-1-piperazinyl)propyl]piperazine-2,6-dione; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)- (9CI); 4-[(2S)-2-[3,5-bis(oxidanylidene)piperazin-1-yl]propyl]piperazine-2,6-dione; 6-hydroxy-4-[(2S)-2-(5-hydroxy-3-oxo-1,2,3,6-tetrahydropyrazin-1-yl)propyl]-2,3,4,5-tetrahydropyrazin-2-one" Small molecule "1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1" BMKDZUISNHGIBY-ZETCQYMHSA-N CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 C11H16N4O4 CAS 24584-09-6 CHEBI:50223 . . . DB00380 . DR5481 3-bromopyruvate . . Investigative Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 70684 Anticancer Treatment "3-bromopyruvic acid; bromopyruvic acid; 1113-59-3; 3-bromo-2-oxopropanoic acid; 3-Bromo-2-oxopropionic acid; bromopyruvate; 3-bromopyruvate; Bromopyruvicacid; Pyruvic acid, bromo-; Propanoic acid, 3-bromo-2-oxo-; UNII-63JMV04GRK; MFCD00002587; .beta.-Bromopyruvic acid; 63JMV04GRK; 3-bromo-2-oxo-propionic acid; C3H3BrO3; 3-BrPA; EINECS 214-206-5; NSC 11731; NSC 62343; BRN 1746786; BPV; bromo-2-oxopropanoic acid; ACMC-1C0WT; SCHEMBL8126; NCIOpen2_000241; 3-BP; 3-bromo-2-keto-propionic acid; CHEMBL177837; 3-Bromo-2-oxopropanoic acid #; 3-Bromopyruvic acid hydrate,98; DTXSID7040940; CHEBI:95046; CHEBI:131461; Hexokinase II Inhibitor II;3-BP; HMS3741K19; HMS3866H13; ACT09279; NSC11731; NSC62343; ZINC1718542; ANW-43645; NSC-11731; NSC-62343; NSC782120; s5426; SBB053571; Bromopyruvic acid, >=97.0% (T); AKOS015892643; AM84337; CCG-266336; CS-5517; MCULE-4768170572; NSC-782120; AS-16146; DA-15474; HY-19992; S691; AK00558616; B1153; FT-0623262; ST51037166; EN300-67360; A-2150; Bromopyruvic acid; 3-bromo-2-oxopropanoic acid; J-511892; J-650255; Q3608257; BRD-K92980438-001-01-7; Hexokinase II Inhibitor II, 3-BP - CAS 1113-59-3; Z2690354216" Small molecule "1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)" PRRZDZJYSJLDBS-UHFFFAOYSA-N C(C(=O)C(=O)O)Br C3H3BrO3 CAS 1113-59-3 CHEBI:95046 . . . . . DR7080 Brinzolamide D01MUR D01MUR Approved Glaucoma ICD-11: 9C61 CID: 68844 Anticancer Treatment "Brinzolamide; 138890-62-7; Azopt; AL-4862; AL 4862; Birnzolamide; MFCD08067749; UNII-9451Z89515; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; CHEBI:3176; (R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; 2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4R)-; DSSTox_CID_25531; DSSTox_RID_80934; DSSTox_GSID_45531; 138890-50-3; BZ1; 9451Z89515; C12H21N3O5S3; (4R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; Brinzolamide (BRZ); Azopt (TN); Brinzolamide (JAN/USP/INN); 3znc; NCGC00016979-01; Brinzolamide [USAN:USP:INN:BAN]; CAS-138890-62-7; Prestwick0_000365; Prestwick1_000365; Prestwick2_000365; Prestwick3_000365; SCHEMBL24636; BSPBio_000489; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)-; cc-163; MLS002153787; BIDD:GT0039; SPBio_002410; AMY372; BPBio1_000539; CHEMBL220491; GTPL6797; DTXSID6045531; BDBM10885; Brinzolamide, >=98% (HPLC); HMS1569I11; HMS2096I11; HMS2234K06; HMS3713I11; HMS3885I11; BCP22330; EBD27046; HY-B0588; ZINC3953037; Tox21_110722; ABP001062; s3178; AKOS005145708; Tox21_110722_1; AC-5277; CCG-220365; CCG-222516; DB01194; NSC 760050; NCGC00179542-03; NCGC00179542-10; AS-35084; SMR001233169; AB0012787; AB00513824; B4258; SW197152-3; AL4862;AL 4862;AL-4862; C07760; D00652; AB00513824_06; Q411517; SR-01000838832; Q-200751; SR-01000838832-2; BRD-K74913225-001-03-3; Brinzolamide, United States Pharmacopeia (USP) Reference Standard; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide; (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide-1,1-dioxide; (4R)-4-ethylamino-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[4,5-e]thiazine-6-sulfonamide; (5R)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2,9-dithia-3-azabicyclo[4.3.0]nona-1(6)7-diene-8-sulfonamide; (5R)-5-Ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2?6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide; (R)- 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide, (R)-" Small molecule "1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1" HCRKCZRJWPKOAR-JTQLQIEISA-N CCNC1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC C12H21N3O5S3 CAS 138890-62-7 CHEBI:3176 . . . DB01194 . DR0261 Zoledronic D0VM2L D0VM2L Approved Mineral excesses ICD-11: 5B91 CID: 68740 Anticancer Treatment "Zoledronic acid; Zoledronate; 118072-93-8; Zometa; Reclast; Aclasta; (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; CGP 42446; (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; ZOL; CGP-42446; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); Orazol; UNII-70HZ18PH24; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-; C5H10N2O7P2; Reclast (TN); Zometa (TN); CHEMBL924; CHEBI:46557; [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid; 70HZ18PH24; CGP-42446A; NCGC00159521-02; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; Zoledronic acid [USAN:INN:BAN]; Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-; Zomera; 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid; Bisphosphonate 3; Zometa (Novartis); Aclasta and Reclast; AK-156; Zoledronic acid (INN); Zoledronic Acid Anhydrous; [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid; zoledronic-acid; BPH 91; ZOL 446; PubChem14894; Anhydrous Zoledronic Acid; Zoledronic Acid, Anhydrous; DSSTox_CID_22668; DSSTox_RID_80065; Zoledronic acid, Zoledronate; BIDD:PXR0134; DSSTox_GSID_42668; SCHEMBL19054; BIDD:GT0292; Zoledronic Acid (Zoledronate); GTPL3177; JMC515594 Compound 55; PHO012; DTXSID0042668; BDBM12578; HMS2089O09; BCP22750; EBD33252; ZINC3803652; Tox21_111739; [1-HYDROXY-2-(1H-IMIDAZOL-1-YL)-ETHYLIDENE]BISPHOSPHONIC ACID; ANW-57498; MFCD00867791; NSC721517; s1314; STL452893; AKOS005145739; AB07564; AC-1092; CS-1829; DB00399; HS-0091; MCULE-1604726355; NSC 721517; NSC-721517; NCGC00159521-03; NCGC00159521-04; NCGC00159521-05; NCGC00159521-09; NCGC00159521-18; AK-81486; HY-13777; AB0013187; CAS-118072-93-8; FT-0601384; Y1607; D08689; S00092; Z-1463; 42181-EP2270008A1; 42181-EP2292617A1; 42181-EP2295426A1; 42181-EP2295427A1; 42181-EP2308855A1; 42181-EP2311808A1; 42181-EP2311829A1; AB01273947-01; AB01273947-02; AB01273947-03; AB01273947_04; 072Z938; Q218507; SR-05000001436; Q-201946; SR-05000001436-1; [1-hydroxy-(1H-imidazol-1-yl)-phosphonoethyl] phos; 1-Hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid; Z1691545083; Phosphonic acid, P,P'-[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-" Small molecule "1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)" XRASPMIURGNCCH-UHFFFAOYSA-N C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O C5H10N2O7P2 CAS 118072-93-8 CHEBI:46557 . . . DB00399 . DR7956 Oseltamivir D0O5NK D0O5NK Approved Influenza ICD-11: 1E30-1E32 CID: 65028 Anticancer Treatment "oseltamivir; 196618-13-0; Tamvir; Tamiflu-Free; GS-4104; (-)-oseltamivir; GS 4104; GS4104; HSDB 7433; UNII-20O93L6F9H; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; GOP-A-Flu; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; Ro-640796; Ro-64-0796; CHEBI:7798; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-; 20O93L6F9H; (3R,4R,5S)-Ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate; Ro 640796; ebilfumin; Oseltamivir [INN:BAN]; oseltamivirum; Agucort; ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; Agucort (TN); Oseltamivir (INN); Tamiflu (*Phosphate salt 1:1*); SR-05000001499; oseltamivir-phosphate; CHEMBL1229; SCHEMBL32035; BIDD:GT0426; BDBM5025; GS-4071 ETHYL ESTER; DTXSID9044291; GTPL11427; HMS2090C11; EX-A3415; ZINC3929508; CO0039; AKOS015843442; AKOS015960501; CS-0552; DB00198; DT-0013; MCULE-1441617774; (3R,5S)-ETHYL 4-ACETAMIDO-5-AMINO-3-(PENTAN-3-YLOXY)CYCLOHEX-1-ENECARBOXYLATE; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohexene-1-carboxylate; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxy-cyclohexene-1-carboxylate; Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate; NCGC00095191-12; NCGC00178698-01; NCGC00178698-02; NCGC00178698-04; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-; HY-13317; RO640796; Oseltamivir 100 microg/mL in Acetonitrile; RO64-0796; C08092; D08306; W-5250; AB00173476-02; AB00173476_04; 618O130; AR-270/43507961; Q211509; SR-05000001499-1; BRD-K76011241-045-01-5; (3R,5S)-ethyl4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate; Ethyl (3R, 4R, 5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; (3r,4r,5s)-4-acetylamino-5-amino-3(1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester; (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester; (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)cyclohex-1-enecarboxylic acid ethyl ester" Small molecule "1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1" VSZGPKBBMSAYNT-RRFJBIMHSA-N CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC C16H28N2O4 CAS 196618-13-0 CHEBI:7798 . . . DB00198 . DR7139 AMD3100 D0L5RW D0L5RW Approved Malignant haematopoietic neoplasm ICD-11: 2B33 CID: 65015 Anticancer Treatment "Plerixafor; 110078-46-1; Mozobil; AMD3100; 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene; Amd 3100; bicyclam JM-2987; plerixafor (amd3100); Plerixafor hydrochloride; AMD-3100; SDZ SID 791; JM3100; JM 3100; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane; JM-3100; UNII-S915P5499N; JKL 169; CHEMBL18442; 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane; S915P5499N; SID791; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; Mozobil (TN); plerixaforum; Plerixafor [USAN:INN:BAN]; 1,1'-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane); Plerixafor 8HCl; GNA & AMD-3100; HHA & AMD-3100; JM 2987; Plerixafor(AMD3100); 1,4,8,11-Tetraazacyclotetradecane, 1,1'-[1,4-phenylenebis(methylene)]bis-, hydrochloride (1:8); Plerixafor-d4 (deuterated); SCHEMBL19038; GTPL844; cc-304; Plerixafor (JAN/USAN/INN); AOB5591; DTXSID70869520; AMD-3100 (CXCR4); CHEBI:125354; BCPP000104; BCP02337; C28H54N8; EX-A1762; ANW-73610; BDBM50035696; MFCD05662218; NSC754363; NSC761388; s8030; ZINC22443609; 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; AKOS005266706; CCG-269710; CS-0451; DB06809; NSC-754363; NSC-761388; NCGC00165722-01; NCGC00165722-02; NCGC00165722-03; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); AC-26837; AK-41732; AS-42504; HY-10046; AB0009909; FT-0660392; FT-0673966; A25446; D08971; S-7677; AB01566900_01; 078P461; A809618; L000104; Q905835; SR-01000941593; J-503718; SR-01000941593-1; 11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane; BRD-K33240821-367-01-8; Z2196779619; 1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1,1'-(benzene-1,4-diyldimethanediyl)bis(1,4,8,11-tetraazacyclotetradecane); 1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane; 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA); 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane; 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O); 1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane; 1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane; 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester" Small molecule "1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2" YIQPUIGJQJDJOS-UHFFFAOYSA-N C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3 C28H54N8 CAS 110078-46-1 CHEBI:125354 . . . DB06809 . DR0944 Nelfinavir . . Phase 2 Colorectal cancer ICD-11: 2B91 CID: 64143 Anticancer Treatment "nelfinavir; 159989-64-7; Viracept; AG-1343; UNII-HO3OGH5D7I; Nelfinavir free base; C32H45N3O4S; Viracept (TN); HO3OGH5D7I; CHEBI:7496; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; 159989-65-8; 159989-64-7 (free base); 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; NLF; Nelfinavir [INN:BAN]; NFV; CHEMBL1205; (3S,4aS,8aS)-N-(tert-Butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methyl-benzoyl)amino]-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; Nelfinavir (INN); SMR000596515; NSC722664; NCGC00090782-03; NELFINAVIR MESYLATE AG1343; Met-SDF-1.beta. & Nelfinavir; 1ohr; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; CHEMBL584; BIDD:PXR0143; SCHEMBL38218; MLS001195634; MLS001304729; N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-; BIDD:GT0395; DTXSID5035080; GTPL11090; HMS2232I04; Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir; ZINC3833846; BDBM50061306; NSC747167; AKOS000280862; AM84529; CS-0677; DB00220; NSC 747167; NSC-747167; MRF-0000208; NCGC00090782-04; NCGC00090782-05; NCGC00090782-17; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-; AC-20032; AS-75258; HY-15287; 89N647; C07257; D08259; AB00698259-15; A810096; Q423366; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4abeta,8abeta)-N-tert-Butyl-2-[(2R,3R)-2-hydroxy-3-(2-methyl-3-hydroxybenzoylamino)-4-(phenylthio)butyl]decahydroisoquinoline-3alpha-carboxamide; (3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide; compound with methanesulfonic acid; (3S,4aS,8aS)-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-{[(3-hydroxy-2-methylphenyl)carbonyl]amino}-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-3-[(2-methyl-3-oxidanyl-phenyl)carbonylamino]-2-oxidanyl-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethyl ethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, [3S-[2(2S*,3S*),3.alpha.,4a.beta.,8a.beta.]]-" Small molecule "1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1" QAGYKUNXZHXKMR-HKWSIXNMSA-N CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O C32H45N3O4S CAS 159989-64-7 CHEBI:7496 . . . DB00220 . DR8801 Ibandronate D08SJZ D08SJZ Approved Low bone mass disorder ICD-11: FB83 CID: 60852 Anticancer Treatment "Ibandronic Acid; Ibandronate; 114084-78-5; Bondronat; Boniva; Bonviva; (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonic acid; UNII-UMD7G2653W; Bondenza; CHEMBL997; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; UMD7G2653W; Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-; {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid; Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-; Acid ibandronico; BFQ; Ibandronic acid [INN:BAN]; Bisphosphonate 2; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphonic acid; Ibandronic acid (INN); SR-05000001496; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; 1-hydroxy-3-(methylpentylamino)propylidene bisphosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; SCHEMBL9183; C9H23NO7P2; GTPL3059; JMC515594 Compound 53; DTXSID5048340; BDBM12577; HY-B0515A; HMS2090A13; ACT05527; BCP13798; ZINC1533877; AC-521; MFCD00868772; AKOS015855723; DB00710; NSC 722623; AS-12948; FT-0602640; FT-0670253; D08056; M-1207; AB01275485-01; 084I785; Q166825; J-003052; SR-05000001496-1; SR-05000001496-2; BRD-K08681769-323-01-1; 1-hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyldiphosphonic acid; {1-hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid); Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-" Small molecule "1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)" MPBVHIBUJCELCL-UHFFFAOYSA-N CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O C9H23NO7P2 CAS 114084-78-5 . . . . DB00710 . DR3634 Duloxetine D01AXB D01AXB Approved Depression ICD-11: 6A70-6A71 CID: 60835 Anticancer Treatment "duloxetine; 116539-59-4; (S)-Duloxetine; Cymbalta; Yentreve; (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; LY 248686; 136434-34-9; UNII-O5TNM5N07U; Ariclaim; Xeristar; LY248686; Yentreve (TN); (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; O5TNM5N07U; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-; N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine; CHEBI:36795; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; MFCD06801358; LY-248686; methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine; (3s)-N-Methyl-3-(Naphthalen-1-Yloxy)-3-(Thiophen-2-Yl)propan-1-Amine; Duloxetine [INN:BAN]; Duloxetine (INN); SMR000449282; HSDB 7368; NCGC00164559-01; Duloxetine Boehringer Ingelheim; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine; 29E; CPD000449282; SCHEMBL8291; CHEMBL1175; GTPL202; cc-636; MLS000758267; MLS001423946; (S)-Duloxetine;LY248686; DTXSID6048385; BDBM84745; HMS2051I05; HMS3886K11; HY-B0161; ZINC1536779; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-; ANW-63714; PDSP1_000969; PDSP1_001385; PDSP2_000953; PDSP2_001369; s5071; AKOS015851058; CCG-100763; CM14423; DB00476; NC00013; SB19317; VA11973; NCGC00164559-02; NCGC00164559-04; AC-15704; AS-35259; SBI-0206832.P001; CAS_136434-34-9; D07880; AB00639911-13; AB00639911_15; AB00639911_16; 539D594; Q411932; J-003455; J-523680; (+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamin; (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine; (S)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1 amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1-amine; (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1amine; (S)-(+)-N-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine" Small molecule "1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1" ZEUITGRIYCTCEM-KRWDZBQOSA-N CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32 C18H19NOS CAS 116539-59-4 CHEBI:36795 . . . DB00476 . DR6878 lamivudine D07TQV D07TQV Approved Hepatitis virus infection ICD-11: 1E51 CID: 60825 Anticancer Treatment "lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Heptodin; 3TC; BCH-189; (-)-2'-Deoxy-3'-thiacytidine; 2',3'-Dideoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 3'-Thia-2',3'-dideoxycytidine; GR-109714X; (-)-BCH-189; beta-L-2',3'-Dideoxy-3'-thiacytidine; beta-L-3'-Thia-2',3'-dideoxycytidine; (-)NGPB-21; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; GR 109714X; 136891-12-8; UNII-2T8Q726O95; BCH 189, (-)-; Hepitec; MFCD00869739; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; CHEBI:63577; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; 2T8Q726O95; Heptivir; Lamivir; Zefix; 4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR109714X; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE; BCH 189; Lamivudine [USAN:BAN:INN]; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; Epivir(TM); HHA & Lamivudine; Lamivudine & GNA; SMR000466319; Epivir (TN); (-)-BCH 189; DTHC; CHEMBL141; HSDB 7155; DRG-0126; 3TC and NV-01; (-)-SddC; Lamivudeine; Lamivudine (JAN/USP/INN); 3TC & GNA; 3TC & SST; HHA & 3TC; (+/-)-SddC; CCRIS 9274; NSC620753; 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; BCH-790; Lamivudine [USAN:USP:INN:BAN]; NCGC00159341-04; Lamivudine, 98%; GG-714; Lamivudine (EPIVIR); CPD000466319; (+/-)-3TC; (+/-)-BCH-189; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; MLS000759424; MLS001424097; MLS006011910; BIDD:GT0033; SCHEMBL109675; AMY384; PYR356; ZINC12346; HMS2051D21; HMS3259F08; HMS3713C16; HY-B0250; ANW-43098; BBL033871; BDBM50366817; s1706; SBB066293; STK801940; lamivudine & TNF-alpha & IFN-gamma; AKOS005622556; AKOS015854841; Lamivudine, >=98% (HPLC), powder; AB07588; AC-1416; CCG-100984; DB00709; KS-1073; MCULE-2096184994; NC00234; NC00705; NSC 760061; NCGC00159341-05; NCGC00159341-18; L0217; SW197614-3; C07065; D00353; J10244; M-9795; 24222-EP2269989A1; 24222-EP2272516A2; 24222-EP2272825A2; 24222-EP2292227A2; 24222-EP2298761A1; 24222-EP2298783A1; 24222-EP2305243A1; 24222-EP2305640A2; 24222-EP2305680A2; 24222-EP2314590A1; AB00639995-06; AB00639995-08; AB00639995_09; Lamivudeine 100 microg/mL in Acetonitrile:Water; 200973-EP2272825A2; 678L174; Q422631; SR-01000759420; J-700183; Q-201275; SR-01000759420-5; Lamivudine, British Pharmacopoeia (BP) Reference Standard; Lamivudine, European Pharmacopoeia (EP) Reference Standard; (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Lamivudine, United States Pharmacopeia (USP) Reference Standard; (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIR; Lamivudine, 1.0 mg/mL in methanol, certified reference material; Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis); 3-[(5S,2R)-2-(hydroxymethyl)(1,3-oxathiolan-5-yl)]-6-amino-3-hydropyrimidin-2- one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one; cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard; Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard; 1117764-41-6; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)" Small molecule "1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1" JTEGQNOMFQHVDC-NKWVEPMBSA-N C1C(OC(S1)CO)N2C=CC(=NC2=O)N C8H11N3O3S CAS 134678-17-4 CHEBI:63577 . . . DB00709 . DR3599 Atorvastatin D01QIN D01QIN Approved Cardiovascular disease ICD-11: BA00-BE2Z CID: 60823 Anticancer Treatment "atorvastatin; 134523-00-5; Cardyl; Lipitor; ATORVASTATIN CALCIUM; Torvast; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; UNII-A0JWA85V8F; 110862-48-1; CI 981; Lipitor (TN); Tozalip; Xavator; A0JWA85V8F; CHEMBL1487; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; CHEBI:39548; 134523-00-5 (free acid); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 134523-03-8; Atorvastatin [INN:BAN]; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; Atorvastatin calcium salt; atorvastatina; atorvastatine; atrovastin; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Atorvastatin (INN); Sortis (TN); CCRIS 7159; MFCD00899261; C33H35FN2O5; HSDB 7039; NCGC00159458-03; atorvastatinum; rel-Atorvastatin; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin & Primycin; DSSTox_CID_9868; SCHEMBL3831; DSSTox_RID_78825; DSSTox_GSID_29868; BIDD:GT0336; Atorvastatin (Relative Stereo); GTPL2949; DTXSID8029868; BDBM22164; DTXSID60274003; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; ACT03225; HY-B0589; ZINC3920719; Tox21_302417; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MCULE-2368532812; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; AS-35260; H942; CAS-134523-00-5; C06834; D07474; S-2492; Y-8867; 28052-EP2269989A1; 28052-EP2269990A1; 28052-EP2270011A1; 28052-EP2270505A1; 28052-EP2272825A2; 28052-EP2272841A1; 28052-EP2280001A1; 28052-EP2284158A1; 28052-EP2287165A2; 28052-EP2287166A2; 28052-EP2292600A1; 28052-EP2292620A2; 28052-EP2295406A1; 28052-EP2295409A1; 28052-EP2295417A1; 28052-EP2295422A2; 28052-EP2298731A1; 28052-EP2298742A1; 28052-EP2298745A1; 28052-EP2298769A1; 28052-EP2298772A1; 28052-EP2298776A1; 28052-EP2298779A1; 28052-EP2301923A1; 28052-EP2301931A1; 28052-EP2301936A1; 28052-EP2308839A1; 28052-EP2308878A2; 28052-EP2314588A1; 523A005; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; UNII-36TN91XZ0V component XUKUURHRXDUEBC-KAYWLYCHSA-N; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (beta-R,delta-R)-;" Small molecule "1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1" XUKUURHRXDUEBC-KAYWLYCHSA-N CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4 C33H35FN2O5 CAS 134523-00-5 CHEBI:39548 . . . DB01076 . DR4000 Marbofloxacin . . Investigative Chronic obstructive pulmonary disease ICD-11: CA22 CID: 60651 Anticancer Treatment "Marbofloxacin; 115550-35-1; Zeniquin; Marbocyl; UNII-8X09WU898T; 8X09WU898T; MFCD00864820; 7H-Pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; NCGC00166310-01; DSSTox_CID_26600; DSSTox_RID_81755; DSSTox_GSID_46600; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; Marbofloxacine [INN-French]; Marbofloxacinum [INN-Latin]; 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic Acid; Marbofloxacino [INN-Spanish]; CAS-115550-35-1; Marbofloxacin [INN:BAN]; Marbofloxacine/; CCRIS 8212; 9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; PubChem16145; Marbofloxacin (USP/INN); Oprea1_079403; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid; cc-422; SCHEMBL134860; CHEMBL478120; DTXSID4046600; CHEBI:94723; EX-A015; ZINC537947; HY-B0126; RKL10084; Tox21_112406; ABP000382; ANW-42471; s1464; AKOS015853291; Tox21_112406_1; BCP9000896; CCG-229989; CS-1892; DB11426; GS-3323; NCGC00166310-02; NCGC00166310-03; 7H-Pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-piperazino)-7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid; AC-24289; AK327608; AB0105713; DB-041275; FT-0628168; M2240; D08156; AB01566820_01; 550M351; Marbofloxacin, VETRANAL(TM), analytical standard; Q909359; SR-01000772975; Q-201338; SR-01000772975-2; Marbofloxacin, European Pharmacopoeia (EP) Reference Standard; Marbofloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2- diazatricyclo[7.3.1.0^5,13^]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13}]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl -1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)- 7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid" Small molecule "1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)" BPFYOAJNDMUVBL-UHFFFAOYSA-N CN1CCN(CC1)C2=C(C=C3C4=C2OCN(N4C=C(C3=O)C(=O)O)C)F C17H19FN4O4 CAS 115550-35-1 CHEBI:94723 . . . DB11426 . DR6219 Esmolol D03XTC D03XTC Approved Supraventricular tachyarrhythmia ICD-11: BC81 CID: 59768 Anticancer Treatment "ESMOLOL; 81147-92-4; 103598-03-4; Brevibloc; ASL 8052-001; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; CHEBI:88206; (+-)-Esmolol; Esmolol [INN:BAN]; Esmolol (INN); NCGC00185766-01; BRN 5287174; SR-01000763706; Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester; (+/-)-esmolol; CHEMBL768; SCHEMBL3605; GTPL7178; DTXSID4022995; HMS2090P06; HMS3743M15; HMS3886F03; methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; BDBM50404796; CE0048; methyl 3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanoate; methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; MFCD00864566; s5778; AKOS015960734; methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate; methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; DB00187; SL-8052; MRF-0000253; NCGC00185766-02; NCGC00185766-05; AC-12058; ASL-8052-001; DB-015362; E1106; FT-0630886; C06980; D07916; AB00698516-07; AB00698516-09; AB00698516_10; 147E924; L001332; Q418139; SR-01000763706-3; (+/-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionate; 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester; 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionic Acid Methyl Ester; Methyl 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionate / 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionic Acid Methyl Ester" Small molecule "1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3" AQNDDEOPVVGCPG-UHFFFAOYSA-N CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O C16H25NO4 CAS 81147-92-4 CHEBI:88206 . . . DB00187 . DR0268 Imiquimod D06CTE D06CTE Approved Skin cancer ICD-11: 2C30-2C37 CID: 57469 Anticancer Treatment "IMIQUIMOD; 99011-02-6; Aldara; Zyclara; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; Beselna; R 837; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline; R-837; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; S-26308; C14H16N4; 9050-31-1; UNII-P1QW714R7M; MFCD00866946; 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-; CHEMBL1282; 1-isobutylimidazo[4,5-c]quinolin-4-amine; P1QW714R7M; 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; CHEBI:36704; S26308; 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-; NCGC00070736-02; Zartra; Imiquimod acetate; DSSTox_CID_21047; DSSTox_RID_79617; DSSTox_GSID_41047; Aldara (TN); CAS-99011-02-6; S 26308; SR-01000611320; Imiquimodum; Imiquimod [USAN:INN:BAN]; Vyloma; MTD-39; HSDB 8129; zlchem 9; TMX 101; TMX-101; Aldara; ; ; Beselna; Imiquimod,(S); 6T0; Imiquimod - Aldara; Zyclara (TN); DZ-2636; PubChem21071; ACMC-209stx; (non-labelled)Imiquimod-d9; Imiquimod (JAN/USP/INN); SCHEMBL26136; MLS000083577; BIDD:GT0859; GTPL5003; DTXSID7041047; AOB6939; ZLA0010; HMS2090M14; HMS2232G07; HMS3373B13; HMS3715N19; HMS3747A13; Pharmakon1600-01502351; BCP05151; EBD27815; HY-B0180; Tox21_110985; AC-529; ANW-41635; BBL010772; BDBM50240849; NSC369100; NSC759651; s1211; STK583860; ZINC19632912; Imiquimod - CAS 99011-02-6; Imiquimod, >=98% (HPLC), solid; AKOS005507352; Tox21_110985_1; 1H-Imidazo[4, 1-(2-methylpropyl)-; CCG-208015; CS-2058; DB00724; KS-5218; MCULE-9421195760; NSC 369100; NSC 741062; NSC 759651; NSC-369100; NSC-759651; Imiquimod 100 microg/mL in Acetonitrile; NCGC00070736-03; NCGC00070736-04; AK209015; SMR000048307; SY017571; FT-0602727; I0747; D02500; J10325; Z-4416; 1-isobutyl-1H-imidazo [4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine; AB00399298-05; AB00399298-06; AB00399298-07; AB00399298_08; AB00399298_09; 011I026; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine; A845945; Q423417; 1-(2-methylpropyl)-4-imidazo[4,5-c]quinolinamine; SR-01000611320-2; SR-01000611320-3; BRD-K26657438-001-01-2; BRD-K26657438-001-13-7; 1-(2-methylpropyl)-1Himidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine;; Imiquimod, United States Pharmacopeia (USP) Reference Standard; 4-Amino- 1-isobutyl-1H-imidazo[4,5-c]quinoline; 1-(2-Methylpropyl)-1H-imidazo[4,5-C]quinolin-4-amine" Small molecule "1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)" DOUYETYNHWVLEO-UHFFFAOYSA-N CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N C14H16N4 CAS 99011-02-6 CHEBI:36704 . . . DB00724 . DR9491 Atamestane . . Investigative Breast cancer ICD-11: 2C60 CID: 57050 Anticancer Treatment "ATAMESTANE; 96301-34-7; 1-Methylandrosta-1,4-diene-3,17-dione; UNII-62GA3K28B6; SH-489; 62GA3K28B6; Atamestane [INN]; Atamestanum [Latin]; Atamestano [Spanish]; Atamestano; Atamestanum; (8R,9S,10S,13S,14S)-1,10,13-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; CCRIS 6528; Androsta-1,4-diene-3,17-dione, 1-methyl-; Biomed-777; 1-methyl-1,4-androstadiene-3,17-dione; SCHEMBL59128; CHEMBL2105987; ZINC4214890; DB12194; 1-Methyl-androsta-1,4-diene-3,17-dione; 1-Methyl-androsta-1,4 -diene-3,17-dione; Q4812727" Small molecule "1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1" PEPMWUSGRKINHX-TXTPUJOMSA-N CC1=CC(=O)C=C2C1(C3CCC4(C(C3CC2)CCC4=O)C)C C20H26O2 CAS 96301-34-7 . . . . DB12194 . DR8760 Itraconazole D0V4IB D0V4IB Approved Fungal infection ICD-11: 1F29-1F2F CID: 55283 Anticancer Treatment "itraconazole; Oriconazole; 84625-61-6; Sporanox; Itrizole (TN); Sporanox (TN); ITCZ; Itraconazole (Sporanox); Itraconazol [Spanish]; Itraconazolum [Latin]; CHEMBL22587; C35H38Cl2N8O4; cis-Itraconazole; CHEBI:6076; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; ITZ; DSSTox_CID_3180; DSSTox_RID_76908; DSSTox_GSID_23180; 1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-sec-butyl-1,2,4-triazol-3-one; CAS-84625-61-6; R-51211; Intraconazole; Sporanox(TM); NCGC00018268-03; 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; R51211; Itraconazole & Nyotran; Itraconazole (JP17/USP); SCHEMBL23934; 84604-65-9; MLS006011958; AMY922; DTXSID3023180; GTPL11426; Pharmakon1600-01505756; Tox21_110854; 2485AH; AC-542; BDBM50127138; CI0042; MFCD00941396; NSC759239; s2476; AKOS015842738; AKOS015961385; Tox21_110854_1; CCG-270391; DB01167; KS-1268; MCULE-2446846552; NE57775; NSC-759239; NCGC00274068-01; NCGC00274068-02; NCGC00274068-07; 4-(4-(4-(4-(((2R,4S)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 873066-43-4; HY-17514; SMR001827898; Itraconazole & Nyotran(Liposomal Nystatin); SBI-0206914.P001; AB0012897; SW219756-1; Itraconazole 2.0 mg/ml in Dimethyl Sulfoxide; D00350; 24236-EP2281816A1; 24236-EP2314590A1; AB01274818-01; AB01274818_02; AB01274818_03; Q411229; BRD-A23067620-001-01-7; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-[4-[4-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazole-1-ylmethyl)-1,3-dioxolane-4-yl]methoxy]phenyl]piperazino]phenyl]-2-(1-methylpropyl)-4H-1,2,4-triazole-3(2H)-one" Small molecule "1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1" VHVPQPYKVGDNFY-ZPGVKDDISA-N CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl C35H38Cl2N8O4 CAS 84625-61-6 CHEBI:6076 . . . DB01167 . DR3472 Mifepristone D0Z4EI D0Z4EI Approved Cushing syndrome ICD-11: 5A70 CID: 55245 Anticancer Treatment "mifepristone; 84371-65-3; Mifegyne; Mifeprex; RU-486; Corlux; Korlym; RU486; RU 486; RU 38486; Mifepriston; RU-38486; UNII-320T6RNW1F; MLS000069785; 320T6RNW1F; VGX-410C; CHEBI:50692; VGX-410; Mifepristone, 98%; NCGC00025179-05; SMR000058481; Mifepristonum [Latin]; Mifepristona [Spanish]; DSSTox_CID_3322; DSSTox_RID_76976; DSSTox_GSID_23322; (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE; Mifepristona; Mifepristonum; (11beta,17beta)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one; (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one; (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-6,7,8,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; RU486 (tetramethyl-rhodamine conjugated); Mifepristone [USAN:INN:BAN]; HSDB 6841; SR-01000076011; R 38486; BRN 5779404; Pictovir; RU 486-6; CCRIS 9332; 1nhz; 11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; Mifeprex (TN); Pictovir (TM); Prestwick_570; CAS-84371-65-3; Korlym (TN); 2w8y; Mifepristone (Mifeprex); Mifepristone(Mifeprex)/; Opera_ID_562; Mifepristone, >=98%; Prestwick0_000299; Prestwick1_000299; Prestwick2_000299; Prestwick3_000299; Spectrum5_002045; 11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on; 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one; BIDD:PXR0123; Lopac0_000801; SCHEMBL16087; BSPBio_000238; 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on; 11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one; MLS001074115; MLS001424271; (non-labelled)Mifepristone-d3; ARONIS27015; SPBio_002457; RU-486; MIFEPRISTONE; BPBio1_000262; CHEMBL438575; GTPL2805; Mifepristone (JAN/USAN/INN); CHEMBL1276308; DTXSID5023322; BDBM18627; AOB6893; HMS1568L20; HMS2052L05; HMS2090L22; HMS2095L20; HMS2230P21; HMS3262B03; HMS3412D17; HMS3649J08; HMS3676D17; HMS3712L20; HMS3884D12; ACT02598; BCP02145; ZINC3831128; Tox21_110952; Tox21_301841; Tox21_500801; ABP000437; ANW-41472; BDBM50072024; HSCI1_000369; MFCD00867226; s2606; VX-410; AKOS015895416; Tox21_110952_1; CCG-101164; CI-1073; CS-1435; DB00834; LP00801; NC00414; NSC 759862; SDCCGSBI-0050778.P002; Mifepristone 1.0 mg/ml in Acetonitrile; NCGC00025179-06; NCGC00025179-07; NCGC00025179-08; NCGC00025179-09; NCGC00025179-12; NCGC00025179-13; NCGC00025179-23; NCGC00179632-01; NCGC00255152-01; NCGC00261486-01; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; AS-13938; CPD000058481; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-; HY-13683; RU486;C-1073; EU-0100801; C07652; D00585; M 8046; W-5163; 29523-EP2272827A1; 29523-EP2275420A1; 29523-EP2295055A2; 29523-EP2295416A2; 29523-EP2298748A2; 29523-EP2298764A1; 29523-EP2298765A1; 29523-EP2305642A2; 29523-EP2308880A1; 29523-EP2311453A1; 29523-EP2311808A1; 29523-EP2311829A1; 29523-EP2311842A2; 75603-EP2269977A2; 75603-EP2308880A1; 371M653; A840767; Q411240; SR-01000721888; Q-201405; SR-01000076011-1; SR-01000076011-3; SR-01000076011-5; SR-01000076011-9; SR-01000721888-4; BRD-K37270826-001-04-5; BRD-K37270826-001-31-8; Mifepristone, United States Pharmacopeia (USP) Reference Standard; (11?,17?)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11.beta.-[4-(Dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; 11beta-(4-Dimethyl-amino)-phenyl-17beta-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11ss-[p-(Dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one; (11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 122742-25-0; 83203-42-3; Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-" Small molecule "1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1" VKHAHZOOUSRJNA-GCNJZUOMSA-N CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O C29H35NO2 CAS 84371-65-3 CHEBI:50692 . . . DB00834 . DR5662 Pravastatin D02RQU D02RQU Approved Hyper-lipoproteinaemia ICD-11: 5C80 CID: 54687 Anticancer Treatment "pravastatin; 81093-37-0; Pravastatina; Pravastatine; Pravastatinum; Pravachol; Pravastatin acid; PRAVASTATIN SODIUM; UNII-KXO2KT9N0G; KXO2KT9N0G; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; CHEMBL1144; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; Eptastatin; CHEBI:63618; Pravastatine [French]; Pravastatinum [Latin]; Pravastatina [Spanish]; Pravastatin [INN:BAN]; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Mevalothin; Pravator (TN); (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid; Pravastatin (INN); CCRIS 7557; C10AA03; 3beta-Hydroxycompactin; KS-5015; SCHEMBL1117; BIDD:GT0773; GTPL2953; DTXSID6023498; BDBM20688; HSDB 8368; HMS3715P11; ACT02637; HY-B0165; ZINC3798763; 1,4-Butanedisulfonicaciddisodiumsalt; LMFA05000695; s5713; AKOS015895229; CCG-221195; DB00175; NCGC00188962-01; NCGC00188962-02; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-; C01844; D08410; 093P370; SR-01000781259; Q1240093; SR-01000781259-2; BRD-K60511616-236-01-4; BRD-K60511616-236-02-2; BRD-K60511616-236-08-9; (3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-((S)-2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid" Small molecule "1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1" TUZYXOIXSAXUGO-PZAWKZKUSA-N CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O C23H36O7 CAS 81093-37-0 CHEBI:63618 . . . DB00175 . DR6727 Balsalazide D0A6KR D0A6KR Approved Indeterminate colitis ICD-11: DD72 CID: 54585 Anticancer Treatment "BALSALAZIDE; 80573-04-2; Balsalazido; Balsalazida; Balsalazidum; Balsalazidum [Latin]; Balsalazida [Spanish]; Balsalazido [Spanish]; Balsalazide Disodium; Colazide; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; UNII-P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; P80AL8J7ZP; CHEMBL1208641; CHEBI:267413; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid; C17H15N3O6; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; Giazo; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; NCGC00164634-01; Balsalazide [INN:BAN]; DSSTox_CID_20653; DSSTox_RID_79523; DSSTox_GSID_40653; 3-[[4-[(2-carboxyethylamino)-oxomethyl]phenyl]hydrazinylidene]-6-oxo-1-cyclohexa-1,4-dienecarboxylic acid; 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid; (E)-5-[[[-4-(2-Carboxyethyl)aminocarbonyl]phenyl]azo]-2-hydroxybenzoic acid; Balsalazide (INN); CAS-80573-04-2; Balsalazide-[d3]; (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; MLS001424257; BIDD:GT0772; SCHEMBL118300; SCHEMBL138311; SCHEMBL142548; CHEMBL1201346; DTXSID7040653; SCHEMBL15841310; CHEBI:94605; GTPL11569; HMS2052K19; HMS2233C19; HMS3369E09; HMS3394K19; HY-B0667; ZINC3952881; Tox21_112252; ANW-61237; MFCD00868204; s4842; ZINC13863965; AKOS015892568; Tox21_112252_1; ZINC100050064; ZINC100056740; ZINC242522365; AC-8500; CCG-101140; DB01014; KS-5215; NC00390; NE31766; VA10368; Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-; NCGC00164634-02; (3E)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; AS-17568; SMR000469221; AB0020029; FT-0602905; V0740; D07488; AB01209737-01; 573B042; A839951; Q347337; Q-200671; Q27166431; 5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic acid; Bacitracin zinc, Antibiotic for Culture Media Use Only; (E)-5-((4-(2-carboxyethylcarbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; 5-((4-((2-carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; 5-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl)-2-hydroxybenzoic acid; (3E)-3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 3-[[4-(3-hydroxy-3-oxopropylcarbamoyl)phenyl]hydrazinylidene]-6-oxidanylidene-cyclohexa-1,4-diene-1-carboxylic acid; 399030-81-0" Small molecule "1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)" IPOKCKJONYRRHP-UHFFFAOYSA-N C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O C17H15N3O6 CAS 80573-04-2 CHEBI:267413 . . . DB01014 . DR2980 Simvastatin D0H0ND D0H0ND Approved Hyper-lipoproteinaemia ICD-11: 5C80 CID: 54454 Anticancer Treatment "simvastatin; 79902-63-9; Zocor; Synvinolin; Sinvacor; Denan; Lipex; MK-733; Sivastin; Lodales; Simvastatine; Cholestat; Colemin; Simovil; Medipo; Pantok; Simvastatina; Simvastatinum; Velostatin; Zocord; Zorced; Simvastatin lactone; Simvastatin (Zocor); Lipovas; Simcard; Simvacor; Simvoget; Rechol; Simlup; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; MK-0733; UNII-AGG2FN16EV; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; AGG2FN16EV; CHEBI:9150; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Labistatin; Coledis; Corolin; Nivelipol; Rendapid; Vasotenal; Simcor; Simvastatin, 98%; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; C25H38O5; Simvastatine [French]; Simvastatinum [Latin]; Simvastatina [Spanish]; DSSTox_CID_3581; DSSTox_RID_77090; DSSTox_GSID_23581; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Zosta; Simvast CR; DRG-0320; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; SMR000718785; MK 0733; CCRIS 7558; Zocor (TN); HSDB 7208; Simvastatin & Primycin; SR-05000001894; MK 733; L 644128-000U; BRN 4768037; Kolestevan; Lipinorm; Modutrol; Simvotin; Sinvascor; Valemia; Eucor; MFCD00072007; Nor-Vastina; Simvastatin,(S); C10AA01; simvastatin predrug; (+)-Simvastatin; NCGC00016940-01; inactive simvastatin; 8-[2-((2R,4R)-4-hydroxy-6-oxo(2H-3,4,5-trihydropyran-2-yl))ethyl](1S,7S,8S,3R, 8aR)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthyl 2,2-dimethylbutanoate; Simvastatin [USAN:USP:INN:BAN]; TNP00259; Prestwick_171; CAS-79902-63-9; KS-1113; Spectrum_001717; SpecPlus_000895; Prestwick0_000865; Prestwick1_000865; Prestwick2_000865; Prestwick3_000865; Spectrum2_001671; Spectrum3_000669; Spectrum4_000632; Spectrum5_001428; SCHEMBL2471; CHEMBL1064; BSPBio_000909; BSPBio_002337; KBioGR_001244; KBioSS_002197; MLS001304029; MLS001333077; MLS001333078; MLS002154038; MLS006011866; ARONIS24119; BIDD:GT0769; DivK1c_006991; SPECTRUM1504236; SPBio_001881; SPBio_002830; BPBio1_001001; GTPL2955; Simvastatin (JP17/USP/INN); Simvastatin, analytical standard; DTXSID0023581; BCBcMAP01_000007; KBio1_001935; KBio2_002197; KBio2_004765; KBio2_007333; KBio3_001557; RYMZZMVNJRMUDD-HGQWONQESA-; HMS1570N11; HMS1922H13; HMS2089D12; HMS2093E06; HMS2097N11; HMS2231N22; HMS3259B12; HMS3412P08; HMS3676P08; HMS3714N11; HMS3884G10; Pharmakon1600-01504236; ZINC3780893; Tox21_110696; Tox21_300400; BBL024390; BDBM50139181; CCG-39069; NSC633782; NSC758706; s1792; SBB080618; STK801938; AKOS005111006; AKOS015842733; Simvastatin, >=97% (HPLC), solid; Tox21_110696_1; AC-1530; AT-7048; DB00641; MCULE-8390617062; NC00719; NSC 758706; NSC-633782; NSC-758706; MRF-0000729; NCGC00017324-01; NCGC00017324-02; NCGC00017324-03; NCGC00017324-04; NCGC00017324-05; NCGC00017324-07; NCGC00017324-08; NCGC00017324-09; NCGC00254418-01; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-; HY-17502; ST057168; SBI-0206773.P001; Simvastatin 100 microg/mL in Acetonitrile; AB0069097; D00434; J10128; W-3044; 28049-EP2269989A1; 28049-EP2269990A1; 28049-EP2270011A1; 28049-EP2270505A1; 28049-EP2272825A2; 28049-EP2272841A1; 28049-EP2277865A1; 28049-EP2280001A1; 28049-EP2280006A1; 28049-EP2281813A1; 28049-EP2284158A1; 28049-EP2287165A2; 28049-EP2287166A2; 28049-EP2292620A2; 28049-EP2295406A1; 28049-EP2295409A1; 28049-EP2295417A1; 28049-EP2295422A2; 28049-EP2298731A1; 28049-EP2298742A1; 28049-EP2298745A1; 28049-EP2298769A1; 28049-EP2298772A1; 28049-EP2298776A1; 28049-EP2298779A1; 28049-EP2301923A1; 28049-EP2301931A1; 28049-EP2301936A1; 28049-EP2305219A1; 28049-EP2305648A1; 28049-EP2308839A1; 28049-EP2308878A2; 28049-EP2314588A1; 96639-EP2287163A1; 96639-EP2305678A1; 99548-EP2270011A1; 99548-EP2298779A1; 99548-EP2301923A1; 99548-EP2301931A1; AB00053395-07; AB00053395-08; AB00053395-10; AB00053395_11; AB00053395_13; 902S639; Q670131; SR-05000001894-1; SR-05000001894-2; BRD-K22134346-001-05-8; BRD-K22134346-001-11-6; BRD-K22134346-001-15-7; Z1741982918; Simvastatin, British Pharmacopoeia (BP) Reference Standard; Simvastatin, European Pharmacopoeia (EP) Reference Standard; Simvastatin, United States Pharmacopeia (USP) Reference Standard; Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material; Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyly-2,2-dimethyl butanoate; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbu; (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate" Small molecule "1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1" RYMZZMVNJRMUDD-HGQWONQESA-N CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C C25H38O5 CAS 79902-63-9 CHEBI:9150 . . . DB00641 . DR7302 Latamoxef D0O5LU D0O5LU Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 47499 Anticancer Treatment "Latamoxef; moxalactam; Lamoxactam; Latamoxefum; 64952-97-2; Oxa-cephem; Festamoxin; LMOX; Moxam; Listeria mox supplement; CHEBI:599928; Disodium Moxalactam; 64952-97-2 (FREE ACID); Latamoxefum [INN-Latin]; (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Latamoxef [INN:BAN]; Latamoxef (INN); EINECS 265-287-9; Spectrum_000971; Prestwick0_000819; Prestwick1_000819; Prestwick2_000819; Spectrum2_001067; Spectrum3_000510; Spectrum4_000064; Spectrum5_001371; MOXALACTAMSUPPLEMENT; Epitope ID:180870; BSPBio_002039; KBioGR_000587; KBioSS_001451; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid; CHEMBL74632; DivK1c_000909; SCHEMBL194012; SPBio_001054; SPBio_002638; DTXSID9023338; KBio1_000909; KBio2_001451; KBio2_004019; KBio2_006587; KBio3_001539; NINDS_000909; BCP12584; 7002AB; BDBM50370589; DB04570; Moxalactam Supplement, for microbiology; IDI1_000909; SMP1_000200; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (6R-(6alpha,7alpha,7(S*)))-; 79120-38-0; SBI-0051450.P003; C07231; D08109; 649L972; Q3827439; (6R,7R)-7-(2-carboxy-2-(4-hydroxyphenyl)acetamido)-7-methoxy-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxo-propanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[2-Carboxy-2-(p-hydroxyphenyl)acetylamino]-7-methoxy-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7alpha,7(S*)))-; 5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-; 5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2R)-carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,(6R,7R)-" Small molecule "1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1" JWCSIUVGFCSJCK-CAVRMKNVSA-N CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O C20H20N6O9S CAS 64952-97-2 CHEBI:599928 . . . DB04570 . DR8953 Captopril D0I0EG D0I0EG Approved Hypertension ICD-11: BA00-BA04 CID: 44093 Anticancer Treatment "captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Acepress; Captoril; Dilabar; Garranil; Hypertil; Tenosbon; Alopresin; Acepril; Lopril; Captoprilum; Acediur; Aceplus; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; Tensobon; Apopril; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; SQ 14,225; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; SA 333; D-3-Mercapto-2-methylpropionylproline; 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; UNII-9G64RSX1XD; Hipertil; CHEBI:3380; L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-; L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-; 9G64RSX1XD; CHEMBL1560; 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline; MLS000069484; Asisten; Isopresol; (-)-Captopril; C9H15NO3S; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; Captopril, 98%; MFCD00168073; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; NCGC00023654-04; SMR000059061; Lopirin [Switzerland]; (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid; 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)-; DSSTox_CID_17197; DSSTox_RID_79306; DSSTox_GSID_37197; L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)-; Novocaptopril; Captril; Farcopril; Hypopress; Tensiomin; Zapto; Captopril (Capoten); Capozide (Salt/Mix); 3-Mercapto-2-methylpropionyl-proline; X8Z; Apopril (TN); Capoten (TN); HSDB 6527; 1-[(2s)-3-mercapto-2-methylpropionyl]-l-proline; SR-01000075603; EINECS 263-607-1; component of Captea (Salt/Mix); component of Acezide (Salt/Mix); component of Ecazide (Salt/Mix); 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); (2S)-1-((2S)-2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid; C09AA01; Captopril,(S); Prestwick_103; Captopril [USAN:USP:INN:BAN:JAN]; SQ14534; SCHEMBL4; Spectrum_000688; Opera_ID_1041; Prestwick3_000019; Spectrum2_001211; Spectrum3_001388; Spectrum4_000811; Spectrum5_001587; Lopac-C-4042; 1-((2S)-2-Methyl-3-sulfanylpropanoyl)-L-proline #; Epitope ID:114065; UPCMLD-DP003; C 4042; Lopac0_000302; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline; BSPBio_000057; BSPBio_002976; KBioGR_001321; KBioSS_001168; MLS001076488; DivK1c_000208; SPECTRUM1500682; SPBio_001022; Captopril (JP17/USP/INN); (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; BPBio1_000063; GTPL5158; DTXSID1037197; UPCMLD-DP003:001; BDBM21642; HMS500K10; KBio1_000208; KBio2_001168; KBio2_003736; KBio2_006304; KBio3_002196; ZINC57001; 1j37; NINDS_000208; HMS1921C12; HMS2089P19; HMS2092I12; HMS2095C19; HMS2233I04; HMS3259G10; HMS3260N06; HMS3712C19; Pharmakon1600-01500682; HY-B0368; Tox21_110890; Tox21_500302; BBL033600; CCG-39104; EI-213; KM0635; NSC757419; s2051; SA-333; SBB017523; STK802012; AKOS005622581; Captopril, >=98% (HPLC), powder; Tox21_110890_1; AB04252; BCP9000485; CS-2425; DB01197; KS-5025; LP00302; MCULE-1716939647; NC00554; NSC 757419; NSC-757419; SDCCGSBI-0050290.P006; IDI1_000208; SMP1_000056; NCGC00015235-01; NCGC00015235-02; NCGC00023654-03; NCGC00023654-05; NCGC00023654-06; NCGC00023654-07; NCGC00023654-08; NCGC00023654-09; NCGC00023654-10; NCGC00023654-11; NCGC00023654-13; NCGC00023654-25; NCGC00260987-01; AC-12047; AC-32120; ST079562; SBI-0050290.P004; AB0007072; Captopril, meets USP testing specifications; SQ -14225; EU-0100302; ((S)-3-mercapto-2-methylpropanoyl)-L-proline; BIM-0050290.0001; C06867; D00251; J10167; 54254-EP2269989A1; 54254-EP2270011A1; 54254-EP2272841A1; 54254-EP2277879A1; 54254-EP2287165A2; 54254-EP2287166A2; 54254-EP2292620A2; 54254-EP2295406A1; 54254-EP2298742A1; 54254-EP2298772A1; 54254-EP2298776A1; 54254-EP2298779A1; 54254-EP2301923A1; 54254-EP2301931A1; 54254-EP2301936A1; 54254-EP2305219A1; 54254-EP2305648A1; 54254-EP2308562A2; 54254-EP2308839A1; AB00052156-16; AB00052156_17; AB00052156_18; 571C862; Q421119; SR-01000000039; 1-[(2S)-3-Mercapto-2-methylpropionyl]- L-proline; SR-01000000039-2; SR-01000075603-1; SR-01000075603-3; 1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline; BRD-K54529596-001-04-0; BRD-K54529596-001-15-6; Captopril, British Pharmacopoeia (BP) Reference Standard; Z2786051697; Captopril, European Pharmacopoeia (EP) Reference Standard; Captopril, United States Pharmacopeia (USP) Reference Standard; Captopril, Pharmaceutical Secondary Standard; Certified Reference Material; L-?Proline, 1-?[(2S)?-?3-?mercapto-?2-?methyl-?1-?oxopropyl]?-; Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard" Small molecule "1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1" FAKRSMQSSFJEIM-RQJHMYQMSA-N CC(CS)C(=O)N1CCCC1C(=O)O C9H15NO3S CAS 62571-86-2 CHEBI:3380 . . . DB01197 . DR6681 Epirubicin D0C9XJ D0C9XJ Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 41867 Anticancer Treatment "Epirubicin; Epiadriamycin; Epidoxorubicin; 4'-Epiadriamycin; Ellence; 56420-45-2; Epirubicine; Epirubicinum; Pidorubicina; Pidorubicine; Pidorubicinum; Epirubicina; 4'-epidoxorubicin; 4-Epidoxorubicin; Epirubicin hydrochloride; Pidorubicin; Epirubicin free base; UNII-3Z8479ZZ5X; Ridorubicin; NSC 256942; CHEBI:47898; Epi-DX; Epirubicine [French]; Epirubicinum [Latin]; 3Z8479ZZ5X; Epirubicina [Spanish]; IMI 28; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Epirubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; 56420-45-2 (FREE BASE); Pidorubicina [INN-Spanish]; Epirubicin [INN:BAN]; NSC-256942; WP 697; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; Epirubicin (INN); Farmorubicin (TN); CCRIS 2261; HSDB 6962; NSC256942; BRN 1445813; DM6; Acid, 8; CHEMBL417; SCHEMBL8582; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; DTXSID0022987; EPIRUBICIN(Hydrochloride form); BDBM43839; Doxorubicin-13CD3 (discontinued); ZINC3938704; DB00445; VA10821; NCGC00263918-04; NCGC00263918-08; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; HY-13624; SBI-0206890.P001; A12409; C11230; D07901; 15206-EP2269994A1; 15206-EP2270008A1; 15206-EP2270018A1; 15206-EP2272827A1; 15206-EP2275420A1; 15206-EP2280012A2; 15206-EP2281815A1; 15206-EP2289892A1; 15206-EP2292615A1; 15206-EP2292617A1; 15206-EP2295055A2; 15206-EP2295416A2; 15206-EP2295426A1; 15206-EP2295427A1; 15206-EP2298748A2; 15206-EP2298764A1; 15206-EP2298765A1; 15206-EP2298768A1; 15206-EP2298778A1; 15206-EP2298780A1; 15206-EP2301928A1; 15206-EP2301933A1; 15206-EP2305640A2; 15206-EP2305642A2; 15206-EP2305671A1; 15206-EP2305689A1; 15206-EP2308855A1; 15206-EP2308861A1; 15206-EP2311453A1; 15206-EP2311808A1; 15206-EP2311825A1; 15206-EP2311827A1; 15206-EP2311829A1; 15206-EP2311840A1; 15206-EP2311842A2; 15206-EP2316832A1; 15206-EP2316833A1; AB00698552-11; AB00698552-13; AB00698552-14; AB00698552_15; AB00698552_16; A831042; Q425122; BRD-K04548931-003-16-5; (7S,9S)-7-[(2R,4S,5R,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; 4'-Epidoxorubicin; ; ; 4'-Epiadriamycin; ; ; (8S,10S)-10-(((2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-; 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-" Small molecule "1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1" AOJJSUZBOXZQNB-VTZDEGQISA-N CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O C27H29NO11 CAS 56420-45-2 CHEBI:47898 . . . DB00445 . DR1112 Nitazoxanide D08EBN D08EBN Approved Bowel habit change ICD-11: ME05 CID: 41684 Anticancer Treatment "NITAZOXANIDE; 55981-09-4; Alinia; Nitazoxamide; 2-((5-nitrothiazol-2-yl)carbamoyl)phenyl acetate; Daxon; Nitazoxanidum [INN-Latin]; Nitazoxanida [INN-Spanish]; Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)-; 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate; 2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide; C12H9N3O5S; [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate; UNII-SOA12P041N; NTZ; NSC697855; 2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide; Nitazoxanide (Alinia, Annita); SOA12P041N; Nitazoxanida; Nitazoxanide-d4; 2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide; MFCD00416599; NSC-697855; PH 5776; PH-5776; NCGC00090774-01; Nitazoxanid; Nitazoxanidum; Colufase; Cryptaz; Heliton; DSSTox_CID_13757; DSSTox_RID_79095; DSSTox_GSID_33757; Phavic-1; acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester; SMR000466367; NSC 697855; Alinia (TN); AZT + Nitazoxanide; CAS-55981-09-4; 1246819-17-9; EINECS 259-931-8; Nitazoxanide (USAN/INN); (2-((5-Nitro-2-thiazolyl)carbamoyl)phenyl)acetat; BRN 1225475; N-(5-Nitro-2-thiazolyl)salicylamide acetate (ester); Nitrazoxanide; Pacovanton; Dexidex; Kidonax; Nitazox; Paramix; Nitax; Toza; Nitazoxanide [USAN:INN:BAN]; Alinia(TM); N-(5-Nitrothiazol-2-yl)salicylamide acetate ester; o-(N-(5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate; Salicylamide, N-(5-nitro-2-thiazolyl)-, acetate (ester); CPD000466367; NCIMech_000843; CHEMBL1401; Oprea1_263587; SCHEMBL40981; MLS000759492; MLS001424074; MLS006010127; [2-[(5-nitrothiazol-2-yl)carbamoyl]phenyl] acetate; DTXSID5033757; CHEBI:94807; Nitazoxanide, >=98% (HPLC); NTZ;NSC 697855; HMS2051L04; HMS3393L04; HMS3655M11; HMS3715F10; Pharmakon1600-01503843; BCP13918; HY-B0217; ZINC3956788; Tox21_111018; Tox21_201226; BDBM50075050; CCG-35851; CN0040; MMV688991; NSC760057; STK395664; AKOS015915393; Tox21_111018_1; AC-1302; DB00507; KS-1160; MCULE-8701444531; NC00246; NSC-760057; NCGC00090774-02; NCGC00090774-03; NCGC00090774-04; NCGC00090774-05; NCGC00258778-01; AK-26130; NCI60_034935; AB0010620; FT-0601547; N1031; Nitrazoxanide 100 microg/mL in Acetonitrile; S1627; ST51059722; SW197626-2; 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl acetate; D02486; J10428; S-3645; AB00639988-07; AB00639988-09; AB00639988_10; AB00639988_11; 981N094; A830877; Q-201475; Q2943789; NTZ; 2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide; Salicylamide, N-(5-nitro-2-thiazolyl)- acetate (ester); Z1514087129; 2-[N-(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate; [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] ethanoate; Nitazoxanide, United States Pharmacopeia (USP) Reference Standard; [2,3,4,5-tetradeuterio-6-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate; Zox" Small molecule "1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)" YQNQNVDNTFHQSW-UHFFFAOYSA-N CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-] C12H9N3O5S CAS 55981-09-4 CHEBI:94807 . . . DB00507 . DR2507 Trolox . . Investigative Lung cancer ICD-11: 2C25 CID: 40634 Anticancer Treatment "trolox; 53188-07-1; 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; TROLOX C; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-; MFCD00006846; 56305-04-5; CHEBI:82625; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; Trolox(R), 97%; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-chromane-2-carboxylic acid; EINECS 258-422-8; BRN 5052542; Trolox?; Trolox; Trolox(TM); Prestwick_855; ACMC-20apju; ACMC-1ATBW; Prestwick0_000530; Prestwick1_000530; Prestwick2_000530; Prestwick3_000530; CHEMBL153; SCHEMBL3226; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-, (+-)-; Oprea1_727377; BSPBio_000519; MLS002153860; SPBio_002440; BPBio1_000571; DTXSID60866306; HMS1569J21; HMS2096J21; HMS2230A15; HMS3369E20; HMS3713J21; HMS3885K19; BCP16474; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid; ANW-31653; BBL103047; BDBM50359629; GEO-03688; s3665; SBB005933; STL556856; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid; AKOS015856256; CCG-207912; CS-8035; MCULE-8649288753; NCGC00179534-01; AK116067; AS-30121; SMR001233218; ST057520; DB-052268; DB-071631; HY-101445; FT-0621156; FT-0770514; Q245489; SR-01000841227; SR-01000841227-2; BRD-A17846016-001-03-0; BRD-A17846016-001-07-1; 6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromancarboxylic acid; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid #; 6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)carboxylic acid; (+/-)- 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; (+/-)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, 97%; (S)-(-)-6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLICACID; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzo-pyran-2-carboxylic Acid; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic Acid;; 6-hydroxy-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid" Small molecule "1S/C14H18O4/c1-7-8(2)12-10(9(3)11(7)15)5-6-14(4,18-12)13(16)17/h15H,5-6H2,1-4H3,(H,16,17)" GLEVLJDDWXEYCO-UHFFFAOYSA-N CC1=C(C2=C(CCC(O2)(C)C(=O)O)C(=C1O)C)C C14H18O4 CAS 53188-07-1 CHEBI:82625 . . . . . DR2430 Deoxynivalenol . . Investigative Lung cancer ICD-11: 2C25 CID: 40024 Anticancer Treatment "DEOXYNIVALENOL; 51481-10-8; Vomitoxin; Dehydronivalenol; 4-Deoxynivalenol; 4-Desoxynivalenol; Desoxynivalenol; UNII-JT37HYP23V; Rd toxin; JT37HYP23V; 3alpha,7alpha,15-Trihydroxy-12,13-epoxytrichothec-9-en-8-one; 3?,7?,15-Trihydroxy-12,13-epoxytrichothec-9-en-8-one; (3beta,7alpha)-3,7,15-Trihydroxy-12,13-Epoxytrichothec-9-En-8-One; Trichothec-9-en-8-one, 12,13-epoxy-3,7,15-trihydroxy-, (3a,7a)-; NSC 269144; CCRIS 7801; (3alpha,7alpha)-3,7,15-trihydroxy-12,13-epoxytrichothec-9-en-8-one; Deoxynivalenol 100 microg/mL in Acetonitrile; HSDB 7245; 12,13-Epoxy-3-alpha,7-alpha,15-trihydroxy-9-trichothecen-8-one; CHEMBL513300; SCHEMBL2694361; DTXSID3020382; CHEBI:10022; Deoxynivalenol, reference material; HY-N6684; ZINC5457778; CD0228; MFCD09039270; AKOS024457908; CS-W012154; Trichothec-9-en-8-one, 12,13-epoxy-3,7,15-trihydroxy-, (3-alpha,7-alpha)-; B7557; Q420518; (3beta,7alpha,12R)-3,7,15-trihydroxy-12,13-epoxytrichothec-9-en-8-one; 4-Deoxynivalenol in acetonitrile, IRMM(R) certified Reference Material; Deoxynivalenol solution, 100 mug/mL in acetonitrile, analytical standard; Deoxynivalenol solution, 200 mug/mL in ethyl acetate: methanol (95:5), analytical standard; 3J6; Deoxynivalenol solution, certified reference material, 200 mug/mL in ethyl acetate: methanol (95:5), ampule of 1 mL" Small molecule "1S/C15H20O6/c1-7-3-9-14(5-16,11(19)10(7)18)13(2)4-8(17)12(21-9)15(13)6-20-15/h3,8-9,11-12,16-17,19H,4-6H2,1-2H3/t8-,9-,11-,12-,13-,14-,15+/m1/s1" LINOMUASTDIRTM-QGRHZQQGSA-N CC1=CC2C(C(C1=O)O)(C3(CC(C(C34CO4)O2)O)C)CO C15H20O6 CAS 51481-10-8 CHEBI:10022 . . . . . DR2599 Vecuronium D0Z8HG D0Z8HG Approved Tonus and reflex abnormality ICD-11: MB47 CID: 39765 Anticancer Treatment "Vecuronium; 86029-43-8; CHEBI:9939; UNII-5438723848; Piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-; 50700-72-6; ORG-NC 45; 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium; NCGC00167467-01; Musculax; Vecuronium cation; Epitope ID:116647; GTPL4002; CHEMBL1201219; DTXSID1044146; SCHEMBL13575838; HMS2090D22; ZINC4097404; BDBM50424713; ORG NC 45 / ORG-NC 45; AKOS025290368; DB01339; MCULE-4520566918; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; C07553; AB00698366-05; AB00698366-07; AB00698366_08; Q421224; BRD-K20168442-004-06-3" Small molecule "1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1" BGSZAXLLHYERSY-XQIGCQGXSA-N CC(=O)OC1CC2CCC3C(C2(CC1N4CCCCC4)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C C34H57N2O4+ CAS 86029-43-8 CHEBI:9939 . . . DB01339 . DR2116 Lonidamine D09SIR D09SIR Discontinued in Phase 3 Prostate hyperplasia ICD-11: GA90 CID: 39562 Anticancer Treatment "lonidamine; 50264-69-2; 1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid; Diclondazolic acid; Doridamina; DICA; Lonidamina; Lonidaminum; Lonidamin; AF 1890; 1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid; 1-(2,4-Dichlorbenzyl)-indazole-3-carboxylic acid; UNII-U78804BIDR; C15H10Cl2N2O2; 1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid; 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid; AF-1890; MLS000028822; U78804BIDR; CHEBI:50138; 1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-; AF-1890;Diclondazolic Acid;DICA; MFCD00866285; NCGC00015609-03; SMR000058467; DSSTox_CID_782; DSSTox_RID_75787; DSSTox_GSID_20782; Lonidaminum [INN-Latin]; Lonidamina [INN-Spanish]; Doridamina (TN); Dichlondazolic acid; Lonidamine (INN); CAS-50264-69-2; CCRIS 3516; Lonidamine [INN:BAN]; SR-01000075961; EINECS 256-510-0; BRN 0894483; KN-228; TH-070; Tocris-1646; Lopac-L-4900; L 4900; SCHEMBL7134; Lopac0_000718; cid_39562; ZINC1632; CHEMBL1257030; DTXSID5020782; BDBM59775; 1H-Indazole-3-carboxylic acid, 1-(2,4-dichlorobenzyl)-; HMS2234H24; HMS3262O17; HMS3268K09; HMS3369I01; HMS3412P05; HMS3651F09; HMS3676P05; HMS3874D03; Pharmakon1600-01503225; 1H-Indazole-3-carboxylicacid, 1-[(2,4-dichlorophenyl)methyl]-; ACT02617; BCP06555; HY-B0486; Tox21_110181; Tox21_202306; Tox21_500718; NSC741419; NSC758419; s2610; AKOS012842739; Tox21_110181_1; AC-5626; CCG-204803; DB06266; LP00718; NSC 741419; NSC 758419; NSC-741419; NSC-758419; SDCCGSBI-0050696.P003; NCGC00015609-01; NCGC00015609-02; NCGC00015609-04; NCGC00015609-05; NCGC00015609-06; NCGC00015609-07; NCGC00015609-08; NCGC00015609-09; NCGC00015609-16; NCGC00025244-01; NCGC00025244-02; NCGC00025244-03; NCGC00259855-01; NCGC00261403-01; AS-11653; SBI-0050696.P002; AB0010495; AM20060642; EU-0100718; FT-0650359; SW219810-1; Lonidamine, mitochondrial hexokinase inhibitor; D07257; J90044; S-4929; AB00597141_08; AB00597141_10; 264L692; Q-201318; Q3836670; SR-01000075961-1; SR-01000075961-3; SR-01000075961-6; BRD-K78513633-001-03-3; BRD-K78513633-001-06-6; Z1741977188; 1-[(2,4-dichlorophenyl)methyl]-3-indazolecarboxylic acid; 1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)- (9CI)" Small molecule "1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21)" WDRYRZXSPDWGEB-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O C15H10Cl2N2O2 CAS 50264-69-2 CHEBI:50138 . . . DB06266 . DR9285 Diltiazem D0OB1J D0OB1J Approved Hypertension ICD-11: BA00-BA04 CID: 39186 Anticancer Treatment "diltiazem; 42399-41-7; d-cis-Diltiazem; Cardizem; Dilt-cd; Diltiazemum; Anoheal; Diltzac; Tiamate; (+)-diltiazem; Cardil; Dilren; Tiazac; (+)-cis-diltiazem; Diltiazen; UNII-EE92BBP03H; Diltiazem free base; CRD-401; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; CHEMBL23; Dilcontin; Dilticard; Endrydil; Acalix; Dilzen; Dilta-Hexal; EE92BBP03H; Incoril AP; CHEBI:101278; 42399-41-7 (free base); (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; NCGC00024309-05; DSSTox_CID_2940; Diltiazem [INN:BAN]; Dilacor-XR; DSSTox_RID_76797; Diltiazemum [INN-Latin]; DSSTox_GSID_22940; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; Diltiazem (INN); [(2~{S},3~{S})-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxidanylidene-2,3-dihydro-1,5-benzothiazepin-3-yl] ethanoate; Surazem (TN); CAS-42399-41-7; HSDB 6528; Cardizem (Hydrochloride); MK-793 (Malate); RG-83606; EINECS 255-796-4; BRN 3573079; tetrahydrobenzo; RG 83606 (Hydrochloride); Diltiazem HCI; D-(cis)-diltiazem; Tocris-0685; 103532-26-9; Prestwick0_000134; Prestwick1_000134; Prestwick2_000134; Prestwick3_000134; Lopac0_000327; SCHEMBL17776; BSPBio_000208; BSPBio_001311; LITHIUMDICYCLOHEXYLAMIDE; BIDD:GT0548; SPBio_002147; BPBio1_000230; GTPL2298; DTXSID9022940; Bio1_000371; Bio1_000860; Bio1_001349; HMS1791B13; HMS1989B13; HMS2089H09; ZINC621893; [b][1,4]thiazepin-3-yl acetate; Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; methoxyphenyl)-4-oxo-2,3,4,5-; Tox21_110898; AC-936; BDBM50004704; CD0163; AKOS015897257; Tox21_110898_1; CCG-204422; DB00343; MCULE-9931403933; SDCCGSBI-0050315.P002; VA10739; NCGC00024309-02; NCGC00024309-04; NCGC00024309-06; NCGC00024309-07; NCGC00024309-08; NCGC00024309-09; NCGC00024309-10; NCGC00024309-11; NCGC00024309-17; NCGC00024309-21; NCGC00024309-27; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)-; C06958; D07845; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-; Q422229; W-106274; BRD-K24023109-001-02-5; BRD-K24023109-003-03-9; BRD-K24023109-003-11-2; BRD-K24023109-003-20-3; 8-Chloro-1-methyl-6-phenyl-4H-2,3,5,10b-tetraaza-benzo[e]azulene; 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester(Diltiazem)Acetic acid; Acetic acid (S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester (Diltiazem); Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester(cis-(+)-Diltiazem); Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; hydrochloride; C9F; cis-Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; diltiazem;Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester" Small molecule "1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1" HSUGRBWQSSZJOP-RTWAWAEBSA-N CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC C22H26N2O4S CAS 56209-45-1 CHEBI:101278 . . . DB00343 . DR5893 Bezafibrate D00WCX D00WCX Approved Hyper-lipoproteinaemia ICD-11: 5C80 CID: 39042 Anticancer Treatment "bezafibrate; 41859-67-0; Bezalip; Cedur; Bezafibrat; Befizal; Sklerofibrat; Azufibrat; Bezatol; Bezafibratum; Bezafibrato; Bezafibratum [INN-Latin]; Bezafibrato [INN-Spanish]; Bezatol SR (TN); BM-15.075; UNII-Y9449Q51XH; Difaterol; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; BM 15.075; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid; BM-15075; MLS000028533; CHEMBL264374; durabezur; Reducterol; Bezabeta; Bezacur; Bezamerck; Eulitop; Solibay; CHEBI:47612; Lipox; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; Bezafibrat PB; Y9449Q51XH; Beza-Lande; Beza-Puren; Regadrin B; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid; Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-; MFCD00078970; BM15075; NCGC00016850-01; SMR000058298; Bezafibrato [Spanish]; Bezalip Retard; CAS-41859-67-0; DSSTox_CID_9869; Propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; DSSTox_RID_78826; DSSTox_GSID_29869; 2-(4-(2-(4-Chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic acid; 2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid; BM 15075; LO 44; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid; 2-[P-[2-P-CHLOROBENZAMIDO)ETHYL]PHENOXY]-2-METHYLPROPIONIC ACID; BF-759; CCRIS 9085; SR-01000000106; EINECS 255-567-9; BRN 4267656; Bezalip SR; Bezafibrate,(S); Bezafibrate [USAN:INN:BAN:JAN]; PEM; Prestwick_724; BENAFIBRATE; PubChem4066; Spectrum_001443; Opera_ID_376; Prestwick0_000378; Prestwick1_000378; Prestwick2_000378; Prestwick3_000378; Spectrum2_000922; Spectrum3_001500; Spectrum4_000325; Spectrum5_001079; Spectrum5_001967; SCHEMBL16299; Bezafibrate-d6(dimethyl-d6); BSPBio_000535; BSPBio_001314; BSPBio_003119; KBioGR_000034; KBioGR_000669; KBioSS_000034; KBioSS_001923; MLS001148205; Bezafibrate, >=98%, solid; DivK1c_000092; SPECTRUM1502046; SPBio_000824; SPBio_002456; BPBio1_000589; GTPL2668; DTXSID3029869; BDBM28701; Bezafibrate (JP17/USAN/INN); HMS500E14; KBio1_000092; KBio2_000034; KBio2_001923; KBio2_002602; KBio2_004491; KBio2_005170; KBio2_007059; KBio3_000067; KBio3_000068; KBio3_002619; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; NINDS_000092; Bio2_000034; Bio2_000514; HMS1361B16; HMS1569K17; HMS1791B16; HMS1921H16; HMS1989B16; HMS2089F04; HMS2092B12; HMS2096K17; HMS2233E22; HMS3261D21; HMS3369B13; HMS3402B16; HMS3650K22; HMS3652M22; HMS3713K17; Pharmakon1600-01502046; BCP03700; HY-B0637; ZINC3956919; Tox21_110645; Tox21_301845; Tox21_500500; ANW-42342; CCG-39683; NSC758174; s4159; AKOS005107743; Tox21_110645_1; AB03023; AC-6817; BCP9000398; DB01393; HS-0040; LP00500; MCULE-9775992840; NSC 758174; NSC-758174; SB17361; SDCCGSBI-0051715.P003; VA10400; IDI1_000092; IDI1_033784; NCGC00016850-02; NCGC00016850-03; NCGC00016850-04; NCGC00016850-05; NCGC00016850-06; NCGC00016850-07; NCGC00016850-08; NCGC00016850-09; NCGC00016850-10; NCGC00016850-11; NCGC00016850-12; NCGC00016850-15; NCGC00016850-25; NCGC00023317-03; NCGC00023317-04; NCGC00023317-05; NCGC00023317-06; NCGC00023317-07; NCGC00023317-08; NCGC00255376-01; NCGC00261185-01; Bezafibrate, analytical reference material; BCP0726000153; Bezafibrate 100 microg/mL in Acetonitrile; SBI-0051715.P002; 2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy); AB00052265; B3346; FT-0622617; ST51014927; SW196871-4; D01366; K-8763; AB00052265-15; AB00052265_16; AB00052265_17; 859B670; Q577387; SR-01000000106-3; SR-01000000106-4; SR-01000000106-5; W-106291; BRD-K46018455-001-06-0; BRD-K46018455-001-17-7; SR-01000000106-10; Bezafibrate, European Pharmacopoeia (EP) Reference Standard; 2-(4-(2-parachlorobenzamidoethyl)phenoxy)-2-methylpropionic acid; 2-[4-[2-(4-chlorobezamide)ethyl]phenoxy]-2-methylpropanoic acid; 2-(4-{2-[(4-chlorophenyl)carbonylamino]ethyl}phenoxy)-2-methylpropanoic acid; 2-[4-(2-{[(4-chlorophenyl)carbonyl]amino}ethyl)phenoxy]-2-methylpropanoic acid; BF; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl propanoic acid" Small molecule "1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)" IIBYAHWJQTYFKB-UHFFFAOYSA-N CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl C19H20ClNO4 CAS 41859-67-0 CHEBI:47612 . . . DB01393 . DR5724 Ribavirin D0H3WI D0H3WI Approved Hepatitis virus infection ICD-11: 1E51 CID: 37542 Anticancer Treatment "ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Copegus; Vilona; Ribavirine; Viramid; Ribamide; Ribamidil; Ribasphere; Ribavirina; Ribavirinum; Ribavirine [INN-French]; Ribavirinum [INN-Latin]; ICN-1229; Ribavirina [INN-Spanish]; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; RTCA; RBV; SCH 18908; UNII-49717AWG6K; Ribamidyl; Ribavirin (Copegus); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; MFCD00058564; Rebetron; Varazid; Ribavirin Capsules; CHEBI:63580; 49717AWG6K; Ribavirin, 98%; 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide; Rebretron; Virazid; Virazide; Ribav; DSSTox_CID_3557; DSSTox_RID_77081; DSSTox_GSID_23557; RTC; 1-(beta-D-Ribofuranosyl)-1,2,4-triazole-3-carboxamide; Cotronak; Ravanex; Ribacine; NSC-163039; C-Virin; DRG-0028; Ribasphere (TN); Virazole (TN); SMR000058315; Copegus (TN); Rebetol (TN); HSDB 6513; SR-01000076112; BRN 0892462; Ribavirine;; NSC163039; Ribavirin [USAN:USP:INN:BAN]; Ribavirin,(S); NCGC00015904-02; Ribavirin, antiviral; CAS-36791-04-5; RG-964; PubChem14187; Ro-20-9963; Spectrum_001826; 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; 4pb1; ribofluranosyl carboxamide; Prestwick3_000993; Spectrum3_001876; Spectrum4_001252; Spectrum5_002075; R-964; R 9644; SCHEMBL3727; CHEMBL1643; Lopac0_001063; BSPBio_001085; BSPBio_003352; KBioGR_001804; KBioSS_002331; cid_37542; MLS000028486; MLS002222317; DivK1c_000782; SPECTRUM1503938; Ribavirin (JP17/USP/INN); BPBio1_001195; GTPL6842; 1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; 1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; DTXSID8023557; HMS502H04; KBio1_000782; KBio2_002328; KBio2_004896; KBio2_007464; KBio3_002854; NINDS_000782; HMS2090L15; HMS2094O09; HMS2098G07; HMS2232P07; HMS3263E08; HMS3715G07; Pharmakon1600-01503938; HY-B0434; ZINC1035331; Tox21_110259; Tox21_200967; Tox21_501063; BDBM50154375; CCG-38985; NSC758650; s2504; SCH-18908; AKOS001715163; Tox21_110259_1; DB00811; GS-3572; LP01063; MCULE-9495128592; NSC-758650; SDCCGSBI-0051033.P004; IDI1_000782; SMP1_000261; NCGC00090726-01; NCGC00090726-03; NCGC00090726-04; NCGC00090726-05; NCGC00090726-06; NCGC00090726-07; NCGC00090726-08; NCGC00090726-09; NCGC00090726-12; NCGC00090726-25; NCGC00258520-01; NCGC00261748-01; 252269-50-4; AS-34178; BCP0726000138; SBI-0051033.P003; AB0068936; AB00430481; EU-0101063; R0077; EN300-59237; D00423; J10190; M-7546; AB00430481-15; AB00430481-16; AB00430481_17; AB00430481_18; 1-beta-Ribofuranosyl-1,2,4-triazole-3-carboamide; 791R045; Q421862; Ribavirin 100 microg/mL in Acetonitrile:Methanol; SR-01000721904; SR-01000076112-2; SR-01000076112-3; SR-01000076112-4; SR-01000721904-2; 1-??-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; BRD-K60369935-001-02-7; BRD-K60369935-001-18-3; SR-01000076112-11; 1-?-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; Ribavirin, British Pharmacopoeia (BP) Reference Standard; Z1522567185; 1-(beta -D-ribofuranosyl)-1,2,4-triazole-3-carboxamide; Ribavirin, European Pharmacopoeia (EP) Reference Standard; Ribavirin, United States Pharmacopeia (USP) Reference Standard; Ribavirin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide" Small molecule "1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1" IWUCXVSUMQZMFG-AFCXAGJDSA-N C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N C8H12N4O5 CAS 36791-04-5 CHEBI:63580 . . . DB00811 . DR1725 S-adenosylmethionine D0U3YU D0U3YU Approved Hepatic fibrosis/cirrhosis ICD-11: DB93 CID: 34755 Anticancer Treatment "S-adenosyl-L-methionine; S-adenosylmethionine; Ademetionine; AdoMet; 29908-03-0; SAM-e; SAMe; Donamet; L-S-Adenosylmethionine; Methioninyladenylate; S Amet; adenosylmethionine; Active methionine; L-Methionine, S-adenosyl-; CCRIS 7130; S-adenosyl-L-methioninate; (R)-ademetionine; (S)-ademetionine; UNII-6EZ5466ZUX; UNII-K093C397UL; Methionine, S-adenosyl-; (2S)-2-Amino-4-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(methyl)sulfonio)butanoate; SAM; 6EZ5466ZUX; CHEBI:67040; UNII-7LP2MPO46S; K093C397UL; Adenosine, 5'-((3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt, (3S)-; (3S)-5'-((3-Amino-3-carboxylatopropyl)methylsulphonio)-5'-deoxyadenosine; S-adenosyl-L-methioninate (deprotonated carboxy group); 2-S-adenosyl-L-methionine; 7LP2MPO46S; (3S)-5'-[(3-amino-3-carboxylatopropyl)methylsulphonio]-5'-deoxyadenosine; 17176-17-9; Adenosine, 5'-(((3S)-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt; S-Adenosyl-L-Methtonine; Ademetionine, (R)-; R,S-adenosylmethionine; S,S-Adenosylmethionine; Adenosine, 5'-((L-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, hydroxide, inner salt; EINECS 249-946-8; (R,S)-S-Adenosyl-L-methionine; (S,S)-S-Adenosyl-L-methionine; S-adenosylmethione; Adenosine, 5'-[[(3S)-3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, inner salt; S. Amet; [14COOH]AdoMet; 24346-00-7; S-Adenosyl-L-methionine HCl; SCHEMBL1300198; CHEMBL1088977; DTXSID6032019; BDBM28422; MSI-195; HY-B0617; AKOS015963176; S-adenosyl-L-[carboxy-14C]methionine; CCG-268635; DB00118; Adenosine, 5'-((R)-((3S)-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt; Adenosine, 5'-((S)-((3S)-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt; NCGC00485915-01; S-(5'desoxyadenosin-5'yl)-L-methionine; 91279-78-6; AC-19717; AS-57895; C00019; Methionine, S-adenosyl- (6CI) Active methionine; Q27135598; Q27264758; Q27281766; S-Adenosyl-L-methionine;S-Adenosyl methionine;SAMe;AdoMet; UNII-7LP2MPO46S component MEFKEPWMEQBLKI-FCKMPRQPSA-N; UNII-7LP2MPO46S component MEFKEPWMEQBLKI-TYYLHDHTSA-N; (3S)-5'-[(3-amino-3-carboxylatopropyl)methylsulphonio]-5'-deoxyadenosine inner salt; [(3S)-3-amino-3-carboxylatopropyl](5'-deoxyadenosin-5'-yl)(methyl)sulfonioacetate; (2S)-2-amino-4-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)sulfaniumyl)butanoate; (2S)-2-amino-4-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)sulfanylium)butanoate; (2S)-2-amino-4-[{[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}(methyl)sulfonio]butanoate (non-preferred name); [(3S)-3-amino-4-hydroxy-4-oxo-butyl]-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-methyl-sulfonium; Adenosine, 5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, hydroxide, inner salt, (3S)-; Adenosine, 5'-[(L-3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, hydroxide, inner salt (8CI)" Small molecule "1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1" MEFKEPWMEQBLKI-AIRLBKTGSA-N C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O C15H22N6O5S CAS 29908-03-0 CHEBI:67040 . . . DB00118 . DR3931 Amoxicillin D0F6EO D0F6EO Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 33613 Anticancer Treatment "amoxicillin; Amoxycillin; Amoxicillin anhydrous; 26787-78-0; Amoxicilline; p-Hydroxyampicillin; Amopenixin; Amolin; Moxal; D-Amoxicillin; Clamoxyl; Amoxil; Amoxicillinum; Amoxicilina; Imacillin; Hiconcil; Moxatag; Robamox; Amoxicilina [INN-Spanish]; Amoxicillin trihydrate; Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; alpha-Amino-p-hydroxybenzylpenicillin; Histocillin; Amoclen; Flemoxin; Unicillin; AMPC; Amoxycillin Trihydrate; BRL-2333; AMOXICILLIN CRYSTALLINE; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; Amoxicillin (INN); Amoxicillin [INN]; CHEBI:2676; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; UNII-9EM05410Q9; Amoxicillin hydrate; Bristamox; Delacillin; Amoxiden; Amoxivet; Anemolin; Aspenil; Cemoxin; Efpenix; Piramox; Vetramox; Amoxi; Sumox; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Amoxi-Mast; Sawamox PM; Metafarma capsules; Metifarma capsules; (2S,5R,6R)-6-((R)-2-Amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ospamox; Amopen; Amoxicillin, 96%; 9EM05410Q9; NSC-277174; Amoxicaps; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; BRL 2333; Apo-Amoxi; AMOX; DSSTox_CID_17044; DSSTox_RID_79299; DSSTox_GSID_37044; AX; AMOXICILLIN PEDIATRIC; amoxicillanyl; Amoxicillin (anhydrous); AMOXICILLINTRIHYDRATE; BLP 1410; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; Amoxicillin (TN); (2S,5R,6R)-6-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; SMR000058707; Amoxicillin (Amoxycillin); Ro 10-8756; HSDB 3204; EINECS 248-003-8; BL-P 1410; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; NSC 277174; amoxycilin; Amoxi-Inject; Amoxi-Tabs; NSC277174; notoginsenoside-fe; 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; NCGC00016797-02; NCGC00094586-01; Prestwick_713; CAS-26787-78-0; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; MFCD00056860; Prestwick0_000357; Prestwick1_000357; Prestwick2_000357; Prestwick3_000357; Epitope ID:114241; Epitope ID:116054; EC 248-003-8; SCHEMBL3427; CHEMBL1082; BSPBio_000453; MLS000028632; MLS002222248; SPBio_002374; BPBio1_000499; DTXSID3037044; CHEBI:53712; GTPL10895; HY-B0467A; HMS1569G15; HMS2096G15; HMS2231K23; HMS3259P17; HMS3713G15; ZINC3830215; Tox21_111302; BDBM50350464; s3015; AKOS025395540; Tox21_111302_1; CCG-220357; DB01060; DS-3835; MCULE-5710225015; NC00670; NE41275; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; NCGC00179554-01; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 4-Thia-1-azobicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S)))-; AC-12263; Amoxicillin, potency: >=900 mug per mg; co-amoxiclav (amoxicillin + clavulanic acid); C06827; D07452; Q201928; SR-01000721886; SR-01000721886-2; BRD-K55044200-001-03-9; BRD-K55044200-001-15-3; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI); 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino (4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]-" Small molecule "1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1" LSQZJLSUYDQPKJ-NJBDSQKTSA-N CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C C16H19N3O5S CAS 26787-78-0 CHEBI:2676 . . . DB01060 . DR0374 Benznidazole D04XGT D04XGT Approved Chagas disease ICD-11: IF53 CID: 31593 Anticancer Treatment "BENZNIDAZOLE; 22994-85-0; Radanil; Benznidazol; Benzonidazole; Benznidazolum; Ro 07-1051; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)-; N-Benzyl-2-nitroimidazole-1-acetamide; N-Benzyl-2-nitroimidazol-1-yl-acetamide; N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide; 2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide; UNII-YC42NRJ1ZD; N-Benzyl-2-nitro-1H-imidazole-1-acetamide; N-benzyl-2-(2-nitroimidazol-1-yl)acetamide; Imidazole-1-acetamide, N-benzyl-2-nitro-; YC42NRJ1ZD; CHEMBL110; MMV688773; NSC299972; NSC-299972; Ro-7-1051; NCGC00166238-01; Ro 07-1051;Ro 71051; DSSTox_CID_26570; DSSTox_RID_81729; DSSTox_GSID_46570; Rochagan; Benznidazol [INN-Spanish]; Benznidazolum [INN-Latin]; Ro 71051; SMR000857153; NSC 299972; CAS-22994-85-0; CCRIS 2200; N-benzyl-2-nitro-1-imidazoleacetamide; BRN 0551486; Ragonil; Acetamide, N-benzyl-2-(nitroimidazol-1-yl)-; benznidazole (TN); Rochagan (TN); Radanil (TN); Benznidazole (USAN/INN); Benznidazole [USAN:INN]; SCHEMBL45081; MLS001332409; MLS001332410; MLS001360496; DTXSID9046570; SCHEMBL22493029; ZINC56949; CHEBI:133833; HMS2233G13; HMS3369C11; HY-B1548; Tox21_112364; BDBM50089916; MFCD00243089; s3741; AKOS015916722; AKOS024283499; Tox21_112364_1; CCG-267054; DB11989; MCULE-5592629788; 2-(2-nitroimidazolyl)-N-benzylacetamide; NCGC00166238-02; AK323200; AS-68694; QC-10765; ST069365; CS-0013411; FT-0662547; RO-07-1051; Benznidazol (Ro 07-1051; Ro 71051); D02489; N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide; N-benzyl-2-(2-nitro-1Himidazol-1-yl)acetamide; N-benzyl-2-(2-nitro-1H-imidazol-5-yl)acetamide; N-Benzyl-2-nitro-1H-imidazole-1-acetamide, 97%; Q425300; SR-01000841264; 2-(2-nitroimidazol-1-yl)-N-(phenylmethyl)acetamide; J-014932; SR-01000841264-3; BRD-K56156805-001-05-4; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)- (9CI); N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide (Benznidazole); Pyridinium,1-dodecyl-2-[(hydroxyimino)methyl]-,iodide(1:1)" Small molecule "1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)" CULUWZNBISUWAS-UHFFFAOYSA-N C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-] C12H12N4O3 CAS 22994-85-0 CHEBI:133833 . . . DB11989 . DR3335 Dichloroacetate D7I9JH D7I9JH Phase 4 Insulin-resistance syndrome ICD-11: 5A44 CID: 25975 Anticancer Treatment "Dichloroacetate; 2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050" Small molecule "1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1" JXTHNDFMNIQAHM-UHFFFAOYSA-M C(C(=O)[O-])(Cl)Cl C2HCl2O2- CAS 13425-80-4 CHEBI:28240 . . . DB08809 . DR9535 Coralyne . . Investigative Acute lymphoblastic leukemia ICD-11: 2B33 CID: 23306 Anticancer Treatment "Coralyne chloride; Coralyne; 38989-38-7; (-)-Coralyne chloride hydrate; 6872-73-7; NSC96349; 2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium chloride; 2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium;chloride; EINECS 254-239-2; NSC 96349; NSC 154891; Dibenzo[a, 2,3,10,11-tetramethoxy-8-methyl-, chloride; 2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinoline, chloride; 8-Methyl-2,3,10,11-tetramethoxydibenzo(a,g)quinolizinium chloride; 5,6,7,8,13,13a-Hexadehydro-8-methyl-2,3,10,11-tetramethoxyberbinium chloride; DIBENZO(a,g)QUINOLIZINIUM, 8-METHYL-2,3,10,11-TETRAMETHOXY-, CHLORIDE; SPECTRUM1500861; CHEMBL363506; SCHEMBL3320097; DTXSID50959832; HMS1921K20; 2,3,10,11-Tetramethoxy-8-methyldibenzo(a,g)quinolizinium chloride; 5,6,7,8,13,13a-Hexahydro-8-methyl-2,3,10,11-tetramethoxyberbinium; CCG-38524; NSC-96349; NSC154891; SBB056946; AKOS024348916; MCULE-4271694490; NSC-154891; BERBINIUM, 5,6,7,8,13,13a-HEXADEHYDRO-2,3,10,11-TETRAMETHOXY-8-METHYL-, CHLORIDE; NCGC00094866-01; NCGC00094866-02; ST50826325; SR-05000002641; SR-05000002641-1; 2,3,10,11-Tetramethoxy-8-methylisoquinolino[3,2-a]isoquinolin-7-ium chloride; Dibenzo(a,g)quinolizinium, 2,3,10,11-tetramethoxy-8-methyl-, chloride (9CI)" Small molecule "1S/C22H22NO4.ClH/c1-13-16-11-21(26-4)20(25-3)10-15(16)8-18-17-12-22(27-5)19(24-2)9-14(17)6-7-23(13)18;/h6-12H,1-5H3;1H/q+1;/p-1" PDYBUYVOPAJLKP-UHFFFAOYSA-M CC1=C2C=C(C(=CC2=CC3=[N+]1C=CC4=CC(=C(C=C43)OC)OC)OC)OC.[Cl-] C22H22ClNO4 CAS 38989-38-7 . . . . . . DR2951 Betamethasone dipropionate D0MD6C D0MD6C Phase 3 Psoriasis ICD-11: EA90 CID: 21800 Anticancer Treatment "BETAMETHASONE DIPROPIONATE; Diprolene; Diprosone; Diprolene AF; 5593-20-4; Alphatrex; Diproderm; Maxivate; Betamethasone 17,21-dipropionate; Diprosis; Psorion; Sch 11460; Betamethasone-17,21-dipropionate; Sch-11460; UNII-826Y60901U; S-3440; CHEBI:31276; beta-Methasone 17,21-dipropionate; 826Y60901U; Rinderon DP; Sernivo; (11-beta,16-beta)-9-Chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-fluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate; (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate.; [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate; 2-((2S,10S,11S,13S,15S,17S,1R,14R)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxo -14-propanoyloxytetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl)-2-o xoethyl propanoate; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate; EINECS 227-005-2; BRN 3638108; Betamethasone Dipropionate (Diprolene); S 3440; Diprolene (TN); NCGC00159360-02; NCGC00159443-02; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)-; Sernivo (TN); Rinderon-DP (TN); Betamethasone dipropionate [USAN:USP:JAN]; betamethasone-dipropionate; DSSTox_CID_2672; BETAMETHASONE DIPROP; SCHEMBL7519; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; DSSTox_RID_76683; DSSTox_GSID_22672; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(propionate); CHEMBL1200384; DTXSID2022672; component of Betasone (Salt/Mix); component of Alphatrex (Salt/Mix); AMY22130; ZINC4212137; Tox21_113343; BDBM50421892; s1688; AKOS015969733; Betamethasone dipropionate (JP17/USP); CCG-269732; CS-7549; EBD2157850; KS-5303; NSC 758415; NCGC00159443-01; NCGC00159443-05; (11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate; HY-13571; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 17,21-dipropionate; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta); ST024761; CAS-5593-20-4; B3166; D01637; AB01274713-01; AB01274713_02; Q4897349; BRD-K58148589-001-03-6; Betamethasone-17,21-dipropionate 100 microg/mL in Acetonitrile; (11.beta.,16.beta.)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; 9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; 9-Fluoro-11.beta.-hydroxy-16.beta.-methyl-3,20-dioxo-17-(propionyloxy)pregna-1,4-dien-21-yl propionate #; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate; 9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene- 17,21-diyl dipropionate; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-.beta.,17,21-trihydroxy-16-.beta.-methyl-,17,21-dipropionate" Small molecule "1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1" CIWBQSYVNNPZIQ-XYWKZLDCSA-N CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC C28H37FO7 CAS 5593-20-4 CHEBI:31276 . . . DB00443 . DR1651 Buthionine sulfoximine D0Z6VR D0Z6VR Investigative Malaria ICD-11: 1F40-1F45 CID: 21157 Anticancer Treatment "BUTHIONINE SULFOXIMINE; 5072-26-4; Buthionine sulphoximine; DL-Buthionine-[S,R]-sulfoximine; Butionine sulfoximine; Buthionine sulfoxamine; D,L-Buthionine-(S,R)-sulfoximine; DL-Buthionine-sulfoximine; Buthionine-S,R-sulfoximine; 2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; 2-Amino-4-(butylsulfonimidoyl)butanoic acid; DL-Buthionine-(S,R)-sulfoximine; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-; CHEBI:28714; DL-butathionine-(S,R)-sulfoximine; MFCD00070309; NSC326231; NSC381100; L-Buthionine-(S,R)-sulfoximine; S-butyl-DL-homocysteine (S,R)-sulfoximine; S-Butyl-DL-homocysteine-[S,R]-sulfoximine; 2-amino-4-(S-butylsulfonimidoyl)butyric acid; NSC 326231; BRN 2367136; Buthione sulfoximine; DL-Buthionine (S,R)-sulfoximine, 99%; 71765-30-5; NSC 381100; DL-Buthionine-S,R-sulfoximine; l-buthionine (s,r)-sulfoximine; dl-buthionine (s,r)-sulfoximine; NSC-381100; BSO; Sulfoximine, S-(3-amino-3-carboxypropyl)-S-butyl-; Lopac0_000231; SCHEMBL62033; BSPBio_002464; SPECTRUM1505108; dl-Buthionine(S,R)-sulfoximine; CHEMBL1256575; CHEMBL1627290; DTXSID6044434; CHEBI:176510; HMS3260P03; BCP24029; BCP27775; Tox21_500231; s2433; STL328818; AKOS022106364; CCG-204326; DB12870; LP00231; MCULE-8178742509; SDCCGSBI-0050219.P003; NCGC00015148-03; NCGC00015148-04; NCGC00015148-05; NCGC00015148-06; NCGC00015148-07; NCGC00015148-13; NCGC00093696-01; NCGC00093696-02; NCGC00093696-03; NCGC00260916-01; AS-67962; NCI60_002827; HY-106376; CS-0025687; EU-0100231; FT-0624379; FT-0627738; FT-0663956; ST51012445; DL-Buthionine-sulfoximine, >=99.0% (TLC); 2-Amino-4-(butylsulfonimidoyl)butanoic acid #; B 2640; C04543; SR-01000075713; Q5002519; SR-01000075713-1; 2-amino-4-[butyl(imino)oxo-??-sulfanyl]butanoic acid; BRD-A04020513-001-01-9; D,L-Buthionine-(S,R)-sulfoximine (Butionine sulfoximine)" Small molecule "1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)" KJQFBVYMGADDTQ-UHFFFAOYSA-N CCCCS(=N)(=O)CCC(C(=O)O)N C8H18N2O3S CAS 5072-26-4 CHEBI:28714 . . . DB12870 . DR5762 Trimetazidine D0Q4YI D0Q4YI Approved Angina pectoris ICD-11: BA40 CID: 21109 Anticancer Treatment "TRIMETAZIDINE; 5011-34-7; 1-(2,3,4-Trimethoxybenzyl)piperazine; 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine; 1-(2,3,4-Trimethoxy-benzyl)-piperazine; UNII-N9A0A0R9S8; Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-; N9A0A0R9S8; Vasartel; Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-; Trimetazidina; Trimetazidinum; MLS001240268; Trimetazidinum [INN-Latin]; Trimetazidina [INN-Spanish]; Trimetazidine [INN:BAN:DCF]; 1,2,3-trimethoxy-4-(piperazinylmethyl)benzene; NCGC00016697-01; SMR000674573; EINECS 225-690-2; CAS-13171-25-0; Preductal; Vasorel; Preductal MB; Dilatan (TN); Trimetazidine (INN); BAS 06612844; Prestwick0_000549; Prestwick1_000549; Prestwick2_000549; Prestwick3_000549; Oprea1_279550; Piperazine,1-[(2,3,4-trimethoxyphenyl)methyl]-; BSPBio_000597; MLS001331735; SCHEMBL230374; SPBio_002518; BPBio1_000657; CHEMBL203266; DTXSID2048531; BDBM80613; CHEBI:94789; cid_9926449; HY-B0968A; HMS2230L07; HMS3374D04; ALBB-004703; BCP16534; BBL013084; MFCD00868263; s5779; SBB007020; STK315643; ZINC19358638; AKOS000308094; 4-(2,3,4-Trimethoxybenzyl)piperazine; DB09069; MCULE-9820869946; 1-(2,3,4-trimethoxy benzyl)piperazine; NCGC00016697-02; SMR000814701; 1-(2,3,4-trimethoxyphenyl)methylpiperazine; 1-(2,3,4-trimethoxyphenylmethyl)piperazine; AB0111344; DB-051731; BB 0220635; CS-0099250; R3927; ST45134749; EN300-14439; 71T250; A25088; D08642; A827982; A837947; Q674703; 1-(2,3,4-trimethoxybenzyl)piperazine;hydrochloride; 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride; BRD-K88366685-300-03-7; BRD-K88366685-300-04-5; Z99601262; 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine;hydrochloride; 1-((2,3,4-trimethoxyphenyl)methyl)-piperazindihydrochloride;1-(2,3,4-trimethoxybenzyl)-piperazindihydrochloride; 127881-54-3" Small molecule "1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3" UHWVSEOVJBQKBE-UHFFFAOYSA-N COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC C14H22N2O3 CAS 5011-34-7 CHEBI:94789 . . . DB09069 . DR6690 Streptomycin D0N0EQ D0N0EQ Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 19649 Anticancer Treatment "streptomycin; 57-92-1; Streptomycin A; Strepcen; Gerox; Streptomycine; Streptomycin sulphate; Chemform; Streptomycin sulfate; CHEBI:17076; UNII-Y45QSO73OB; Estreptomicina; NSC-14083; Streptomycin A sulfate; Y45QSO73OB; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; Agrimycin; Agrept; Neodiestreptopab; Streptomicina; Streptomycinum; Streptomyzin; Hokko-mycin; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}; 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; SRY; Streptomycin Sesquisulfate Hydrate; Caswell No. 804; Streptomyzin [German]; Streptomicina [Italian]; NCGC00159339-02; Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; streomycin; Geroxeg; Estreptomicina [INN-Spanish]; CCRIS 5730; HSDB 1768; Streptomycin,(S); 1-[(1S,2R,3R,4S,5R,6R)-2-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)tetrahydropyran-2-yl]oxy-4-formyl-4-hydroxy-5-methyl-tetrahydrofuran-2-yl]oxy-5-guanidino-3,4,6-trihydroxy-cyclohexyl]guanidine; Streptomycin (TN); EINECS 200-355-3; Streptomycin (INN); EPA Pesticide Chemical Code 006306; Liposomal Streptomycin; NSC14083; BRN 0074498; Epitope ID:224553; SCHEMBL3276; 4-18-00-07540 (Beilstein Handbook Reference); D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)-; CHEMBL372795; DTXSID4023597; GTPL10923; Streptomycin Sesquisulphate Hydrate; ZINC8214681; BDBM50103513; MFCD00072108; AKOS015969759; AM84920; DB01082; AS-35042; tetrahydro-2H-pyran-2-yloxy)-4-formyl-4; 280-EP2269990A1; 280-EP2270001A1; 280-EP2270006A1; 280-EP2270008A1; 280-EP2270014A1; 280-EP2272832A1; 280-EP2275420A1; 280-EP2275422A1; 280-EP2277861A1; 280-EP2277876A1; 280-EP2277880A1; 280-EP2277898A2; 280-EP2281563A1; 280-EP2281824A1; 280-EP2284154A1; 280-EP2284169A1; 280-EP2284171A1; 280-EP2284172A1; 280-EP2286812A1; 280-EP2287161A1; 280-EP2287162A1; 280-EP2289876A1; 280-EP2289882A1; 280-EP2289886A1; 280-EP2289892A1; 280-EP2289893A1; 280-EP2292088A1; 280-EP2292592A1; 280-EP2292608A1; 280-EP2292610A1; 280-EP2292612A2; 280-EP2292614A1; 280-EP2292617A1; 280-EP2295055A2; 280-EP2295402A2; 280-EP2295411A1; 280-EP2295416A2; 280-EP2295417A1; 280-EP2295434A2; 280-EP2298748A2; 280-EP2301536A1; 280-EP2301538A1; 280-EP2301544A1; 280-EP2301940A1; 280-EP2305033A1; 280-EP2305652A2; 280-EP2305658A1; 280-EP2305662A1; 280-EP2305684A1; 280-EP2305688A1; 280-EP2308562A2; 280-EP2308844A2; 280-EP2308845A2; 280-EP2308846A2; 280-EP2308855A1; 280-EP2308857A1; 280-EP2308872A1; 280-EP2308960A1; 280-EP2311453A1; 280-EP2311455A1; 280-EP2311494A1; 280-EP2311806A2; 280-EP2311836A1; 280-EP2314583A1; 280-EP2316452A1; 280-EP2316459A1; 280-EP2316829A1; 280-EP2316832A1; 280-EP2316833A1; 280-EP2316937A1; 280-EP2371811A2; C00413; D08531; 3-((2S,3S,4S,5R,6S)-4,5-dihydroxy-6; AB00443813_02; 057S921; 2,5,6-trihydroxycyclohexane-1,3-diyl)diguanidine; Q192717; BRD-K07166362-330-02-8; 1,-((1R,2R,3S,4R,5R,6S)-4-((2R,3R,4R,5S)-; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-glucopyranosyl)-3-formylpentofuranoside; D-Streptamine, O-2-deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-; D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1.fwdarw.2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1.fwdarw.4)-N,N'-bis(aminoiminomethyl)-; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome" Small molecule "1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1" UCSJYZPVAKXKNQ-HZYVHMACSA-N CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O C21H39N7O12 CAS 57-92-1 CHEBI:17076 . . . DB01082 . DR4517 Tetramethylpyrazine D09WFI D09WFI Discontinued in Phase 2 Dissociative neurological symptom disorder ICD-11: 6B60 CID: 14296 Anticancer Treatment "2,3,5,6-Tetramethylpyrazine; TETRAMETHYLPYRAZINE; 1124-11-4; Ligustrazine; Pyrazine, tetramethyl-; Bs factor; Tetramethylpyrazin; Tetrapyrazine; Chuanxiongzine; Liqustrazine; Ligustizine; 2,3,5,6-Tetramethyl pyrazine; TMPZ; chuanxingzine; FEMA No. 3237; UNII-V80F4IA5XG; MFCD00006146; 2,3,5,6,-Tetramethyl-1,4-pyrazine; V80F4IA5XG; MLS000069594; FEMA 3237; Pyrazine, 2,3,5,6-tetramethyl-; SMR000059042; 2,5,6-Tetramethylpyrazine; EINECS 214-391-2; NSC 36080; NSC 46451; 2,3,5,6-Tetramethylpyrazine (natural); Ligustrazin; PubChem8617; Opera_ID_849; TMP?; ACMC-2099er; DSSTox_CID_27070; DSSTox_RID_82085; DSSTox_GSID_47070; SCHEMBL77624; CHEMBL303697; ZINC4042; 2,3,5,6-Tetramethyl-pyrazine; DTXSID6047070; FINHMKGKINIASC-UHFFFAOYSA-; CHEBI:133246; Pyrazine, 2,3,5,6-tetramethyl; HMS2235K03; HMS3371J08; Nat.2,3,5,6-Tetramethylpyrazine; ACN-S003305; HY-N0264; NSC36080; NSC46451; Tox21_302313; ANW-16465; BBL012277; CT0189; NSC-36080; NSC-46451; s3956; SBB085945; STL163591; 2,3,5,6-Tetramethylpyrazine, 98%; AKOS003398567; CCG-207974; CS-W023183; MCULE-2834033564; NCGC00247063-01; NCGC00256097-01; AC-10515; AK-47432; AS-13206; H601; SY011353; CAS-1124-11-4; DB-003786; AM20070299; FT-0609443; N1918; ST45025457; 2,3,5,6-Tetramethylpyrazine, >=98%, FG; M-4966; 2,3,5,6-Tetramethylpyrazine, analytical standard; A802574; AC-907/25014219; Q-100069; 2,3,5,6-Tetramethylpyrazine, natural, >=98%, FG; Q11319317; Z1741976694; 2,3,5,6-Tetramethylpyrazine, Vetec(TM) reagent grade, 98%" Small molecule 1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3 FINHMKGKINIASC-UHFFFAOYSA-N CC1=C(N=C(C(=N1)C)C)C C8H12N2 CAS 1124-11-4 CHEBI:133246 . . . . . DR5938 Ethambutol D08QME D08QME Approved Tuberculosis ICD-11: 1B10 CID: 14052 Anticancer Treatment "ethambutol; 74-55-5; Ethambutolum; Aethambutolum; D-Ethambutol; (+)-S,S-Ethambutol; Ethambutol Hydrochloride; (+)-ethambutol; (S,S)-ethambutol; Myambutol; (2S,2'S)-2,2'-(Ethane-1,2-diylbis(azanediyl))bis(butan-1-ol); Etambutolo [DCIT]; Tibutol; Etambutol [INN-Spanish]; Ethambutolum [INN-Latin]; S,S-Ethambutol; Diambutol; CHEBI:4877; UNII-8G167061QZ; (+)-2,2'-(Ethylenediimino)di-1-butanol; Purderal; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; EMB; 8G167061QZ; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)-; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; Etambutolo; C10H24N2O2; Ebutol; D-2,2'-(Ethylenediimino)di-1-butanol; D-2,2'-(Ethylenediimino)bis(1-butanol); 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (S-(R*,R*))-; Ethambutol, racemic mixture; 1-Butanol, 2,2'-(ethylenediimino)di-, (+)-; d,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; Ethambutol [INN:BAN]; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; NCGC00178864-03; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R-(R*,R*))-; HSDB 3078; Servambutol (TN); 95E; Ethambutol (INN); EINECS 200-810-6; Spectrum_001058; Spectrum2_001014; Spectrum3_000426; Spectrum4_000545; Spectrum5_000702; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R)-; Myambutol (dihydrochloride); SCHEMBL3399; BSPBio_002012; KBioGR_001209; KBioSS_001538; CHEMBL44884; DivK1c_000561; SPBio_001167; CL 40881 (dihydrochloride); DTXSID8023006; KBio1_000561; KBio2_001538; KBio2_004106; KBio2_006674; KBio3_001232; NINDS_000561; HY-B0535; 2860AH; BDBM50448407; ZINC19364219; DB00330; MCULE-9663372083; IDI1_000561; NCGC00178864-01; SBI-0051375.P003; C06984; D07925; E-3950; AB00053473_04; AB00053473_05; Q412318; (S,S)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; BRD-K93231391-300-03-1; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; Ethambutol dihydrochloride, Antibiotic for Culture Media Use Only; (2S)-2-[(2-{[(2S)-1-hydroxybutan-2-yl]amino}ethyl)amino]butan-1-ol; (2S)-2-[2-[[(1S)-1-(hydroxymethyl)propyl]amino]ethylamino]butan-1-ol" Small molecule "1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1" AEUTYOVWOVBAKS-UWVGGRQHSA-N CCC(CO)NCCNC(CC)CO C10H24N2O2 CAS 74-55-5 CHEBI:4877 . . . DB00330 . DR7688 Erythromycin D02YIZ D02YIZ Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 12560 Anticancer Treatment "erythromycin; 114-07-8; Erythromycin A; E-Mycin; Erythrocin; Abomacetin; Erythromycinum; Erymax; Emgel; Eritromicina; Erythromycine; Erythro-Statin; Ilotycin; Erythromycin base; E-Glades; Ery-Tab; E-Base; Eryacne; Torlamicina; Erycette; Robimycin; Bristamycin; Erypar; erythro; Erythroguent; Eritrocina; Erythrogran; Stiemycin; Ermycin; Erycen; Erygel; Aknin; ERYC; Pfizer-E; Theramycin Z; Ak-Mycin; Erythromast 36; Erythromycin Lactate; T-Stat; Benzamycin; MFCD00084654; Emycin; Erytab; Inderm; Retcin; UNII-63937KV33D; CHEMBL532; erythromycin-A; Dumotrycin; Mephamycin; CHEBI:42355; Sansac; Wemid; (-)-ERYTHROMYCIN; Eryc Sprinkles; Erythra-Derm; A/T/S; Akne-Mycin; 63937KV33D; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; R-P Mycin; Endoeritrin; Eritomicina; Erythroderm; Erytrociclin; Paediathrocin; Pharyngocin; Proterytrin; Acneryne; Acnesol; Aknemycin; Derimer; Deripil; Erisone; Eryacnen; Erydermer; Eryhexal; Erysafe; Iloticina; Latotryd; Lederpax; Mercina; Oftamolets; Pantoderm; Pantodrin; Primacine; Romycin; Stiemicyn; Tiloryth; Tiprocin; E-Solve 2; Emuvin; Erecin; Erymed; Erytop; NCI-C55674; AustriaS; Eros; Ery-maxin; Erythro-Teva; Sans-acne; DSSTox_CID_2991; Erimycin-T; Ery-Diolan; Inderm Gel; Del-Mycin; Aknederm Ery Gel; Udima Ery Gel; (-)-Erythromycin, 98%; Eryc 125; UNII-8HPH7ND0LN; DSSTox_RID_76820; DSSTox_GSID_22991; Emu-Ve; 8HPH7ND0LN; Skid Gel E; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione; Akne Cordes Losung; ERY; Ilosone (estolate); Ilotycin T.S.; E-Mycin (base); Ery-Tab (base); (-)-Erythromycin, Eur.Ph.; Emu-V; Ery-B; E-Base (base); ERYC (base); C-Solve-2; N-Methylerythromycin A; PCE Dispertab (base); Eryc-125; Eryc-250; Eritromicina [INN-Spanish]; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Oftalmolosa Cusi Eritromicina; Staticin (TN); Akne-mycin (TN); Erygel (TN); Eryc (TN); T-stat (TN); Pce (TN); SR-05000001618; Sentry AQ mardel maracyn; 7704-67-8; 9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; erthromycin; Erythromycines; NSC55929; CCRIS 9078; NSC-55929; HSDB 3074; NCGC00094670-01; Erythromycin [USP:INN:BAN:JAN]; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; CAS-114-07-8; Prestwick_205; EINECS 204-040-1; Erythromycin C-13; NSC 55929; Spectrum_000115; Spectrum_000659; AI3-50138; EM-A; Prestwick3_000151; Spectrum2_000759; Spectrum2_001263; Spectrum4_000538; Spectrum5_001596; E0751; Erythromycin A, B + C; EC 204-040-1; SCHEMBL2601; BSPBio_000282; BSPBio_002480; Erythromycin standard solution; KBioGR_001175; KBioSS_000555; KBioSS_001139; MLS001066618; BIDD:GT0017; DivK1c_000294; DivK1c_000397; DivK1c_000702; SPECTRUM1500280; SPBio_000778; SPBio_001226; BPBio1_000312; GTPL1456; DTXSID4022991; Erythromycin (JP17/USP/INN); HMS500O16; KBio1_000294; KBio1_000397; KBio1_000702; KBio2_000555; KBio2_001139; KBio2_003123; KBio2_003707; KBio2_005691; KBio2_006275; J01FA01; Erythromycin (mixture of A,B,C); NINDS_000294; NINDS_000397; NINDS_000702; HMS1920M04; HMS2091D05; HMS2095O04; HMS3712O04; Pharmakon1600-01500280; [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione; ACT03320; HY-B0220; RKL10096; Tox21_111311; Tox21_111869; Tox21_300515; BDBM50344942; CCG-38992; LMPK04000006; NSC756759; ZINC85534336; Erythromycin, labeled with carbon-13; AKOS015895249; DB00199; MCULE-4566208867; NSC-756759; IDI1_000294; IDI1_000397; IDI1_000702; SMP1_000119; NCGC00179619-01; NCGC00179619-02; NCGC00179619-03; NCGC00254234-01; 82343-12-2; AC-12744; AC-12901; SMR000544946; Erythromycin, potency: >=850 mug per mg; Erythromycin, tested according to Ph.Eur.; SBI-0051368.P003; Erythromycin, N-demethyl-N-(methyl-11C)-; Erythromycin, meets USP testing specifications; C01912; D00140; E-3250; Erythromycin, plant cell culture tested, ~98%; 44496-EP2272846A1; 44496-EP2275422A1; 44496-EP2292608A1; 44496-EP2305644A1; 44496-EP2308866A1; 44496-EP2311814A1; 44496-EP2311828A1; 44496-EP2380568A1; AB00051981_09; AB00051981_10; Erythromycin standard solution, 1 mg/mL in H2O; Erythromycin, Biotechnology Performance Certified; 114E078; Erythromycin estolate impurity, free erythromycin-; Q213511; SR-01000799155; Erythromycin, Antibiotic for Culture Media Use Only; Erythromycin, BioReagent, suitable for cell culture; SR-01000799155-2; SR-05000001618-1; SR-05000001618-2; BRD-K63550407-001-13-5; BRD-K63550407-028-03-9; Erythromycin (mixture of A,B,C) 100 microg/mL in Acetonitrile; Erythromycin A, British Pharmacopoeia (BP) Reference Standard; Erythromycin A, European Pharmacopoeia (EP) Reference Standard; Erythromycin, United States Pharmacopeia (USP) Reference Standard; Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard; Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name); 215031-94-0" Small molecule "1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1" ULGZDMOVFRHVEP-RWJQBGPGSA-N CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O C37H67NO13 CAS 114-07-8 CHEBI:42355 . . . DB00199 . DR6428 N-acetylcysteine D06XGW D06XGW Approved Liver disease ICD-11: DB90-BD99 CID: 12035 Anticancer Treatment "N-Acetyl-L-cysteine; acetylcysteine; 616-91-1; N-Acetylcysteine; mercapturic acid; Acetadote; L-Acetylcysteine; Mucomyst; N-Acetyl-cysteine; Broncholysin; Fluimucil; Parvolex; Fluprowit; Acetein; Airbron; Fabrol; Fluimucetin; Flumucetin; Mucosolvin; Mucosil; Brunac; Fluimicil Infantil; Acetilcisteina; Acetylcysteinum; Lysomucil; Mucofilin; Respaire; Exomuc; Inspir; Ac-Cys-OH; Mucolyticum Lappe; Mucolytikum Lappe; (R)-2-Acetamido-3-mercaptopropanoic acid; N-Acetyl cysteine; Mucolyticum; LNAC; N-Acetyl-3-mercaptoalanine; N-Acetyl-L-(+)-cysteine; Neo-fluimucil; NAC-TB; Acetyl-L-cysteine; component of Naxid; Mercapturic acid, (R)-; Cysteine, N-acetyl-, L-; cysteine, N-acetyl-; L-Cysteine, N-acetyl-; (R)-mercapturic acid; Fluatox; Mucolator; Mucret; Tixair; N-acetylcystein; UNII-WYQ7N0BPYC; (2R)-2-acetamido-3-sulfanylpropanoic acid; (2R)-2-Acetamido-3-sulfanyl-propanoic acid; L-alpha-Acetamido-beta-mercaptopropionic acid; MFCD00004880; NSC 111180; Mucolyticum-Lappe; WYQ7N0BPYC; MLS000028419; CHEBI:28939; NSC-111180; RK-0202; NCGC00022304-05; SMR000058377; DSSTox_CID_21; (R)-2-acetylamino-3-mercaptopropanoic acid; (2R)-2-acetylamino-3-sulfanylpropanoic acid; (2R)-2-(acetylamino)-3-sulfanylpropanoic acid; DSSTox_RID_75324; DSSTox_GSID_20021; N-Acetyl-L-cysteine, 98%; Syntemucol; Cetylev; acetyl cysteine; Flumil; Ilube; Muco sanigen; MUCOSIL-10; MUCOSIL-20; Acetylcysteinum [INN-Latin]; CAS-616-91-1; Acetilcisteina [INN-Spanish]; CCRIS 3764; HSDB 3003; SR-01000075439; EINECS 210-498-3; Mucocedyl; AcCys; NSC111180; N-acetyl-l-cys; Sodium 2-acetamido-3-mercaptopropionate; SC2; Ilube (eye drops); N-A-C Sustain; N-acetyl-L-cystein; Naxid (Salt/Mix); N-Acety-L-Cysteine; L-N-acetyl-Cysteine; Acetyl Cysteine,(S); PubChem12963; Acetylcysteine [USAN:USP:INN:BAN:JAN]; N-acetyl-(R)-cysteine; Opera_ID_452; MUCOMYST (TN); Acetylcysteine Ph. Eur.; Spectrum2_000086; Spectrum3_000287; Spectrum4_000137; Spectrum5_000764; CHEMBL600; NAC & TNF; SCHEMBL5292; Lopac0_000081; BSPBio_001794; KBioGR_000554; MLS001076125; MLS006011563; SPECTRUM1500105; SPBio_000012; DTXSID5020021; GTPL10945; KBio3_001294; N-Acetyl-L-cysteine, USP grade; Acetylcysteine (JP17/USP/INN); HMS1920A11; HMS2091G11; HMS2234J22; HMS3260A04; HMS3655G11; HMS3715D03; HMS3884E04; HY-B0215; ZINC3589203; 2-Acetylamino-3-mercapto-propionate; Tox21_110877; Tox21_201078; Tox21_500081; acetylcysteine (n-acetyl-l-cysteine); ANW-33915; BDBM50420190; CCG-38902; s1623; AKOS015841009; Tox21_110877_1; CCG-204176; DB06151; GS-3121; LP00081; SDCCGSBI-0050069.P002; NCGC00015086-04; NCGC00022304-03; NCGC00022304-04; NCGC00022304-06; NCGC00022304-07; NCGC00022304-08; NCGC00022304-17; NCGC00258631-01; NCGC00260766-01; AC-16071; AC-24117; BP-12854; I630; SBI-0051272.P003; AB0013800; DB-038288; A0905; AM20100502; EU-0100081; ST50824849; SW199597-2; (2R)-2-acetylamino-3-mercapto-propionic acid; EN300-72028; 16A911; A 7250; A-1100; C06809; D00221; L-Cysteine, N-acetyl- & Tumor necrosis factor; N-Acetyl-L-cysteine, BioXtra, >=99% (TLC); 66233-EP2298305A1; 66233-EP2308851A1; AB00051908_02; AB00382974-12; AB00382974_13; L-.alpha.-Acetamido-.beta.-mercaptopropionic acid; Q375613; J-507685; N-Acetyl-L-cysteine & Tumor necrosis factor (TNF); N-Acetyl-L-cysteine 100 microg/mL in Acetonitrile; SR-01000075439-1; SR-01000075439-3; SR-01000075439-5; BRD-K59058747-001-20-9; N-Acetyl-L-cysteine, cell culture tested, BioReagent; N-Acetyl-L-cysteine, Vetec(TM) reagent grade, 98%; F1905-7178; CABC898A-E48B-4E13-9F72-98D0609A1854; N-Acetyl-L-cysteine, SAJ special grade, 98.0-102.0%; N-Acetyl-L-cysteine, Sigma Grade, >=99% (TLC), powder; UNII-2SPH1IMO2V component PWKSKIMOESPYIA-BYPYZUCNSA-N; Acetylcysteine, British Pharmacopoeia (BP) Reference Standard; Acetylcysteine, European Pharmacopoeia (EP) Reference Standard; Acetylcysteine, United States Pharmacopeia (USP) Reference Standard; N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material; N-Acetyl-L-cysteine, PharmaGrade, Ajinomoto, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture" Small molecule "1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1" PWKSKIMOESPYIA-BYPYZUCNSA-N CC(=O)NC(CS)C(=O)O C5H9NO3S CAS 616-91-1 CHEBI:28939 . . . DB06151 . DR0832 Megestrol acetate . . Approved Cancer cachexia ICD-11: MG20 CID: 11683 Anticancer Treatment "MEGESTROL ACETATE; 595-33-5; Megace; Megace ES; Magestin; Niagestin; Megestryl acetate; Megeron; Megestat; Ovaban; Ovarid; Maygace; Pallace; BDH 1298; SC 10363; NSC-71423; Volidan; SC10363; UNII-TJ2M0FR8ES; 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 17alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17alpha-acetoxyprogesterone; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate; 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate; TJ2M0FR8ES; [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; SC-10363; 17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione; MLS000028633; Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-; BDH-1298; SMR000058691; DSSTox_CID_20683; DSSTox_RID_79539; DSSTox_GSID_40683; Megestil; 6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione; Ovaban (Veterinary); 6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone; MegestrolAcetate; 6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate; Megestrol-Acetate; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; CCRIS 372; Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate; Megestrol-17-acetate; EINECS 209-864-5; Megestin; Megestrol acetole [Progestins]; Megestrol acetate [USAN:USP]; Megestrol acetole; BDH1298; 17-alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17-alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17-alpha-acetoxyprogesterone; NCGC00016516-01; (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; CAS-595-33-5; Megace (TN); 17alpha-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate; 6-Methyl-6-dehydro-17.alpha.-acetylprogesterone; 6-Methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone; 6-Methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate; 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone; 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone; Megestrol acetate (USP); Opera_ID_1511; Prestwick0_000956; Prestwick1_000956; Prestwick2_000956; Prestwick3_000956; 6-Methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate; SCHEMBL745; BSPBio_000952; MLS000759501; MLS001074091; MLS001424055; par-100,2; SPBio_003101; BPBio1_001048; CHEBI:6723; CHEMBL1201139; DTXSID9040683; BCPP000168; HMS1570P14; HMS2051I20; HMS2090N04; HMS2097P14; HMS2235D16; HMS3714P14; Nia; NSC71423; ZINC4097467; Tox21_110469; Tox21_302360; ANW-43468; LMST02030118; MFCD00056470; s1304; AKOS015894927; Tox21_110469_1; BCP9000904; CCG-100899; CS-2065; DB00351; NC00149; 17-Acetoxy-6-methylpregna-4,20-dione; NCGC00024196-03; NCGC00024196-05; NCGC00255456-01; AC-24570; AS-13384; HY-13676; I040; 17.alpha.-Acetoxy-6-methyl-4,20-dione; AB00490013; B1377; 17-Hydroxy-6-methylpregna-4,20-dione acetate; 17.alpha.-Acetoxy-6-methylpregna-4,20-dione; C08151; D00952; 14365-EP2311464A1; 14365-EP2316836A1; AB00383046-13; AB00383046-14; AB00383046-15; AB00383046_16; Pregna-4,20-dione, 17-(acetyloxy)-6-methyl-; 595M335; SR-01000000258; Megestrol-17-acetate 100 microg/mL in Acetonitrile; Pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate; Q-201346; Q6808975; SR-01000000258-4; BRD-K19507340-001-03-1; Megestrol acetate, VETRANAL(TM), analytical standard; 17alpha-Acetoxy-6-methyl-4,6-pregnadiene-3,20-dione; Megestrol acetate, analytical standard, for drug analysis; WLN: L E5 B666 OV KU MUTJ A1 E1 FV1 FOV1 L1; 6-Methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate; Megestrol acetate, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate, United States Pharmacopeia (USP) Reference Standard; Megesgtrol Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Megestrol acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate for system suitability, European Pharmacopoeia (EP) Reference Standard" Small molecule "1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1" RQZAXGRLVPAYTJ-GQFGMJRRSA-N CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C C24H32O4 CAS 595-33-5 CHEBI:6723 . . . DB00351 . DR1036 Dicyclohexylcarbodiimide . . Investigative Prostate cancer ICD-11: 2C82 CID: 10868 Anticancer Treatment "DICYCLOHEXYLCARBODIIMIDE; 538-75-0; N,N'-Dicyclohexylcarbodiimide; DCCD; 1,3-Dicyclohexylcarbodiimide; Carbodicyclohexylimide; DCCI; n,n-dicyclohexylcarbodiimide; Bis(cyclohexyl)carbodiimide; DCC; Cyclohexanamine, N,N'-methanetetraylbis-; n,n'-methanediylidenedicyclohexanamine; Carbodiimide, dicyclohexyl-; Dicylcohexylcarbodiimide; DCC Crosslinker; N,N'-Methanetetraylbiscyclohexaamine; N,N'-Dicyclohexylcarbodiimide (DCC); NSC 30022; dicyclohexylmethanediimine; N,N'-dicyclohexylmethanediimine; CHEBI:53090; dicyclohexyl carbodiimide; UNII-0T1427205E; Dicyclohexyl-Carbodiimide; MFCD00011659; N,N'-DICYCLOHEXYL-CARBODIIMIDE; n,n-dicychohexylcarbodiimide; n,n'-dicylohexylcarbodiimide; n,n-dichyclohexylcarbodiimide; n,n-dicyclohexyl carbodiimide; n,n'-dicyclohexyl carbodiimide; 0T1427205E; DSSTox_CID_3817; DSSTox_RID_77197; DSSTox_GSID_23817; Cyclohexanamine,N'-methanetetraylbis-; N,N'-Dicyclohexylcarbodiimide, 99%; CAS-538-75-0; Dicyclimide;1,3-dicyclohexylcarbodiimide;N,N-Dicyclohexylcarbodiimide;N,N'-Methanediylidenedicyclohexanamine; 1,3-dicyclohexyl-1,3-diazapropa-1,2-diene; EINECS 208-704-1; n,n'-dicyclohexylcarbodiimid; BRN 0610662; N,N'-dicyclohexylcarbodimide; AI3-08191; CCRIS 9266; HSDB 8049; dicyclohexylcarbodiimid; dicyclohexylcarbodimide; dicylohexylcarbodiimide; Dicylcohexylcarbodimide; dicyciohexylcarbodiimide; Dicyclohexyicarbodiimide; dicyclohexyl carbodimide; dicylohexyl-carbodiimide; PubChem12523; dicyclo-hexylcarbodiimide; dicyclohe-xylcarbodiimide; dicyclohexylcarbo-diimide; dicyclohexylcarbod iimide; dicyclohexylcarbodi-imide; ACMC-1ASTJ; Dicyclohexyl carbo diimide; Dicyclohexyl-carboxydilmide; SCHEMBL303; 1,3dicyclohexylcarbodiimide; Epitope ID:114067; EC 208-704-1; 1,3-dicyclohexylcarbodiimid; 1,3-dicyclohexylcarbodimide; 1.3-dicyclohexylcarbodimide; N,N'dicyclohexylcarbodiimide; 1,3-dicylcohexylcarbodiimide; 1.3-dicyclohexylcarbodiimide; N, N'dicyclohexylcarbodimide; 1,N'-dicyclohexylcarbodimide; n.n'-dicyclohexylcarbodiimide; N,N'-dicylcohexylcarbodiimide; 4-12-00-00072 (Beilstein Handbook Reference); 1, 3-dicyclohexylcarbodiimide; 1,3- dicyclohexylcarbodiimide; 1,3-dicyclo-hexylcarbodiimide; 1,3-dicyclohexyl carbodiimide; 1,3-dicyclohexyl-carbodiimide; 1,3-dicyclohexylcarbo-diimide; N, N'-dicyclohexylcarbodimide; N,N'-Dicyclohexyl carbodimide; n,n' dicyclohexyl carbodiimide; N, N'-dicyclohexylcarbodiimide; N,N'-dicyclo hexylcarbodiimide; N,N'-dicyclo-hexylcarbodiimide; 1,3-di-cyclohexyl carbodiimide; 1,3-dicyclo hexyl carbodiimide; 1,3-dicyclohexyl carbo-diimide; 1,3-dicyclohexyl- carbodiimide; CARBODIIMIDE,DICYCLOHEXYL; CHEMBL162598; N,N,-dichyclohexyl-carbodiimide; DTXSID1023817; N, N'-dicyclohexyl carbodiimide; N,N'- dicyclohexyl carbodiimide; N,N'-dicyclo hexyl carbodiimide; N.N' - dicyclohexylcarbodiimide; BDBM129231; ACT09818; DCC, 99%; Methanediimine, N,N'-dicyclohexyl-; NSC30022; NSC53373; NSC57182; ZINC8585900; DCC, 1.0 M in methylene chloride; Tox21_203000; Tox21_303237; ANW-31872; BBL012208; N,N'-Methanetetraylbiscyclohexanamine; NSC-30022; NSC-53373; NSC-57182; SBB059225; STL089892; AKOS000120067; US8815951, dicyclohexylcarbodiimide; AM83818; CS-W020097; MCULE-5242025177; N,N'-methanediylidene-dicyclohexanamine; US8815951, N/A; DCC, puriss., >=99.0% (GC); NCGC00091497-01; NCGC00091497-02; NCGC00091497-03; NCGC00091497-04; NCGC00257167-01; NCGC00260545-01; AK-43977; BP-13398; DB-002694; N-(N-cyclohexylcarboximidoyl)cyclohexanamine; D0436; D0437; FT-0629452; N-((cyclohexylimino)methylene)cyclohexanamine; ST50825552; N-((cyclohexylimino)methylene) cyclohexanamine; Cyclohexaamine, N,N'-methanetetraylbis- (9CI); 538D750; Q306565; Q-200966; Dicyclohexylcarbodiimide solution, 60 wt. % in xylenes; F0001-1397; N,N'-Dicyclohexylcarbodiimide, 1M solution in dichloromethane, AcroSeal(R)" Small molecule "1S/C13H22N2/c1-3-7-12(8-4-1)14-11-15-13-9-5-2-6-10-13/h12-13H,1-10H2" QOSSAOTZNIDXMA-UHFFFAOYSA-N C1CCC(CC1)N=C=NC2CCCCC2 C13H22N2 CAS 538-75-0 CHEBI:53090 . . . . . DR1338 Dibenzoylmethane D02BDL D02BDL Investigative Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 8433 Anticancer Treatment "Dibenzoylmethane; 120-46-7; 1,3-Diphenylpropane-1,3-dione; 1,3-DIPHENYL-1,3-PROPANEDIONE; 1,3-Propanedione, 1,3-diphenyl-; 2-Benzoylacetophenone; Phenyl phenacyl ketone; Rhodiastab 83; omega-Benzoylacetophenone; Dibenzoyl-methane; MFCD00003085; UNII-ANS7ME8OKC; 1,3-Diphenyl-propane-1,3-dione; NSC 6266; ANS7ME8OKC; .omega.-Benzoylacetophenone; CHEBI:75417; NSC-6266; Dibenzoylmethane, 98%; Karenzu DK2; dibenzoyl methane; EINECS 204-398-9; BRN 0514910; AI3-19022; CCRIS 8445; Karenzu DK 2; Dibenzoylmethane?DBM); 1, 1,3-diphenyl-; Spectrum2_000038; Spectrum3_001950; ACMC-209a7j; EC 204-398-9; DSSTox_CID_21247; DSSTox_RID_79661; DSSTox_GSID_41247; SCHEMBL39582; BSPBio_003550; MLS002695996; SPECTRUM1505311; SPBio_000135; CHEMBL371523; 1,3-diphenyl-1,3-propandione; 1,3-diphenyl-1,3-propanedion; DTXSID3041247; BDBM22727; KBio3_002841; NSC6266; 1,3-Diphenyl-Propan-1,3-Dion; HMS3091A20; STR01439; ZINC4530702; 1,3-Diphenylpropanedione (Related); Tox21_300686; ANW-17501; CCG-40047; STK372683; AKOS000119639; CS-W010447; MCULE-6320643310; NE10265; 1,3-Diphenyl-1,3-propanedione, 98%; UPCMLD0ENAT5883819:001; NCGC00095298-01; NCGC00095298-02; NCGC00095298-03; NCGC00095298-04; NCGC00254594-01; AC-11379; AK-94186; CAS-120-46-7; M261; SMR001253722; SY014045; DB-041558; AM20020283; D0910; FT-0624640; ST50319429; Dibenzoylmethane 1,3-Diphenyl-1,3-propanedione; Q5272260; W-108476; BRD-K01555864-001-02-8; F0001-0329; Z256709078" Small molecule "1S/C15H12O2/c16-14(12-7-3-1-4-8-12)11-15(17)13-9-5-2-6-10-13/h1-10H,11H2" NZZIMKJIVMHWJC-UHFFFAOYSA-N C1=CC=C(C=C1)C(=O)CC(=O)C2=CC=CC=C2 C15H12O2 CAS 120-46-7 CHEBI:75417 . . . . . DR7371 Diethylpropion D0B7OD D0B7OD Approved Obesity ICD-11: 5B81 CID: 7029 Anticancer Treatment "Amfepramone; DIETHYLPROPION; Diethylpropione; Anorex; Tepanil; 90-84-6; Frekentine; Danylen; Dobesin; Magrene; Tylinal; alpha-Benzoyltriethylamine; Amfepramonum; Prefamone; Regenon; alpha-Diethylaminopropiophenone; Anfepramona; 1-Propanone, 2-(diethylamino)-1-phenyl-; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; 2-(Diethylamino)propiophenone; Amfepramone [INN]; 1-Phenyl-2-diethylamino-1-propanone; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; Moderatan; Tenuate; Amfepramon; Amfepramone hydrochloride; DEA No. 1610; Propiophenone, 2-(diethylamino)-; Amfepramone (INN); Amphepramon; Amphepramone; Nopropiophenone; Adiposon; Neobes; Tenuate Dospan; Amphepramonum hydrochloride; Diethylpropione hydrochloride; Cegramine; Obesitex; Silutin; Derfon; Regenon hydrochloride; CHEBI:4530; Anfamon; Keramik; Keramin; Modulor; Parabolin; UNII-I535TOV6LY; UNII-P1A5AE6Q2R; C06954; D07444; Tenuate hydrochloride; (+)-Amfepramone; (-)-Amfepramone; UR 1423; (+-)-diethylpropion; Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton [Czech]; Amfepramone, (+)-; Amfepramone, (-)-; Fenyl-(1-diethylaminoethyl)keton; HSDB 3059; I535TOV6LY; P1A5AE6Q2R; Diethylpropion, (+}-; Diethylpropion, (-)-; NCGC00167475-01; EINECS 202-019-1; BRN 2804400; 1-Phenyl-2-diethylaminopropanone-1 hydrochloride; Propiophenone, 2-(diethylamino)-, hydrochloride; Propiophenone, 2-diethylamino-; (+)-2-Diethylaminopropiophenone; (-)-2-Diethylaminopropiophenone; (+/-)-diethylpropion; SCHEMBL27330; 1-Propanone, 2-(diethylamino)-1-phenyl-, (+)-; 1-Propanone, 2-(diethylamino)-1-phenyl-, (-)-; 4-14-00-00144 (Beilstein Handbook Reference); GTPL7161; CHEMBL1194666; DTXSID6022929; MFCD00056154; AKOS025401369; DIETHYLPROPION, DONYLEN,DOBESIN; DB00937; J4.327C; MCULE-3905795013; 2-Diethylaminopropiophenone hydrochloride; 39648-49-2; 39648-50-5; AC-13099; 2-(Diethylamino)-1-phenyl-1-propanone #; 1-Phenyl-2-diethylamino-1-propanone hydrochloride; Q2356505; BRD-A37288617-003-01-4" Small molecule "1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3" XXEPPPIWZFICOJ-UHFFFAOYSA-N CCN(CC)C(C)C(=O)C1=CC=CC=C1 C13H19NO CAS 90-84-6 CHEBI:4530 . . . DB00937 . DR0161 Methylprednisolone D08PIQ D08PIQ Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 6741 Anticancer Treatment "methylprednisolone; 83-43-2; Medrol; Medrone; Metilprednisolone; Urbason; 6alpha-Methylprednisolone; Metilbetasone; Medrate; Dopomedrol; Promacortine; Besonia; Medesone; Mesopren; Metastab; Metrisone; Moderin; Noretona; Solomet; Urbasone; Wyacort; Methylprednisolon; Methyleneprednisolone; 6-alpha-Methylprednisolone; Metilprednisolone [DCIT]; delta(1)-6alpha-Methylhydrocortisone; 1-Dehydro-6alpha-methylhydrocortisone; Metilprednisolona; Methylprednisolonum; NSC-19987; Methylprednisolonum [INN-Latin]; Metilprednisolona [INN-Spanish]; Suprametil; Medrol dosepak; Medrol adt pak; 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione; UNII-X4W7ZR7023; CHEBI:6888; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Prednisolone, methyl-; Methylprednisolone, 6-alpha; 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; 6alpha-Methylprednisolone base; U 7532; MLS000028541; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; Sieropresol; Esametone; Firmacort; Medixon; Metrocort; Metysolon; Nirypan; Reactenol; Lemod; Artisone-wyeth; X4W7ZR7023; MEPRDL; Predni N Tablinen; Medlone 21; SMR000058330; Summicort;; 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione; DSSTox_CID_3300; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6a,11b)-; Prednol- L; DSSTox_RID_76965; DSSTox_GSID_23300; Depo-Medrol (acetate); CAS-83-43-2; Prednisolone, 6alpha-methyl-; HSDB 3127; MLS002638721; EINECS 201-476-4; Prednisolone, 6.alpha.-methyl-; BRN 2340300; delta(sup 1)-6-alpha-Methylhydrocortisone; .DELTA.1-6.alpha.-Methylhydrocortisone; NCGC00016330-01; Prestwick_622; Medrol (TN); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-; 6?-Methylprednisolone; Methylprednisolone [USP:INN:BAN:JAN]; Opera_ID_1576; Prestwick0_000279; Prestwick1_000279; Prestwick2_000279; Prestwick3_000279; 6alpha-methyl prednisolone; 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-; CHEMBL650; EC 201-476-4; 6.alpha.-Methylprednisolone; SCHEMBL5084; BSPBio_000158; 4-08-00-03498 (Beilstein Handbook Reference); MLS001148159; MLS002207191; SPBio_002377; BPBio1_000174; GTPL7088; DTXSID7023300; HMS1568H20; HMS2090B13; HMS2095H20; HMS2230D16; HMS3259J04; HMS3712H20; 6alpha-Methylprednisolone, >=98%; HY-B0260; NSC19987; ZINC3875560; Tox21_110376; Tox21_302018; BDBM50103616; LMST02030178; Methylprednisolone (JP17/USP/INN); MFCD00010591; s1733; AKOS015969744; Pregna-1,4-diene-3,20-dione, 6-alpha-methyl-11-beta-17,21-trihydroxy-; Tox21_110376_1; ACN-037579; CCG-220279; DB00959; J3.872E; KS-1273; NC00691; NCGC00022735-03; NCGC00022735-06; NCGC00255269-01; H972; NCI60_001657; M1665; 2639-EP2277861A1; 2639-EP2286811A1; 2639-EP2292595A1; 2639-EP2295409A1; 2639-EP2298778A1; 2639-EP2305660A1; 2639-EP2308562A2; 2639-EP2314590A1; 2639-EP2371811A2; D00407; 010M591; 124684-EP2295426A1; 124684-EP2295427A1; Q417222; SR-01000003089; Q-201395; SR-01000003089-2; BRD-K35240538-001-03-1; BRD-K35240538-001-11-4; BRD-K35240538-001-26-2; 6-alpha-Methylprednisolone 100 microg/mL in Acetonitrile; 6alpha-Methylprednisolone, VETRANAL(TM), analytical standard; 11?,17?,21-Trihydroxy-6?-methyl-1,4-pregnadiene-3,20-dione; 11beta,17,21-trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; Methylprednisolone, British Pharmacopoeia (BP) Reference Standard; Methylprednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-; Pregna-1,20-dione, 6.alpha.-methyl-11.beta.-17,21-trihydroxy-; (6?,11?)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; Methylprednisolone, United States Pharmacopeia (USP) Reference Standard; Methylprednisolone for system suitability A, EuropePharmacopoeia (EP) Reference Standard; Methylprednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Methylprednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; Pregna-1,20-dione, 11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6I+/-,11I(2))-; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)" Small molecule "1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1" VHRSUDSXCMQTMA-PJHHCJLFSA-N CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O C22H30O5 CAS 83-43-2 CHEBI:6888 . . . DB00959 . DR8384 Fluocinolone acetonide D02QJH D02QJH Approved Postoperative inflammation ICD-11: 1A00-CA43 CID: 6215 Anticancer Treatment "FLUOCINOLONE ACETONIDE; 67-73-2; Synalar; Flucinar; Synandone; Fluonid; Jellin; Synamol; Synemol; Coriphate; Fluovitif; Flupollon; Percutina; Synandrone; Dermalar; Localyn; Omniderm; Radiocin; Sinalar; Synotic; Tefunote; Synsac; Fluotrex; Retisert; Synalar-HP; Fluocet; Localyn Syntex; Derma-smoothe/fs; Cortiplastol; Prodermin; Fluocinolonacetonidum; Flucort; Fluocinolone 16,17-acetonide; Iluvien; Capex; 6alpha-Fluorotriamcinolone acetonide; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; RS-1401 AT; Fluocinoloni acetonidum [INN-Latin]; Acetonide de fluocinolone; C24H30F2O6; component of Neo-Synalar; Fluocinolone (Acetonide); UNII-0CD5FD6S2M; Dermatin (steroid); 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; MFCD00010525; NSC-92339; 0CD5FD6S2M; MLS000028545; CHEBI:31623; Fluocinolone acetonide (Flucort-N); Fs Shampoo; NSC92339; flucinolone; SMR000058329; DSSTox_CID_20674; DSSTox_RID_79533; DSSTox_GSID_40674; Acetonida de fluocinolona; RS 1401AT; Flucort-N; 6.alpha.-Fluorotriamcinolone acetonide; CAS-67-73-2; Retisert (TN); (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one; (6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; Fluocet (TN); Synalar (TN); Acetonide de fluocinolone [INN-French]; Acetonida de fluocinolona [INN-Spanish]; CCRIS 3250; HSDB 3083; 6.Alpha.,9-Difluoro; EINECS 200-668-5; NSC 92339; Dermatin; Fluzon [Steroid]; NCGC00021301-04; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; Fluocinoloneacetonide; fluocinolone-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Fluocinolone acetonide intravitreal implant; acetonido de fluocinolona; 6.alpha.,17-acetonide; Opera_ID_1295; F0657; Fluocinolone acetonide [USAN:USP:INN:JAN]; CHEMBL989; SCHEMBL4795; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; MLS001076276; ARONIS24561; GTPL7077; DTXSID0040674; EBD4852; HMS2090I14; HMS2230D13; HMS3259G12; HMS3715J11; HY-B0415; ZINC3977981; Tox21_110869; Tox21_302364; AC-429; s2470; AKOS015963144; Tox21_110869_1; ACN-043362; CCG-221165; DB00591; NC00562; Fluocinolone acetonide (JP17/USP/INN); NCGC00021301-06; NCGC00255654-01; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; AS-13690; NCI60_042042; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Fluocinolone acetonide, analytical standard; D01825; J10113; AB00383017-10; AB00383017_11; 010F525; Q924467; SR-01000000109; SR-01000000109-2; W-104704; BRD-K94353609-001-21-6; difluoro-hydroxy-(2-hydroxyacetyl)-tetramethyl-[?]one; 6.alpha., 9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide, European Pharmacopoeia (EP) Reference Standard; Fluocinolone acetonide, United States Pharmacopeia (USP) Reference Standard; Fluocinolone acetonide for system suitability, European Pharmacopoeia (EP) Reference Standard; Fluocinolone Acetonide, Pharmaceutical Secondary Standard; Certified Reference Material; WLN: T F5 E5 B666 GO IO RV AHTTTT&J A BF CQ E FVIQ H H OF -A&BHO -B&ACEF; (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one; (2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one; 6.alpha.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-difluoro-11beta,21-dihydroxy-16alpha-17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione;; Fluocinolone acetonide for peak identification, European Pharmacopoeia (EP) Reference Standard; Pregna-1,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone" Small molecule "1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1" FEBLZLNTKCEFIT-VSXGLTOVSA-N CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)F)C C24H30F2O6 CAS 67-73-2 CHEBI:31623 . . . DB00591 . DR4436 Oxacillin D0MB8I D0MB8I Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 6196 Anticancer Treatment "oxacillin; Oxazocillin; MPI-penicillin; 66-79-5; Bactocill; Prostaphlin; OXACILLIN SODIUM; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; UNII-UH95VD7V76; CHEBI:7809; C19H19N3O5S; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Penicillin, (5-methyl-3-phenyl-4-isoxazolyl)-; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid; UH95VD7V76; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ossacillina; Oxacilline; Oxacillinum; Prostaphlyn; Oxacilina; Ossacillina [DCIT]; MPi-PC; Oxacillin [INN:BAN]; Oxacilina [INN-Spanish]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; 1173-88-2; Oxacilina (TN); Oxacillin (INN); EINECS 200-635-5; Oxacillin,(S); (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-isoxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, (2S-(2alpha,5alpha,6beta))-; CHEMBL819; Epitope ID:181859; SCHEMBL3817; DTXSID8023397; GTPL10943; phenylisoxazole-4-carboxamido)-7-; ZINC3875439; BDBM50350483; DB00713; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-(5-methyl-3-phenyl-1,2-oxazole-4-amido)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(5-methyl-3-phenyl-4-isoxazolecarboxamide)-7-oxo-; 5-Methyl-3-phenyl-4-isooxazolylpenicillin; oxo-4-thia-1-azabicyclo[3.2.0]heptane-; X6829; C07334; D08307; (2S,5R,6R)-3,3-dimethyl-6-(5-methyl-3-; Q418725; BRD-K96786677-236-01-6; BRD-K96786677-236-02-4; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, (2S-(2.alpha.,5.alpha.,6.beta.))-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]amino]-7-oxo-, (2S,5R,6R)-" Small molecule "1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1" UWYHMGVUTGAWSP-JKIFEVAISA-N CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O C19H19N3O5S CAS 66-79-5 CHEBI:7809 . . . DB00713 . DR5094 Methylene blue D09NYS D09NYS Approved Acquired methaemoglobinaemia ICD-11: 3A93 CID: 6099 Anticancer Treatment "methylene blue; 61-73-4; Basic blue 9; Methylthioninium chloride; Swiss Blue; Solvent blue 8; Chromosmon; 3,7-Bis(dimethylamino)phenothiazin-5-ium chloride; Methylene Blue N; Methylene Blue BB; Methylene Blue anhydrous; Bleu de methylene; Methylene Blue chloride; External Blue 1; Methylene Blue A; Methylene Blue B; Methylene Blue D; Methylene Blue G; C.I. Basic Blue 9; Calcozine Blue ZF; Methylene Blue BD; Methylene Blue BP; Methylene Blue BX; Methylene Blue BZ; Methylene Blue FZ; Methylene Blue GZ; Methylene Blue NZ; Methylene Blue SG; Methylene Blue SP; Methylene Blue ZF; Methylene Blue ZX; Tetramethylene Blue; Methylene Blue 2B; Methylenium ceruleum; Methylene Blue BBA; Methylene Blue BPC; Methylene Blue HGG; Methylene Blue IAD; Methylene Blue JFA; Sandocryl Blue BRL; Methylenblau; Methylene Blue 2BF; Methylene Blue 2BN; Methylene Blue 2BP; M-B Tabs; Rember; Mitsui Methylene Blue; Methylthionium chloride; Leather Pure Blue HB; Methylthionine chloride; Modr methylenova; Schultz No. 1038; Aizen Methylene Blue BH; Aizen Methylene Blue FZ; Methylene Blue polychrome; Methylene Blue Zinc Free; Yamamoto Methylene Blue B; D And C Blue Number 1; Tetramethylthionine chloride; Methylene Blue (Medicinal); Yamamoto Methylene Blue ZF; Ext D and C Blue No. 1; Methylene Blue I (Medicinal); Cloruro de metiltioninio; Methylene Blue NF (Medicinal); Methylthioninii chloridum; Hidaco Methylene Blue Salt Free; Methylene Blue BB (Zinc Free); Methylene Blue USP (Medicinal); Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride; Chlorure de methylthioninium; Methylene Blue USP XII (Medicinal); UNII-8NAP7826UB; Methylene Blue Chloride (Biological stain); C.I. 52015; X 138; 3,7-Bis(dimethylamino)phenazathionium chloride; MFCD00012111; 8NAP7826UB; CHEBI:6872; Urolene blue; Methylene Blue (C.I. 52015); CI 52015; azul de metileno; Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride (1:1); DSSTox_CID_3296; N-[7-(dimethylamino)-3H-phenothiazin-3-ylidene]-N-methylmethanaminium chloride; Ceruleum methylenum; DSSTox_RID_76963; DSSTox_GSID_23296; 12262-49-6; Methylenum coeruleum; CI-52015; CI Basic Blue 9; Caswell No. 567; Methylenblau [German]; Methylthionini chloridum; 3H-Phenothiazine, 3-methochloride; Modr Methylenova [Czech]; CHEMBL405110; Modr zasadita 9; Modr Zasadita 9 [Czech]; CAS-61-73-4; N-(7-(dimethylamino)-3H-phenothiazin-3-ylidene)-N-methylmethanaminium chloride; NSC3089; CCRIS 833; Metiltioninio cloruro [DCIT]; Metiltioninio cloruro; Modr Rozpoustedlova 8 [Czech]; 3H-Phenothiazine, 7-(dimethylamino)-3-(methylimino)-, 3-methochloride; Modr rozpoustedlova 8; NSC215213; NSC617593; C.I. 52 015; HSDB 1405; Methylene Blue, pure, certified, residual water; NSC-215213; NSC-617593; NCGC00167496-01; NCGC00167496-03; Phenothiazin-5-ium,7-bis(dimethylamino)-, chloride; EINECS 200-515-2; Methylthioninii chloridum [INN-Latin]; EPA Pesticide Chemical Code 039505; NSC 215213; Cloruro de metiltioninio [INN-Spanish]; WLN: T C666 BS EY INJ EUK1&1 MN1&1 &G &421; Provayblue; Chlorure de methylthioninium [INN-French]; [7-(dimethylamino)phenothiazin-3-ylidene]dimethylamine, chloride; Lowacryl blue 9; Methylene Azure II; Prestwick_326; Ehrlichs reagent III; Loefflers Methylene Blue; Methylene Blue (Inhibitor); SCHEMBL1351; MLS000719838; DOG (COUCH) GRASS Powder; DTXSID0023296; Methylthioninium chloride [INN]; C.I. Basic Blue 9 (8CI); HMS2598O03; Pharmakon1600-01505444; CI NO 52015; NSC-3089; Tox21_112497; Tox21_302087; NSC759135; s4535; SBB060907; STK018918; AKOS000486124; AKOS015916406; Tox21_112497_1; CCG-267696; DB09241; MCULE-7744087830; NSC-759135; 4-(1-HYDROXY-ETHYL)-BENZOICACID; NCGC00255351-01; 105504-42-5; AC-15225; AK326199; AS-35256; Basic Blue 9;Tetramethylthionine chloride; HY-14536; Methylene Blue, 1% w/v aqueous solution; SMR000304367; ST093058; SY076497; Methylthioninium Chloride (Methylene Blue); Methylene Blue (C.I. 52015) BioChemica; A0574; FT-0622580; M0501; ST50406802; C00220; 3,7-Bis(dimethylamino)-5-phenothiazinium Chloride; Q422134; 3,7-bis(dimethylamino)-phenothiazin-5-ium chloride salt; [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride; [7-(dimethylamino)dibenzo[b,e]1,4-thiazin-3-yl]dimethylamine, chloride; 3-N,3-N,7-N,7-N-tetramethylphenothiazin-5-ium-3,7-diamine;chloride; 1341-90-8; 152071-32-4; 6476-03-5; 97130-83-1" Small molecule "1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1" CXKWCBBOMKCUKX-UHFFFAOYSA-M CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] C16H18ClN3S CAS 61-73-4 CHEBI:6872 . . . DB09241 . DR2449 Phenylephrine D0O6IU D0O6IU Approved Thyrotoxicosis ICD-11: 5A02 CID: 6041 Anticancer Treatment "phenylephrine; L-Phenylephrine; 59-42-7; Metasympatol; Mezaton; Metasynephrine; Neosynephrine; Metaoxedrin; m-Oxedrine; Metaoxedrine; Mesaton; Mesatone; Visadron; m-Sympatol; Isophrin; m-Synephrine; m-Sympathol; R(-)-Phenylephrine; Metaoxedrinum; Mesatonum; Neo-Synephrine; Fenilefrina; Phenylephrinum; m-Methylaminoethanolphenol; Isophrim; Ak-dilate; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol; Mydfrin; Nostril; Cyclomydril; Alcon Efrin; l-(3-Hydroxyphenyl)-N-methylethanolamine; Dionephrine; Adrianol; Biomydrin; Neophryn; Prefrin; Rhinall; Isopto Frin; Prefrin Liquifilm; (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-3-(1-hydroxy-2-(methylamino)ethyl)phenol; Duo-Medihaler; l-1-(m-Hydroxyphenyl)-2-methylaminoethanol; UNII-1WS297W6MV; R(-)-Mezaton; CHEBI:8093; R-PHENYLEPHRINE; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-; 1WS297W6MV; Benzyl alcohol, m-hydroxy-alpha-((methylamino)methyl)-, (-)-; Phenylephrine Tannate; Ah-Chew; 1416-03-1; Spersaphrine; Dilatair; Doktors; Duration; Neofrin; Ocugestrin; Phenoptic; Fenilefrina [INN-Spanish]; Phenylephrinum [INN-Latin]; Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (R)-; Ak-nefrin; I-Phrine; 61-76-7; Phenylephrine, l-; Nostril Spray Pump; Phenylephrine [INN:BAN]; Minims Phenylephrine; Hemorid; Nostril Spray Pump Mild; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; (-)-phenylephrine; (-)-m-Oxedrine; (R)-(-)-phenylephrine; Relief Eye Drops for Red Eyes; Phenylephrine (INN); (R)-(-)-Phenylephrine hydrochloride; HSDB 3383; UNII-DU5ATO7HYP; EINECS 200-424-8; Phenylephrine Minims (TN); phenylene; l-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; AI3-02402; CCRIS 8464; l-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Phenylephrine HCI; Phenylephrine mixture with Tannins; EINECS 215-810-1; Mydfrin (Salt/Mix); Nostril (Salt/Mix); Prefrin (Salt/Mix); Adrianol (Salt/Mix); Neophryn (Salt/Mix); Biomydrin (Salt/Mix); R-(-)-Phenylephrine; Spectrum_001101; Ak-dilate (Salt/Mix); Ak-nefrin (Salt/Mix); DU5ATO7HYP; Alcon efrin (Salt/Mix); Spectrum2_001280; Spectrum3_000770; Spectrum4_000967; Spectrum5_001411; Lopac-P-6126; EC 200-424-8; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; SCHEMBL4711; CHEMBL1215; Lopac0_000920; BSPBio_002420; GTPL485; KBioGR_001313; KBioSS_001581; BIDD:GT0157; DivK1c_000597; SPBio_001280; Benzyl alcohol, m-hydroxy-.alpha.-((methylamino)methyl)-, (-)-; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; component of Entex (Salt/Mix); component of Relief (Salt/Mix); DTXSID9023465; component of Comhist (Salt/Mix); component of Demazin (Salt/Mix); KBio1_000597; KBio2_001581; KBio2_004149; KBio2_006717; KBio3_001640; AB-101 (PHENYLEPHRINE); component of Vasosulf (Salt/Mix); component of Zincfrin (Salt/Mix); NINDS_000597; ZINC113355; component of Cerose dm (Salt/Mix); component of Prefrin-a (Salt/Mix); HY-B0769; component of Cyclomydril (Salt/Mix); ANW-42493; BDBM50067212; MFCD00044749; Neo-Synephrine Pediatric Nasal Drops; PDSP1_001108; PDSP2_001092; component of Decongestant (Salt/Mix); component of Dristan cold (Salt/Mix); Ocu-Phrin Sterile Ophthalmic Solution; AKOS006282042; CCG-205002; CS-6187; DB00388; J8.601K; MCULE-8302708533; SDCCGSBI-0050895.P005; component of Histalet forte (Salt/Mix); component of Ru-tuss liquid (Salt/Mix); IDI1_000597; component of Pv tussin syrup (Salt/Mix); component of Ru-tuss tablets (Salt/Mix); NCGC00015825-01; NCGC00015825-02; NCGC00024257-03; NCGC00024257-05; NCGC00024257-06; NCGC00024257-07; NCGC00024257-19; AM100999; AS-13635; R780; component of Hycomine compound (Salt/Mix); SBI-0050895.P004; AB0018328; component of Dristan nasal mist (Salt/Mix); P0395; 1400-EP2281815A1; 1400-EP2295409A1; 1400-EP2301933A1; 1400-EP2305640A2; 1400-EP2311827A1; 1400-EP2314590A1; 3-[(1R)-1-hydroxy-2-methylaminoethyl]phenol; C07441; D08365; J10016; M-2869; AB00053522_11; AB00053522_12; 044P749; 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, (R)-; A832309; AT-057/40243664; Q421910; 3-[(1R)-2-(methylamino)-1-oxidanyl-ethyl]phenol; Q-201560; (-)-m-Hydroxy-.alpha.-(methylaminomethyl)benzyl alcohol; l-m-Hydroxy-.alpha.-((methylamino)methyl)benzyl alcohol; (R)-3-Hydroxy-.alpha.-[(methylamino)methyl]benzenemethanol; UNII-RH8FKZ05H0 component SONNWYBIRXJNDC-VIFPVBQESA-N; 3-[(1R)-1-Hydroxy-2-(methylamino)ethyl]phenol, AldrichCPR; l-.alpha.-Hydroxy-.beta.-methylamino-3-hydroxy-l-ethylbenzene; (-)- m-Hydroxy-a-[(methylamino)methyl]benzyl alcohol hydrochloride; Benzenemethanol, 3-hydroxy-a-[(methylamino)methyl]-, (.alpha.R)-; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)- (9CI); 1228015-39-1" Small molecule "1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1" SONNWYBIRXJNDC-VIFPVBQESA-N CNCC(C1=CC(=CC=C1)O)O C9H13NO2 CAS 61-76-7 CHEBI:8093 . . . DB00388 . DR8802 Idoxuridine D09PZO D09PZO Approved Herpes simplex infection ICD-11: 1F00 CID: 5905 Anticancer Treatment "idoxuridine; 5-Iodo-2'-deoxyuridine; 54-42-2; 5-Iododeoxyuridine; Idoxuridin; Iododeoxyridine; Iodoxuridine; (+)-5-Iodo-2'-deoxyuridine; 2'-Deoxy-5-iodouridine; IDUR; IUDR; Joddeoxiuridin; Herplex; Allergan 211; Virudox; 5IUDR; Idoxuridinum; Idoxuridina; Dendrid; Allergan 201; IDU; 5-Iodouracil deoxyriboside; Idossuridina [DCIT]; IdUrd; 5-IUDR; Idoxene; Stoxil; Iduridin; Kerecid; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 5IdU; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; SK&F-14287; MFCD00134656; NSC-39661; URIDINE, 2'-DEOXY-5-IODO-; Allergan-211; UNII-LGP81V5245; CHEBI:147675; 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione; (+)-5-Iodo-2-deoxyuridine; Antizona; Heratil; LGP81V5245; SK&F 14287; ID2; Iduoculos; DSSTox_CID_25238; DSSTox_RID_80769; DSSTox_GSID_45238; Idoxuridinum [INN-Latin]; ent-Idoxuridine; Idoxuridina [INN-Spanish]; (+)-5-Iodo-2 -deoxyuridine; Idossuridina; C9H11IN2O5; 5-Iododesoxyuridine; 5-Iodo-deoxyuridine; (+)-5-Iodo-2'-deoxyuridine, 99%; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; uridine, 2'-deoxy-5-(iodo-131I)-; CCRIS 2827; SR-05000001510; EINECS 200-207-8; BRN 0030397; AI3-50861; HSDB 7479; CAS-54-42-2; NCGC00016243-01; Dendrid (TN); Uracil, 5-iodo-1-(2-deoxy-beta-D-ribofuranosyl)-; Idoxuridine [USAN:USP:INN:BAN:JAN]; 5-iodo-2'deoxyuridine; Idoxuridine (5-IdU); PubChem14202; HERPLEX (TN); Prestwick3_000018; CHEMBL788; Epitope ID:138107; 5-I-2'-dUrd; SCHEMBL3683; 2???-Deoxy-5-iodouridine; BSPBio_000055; 4-24-00-01235 (Beilstein Handbook Reference); MLS002154175; 5-IODO-2-DEOXYURIDINE; BPBio1_000061; Idoxuridine (JP17/USP/INN); DTXSID2045238; SCHEMBL15850897; AOB5602; HMS2090M10; HMS2095C17; HMS2230E10; HMS3712C17; BCP29428; HY-B0307; ZINC3834173; 5-IUdR; IDU; IdUrd; Idoxuridine; Tox21_110324; ANW-32073; BDBM50370388; s1883; AKOS015920431; Tox21_110324_1; (+)-5-Iodo-2'-deoxyuridine, 98%; AC-8219; CCG-220018; DB00249; MCULE-5585466189; SMP2_000072; NCGC00179673-01; NCGC00179673-03; AS-13469; I381; SMR001233472; Idoxuridine 100 microg/mL in Acetonitrile; AB0013659; DB-009133; 5-Iodo-2'-deoxyuridine, >=99% (HPLC); I0258; SW198484-2; 1-(2-Deoxy-??-D-ribofuranosyl)-5-iodouracil; 1-(2-Deoxy-ss -D-ribofuranosyl)-5-iodouracil; C-1149; D00342; 16509-EP2281563A1; 16509-EP2316459A1; 20495-EP2272827A1; 20495-EP2298768A1; 20495-EP2314585A1; 5-Iodo-2 inverted exclamation marka-deoxyuridine; 134I656; Q409765; J-009907; J-700180; SR-05000001510-1; SR-05000001510-3; SR-05000001510-4; BRD-K76634210-001-14-7; Idoxuridine, European Pharmacopoeia (EP) Reference Standard; Idoxuridine, United States Pharmacopeia (USP) Reference Standard; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-iodo-pyrimidine-2,4-dione; 889872-67-7" Small molecule "1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1" XQFRJNBWHJMXHO-RRKCRQDMSA-N C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O C9H11IN2O5 CAS 54-42-2 CHEBI:147675 . . . DB00249 . DR2755 Penicillin G D00QAR D00QAR Phase 4 Syphilis ICD-11: 1A60-1A62 CID: 5904 Anticancer Treatment "penicillin g; Benzylpenicillin; Benzylpenicillinic acid; Free penicillin II; Pfizerpen; Benzyl penicillin; Bencilpenicilina; Benzylpenicillinum; 61-33-6; Benzylpenicilline; Benzylpenicillin G; 6-(2-Phenylacetamido)penicillanic acid; Free penicillin G; Benzopenicillin; Dropcillin; Gelacillin; Liquacillin; Pharmacillin; Cilopen; Pradupen; Specilline G; Benzylpenicillin potassium; (5R,6R)-Benzylpenicillin; Penicillin, (phenylmethyl)-; Galofak; Free benzylpenicillin; Penicillin-G potassium; Compocillin G; bensylpenicillin; benzyl benicillin; Pfizerpen-AS; Penicillinic acid, (phenylmethyl)-; Phenylacetamidopenicillanic acid; Pencillin G; UNII-Q42T66VG0C; Cilloral; Cosmopen; PENICILLIN-2; CHEBI:18208; Benzyl-6-aminopenicillinic acid; Penicillinic acid, benzyl-; (Phenylmethyl)penicillin; Q42T66VG0C; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ursopen; (Phenylmethyl)penicillinic acid; 61-33-6 (FREE ACID); (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)- (2S-(2alpha,5alpha,6beta))-; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-; Cillora; PenicillinG; Bencilpenicilina [Spanish]; Benzylpenicilline [French]; Benzylpenicillinum [Latin]; Benzylpenicillin [INN:BAN]; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- [2S-(2alpha,5alpha,6beta)]-; PNN; SMR000538912; HSDB 3166; EINECS 200-506-3; NSC 193396; BRN 0044740; NSC-193396; J01CE01; Penicillin,(S); 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-; PENICILLIN-G; Spectrum_000933; Benzylpenicillin (INN); CHEMBL29; Prestwick0_001078; Prestwick1_001078; Prestwick2_001078; Prestwick3_001078; Spectrum2_000518; Spectrum3_000542; Spectrum4_000471; Spectrum5_001108; Epitope ID:114070; SCHEMBL3783; BSPBio_001096; BSPBio_002183; KBioGR_000942; KBioSS_001413; 4-27-00-05861 (Beilstein Handbook Reference); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-, (2S-(2alpha,5alpha,6beta))-; MLS000766897; MLS001032123; MLS001173382; DivK1c_000316; SPBio_000475; SPBio_002998; BPBio1_001206; GTPL4796; DTXSID5046934; KBio1_000316; KBio2_001413; KBio2_003981; KBio2_006549; KBio3_001683; NINDS_000316; HMS2875L09; ZINC3871701; BDBM50022787; Phenylacetyl-6-aminopenicillanic acid; AKOS005203091; DB01053; IDI1_000316; NCGC00159348-02; NCGC00159348-03; (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-[(PHENYLACETYL)AMINO]-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC ACID; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6- (2-phenylacetamido)-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-; SBI-0051476.P003; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-; Bicillin (*Benzathine Salt, Tetrahydrate*); C05551; D02336; (2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]; 061P336; Q258450; W-109262; BRD-K55191674-236-03-7; BRD-K55191674-237-02-7; BRD-K55191674-237-12-6; Benzylpenicillin, Antibiotic for Culture Media Use Only; 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid; (+)-3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid(penicillin G); (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion (Penicillin G); 3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid(penicillin G); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)- (8CI); 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-, (2S,5R,6R)-" Small molecule "1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1" JGSARLDLIJGVTE-MBNYWOFBSA-N CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C C16H18N2O4S CAS 61-33-6 CHEBI:18208 . . . DB01053 . DR5153 Spironolactone D0EP0C D0EP0C Approved Heart failure ICD-11: BD10 CID: 5833 Anticancer Treatment "spironolactone; 52-01-7; Aldactone; Spirolactone; Verospiron; Euteberol; Spirolang; Verospirone; Spiroctan; Acelat; Aldactone A; Spironocompren; Melarcon; Spiresis; Spiridon; Uractone; Urusonin; Alderon; Spirone; Xenalon; Dira; Spiro-Tablinen; Spironolactone A; spironolattone; Aquareduct; Aldopur; Espironolactona; Spironolactonum; Aldace; Almatol; Deverol; Altex; Berlactone; SC 9420; SC-9420; UNII-27O7W4T232; MFCD00082250; CHEMBL1393; C24H32O4S; CHEBI:9241; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); Spironolattone [DCIT]; 27O7W4T232; NSC-150399; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate; Spironolactone, 99%; Aldactide; Spiractin; Spironolactonum [INN-Latin]; Espironolactona [INN-Spanish]; DSSTox_CID_14186; DSSTox_RID_79120; DSSTox_GSID_34186; SC 15983; (1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan]-6'-ene-5,5'-dione; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate; Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Diatense; Aldactone (TN); 17-Hydroxy-7-alpha-mercapto-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid-gamma-lactone-7-acetate; SMR000471892; HSDB 3184; EINECS 200-133-6; NSC 150399; BRN 0057767; spirotone; Spiranolactone; Carospir; 2oax; 3vhu; CAS-52-01-7; NCGC00015948-02; 3-(3-Keto-7.alpha.-acetylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)propionic acid lactone; 7-.alpha.-(acetylthio)-17-.alpha.-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, .gamma.-lactone; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; S-((7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl) ethanethioate; Spironolactone [USP:INN:BAN:JAN]; Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, gamma-lactone, (7alpha,17alpha)-; Prestwick0_000128; Prestwick1_000128; Prestwick2_000128; Prestwick3_000128; 17-Hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone acetate; 3'-(3-Oxo-7-alpha-acetylthio-17-beta-hydroxyandrost-4-en-17-beta-yl)propionic acid lactone; 3-(3-Keto-7-alpha-acetylthio-17-beta-hydroxy-4-androsten-17-alpha-yl)propionic acid lactone; BIDD:PXR0071; SCHEMBL20939; BSPBio_000176; 17alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7alpha-mercapto-3-oxo-, gamma-lactone, acetate; 4-18-00-01601 (Beilstein Handbook Reference); MLS001074672; MLS001333253; MLS001333254; MLS002153245; MLS002207058; MLS002548846; SPBio_002115; BPBio1_000194; GTPL2875; DTXSID6034186; Spironolactone (JP17/USP/INN); HMS1568I18; HMS2090N21; HMS2095I18; HMS2236E06; HMS3259G11; HMS3712I18; ACT02596; AMY40521; HY-B0561; Spironolactone, 97.0-103.0%; ZINC3861599; Tox21_113047; Tox21_302154; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; BDBM50228080; NSC150399; s4054; 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; AKOS015896401; AC-4214; CCG-220128; DB00421; KS-5234; MCULE-4394091100; NC00482; NCGC00164397-01; NCGC00164397-02; NCGC00164397-03; NCGC00164397-05; NCGC00255229-01; 17-alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-alpha-mercapto-3-oxo-, gamma-lactone acetate; AK546740; CPD000471892; H490; Spironolactone 1.0 mg/ml in Acetonitrile; AB00513806; S0260; 7080-EP2269989A1; 7080-EP2270011A1; 7080-EP2272841A1; 7080-EP2295406A1; 7080-EP2298772A1; 7080-EP2298776A1; 7080-EP2301936A1; 7080-EP2308562A2; 7080-EP2308839A1; C07310; D00443; AB01275520-01; AB01275520_02; 082S250; Q422188; SR-01000765419; SR-05000000452; Q-201737; SR-01000765419-2; SR-05000000452-2; BRD-K90027355-001-03-4; BRD-K90027355-001-19-0; Z1551900341; Spironolactone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone acetate; Spironolactone, United States Pharmacopeia (USP) Reference Standard; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, acetate; Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, (7.alpha.,17.alpha.)-; (7?,17?)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid ?-lactone; 7alpha-(Acetylthio)-17alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid gamma-lactone; Spironolactone for system suitability, European Pharmacopoeia (EP) Reference Standard; 17-HYDROXY-7ALPHA-MERCAPTO-3-OXO-17ALPHA-PREGN-4-ENE-21- CARBOXYLIC ACID; GAMMA-LACTONE ACETATE; 2'',15''-dimethyl-5,5''-dioxo-(9''R)-spiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate(Spiranolactone); 7-alpha-(acetylthio)-17-alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, gamma-lactone (9CI); S-(2''R,7R,8R,9S,10R,13S,14S)-10,13-dimethyl-3,5''-dioxo-1,2,3,4'',5'',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3''H-spiro[cyclopenta[a]phenanthrene-17,2''-furan]-7-yl ethanethioate" Small molecule "1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1" LXMSZDCAJNLERA-ZHYRCANASA-N CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C C24H32O4S CAS 52-01-7 CHEBI:9241 . . . DB00421 . DR8725 Levothyroxine D06RGG D06RGG Approved Hypo-thyroidism ICD-11: 5A00 CID: 5819 Anticancer Treatment "L-thyroxine; levothyroxine; 51-48-9; thyroxine; thyroxin; Tetraiodothyronine; Thyrax; 3,3',5,5'-Tetraiodo-L-thyronine; synthroid; Thyratabs; Thyreoideum; Thyroxinal; Thyroxine iodine; Levothyroxin; (-)-Thyroxine; L-Thyroxin; 3,5,3',5'-Tetraiodo-L-thyronine; L-T4; Thyroxine (l); Levothyroxine sodium; DL-Thyroxin; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; t4; Thyroxine (VAN); 3,5,3',5'-Tetraiodothyronine; Laevothyroxinum; T4 (Hormone); L-3,5,3',5'-Tetraiodothyronine; Levothyroxinum (acid); Laevothyroxinum (acid); Thryroxine, l-; Tetramet; Thyroxine I 125; Forthyron (TN); NSC 36397; Levothyroxinum; 3,3',5,5''-Tetraiodo-L-thyronine; CCRIS 6739; Henning; HSDB 3108; 3,5,3'5'-Tetraiodo-L-thyronine; UNII-Q51BO43MG4; Prestwick_548; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine; CHEBI:18332; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; (S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoic acid; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; CHEMBL1624; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; C15H11I4NO4; Q51BO43MG4; 51-48-9 (free); THX; MFCD00002595; NCGC00164336-01; L-Thyroxine, 97+%; DSSTox_CID_3214; DSSTox_RID_76927; DSSTox_GSID_23214; Eutirox; Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; LT4; SMR000059176; T44; Levothyroxine (BAN); EINECS 200-101-1; Levothyroxine [INN:BAN]; Synthroid (*Sodium salt*); BRN 2228515; SR-01000759430; NSC-36397; 2ceo; L-Tyrosine,; CAS-51-48-9; Spectrum_001076; 1hk1; 1hk2; 1hk3; 1hk4; 1hk5; 1y0x; CPD000059176; L-Thyroxine, free acid; SpecPlus_000871; Prestwick0_000403; Prestwick1_000403; Prestwick2_000403; Prestwick3_000403; Spectrum2_000573; Spectrum3_000611; Spectrum4_000128; Spectrum5_001500; Thyroxine, L- (8CI); bmse000923; Epitope ID:123889; T-3850; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]propanoic acid; L-Thyroxine (T4) solution; BIDD:PXR0161; Levothroid (*Sodium salt*); SCHEMBL23098; BSPBio_000326; BSPBio_002142; KBioGR_000516; KBioSS_001556; MLS000028647; MLS002548901; DivK1c_006967; SPECTRUM1500774; SPBio_000386; SPBio_002265; BPBio1_000360; GTPL2635; DTXSID8023214; KBio1_001911; KBio2_001556; KBio2_004124; KBio2_006692; KBio3_001642; HMS1569A08; HMS1921I06; HMS2090P18; HMS2092K12; HMS2096A08; HMS2233J18; HMS3259M11; HMS3713A08; L-Thyroxine, >=98% (HPLC); Pharmakon1600-01500774; ZINC3830993; Tox21_112101; Tox21_302156; BDBM50301375; CCG-38738; NSC757434; s2599; AKOS015905129; Tox21_112101_1; AC-7504; AM83594; CS-1819; DB00451; NC00485; NSC-757434; SDCCGMLS-0066571.P001; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3'',5,5''-tetraiodo-L-thyronine; 3,5,3'',5''-tetraiodo-L-thyronine; NCGC00094852-03; NCGC00164336-02; NCGC00164336-03; NCGC00164336-04; NCGC00164336-05; NCGC00164336-06; NCGC00255368-01; AC-10465; HY-18341; SBI-0051608.P002; AB0010528; DB-006261; SW196731-3; C01829; D08125; J10324; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; AB00052176-08; AB00052176_09; AB00052176_10; 002T595; Q773449; SR-05000001567; SR-01000759430-2; SR-05000001567-1; BRD-K30685142-001-05-5; BRD-K30685142-001-08-9; Thyroxine (T4), IRMM(R) certified Reference Material; L-Thyroxine, powder, BioReagent, suitable for cell culture; UNII-QR0BV3BRIA component XUIIKFGFIJCVMT-LBPRGKRZSA-N; Levothyroxine, United States Pharmacopeia (USP) Reference Standard; Levothyroxine, Pharmaceutical Secondary Standard; Certified Reference Material; L-Thyroxine (T4) solution, 100 mug/mL in methanol with 0.1N NH3, ampule of 1 mL, certified reference material" Small molecule "1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1" XUIIKFGFIJCVMT-LBPRGKRZSA-N C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N C15H11I4NO4 CAS 51-48-9 CHEBI:18332 . . . DB00451 . DR3168 Phentolamine D01JUF D01JUF Approved Gangrene ICD-11: MC85 CID: 5775 Anticancer Treatment "phentolamine; Regitine; 50-60-2; Regitin; Fentolamin; Dibasin; Rogitine; Phentolaminum; Fentolamina; C 7337 Ciba; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 3-(((4,5-Dihydro-1H-imidazol-2-yl)methyl)(p-tolyl)amino)phenol; Phentolamine mesylas; C 7337; UNII-Z468598HBV; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-; 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; Phenol, m-(N-(2-imidazolin-2-ylmethyl)-p-toluidino)-; MLS000040874; CHEBI:8081; 2-Imidazoline, 2-((N-(m-hydroxyphenyl)-p-toluidino)methyl)-; Z468598HBV; NCGC00016311-10; Phenotolamine; Phentalamine; Regitipe; SMR000058051; DSSTox_CID_3462; Phenol, 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]-; DSSTox_RID_77036; DSSTox_GSID_23462; Phentolamine [INN:BAN]; Fentolamina [INN-Spanish]; Phentolaminum [INN-Latin]; Fentolamine; CAS-50-60-2; Phentolamine (INN); HSDB 3382; EINECS 200-053-1; BRN 0272944; C-7337; Regitina; phentol amine; Rogitine (Salt/Mix); Spectrum_000077; Opera_ID_116; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; Prestwick0_000230; Prestwick1_000230; Prestwick2_000230; Prestwick3_000230; Spectrum3_000788; Spectrum4_000899; Spectrum5_001704; CHEMBL597; cid_5775; SCHEMBL5653; Lopac0_000982; BSPBio_000279; BSPBio_001435; BSPBio_002496; GTPL502; KBioGR_001338; KBioSS_000477; 5-25-09-00365 (Beilstein Handbook Reference); cid_91430; MLS001201741; DivK1c_000807; SPBio_002200; BPBio1_000307; PHE035; DTXSID4023462; BCBcMAP01_000014; BDBM31046; KBio1_000807; KBio2_000477; KBio2_003045; KBio2_005613; KBio3_001716; ZINC20251; NINDS_000807; HMS1791H17; HMS1989H17; HMS2089E03; HMS2235D17; HMS3372H21; HMS3402H17; Tox21_110364; BBL010978; STK802099; AKOS004119917; Tox21_110364_1; CCG-205062; DB00692; SDCCGSBI-0050955.P005; CAS-73-05-2; IDI1_000807; SMP1_000236; NCGC00016311-01; NCGC00016311-02; NCGC00016311-03; NCGC00016311-04; NCGC00016311-05; NCGC00016311-06; NCGC00016311-07; NCGC00016311-08; NCGC00016311-09; NCGC00016311-11; NCGC00016311-12; NCGC00016311-13; NCGC00016311-14; NCGC00016311-15; NCGC00016311-16; NCGC00016311-17; NCGC00016311-19; NCGC00016311-33; NCGC00021804-06; NCGC00021804-07; NCGC00021804-08; NCGC00021804-09; NCGC00021804-10; SBI-0050955.P004; DB-050268; FT-0603219; EN300-51916; D08362; AB00053768-28; AB00053768_29; AB00053768_30; 242P985; L001116; Q420360; m-[N-(2-Imidazolin-2-ylmethyl)-p-toluidino]phenol; W-105944; BRD-K90333595-001-02-8; BRD-K90333595-003-04-0; 2-[N-(3-Hydroxyphenyl)-p-toluidinomethyl]-2-imidazolidine; 3-[(4,5-Dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol #; 3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol; 3-[N-(2-imidazolin-2-ylmethyl)-4-methyl-anilino]phenol;hydrochloride; 3-[N-(2-imidazolin-2-ylmethyl)-4-methyl-anilino]phenol;mesylic acid; 3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol;methanesulfonic acid" Small molecule "1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)" MRBDMNSDAVCSSF-UHFFFAOYSA-N CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O C17H19N3O CAS 50-60-2 CHEBI:8081 . . . DB00692 . DR5145 Prednisolone D0D1SG D0D1SG Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 5755 Anticancer Treatment "prednisolone; 50-24-8; Metacortandralone; Hydroretrocortine; Predonine; Delta-Cortef; Deltacortril; Meticortelone; Deltahydrocortisone; Prenolone; Hydroretrocortin; PRDL; Deltacortenol; Hydrodeltalone; Hydrodeltisone; Codelcortone; Cortalone; Cotogesic; Decaprednil; Delcortol; Deltisilone; Dicortol; Donisolone; Dydeltrone; Erbacort; Erbasona; Estilsona; Fernisolone; Hydeltra; Hydeltrone; Lentosone; Paracortol; Paracotol; Precortancyl; Precortilon; Precortisyl; Prednelan; Prednicen; Predniliderm; Predonin; Rolisone; Scherisolon; Sterolone; Cordrol; Prednis; Prelone; Steran; Ulacort; Fernisolone P; Hostacortin H; Ultracorten H; Ultracortene-H; Delta-stab; Predne-Dome; Decortin H; CO-Hydeltra; Eazolin D; Meti-Derm; Di-adreson F; Delta F; Derpo PD; 1-Dehydrohydrocortisone; Solone; delta(1)-Hydrocortisone; delta(1)-Dehydrocortisol; Delta-Ef-Cortelan; Dexa-Cortidelt hostacortin H; 1,2-Dehydrohydrocortisone; Prednisolona; Prednisolonum; Prednisolonum [INN-Latin]; Prednisolona [INN-Spanish]; 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione; (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione; Ultracortene-hydrogen; Delta(1)-dehydrohydrocortisone; 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol; UNII-9PHQ9Y1OLM; 3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene; 11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; K 1557; .DELTA.1-Cortisol; MFCD00003649; .DELTA.1-Hydrocortisone; 9PHQ9Y1OLM; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; .DELTA.1-Dehydrocortisol; CHEMBL131; CHEBI:8378; .DELTA.1-Dehydrohydrocortisone; 50-24-8 (free); Predniretard; Poly-Pred; .delta.-Cortef; 1-Dehydrocortisol; Neo-Delta-Cortef; Fernisolone-P; .delta.-Stab; NSC-9120; NSC-9900; Prednisolone, 99%; component of Ataraxoid; 11beta,17alpha,21-Trihydroxypregna-1,4-diene-3,20-dione; Cotolone; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; DSSTox_CID_1184; component of K-Predne-Dome; DSSTox_RID_75996; DSSTox_GSID_21184; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; delta(1)-Cortisol; Deltasolone; Klismacort; Panafcortelone; delta(sup 1)-Cortisol; Bubbli-Pred; delta(sup 1)-Hydrocortisone; delta(sup 1)-Dehydrocortisol; SMR000718761; CCRIS 980; Prednisolone [INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; HSDB 3385; delta(sup 1)-Dehydrohydrocortisone; MLS002638110; NSC 9120; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-; EINECS 200-021-7; Predisolone Sodium Phosphate; BRN 1354103; prednisolon; Preflam; Pregna-1,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; CAS-50-24-8; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; NCGC00094764-01; delta-hydrocortisone; Prestwick_404; delta-dehydrocortisol; DELTA.1-Cortisol; Delta-Cortef (TN); 11-beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; T-Pred (Salt/Mix); 1,4-Pregnadien-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-beta,17-alpha,21-triol; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-; Prednisolone, >=99%; Prestwick0_000274; Prestwick1_000274; Prestwick2_000274; Prestwick3_000274; delta-dehydrohydrocortisone; EC 200-021-7; SCHEMBL3233; K-Predne-Dome (Salt/Mix); .DELTA.(sup 1)-Cortisol; BSPBio_000148; 4-08-00-03467 (Beilstein Handbook Reference); MLS001304083; MLS002154250; MLS002207037; MLS002548883; SPBio_002367; BPBio1_000164; GTPL2866; DTXSID9021184; .DELTA.(sup 1)-Hydrocortisone; BDBM19190; Prednisolone (JP17/USP/INN); NSC9120; NSC9900; .DELTA.(sup 1)-Dehydrocortisol; HMS1568H10; HMS2090J05; HMS2095H10; HMS2230P10; HMS3259E09; HMS3712H10; BCP09053; ZINC3833821; Tox21_111327; Tox21_201673; Tox21_302987; CP0099; LMST02030179; s1737; .DELTA.(sup 1)-Dehydrohydrocortisone; AKOS015894935; Tox21_111327_1; AC-1773; CCG-220274; DB00860; NC00473; NCGC00179649-01; NCGC00179649-02; NCGC00179649-03; NCGC00179649-04; NCGC00179649-06; NCGC00256577-01; NCGC00259222-01; AS-13665; HY-17463; P0637; EN300-53017; 5948-EP0930075A1; 5948-EP2272832A1; 5948-EP2277565A2; 5948-EP2277566A2; 5948-EP2277567A1; 5948-EP2277568A2; 5948-EP2277569A2; 5948-EP2277570A2; 5948-EP2277861A1; 5948-EP2277865A1; 5948-EP2281815A1; 5948-EP2292280A1; 5948-EP2295426A1; 5948-EP2295427A1; 5948-EP2298778A1; 5948-EP2301933A1; 5948-EP2305219A1; 5948-EP2305248A1; 5948-EP2305663A1; 5948-EP2308562A2; 5948-EP2308880A1; 5948-EP2311827A1; 5948-EP2314585A1; 5948-EP2314590A1; 5948-EP2316832A1; 5948-EP2316833A1; 5948-EP2371811A2; C07369; D00472; J10078; Prednisolone, VETRANAL(TM), analytical standard; 003P649; SR-01000837502; Q-201616; SR-01000837502-2; 11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione; BRD-K98039984-001-03-0; BRD-K98039984-001-06-3; Q11426176; 11beta,17,21-trihydroxy-1,4-pregnadiene-3,20-dione; delta-1-Cortisol; Prednicarbate EP Imp A; Supercortisol; Prednisolone, British Pharmacopoeia (BP) Assay Standard; Z1245633279; 11-.beta.,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-1,4-pregnadiene-3,20-dione; (11alpha)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione; 1,4-Pregnadien-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-.beta.,17-.alpha.,21-triol; Prednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11.beta.,17,21-trihydroxy-; 11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (11.beta.)-; 11-.beta.,17-.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 11-.beta.,17-.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; Prednisolone, United States Pharmacopeia (USP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8CI); Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard; Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one; Prednisolone solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; TUA" Small molecule "1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1" OIGNJSKKLXVSLS-VWUMJDOOSA-N CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O C21H28O5 CAS 50-24-8 CHEBI:8378 . . . DB00860 . DR1960 3'-azido-3'-deoxythymidine . . Approved Human immunodeficiency virus disease ICD-11: 1C62 CID: 5726 Anticancer Treatment "NSC602670; Azidothymidine (AZT); BW-A 509U; Aztec; 3'-Deoxy-3'-azidothymidine; Azitidin; Timazid; Zidovudine, AZT; NSC 602670; NSC-602670; Thymidine, 8CI,; Trizivir (Salt/Mix); ACMC-209hgl; 3-Azido-3-deoxythymidine; 1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; CHEMBL178240; SCHEMBL13609910; 3'-epi-Azido-3'-deoxythymidine; component of Combivir (Salt/Mix); HMS3369K15; HMS3656A20; BCP03622; STL451000; STL454167; ZINC04164448; AKOS015949577; AKOS037482514; CCG-229922; MCULE-3669241621; NCGC00015044-03; NCGC00015044-04; NCGC00015044-05; NCGC00094963-01; NCGC00094963-02; NCI60_004566; FT-0601543; 1-(3-azido-2,3-dideoxypentofuranosyl)-2-hydroxy-5-methylpyrimidin-4(1H)-one; 1-(3-azido-2,3-dideoxypentofuranosyl)-4-hydroxy-5-methylpyrimidin-2(1H)-one; ZVD" Small molecule "1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)" HBOMLICNUCNMMY-UHFFFAOYSA-N CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-] C10H13N5O4 CAS 30516-87-1 . . . . DB03666 . DR4671 Zafirlukast D05DVP D05DVP Approved Asthma ICD-11: CA23 CID: 5717 Anticancer Treatment "zafirlukast; 107753-78-6; Accolate; Olmoran; ICI-204219; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; Accoleit; ICI 204219; ICI 204,219; C31H33N3O6S; UNII-XZ629S5L50; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Zafirlukast (Accolate); CHEMBL603; Aeronix; CHEBI:10100; XZ629S5L50; MFCD00864775; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; NCGC00164547-01; NCGC00164547-06; Vanticon; DSSTox_CID_3746; DSSTox_RID_77181; DSSTox_GSID_23746; cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Zafirst; Respix; Accolate (TN); Cyclopentyl 3-{2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl}-1-methyl-1H-indol-5-ylcarbamate; cyclopentyl N-{3-[(2-methoxy-4-{[(2-methylbenzene)sulfonyl]carbamoyl}phenyl)methyl]-1-methyl-1H-indol-5-yl}carbamate; N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic Acid Cyclopentyl Ester; SMR000466316; CAS-107753-78-6; SR-01000759386; Zafirlucast; Zafirlukast (JAN/USAN/INN); Zafirlukast [USAN:INN:BAN]; Zafirlukast(Accolate); PubChem18223; CPD000466316; ACMC-209wlw; cc-92; SCHEMBL4175; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; MLS000759421; MLS001424064; MLS006011771; BIDD:GT0267; GTPL3322; DTXSID5023746; Zafirlukast, >=98% (HPLC); HMS2051F12; HMS2089J10; HMS3393F12; HMS3650A04; HMS3655E13; HMS3713J08; HMS3745K03; ZINC896717; BCP05226; Tox21_112176; ANW-46530; BDBM50009073; s1633; STK646780; AKOS005577888; Tox21_112176_1; AC-9018; CCG-101025; DB00549; MCULE-2053856450; NC00275; SB19079; NCGC00164547-02; NCGC00164547-03; NCGC00164547-04; NCGC00164547-05; AS-12943; cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; cyclopentyl N-[3-[[2-methoxy-4-(o-tolylsulfonylcarbamoyl)phenyl]methyl]-1-methyl-indol-5-yl]carbamate; HY-17492; AB0012638; FT-0601575; MLS000759421-02; SW197655-3; C07206; D00411; 32256-EP2270008A1; 32256-EP2280006A1; 32256-EP2281813A1; 32256-EP2281815A1; 32256-EP2281819A1; 32256-EP2284166A1; 32256-EP2292617A1; 32256-EP2292619A1; 32256-EP2295409A1; 32256-EP2298415A1; 32256-EP2301933A1; 32256-EP2305640A2; 32256-EP2305659A1; 32256-EP2308562A2; 32256-EP2311818A1; 32256-EP2311827A1; AB00639922-06; AB00639922-08; AB00639922_09; 753Z786; A801752; L001011; Q928378; Q-201940; SR-01000759386-4; SR-01000759386-5; SR-01000759386-9; BRD-K71289571-001-06-4; Z1551429730; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)-carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; cyclopentyl 3-(2-methoxy-4-(o-tolylsulfonylcarbamoyl)benzyl)-1-methyl-1H-indol-5-ylcarbamate; cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methyl-1H-indol-5-yl]carbamate; cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]carbamate; Cyclopentyl N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamate; N-[3-[[2-methoxy-4-[[(2-methylphenyl)sulfonylamino]-oxomethyl]phenyl]methyl]-1-methyl-5-indolyl]carbamic acid cyclopentyl ester; ZLK" Small molecule "1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)" YEEZWCHGZNKEEK-UHFFFAOYSA-N CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC C31H33N3O6S CAS 107753-78-6 CHEBI:10100 . . . DB00549 . DR3619 Venlafaxine D0P1UX D0P1UX Approved Depression ICD-11: 6A70-6A71 CID: 5656 Anticancer Treatment "venlafaxine; 93413-69-5; Elafax; D,L-Venlafaxine; Venlafaxina; Venlafaxinum; Effexor; 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; Efectin; CHEBI:9943; Venlafaxine [INN:BAN]; NCGC00095109-01; Venlafaxinum [INN-Latin]; Venlafaxin; Venlafaxina [INN-Spanish]; Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-; DSSTox_CID_3737; DSSTox_RID_77175; DSSTox_GSID_23737; Venlafexine; Efectin (TN); Venlafaxine (INN); CAS-93413-69-5; SR-01000762930; DL-Venlafaxine; Venflaxine EP; HSDB 6699; Venlafaxine-d6 HCl; Spectrum_001671; SpecPlus_000842; Spectrum2_000542; Spectrum3_000989; Spectrum4_001115; Spectrum5_001516; Venlafaxine EP Impurity H; CHEMBL637; EC 618-944-2; N,N,O-Didesmethylvenlafaxine; SCHEMBL35154; BSPBio_002657; KBioGR_001590; KBioSS_002151; MLS006011859; DivK1c_006938; SPECTRUM1504171; SPBio_000583; GTPL7321; DTXSID6023737; BDBM82071; KBio1_001882; KBio2_002151; KBio2_004719; KBio2_007287; KBio3_001877; HMS1922F05; HMS2090F04; HMS2093A12; HMS3714K11; HMS3886K14; Pharmakon1600-01504171; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol; AMY39116; HY-B0196; Tox21_111425; CCG-39577; MFCD00864385; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; NSC_62923; NSC758676; s5655; STK621394; AKOS005555049; Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, (+-)-; Tox21_111425_1; AC-1547; AT-6375; DB00285; MCULE-6632261838; NSC 758676; NSC-758676; SDCCGSBI-0052740.P003; NCGC00095109-02; NCGC00095109-03; NCGC00095109-04; NCGC00095109-05; NCGC00095109-06; NCGC00095109-08; NCGC00095109-20; K700; SMR002204138; WY-45655; SBI-0052740.P002; CAS_93413-69-5; CAS_99300-78-4; DB-057399; FT-0642242; FT-0675793; FT-0675795; C07187; D08670; AB00053751-08; AB00053751-10; AB00053751-11; AB00053751_12; AB00053751_13; 413V695; Q898407; SR-01000762930-3; SR-01000762930-4; BRD-A51714012-001-02-3; BRD-A51714012-003-01-1; 1-[2-dimethylamino-1-(4-methoxylphenyl)ethyl]cyclohexanol; (RS)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 540726-98-5" Small molecule "1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3" PNVNVHUZROJLTJ-UHFFFAOYSA-N CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O C17H27NO2 CAS 93413-69-5 CHEBI:9943 . . . DB00285 . DR1567 Terazosin D0P9RF D0P9RF Approved Prostate hyperplasia ICD-11: GA90 CID: 5401 Anticancer Treatment "terazosin; Terazosine; 63590-64-7; Hytrin; Terazosina; Terazosinum; Flumarc; Fosfomic; Vasomet; Blavin; Terazosine [INN-French]; Terazosinum [INN-Latin]; Terazosina [INN-Spanish]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; CHEMBL611; MLS000069703; Abbott-45975; CHEBI:9445; Terazosin (hydrochloride); [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; SMR000058309; Terazosin [INN:BAN]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine; (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Abbott 45975; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine; Terazosabb (TN); Terazosin (INN); 141269-45-6; MFCD00467965; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine; terazosin a; terazosinhydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride; Opera_ID_1910; Prestwick0_000751; Prestwick1_000751; Prestwick2_000751; Prestwick3_000751; 141269-44-5; SCHEMBL6528; Lopac0_001138; REGID_for_CID_5401; BSPBio_000762; MLS001201836; MLS006011889; SPBio_002701; BPBio1_000840; GTPL7302; MET029; DTXSID3023639; HMS2090P21; HMS2232N21; HMS3259F04; HMS3369P14; HMS3371E20; HMS3742I09; 109351-34-0; HY-B0371; 4097AH; BBL010743; BDBM50033111; STK567029; AKOS005266642; CCG-205212; DB01162; MCULE-4030111564; NC00689; SDCCGSBI-0051105.P002; VA11839; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-; NCGC00016026-04; NCGC00016026-05; NCGC00016026-08; NCGC00016026-11; NCGC00025191-03; AC-11120; H963; LS-14728; FT-0630739; C07127; D08569; 590T647; L000692; Q280786; BRD-A22256192-003-03-7; BRD-A22256192-003-14-4; Z1172269406; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-{(tetnaphydro-2-furanyl)carbonyl}piperazine; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-imine; 6,7-Dimethoxy-2-[4-(tetrahydro-2-furanylcarbonyl)-1-piperazinyl]-4-quinazolinamine #; 6,7-dimethoxy-2-{4-[(oxolan-2-yl)carbonyl]piperazin-1-yl}quinazolin-4-amine; Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-; 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine" Small molecule "1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)" VCKUSRYTPJJLNI-UHFFFAOYSA-N COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC C19H25N5O4 CAS 63590-64-7 CHEBI:9445 . . . DB01162 . DR9295 Tegafur D0F3SY D0F3SY Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 5386 Anticancer Treatment "tegafur; Ftorafur; 17902-23-7; Futraful; Fluorofur; Sinoflurol; Citofur; Florafur; Fental; Neberk; Coparogin; Franroze; Furafluor; Furflucil; Furofutran; Nitobanil; Exonal; Fulfeel; Lifril; Sunfral; Lamar; Riol; Tefsiel C; FT-207; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; Phthorafur; 1-(2-Tetrahydrofuryl)-5-fluorouracil; 5-Fluoro-1-(tetrahydro-2-furyl)uracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; MJF-12264; NSC-148958; N1-(2-tetrahydrofuryl)-5-fluorouracil; 1-(Tetrahydrofuran-2-yl)-5-fluorouracil; 5-Fluoro-1-(tetrahydrofuran-2-yl)uracil; URACIL, 5-FLUORO-1-(TETRAHYDRO-2-FURYL)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione; Uracil, 1-(tetrahydrofuran-2-yl)-5-fluoro-; FT 207; MFCD00012351; 5-Fluoro-1-(tetrahydro-3-furyl)uracil; 1-(Tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione; MLS000069497; 5-FLUORO-1-(TETRAHYDRO-2-FURFURYL)URACIL; CHEBI:32188; 1-(2-TETRAHYDROFORMYL)-5-FLUOROURACIL; C8H9FN2O3; 5-fluoro-1-tetrahydrofuran-2-yl-pyrimidine-2,4-dione; NCGC00159418-02; NCGC00159418-05; SMR000059106; Racemic Ftorafur; DSSTox_CID_1305; DSSTox_RID_76070; DSSTox_GSID_21305; Phthorafur [Czech]; Fluorafur; Tegafurum; Tegafurum [INN-Latin]; CAS-37076-68-9; CCRIS 2762; FT-207 (NSC 148958); FT207; EINECS 241-846-2; BRN 0525766; Franrose; N1-(2'-Tetrahydrofuryl)-5-fluorouracil; Sunfural; Fulaid; 1-(Tetrahydro-2-furanyl)-5-fluorouracil; N(sub 1)-(2-Tetrahydrofuryl)-5-fluorouracil; Tegafur [USAN:INN:BAN:JAN]; N(sub 1)-(2'-Furanidyl)-5-fluouracil [Czech]; Atillon (TN); Tegafur ,(S); N(sub 1)-(2'-Furanidyl)-5-fluouracil; TS-1 (Salt/Mix); Opera_ID_1726; UPCMLD-DP063; SCHEMBL4552; 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione; 5-24-06-00285 (Beilstein Handbook Reference); MLS000759414; MLS001076521; MLS001424119; CHEMBL20883; Tegafur (JP17/USAN/INN); F-5-FU; UPCMLD-DP063:001; GTPL10513; DTXSID001009966; HMS1665I05; HMS2051B15; HMS2090K04; HMS2232E05; HMS3371H21; HMS3393B15; HMS3654P13; HMS3715D14; N1-(2'-Furanidyl)-5-fluouracil; 2,4(1H,3H)Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione; BCP22714; 5-fluoro-1-(tetrahydrofuran-2-yl); N1-(2'-Furanidyl)-5-fluorouracil; Tox21_111649; Tox21_301812; BBL027795; CCG-50110; STK528044; Tegafur, >=98% (HPLC), powder; 5-Fluoro-1-(2-tetrahydrofuryl)uracil; AKOS000121279; Tox21_111649_1; AC-2112; CCG-100959; CS-1128; DB09256; MCULE-1366455644; NC00209; 1-(tetrahydro-2-furyl)-5-fluorouracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, didehydroderiv.; 5-fluoro-1-(2-tetrahydrofuranyl)uracil; N1 -(2-tetrahydrofuryl)-5-fluorouracil; NCGC00159418-04; NCGC00255222-01; 79107-97-4; 82294-77-7; AK468738; AS-13528; HY-17400; I580; FT-0653732; FT-0654170; FT-0674829; FT-0693965; C12673; D01244; J10344; W-5041; AB00572620-15; 902T237; Q413370; SR-01000639511; Q-201784; SR-01000639511-1; SR-01000639511-4; 5-fluoro-1-tetrahydro-furan-2-yl-1H-pyrimidine-2,4-dione; 5-Fluoro-1-tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione; 2, 4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (R)-" Small molecule "1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)" WFWLQNSHRPWKFK-UHFFFAOYSA-N C1CC(OC1)N2C=C(C(=O)NC2=O)F C8H9FN2O3 CAS 17902-23-7 CHEBI:32188 . . . DB09256 . DR2918 Salazosulfapyridine D02ZTJ D02ZTJ Approved Rheumatoid arthritis ICD-11: FA20 CID: 5339 Anticancer Treatment "sulfasalazine; 599-79-1; Azulfidine; Salicylazosulfapyridine; Salazosulfapyridine; Sulphasalazine; Salazopyrin; Asulfidine; Salazopyridin; Accucol; Azopyrin; Sulcolon; Colo-Pleon; Salazopiridazin; Azopyrine; Benzosulfa; Reupirin; Salisulf; Salazosulfapyridin; w-t Sasp oral; Sulfasalazin; Azulfidine EN; Sulfasalazina; Sulfasalazinum; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Salazosulfapyridinum; Sas-500; SASP; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; S.A.S.-500; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; NSC 667219; CHEBI:9334; NSC 203730; S.A.S. 500; C18H14N4O5S; UNII-3XC8GUZ6CB; 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid; MFCD00057363; Benzoic acid, 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-; (E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 3XC8GUZ6CB; Sulfasalazine (Azulfidine); CHEMBL421; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)-; S.A.S.; Azosulfidin; 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 5-[p-(2-Pyridylsulfamoyl)phenylazo]salicylic acid; 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID; NSC203730; NSC667219; NSC-203730; NSC-667219; (3Z)-6-Oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)-; SSZ; NCGC00090903-01; Salazo-sulfapyridinum; CAS-599-79-1; 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid; DSSTox_CID_1256; 2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid; DSSTox_RID_76043; 5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic acid; DSSTox_GSID_21256; Q63398427; Sulfasalazinum [INN-Latin]; Sulfasalazina [INN-Spanish]; Salicylic acid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]-; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; Salazosulfapyridinum [INN-Latin]; Salazosulfapiridina [INN-Spanish]; SI-88; 2-Hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid; Azulfidine (TN); 6-oxo-3-[[4-(2-pyridinylsulfamoyl)phenyl]hydrazinylidene]-1-cyclohexa-1,4-dienecarboxylic acid; 737754-28-8; SMR000059146; Sulphasalazine, N-; CCRIS 4713; HSDB 3395; 13gs; 5-(p-(2-Pyridylsulfamoyl)phenylazo)salicylic acid; SR-05000001721; EINECS 209-974-3; 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; Sulfasalazine (USP/INN); BRN 0356241; Iwata; 2-hydroxy-5-({4-[(2-pyridylamino)sulfonyl]phenyl}diazenyl)benzoic acid; Prestwick_848; Sulfasalazine [USAN:USP:INN:BAN]; Spectrum_000998; Prestwick0_000520; Prestwick1_000520; Prestwick2_000520; Prestwick3_000520; Spectrum2_001216; Spectrum3_001364; Spectrum4_000347; Spectrum5_001443; Epitope ID:122672; SCHEMBL4514; SCHEMBL4515; Salazosulfapyridine (JP17); SCHEMBL18490; BSPBio_000479; BSPBio_002888; KBioGR_000753; KBioGR_002314; KBioSS_001478; KBioSS_002316; 5-22-08-00433 (Beilstein Handbook Reference); MLS000759399; MLS001424109; MLS006011702; BIDD:GT0161; DivK1c_000860; SPECTRUM1500552; SPBio_001032; SPBio_002400; BPBio1_000527; CHEMBL100848; CHEMBL242373; GTPL4840; SCHEMBL1079598; SCHEMBL1229516; CHEMBL1206016; DTXSID0021256; SCHEMBL10289061; CHEBI:94500; HMS502K22; KBio1_000860; KBio2_001478; KBio2_002314; KBio2_004046; KBio2_004882; KBio2_006614; KBio2_007450; KBio3_002108; KBio3_002794; cMAP_000018; NINDS_000860; HMS1569H21; HMS1921C05; HMS2051J21; HMS2090P13; HMS2092K07; HMS2096H21; HMS2232H07; HMS3370D16; HMS3393J21; HMS3655G07; HMS3713H21; HMS3871J13; HMS3884E21; Pharmakon1600-01500552; ALBB-033361; BCP13311; ZINC3831490; Tox21_111037; Tox21_201239; Tox21_300541; ANW-43676; BDBM50097125; BDBM50103596; CCG-39145; DL-510; KM0360; NSC757330; s1576; SBB058178; ZINC14768602; ZINC85550135; AKOS002311709; AKOS025116975; AKOS026749974; Tox21_111037_1; WLN: T6NJ BSWMR DNUNR DQ CVQ; ZINC100030102; ZINC100031653; CCG-100987; DB00795; HS-0062; MCULE-7533021815; NC00237; NSC-757330; VA11798; IDI1_000860; SMP2_000059; NCGC00016518-01; NCGC00090903-02; NCGC00090903-03; NCGC00090903-04; NCGC00090903-05; NCGC00090903-06; NCGC00090903-07; NCGC00090903-08; NCGC00090903-09; NCGC00090903-11; NCGC00186644-01; NCGC00254313-01; NCGC00258791-01; (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; AC-20497; AK163126; H881; HY-14655; SMR004703430; SY052318; SBI-0051526.P003; AB0013330; DB-017797; FT-0603483; FT-0674746; S0580; ST50767935; SW196979-4; C07316; D00448; J10488; AB00052101-04; AB00052101-06; AB00052101_07; AB00052101_08; 599S791; Q420035; Q-201769; SR-05000001721-1; SR-05000001721-2; SR-05000001721-3; Sulfasalazine, analytical standard, >=98% (HPLC); 5-[[4-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; BRD-K10670311-001-06-4; BRD-K10670311-001-08-0; Q27166356; Sulphasalazine, Antibiotic for Culture Media Use Only; F2173-1125; Z2030502809; 4-(Pyridyl-2-amidosulfonyl)-3''-carboxy-4''-hydroxyazobenzene; Sulfasalazine, European Pharmacopoeia (EP) Reference Standard; 2-hydroxy-5-[(E)-[4-(2-pyridylsulfamoyl)phenyl]azo]benzoic acid; 5-{4-[(2-pyridylideneamino)sulfonyl]phenyldiazenyl}salicylic acid; Sulfasalazine, United States Pharmacopeia (USP) Reference Standard; (E)-2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-Hydroxy-5-((4-[(2-pyridinylamino)sulfonyl]phenyl)diazenyl)benzoic acid #; 2-hydroxy-5-{(E)-[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid; 6-oxo-3-(2-[4-(n-pyridin-2-ylsulfamoyl)phenyl]hydrazono)cyclohexa-1,4-dienecarboxylic acid; 6-oxo-3-((4-(pyridin-2-ylsulfamoyl)phenyl) hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid" Small molecule "1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)" NCEXYHBECQHGNR-UHFFFAOYSA-N C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O C18H14N4O5S CAS 599-79-1 CHEBI:9334 . . . DB00795 . DR7498 Sulfamethoxazole D0R9OH D0R9OH Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 5329 Anticancer Treatment "sulfamethoxazole; 723-46-6; Sulphamethoxazole; Gantanol; Sulfisomezole; Sulfamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; Sulpha-methoxizole; Bactrim; Sulfamethalazole; Azo-gantanol; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Sulphamethylisoxazole; Urobak; Ro 4-2130; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; Sulphisomezole; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; MS 53; 3-Sulphanilamido-5-methylisoxazole; Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-; 5-Methyl-3-sulphanil-amidoisoxazole; 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; Sulfamethoxazole-d4; Sulmeprim; Trimeth/Sulfa; A047; SMX; Sulfamethoxazole sodium; UNII-JE42381TNV; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; CHEBI:9332; N'-(5-Methyl-3-isoxazole)sulfanilamide; Sulfamethoxizole; Ro 6-2580/11; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; Sulfanilamide, N'-(5-methyl-3-isoxazolyl)-; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-; 4-AMINO-N-(5-METHYL-3-ISOXAZOYL)BENZENESULFONAMIDE; Sulfametoxazol; Bactrimel; Gamazole; MFCD00010546; CHEMBL443; N1-(5-Methylisoxazol-3-yl)sulfanilamide; MLS000069732; JE42381TNV; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide; Solfametossazolo; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; 5-Methyl-3-sulfonylamidoisoxazole; STX-608; Sulfamethoxazolum; NSC147832; 4-Amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide; NSC-147832; NCGC00016533-05; NCGC00186654-01; CAS-723-46-6; SMR000058223; DSSTox_CID_6064; Solfametossazolo [DCIT]; 3-(p-Aminobenzenesulfonamido)-5-methylisoxazole; DSSTox_RID_78001; DSSTox_GSID_26064; [(4-aminophenyl)sulfonyl](5-methylisoxazol-3-yl)amine; Sulfametoxazol [INN-Spanish]; Sulfamethoxazolum [INN-Latin]; CCRIS 567; HSDB 3186; SR-01000000217; EINECS 211-963-3; NSC 147832; BRN 0226453; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N(1)-(5-methyl-3-isoxazolyl)-; 08D; Prestwick_453; ALBB-002089; Septran (Salt/Mix); Septrin (Salt/Mix); Sulfamethoxazole,(S); Eusaprim (Salt/Mix); Ro-4-2130; Spectrum_000994; Sulfamethoxazole(USAN); Sulfamethoxazole-13C6; Opera_ID_882; Maybridge1_007190; Prestwick0_000177; Prestwick1_000177; Prestwick2_000177; Prestwick3_000177; Spectrum2_000788; Spectrum3_000584; Spectrum4_000345; Spectrum5_000982; Sulfamethoxazole [USAN:USP:INN:BAN:JAN]; Epitope ID:114999; Co-trimoxazole (Salt/Mix); SCHEMBL3656; Oprea1_114486; Oprea1_285680; BSPBio_000073; BSPBio_002028; KBioGR_000749; KBioSS_001474; MLS001055354; MLS001074165; MLS006011871; BIDD:GT0731; DivK1c_000649; SPECTRUM1500550; SPBio_000896; SPBio_001994; ARONIS018156; BPBio1_000081; DTXSID8026064; component of Bactrim (Salt/Mix); GTPL10933; HMS502A11; HMS561O18; JLKIGFTWXXRPMT-UHFFFAOYSA-; KBio1_000649; KBio2_001474; KBio2_004042; KBio2_006610; KBio3_001528; ZINC89763; EBD3403; N1-(5-methylisoxazol-3-yl)-4-aminobenzene-1-sulfonamide; WLN: T5NOJ C1 EMSWR DZ; NINDS_000649; HMS1568D15; HMS1921A21; HMS2092K03; HMS2095D15; HMS2233L13; HMS3259E06; HMS3372M22; HMS3655O22; HMS3712D15; Pharmakon1600-01500550; BCP02881; HY-B0322; Sulfamethoxazole (JP17/USP/INN); Sulfamethoxazole, analytical standard; Tox21_110480; Tox21_200353; ANW-43073; BBL004554; BDBM50029770; CCG-40166; HTS001394; KM1475; NSC757328; Ro-42130; s1915; SBB057675; SBB071655; STK007988; AKOS000200952; component of Azo Gantanol (Salt/Mix); Tox21_110480_1; BS-3542; DB01015; MCULE-1450176600; NC00537; NSC-757328; RP-2145; IDI1_000649; NCGC00016533-01; NCGC00016533-02; NCGC00016533-03; NCGC00016533-04; NCGC00016533-06; NCGC00016533-07; NCGC00016533-08; NCGC00016533-09; NCGC00016533-10; NCGC00016533-11; NCGC00016533-12; NCGC00016533-14; NCGC00021995-03; NCGC00021995-04; NCGC00021995-05; NCGC00257907-01; AC-11118; AK-36221; H463; ST024740; SY018888; BCP0726000283; N'-(5-Methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulphanilamide; SBI-0051524.P003; DB-055629; AB00052099; BB 0242379; FT-0602616; N^1-(5-Methyl-3-isoxazolyl)-Sulfanilamide; ST51006798; SW196670-3; C07315; D00447; J10090; Sulfamethoxazole 100 microg/mL in Acetonitrile; AB00052099-14; AB00052099-16; AB00052099_17; AB00052099_18; Ndimethyl1-(5-methyl-3-isoxazolyl)-Sulfanilamide; Q415843; Q-201762; SR-01000000217-2; SR-01000000217-3; Sulfamethoxazole, VETRANAL(TM), analytical standard; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI); 4-Amino-N-(5-methylisoxazol-3-yl)benzenesulphonamide; BRD-K28494619-001-05-0; BRD-K28494619-001-15-9; BRD-K28494619-001-26-6; Z57198677; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzene sulfonamide; Sulfamethoxazole, British Pharmacopoeia (BP) Reference Standard; Sulfamethoxazole, certified reference material, TraceCERT(R); 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; SMX; SMZ; Sulfamethoxazole, European Pharmacopoeia (EP) Reference Standard; Sulfamethoxazole, United States Pharmacopeia (USP) Reference Standard; Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material; 129378-89-8" Small molecule "1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)" JLKIGFTWXXRPMT-UHFFFAOYSA-N CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N C10H11N3O3S CAS 723-46-6 CHEBI:9332 . . . DB01015 . DR1126 Risedronate D0PA5S D0PA5S Approved Bone paget disease ICD-11: FB85 CID: 5245 Anticancer Treatment "Risedronic acid; Risedronate; 105462-24-6; Atelvia; Risedronic acid monohydrate; Benet; NE-58095; UNII-KM2Z91756Z; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID; KM2Z91756Z; RIS; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); Acido risedronico; Acide risedronique; Acidum risedronicum; Risedronic acid [INN:BAN]; (1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)bis(phosphonic acid); Acide risedronique [INN-French]; Acido risedronico [INN-Spanish]; Acidum risedronicum [INN-Latin]; 115436-72-1; Bisphosphonate 1; C7H11NO7P2.H2O; [1-hydroxy-1-phosphono-2-(3-pyridyl)ethyl]phosphonic acid; Ridron (TN); C7H11NO7P2; MFCD00867080; NE 58019; HSDB 7326; Risedronic acid (INN); 1-Hydroxy-2-(3-pyridyl)-ethan-1,1-bis-phosphonic acid; Risdronate; Risedronate acid; SR-05000001495; M05BA07; (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; PubChem14002; SCHEMBL18378; BIDD:GT0010; GTPL3176; JMC515594 Compound 64; DTXSID2023563; BDBM12576; AMY3524; HMS2090C21; HMS3741A17; BCP13805; HY-B0148; ZINC1531009; 2689AH; s1874; AKOS015892564; AC-1295; CS-1964; DB00884; NCGC00386377-01; AS-13584; I802; AB0013898; FT-0642593; A11675; C08233; D08484; M-1366; AB01275490-01; AB01275490_02; 462R246; A801245; Q408724; SR-05000001495-1; 2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid; Z2684418685; (1-Hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid; (1-oxidanyl-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; [1-hydroxy-1-phosphono-2-(3-pyridinyl)ethyl]phosphonic acid; 1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyldiphosphonic acid" Small molecule "1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)" IIDJRNMFWXDHID-UHFFFAOYSA-N C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O C7H11NO7P2 CAS 105462-24-6 CHEBI:8869 . . . DB00884 . DR3490 Salmeterol D0L5YV D0L5YV Approved Chronic obstructive pulmonary disease ICD-11: CA22 CID: 5152 Anticancer Treatment "Salmeterol; 89365-50-4; Serevent; Aeromax; Salmeterolum [Latin]; GR 33343X; SALMATEROL; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; Salmeterol free base; SN408D; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; Astmerole; CHEBI:64064; 18910-65-1 (free base); GR 33343 X; Salmeterol Fluticasone Propionate Mixture; Salmeterolum; 4-hydroxy-alpha1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; SMR000466295; HSDB 7315; SR-01000076139; Salmeterol (USAN/INN); Salmeterol [USAN:INN:BAN]; NCGC00025247-01; Fluticasonepropiponate; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; CPD000466295; Prestwick3_000945; Salmeterol Dimer Impurity; ACMC-1C1VM; DSSTox_CID_3571; S 2692; SCHEMBL4767; CHEMBL1263; DSSTox_RID_77087; DSSTox_GSID_23571; Lopac0_001100; BSPBio_000910; GTPL559; cc-441; MLS000759000; MLS001424322; Salmeterol Related Compound H; BPBio1_001002; DTXSID6023571; BDBM25771; HMS2052H13; HMS2090E17; HMS2097N12; HMS3268K19; HMS3394H13; HMS3412P13; HMS3714N12; HMS3886G10; AMY37616; BCP04199; EX-A4409; Tox21_113584; CS0057; MFCD00867037; s5527; STK629186; AKOS005561914; CCG-101194; CCG-205176; DB00938; GR-33343-X; NC00444; SDCCGSBI-0633788.P001; 1,3-Benzenedimethanol, 4-hydroxy-.alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-; 1,3-Benzenedimethanol, 4-hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-; MRF-0000468; NCGC00015938-03; NCGC00025247-02; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl-, (+-)-; AK173141; AS-56157; HY-14302; K590; Salmeterol 100 microg/mL in Acetonitrile; CAS-89365-50-4; AB00513972; FT-0674508; FT-0674509; C07241; D05792; AB00513972-07; 365S504; L000532; Q424333; Salmeterol Impurity H (Xinafoate Adduct Impurity); Q-101428; SR-01000076139-2; SR-01000076139-6; BRD-A01320529-001-05-9; 2-hydroxymethyl-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol; 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol; 5-[2-[6-(4-Phenylbutoxy)hexylamino]-1-hydroxyethyl]-2-hydroxybenzenemethanol; ( inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; GR 33343X; 1-hydroxy-2-naphthoic acid;4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-2-methylol-phenol" Small molecule "1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2" GIIZNNXWQWCKIB-UHFFFAOYSA-N C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O C25H37NO4 CAS 89365-50-4 CHEBI:64064 . . . DB00938 . DR6764 Riluzole D0H0KB D0H0KB Approved Motor neuron disease ICD-11: 8B60 CID: 5070 Anticancer Treatment "riluzole; 1744-22-5; Rilutek; 2-Amino-6-(trifluoromethoxy)benzothiazole; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; RP-54274; 2-amino-6-trifluoromethoxybenzothiazole; 2-Benzothiazolamine, 6-(trifluoromethoxy)-; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; PK-26124; RP 54274; C8H5F3N2OS; 2-Benzothiazolamine,6-(trifluoromethoxy)-; UNII-7LJ087RS6F; Riluzole (Rilutek); Amino-2 trifluoromethoxy-6 benzothiazole; MLS000069369; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 2-Amino-6-(trifluoromethoxy)-benzothiazole; MFCD00210213; CHEMBL744; SMR000058231; 7LJ087RS6F; CHEBI:8863; Riluzol; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; BENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-; Riluzole, 98%; 6-(trifluoromethoxy)benzothiazol-2-amine; NCGC00015882-09; Riluzolum; Riluzol [INN-Spanish]; Riluzolum [INN-Latin]; DSSTox_CID_25192; DSSTox_RID_80739; DSSTox_GSID_45192; Rilutek (TN); CAS-1744-22-5; 6-(trifluoromethoxy)benzothiazole-2-ylamine; Amino-2 trifluoromethoxy-6 benzothiazole [French]; 2-amino-6-(trifluoromethoxyl)benzothiazole; Riluzole, solid; Riluzole [USAN:USP:INN:BAN]; BF-37; ALBB-006046; Riluzole(Rilutek)/; Prestwick-03A08; 6-(trifluoromethoxy)-2-benzothiazolamine; PubChem14501; Tocris-0768; 6-trifluoromethoxybenzothiazole-2-yl-amine; Opera_ID_548; Lopac-R-116; Riluzole-13C-15N2; Prestwick0_000167; Prestwick1_000167; Prestwick2_000167; Prestwick3_000167; Spectrum2_000550; Biomol-NT_000245; cid_5070; Riluzole (JAN/USP/INN); Lopac0_001064; SCHEMBL78905; BSPBio_000033; BIDD:GT0055; SPBio_000599; SPBio_001954; ACMC-209e89; BPBio1_000037; BPBio1_000837; GTPL2326; ZINC6481; DTXSID3045192; BDBM30705; Bio1_000416; Bio1_000905; Bio1_001394; HMS1773G08; HMS2089O19; HMS2094G07; HMS2233E14; HMS3263E10; HMS3371A09; HMS3657E13; Pharmakon1600-01505348; AMY14166; BCP02142; BHV-0223; HY-B0211; Riluzole - CAS 1744-22-5; Tiglutik (thickened oral suspension); Tox21_110252; Tox21_501064; ABP000632; AC-730; ANW-22711; BBL013272; CCG-39528; NSC753433; NSC759823; s1614; SBB012436; STK503686; AKOS000265071; Tox21_110252_1; DB00740; KS-5231; LP01064; MCULE-9362288181; NSC 753433; NSC 759823; NSC-753433; NSC-759823; SDCCGSBI-0051034.P003; 2-amino-6-trifluoromethoxy-benzothiazole; 6-trifluoromethoxy-2-amino-benzothiazole; NCGC00015882-01; NCGC00015882-02; NCGC00015882-03; NCGC00015882-04; NCGC00015882-05; NCGC00015882-06; NCGC00015882-07; NCGC00015882-08; NCGC00015882-10; NCGC00015882-11; NCGC00015882-12; NCGC00015882-13; NCGC00015882-15; NCGC00015882-28; NCGC00023141-02; NCGC00023141-04; NCGC00023141-05; NCGC00023141-06; NCGC00261749-01; 6-(trifluoromethoxy)-2-aminobenzothiazole; 6-trifluoromethoxybenzo[d]thiazol-2-amine; AK-59567; ST038494; ST068834; SBI-0051034.P002; 2-Amino-6-(Trifluoromethoxy) Benzothiazole; 6-(Trifluoromethoxy)-2-amino-benzothiazole; AB0012884; DB-030335; EU-0101064; FT-0611194; SW196805-4; EN300-23782; 6-trifluoromethoxy-1,3-benzothiazol-2-ylamine; A-5766; C07937; D00775; J10184; J10441; VU0239571-11; 744R225; Q415744; SR-01000002997-3; BRD-K21283037-001-02-5; BRD-K21283037-003-03-9; BRD-K21283037-003-06-2; F3282-0020; Z166605314; Rilutek; ; ; Rilutor; ; ; 6-(Trifluoromethoxy)-2-benzothiazolamine; Riluzole, United States Pharmacopeia (USP) Reference Standard" Small molecule "1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)" FTALBRSUTCGOEG-UHFFFAOYSA-N C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N C8H5F3N2OS CAS 1744-22-5 CHEBI:8863 . . . DB00740 . DR7308 Pyrimethamine D0C0SK D0C0SK Approved Malaria ICD-11: 1F40-1F45 CID: 4993 Anticancer Treatment "pyrimethamine; 58-14-0; Daraprim; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; Chloridine; Diaminopyritamin; Ethylpyrimidine; Pirimetamin; Chloridin; Chloridyn; Pirimecidan; Pirimetamina; Pyrimethamin; Malocide; Primethamine; Darachlor; Erbaprelina; Khloridin; Tindurin; Malocid; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; Darapram; Daraprime; Malacid; Maloprim; 2,4-Pyrimidinediamine, 5-(4-chlorophenyl)-6-ethyl-; Pyremethamine; Pyrimethaminum; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; RP 4753; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; BW 50-63; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; TCMDC-125860; NCI-C01683; WR 2978; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; UNII-Z3614QOX8W; GNF-Pf-5586; 4753 R.P.; TCMDC-123831; NSC-3061; CHEMBL36; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 2,4-Pyrimidinediamine, 5-(p-chlorophenyl)-6-ethyl-; MLS000028606; MLS002701881; CHEBI:8673; Z3614QOX8W; Daraclor; NSC3061; 5-(4-chlorophenyl)-6-ethyl-pyrimidine-2,4-diamine; Pyrimidine, 2,4-diamino-5-(p-chlorophenyl)-6-ethyl-; Pyrimethamine, 98%; CAS-58-14-0; NCGC00016256-08; SMR000058714; Tinduring; Pirimetamina [Spanish]; DSSTox_CID_1217; DSSTox_RID_76016; DSSTox_GSID_21217; CP6; Pirimetamina [INN-Spanish]; Pyrimethaminum [INN-Latin]; BRD9204; BRD-9204; Daraprim (TN); CCRIS 546; Pyrimethamine (Pyr); SR-01000003150; NSC 3061; EINECS 200-364-2; BRN 0219864; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; AI3-25005; Pyrimethamine (JAN/USP/INN); AZT + Pyrimethamine combination; HSDB 8042; EXR-101; Pyrimethamine [USP:INN:BAN:JAN]; Prestwick_504; MFCD00057350; PubChem9611; BW 5063; Daraclor (Salt/Mix); Spectrum_000906; 4km0; CPD000058714; Opera_ID_1437; Prestwick0_000037; Prestwick1_000037; Prestwick2_000037; Prestwick3_000037; Spectrum2_000886; Spectrum3_001701; Spectrum4_000494; Spectrum5_001447; cid_4993; NCIOpen2_008313; BIDD:PXR0173; SCHEMBL25129; BSPBio_000133; BSPBio_003282; KBioGR_001007; KBioSS_001386; MLS001148621; MLS002454446; BIDD:GT0149; DivK1c_000652; SPECTRUM1500520; SPBio_000672; SPBio_002054; BPBio1_000147; GTPL4800; DTXSID9021217; BDBM18512; HMS502A14; KBio1_000652; KBio2_001386; KBio2_003954; KBio2_006522; KBio3_002502; ZINC57464; NINDS_000652; Pirimecidan;Pirimetamin;RP 4753; HMS1568G15; HMS1920N12; HMS2092E13; HMS2095G15; HMS2235A17; HMS3259C04; HMS3371L07; HMS3655D09; HMS3675P11; HMS3712G15; HMS3743O05; HMS3871I03; Pharmakon1600-01500520; 2, 5-(p-chlorophenyl)-6-ethyl-; 2, 5-(4-chlorophenyl)-6-ethyl-; Tox21_110332; Tox21_201834; Tox21_300129; ANW-44788; CCG-39626; NSC757306; AKOS015892534; Tox21_110332_1; AB02313; AC-7879; CS-1717; DB00205; KS-5223; LS40239; NC00528; NSC-757306; RP-4753; WR-2978; IDI1_000652; NCGC00016256-01; NCGC00016256-02; NCGC00016256-03; NCGC00016256-04; NCGC00016256-05; NCGC00016256-06; NCGC00016256-07; NCGC00016256-09; NCGC00016256-10; NCGC00016256-11; NCGC00016256-12; NCGC00016256-13; NCGC00016256-14; NCGC00016256-16; NCGC00016256-17; NCGC00023188-03; NCGC00023188-04; NCGC00023188-05; NCGC00023188-06; NCGC00023188-07; NCGC00254199-01; NCGC00259383-01; WLN: T6N CNJ BZ DZ ER DG& F2; AK-35735; HY-18062; NCI60_002604; SBI-0051500.P003; AB0011152; DB-053158; AB00052084; FT-0631253; P2037; S2006; SW196698-3; C07391; D00488; M-1612; MLS-0002822.0001; AB00052084-21; AB00052084_22; AB00052084_25; 057P350; 2,4-diamino-5(4-chlorophenyl)-6-ethylpyrimidine; A831755; L000713; Pyrimethamine, VETRANAL(TM), analytical standard; Pyrimidine,4-diamino-5-(p-chlorophenyl)-6-ethyl-; Q421072; 2,4,-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-diamino-5-(4-chloro-phenyl)-6-ethylpyrimidine; 2,4-diamino-6-ethyl-5-(4-chlorophenyl)pyrimidine; Q-201648; SR-01000003150-2; SR-01000003150-4; BRD-K88429204-001-05-4; BRD-K88429204-001-18-7; BRD-K88429204-001-21-1; BRD-K88429204-001-36-9; Z2065727768; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine, 97%; Pyrimethamine, European Pharmacopoeia (EP) Reference Standard; Pyrimethamine, United States Pharmacopeia (USP) Reference Standard" Small molecule "1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)" WKSAUQYGYAYLPV-UHFFFAOYSA-N CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl C12H13ClN4 CAS 58-14-0 CHEBI:8673 . . . DB00205 . DR2863 Procarbazine D08GYO D08GYO Approved Hodgkin lymphoma ICD-11: 2B30 CID: 4915 Anticancer Treatment "procarbazine; 671-16-9; Procarbazin; Ibenzmethyzin; Natulan; Ibenzmethyzine; Procarbazin [German]; Procarbazina; Procarbazinum; Procarbazinum [INN-Latin]; Procarbazina [INN-Spanish]; N-Isopropyl-4-((2-methylhydrazinyl)methyl)benzamide; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-; Ro 4-6467; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; CB 400-497; MIH; Procarbazine free base; UNII-35S93Y190K; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; PCX; Ro 4-6467/1; 671-16-9 (free base); Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-; CHEBI:71417; 35S93Y190K; CB 400-497; Ibenzmethyzine; MIH; p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-; Procarbazine [INN:BAN]; 4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide; Procarbazine (INN); CCRIS 2389; HSDB 3250; NCGC00016438-01; Ro-4646711; CAS-366-70-1; EINECS 211-582-2; p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; BRN 0958270; SR-01000763375; Procarbazine-[d3]; p-Toluamide, N-isopropyl-alpha-(2-methylhydrazino)-; SRI-10847; MBH (Salt/Mix); Matulane (Salt/Mix); Nathulane (Salt/Mix); Natunalar (Salt/Mix); Prestwick0_001112; Prestwick1_001112; Prestwick2_001112; Prestwick3_001112; DSSTox_CID_1189; SCHEMBL4656; CHEMBL1321; DSSTox_RID_75999; NCIOpen2_004074; DSSTox_GSID_21189; BSPBio_001244; BIDD:GT0183; SPBio_003112; BPBio1_001369; GTPL7278; DTXSID4021189; 4-[(2-methylhydrazinyl)methyl]-N-(propan-2-yl)benzamide; HMS2090J09; Pharmakon1600-01502326; RO-4-6467 FREE BASE; BCP12198; Tox21_301738; 0319AC; NSC759626; STL483417; ZINC19166988; AKOS015891211; AC-4547; CCG-213031; DB01168; MCULE-9065058360; NSC-759626; NCGC00016438-02; NCGC00016438-05; NCGC00255280-01; CAS-671-16-9; NCI60_041703; Ro-4-6467/1; SRI-10847-09; SRI-10847-10; SRI-10847_11; SRI-10847_13; DB-082065; RO-4-6467; FT-0737820; C07402; D08423; 671P169; Q418656; N-Isopropyl-.alpha.-(2-methylhydrazino)-p-toluamide; SR-01000763375-3; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide #; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)" Small molecule "1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)" CPTBDICYNRMXFX-UHFFFAOYSA-N CC(C)NC(=O)C1=CC=C(C=C1)CNNC C12H19N3O CAS 671-16-9 CHEBI:71417 . . . DB01168 . DR9432 Probenecid D0L7FM D0L7FM Approved Inborn purine/pyrimidine/nucleotide metabolism error ICD-11: 5C55 CID: 4911 Anticancer Treatment "probenecid; 57-66-9; 4-(Dipropylsulfamoyl)benzoic acid; Probenecid acid; Benemid; Probecid; Benecid; Probenemid; Benuryl; Probalan; Probexin; Prolongine; Tubophan; Uricosid; Apurina; Proben; Synergid R; p-(Dipropylsulfamoyl)benzoic acid; 4-[(dipropylamino)sulfonyl]benzoic acid; Probenecida; Probenecide; Probenecidum; 4-((Dipropylamino)sulfonyl)benzoic acid; 4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; Benzoic acid, 4-[(dipropylamino)sulfonyl]-; NCI-C56097; Benzoic acid, p-(dipropylsulfamoyl)-; 4-(N,N-Dipropylsulfamoyl)benzoic Acid; p-(Dipropylsulfamyl)benzoic acid; MFCD00038402; NSC 18786; CHEBI:8426; Probenecid (Benemid); UNII-PO572Z7917; Benzoic acid, 4-((dipropylamino)sulfonyl)-; CHEMBL897; MLS000028496; 4-Dipropylsulfamoyl-benzoic acid; Benemide; Probenid; Robenecid; Polycillin-BRB; NSC-18786; PO572Z7917; CAS-57-66-9; probenicid; NCGC00016251-08; SMR000058280; DSSTox_CID_1188; DSSTox_RID_75998; DSSTox_GSID_21188; Probenecide [INN-French]; Probenecidum [INN-Latin]; Probenecida [INN-Spanish]; Benemid (TN); CCRIS 3643; HSDB 3387; SR-01000003108; EINECS 200-344-3; BRN 2815775; AI3-50078; Probenecid [USP:INN:BAN:JAN]; Prestwick_809; Spectrum_000834; ColBenemid (Salt/Mix); Opera_ID_677; Prestwick0_000542; Prestwick1_000542; Prestwick2_000542; Prestwick3_000542; Spectrum2_001294; Spectrum3_000554; Spectrum4_000486; Spectrum5_001419; Benemid; Benecid; Benuryl; Epitope ID:180853; SCHEMBL3663; Polycillin-PRB (Salt/Mix); BIDD:PXR0092; Oprea1_416955; WLN: QVR DSWN3&3; BSPBio_000583; BSPBio_002227; KBioGR_000971; KBioSS_001314; MLS001076472; BIDD:GT0626; DivK1c_000056; SPECTRUM1500502; SPBio_001327; SPBio_002504; BPBio1_000643; GTPL4357; Probenecid (JP17/USP/INN); ZINC1982; DTXSID9021188; HMS500C18; KBio1_000056; KBio2_001314; KBio2_003882; KBio2_006450; KBio3_001727; AMY8947; AOB5799; NINDS_000056; HMS1569N05; HMS1920J22; HMS2092C03; HMS2096N05; HMS2233N05; HMS3259G04; HMS3369L18; HMS3652O17; HMS3713N05; HMS3743E07; HMS3885I18; p-(Dipropylsulfamoyl) benzoic acid; Pharmakon1600-01500502; ALBB-025846; BCP21785; HY-B0545; NSC18786; STR06053; Tox21_110328; Tox21_202110; Tox21_302928; BDBM50206509; CCG-39232; KM0133; NSC757292; s4022; SBB028597; STL229614; 4-Dipropylsulfamoyl-benzoic acid anion; AKOS000165123; Tox21_110328_1; 4-(Di-n-propylsulfamoyl)benzoic acid; ; AC-2023; DB01032; HC 5006; MCULE-8664946016; NC00530; NSC-757292; SB17360; IDI1_000056; 4-(Di-n-propylaminosulfonyl)benzoic acid; NCGC00016251-01; NCGC00016251-02; NCGC00016251-03; NCGC00016251-04; NCGC00016251-05; NCGC00016251-06; NCGC00016251-07; NCGC00016251-09; NCGC00016251-10; NCGC00016251-13; NCGC00023829-03; NCGC00023829-04; NCGC00023829-05; NCGC00023829-06; NCGC00023829-07; NCGC00256441-01; NCGC00259659-01; ST099094; 4-(N,N-dipropylaminosulphonyl)benzoic acid; SBI-0051492.P003; 4-Dipropylsulfamoyl-benzoic acid(probenecid); AB00052080; P1975; SW196943-3; EN300-69677; C07372; D00475; J10155; AB00052080_15; AB00052080_16; 038P402; Q900898; Q-201621; SR-01000003108-2; SR-01000003108-3; BRD-K95237249-001-05-9; BRD-K95237249-001-15-8; Z53037954; Probenecid, European Pharmacopoeia (EP) Reference Standard; Probenecid, United States Pharmacopeia (USP) Reference Standard" Small molecule "1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)" DBABZHXKTCFAPX-UHFFFAOYSA-N CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O C13H19NO4S CAS 57-66-9 CHEBI:8426 . . . DB01032 . DR4718 Primaquin D0T1LK D0T1LK Approved Malaria ICD-11: 1F40-1F45 CID: 4908 Anticancer Treatment "PRIMAQUINE; 90-34-6; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; Primachin; Neo-Quipenyl; Primaquin; Primachinum; Primaquinum; Primaquina; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; SN 13,272; S. N. 13272; WR 2975; (RS)-primaquine; NSC 27296; CHEBI:8405; 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; l-Primaquine; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; NSC27296; NSC-27296; 1,4-Pentanediamine, N(4)-(6-methoxy-8-quinolinyl)-; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline; Primachina [DCIT]; Primachina; dl-Primaquine; Primaquine [INN:BAN]; BRN 0019337; Maliride; NSC 27296; Neo-Quipenyl; Primachin; N4-(6-methoxy-8-quinolyl)pentane-1,4-diamine; Primaquinum [INN-Latin]; Primaquina [INN-Spanish]; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; (+/-)-Primaquine; CHEMBL506; MLS001334045; (+)-Primaquine; (-)-Primaquine; Kanaprim (TN); Primaquine (INN); CCRIS 4109; HSDB 6516; 4-22-00-05817 (Beilstein Handbook Reference); 57152-58-6; NCGC00178754-06; N~4~-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SMR000875314; EINECS 201-987-2; 6-Methoxy-8-((4-amino-1-methylbutyl)amino)quinoline; Quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; TG1-296; TG1-297; Spectrum_000830; Prestwick0_000476; Prestwick1_000476; Prestwick2_000476; Prestwick3_000476; Spectrum2_000887; Spectrum3_000552; Spectrum4_000484; Spectrum5_001363; Epitope ID:131792; Oprea1_546209; SCHEMBL22207; BSPBio_000612; BSPBio_002223; KBioGR_000967; KBioSS_001310; DivK1c_000806; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SPBio_000674; SPBio_002551; (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; BPBio1_000674; cid_359247; GTPL9952; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy-; DTXSID8023509; BDBM71542; KBio1_000806; KBio2_001310; KBio2_003878; KBio2_006446; KBio3_001723; NINDS_000806; HMS2090J17; BCP29271; ANW-50074; BBL011330; MFCD00598906; STL146416; 1, N4-(6-methoxy-8-quinolinyl)-; AKOS005721199; DB01087; MCULE-1557087031; WLN: T66 BNJ HO1 JMY1&3Z; WR-2975; IDI1_000806; SMP1_000263; NCGC00178754-01; NCGC00178754-02; NCGC00178754-03; AC-23007; AS-30679; NCI60_001035; NCI60_005887; SN-13272; SBI-0051491.P003; AB00053529; FT-0687514; W9302; C07627; D08420; S-4508; AB00053529-11; AB00053529_12; AB00053529_14; N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 598P906; A843518; N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine; Q419834; BRD-A55913614-316-06-2; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- (9CI); N-[(S)-4-Amino-1-methylbutyl]-6-methoxy-8-quinolinamine; N4-(6-Methoxyquinolin-8-yl)pentane-1,4-diamine (2 H3PO4); N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine;phosphoric acid; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid; (4-amino-1-methyl-butyl)-(6-methoxy-8-quinolyl)amine;phosphoric acid" Small molecule "1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3" INDBQLZJXZLFIT-UHFFFAOYSA-N CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2 C15H21N3O CAS 90-34-6 CHEBI:8405 . . . DB01087 . DR8879 Praziquantel D0L9ZR D0L9ZR Approved Flatworm infection ICD-11: 1F70-1F86 CID: 4891 Anticancer Treatment "praziquantel; 55268-74-1; Biltricide; Droncit; Pyquiton; Cesol; Embay 8440; Azinox; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; MLS000038419; Praziquantel (Biltricide); MFCD00058531; SMR000037139; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; Cutter Tape Tabs; 2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino[2,1-a]isoquinolin-4-one; 4H-Pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; 4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; Praziquantelum; Distocide; Prazinon; DSSTox_CID_1182; DSSTox_RID_75995; DSSTox_GSID_21182; Praziquantelum [INN-Latin]; Cutter; Biltricide (TN); CCRIS 4114; SR-01000003100; EINECS 259-559-6; BRN 0761557; Bay-8440; Praziquantel (JAN/USP/INN); EMBAY-8440; Praziquantel,(S); NCGC00016877-01; Prestwick_402; CAS-55268-74-1; (+-)-Praziquantel; ACMC-20emeg; Praziquantel [USAN:USP:INN:BAN:JAN]; Spectrum_001119; Opera_ID_378; Prestwick0_000260; Prestwick1_000260; Prestwick2_000260; Prestwick3_000260; Spectrum2_001288; Spectrum3_000550; Spectrum4_000482; Spectrum5_001064; CHEMBL976; P 4668; cid_4891; Lopac0_000909; Oprea1_163497; SCHEMBL44153; BSPBio_000080; BSPBio_002199; KBioGR_000963; KBioSS_001599; 135526-78-2; 5-24-03-00361 (Beilstein Handbook Reference); MLS000028528; MLS001201812; MLS001304085; MLS002548849; MLS006011880; DivK1c_000130; SPECTRUM1500494; SPBio_001295; SPBio_002299; Praziquantel-(cyclohexyl-d11); BPBio1_000088; DTXSID9021182; SCHEMBL16019896; BDBM74574; CHEBI:91583; HMS500G12; KBio1_000130; KBio2_001599; KBio2_004167; KBio2_006735; KBio3_001699; NINDS_000130; HMS1568D22; HMS1920J06; HMS2090J19; HMS2092A09; HMS2095D22; HMS3259K07; HMS3262F20; HMS3655O19; HMS3712D22; Pharmakon1600-01500494; AMY16524; BCP17829; BCP28525; BCP30228; HY-B0244; Tox21_110660; Tox21_201950; Tox21_302927; Tox21_500909; CCG-39773; CP0098; NSC757285; Praziquantel, anthelminic, neurogenic; s1691; STK030186; AKOS000541869; AKOS016398525; Tox21_110660_1; AC-8426; DB01058; LP00909; MCULE-1638759858; NC00468; NE56665; NSC 757285; NSC-757285; SDCCGSBI-0050884.P005; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; IDI1_000130; NCGC00015818-04; NCGC00015818-05; NCGC00015818-06; NCGC00015818-07; NCGC00015818-08; NCGC00015818-11; NCGC00015818-12; NCGC00015818-14; NCGC00015818-15; NCGC00015818-26; NCGC00089733-02; NCGC00089733-03; NCGC00089733-04; NCGC00089733-05; NCGC00256422-01; NCGC00259499-01; NCGC00261594-01; AK161796; AS-12459; SY052322; SBI-0050884.P004; AB0011974; DB-052707; (S)-Praziquantel; Praziquantel, (S)-Isomer; AB00052075; EU-0100909; FT-0630676; P2125; ST50904686; SW196645-3; 1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-; C07367; D00471; J10194; AB00052075-13; AB00052075-15; AB00052075_16; AB00052075_17; Praziquantel, VETRANAL(TM), analytical standard; 268P741; Q424145; Praziquantel, Antibiotic for Culture Media Use Only; Q-201612; SR-01000003100-3; SR-01000003100-5; SR-01000003100-7; BRD-A21858158-001-05-2; BRD-A21858158-001-16-9; F0037-0136; Z1563145961; Praziquantel, European Pharmacopoeia (EP) Reference Standard; Praziquantel, United States Pharmacopeia (USP) Reference Standard; 10-(cyclohexylcarbonyl)-5,6,7,11a-tetrahydropiperazino[2,1-a]isoquinolin-8-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1- a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-aisoquinolin-4-one; 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; Praziquantel for system suitability, European Pharmacopoeia (EP) Reference Standard; Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2" FSVJFNAIGNNGKK-UHFFFAOYSA-N C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2 C19H24N2O2 CAS 55268-74-1 CHEBI:91583 . . . DB01058 . DR2168 Pioglitazone D03OFF D03OFF Approved Acute diabete complication ICD-11: 5A2Y CID: 4829 Anticancer Treatment "Pioglitazone; 111025-46-8; Actos; 105355-27-9; Pioglitazona; Pioglitazonum; Glustin; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; Zactos; Duetact; U 72107; AD-4833; Pioglitazone-d4; CHEBI:8228; Pioglitazone (Actos); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; Actos (TN); 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U-72107; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; MFCD00865504; 105390-47-4; Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Piozone; Pioglu; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; pioglitazone (INN); 1134163-31-7; HSDB 7322; U-72107E; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; SR-01000763737; Pioglitazone-[d4]; HS-0047; Spectrum_001623; Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; SCHEMBL4121; BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; SPBio_001897; GTPL2694; DTXSID3037129; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; HMS2089H14; HMS3651D09; HMS3712E16; HMS3884L10; Pharmakon1600-01504401; ACT02635; BCP26474; BBL029068; BDBM50103521; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; AKOS015894953; AKOS022109420; AC-1021; CCG-220107; CS-1700; DB01132; MCULE-2346786634; NSC-758876; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; AK-56326; HY-13956; SMR002204015; SY017473; SBI-0206791.P001; AB0004710; DB-027350; FT-0601906; FT-0645030; SW197561-3; C07675; D08378; J10289; K-0703; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; 355P279; A801204; Q417765; J-002506; J-516181; SR-01000763737-5; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one" Small molecule "1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)" HYAFETHFCAUJAY-UHFFFAOYSA-N CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 C19H20N2O3S CAS 111025-46-8 CHEBI:8228 . . . DB01132 . DR4834 N-palmitoylethanolamine D07ILQ D07ILQ Approved Attention deficit hyperactivity disorder ICD-11: 6A05 CID: 4671 Anticancer Treatment "Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitoyl ethanolamide; N-palmitoylethanolamine; Palmitamide MEA; Hydroxyethylpalmitamide; N-(2-Hydroxyethyl)palmitamide; Palmitoyl-EA; Palmitic acid monoethanolamide; Loramine P 256; palmitylethanolamide; Palmidrolum; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Monoethanolamine palmitic acid amide; Anandamide (16:0); N-palmitoyl ethanolamine; Palmitinsaeure-beta-hydroxyethylamid; UNII-6R8T1UDM3V; NSC 23320; hexadecanoyl ethanolamide; N-hexadecanoylethanolamine; N-hexadecanoyl-ethanolamine; 6R8T1UDM3V; CHEBI:71464; Palmidrol (INN); MFCD00020562; NSC-23320; NCGC00015793-03; AM 3112;Loramine P 256;Mackpeart DR 14V; DSSTox_CID_22254; DSSTox_RID_79975; DSSTox_GSID_42254; MimyX; Palmidrolum [INN-Latin]; CAS-544-31-0; SR-01000076055; EINECS 208-867-9; N-(2-hydroxyethyl) hexadecanamide; Hexadecanamide,N-(2-hydroxyethyl)-; AM 3112; 2-Palmitoylaminoethanol; Palmdrol prodes (TN); Tocris-0879; N-hexadecyl-ethanolamine; Lopac-P-0359; Palmitoylethanolamide-[d4]; Palmityoletanolamide (PEA); CBiol_002043; Lopac0_000905; BSPBio_001454; KBioGR_000174; KBioSS_000174; MLS002153421; SCHEMBL120518; BML2-B10; CHEMBL417675; GTPL3622; DTXSID4042254; Palmidrol; N-palmitoylethanolamine; SCHEMBL19511663; BDBM29083; KBio2_000174; KBio2_002742; KBio2_005310; KBio3_000347; KBio3_000348; Bio1_000329; Bio1_000818; Bio1_001307; Bio2_000174; Bio2_000654; HMS1361I16; HMS1791I16; HMS1989I16; HMS2234L19; HMS3264C10; HMS3266N08; HMS3374K03; HMS3402I16; HMS3411B14; HMS3649L03; HMS3675B14; Pharmakon1600-01506156; Amides, C16-18 and C18-branched, unsatd., N-(hydroxyethyl); BCP29005; CS-D1253; NSC23320; ZINC8035017; Tox21_110222; LMFA08040013; NAE(16:0); NSC760371; s4708; STL454872; AKOS002676363; Tox21_110222_1; CCG-204987; DB14043; LP00905; NSC-760371; SDCCGSBI-0050880.P002; IDI1_033924; NCGC00015793-01; NCGC00015793-02; NCGC00015793-04; NCGC00015793-05; NCGC00015793-06; NCGC00015793-07; NCGC00015793-08; NCGC00015793-09; NCGC00015793-10; NCGC00024840-01; NCGC00024840-02; NCGC00024840-05; NCGC00024840-06; NCGC00024840-07; NCGC00024840-08; NCGC00024840-09; 71060-58-7; AK307896; AS-14094; HY-20685; SMR000058371; Hexadecanoic acid (2-hydroxy-ethyl)-amide; B6485; EU-0100905; FT-0778178; V1640; C16512; D08328; J90064; P 0359; AB00918319_06; Q2159860; SR-01000076055-1; SR-01000076055-3; SR-01000076055-7; BRD-K68095457-001-04-4; Z2687203832; UNII-3VVG2UI23S component HXYVTAGFYLMHSO-UHFFFAOYSA-N; UNII-C80684146D component HXYVTAGFYLMHSO-UHFFFAOYSA-N" Small molecule "1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)" HXYVTAGFYLMHSO-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(=O)NCCO C18H37NO2 CAS 544-31-0 CHEBI:71464 . . . DB14043 . DR4941 Ondansetron D0K7WK D0K7WK Approved Nausea/vomiting ICD-11: MD90 CID: 4595 Anticancer Treatment "ondansetron; 99614-02-5; Zofran; Zudan; Zophren; 9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one; Zuplenz; 116002-70-1; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; GR 38032X; GR 38032; CHEBI:7773; 99614-01-4; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; NCGC00179341-02; DSSTox_CID_3393; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one; 9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one; DSSTox_RID_77011; DSSTox_GSID_23393; GR 38032 (hydrochloride);SN 307 (hydrochloride); ondansetron (Zofran); CAS-99614-02-5; Ondansetron (base and/or unspecified salts); Ondansetron Injection; EUR-1025; Zofran ODT (TN); DESMETHYLONDANSETRON; BRN 3622981; Ondansetron (JAN/USP/INN); Ondansetron [USP:INN:BAN]; SR-01000763250; 9-methyl-3-[(2-methylimidazolyl)methyl]-1,2,3,9-tetrahydro-4aH-carbazol-4-one; A04AA01; GR38032; CHEMBL46; Prestwick0_001058; Prestwick1_001058; Prestwick2_001058; Prestwick3_001058; Odansetron [common misspelling of ondansetron]; SCHEMBL4542; TimTec1_001750; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-; Oprea1_435466; Oprea1_852372; BSPBio_001016; CBDivE_008994; MLS006011928; SPBio_002938; BPBio1_001118; GTPL2290; DTXSID8023393; BDBM85330; HSDB 8304; HY-B0002B; HMS2090H16; HMS3259H08; HMS3371E18; ACT02589; BCP28911; Tox21_113048; BBL010304; CAS_68647; MFCD00833882; NSC_68647; NSC791005; QC-660; s1996; SBB066158; STK370548; AKOS000599484; AKOS016340526; Tox21_113048_1; ACN-049703; BCP9001025; DB00904; KS-5227; MCULE-9438746800; NC00706; NSC 757870; NSC-791005; VA11441; 1,2,3,4-Tetrahydro-9-methyl-3-(2-methyl-1H-imidazol-1-ylmethyl)carbazol-4-one; NCGC00179341-04; NCGC00179341-07; NCGC00179341-12; AC-28927; AK-29654; GR-38032; I544; NCI60_022780; SMR001307702; ST077669; GR-38032F/GR-38032; AB0013753; GR 38032F;GR-C507/75; AB00373674; FT-0631004; 39O049; C07325; D00456; S-2116; AB00373674-15; AB00373674-17; AB00373674_18; AB00373674_19; L000456; Q410011; SR-01000763250-4; BRD-A19736161-001-01-8; BRD-A19736161-003-03-0; Z1741971217; 1,2,3,9,-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H- carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1yl)methyl]-4H-carbazol-4-one; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1 -yl)methyl]-4H-carbazol-4-one; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one; 9-Methyl-3- (2-methyl-imidazol-1ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-Methyl-3-[(2-methyl-1H-imidazolyl)methyl]-1,2,3,9-tetrahydro-4H-carbazole-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1~{H}-carbazol-4-one" Small molecule "1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3" FELGMEQIXOGIFQ-UHFFFAOYSA-N CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C C18H19N3O CAS 99614-02-5 CHEBI:7773 . . . DB00904 . DR0043 Ofloxacin D03NHW D03NHW Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 4583 Anticancer Treatment "ofloxacin; 82419-36-1; Floxin; Ofloxacine; Tarivid; Ocuflox; OFLX; Ofloxacino; Ofloxacinum; Exocin; Hoe-280; DL-8280; Floxin otic; HOE 280; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Oxaldin; Dextrofloxacin; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; DL-ofloxacin; CHEBI:7731; Oflocet; Visiren; CHEMBL4; MFCD00226105; MLS000028749; Ofloxacina; Ofloxacin Otic; Ofloxacin, 98%; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacinum [Latin]; Exocine; Flobacin; SMR000058192; Zanocin; Floxil; Ofloxacino [Spanish]; DSSTox_CID_21085; DSSTox_RID_79623; DSSTox_GSID_41085; 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid; OFX; C18H20FN3O4; FLOXIN IN DEXTROSE 5%; DL 8280; MFCD00865049; PT 01; ORF 18489; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1;(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; Floxin (TN); CCRIS 5233; (+/-)-Floxin; SR-01000076050; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; BRN 3657947; Monoflocet; ofloxacin;; Ofloxacin-d3; HSDB 8030; J01MA01; Ofloxacin,(S); NCGC00016948-01; Ofloxacin (Floxin); CAS-82419-36-1; Exocin (eye drops); Ofloxacin [USAN:USP:INN:BAN:JAN]; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; WP-0405; Spectrum_001186; (R)-Ofloxacin-[d3]; Opera_ID_1114; Prestwick0_000237; Prestwick1_000237; Prestwick2_000237; Prestwick3_000237; Spectrum2_001464; Spectrum3_001499; Spectrum4_000324; Spectrum5_001063; ACMC-20m40v; Epitope ID:116889; O 8757; Lopac0_000904; Oprea1_242882; SCHEMBL24373; BSPBio_000313; BSPBio_003117; KBioGR_000667; KBioSS_001666; fluoro-methyl-(4-methylpiperazin-1-yl)-oxo-[?]carboxylic acid; MLS001074203; MLS006011774; DivK1c_000721; SPECTRUM1502044; SPBio_001387; SPBio_002234; (S)-Ofloxacin;Levaquin;Quixin; Ofloxacin (JP17/USP/INN); BPBio1_000345; DTXSID3041085; SCHEMBL14163982; GTPL10918; HMS502E03; KBio1_000721; KBio2_001666; KBio2_004234; KBio2_006802; KBio3_002617; NINDS_000721; HMS1568P15; HMS1921H12; HMS2090F07; HMS2092B10; HMS2095P15; HMS2235C05; HMS3259G07; HMS3262F10; HMS3369B01; HMS3393K06; HMS3604B17; HMS3712P15; Pharmakon1600-01502044; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3R)-; AMY22220; BCP14346; BCP22048; EBD13209; HY-B0125; RKL10083; Ofloxacin, fluoroquinolone antibiotic; Tox21_110703; Tox21_500904; BBL005605; BDBM50045004; CCG-39210; NSC727071; NSC758178; s1463; STK256723; AKOS001033517; AKOS016042783; Ofloxacine; DL-8280; HOE-280; Tox21_110703_1; AC-7616; BCP9000851; CS-1891; DB01165; KS-5011; LP00904; NC00466; NSC 727071; NSC 758178; NSC-727071; NSC-758178; SDCCGSBI-0050879.P004; VA11432; IDI1_000721; NCGC00015772-02; NCGC00015772-03; NCGC00015772-04; NCGC00015772-05; NCGC00015772-06; NCGC00015772-07; NCGC00015772-08; NCGC00015772-09; NCGC00015772-10; NCGC00015772-12; NCGC00015772-13; NCGC00015772-22; NCGC00094219-01; NCGC00094219-02; NCGC00094219-03; NCGC00094219-04; NCGC00094219-05; NCGC00094219-06; NCGC00178284-01; NCGC00178284-02; NCGC00261589-01; Ofloxacin 100 microg/mL in Acetonitrile; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; 83380-47-6; 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid; AK163167; AK163316; H778; ST073364; SY007392; SBI-0050879.P003; AB0013254; DB-056608; AB00513820; EU-0100904; FT-0627808; FT-0630905; FT-0670773; FT-0673216; O0403; Ofloxacin, VETRANAL(TM), analytical standard; VU0243192-7; 86O854; A10666; C07321; D00453; J10376; O-2800; W-3058; AB00052263-12; AB00052263-13; AB00052263_14; AB00052263_15; Ofloxacin, Antibiotic for Culture Media Use Only; Q411447; SR-01000076050-1; SR-01000076050-4; SR-01000076050-7; BRD-A24228527-001-05-9; BRD-A24228527-001-19-0; Z56761309; F0020-0095; F0472-0226; 138199-71-0 (0.5H2O); 7-Chloro-4-hydroxy-8-methylquinoline-3-carboxylicethylester; Ofloxacin, European Pharmacopoeia (EP) Reference Standard; Ofloxacin, United States Pharmacopeia (USP) Reference Standard; (+/-)-9-Fluoro-2,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 8-Methyl-2,3-dihydrofuro[3,2-e]imidazo-[1,2-c]pyrimidine-9-carboxylicacid; Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material; ()-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoazine-6-carboxylic acid; (+/-)-9-Fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (3R)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; 7-Fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-Fluoro-10-(4-methylpiperazino)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzooxazine-6-carboxylic acid; 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de]-1,4-Benzoxazin-6-carboxylic Acid; 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 9-fluoro-3-methyl-10-(4-methylpiperazino)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid" Small molecule "1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)" GSDSWSVVBLHKDQ-UHFFFAOYSA-N CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O C18H20FN3O4 CAS 82419-36-1 CHEBI:7731 . . . DB01165 . DR1866 Nitroglycerin D07YDE D07YDE Approved Diabetic foot ulcer ICD-11: BD54 CID: 4510 Anticancer Treatment "nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerine; Nitroglycerol; Nitrostat; 55-63-0; Trinitroglycerol; Glycerol trinitrate; Nitro-dur; Minitran; Nitroderm; Nitroglyn; Nitronet; Nitrospan; Tridil; Transderm-nitro; Transderm Nitro; Epinitril; Lenitral; Natispray; Nitrocine; Nitrolan; Nitrolingual; Perlinganit; Susadrin; Sustonit; Trinitrin; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Angiolingual; Cordipatch; Corditrine; Klavikordal; Myoglycerin; Nitroglicerina; Nitroletten; Nitroplast; Nitrorectal; Nitroretard; Nitrostabilin; Nysconitrine; Perglottal; Rectogesic; Temponitrin; Trinitrosan; Adesitrin; Angibid; Angorin; Cardamist; Chitamite; Deponit; Glonoin; Glytrin; Millisrol; Niglycon; Nitrodisc; Nitrogard; Nitroglin; Nitrolowe; Nitromel; Nitromex; Nitromint; Percutol; Suscard; Trinalgon; Triniplas; Trinitrol; Vasoglyn; Myocon; Niglin; Nitora; NitroMist; Gilucor nitro; NitroCor; Soup; Blasting oil; Blasting gelatin; Glyceryl nitrate; Nitro-lent; Nitrozell retard; Transiderm-nitro; propane-1,2,3-triyl trinitrate; Coro-Nitro; Nitro-Span; Nitrine-TDC; Spirit of glonoin; Nitrolingual Spray; Glycerin trinitrate; Nitrogliceryna; Nitronal; Transderm-Nitro TTS; Glyceroltrinitraat; Propanetriol Trinitrate; 1,2,3-Propanetriol, trinitrate; 1,2,3-Propanetriyl nitrate; Glycerol, nitric acid triester; Rectiv; Nitroglycerin, spirits of; Spirit of trinitroglycerin; NG; Rcra waste number P081; SK-106N; Solution glyceryl trinitrate; 1,3-dinitrooxypropan-2-yl nitrate; Spirit of glyceryl trinitrate; 1,2,3-propanetrioltrinitrate; NK-843; Glycerol(trinitrate de); 1,2,3-Propanetriol, 1,2,3-trinitrate; NTG; UNII-G59M7S0WS3; Glycerol Nitric Acid Triester; 1,2,3-Propanetriol trinitrate; Gilustenon; Trinitrolong; Sustak; GTN; NitroBid; G59M7S0WS3; Aldonitrin; Cardiodisco; Colenitral; Discotrine; Glycerylnitrat; Lentonitrina; Nitrobukal; Nitrocerin; Nitrocontin; Nitropatch; Nitropercuten; Nitroperlinit; Nitropront; Nitroprontan; Plastranit; Ratiopharm; TNG; Trinipatch; Angiplex; Angonist; Buccard; Cardabid; Cardinit; Dauxona; Diafusor; DTXSID1021407; Glyceryl; Herwicard; Minitram; Mionitrat; Nitradisc; Nitroard; Nitrobaat; Nitroclyn; Nitrocot; Nitrodyl; Nitrolin; Nitropen; Nitroprol; Nitrorex; Nitrovis; Perganit; Polnitrin; Trinitron; Turicard; Vasolator; Vernies; Willong; Anglix; CHEBI:28787; Herzer; Myovin; Nirmin; Nitrek; Sustac; Nitrol Ointment; Trinitrina Erba; Nitradisc Pad; Nitro-Pflaster; Nitrobid Oint; Nitrong Retard; Niong Retard; Nitro Retard; Aquo-Trimitrosan; Nitro Rorer; Nitromack Retard; Nitromint Retard; Nitronal Aqueous; Nitro-Time; Nitrogard-SR; Mi-Trates; Nitradisc TTS; Nitriderm TTS; Nitro-Par; Top-Nitro; Nitrocine 5; Nitrodyl TTS; Nitromint Aerosol; Nitrong-SR; Deponit 5; Deponit-5; Neos nitro OPT; Nit-Ret; Nitroglycerin-ACC; Transderm-N TTS; Nitro Mack Retard; Nitro-M-Bid; Nitro-Mack Retard; Gepan Nitroglicerin; Nitro Dur TTS; Nitroderm TTS-5; GTN-Pohl; Nitroderm TTS Ext; Nitro-Dur 5; Nitrocontin Continus; Deponit TTS 5; Nitro-Gesanit Retard; Cellegesic; Deponit TTS 10; Nitro-Dur 10; Nitrocap; NitroQuick; NitroQuik; NITRO IV; Glycerintrinitrate; Percutol Oint.; Nitrong parenteral; NitrocapT.D.; Glycerine trinitrate; Nitroglycerin (NG); Corangin Nitrokapseln; Trinitroglicerina Fabra; Anogesic; Glonoinum; Gonitro; Minitro; Nitriderm; Nitroject; Vascana; Buccal; Nitrogliceryna [Polish]; Nitroglycerine [French]; Nitrol (pharmaceutical); Tridil sublin; Trinitrine Simple Laleuf; Nitroglicerina [Italian]; Nitroglicerina [Spanish]; Aquo-trinitrosan; Glycerintrinitrate [Czech]; Glyceroltrinitraat [Dutch]; Trinitrin Tablets; NITROLINGUAL PUMPSPRAY; Nitromist (TN); Minitran (TN); HSDB 30; SDM No. 17; Nitroglycerin in Dextrose 5%; Nitro-bid (TN); Nitro-dur (TN); CCRIS 4089; nitroglycerin ointment; Nitric acid triester of gylcerol; Transderm-nitro (TN); Glycerol(trinitrate de) [French]; Glycerol (trinitrate de) [French]; Glycerol (trinitrate de); EINECS 200-240-8; UN0143; UN1204; UN3064; UN3319; Nitroglycerin [USP:JAN]; RCRA waste no. P081; BRN 1802063; 2,3-dinitrooxypropyl nitrate; Nitrofortin; Nitrolande; Nitrosigma; Reminitrol; Solinitrina; Spirits of Nitroglycerin, (1 to 10%); Corangil; Nitrolar; Nitromed; Sutonit; Myocor; trans-nitro; Glonoine oil; Nitro mack; S.N.G.; 2,3-bis(nitrooxy)propyl nitrate; Glycerol-trinitrat; C01DA02; IMX-150; MQX-503; Nitro-PRN; MED-2002; Diluted nitroglycerin; Nitroglycerin tablets; SK-866; SK-878; UN0144; Nitroglycerin Injection; Spirits of nitroglycerin; Nitroglycerine, spirit of; 1,2,3-trinitrooxypropane; CHEMBL730; EC 200-240-8; Nitroglycerin (JP17/USP); 1,2,3-trinitroglycerin-d5; SCHEMBL15421; 4-01-00-02762 (Beilstein Handbook Reference); UN 0143 (Salt/Mix); UN 0144 (Salt/Mix); UN 1204 (Salt/Mix); BIDD:GT0142; Ex168; Nitroglycerin, liquid, not desensitized [Forbidden]; SDM No. 17 (Salt/Mix); SDM No. 27 (Salt/Mix); 1,2,3-Propanetriol trinatrate; 1,2,3-tris-nitryloxy-propane; GTPL7053; Trinitrate 1,2,3-propanetriol; Nitric acid triester of glycerol; HMS2094M15; ZINC8214625; c0061; AKOS030254238; Nitroglycerin, solution in alcohol with > 5% but not > 10% nitroglycerin; DB00727; Nitroglycerin, liquid, not desensitized; FT-0752897; C07455; D00515; 49060-EP2280014A2; 49060-EP2287168A2; 49060-EP2311823A1; 141831-EP2292593A2; Q162867; SR-01000944510; SR-01000944510-1; Nitroglycerin, solution in alcohol, with not >1% nitroglycerin; Nitroglycerin, solution in alcohol, with >1% but not >10% nitroglycerin; Nitroglycerin, solution in alcohol, with >1% but not >5% nitroglycerin; Nitroglycerin mixture with >2% but not >10% nitroglycerin, by mass, desensitized; Nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass; 27906-99-6; Nitroglycerin 100 microg/mL in Acetonitrile. Short expiry date due to chemical nature of component(s); Nitroglycerin mixture with >2% but not >10% nitroglycerin, by mass, desensitized [UN3319] [Flammable solid]; Nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass [UN0143] [Explosive 1.1D, Poison]; Nitroglycerin, solution in alcohol, with >1% but not >10% nitroglycerin [UN0144] [Explosive 1.1D]; Nitroglycerin, solution in alcohol, with >1% but not >5% nitroglycerin [UN3064] [Flammable liquid]; Nitroglycerin, solution in alcohol, with not >1% nitroglycerin [UN1204] [Flammable liquid]; Trinitroglycerin solution, 1 % (w/w) in propylene glycol, ampule of 1 mL, certified reference material; Trinitroglycerin solution, 1 % (w/w) in propylene glycol, ampule of 5 x 0.2 mL, certified reference material; Trinitroglycerin solution, 1000 mug/mL in acetonitrile, ampule of 1 mL, certified reference material" Small molecule "1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2" SNIOPGDIGTZGOP-UHFFFAOYSA-N C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] C3H5N3O9 CAS 55-63-0 CHEBI:28787 . . . DB00727 . DR1119 Nimesulide D0C0JT D0C0JT Terminated Colorectal cancer ICD-11: 2B91 CID: 4495 Anticancer Treatment "nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Aulin; Flogovital; Sulidene; Nimed; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; R-805; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; R 805; Nisulid; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; MFCD00079470; NCGC00015725-02; SMR000058484; CAS-51803-78-2; DSSTox_CID_17250; DSSTox_RID_79316; DSSTox_GSID_37250; Antifloxil; Nimesulida; Nimesulidum; Guaxan; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; NIM; Nimesulide [INN:BAN]; SR-01000000218; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; Aldoron; Nimedex; Orthobid; CCRIS 8225; Nise Gel; Nimesulide,(S); Prestwick_618; Spectrum_001577; Nimesulide (JAN/INN); Opera_ID_1247; Prestwick0_000194; Prestwick1_000194; Prestwick2_000194; Prestwick3_000194; Spectrum2_001541; Spectrum3_001576; Spectrum4_000178; Spectrum5_000964; Lopac-N-1016; N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide; Lopac0_000855; SCHEMBL24882; BSPBio_000147; BSPBio_001103; BSPBio_003112; KBioGR_000443; KBioGR_000695; KBioSS_000443; KBioSS_002057; MLS001148268; DivK1c_000693; SPECTRUM1503231; SPBio_001382; SPBio_002068; N-(4-nitro-2-phenoxyphenyl); BPBio1_000163; GTPL7401; NIM-03; DTXSID3037250; BCBcMAP01_000034; HMS502C15; KBio1_000693; KBio2_000443; KBio2_002057; KBio2_003011; KBio2_004625; KBio2_005579; KBio2_007193; KBio3_000825; KBio3_000826; KBio3_002612; NINDS_000693; Bio2_000382; Bio2_000862; HMS1362G05; HMS1568H09; HMS1792G05; HMS1922K17; HMS1990G05; HMS2089B14; HMS2095H09; HMS2234K19; HMS3262L11; HMS3269G17; HMS3371J19; HMS3403G05; HMS3414P09; HMS3649A04; HMS3655D13; HMS3678P07; HMS3712H09; HMS3884C22; Pharmakon1600-01503231; BCP10076; HY-B0363; ZINC4617749; Tox21_110207; Tox21_301850; Tox21_500855; BDBM50056999; CCG-39319; CN0038; EI-287; NSC758412; s2040; STL018679; AKOS015897356; Tox21_110207_1; AC-4524; DB04743; KS-1277; LP00855; MCULE-4217888990; NSC 758412; NSC-758412; SDCCGSBI-0050831.P004; IDI1_000693; IDI1_002137; NCGC00015725-01; NCGC00015725-03; NCGC00015725-04; NCGC00015725-05; NCGC00015725-06; NCGC00015725-07; NCGC00015725-08; NCGC00015725-09; NCGC00015725-10; NCGC00015725-11; NCGC00015725-12; NCGC00015725-13; NCGC00015725-15; NCGC00015725-16; NCGC00015725-29; NCGC00021842-03; NCGC00021842-04; NCGC00021842-05; NCGC00021842-06; NCGC00021842-07; NCGC00021842-08; NCGC00255661-01; NCGC00261540-01; AK163559; SBI-0050831.P003; DB-052029; AB00052332; EU-0100855; FT-0630650; N0984; ST51015069; SW196785-3; (methylsulfonyl)(4-nitro-2-phenoxyphenyl)amine; D01049; N 1016; Q20994; AB00052332-16; AB00052332_17; AB00052332_18; n-(4-nitro-2-phenoxy-phenyl)-methanesulfonamide; N-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide; 803N782; A828786; SR-01000000218-2; SR-01000000218-6; SR-01000000218-7; W-105866; BRD-K76775527-001-06-2; BRD-K76775527-001-18-7; SR-01000000218-11; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- (9CI); Nimesulide, European Pharmacopoeia (EP) Reference Standard; Nimesulide, Pharmaceutical Secondary Standard; Certified Reference Material; Nimesulide for peak identification, European Pharmacopoeia (EP) Reference Standard; 1364966-82-4" Small molecule "1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3" HYWYRSMBCFDLJT-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2 C13H12N2O5S CAS 51803-78-2 CHEBI:44445 . . . DB04743 . DR2270 Niclosamide D0J9ZR D0J9ZR Approved Cestodes infection ICD-11: 1F70-1F76 CID: 4477 Anticancer Treatment "niclosamide; 50-65-7; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Niclocide; Bayluscid; Phenasal; Tredemine; Fenasal; Yomesan; 2',5-Dichloro-4'-nitrosalicylanilide; Dichlosale; Helmiantin; Atenase; Cestocid; Devermin; Devermine; Iomesan; Iomezan; Mansonil; Radeverm; Sagimid; Vermitid; Lintex; Nasemo; Sulqui; Mato; Fedal-Telmin; Bayer 73; Zestocarp; Bayer 2353; BAY 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; Chemagro 2353; C13H8Cl2N2O4; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; WR 46234; Salicylanilide, 2',5-dichloro-4'-nitro-; UNII-8KK8CQ2K8G; ENT 25823; 2-Hydroxy-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide; N-(2-Chloro-4-nitrophenyl)-5-chlorosalicylamide; 2-Chloro-4-nitrophenylamide-6-chlorosalicylic acid; 2',5-Dichlor-4'-nitro-salizylsaeureanilid; 5-Chloro-N-(2'-chloro-4'-nitrophenyl)salicylamide; 8KK8CQ2K8G; SR 73; Radewerm; N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid; MFCD00057597; Niclosamide Anhydrous; NSC-178296; Niclosamide, 97+%; CAS-50-65-7; NCGC00015735-07; DSSTox_CID_20362; DSSTox_RID_79485; DSSTox_GSID_40362; N-(2'-Chloro-4'-nitrophenyl)-5-chlorosalicylamide; Niclosamida; Niclosamidum; Cestocide; Niclosamidum [INN-Latin]; Niclosamida [INN-Spanish]; Nitrophenyl chlorsalicylamide; Niclosamide [USAN:INN:BAN]; CCRIS 3437; HSDB 1572; SR-01000076024; Niclosamide [BSI:ISO]; EINECS 200-056-8; NSC 178296; BRN 2820605; Yomensan; AI3-25823; 5-Chlorosalicyloyl-(o-chloro-p-nitranilide); B 2353; Niclocide (TN); Prestwick_354; 2',5-Dichlor-4'-nitro-salizylsaeureanilid [German]; Mollutox (Salt/Mix); N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid [German]; Spectrum_000239; Niclosamide (Niclocide); Clonitralid (Salt/Mix); Clonitralide (Salt/Mix); Prestwick0_000040; Prestwick1_000040; Prestwick2_000040; Prestwick3_000040; Spectrum2_001183; Spectrum3_000667; Spectrum4_000196; Spectrum5_001083; Lopac-N-3510; Niclosamide (USAN/INN); CHEMBL1448; Lopac0_000866; Oprea1_259151; SCHEMBL67182; BSPBio_000139; BSPBio_002333; KBioGR_000771; KBioSS_000719; MLS002154181; DivK1c_000709; SPECTRUM1503265; SPBio_001225; SPBio_002060; BPBio1_000153; CHEBI:7553; GTPL8494; DTXSID7040362; SCHEMBL18563900; WLN: WNR CG DMVR BQ EG; BDBM11242; HMS502D11; KBio1_000709; KBio2_000719; KBio2_003287; KBio2_005855; KBio3_001553; 5-Chloro-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-benzamide; Niclosamide - CAS 50-65-7; NINDS_000709; HMS1568G21; HMS2093A21; HMS2095G21; HMS2231H06; HMS3262N13; HMS3373P08; HMS3712G21; KUC107299N; Pharmakon1600-01503265; BAY-2353; BCP22958; HY-B0497; ZINC3874496; Tox21_110209; Tox21_300749; Tox21_500866; BBL004110; CCG-39641; NSC178296; NSC758440; s3030; Salicylanilide,5-dichloro-4'-nitro-; STK396676; 2,5-dichloro-4-nitrosalicylanilide ?; AKOS003589004; Tox21_110209_1; BCP9000068; DB06803; KS-5210; LP00866; MCULE-9985514311; NSC-758440; SB19414; SDCCGSBI-0050841.P004; 2',5'-Dichloro-4'-nitrosalicylanilide; IDI1_000709; SMP2_000228; 5-chloro-N-(2-chloro-4-nitrophenyl)-; NCGC00015735-01; NCGC00015735-02; NCGC00015735-03; NCGC00015735-04; NCGC00015735-05; NCGC00015735-06; NCGC00015735-08; NCGC00015735-09; NCGC00015735-11; NCGC00015735-12; NCGC00015735-24; NCGC00094190-01; NCGC00094190-02; NCGC00094190-03; NCGC00094190-04; NCGC00254654-01; NCGC00261551-01; AK173020; I012; KSC-18-157-2; SMR000058390; Niclosamide 100 microg/mL in Acetonitrile; SBI-0050841.P003; AB0013423; DB-051812; VU0243604; AB00052340; EU-0100866; FT-0603220; ST50408862; T7903; EN300-92958; D00436; N 3510; AB00052340_08; AB00052340_09; A828227; Q418523; Q-201469; SR-01000076024-1; SR-01000076024-3; SR-01000076024-6; BRD-K35960502-001-06-9; BRD-K35960502-001-11-9; Z57902203; 5-Chloro-N-(2-chloro-4-nitrophenyl) -2-hydroxybenzamide; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-benzamide; (5-chloro-2-hydroxyphenyl)-N-(2-chloro-4-nitrophenyl)carboxamide; 5-chloranyl-N-(2-chloranyl-4-nitro-phenyl)-2-oxidanyl-benzamide; Niclosamide (anhydrous), European Pharmacopoeia (EP) Reference Standard" Small molecule "1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)" RJMUSRYZPJIFPJ-UHFFFAOYSA-N C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O C13H8Cl2N2O4 CAS 50-65-7 CHEBI:7553 . . . DB06803 . DR0176 Neostigmine D08USJ D08USJ Approved Myasthenia gravis ICD-11: 8C6Y CID: 4456 Anticancer Treatment "NEOSTIGMINE; Eustigmin; Eustigmine; Prostigmine; Vagostigmine; Prostigmin; 59-99-4; Juvastigmin; m-Trimethylammoniumphenyldimethylcarbamate; Neostigmine [BAN]; 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; Vagostigmin; Neostigmine (BAN); UNII-3982TWQ96G; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; Prostigmin (TN); Neostigmin; CHEBI:7514; CHEMBL278020; Intrastigmina; Neostigminum; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-; 3982TWQ96G; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium; Benzenaminium, 3-[[(dimethylamino)carbonyl]oxy]-N,N,N-trimethyl-; 3-((dimethylcarbamoyl)oxy)-N,N,N-trimethylbenzenaminium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; sulfonatooxymethane; CCRIS 3079; HSDB 3921; NCGC00163240-01; CAS-114-80-7; BRN 3615946; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; Spectrum_001061; Prestwick0_000468; Prestwick1_000468; Prestwick2_000468; Prestwick3_000468; Spectrum2_001278; Spectrum4_000072; Spectrum5_001234; Lopac-N-2001; bmse000762; Lopac0_000816; SCHEMBL34419; BSPBio_000576; KBioGR_000623; KBioSS_001541; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; DivK1c_000165; DivK1c_000198; SPBio_001276; SPBio_002515; BPBio1_000634; GTPL8993; ZINC1792; DTXSID1023360; ALWKGYPQUAPLQC-UHFFFAOYSA-; KBio1_000165; KBio1_000198; KBio2_001541; KBio2_004109; KBio2_006677; NINDS_000165; NINDS_000198; HMS2089A22; BDBM50022775; STL058953; AKOS005711366; CCG-204900; DB01400; MCULE-3501840981; IDI1_000165; IDI1_000198; MLS-0002855; NCGC00015730-01; NCGC00015730-02; NCGC00015730-03; NCGC00015730-04; NCGC00015730-05; NCGC00015730-06; NCGC00015730-07; NCGC00015730-08; NCGC00015730-09; NCGC00015730-24; NCGC00021658-03; SBI-0050793.P004; AB00053807; C07258; D08261; AB00053807-25; AB00053807-26; AB00053807_27; AB00053807_28; AB00053807_29; Q410546; BRD-K18922609-004-04-1; BRD-K18922609-004-14-0; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl- (9CI)" Small molecule "1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1" ALWKGYPQUAPLQC-UHFFFAOYSA-N CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C C12H19N2O2+ CAS 59-99-4 CHEBI:7514 . . . DB01400 . DR6236 Nalidixic acid D07JGT D07JGT Approved Urinary tract infection ICD-11: GC08 CID: 4421 Anticancer Treatment "nalidixic acid; 389-08-2; Nalidixin; Nevigramon; Nalidixate; Uronidix; NegGram; Innoxalon; Nalidixan; Nalitucsan; Sicmylon; Unaserus; Nalidic acid; Nalidixinic acid; Wintomylon; Dixiben; Dixinal; Jicsron; Nalurin; Naxuril; Nogram; Urisal; Cybis; Nalix; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Nalidicron; Betaxina; Kusnarin; Narigix; Nicelate; Specifen; Specifin; Uralgin; Uriclar; Urodixin; Negram; Poleon; Uriben; Uroman; Uroneg; Uropan; Acide nalidixique; Eucistin; Acide nalidixico; Acido nalidixico; Acidum nalidixicum; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; NSC-82174; Nalidixane; WIN 18,320; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; NCI-C56199; MFCD00006884; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; UNII-3B91HWA56M; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; Nalidixic acid (NegGram); MLS000028504; 3B91HWA56M; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Win 18320; CHEBI:100147; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; NSC82174; NCGC00018181-08; SMR000058264; Wintron; DSSTox_CID_912; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; Acido nalidissico; Nalidixic acid, 99.5%; DSSTox_RID_75859; DSSTox_GSID_20912; Acido nalidissico [DCIT]; Acide nalidixico [Italian]; Acide nalidixique [French]; Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; 1,8-Naphthyridine-3-carboxylic acid,1-ethyl-1,4-dihydro-7-methyl-4-oxo-; CAS-389-08-2; NegGram (TN); CCRIS 2365; HSDB 3241; EINECS 206-864-7; BRN 0750515; Innoxalomn; Eucisten; nalidixic-acid; SR-01000003086; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; WIN-18320; WIN 183203; CHEMBL5; Spectrum_000918; Nalidixic acid [USAN:USP:INN:BAN:JAN]; Maybridge1_007101; Opera_ID_1064; Prestwick0_000187; Prestwick1_000187; Prestwick2_000187; Prestwick3_000187; Spectrum2_001360; Spectrum3_000075; Spectrum4_000817; Spectrum5_001540; Nalidixic acid, >=98%; UPCMLD-DP129; N-1200; NCIOpen2_004342; Lopac0_000837; Oprea1_010545; SCHEMBL21736; BSPBio_000113; BSPBio_001889; KBioGR_001333; KBioSS_001398; 5-25-07-00384 (Beilstein Handbook Reference); MLS001148578; MLS002303041; MLS004820190; MLS006011875; 1-ethyl-7-methyl-4-oxo-1; BIDD:GT0529; DivK1c_000058; SPECTRUM1500756; SPBio_001579; SPBio_002034; BPBio1_000125; DTXSID3020912; UPCMLD-DP129:001; BDBM21691; HMS500C20; HMS561K17; KBio1_000058; KBio2_001398; KBio2_003966; KBio2_006534; KBio3_001109; ZINC57421; NINDS_000058; HMS1921G10; HMS2092K04; HMS2232H24; HMS3259O13; HMS3374G11; HMS3656K05; Pharmakon1600-01500756; Nalidixic acid (JP17/USP/INN); Nalidixic acid, analytical standard; ALBB-021275; HY-B0398; Tox21_110835; Tox21_201477; Tox21_302754; ANW-42195; BBL012279; CCG-39298; NSC757432; SBB002146; STK735579; 1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; AKOS000120074; Tox21_110835_1; DB00779; MCULE-6808033849; NC00494; NSC-757432; SDCCGSBI-0050814.P004; IDI1_000058; NCGC00018181-01; NCGC00018181-02; NCGC00018181-03; NCGC00018181-04; NCGC00018181-05; NCGC00018181-06; NCGC00018181-07; NCGC00018181-09; NCGC00018181-10; NCGC00018181-12; NCGC00018181-13; NCGC00021730-03; NCGC00021730-04; NCGC00021730-05; NCGC00021730-06; NCGC00021730-07; NCGC00256581-01; NCGC00259028-01; AK163550; AS-13289; H816; NCI60_041807; SMR004703506; WLN: T66 BN EV JNJ B2 DVQ I1; SBI-0050814.P003; AB0013282; DB-049349; 1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; BB 0242389; FT-0603390; N0490; S2328; SW219624-1; 1-Ethyl-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,8-naphthyridine-3-carboxylic acid; Nalidixic acid 100 microg/mL in Acetonitrile; VU0239598-6; C05079; D00183; K-8443; Nalidixic acid, meets USP testing specifications; 389N082; Q281082; SR-01000003086-4; SR-01000003086-6; BRD-K47886988-323-03-0; Nalidixic acid, Antibiotic for Culture Media Use Only; SR-01000003086-10; F0850-6751; Z256708444; 1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid; Nalidixic acid, European Pharmacopoeia (EP) Reference Standard; Nalidixic acid, United States Pharmacopeia (USP) Reference Standard; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naph thyridine-3-carboxylic acid; 1-ethyl-7-methyl-4-oxohydropyridino[2,3-b]pyridine-3-carboxylic acid; N-benzyl-4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-N-ethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide" Small molecule "1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)" MHWLWQUZZRMNGJ-UHFFFAOYSA-N CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O C12H12N2O3 CAS 389-08-2 CHEBI:100147 . . . DB00779 . DR7967 Entinostat D0M8FD D0M8FD Phase 3 Breast cancer ICD-11: 2C60-2C65 CID: 4261 Anticancer Treatment "Entinostat; 209783-80-2; ms-275; SNDX-275; MS 275; MS-27-275; SNDX 275; Entinostat (MS-275); MS 27-275; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate; MS275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; UNII-1ZNY4FKK9H; Entinostat (MS-275,SNDX-275); 1ZNY4FKK9H; BAY 86-5274; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; CHEMBL27759; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; NSC706995; BAY86-5274; NSC-706995; N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate.; pyridin-3-ylmethyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate; Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Histone Deacetylase Inhibitor I; entinostatum; N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide; Entinostat, free base; PubChem24433; Entinostat [USAN:INN]; MS-275 (Entinostat); MS-275 - Entinostat; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate; benzamide-type inhibitor, 3; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; cc-216; MLS006010183; Entinostat (JAN/USAN/INN); SCHEMBL148309; GTPL7007; DTXSID0041068; BDBM19410; AOB2570; EX-A038; SYN3039; CHEBI:132082; BCPP000155; HMS3426G07; HMS3648K12; HMS3654O11; HMS3744O17; ACT06782; AMY31163; BCP01824; MS-275,Entinostat,SNDX-275/; ZINC1488870; ABP000145; MFCD08272435; NSC756642; s1053; 3-pyridylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; AKOS024262667; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; AC-8968; BCP9000967; Carbamic acid, 3-pyridinylmethyl ester; CCG-208680; CS-0511; DB11841; Entinostat (MS-275, SNDX-275); NSC 706995; NSC-756642; SB16665; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; NCGC00165833-01; NCGC00165833-02; NCGC00165833-03; NCGC00165833-04; NCGC00165833-13; AK158952; AS-17906; Carbamic acid, N-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- pyridinylmethyl ester; HY-12163; MS27-275; NCI60_038022; SMR004458705; MS-275, A HDAC1 and HDAC3 inhibitor; AB0021206; MS-275-27; ZK 244894; FT-0667871; SW219667-1; V2451; EC-000.2117; D09338; W-5370; 48247-EP2298768A1; 48247-EP2305643A1; 48247-EP2308868A1; 48247-EP2311494A1; 48247-EP2311840A1; 783M802; A815057; MS-275,Entinostat, SNDX-275, MS-27-275; SR-01000946382; Q1281020; SR-01000946382-1; W-201831; BRD-K77908580-001-02-1; BRD-K77908580-001-04-7; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; [4-(2-Amino-phenylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]-3-pyridinylmethyl ester, carbamic acid; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; 442532-99-2" Small molecule "1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)" INVTYAOGFAGBOE-UHFFFAOYSA-N C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3 C21H20N4O3 CAS 209783-80-2 CHEBI:132082 . . . DB11841 . DR7618 Mitotane D0Z5OE D0Z5OE Approved Adrenal cancer ICD-11: 2D11 CID: 4211 Anticancer Treatment "mitotane; 53-19-0; Mitotan; Lysodren; Chloditan; o,p'-DDD; Chlodithane; Khlodithan; Chlodithan; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 2,4'-Ddd; Mitotano; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; NCI-C04933; o,p'-TDE; 2,4'-Dichlorodiphenyldichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; o,p'-Dichlorodiphenyldichloroethane; Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-; 2,4'-Dichlorophenyldichlorethane; CB 313; NSC 38721; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; NSC38721; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; CB-313; NSC-38721; 2,4'-DDD;o,p'-DDD; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-; MFCD00000850; Mitotanum [INN-Latin]; o,p-Tde; NCGC00015226-07; 1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene; Mitotanum; DSSTox_CID_372; Mitotano [INN-Spanish]; DSSTox_RID_75548; DSSTox_GSID_20372; 2,4'-(2,2-dichloroethane-1,1-diyl)bis(chlorobenzene); Opeprim; 2,4 -Dichlorodiphenyldichloroethane; Mitotane (Lsodren); CB313; DDD, o,p'-; CAS-53-19-0; Lysodren (TN); SMR000326696; CCRIS 4397; HSDB 3240; SR-01000075751; EINECS 200-166-6; (o,p)-DDD; Mitotane (JAN/USP/INN); BRN 2056007; AI3-07575; Prestwick_75; Ethane,1-dichloro-; Mitotane (Lysodren); Mitotane [USAN:USP:INN:BAN:JAN]; (2,4'-Dichlorodiphenyl)dichloroethane; PubChem14974; Spectrum_001959; DDD-o,p'; (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; Spectrum2_000916; Spectrum3_000869; Spectrum4_000709; Spectrum5_002060; C 3010; (o,p')-DDD; SCHEMBL4040; CHEMBL1670; Lopac0_000251; WLN: GYGYR BG&R DG; BSPBio_002517; KBioGR_001237; KBioSS_002513; SPECTRUM330082; MLS001335899; MLS001335900; MLS002152914; MLS002153233; DivK1c_000703; SPBio_000792; CHEBI:6954; GTPL6957; Mitotane, >=98% (HPLC); DTXSID9020372; 2,4'-DDD, analytical standard; HMS502D05; KBio1_000703; KBio2_002505; KBio2_005073; KBio2_007641; KBio3_002017; NINDS_000703; HMS1923K19; HMS2091E07; HMS2232C16; HMS3260D04; HMS3369H10; HMS3655G06; HMS3715H07; HMS3869F13; Pharmakon1600-00330082; BCP11663; 2,4 inverted exclamation marka-DDD; Tox21_110103; Tox21_302804; Tox21_500251; CCG-40014; NSC755849; s1732; 1,2-bis(2,4'-dichlorophenyl)ethane; AKOS006028802; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-, (+-)-; Tox21_110103_1; CS-1500; DB00648; LP00251; MCULE-2068358149; NSC-755849; SDCCGSBI-0050239.P006; IDI1_000703; NCGC00015226-02; NCGC00015226-03; NCGC00015226-04; NCGC00015226-05; NCGC00015226-06; NCGC00015226-08; NCGC00015226-09; NCGC00015226-10; NCGC00015226-11; NCGC00015226-12; NCGC00091374-01; NCGC00091374-02; NCGC00091374-03; NCGC00091374-04; NCGC00091374-05; NCGC00091374-06; NCGC00256452-01; NCGC00260936-01; 2,4'-DDD 10 microg/mL in Cyclohexane; AK546750; AS-11690; HY-13690; NCI60_003688; 2,4'-DDD 100 microg/mL in Cyclohexane; SBI-0050239.P004; AB0010565; EU-0100251; FT-0605518; ST51016017; SW199619-3; EN300-37268; 2,4 inverted exclamation marka-DDD;o,p'-DDD; 2,4'-DDD, PESTANAL(R), analytical standard; D00420; W-5031; AB00052337-09; AB00052337_10; 000M850; Q417465; SR-01000075751-1; SR-01000075751-3; SR-01000075751-6; Z425389592; 1-(o-Chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane; 1-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-2-chlorobenzene; Ethane,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene #; Mitotane, United States Pharmacopeia (USP) Reference Standard; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8CI); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, analytical standard; o,p'-DDD; ; ; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; ; ; Mitotane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane for diagnostic uses (cancer investigation), >=98% (HPLC); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, for diagnostic uses (cancer investigation), >=98% (HPLC)" Small molecule "1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H" JWBOIMRXGHLCPP-UHFFFAOYSA-N C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl C14H10Cl4 CAS 53-19-0 CHEBI:6954 . . . DB00648 . DR9574 Metronidazole D0A2ZX D0A2ZX Approved Amoebiasis ICD-11: 1A36 CID: 4173 Anticancer Treatment "metronidazole; 443-48-1; Flagyl; Metronidazol; 2-Methyl-5-nitroimidazole-1-ethanol; Anagiardil; Trichazol; MetroGel; Bayer 5360; Gineflavir; Meronidal; Metronidaz; Novonidazol; Trichopol; Trivazol; Danizol; Mexibol; Vagilen; Clont; 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethanol; Flagemona; Giatricol; Metronidazolo; Sanatrichom; Takimetol; Trichocide; Trichomol; Trikacide; Acromona; Atrivyl; Deflamon; Efloran; Entizol; Flagesol; Monagyl; Monasin; Orvagil; Trichex; Tricocet; Trikamon; Trikojol; Trikozol; Trimeks; Vagimid; Vertisal; Wagitran; Arilin; Bexon; Elyzol; Eumin; Flagil; Klion; Klont; Nalox; Tricom; neo-Tric; Tricowas B; Deflamon-wirkstoff; Protostat; Satric; MetroCream; MetroLotion; MetroGel-Vaginal; CONT; NIDA; Methronidazole; Metromidol; Trichopal; Flegyl; Fossyol; 1H-Imidazole-1-ethanol, 2-methyl-5-nitro-; Flagyl Er; Metronidazolum; Metro I.V.; Metrolyl; Metric 21; Trichomonacid 'pharmachim'; 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; RP 8823; NSC-50364; Metronidazole in Plastic Container; 2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole; 2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole; SC 10295; MFCD00009750; 1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole; 1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole; 1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; Imidazole-1-ethanol, 2-methyl-5-nitro-; 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-ol; FLAGYL I.V. RTU IN PLASTIC CONTAINER; 1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole; NSC 50364; UNII-140QMO216E; 2-(2-methyl-5-nitro-1-imidazolyl)ethanol; 2-(2-methyl-5-nitro-imidazol-1-yl)ethanol; BAY-5360; NSC69587; Noritate; MLS000028590; CHEBI:6909; 140QMO216E; Metro Gel; NSC50364; NSC-69587; Metronidazole, 99%; NCGC00016446-06; CAS-443-48-1; Metrolag; Metrotop; Rathimed; SMR000058175; Vandazole; Zadstat; 2-(2-methyl-5-nitroimidazolyl)ethan-1-ol; Tricho cordes; DSSTox_CID_892; Metronidazolo [DCIT]; Tricho-gynaedron; DSSTox_RID_75848; DSSTox_GSID_20892; Mexibol 'silanes'; 99616-64-5; Metro I.V. In Plastic Container; 1-(.beta.-Ethylol)-2-methyl-5-nitro-3-azapyrrole; 1-(.beta.-Hydroxyethyl)-2-methyl-5-nitroimidazole; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Metronidazole-13C2,15N2; Flagyl I.V. RTU; Flagyl 375; Trichobrol; Florazole; Mepagyl; Nidagyl; Rosased; Zidoval; Caswell No. 579AA; WLN: T5N CNJ A2Q B1 ENW; Noritate (TN); CCRIS 410; Metro cream & gel; Flagyl (TN); HSDB 3129; WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW; SR-01000000244; EINECS 207-136-1; NSC 69587; EPA Pesticide Chemical Code 120401; BRN 0611683; Polibiotic; Trikhopol; Donnan; Flazol; CB-01-14 MMX; Metro IV; Vandazole (TN); Metronidazole,(S); Prestwick_334; Nuvessa (TN); IDR-90105; Cimetrol 500LPCI; Metronidazole solution; RP-8823; Metronidazole, BioXtra; Metronidazole (Flagyl); PubChem15970; Spectrum_001035; Metronidazole [USAN:USP:INN:BAN:JAN]; ACMC-209jxc; HELIDAC (Salt/Mix); Maybridge1_001999; Opera_ID_1585; Prestwick0_000081; Prestwick1_000081; Prestwick2_000081; Prestwick3_000081; Spectrum2_000883; Spectrum3_000506; Spectrum4_000060; Spectrum5_001289; M0924; CHEMBL137; NCIOpen2_000337; SCHEMBL23042; BSPBio_000002; BSPBio_002031; KBioGR_000559; KBioSS_001515; 5-23-05-00063 (Beilstein Handbook Reference); MLS000758286; MLS001424018; ARONIS24285; BIDD:GT0107; DivK1c_000007; SPECTRUM1500412; SPBio_000666; SPBio_001941; BAYER-5360; BPBio1_000004; DTXSID2020892; Flagyl I.V. RTU (Salt/Mix); BCBcMAP01_000184; GTPL10914; HMS500A09; HMS547C19; KBio1_000007; KBio2_001515; KBio2_004083; KBio2_006651; KBio3_001531; Metronidazole (JP17/USP/INN); Metronidazole, analytical standard; NINDS_000007; HMS1568A04; HMS1920N19; HMS2051G07; HMS2090B19; HMS2091F14; HMS2095A04; HMS2231E11; HMS3373O05; HMS3393G07; HMS3655E22; HMS3712A04; Pharmakon1600-01500412; ZINC113442; BCP13757; HY-B0318; Tox21_110441; Tox21_202413; Tox21_302794; ANW-30094; BBL005452; BDBM50375309; CCG-40016; FP-250; NSC757118; s1907; SBB001486; SBB041018; STK177359; Metronidazole 2.0 mg/ml in Methanol; AKOS000269646; AKOS005169650; Tox21_110441_1; DB00916; KS-5140; MCULE-6891596695; NC00020; NSC-757118; 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole N-(5-carboxy-5-aminopentane)carbamate; IDI1_000007; SMP1_000189; NCGC00016446-01; NCGC00016446-02; NCGC00016446-03; NCGC00016446-04; NCGC00016446-05; NCGC00016446-07; NCGC00016446-08; NCGC00016446-09; NCGC00016446-11; NCGC00016446-12; NCGC00016446-17; NCGC00022059-03; NCGC00022059-04; NCGC00022059-05; NCGC00256513-01; NCGC00259962-01; AC-23968; AK-77146; ST024769; SY002821; SBI-0051447.P003; AB0008438; DB-051212; Metronidazole, SAJ first grade, >=99.0%; AB00052046; BB 0218386; FT-0603394; SW196613-4; C07203; D00409; M-2794; 74568-EP2275420A1; 74568-EP2292612A2; 74568-EP2305640A2; 74568-EP2305662A1; 74568-EP2308857A1; AB00052046-17; AB00052046_18; AB00052046_19; A826552; Metronidazole, VETRANAL(TM), analytical standard; Q169569; 2-(2-methyl-5-nitro-1H-imidazol-1-yl)-1-ethanol; 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethanol #; Metronidazole, Antibiotic for Culture Media Use Only; Q-201403; SR-01000000244-4; SR-01000000244-5; BRD-K52020312-001-05-2; BRD-K52020312-001-15-1; Z87001124; F1773-0073; Metronidazole, certified reference material, TraceCERT(R); Metronidazole, British Pharmacopoeia (BP) Reference Standard; Metronidazole, European Pharmacopoeia (EP) Reference Standard; Metronidazole, United States Pharmacopeia (USP) Reference Standard; Metronidazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3" VAOCPAMSLUNLGC-UHFFFAOYSA-N CC1=NC=C(N1CCO)[N+](=O)[O-] C6H9N3O3 CAS 443-48-1 CHEBI:6909 . . . DB00916 . DR9621 Methylphenidate D02PPN D02PPN Approved Attention deficit hyperactivity disorder ICD-11: 6A05 CID: 4158 Anticancer Treatment "methylphenidate; Methylphenidan; Phenidylate; Concerta; Calocain; Plimasine; Meridil; 113-45-1; Methyl phenidylacetate; Methyl phenidate; Metilfenidato [Italian]; Methylphenidatum; Metilfenidato [INN-Spanish]; Methylphenidatum [INN-Latin]; Methylin; 4311/B Ciba; Methyl phenidyl acetate; methyl phenyl(piperidin-2-yl)acetate; Ritalin; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; alpha-Phenyl-2-piperidineacetic acid methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester; Methylphenidate HCl; NCI-C56280; Methyl alpha-phenyl-alpha-2-piperidinylacetate; CHEMBL796; 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; Methyl 2-phenyl-2-(piperidin-2-yl)acetate; Methylfenidan; CHEBI:84276; Metilfenidato; Methylphenidylacetate hydrochloride; .alpha.-Phenyl-2-piperidineacetic acid methyl ester; d-methylphenidate HCl; Daytrana (TN); HSDB 3126; Methyl (2-phenyl-2-(2-piperidyl)acetate); EINECS 204-028-6; C 4311; Methylphenidate (USAN/INN); Rubifen; alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Adhd patch; DEA No. 1724; Methylphenidate [USAN:INN:BAN]; Cotempla XR-ODT; Ritalin (Salt/Mix); Methylin (Salt/Mix); Ritaline (Salt/Mix); Centedein (Salt/Mix); Centedrin (Salt/Mix); Centedrine (Salt/Mix); SCHEMBL37178; GTPL7236; DTXSID5023299; Jornay PM (a.k.a. HLD200); 40572-71-2; BCP18286; HY-B1091; BDBM50062912; methyl alpha-piperid-2-ylphenylacetate; Methyl phenyl(2-piperidinyl)acetate #; CS-4657; DB00422; NCGC00248587-01; NCGC00248587-03; Methyl .alpha.-phenyl-2-piperidineacetate; SBI-0206868.P001; Methyl .alpha.-phenyl-2-piperidine-acetate; C07196; D04999; phenyl-piperidin-2-yl-acetic acid methyl ester; AB01563134_01; L001307; Q422112; Methyl .alpha.-phenyl-.alpha.-(2-piperidyl)acetate; Methyl .alpha.-phenyl-.alpha.-2-piperidinylacetate; (S,2S)--Phenyl-2-piperidineacetic acid methyl ester; BRD-A19585813-003-01-7" Small molecule "1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3" DUGOZIWVEXMGBE-UHFFFAOYSA-N COC(=O)C(C1CCCCN1)C2=CC=CC=C2 C14H19NO2 CAS 113-45-1 CHEBI:84276 . . . DB00422 . DR1885 Mesalazine D0C4YC D0C4YC Approved Ulcerative colitis ICD-11: DD71 CID: 4075 Anticancer Treatment "5-Aminosalicylic acid; mesalamine; Mesalazine; 5-Amino-2-hydroxybenzoic acid; 89-57-6; Asacol; Pentasa; Claversal; Canasa; 5-ASA; Salofalk; Rowasa; m-Aminosalicylic acid; Mesasal; Lialda; Benzoic acid, 5-amino-2-hydroxy-; Fisalamine; Lixacol; Apriso; p-Aminosalicylsaeure; Asacolitin; Mesalazina; Mesalazinum; sfRowasa; 5-amino-2-hydroxy-benzoic acid; Asacol HD; 5-Amino Salicylic Acid; SALICYLIC ACID, 5-AMINO-; MFCD00007877; 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; UNII-4Q81I59GXC; NSC 38877; MAX-002; MLS001424012; 4Q81I59GXC; CHEBI:6775; NSC-38877; CAS-89-57-6; NCGC00016344-03; Mesalazinum [Latin]; SMR000145728; DSSTox_CID_4506; DSSTox_RID_77435; DSSTox_GSID_24506; 5-Aminosalicylic acid, 99%; Mesalazina [Spanish]; p-Aminosalicylsaeure [German]; Mesavancol; Delzicol; Mesavance; Mezavant; Iialda; Mesalazine MMX; Mezavant XL; Mesalamine (USP); Pentasa (TN); Salofalk Granu-Stix; Apriso (TN); Asacol (TN); Canasa (TN); Lialda (TN); Rowasa (TN); 5-AS; CCRIS 7334; SR-01000763486; Mesalamine [USAN:USP]; EINECS 201-919-1; BRN 2090421; AI3-15564; HSDB 7512; AJG-501; SPD 476; SPD-476; SPD-480; Mesalamine (TN); Delzicol (TN); Sfrowasa (TN); Mesalazine [INN]; mesalamine (USAN); Mesalamine (Lialda); 5-aminosalicylic_acid; MD-0901; 5-Aminosalicyclic acid; 5-amino-salicylic acid; PubChem17623; Mesalamine; ; ; Mesalazine; ACMC-1BKFR; Prestwick0_001069; Prestwick1_001069; Prestwick2_001069; Prestwick3_001069; WLN: ZR DQ CVQ; Z-206; CHEMBL704; Mesalazine (JP17/INN); EC 201-919-1; cid_4075; Oprea1_847633; SCHEMBL31297; 3amino-6-hydroxybenzoic acid; BSPBio_001058; KBioGR_002425; KBioSS_002431; 4-14-00-02058 (Beilstein Handbook Reference); MLS000758287; 5-Aminosalicylic acid, 95%; 5-Aminosalicylic acid, tablet; ARONIS23914; BIDD:GT0811; 3-amino-6-hydroxybenzoic acid; SPBio_002969; BPBio1_001164; GTPL2700; ZINC1688; 5-Amino 2-hydroxy benzoic acid; DTXSID5024506; SCHEMBL18038934; 5-Aminosalicylic acid, >=99%; BDBM60918; KBio2_002425; KBio2_004993; KBio2_007561; KBio3_002904; cMAP_000045; HMS1571E20; HMS2051M21; HMS2090I09; HMS2098E20; HMS3393M21; HMS3649K15; HMS3651M15; HMS3715E20; Pharmakon1600-01505993; BCP05326; NSC38877; Tox21_110384; Tox21_201610; Tox21_303125; 5-?Aminosalicylic Acid (Mesalazine); ANW-39326; BBL013046; NSC759301; s1681; SBB052617; STK301678; AKOS000118959; Tox21_110384_1; AC-2764; BCP9000175; CCG-100829; DB00244; HS-0100; LS11426; MCULE-5752745805; NC00079; NSC-759301; NCGC00016344-01; NCGC00016344-02; NCGC00016344-04; NCGC00016344-05; NCGC00016344-07; NCGC00090934-01; NCGC00090934-02; NCGC00257142-01; NCGC00259159-01; 5-amino-2-hydroxobenzoic acid monohydrate; AK-72925; BP-13074; HY-15027; SY002854; 5-Aminosalicylic acid, analytical standard; ST4109571; A0317; AB00374979; AM20060091; FT-0619950; SW197303-4; 1764-EP2272825A2; 1764-EP2275420A1; C07138; D00377; M-7246; 24215-EP2289518A1; 24215-EP2295053A1; 24215-EP2295409A1; 24215-EP2314574A1; 24215-EP2314590A1; 90701-EP2371811A2; AB00374979-09; AB00374979-10; AB00374979_11; AB00374979_12; Q412479; 5-amino-2-hydroxybenzoic acid,5-Aminosalicylic acid; Q-201355; SR-01000763486-3; SR-01000763486-4; SR-01000763486-9; Z57127471; F1918-0003; Mesalazine, European Pharmacopoeia (EP) Reference Standard; Mesalamine, United States Pharmacopeia (USP) Reference Standard; Mesalamine, Pharmaceutical Secondary Standard; Certified Reference Material; Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard; 51481-17-5" Small molecule "1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)" KBOPZPXVLCULAV-UHFFFAOYSA-N C1=CC(=C(C=C1N)C(=O)O)O C7H7NO3 CAS 89-57-6 CHEBI:6775 . . . DB00244 . DR1508 Edaravone D06DLI D06DLI Approved Motor neuron disease ICD-11: 8B60 CID: 4021 Anticancer Treatment "edaravone; 89-25-8; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 1-Phenyl-3-methyl-5-pyrazolone; Norphenazone; Radicut; MCI-186; Methylphenylpyrazolone; Developer Z; Norantipyrine; Phenylmethylpyrazolone; C.I. Developer 1; Phenyl methyl pyrazolone; 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; Radicava; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-; 5-methyl-2-phenyl-4H-pyrazol-3-one; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-Methyl-1-phenylpyrazol-5-one; 3-Methyl-1-phenyl-2-pyrazoline-5-one; NCI-C03952; 2-Pyrazolin-5-one, 3-methyl-1-phenyl-; 5-Pyrazolone, 3-methyl-1-phenyl-; Edaravone (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; MFCD00003138; 3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one; CHEBI:31530; NSC-2629; NSC-26139; Antipyrine related compound a; MLS000069602; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE (MCI-186); CI Developer 1; NCGC00164015-01; SMR000059020; DSSTox_CID_1130; DSSTox_RID_75961; DSSTox_GSID_21130; Monopyrazolone; WLN: T5NMV DHJ BR& E1; 1-Phenyl-3-methyl-2-pyrazolin-5-on; CAS-89-25-8; CCRIS 512; Radicut (TN); 3-Methyl-1-phenyl-2-pyrazolin-5-one, 99%; HSDB 4102; 3H-Pyrazol-3-one,4-dihydro-5-methyl-2-phenyl-; SR-01000000135; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; EINECS 201-891-0; BRN 0609575; AI3-03557; Radicava (TN); (MCI-186); CDS1_000986; PubChem13301; Spectrum_000267; Tocris-0786; MCI-186; Edaravone; Edaravone [USAN:INN]; Maybridge1_005738; Opera_ID_1057; Spectrum2_001574; Spectrum3_000971; Spectrum4_001091; Spectrum5_001217; M0687; EC 201-891-0; SCHEMBL4704; BSPBio_001235; BSPBio_002601; KBioGR_000575; KBioGR_001502; KBioSS_000575; KBioSS_000747; AE-641/00371017; MLS001146878; MLS002415675; MLS006011753; DivK1c_001018; DivK1c_002026; SPECTRUM1503635; SPBio_001508; CHEMBL290916; Edaravone (USAN/JP17/INN); DTXSID9021130; BCBcMAP01_000127; HMS503K17; HMS557M18; KBio1_001018; KBio2_000575; KBio2_000747; KBio2_003143; KBio2_003315; KBio2_005711; KBio2_005883; KBio3_001029; KBio3_001030; KBio3_001821; NSC2629; NINDS_001018; BCPP000246; Bio1_000438; Bio1_000927; Bio1_001416; Bio2_000448; Bio2_000928; HMS1362M17; HMS1792M17; HMS1990M17; HMS2234M19; HMS3266F04; HMS3403M17; HMS3411L05; HMS3654L15; HMS3675L05; HMS3884A11; Pharmakon1600-01503635; ACT07289; BCP26336; HY-B0099; NSC26139; Tox21_112077; Tox21_201747; Tox21_302819; BBL011741; BDBM50200541; CCG-39352; NSC758622; s1326; STK201315; ZINC18203737; 3-methyl-1-phenyl-2-pyrazolin-5one; AKOS000313817; Tox21_112077_1; AC-4745; BCP9000635; CS-1832; DB12243; NE10266; NSC-758622; SB19128; IDI1_001018; IDI1_002203; 1-PEHNYL-3-METHYL-5-PYRAZALONE; NCGC00018218-01; NCGC00018218-02; NCGC00018218-03; NCGC00018218-04; NCGC00018218-05; NCGC00018218-06; NCGC00018218-07; NCGC00018218-08; NCGC00018218-10; NCGC00018218-17; NCGC00022665-02; NCGC00022665-04; NCGC00022665-05; NCGC00022665-06; NCGC00256515-01; NCGC00259296-01; AK128848; ST012744; SBI-0051836.P002; DB-002517; AM20060748; FT-0608243; SW148216-2; 5-methyl-2-phenyl-2,4-dihydro-3-pyrazolone; 5-methyl-2-phenyl-2,4-dihydropyrazol-3-one; 3-Methyl-1-phenyl-2-pyrazoline-5-one, 99%; 4E-901; 5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one; C13008; D01552; AB00375776_14; AB00375776_15; 2 4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 2,4-dihydro-2-phenyl-5-methyl-3H-pyrazol-3-one; Q335099; Q-200386; SR-01000000135-2; SR-01000000135-3; SR-01000000135-5; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one #; BRD-K35458079-001-04-2; BRD-K35458079-001-12-5; BRD-K35458079-001-23-2; Z50145861; F0391-0021; 3-Methyl-1-phenyl-2-pyrazoline-5-one, SAJ special grade; 3-Methyl-1-phenyl-2-pyrazoline-5-one, purum, >=98.0% (NT); 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (Edaravone); Phenazone impurity A, European Pharmacopoeia (EP) Reference Standard; Antipyrine Related Compound A, United States Pharmacopeia (USP) Reference Standard" Small molecule "1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3" QELUYTUMUWHWMC-UHFFFAOYSA-N CC1=NN(C(=O)C1)C2=CC=CC=C2 C10H10N2O CAS 89-25-8 CHEBI:31530 . . . DB12243 . DR3561 LY294002 D09SFV D09SFV Phase 1 Adrenal cancer ICD-11: 2D11 CID: 3973 Anticancer Treatment "154447-36-6; LY294002; LY 294002; LY-294002; 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2-morpholino-8-phenyl-4H-chromen-4-one; 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one; UNII-31M2U1DVID; 2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one; NSC 697286; 31M2U1DVID; 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE; CHEMBL98350; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-; CHEBI:65329; LY2; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl; LY-294,002; 2-Morpholin-4-yl-8-phenyl-chromen-4-one; BMK1-D5; Lys 294002; 4azt; 2-morpholino-8-phenyl-chromen-4-one; 15447-36-6; SF 1101; Kinome_3543; PubChem16766; Tocris-1130; 1yi3; BiomolKI_000029; 2-(morpholin-4-yl)-8-phenylchromen-4-one; Lopac-L-9908; 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one; BiomolKI2_000037; cc-58; CBiol_002046; Lopac0_000710; SCHEMBL94377; BSPBio_001223; KBioGR_000563; KBioSS_000563; MLS006010131; 2-Morpholino-8-phenylchromone; 2-(4-morpholino)-8-phenyl-4H-1-benzopyran-4-one; GTPL6004; ZINC6014; DTXSID6042650; BCBcMAP01_000117; BDBM12915; KBio2_000563; KBio2_003131; KBio2_005699; KBio3_001005; KBio3_001006; EX-A073; SYN1108; BCPP000177; Bio1_000332; Bio1_000821; Bio1_001310; Bio2_000442; Bio2_000922; HMS1362M05; HMS1792M05; HMS1990M05; HMS3229G17; HMS3403M05; HMS3649E04; HMS3654M21; AMY40921; BCP00195; HSCI1_000206; NSC697286; NSC755769; s1105; AKOS017344742; BCP9000880; CCG-100633; CS-0150; DB02656; NSC-697286; NSC-755769; QC-7260; SB10965; SDCCGSBI-0050688.P003; SF-1101; IDI1_002197; NCGC00015622-01; NCGC00015622-02; NCGC00015622-03; NCGC00015622-04; NCGC00015622-05; NCGC00015622-06; NCGC00015622-07; NCGC00015622-23; NCGC00025020-01; NCGC00025020-02; NCGC00025020-03; NCGC00025020-04; NCGC00179253-01; AC-30295; AK162301; AS-16252; HY-10108; NCI60_034712; SMR002530642; AB0033714; LY-924002; FT-0660382; M2410; SW217688-2; X7411; EC-000.2341; 2-Morpholino-8-phenyl-4-oxo-4H-1-benzopyran; C15195; K00235; S-7706; J-510126; Q4042503; SR-01000076245-7; 4H-1-Benzopyran-4-one,2-(4-morpholinyl)-8-phenyl-; BRD-K27305650-001-05-9; InSolution LY 294002 - CAS 154447-36-6; LY-294,002 hydrochloride, solid, >=98% (HPLC); LY 294002 - CAS 154447-36-6; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); LY 294002; 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one" Small molecule "1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2" CZQHHVNHHHRRDU-UHFFFAOYSA-N C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4 C19H17NO3 CAS 154447-36-6 CHEBI:65329 . . . DB02656 . DR5656 Loxoprofen . . Phase 4 Ankylosing spondylitis ICD-11: FA92 CID: 3965 Anticancer Treatment "Loxoprofen; 68767-14-6; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; Loxoprofene; Loxoprofeno; Koloxo; Loxoprofenum; Loxoprofen [INN]; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; UNII-3583H0GZAP; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; MFCD00864331; CHEMBL19299; 3583H0GZAP; Loxoprofen sodium hydrate; CHEBI:76172; CS-600; sodium loxoprofen; Loxoprofen (INN); Oxeno; NCGC00015594-02; DSSTox_CID_25164; DSSTox_RID_80714; DSSTox_GSID_45164; Loxoprofene [French]; Loxoprofenum [Latin]; Loxoprofeno [Spanish]; yl]-propionic acid; CAS-68767-14-6; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; Loxoprofen, solid; 80382-23-6; Lopac0_000677; SCHEMBL24423; C15H17NaO3; (+-)-p-((2-Oxocyclopentyl)methyl)hydratropic acid; DTXSID1045164; alpha-Methyl-4-[(2-oxocyclopentyl)methyl]benzeneacetic acid; HMS3262G15; HMS3885N16; Loxoprofen (low-melting polymorph); BCP10971; EBD24378; HY-B0578; Loxoprofen (high-melting polymorph); Tox21_110178; Tox21_500677; ANW-43655; BDBM50140320; s4682; AKOS015906359; Tox21_110178_1; AC-8108; AT-7141; CCG-204763; DB09212; GS-3193; LP00677; SDCCGSBI-0050656.P002; NCGC00015594-03; NCGC00015594-04; NCGC00015594-08; NCGC00094037-01; NCGC00094037-02; NCGC00261362-01; NCGC00263577-01; AC-15776; AK-72809; H883; SY113439; AB0012364; DB-055188; EU-0100677; FT-0641207; L0244; CS-600; CS600; CS 600; D08149; L 0664; M-9376; (+-)-((2-oxocyclopentyl)methyl)hydratropic acid; 767L146; A836244; SR-01000075955; Q-201324; Q-300011; Q2759348; SR-01000075955-1; 2-[4-[(2-Oxocyclopentyl)methyl]phenyl]propionic Acid; 2-(4-((2-Oxocyclopentyl)methyl)-phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phenyl]-propionic acid; 2-[4-(2-oxocyclopentan-1-ylmethyl)phenyl]propionic acid; 2-[4-(2-Oxocyclopentan-1-ylmethyl)phenyl]-propionic Acid; 2-[4-[(2-oxidanylidenecyclopentyl)methyl]phenyl]propanoic acid; Benzeneacetic acid, alpha-methyl-4-((2-oxocyclopentyl)methyl)-; Benzeneacetic acid, .alpha.-methyl-4-[(2-oxocyclopentyl)methyl]-" Small molecule "1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)" YMBXTVYHTMGZDW-UHFFFAOYSA-N CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O C15H18O3 CAS 68767-14-6 CHEBI:76172 . . . DB09212 . DR1895 Losartan D0DD0K D0DD0K Approved Hypertension ICD-11: BA00-BA04 CID: 3961 Anticancer Treatment "losartan; 114798-26-4; DUP 89; Lortaan; Cozaar; LOSARTAN POTASSIUM; Hyzaar; UNII-JMS50MPO89; CHEBI:6541; MK-954; JMS50MPO89; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; DTXSID7023227; DuP 753; MFCD00865831; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; NCGC00095125-01; Losartan [INN:BAN]; DSSTox_CID_3227; DSSTox_RID_76933; DSSTox_GSID_23227; (1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; (1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)-; 1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; C22H23ClN6O; (1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; [3H]losartan; Losartan (INN); Losartic (TN); 2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL; [3H]-losartan; CAS-114798-26-4; SR-01000763170; lorastan; 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; [2-butyl-5-chloro-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; Losartan-[d3]; PubChem9176; Dup89; Spectrum_001713; SCHEMBL60; Spectrum2_001677; Spectrum3_000998; Spectrum4_001126; Spectrum5_001466; Epitope ID:140137; EC 601-329-8; Oprea1_644635; US9624243, Losartin; BSPBio_002695; GTPL590; KBioGR_001611; KBioSS_002193; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; BIDD:GT0286; SPECTRUM1504268; SPBio_001893; DUP-89; GTPL3941; BDBM82258; HSDB 7043; KBio2_002193; KBio2_004761; KBio2_007329; KBio3_001915; HGP1405; BCPP000183; BDBM318822; EX 89; HMS1922J13; HMS2093E22; HMS3715L11; Pharmakon1600-01504268; BCP27731; HGP-1405; NSC_3961; ZINC3873160; Tox21_111435; CCG-39095; NSC758699; s5067; STL419984; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; AKOS015917390; AKOS015994740; Tox21_111435_1; AB07507; BCP9000861; DB00678; KS-5004; MCULE-5204931675; NSC 758699; NSC-758699; (2-butyl-4-chloro-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; NCGC00095125-02; NCGC00095125-03; NCGC00095125-05; NCGC00095125-08; [2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; AK326126; HY-17512; I497; SBI-0206766.P001; AB0013723; CAS_114798-26-4; FT-0631074; C07072; D08146; 54244-EP2269989A1; 54244-EP2270011A1; 54244-EP2272841A1; 54244-EP2277879A1; 54244-EP2287165A2; 54244-EP2287166A2; 54244-EP2292620A2; 54244-EP2295053A1; 54244-EP2295406A1; 54244-EP2298772A1; 54244-EP2298776A1; 54244-EP2298779A1; 54244-EP2301923A1; 54244-EP2301931A1; 54244-EP2301936A1; 54244-EP2305219A1; 54244-EP2308562A2; 54244-EP2308839A1; AB01563296_01; 798L264; A803239; L000351; Q410074; Q-201321; SR-01000763170-3; SR-01000763170-4; BRD-K76205745-001-02-5; BRD-K76205745-001-04-1; F2173-0506; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolyl]methanol; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; (1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol; {2-Butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-yl}-methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); 2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol; 2-butyl-4-chloro-1-[2'-(2H-tetrazol-5-yl)-1,1'-biphenyl-4-ylmethyl]-1H- imidazole-5-methanol; 2-butyl-4-chloro-5-(hydroxymethyl)-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole" Small molecule "1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)" PSIFNNKUMBGKDQ-UHFFFAOYSA-N CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl C22H23ClN6O CAS 114798-26-4 CHEBI:6541 . . . DB00678 . DR7258 Leflunomide D08ROP D08ROP Approved Rheumatoid arthritis ICD-11: FA20 CID: 3899 Anticancer Treatment "leflunomide; 75706-12-6; Arava; lefunamide; Leflunomida; Leflunomidum; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; HWA 486; Leflunomidum [INN-Latin]; HWA-486; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide; SU101; Arava (TN); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; UNII-G162GK9U4W; SU-101; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; CHEMBL960; RS-34821; MLS000069648; CHEBI:6402; G162GK9U4W; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); MFCD00867593; NCGC00015610-02; SMR000058209; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-; CAS-75706-12-6; DSSTox_CID_3201; DSSTox_RID_76923; DSSTox_GSID_23201; Leflunomida [INN-Spanish]; SU 101 (pharmaceutical); Repso; Lefunomide [Inn-Spanish]; HSDB 7289; SR-01000000191; Arabloc; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; L04AA13; Prestwick_87; Leflunomide [USAN:USP:INN:BAN]; SU 101; SULOL; 1189987-23-2; Spectrum_000322; Opera_ID_1709; Prestwick0_000772; Prestwick1_000772; Prestwick2_000772; Prestwick3_000772; Spectrum5_000850; Lopac-L-5025; L 5025; SCHEMBL5057; BIDD:PXR0189; Lopac0_000649; BSPBio_000844; KBioSS_000802; Leflunomide, Immunosuppressant; MLS001076267; DivK1c_000916; Leflunomide (JAN/USP/INN); SPECTRUM1503927; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; SPBio_002783; BPBio1_000930; GTPL6825; ISO054; ZINC4840; DTXSID9023201; HMS502N18; KBio1_000916; KBio2_000802; KBio2_003370; KBio2_005938; AOB5964; NINDS_000916; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 5-methyl-n-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamid; HMS1570K06; HMS1922M06; HMS2090O12; HMS2097K06; HMS2235C07; HMS3262A19; HMS3268D12; HMS3371F21; HMS3414P03; HMS3654F07; HMS3673M17; HMS3678N21; HMS3714K06; HMS3865I13; Pharmakon1600-01503927; ALBB-019233; BCP22241; EBD46417; HY-B0083; Tox21_110182; Tox21_301873; Tox21_500649; ABP001076; BDBM50054601; DL-433; NSC677411; NSC759864; s1247; STL426823; AKOS000265193; Tox21_110182_1; AC-6796; BCP9000846; CCG-204736; CS-1781; DB01097; KS-1076; LP00649; MCULE-9490869974; NSC 677411; NSC 759864; NSC-677411; NSC-759864; SB17287; SDCCGSBI-0050629.P003; IDI1_000916; NCGC00015610-01; NCGC00015610-03; NCGC00015610-04; NCGC00015610-05; NCGC00015610-06; NCGC00015610-07; NCGC00015610-08; NCGC00015610-09; NCGC00015610-10; NCGC00015610-11; NCGC00015610-12; NCGC00015610-13; NCGC00015610-14; NCGC00015610-17; NCGC00015610-18; NCGC00015610-30; NCGC00022625-03; NCGC00022625-04; NCGC00022625-05; NCGC00022625-06; NCGC00022625-07; NCGC00022625-08; NCGC00255370-01; NCGC00261334-01; AK161855; H527; ST079287; Leflunomide 100 microg/mL in Acetonitrile; AB0007396; A9622; AB00052389; EU-0100649; FT-0621959; L0250; R3926; SW196399-3; C07905; D00749; MLS-0003109.0001; AB00052389-17; AB00052389-18; AB00052389_19; AB00052389_21; 706L126; Q248550; Q-201289; SR-01000000191-2; SR-01000000191-4; SR-01000000191-7; BRD-K78692225-001-03-9; BRD-K78692225-001-11-2; 5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole; 5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole; Leflunomide, European Pharmacopoeia (EP) Reference Standard; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide;; 5-Methyl-N-[4-(trifluoromethyl)-phenyl]isoxazole-4-carboxamide; 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide; N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide; (5-methylisoxazol-4-yl)-N-[4-(trifluoromethyl)phenyl]carboxamide; Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; Leflunomide, United States Pharmacopeia (USP) Reference Standard; HWA486; RS-34821; SU101;HWA 486; RS 34821; SU 101; Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material; Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard" Small molecule "1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)" VHOGYURTWQBHIL-UHFFFAOYSA-N CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F C12H9F3N2O2 CAS 75706-12-6 CHEBI:6402 . . . DB01097 . DR2114 Lamotrigine D03FLC D03FLC Approved Bipolar disorder ICD-11: 6A60 CID: 3878 Anticancer Treatment "lamotrigine; 84057-84-1; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamictal; Lamictal Cd; Lamictal XR; Lamotriginum [Latin]; Lamotrigina [Spanish]; Lamotriginum; BW 430C; BW-430C; Lamotrigina; Lamictal ODT; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; C9H7Cl2N5; LTG;BW430C; UNII-U3H27498KS; MFCD00865333; CHEMBL741; MLS000069685; CHEBI:6367; U3H27498KS; Lamotrigine, 98%; Lamotrigine-13C3; NCGC00015605-06; Labileno; Lamitor; SMR000058464; DSSTox_CID_3195; DSSTox_RID_76918; DSSTox_GSID_23195; Lamictal (TN); CAS-84057-84-1; BW430C; SR-01000000187; EINECS 281-901-8; HSDB 7526; EUR-1048; Lamotrigine [USAN:USP:INN:BAN]; zine-3,5-diamine; GI 267119X; 1188265-38-4; Lamotrigine-13C-d3; Opera_ID_12; Tocris-1611; hydroxymethyl progesterone; Lopac-L-3791; L 3791; Lopac0_000688; SCHEMBL35439; MLS000759486; MLS001077325; MLS001423991; BIDD:GT0794; Lamotrigine (JAN/USP/INN); Lamotrigine, >=98%, powder; GTPL2622; TRI020; DTXSID2023195; ZINC13156; HMS2051C10; HMS2089M08; HMS2093P21; HMS2230L04; HMS3262I17; HMS3268G17; HMS3371O16; HMS3393C10; HMS3657A17; HMS3715H21; HMS3885M03; Pharmakon1600-01505610; AMY40805; BCP12156; HY-B0495; Lamotrigine 1.0 mg/ml in Methanol; Tox21_110179; Tox21_500688; ANW-44921; BDBM50031299; NSC746307; NSC759171; s3024; STK628377; AKOS005561147; Tox21_110179_1; 6-(2,2,4-triazine-3,5-diyldiamine; CCG-100856; DB00555; KS-1074; LP00688; MCULE-7648410888; NC00106; NE61394; NSC 746307; NSC 759171; NSC-746307; NSC-759171; SDCCGSBI-0050666.P003; SMP2_000303; NCGC00015605-01; NCGC00015605-02; NCGC00015605-03; NCGC00015605-04; NCGC00015605-05; NCGC00015605-07; NCGC00015605-08; NCGC00015605-09; NCGC00015605-10; NCGC00015605-23; NCGC00015605-24; NCGC00022936-02; NCGC00022936-04; NCGC00022936-05; NCGC00261373-01; AC-10298; AC-32483; AK-72807; AT-15488; K499; Lamotrigine 100 microg/mL in Acetonitrile; SBI-0050666.P002; 6-(2,3-Dichloro-phenyl)-[1,2,4]tria; AB0014255; DB-014839; B2249; EU-0100688; FT-0602546; FT-0670713; FT-0670714; L-205; L0241; SW197486-3; 57L841; A11873; D00354; J10032; AB00384359-16; AB00384359_17; AB00384359_18; A840709; Q410346; 3,5-diamino-(2,3-dichlorophenyl)-1,2,4-triazine; Q-201221; SR-01000000187-2; SR-01000000187-4; SR-01000000187-7; BRD-K93460210-071-01-6; SR-01000000187-10; 3,5-diamino-6-(2,3,-dichlorophenyl)-1,2,4-triazine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine.; F2173-0540; Z1550648755; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine; 6-[2,3-bis(chloranyl)phenyl]-1,2,4-triazine-3,5-diamine; Lamotrigine, British Pharmacopoeia (BP) Reference Standard; Lamotrigine, European Pharmacopoeia (EP) Reference Standard; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine(lamotrigine); GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamotrigine, United States Pharmacopeia (USP) Reference Standard; Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material; Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard; Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard; Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material" Small molecule "1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)" PYZRQGJRPPTADH-UHFFFAOYSA-N C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N C9H7Cl2N5 CAS 84057-84-1 CHEBI:6367 . . . DB00555 . DR5623 Ketamine D0UM7O D0UM7O Approved Corneal disease ICD-11: 9A78 CID: 3821 Anticancer Treatment "ketamine; Ketaject; Ketalar; dl-Ketamine; CI 581 base; Special K; (+-)-Ketamine; Ketaminum; CLSTA 20; Ketanest; 6740-88-1; Ketalar base; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-Ketamine; KETAMINE HCL; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; Ketolar; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; NSC 70151; CHEMBL742; CHEBI:6121; Calypsol; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-; NSC-70151; 100477-72-3; DEA No. 7285; NCGC00159480-02; NCGC00159480-03; Cetamina; Ketamine Base; Ketamine [INN:BAN]; DSSTox_CID_3187; Ketaminum [INN-Latin]; Cetamina [INN-Spanish]; DSSTox_RID_76912; Special K [street name]; DSSTox_GSID_23187; Ketoject; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI); Ketamine (INN); PMI-150; CAS-6740-88-1; Tekam (TN); EINECS 229-804-1; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; BRN 2216965; ketamina; HSDB 2180; Ketolar (Salt/Mix); Vetalar (Salt/Mix); Kalipsol (Salt/Mix); Ketanest (Salt/Mix); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+-)-; (.+/-.)-Ketamine; EC 229-804-1; Cyclohexanone, (.+-.)-; SCHEMBL16103; MLS001331674; DivK1c_000217; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-; GTPL4233; (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; DTXSID8023187; SCHEMBL17084881; KBio1_000217; NINDS_000217; HMS2272G05; NSC70151; Tox21_111703; Tox21_111704; BDBM50044140; DB01221; MCULE-4905246871; IDI1_000217; SMR000238141; C07525; D08098; Q243547; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone #; J-505587; (.+/-.)-2-(O-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone(Ketamine); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+/-)-; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)" Small molecule "1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3" YQEZLKZALYSWHR-UHFFFAOYSA-N CNC1(CCCCC1=O)C2=CC=CC=C2Cl C13H16ClNO CAS 6740-88-1 CHEBI:6121 . . . DB01221 . DR3313 Isoniazid D09XQF D09XQF Approved HIV-infected patients with tuberculosis ICD-11: 1B10-1B1Z CID: 3767 Anticancer Treatment "isoniazid; 54-85-3; Isonicotinic acid hydrazide; Isonicotinohydrazide; pyridine-4-carbohydrazide; Isoniazide; Nydrazid; Rimifon; Isonicotinic hydrazide; Laniazid; Isonicotinylhydrazine; Andrazide; Cotinazin; Dinacrin; Hydrazid; Neoteben; Nicizina; Nicotibina; Nicozide; Pycazide; Tubazide; Ditubin; Iscotin; Isolyn; Isonex; Mybasan; Niconyl; Hyzyd; Isonicotinhydrazid; Antimicina; Atcotibine; Chemiazid; Hidranizil; Hidrasonil; Hydrazide; Isobicina; Isocidene; Isohydrazide; Isonicotan; Isonicotil; Isonidrin; Isonikazid; Isonindon; Isonizide; Isotebezid; Neumandin; Pyricidin; Pyrizidin; Stanozide; Armazid; Armazide; Cemidon; Chemidon; Defonin; Diforin; Ebidene; Ertuban; Eutizon; Fimalene; Hidrulta; Hycozid; Idrazil; Isidrina; Ismazide; Isocotin; Isonerit; Isonicid; Isonico; Isonide; Isonilex; Isonirit; Isoniton; Isozide; Niadrin; Nicetal; Nidaton; Nidrazid; Nikozid; Nitadon; Nyscozid; Pelazid; Raumanon; Retozide; Rimicid; Rimitsid; Tubazid; Azuren; Cedin; Eralon; Evalon; Hidrun; Inizid; Isocid; Isonin; Isozyd; Neoxin; Nevin; Niplen; Antituberkulosum; Inah; Ido-tebin; 4-Pyridinecarboxylic acid, hydrazide; Bacillin; Isoniacid; Isotinyl; Nicazide; Nicotibine; Nicotisan; Phthisen; Pyreazid; Rimiphone; Tubilysin; Isotebe; Percin; Razide; Tyvid; Isoniazid SA; Neo-Tizide; GINK; Armacide; Cortinazine; Cotinizin; Isonicazide; Isotamine; Robisellin; Sauterazid; Teebaconin; Tibinide; Unicozyde; Vazadrine; Zonazide; Dibutin; Hyozid; Isonicotinoyl hydrazide; Tebecid; Tekazin; Tubeco; Tubicon; Tubomel; Vederon; Zinadon; Preparation 6424; Isonicotinyl hydrazide; TB-Razide; Sanohidrazina; Tisiodrazida; Laniozid; Niteban; Pyridicin; Robiselin; Roxifen; Sauterzid; Tebenic; Tebexin; Tebilon; Tibazide; Tibison; Tibivis; Tibizide; Tibusan; Tuberian; Tubizid; Unicocyde; Tebos; Tisin; Tizide; 4-Pyridinecarboxylic acid hydrazide; Dow-Isoniazid; FSR 3; TB-Vis; Inh-Burgthal; INH; TB-Phlogin; Zidafimia; Isokin; Nitebannsc 9659; In-73; RU-EF-Tb; isonicotinoylhydrazide; Isonicotinoylhydrazine; 4-Pyridinecarbonylhydrazine; BP 5015; FSR-3; Isonicotinsaeurehydrazid; 4-(Hydrazinocarbonyl)pyridine; 4-pyridinecarbohydrazide; 4-Pyridylcarbonylhydrazide; NSC 9659; MFCD00006426; HIA; RP-5015; UNII-V83O1VOZ8L; pyridine-4-carboxylic acid hydrazide; Isonicotinylhydrazide; L 1945; 5015 RP; CHEBI:6030; isonicotinate hydrazide; 5015 R.P.; CHEMBL64; V83O1VOZ8L; MLS000069444; Isozid; NSC9659; Isoniazid-d4; NSC-9659; Cedin (Aerosol); CAS-54-85-3; bacillen; tebemid; tubercid; NCGC00016244-09; Continazine; Isoniazidum; Tubecotubercid; Abdizide; Anidrasona; Isoniazida; Isonizida; SMR000059082; Tibemid; Tibiazide; Fetefu; Hydra; DSSTox_CID_755; DSSTox_RID_75771; DSSTox_GSID_20755; LANIZID; 4-Pyridinecarboxylic hydrazide; Isonicotinic acid hydrazide, 99%; RY-EF-Tb; Isoniazidum [INN-Latin]; Isoniazida [INN-Spanish]; AZT + Isoniazid; FRS-3; Isoniazid(Tubizid); Laniazid (TN); CCRIS 351; Usaf cb-2; HSDB 1647; Isonicotinsaeurehydrazid [German]; INHd20; SR-01000003025; EINECS 200-214-6; RP 5015; Mayambutol; AI3-23936; I.A.I.; Idrazide dell'acido isonicotinico [Italian]; isoniazid (inh); Isoniazid/INH; Idrazide dell'acido isonicotinico; Isoniazid [USP:INN:BAN:JAN]; isonicotinhydrazide; Soniazid,(S); NIZ; Prestwick_578; Isoniazid (Tubizid); Rifater (Salt/Mix); Isonicotinic acid hydrazide (Isoniazid); Spectrum_000853; ACMC-209ljq; Opera_ID_454; isonicotinicacid hydrazide; isonicotinic acid hydrazid; Prestwick0_000161; Prestwick1_000161; Prestwick2_000161; Prestwick3_000161; Spectrum2_000107; Spectrum3_000472; Spectrum4_000022; Spectrum5_000876; I0138; WLN: T6NJ DVMZ; isonicotinic acid hydrazone; SCHEMBL228; Biomol-NT_000288; Epitope ID:141801; 4-Pyridylcarbonyl hydrazide; Oprea1_396155; BSPBio_000021; BSPBio_002204; KBioGR_000423; KBioSS_001333; MLS001055327; ARONIS25141; BIDD:GT0140; DivK1c_000070; SPECTRUM1500355; SPBio_000094; SPBio_001942; Isoniazid (JP17/USP/INN); BPBio1_000025; BPBio1_001322; SCHEMBL2998929; ZINC1590; component of Niadox (Salt/Mix); DTXSID8020755; HMS500D12; KBio1_000070; KBio2_001333; KBio2_003901; KBio2_006469; KBio3_001424; NINDS_000070; HMS1568B03; HMS1920H09; HMS2089I16; HMS2091N19; HMS2095B03; HMS2234G04; HMS3259E19; HMS3373O01; HMS3655L03; HMS3712B03; KUC109571N; Pharmakon1600-01500355; 4-pyridinecarbohydrazide(Isoniazid); BCP13791; HY-B0329; STR00210; [(4-Pyridinylcarbonyl)oxy]hydrazine; Anti-TNF monoclonal antibody & INH; Tox21_113640; Tox21_201367; Tox21_300193; ANW-32196; BBL008409; BDBM50336507; CCG-39710; NSC757078; s1937; SBB004195; STK086288; AKOS000119062; Isonicotinic acid hydrazide(Isoniazid); Tox21_113640_1; DB00951; KSC-27-048; MCULE-6324947959; NC00513; NSC-757078; PS-4129; IDI1_000070; UPCMLD0ENAT5791176:001; NCGC00016244-01; NCGC00016244-02; NCGC00016244-03; NCGC00016244-04; NCGC00016244-05; NCGC00016244-06; NCGC00016244-07; NCGC00016244-08; NCGC00016244-10; NCGC00016244-11; NCGC00016244-12; NCGC00016244-14; NCGC00016244-15; NCGC00022648-03; NCGC00022648-04; NCGC00022648-05; NCGC00022648-06; NCGC00022648-07; NCGC00254094-01; NCGC00258919-01; AK-46317; ST078858; SY010614; Isoniazid, Vetec(TM) reagent grade, 98%; SBI-0051419.P003; [NH-]NC(=[OH+])C1=CC=NC=C1; AB00052025; BB 0240534; FT-0627424; FT-0670476; SW196752-3; T7976; ISONICOTINIC ACID HYDRAZIDE(ISONIAZIDE); C07054; D00346; Isoniazid, analytical standard, >=99% (TLC); 10319-EP2272972A1; 10319-EP2272973A1; 10319-EP2274983A1; 10319-EP2275102A1; 10319-EP2275401A1; 10319-EP2277872A1; 10319-EP2280000A1; 10319-EP2280012A2; 10319-EP2281563A1; 10319-EP2289510A1; 10319-EP2289876A1; 10319-EP2295407A1; 10319-EP2295411A1; 10319-EP2295416A2; 10319-EP2295433A2; 10319-EP2298312A1; 10319-EP2298736A1; 10319-EP2298747A1; 10319-EP2298748A2; 10319-EP2301536A1; 10319-EP2301538A1; 10319-EP2301924A1; 10319-EP2305640A2; 10319-EP2305642A2; 10319-EP2305808A1; 10319-EP2308852A1; 10319-EP2311455A1; 10319-EP2311824A1; 10319-EP2311830A1; 10319-EP2314584A1; 10319-EP2316452A1; 10319-EP2316459A1; 10319-EP2380872A1; 40687-EP2298761A1; 40687-EP2311830A1; AB00052025-20; AB00052025-21; AB00052025_22; AB00052025_23; AB00052025_24; AB00052025_25; 101033-EP2272832A1; 101033-EP2272972A1; 101033-EP2272973A1; 101033-EP2277872A1; 101033-EP2295053A1; 101033-EP2298776A1; 101033-EP2301544A1; AE-641/02310003; Q423169; SR-01000003025-2; SR-01000003025-3; BRD-K87202646-001-26-8; Isoniazid, certified reference material, TraceCERT(R); Z58981801; F0391-0007; Isoniazid, European Pharmacopoeia (EP) Reference Standard; Isoniazid, United States Pharmacopeia (USP) Reference Standard; Isoniazid, Pharmaceutical??Secondary??Standard;??Certified??Reference??Material" Small molecule "1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)" QRXWMOHMRWLFEY-UHFFFAOYSA-N C1=CN=CC=C1C(=O)NN C6H7N3O CAS 54-85-3 CHEBI:6030 . . . DB00951 . DR1897 Ipriflavone D0R2OA D0R2OA Approved Low bone mass disorder ICD-11: FB83 CID: 3747 Anticancer Treatment "ipriflavone; 35212-22-7; Osten; Osteofix; Yambolap; 7-Isopropoxyisoflavone; Iprosten; Ipriflavonum; Ipriflavona; Osteoquine; 7-isopropoxy-3-phenyl-4H-chromen-4-one; 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one; Ipriflavone (Osteofix); Ipriflavone [INN:JAN]; 3-phenyl-7-propan-2-yloxychromen-4-one; Osten (TN); Osteochin; TC 80; 7-(1-Methylethoxy)-3-phenyl-4H-1-benzopyran-4-one; UNII-80BJ7WN25Z; FL 113; FL-113; MLS000069470; 3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one; SMR000059060; 4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-; 80BJ7WN25Z; CHEBI:31719; MFCD00221719; NCGC00024094-04; Quinogin; DSSTox_CID_20679; DSSTox_RID_79537; DSSTox_GSID_40679; Iprivone; Ostivone; Ipriflavonum [INN-Latin]; Ipriflavona [INN-Spanish]; CAS-35212-22-7; CCRIS 1920; BRN 4754346; Ipriflavon; (Ipriflavone); Ipriflavone, INN; 7-Isoproxyisoflavone; 7-isopropoxy-isoflavone; 7-isopropyloxy-isoflavone; Ipriflavone (JAN/INN); Opera_ID_1176; Ipriflavone (JP17/INN); Cambridge id 6663564; cid_3747; Oprea1_106310; Oprea1_275552; MLS000759494; MLS001146879; MLS001424060; MLS006011644; SCHEMBL111472; 7-isopropoxy-3-phenyl-chromone; CHEMBL165790; ZINC4016; Ipriflavone, analytical standard; DTXSID5040679; BDBM43662; SFBODOKJTYAUCM-UHFFFAOYSA-; FL113; HMS2051J15; HMS2234M05; HMS3371E17; HMS3393J15; HMS3656K19; HMS3715D04; TC-80; TN-39; AMY25650; HY-N0094; Tox21_111532; Tox21_113172; ANW-41668; s2422; STL512460; AKOS003627375; Tox21_111532_1; Tox21_113172_1; AC-8130; CCG-100963; CS-6395; DB13618; MCULE-4241728982; NC00213; NSC 755888; VA11103; 7-(methylethoxy)-3-phenylchromen-4-one; NCGC00018139-01; NCGC00018139-02; NCGC00018139-03; NCGC00018139-04; NCGC00018139-05; NCGC00018139-07; NCGC00018139-08; AK555354; AS-12306; ST083683; 3-phenyl-7-propan-2-yloxy-chromen-4-one; DB-048754; FT-0621442; I0669; SW197593-2; 3-phenyl-7-propan-2-yloxy-1-benzopyran-4-one; D01338; AB00384280-21; 212I227; SR-01000000042; 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one 97%; Q1097778; SR-01000000042-2; 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one, 97%; F0196-0909" Small molecule "1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3" SFBODOKJTYAUCM-UHFFFAOYSA-N CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3 C18H16O3 CAS 35212-22-7 CHEBI:31719 . . . DB13618 . DR4184 Indomethacin D0R1RS D0R1RS Approved Rheumatoid arthritis ICD-11: FA20 CID: 3715 Anticancer Treatment "indomethacin; 53-86-1; indometacin; Indocin; Indometacine; Indomethacine; Indocid; Metindol; Indomethazine; Imbrilon; Amuno; Tannex; Indomethacinum; Artracin; Artrinovo; Artrivia; Confortid; Idomethine; Indomecol; Indoptic; Indoptol; Inflazon; Infrocin; Metartril; Methazine; Mikametan; Reumacide; Sadoreum; Dolovin; Inacid; Indacin; Indomed; Indomee; Lausit; Metacen; Mobilan; Indo-rectolmin; Indo-tablinen; Inteban sp; Indometacyna; Indometicina; Mezolin; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-; 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid; Indometacina; Indometacinum; Dolcidium; Durametacin; Elmetacin; Indomethine; Indorektal; Catlep; Indoxen; Vonum; Indo-phlogont; Chibro-amuno; Rheumacin LA; Osmosin; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid; MFCD00057095; CCRIS 3502; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; HSDB 3101; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; NCI-C56144; UNII-XXE1CET956; CHEMBL6; 1-(p-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid; IMN; Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid; Indo-Lemmon; [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid; Indocin Sr; XXE1CET956; N-p-Chlorbenzoyl-5-methoxy-2-methylindole-3-acetic acid; MLS000069402; Indomethacin (Indocid, Indocin); (1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetic acid; CHEBI:49662; 1-(p-Chlorobenzoyl)-2-methoxy-3-methyl-1H-indole-3-acetic Acid; Indomet 140; alpha-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid; {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid; CAS-53-86-1; 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico; NCGC00015562-18; Indmethacine; Indomethancin; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid; Arthrexin; Bonidin; Bonidon; Indameth; Indomod; Miametan; SMR000058195; Indomo; Flexin continus; Hicin; Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy; Chrono-indicid; Chrono-indocid; Indometacyna [Polish]; DSSTox_CID_740; Bonidon Gel; Indometicina [Spanish]; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid; Dolcidium PL; Indo-Spray; Indolar SR; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1h-indol-3-yl}acetic acid; DSSTox_RID_75763; DSSTox_GSID_20740; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indometacina [INN-Spanish]; 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid; Tivorbex; Aconip; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]acetic acid; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl}acetic acid; Indocin-SR; Indochron E-R; Indocin (TN); Aconip (TN); Indomethacin (USP); FLAM; NSC-77541; Indocid (pharmaceutical); SR-01000000014; EINECS 200-186-5; Indomethacin & MAP-30; Indomethacin [USAN:USP]; BRN 0497341; Indocollyre; Indonol; Innamit; Inteban; 2-{1-((4-chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl}acetic acid; 4kyk; Indomethacin,(S); Prestwick_597; Indometacin [INN]; Opera_ID_56; PubChem17620; Spectrum_000919; Tocris-1708; 1z9h; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure [German]; 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico [Spanish]; Prestwick0_000272; Prestwick1_000272; Prestwick2_000272; Prestwick3_000272; Spectrum2_000970; Spectrum3_000468; Spectrum4_000018; Spectrum5_000868; Lopac-I-7378; Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy [Polish]; MolMap_000032; UPCMLD-DP023; EC 200-186-5; I 7378; Indometacin (JP17/INN); SCHEMBL9300; Lopac0_000692; Oprea1_686105; BSPBio_000144; BSPBio_001149; BSPBio_002176; KBioGR_000395; KBioGR_000489; KBioSS_000489; KBioSS_001399; 5-22-05-00239 (Beilstein Handbook Reference); MLS001074194; MLS006011845; ARONIS27005; BIDD:GT0132; DivK1c_000271; SPECTRUM1500350; SPBio_000979; SPBio_002363; BPBio1_000160; GTPL1909; DTXSID9020740; Indomethacin, >=99% (TLC); UPCMLD-DP023:001; BDBM17638; CGIGDMFJXJATDK-UHFFFAOYSA-; HMS500N13; KBio1_000271; KBio2_000489; KBio2_001399; KBio2_003057; KBio2_003967; KBio2_005625; KBio2_006535; KBio3_000897; KBio3_000898; KBio3_001396; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure; Indomethacin - CAS 53-86-1; NINDS_000271; Bio2_000405; Bio2_000885; HMS1362I11; HMS1568H06; HMS1792I11; HMS1920F21; HMS1990I11; HMS2089N19; HMS2091N09; HMS2095H06; HMS2231J10; HMS3262K05; HMS3268A14; HMS3374F07; HMS3403I11; HMS3414N13; HMS3430L03; HMS3649K17; HMS3655O04; HMS3678N11; HMS3712H06; HMS3747K21; HMS3884E08; Pharmakon1600-01500350; ZINC601283; ACT02579; BCP18951; Indomethacin, >=99.0% (TLC); Tox21_113109; Tox21_201791; Tox21_300266; Tox21_500692; AC-532; ANW-42683; CCG-40186; NSC757061; s1723; SBB057417; STL257874; AKOS000592893; Tox21_113109_1; DB00328; Indometacin 1.0 mg/ml in Acetonitrile; KS-5255; LP00692; MCULE-5636486088; NE11089; NSC 757061; NSC-757061; SDCCGSBI-0050670.P005; IDI1_000271; IDI1_002160; NCGC00015562-01; NCGC00015562-02; NCGC00015562-03; NCGC00015562-04; NCGC00015562-05; NCGC00015562-06; NCGC00015562-07; NCGC00015562-08; NCGC00015562-09; NCGC00015562-10; NCGC00015562-11; NCGC00015562-12; NCGC00015562-13; NCGC00015562-14; NCGC00015562-15; NCGC00015562-16; NCGC00015562-17; NCGC00015562-19; NCGC00015562-20; NCGC00015562-21; NCGC00015562-22; NCGC00015562-24; NCGC00015562-25; NCGC00015562-40; NCGC00024135-02; NCGC00024135-04; NCGC00024135-05; NCGC00024135-06; NCGC00024135-07; NCGC00024135-08; NCGC00024135-09; NCGC00024135-10; NCGC00024135-11; NCGC00024135-12; NCGC00024135-13; NCGC00024135-14; NCGC00024135-15; NCGC00254075-01; NCGC00259340-01; NCGC00261377-01; BP-30207; H911; HY-14397; NCI60_041708; SBI-0050670.P004; DB-052413; AB00052022; EU-0100692; FT-0603227; I0655; ST50320042; SW196768-5; Indomethacin, meets USP testing specifications; BIM-0050670.0001; C01926; D00141; J10170; S00108; AB00052022-20; AB00052022-21; AB00052022_23; AB00052022_24; L000959; Q409231; Indomethacin, Antibiotic for Culture Media Use Only; Q-201239; SR-01000000014-2; SR-01000000014-4; SR-01000000014-6; BRD-K57222227-001-06-1; BRD-K57222227-001-18-6; BRD-K57222227-001-27-7; SR-01000000014-10; SR-01000000014-16; Z56784896; 1-p-chlorobenzoyl-2-methyl-5-methoxyindol-3-acetic acid; 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indoleacetic acid; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindol-3-acetic acid; 1-(4-chloro-benzoyl)-5-methoxy-2-methyl-3-indolyl-acetic acid; 1-(4-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid; 1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indole-acetic acid; 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indol acetic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methyl-Indole-3-acetic acid; Indomethacin, European Pharmacopoeia (EP) Reference Standard; N-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid; Indomethacin, United States Pharmacopeia (USP) Reference Standard; .alpha.-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid; [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid #; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid & MAP-30; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9CI); 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2 methylindol-3-yl}acetic acid; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2methylindol-3-yl}acetic acid; Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8CI); Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)" CGIGDMFJXJATDK-UHFFFAOYSA-N CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O C19H16ClNO4 CAS 53-86-1 CHEBI:49662 . . . DB00328 . DR3248 Imipramine D06ZUK D06ZUK Approved Depression ICD-11: 6A70-6A71 CID: 3696 Anticancer Treatment "imipramine; Melipramine; Imidobenzyle; 50-49-7; Antideprin; Berkomine; Dimipressin; Melipramin; Tofranil; Intalpram; Nelipramin; Dynaprin; Janimine; Timolet; Irmin; Dpid; Dyna-zina; Impramine; Promiben; Censtim; Censtin; Imiprin; Iramil; Imipramina; Declomipramine; Eupramin; Imipramin; Imipraminum; Psychoforin; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Imavate; Imizine; Surplix; Imizin; Tofranil, base; Imipramine Hcl; Tofranil-PM; Imizinum; Pramine; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; Tofranil (free base); SK-Pramine; UNII-OGG85SX4E4; NSC 169866; CHEMBL11; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; OGG85SX4E4; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; CHEBI:47499; 5,e)azepine; 5,e]azepine; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; Imipramine-d6; Imidol; NSC-169866; 113-52-0 (HCl); NCGC00015563-07; Imipramina [Italian]; Tofranil (TN); 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE; N-(.gamma.-Dimethylaminopropyl)iminodibenzyl; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; Imipramine [INN:BAN]; DSSTox_CID_23881; DSSTox_RID_80080; DSSTox_GSID_43881; Imipraminum [INN-Latin]; Imipramina [INN-Spanish]; 3-(10,11-dihydro-5h-dibenz[b,f]azepin-5-yl)propyldimethylamine; G-22355; 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride; CAS-50-49-7; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine;3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Imipramine (INN); CCRIS 9173; HSDB 3100; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine; Janimine (hydrochloride); Tofranil (hydrochloride); CAS-113-52-0; EINECS 200-042-1; BRN 0256892; 5H-Dibenz(b, 5-(3-(dimethylamino)propyl)-10,11-dihydro-; 5H-Dibenz[b, 5-[3-(dimethylamino)propyl]-10,11-dihydro-; Tofranil base; 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-; Imipramine-d3 HCl; Imizin (Salt/Mix); Imavate (Salt/Mix); Imizine (Salt/Mix); Surplix (Salt/Mix); Eupramin (Salt/Mix); Imizinum (Salt/Mix); Tofranil (Salt/Mix); PubChem21397; Spectrum_000915; Psychoforin (Salt/Mix); Prestwick0_000072; Prestwick1_000072; Prestwick2_000072; Prestwick3_000072; SK-Pramine (Salt/Mix); Spectrum2_000990; Spectrum3_000466; Spectrum4_000016; Spectrum5_000864; Lopac-I-7379; Lopac0_000702; Oprea1_200908; SCHEMBL34282; BSPBio_000283; BSPBio_002172; GTPL357; KBioGR_000391; KBioSS_001395; BIDD:GT0116; DivK1c_000559; SPBio_001059; SPBio_002204; G-22355 (Salt/Mix); BPBio1_000313; Clomipramine HCl EP Impurity B; DTXSID1043881; KBio1_000559; KBio2_001395; KBio2_003963; KBio2_006531; KBio3_001392; ZINC20245; NINDS_000559; HMS2089G08; ORG-2463; Tox21_110174; BDBM50010859; CCG-36485; MFCD31699979; NSC169866; STL416211; AKOS016010320; N,N-Dimethyl-10,11-dihydro-5H-dibenzo[b,f]azepine-5-propanamine-2,8-D2; Tox21_110174_1; DB00458; MCULE-9471074673; SDCCGSBI-0050680.P005; IDI1_000559; MRF-0000592; NCGC00015563-01; NCGC00015563-02; NCGC00015563-03; NCGC00015563-04; NCGC00015563-05; NCGC00015563-06; NCGC00015563-08; NCGC00015563-09; NCGC00015563-10; NCGC00015563-11; NCGC00015563-13; NCGC00015563-25; NCGC00024253-03; NCGC00024253-04; 112898-42-7; 2241983-10-6; 5-(3-Dimethylaminopropyl)-10,f)azepine; SY246340; Trimipramine maleate impurity, imipramine-; SBI-0050680.P004; WLN: T C676 BN&T&J B3N1&1; 5-(3-(Dimethylamino)propyl)-10,f)azepine; AB00053486; FT-0670319; FT-0697093; W0042; 5H-Dibenz[b, 10,11-dihydro-N,N-dimethyl-; C07049; D08070; Q58396; AB00053486-15; AB00053486_16; AB00053486_17; 1-(3-Dimethylaminopropyl)-4,3,6,7-dibenzazepine; L000739; W-109253; BRD-K38436528-003-05-5; BRD-K38436528-003-15-4; 5H-Dibenz(b, 10,11-dihydro-5-(3-(dimethylamino)propyl)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl- (9CI); 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine #; 5H-Dibenz(b,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; Clomipramine EP Impurity B; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine; 5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz[b,f]azepine;10,11-Dehydroimipramine;Depramine" Small molecule "1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3" BCGWQEUPMDMJNV-UHFFFAOYSA-N CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31 C19H24N2 CAS 50-49-7 CHEBI:47499 . . . DB00458 . DR2911 Lidocaine D0X4RN D0X4RN Approved Corneal disease ICD-11: 9A78 CID: 3676 Anticancer Treatment "lidocaine; 137-58-6; Lignocaine; Xylocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Lidoderm; Anestacon; Esracaine; Duncaine; Alphacaine; Cappicaine; Gravocain; Isicaina; L-Caine; Leostesin; Maricaine; Xylocain; Xylocitin; Solcain; Isicaine; Xylestesin; Rucaina; Xilina; Xycaine; Xylotox; Cito optadren; Lida-Mantle; Dalcaine; 2-(Diethylamino)-2',6'-acetoxylidide; Xyloneural (free base); Cuivasil; Jetocaine; Remicaine; Xilocaina; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-; Diethylaminoaceto-2,6-xylidide; ELA-Max; 2',6'-Acetoxylidide, 2-(diethylamino)-; alpha-Diethylamino-2,6-dimethylacetanilide; Lidocaton; alfa-Dietilamino-2,6-dimetilacetanilide; CHEBI:6456; UNII-98PI200987; Xylocaine (TN); CHEMBL79; LIDOPEN; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; MLS000069724; Dentipatch; Lignocainum; Xllina; NSC-40030; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; Lidocaine (VAN); .alpha.-Diethylaminoaceto-2,6-xylidide; NCGC00015611-10; Xilocaina [Italian]; Dilocaine; Lidocaina; Lidocaine, 97.5%; Lidocainum; SMR000058189; .alpha.-(Diethylamino)-2,6-acetoxylidide; Lidocaine Base; .alpha.-Diethylamino-2,6-dimethylacetanilide; .omega.-Diethylamino-2,6-dimethylacetanilide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide; 98PI200987; Lidocainum [INN-Latin]; DSSTox_CID_25166; DSSTox_RID_80716; DSSTox_GSID_45166; Lidocaina [INN-Spanish]; N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamide; 2-(Diethylamino)-N-(2,6-Dimethylphenyl)ethanamide; EMBOLEX; Versatis; Ztilido; ZTlido; Dentipatch (TN); CAS-137-58-6; LQZ; HSDB 3350; EINECS 205-302-8; NSC 40030; alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; BRN 2215784; Qualigens; Xyline; Lignocaine base; LidocaineHClH2O; Lidocaine [USP:INN:BAN:JAN]; Lidocaine, powder; Lidocaine-D10; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; N1-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide; Zingo (Salt/Mix); MFCD00026733; 851528-09-1; CDS1_000283; Lidocaine (Alphacaine); Spectrum_001118; Lidothesin (Salt/Mix); Xyloneural (Salt/Mix); Opera_ID_385; Maybridge1_002571; Prestwick0_000050; Prestwick1_000050; Prestwick2_000050; Prestwick3_000050; Spectrum2_001343; Spectrum3_001392; Spectrum4_000070; Spectrum5_001549; Lopac-L-5647; Lidaform HC (Salt/Mix); Epitope ID:116205; Lidamantle HC (Salt/Mix); 2', 2-(diethylamino)-; Neosporin Plus (Salt/Mix); Lopac0_000669; SCHEMBL15689; BSPBio_000179; BSPBio_001359; BSPBio_003004; KBioGR_000079; KBioGR_000599; KBioSS_000079; KBioSS_001598; 4-12-00-02538 (Beilstein Handbook Reference); MLS000758263; MLS001074177; MLS001423964; ARONIS23855; BIDD:GT0342; Diethylaminoacet-2,6-xylidide; DivK1c_000174; DivK1c_001323; Lidocaine, analytical standard; SPBio_001525; SPBio_002100; Lidocaine (JP17/USP/INN); ALGRX 3268; ALGRX-3268; BPBio1_000197; GTPL2623; DTXSID1045166; SCHEMBL17967359; HMS548M19; KBio1_000174; KBio2_000079; KBio2_001598; KBio2_002647; KBio2_004166; KBio2_005215; KBio2_006734; KBio3_000157; KBio3_000158; KBio3_002224; ZINC20237; Lidocaine 1.0 mg/ml in Methanol; NINDS_000174; Bio1_000379; Bio1_000868; Bio1_001357; Bio2_000079; Bio2_000559; HMS1791D21; HMS1989D21; HMS2051C21; HMS2089E15; HMS2235O14; HMS3371J04; HMS3393C21; HMS3428O07; HMS3651G09; AMY25560; BCP09081; HY-B0185; NSC40030; Tox21_110183; ANW-42187; BBL005525; BDBM50017662; NSC789222; s1357; SBB080556; STK552033; AKOS001026768; Tox21_110183_1; CCG-100824; CS-2070; DB00281; MCULE-9294700940; NC00074; NSC-789222; SB19118; SDCCGSBI-0050648.P005; WLN: 2N2 & 1VMR B1 F1; .alpha.-Diethylamino-2,6-acetoxylidide; CAS-73-78-9; IDI1_000174; IDI1_033829; NCGC00015611-01; NCGC00015611-02; NCGC00015611-03; NCGC00015611-04; NCGC00015611-05; NCGC00015611-06; NCGC00015611-07; NCGC00015611-08; NCGC00015611-09; NCGC00015611-11; NCGC00015611-12; NCGC00015611-13; NCGC00015611-14; NCGC00015611-15; NCGC00015611-16; NCGC00015611-18; NCGC00015611-31; NCGC00022176-05; NCGC00022176-06; NCGC00022176-07; NCGC00022176-08; NCGC00022176-09; AC-10282; AS-13718; M620; ST023341; 2-(Diethylamino)-2'',6''-acetoxylidide; SBI-0050648.P004; AB00053581; L0156; SW196598-4; A18187; C07073; D00358; J10173; K-4450; M06299; AB00053581-27; AB00053581-28; AB00053581_29; AB00053581_30; Q216935; (2,6-dimethylphenyl)carbamoylmethyl-diethyl-azanium; N1-(2,6-dimethylphenyl)-2-(diethylamino)acetamide; W-108233; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide #; BRD-K52662033-001-02-6; BRD-K52662033-003-05-5; BRD-K52662033-003-14-7; Z55135799; Lidocaine, British Pharmacopoeia (BP) Reference Standard; Lidocaine, European Pharmacopoeia (EP) Reference Standard; N~1~-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine, United States Pharmacopeia (USP) Reference Standard; Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material; Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 91484-71-8" Small molecule "1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)" NNJVILVZKWQKPM-UHFFFAOYSA-N CCN(CC)CC(=O)NC1=C(C=CC=C1C)C C14H22N2O CAS 137-58-6 CHEBI:6456 . . . DB00281 . DR1849 Hydroxyurea D07CWD D07CWD Approved Myeloproliferative neoplasm ICD-11: 2A20 CID: 3657 Anticancer Treatment "hydroxyurea; Hydroxycarbamide; 127-07-1; N-Hydroxyurea; Hydrea; 1-HYDROXYUREA; Oxyurea; Carbamoyl oxime; Biosupressin; Hydroxycarbamine; Urea, hydroxy-; Onco-carbide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamyl hydroxamate; Hydura; Litalir; Hydurea; N-Carbamoylhydroxylamine; Droxia; Hidrix; Hydroxicarbamidum; Siklos; Hydroxylurea; Hydreia; Litaler; Idrossicarbamide [DCIT]; Hidroxicarbamida; Hydroxyharnstoff; Hydroxycarbamidum; Carbamohydroxyamic acid; N-Hydroxymocovina; Hydroxylamine, N-carbamoyl-; SQ 1089; urea, N-hydroxy-; Hydroxyharnstoff [German]; N-Hydroxymocovina [Czech]; NCI-C04831; Hydroxylamine, N-(aminocarbonyl)-; SK 22591; Hydroxycarbamidum [INN-Latin]; Hidroxicarbamida [INN-Spanish]; HU; CCRIS 958; HYDROXY-UREA; NSC 32065; hydroxy urea; UNII-X6Q56QN5QC; NSC32065; MFCD00007943; AI3-51139; Hydroxyurea (Cytodrox); CHEMBL467; SQ-1089; X6Q56QN5QC; CHEBI:44423; Hydroxyurea, 98%; NSC-32065; Hydroxy Urea-15N; NCGC00015520-03; Hydroxycarbamid; Oncocarbide; Idrossicarbamide; DSSTox_CID_5438; DSSTox_RID_77787; DSSTox_GSID_25438; NHY; Hydroxyurea (D4); N-HYDROXY UREA; Mylocel; carbamide oxide; CAS-127-07-1; SMR000059149; Hydroxyurea (USP); Droxia (TM); Droxia (TN); Hydrea (TM); hydroxyaminomethanamide; HSDB 6887; SR-01000075919; DRG-0253; EINECS 204-821-7; HYDREA (TN); Hydroxyurea [USAN:USP]; BRN 1741548; Hydroxycarbamide (JAN/INN); hydroxyl urea; Xromi; 1-oxidanylurea; S-phase/G-1 interface inhibitor; 15N Hydroxyurea; aminohydroxamic acid; carbamic acid oxime; Carbomohydroxamic acid; Spectrum_000909; Hydroxycarbamide [INN]; WLN: ZVMQ; Hydrea (Bristol Meyers); Spectrum2_000064; Spectrum3_000462; Spectrum4_000012; Spectrum5_000836; Lopac-H-8627; MolMap_000029; H 8627; NCIMech_000139; Hydroxyurea, 98%, powder; ACMC-1C22W; Lopac0_000596; BSPBio_002164; KBioGR_000383; KBioSS_001389; 4-03-00-00170 (Beilstein Handbook Reference); 8029-68-3; hydroxycarbamide (hydroxyurea); MLS001332381; MLS001332382; MLS002153389; DivK1c_000556; N-(Aminocarbonyl)hydroxylamine; SPECTRUM1500344; SPBio_000247; GTPL6822; NC(=O)N[O]; DTXSID6025438; tetratogen: inhibits ribonucleoside diphosphate reductase; HMS501L18; KBio1_000556; KBio2_001389; KBio2_003957; KBio2_006525; KBio3_001384; NINDS_000556; Bio1_000451; Bio1_000940; Bio1_001429; HMS1920F09; HMS2091L17; HMS2234I03; HMS3261H14; HMS3373G18; HMS3655K20; HMS3869C03; NCI C04831; Pharmakon1600-01500344; ACT02611; ALBB-028465; AMY40858; EBD12517; HY-B0313; STR02555; ZINC8034120; Tox21_110168; Tox21_300319; Tox21_500596; ANW-18958; BBL009928; BDBM50017811; CCG-35236; NSC757072; s1896; STL145898; AKOS005716276; AKOS006222547; Tox21_110168_1; ZINC100019199; DB01005; LP00596; MCULE-9465284053; NSC-757072; SDCCGSBI-0050578.P006; IDI1_000556; NCGC00015520-01; NCGC00015520-02; NCGC00015520-04; NCGC00015520-05; NCGC00015520-06; NCGC00015520-07; NCGC00015520-08; NCGC00015520-09; NCGC00015520-10; NCGC00015520-11; NCGC00015520-20; NCGC00093974-01; NCGC00093974-02; NCGC00093974-03; NCGC00093974-04; NCGC00093974-05; NCGC00254007-01; NCGC00261281-01; AC-22674; AK128930; NCI60_002773; SBI-0050578.P004; AB0013265; DB-041849; EU-0100596; FT-0627160; FT-0627175; FT-0670210; SW218071-2; C07044; D00341; Hydroxyurea, Vetec(TM) reagent grade, >=98%; AB00052018-09; AB00052018-10; AB00052018_11; AB00052018_12; 127H071; A805636; Q212272; J-504798; SR-01000075919-1; SR-01000075919-3; SR-01000075919-8; E0723DBA-5AF3-49D1-B5F6-59420AB87AC9; F8880-0905; Z1522566612; Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard; Hydroxyurea, United States Pharmacopeia (USP) Reference Standard" Small molecule "1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)" VSNHCAURESNICA-UHFFFAOYSA-N C(=O)(N)NO CH4N2O2 CAS 127-07-1 CHEBI:44423 . . . DB01005 . DR9044 Hydroxychloroquine D0OJ4L D0OJ4L Approved Malaria ICD-11: 1F40-1F45 CID: 3652 Anticancer Treatment "hydroxychloroquine; 118-42-3; Plaquenil; Oxichloroquine; Hidroxicloroquina; Hydroxychloroquinum; oxichlorochine; WIN 1258; Quensyl; 2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; 7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline; Polirreumin; Oxychlorochin; CHEBI:5801; 2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol; 7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline; Oxichlorochinum; HYDROXY CHLOROQUINE; HCQ; 2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol; 7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline; 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol; 2-((4-((7-Chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethanol; NSC4375; Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)-; MFCD00242707; Idrossiclorochina [DCIT]; Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-; Idrossiclorochina; 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol; Hidroxicloroquina [INN-Spanish]; Hydroxychloroquinum [INN-Latin]; Hydroxychloroquine [INN:BAN]; 2-[[4-[(7-chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol; 2-{N-[4-(7-Chloro-4-quinolylamino)pentyl]-N-ethylamino}ethanol; Ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)-; 2-({4-[(7-chloro(4-quinolyl))amino]pentyl}ethylamino)ethan-1-ol; 7-chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline; 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline; Polirreumin (TN); NCGC00159483-02; Hydroxychloroquine (INN); EINECS 204-249-8; BRN 0253894; Dolquine; Ethanol, 2-[[4-[(7-chloro-4-quinolyl)amino]pentyl]ethylamino]-; R-Hydroxychloroquine; Ercoquin (Salt/Mix); Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-, sulfate (1:1); (+-)-hydroxychloroquine; Spectrum2_001238; Spectrum5_001697; (+/-)-hydroxychloroquine; SCHEMBL8170; CHEMBL1535; 5-22-10-00280 (Beilstein Handbook Reference); (.+/-.)-Hydroxychloroquine; DivK1c_000942; SPBio_001116; GTPL7198; DTXSID8023135; HMS502P04; KBio1_000942; Win 1258-2; NINDS_000942; 2-[4-[(7-chloro-4-quinolyl)amino]pentyl-ethyl-amino]ethanol; ALBB-022466; BCP30197; BDBM50467780; SBB012559; STL429829; AKOS015997886; CCG-208059; DB01611; DT-0016; HY-W031727; MCULE-6282304706; VZ36170; IDI1_000942; NCGC00159483-03; NCGC00159483-06; M566; ST072188; SY270913; SBI-0052759.P002; CS-0075751; FT-0627143; FT-0669455; FT-0669456; C07043; D08050; AB00053257_02; 118H423; Q421094; BRD-A99117172-065-01-6; BRD-A99117172-065-02-4; F2173-0553; 2-((4-(7-chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol; 2-[(4-[(7-Chloro-4-quinolinyl)amino]pentyl)(ethyl)amino]ethanol #; 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl](ethyl)amino]ethanol; 7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]-quinoline; 7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]quinoline; 7-Chloro-4-(4-(N-ethyl-N-.beta.-hydroxyethylamino)-1-methylbutylamino)quinoline; Oxichloroquine;Oxychlorochin;2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol" Small molecule "1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)" XXSMGPRMXLTPCZ-UHFFFAOYSA-N CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO C18H26ClN3O CAS 118-42-3 CHEBI:5801 . . . DB01611 . DR2819 Hydrochlorothiazide D0U4UQ D0U4UQ Approved Hypertension ICD-11: BA00-BA04 CID: 3639 Anticancer Treatment "hydrochlorothiazide; 58-93-5; HCTZ; Esidrix; Hypothiazide; Oretic; Dichlotiazid; Hidrotiazida; Hydrochlorothiazid; Hydrochlorthiazide; Hydrodiuretic; Hydrosaluric; Servithiazid; Aquarills; Aquarius; Dichlotride; Diclotride; Disalunil; Hypothiazid; Idrotiazide; Maschitt; Megadiuril; Newtolide; Thiuretic; Vetidrex; Drenol; Esidrex; Hidril; Hydril; Nefrix; Chlorosulthiadil; Hidrochlortiazid; Hydro-Diuril; Hydro-Aquil; Dihydrochlorothiazide; Jen-Diril; HydroDIURIL; Dihydrochlorothiazid; Dihydrochlorothiazidum; Apresazide; Carozide; Chlorzide; Dichlorosal; Hidroronol; Hydrothide; Hydrozide; Moduretic; Neoflumen; Urodiazin; Bremil; Cidrex; Diaqua; Direma; Dyazide; Fluvin; Ivaugan; Panurin; Ro-hydrazide; Neo-codema; Acuretic; Caplaril; Hydrocot; Microzide; Thlaretic; Timolide; Aquazide H; Lotensin HCT; 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydrochlorothiazide; Thiaretic; Vaseretic; Ziac; Zide; Apo-Hydro; Lopressor HCT; Hydro-D; Hydrochlorothiazidum; Unipres; Dihydrochlorurit; Dihydrochlorurite; Hidroclorotiazida; Su 5879; Aldactazide; Inderide; Maxzide; Prinzide; Hydrochlorothiazide Intensol; NCI-C55925; component of Cyclex; component of Esimil; Esidrix (TN); Ser-Ap-Es; C7H8ClN3O4S2; component of Aldoril; component of Dyazide; component of Caplaril; HCZ; Chlorsulfonamidodihydrobenzothiadiazine dioxide; component of Aldactazide; UNII-0J48LPH2TH; component of Butizide Prestabs; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide; Dichlothiazide; MFCD00051765; Diu-melusin; 0J48LPH2TH; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-3,4-dihydro-(2H)-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; MLS000069619; CHEBI:5778; Chlorizide; Disothiazid; Hidrosaluretil; Novodiurex; Spironazide; Acesistem; Acuilix; Aldazida; Briazide; Catiazida; Chlothia; Clorana; Condiuren; Dihydran; Diurogen; Dixidrasi; Esoidrina; H.H. 25/25; H.H. 50/50; Hyclosid; Indroclor; Manuril; Medozide; Mictrin; Mikorten; Modurcen; Natrinax; Pantemon; Saldiuril; Selozide; Tandiur; Urozide; Didral; Hytrid; Nefrol; Unazid; Hidro-Niagrin; Hydro-Saluric; Raunova Plus; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Concor Plus; Aquazide-H; Neo-Flumen; Neo-Minzil; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; Hydro Par; NSC53477; Hydro-T; Hydrochlorthiazidum; NSC-53477; HCT; HCT-Isis; CAS-58-93-5; Mazide 25 mg; NCGC00015508-08; Hydrochlorat; Hydrochlorot; SMR000035778; Idroclorotiazide; Diu 25 Vigt; Hydrex-semi; Aldactazide 25/25; Aldectazide 50/50; Dihydroxychlorothiazidum; DSSTox_CID_713; Inderide 80/25; Hydrochlorothiazide form II; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-,1,1-dioxide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-chloro-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide; Idroclorotiazide [DCIT]; DSSTox_RID_75752; DSSTox_GSID_20713; Hydrochlorzide; Ezide; Hydrozide Injection, Veterinary; Hidroclorotiazida [INN-Spanish]; Hydrochlorothiazidum [INN-Latin]; 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide; Microzide (TN); CCRIS 2082; HSDB 3096; SR-01000000119; EINECS 200-403-3; NSC 53477; BRN 0625101; Hydrokraft; Idrodiuvis; Aquazide; Manschitt; Urirex; HydroPar; 6-chloro-1,1-dioxo-2H,3H,4H-benzo[e]1,2,4-thiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1?^{6},2,4-benzothiadiazine-7-sulfonamide; Prestwick_263; Hydrochloro Thiazide; Hyzaar (Salt/Mix); Aldoril (Salt/Mix); Dutoprol (Salt/Mix); Inderide (Salt/Mix); Prinzide (Salt/Mix); Accuretic (Salt/Mix); Hydropres (Salt/Mix); Thiazide, hydrochloro-; Hydrochlorothiazide [USP:INN:BAN:JAN]; Spectrum_000877; Opera_ID_168; Maybridge1_004336; Prestwick0_000009; Prestwick1_000009; Prestwick2_000009; Prestwick3_000009; Spectrum2_001040; Spectrum3_000456; Spectrum4_000006; Spectrum5_000824; Lopac-H-4759; CHEMBL435; Tekturna HCT (Salt/Mix); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide; H 4759; cid_3639; SCHEMBL9349; Hydrochlorothiazide-13C-d2; Lopac0_000614; Oprea1_357174; BSPBio_000017; BSPBio_002132; KBioGR_000351; KBioSS_001357; AF-614/30832002; ARONIS24316; BIDD:GT0153; DivK1c_000289; SPECTRUM1500335; BMCL182567 Compound 6a; SPBio_001259; SPBio_001938; BPBio1_000019; GTPL4836; Hydrochlorothiazide, crystalline; DTXSID2020713; BDBM13076; component of Dyazide (Salt/Mix); HMS500O11; HMS553N04; KBio1_000289; KBio2_001357; KBio2_003925; KBio2_006493; KBio3_001352; component of Caplaril (Salt/Mix); NINDS_000289; HMS1568A19; HMS1920D19; HMS2091L05; HMS2095A19; HMS2235I09; HMS3259O17; HMS3261L10; HMS3370P11; HMS3428A05; HMS3655M21; HMS3712A19; Pharmakon1600-01500335; ZINC896569; BCP22001; EBD18905; HY-B0252; JFD00715; Tox21_110165; Tox21_201565; Tox21_300292; Tox21_500614; 3,4-dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; CCG-40240; NSC757059; s1708; SBB056984; STK315354; 3,2,4-benzothiadiazine-1,1-dioxide; Hydrochlorothiazide (JP17/USP/INN); AKOS000121373; Tox21_110165_1; AC-8114; DB00999; LP00614; MCULE-6585933943; NC00510; NSC-757059; PS-3162; SDCCGSBI-0050596.P005; SU-5879; IDI1_000289; WLN: T66 BSWM EM DHJ HG ISZW; NCGC00015508-01; NCGC00015508-02; NCGC00015508-03; NCGC00015508-04; NCGC00015508-05; NCGC00015508-06; NCGC00015508-07; NCGC00015508-09; NCGC00015508-10; NCGC00015508-11; NCGC00015508-12; NCGC00015508-13; NCGC00015508-14; NCGC00015508-16; NCGC00015508-17; NCGC00015508-25; NCGC00021906-03; NCGC00021906-04; NCGC00021906-05; NCGC00021906-06; NCGC00021906-07; NCGC00021906-08; NCGC00254017-01; NCGC00259114-01; NCGC00261299-01; NCI60_004317; ST033548; component of Butizide Prestabs (Salt/Mix); Hydrochlorothiazide 1.0 mg/ml in Methanol; SBI-0050596.P004; AB00052012; EU-0100614; FT-0650564; SW196569-3; 6-Chloro-3,2,4-benzothiadiazine 1,1-dioxide; A19550; C07041; D00340; J10079; AB00052012-15; AB00052012_16; AB00052012_17; 051H765; Hydrochlorothiazide 100 microg/mL in Acetonitrile; Q423930; Hydrochlorothiazide, meets USP testing specifications; Q-201210; SR-01000000119-2; SR-01000000119-4; SR-01000000119-6; BRD-K13078532-001-05-2; Z56347248; 6-Chloro-3,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,2,4-benzothiadiazine 1,1-dioxide; Hydrochlorothiazide, drug standard, 1.0 mg/mL in methanol; 6-chloro-3,4-dihydro-1,1-dioxo-7-sulfamoyl-1,2,4-benzothiadiazine; Hydrochlorothiazide, British Pharmacopoeia (BP) Reference Standard; Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothiadiazine-1,1-dioxide; 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2, 4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3, 4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydro-(2H)-1,2,4-benzothiadiazine 1,1-Dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydrobenzo-1,2,4-thiadiazine-1,1-dioxide; Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide; 2H-1,2,4-Benzothiadiazine, 6-chloro-3,4-dihydro-7-sulfamoyl-2, 1,1-dioxide; 2H-1,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide; 6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6,2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1, 1-dioxide; 7-(Aminosulfonyl)-6-chloro-3,4-dihydro-(2H)-1,2,4-benzothiadiazine 1,1-Dioxide; Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard; Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material; 125727-50-6; 3,4-Dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide; 3,4-Dihydrochlorothiazide; Hydrochlorothiazide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material" Small molecule "1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)" JZUFKLXOESDKRF-UHFFFAOYSA-N C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl C7H8ClN3O4S2 CAS 58-93-5 CHEBI:5778 . . . DB00999 . DR5200 Glibenclamide D05LYX D05LYX Approved Acute diabete complication ICD-11: 5A2Y CID: 3488 Anticancer Treatment "glyburide; Glibenclamide; 10238-21-8; Glybenclamide; Glynase; Micronase; Diabeta; Daonil; Euglucon; Maninil; Semi-daonil; Apo-Glibenclamide; Euglucon 5; Azuglucon; Bastiverit; Benclamin; Betanase; Duraglucon; Euglucan; Euglykon; Glibenil; Glucolon; Orabetic; Prodiabet; Renabetic; Yuglucon; Dibelet; Gilemal; Glibens; Glibil; Glimel; Glimide; Humedia; Libanil; Suraben; Tiabet; Adiab; Glybenzcyclamide; Melix; Pira; Med-Glionil; Glibenclamida; Glibenclamidum; 5-Chloro-N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-methoxybenzamide; Glibenclamidum [INN-Latin]; Glibenclamida [INN-Spanish]; HB 419; glyburide (glibenclamide); C23H28ClN3O5S; UR 606; UNII-SX6K58TVWC; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; Neogluconin; 5-Chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide; U 26452; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide; Gewaglucon; Glibenbeta; Glidiabet; Glucobene; Glucohexal; Glucoremed; Hexaglucon; Lederglib; Lisaglucon; Normoglucon; Praeciglucon; Calabren; Cytagon; Euclamin; Glamide; Glibesyn; Glibetic; Gliboral; Glisulin; Glitisol; Glubate; Glucomid; Glucoven; Glycomin; MFCD00056625; Miglucan; Debtan; Gliban; Gliben; Glibet; Glicem; Gluben; Glyben; Nadib; Sugril; SX6K58TVWC; CHEMBL472; Novo-Glyburide; Glibenclamid AL; Gen-Glybe; Norglicem 5; Betanese 5; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; Glibenclamid Fabra; MLS000069721; CHEBI:5441; Glibenclamid Basics; Glibenclamid-Cophar; Glibenclamid Heumann; Semi-Euglucon; Glibenclamid Genericon; Hemi-Daonil; Glibenclamid-Ratiopharm; 5-chloro-N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide; Urea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexyl-; Benzamide, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-; NCGC00015467-11; Abbenclamide; Diabiphage; Glibadone; SMR000058229; Semi-Gliben-Puren N; GBN 5; CAS-10238-21-8; Glibenclamid Riker M.; Glyburide (micronized); 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; Urea, 1-((p-(2-(chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl-; 5-chloro-N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-2-methoxybenzamide; 5-Chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]-amino]sulfonyl]phenyl]-ethyl]-2-methoxybenzamide; DSSTox_CID_17237; DSSTox_RID_79313; DSSTox_GSID_37237; Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-; Micronized glyburide; U-26,452; Glycron; 1-[[p-[2-(5-Chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea; 5-chloro-N-(2-{4-[N-(N-cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide; 5-Chloro-N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)-phenethyl)-2-methoxybenzamide; Glyburide (USP); Micronase (TN); HB-419; 1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonyl}-3-cyclohexylurea;1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonyl}-3-cyclohexylurea; Diabeta (TN); Glynase (TN); SR-01000000196; Glyburide [USAN:USP]; EINECS 233-570-6; BRN 2230085; Amglidia; Delmide; 5-chloro-N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide; Glibenclamide,(S); GBM; Prestwick_569; Glibenclamide B.P.; Glyburide (Diabeta); Glibenclamide [INN]; RP-1127; Spectrum_000250; Tocris-0911; Glybenzcyclamide, 99%; Glibenclamide; Glyburide; Opera_ID_801; Prestwick0_000316; Prestwick1_000316; Prestwick2_000316; Prestwick3_000316; Spectrum2_001816; Spectrum3_001327; Spectrum4_001199; Spectrum5_001631; Lopac-G-0639; ACMC-20a66i; Probes1_000431; Probes2_000378; UPCMLD-DP006; G 0639; Glibenclamide (JP17/INN); N-(4-(beta-(2-Methoxy-5-chlorbenzamido)-aethyl)-benzolsulfonyl)-N'-cyclohexyl-harnstoff; CBiol_001790; Lopac0_000499; Oprea1_764617; SCHEMBL22009; U-26452; BSPBio_000312; BSPBio_001351; BSPBio_003053; KBioGR_000071; KBioGR_001897; KBioSS_000071; KBioSS_000730; MLS001077262; BIDD:GT0239; DivK1c_000481; SPECTRUM2300229; SPBio_001831; SPBio_002531; BPBio1_000344; GTPL2414; DTXSID0037237; UPCMLD-DP006:001; HMS501I03; KBio1_000481; KBio2_000071; KBio2_000730; KBio2_002639; KBio2_003298; KBio2_005207; KBio2_005866; KBio3_000141; KBio3_000142; KBio3_002273; AOB6214; SYN3026; Glybenclamide, >=99% (HPLC); NINDS_000481; Bio1_000076; Bio1_000565; Bio1_001054; Bio2_000071; Bio2_000551; HMS1361D13; HMS1568P14; HMS1791D13; HMS1922L08; HMS1989D13; HMS2089L06; HMS2093P04; HMS2095P14; HMS3259O12; HMS3261D19; HMS3267A15; HMS3402D13; HMS3411F16; HMS3428D15; HMS3651E17; HMS3675F16; HMS3712P14; Pharmakon1600-02300229; ZINC537805; BCP05327; Tox21_110158; Tox21_300758; Tox21_500499; ANW-58936; BDBM50012957; CCG-39618; HD 419; NSC759618; SBB057426; STK362992; Glyburide - CAS 10238-21-8; AKOS001487495; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; Tox21_110158_1; BCP9000729; CS-1075; DB01016; KS-5326; LP00499; MCULE-2351642942; NC00566; NSC 759618; NSC-759618; SB17414; SDCCGSBI-0050483.P004; IDI1_000481; IDI1_033821; Glibenclamide 1.0 mg/ml in Acetonitrile; NCGC00015467-01; NCGC00015467-02; NCGC00015467-03; NCGC00015467-04; NCGC00015467-05; NCGC00015467-06; NCGC00015467-07; NCGC00015467-08; NCGC00015467-09; NCGC00015467-10; NCGC00015467-12; NCGC00015467-13; NCGC00015467-14; NCGC00015467-15; NCGC00015467-16; NCGC00015467-17; NCGC00015467-18; NCGC00015467-20; NCGC00015467-21; NCGC00015467-36; NCGC00015467-37; NCGC00016689-01; NCGC00023447-02; NCGC00023447-04; NCGC00023447-05; NCGC00023447-06; NCGC00023447-07; NCGC00023447-08; NCGC00023447-09; NCGC00023447-10; NCGC00023447-11; NCGC00023447-12; NCGC00254662-01; NCGC00261184-01; HY-15206; ST024780; SBI-0050483.P003; AB0012611; Glyburide, meets USP testing specifications; AB00051949; EU-0100499; FT-0601608; G-150; G0382; S1716; SW195828-5; A19539; C07022; D00336; J10021; W-5054; 78637-EP2270001A1; 78637-EP2270011A1; 78637-EP2272825A2; 78637-EP2272841A1; 78637-EP2275414A1; 78637-EP2287165A2; 78637-EP2287166A2; 78637-EP2292620A2; 78637-EP2298750A1; 78637-EP2298776A1; 78637-EP2298779A1; 78637-EP2301923A1; 78637-EP2301936A1; 78637-EP2305648A1; 78637-EP2308847A1; AB00051949-16; AB00051949-17; AB00051949_18; AB00051949_19; Q420626; U-26,45; SR-01000000196-2; SR-01000000196-4; SR-01000000196-5; SR-01000000196-6; SR-01000000196-8; W-108874; BRD-K36927236-001-06-0; BRD-K36927236-001-17-7; Z277540138; Glybenclamide, European Pharmacopoeia (EP) Reference Standard; Glyburide, United States Pharmacopeia (USP) Reference Standard; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl urea; 5-Chloro-N-[4-(3-cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide.; 5-chloro-N-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenethyl]-2-methoxybenzamide; Glibenclamide for peak identification, European Pharmacopoeia (EP) Reference Standard; Glyburide (Glibenclamide), Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-(.beta.-(2-Methoxy-5-chlorbenzamido)-aethyl)-benzolsulfonyl)-N'-cyclohexyl-harnstoff; N1-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenethyl]-5-chloro-2-methoxybenzamide; (5-chloro-2-methoxyphenyl)-N-[2-(4-{[(cyclohexylamino)carbonylamino]sulfonyl}p henyl)ethyl]carboxamide; 5-Chloro-N-(2-[4-(([(cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-2-methoxybenzamide #; 5-Chloro-N-[2-[4-[[[(Cylcohexylamino)carbonyl]amino]sulphonyl]phenyl]ethyl]-2-methoxybenzamide; N-[(4-{2-[(5-chloro-2-methoxyphenyl)carbonylamino]ethyl}phenyl)sulfonyl](cyclo hexylamino)carboxamide" Small molecule "1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)" ZNNLBTZKUZBEKO-UHFFFAOYSA-N COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3 C23H28ClN3O5S CAS 10238-21-8 CHEBI:5441 . . . DB01016 . DR9241 Gentamicin D0L9UU D0L9UU Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 3467 Anticancer Treatment "gentamicin; Gentavet; Gentamicins; GENTAMYCIN; Gentamicin sulphate sterile; Gentacycol; 1403-66-3; Cidomycin; Gentamicinum; Gentamycinum; Refobacin; Garasol; Refobacin TM; Gentamicina; Gentamicine; Gentocin; Gentamycin-creme; Gentamycins; Gentamicine [INN-French]; Gentamicinum [INN-Latin]; Gentamycin-creme [German]; Gentamicina [INN-Spanish]; Oksitselanim; Centicin; Lyramycin; Septigen; Gentamicin (TN); Gentamicin (BAN); Gentamicin [INN]; HSDB 3087; Gentamicin [INN:BAN]; EINECS 215-765-8; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside; SCHEMBL537630; CHEMBL329592; GTPL2427; SCHEMBL19996168; STL454325; AKOS015961211; DB00798; J4.074F; 2-[4,6-diamino-3-[3-amino-6-(1-methylaminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-methylaminooxane-3,5-diol; AC-13386; FT-0626646; FT-0668965; D08013; 123871-EP2292088A1; 123871-EP2295422A2; 123871-EP2295439A1; Q422482" Small molecule "1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3" CEAZRRDELHUEMR-UHFFFAOYSA-N CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC C21H43N5O7 CAS 1403-66-3 . . . . DB00798 . DR9565 Fluoxetine D0TR5X D0TR5X Approved Depression ICD-11: 6A70-6A71 CID: 3386 Anticancer Treatment "fluoxetine; 54910-89-3; Prozac; Pulvules; Portal; Eufor; Animex-On; Fluoxetina; Fluoxetina [Spanish]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluoxetina [INN-Spanish]; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; Fontex; Reconcile; Fluctine; Fluoxac; Fludac; Fluxil; Fluoxetin; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; CHEMBL41; dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Symbyax; CHEBI:86990; Selfemra; NSC-283480; (+/-)-Fluoxetine; HSDB 6633; NCGC00015428-08; (+/-) -Fluoxetine; Fluval; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; n-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Fluoxetine-d5 solution; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; DSSTox_CID_3067; DSSTox_RID_76861; DSSTox_GSID_23067; Fluoxetine [USAN:INN:BAN]; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; N-methyl-3-[4-(trifluoromethyl)phenoxy]-3-(3-tritiophenyl)propan-1-amine; Fluoxetine (TN); CAS-54910-89-3; Fluoxetine (USAN/INN); methyl{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amine; Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; 1173147-79-9; Spectrum_001679; SpecPlus_000723; Prestwick0_000511; Prestwick1_000511; Prestwick2_000511; Prestwick3_000511; Spectrum2_001658; Spectrum3_001648; Spectrum4_000613; Spectrum5_001518; Benzenepropamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; Biomol-NT_000152; Epitope ID:224550; (+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; SCHEMBL8353; (+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; Lopac0_000558; BSPBio_000461; BSPBio_003375; GTPL203; KBioGR_001166; KBioSS_002159; cid_62857; DivK1c_006819; SPBio_001815; SPBio_002382; BEN445; BPBio1_000354; BPBio1_000509; CHEBI:5118; DTXSID7023067; BDBM30130; KBio1_001763; KBio2_002159; KBio2_004727; KBio2_007295; KBio3_002595; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; HMS2090H14; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; ALBB-025606; AMY32526; BCP28440; HY-B0102; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine; Tox21_110144; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; BBL012251; MFCD00072041; NS-140; NSC283480; SBB017267; STK734483; AKOS003663021; Tox21_110144_1; AC-8478; CCG-204648; DB00472; NSC 283480; NSC 758685; SDCCGSBI-0050541.P004; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; NCGC00015428-06; NCGC00015428-07; NCGC00015428-10; NCGC00015428-11; NCGC00015428-12; NCGC00015428-13; NCGC00015428-15; NCGC00015428-27; NCGC00024879-03; NCGC00024879-04; AS-44989; ST076807; SBI-0050541.P003; AB0107059; DB-015148; AB00053774; FT-0626489; D00326; AB00053774-13; AB00053774-14; AB00053774_15; AB00053774_16; L000931; Q422244; BRD-A31159102-001-01-9; BRD-A31159102-003-05-6; BRD-A31159102-003-16-3; LY-110140;LY 110140;LY110140; N-methyl 3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-3-phenyl-3-(p-trifluoromethylphenoxy)propylamine; Benzenepropanamine, N-methyl-; A-[4-(trifluoromethyl)phenoxy]-; benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine #; Benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)-; methyl{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amine hydrochloride; N-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,.alpha.,.alpha.-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,la,.alpha.-trifluoro-p-tolyl)oxy]propylamine; Benzenepropanamine, N-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, (.+/-.)-; 57226-07-0" Small molecule "1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3" RTHCYVBBDHJXIQ-UHFFFAOYSA-N CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F C17H18F3NO CAS 54910-89-3 CHEBI:86990 . . . DB00472 . DR6366 Fluconazole D09LNI D09LNI Approved Fungal infection ICD-11: 1F29-1F2F CID: 3365 Anticancer Treatment "fluconazole; 86386-73-4; Diflucan; Triflucan; Biozolene; Elazor; Biocanol; Fluconazol; Fungata; Fluconazolum; Flucostat; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; UK 49858; Flusol; Zoltec; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; UK-49858; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; C13H12F2N6O; UNII-8VZV102JFY; 1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-; Pritenzol; Flucazol; Flukezol; Flunizol; Zonal; CHEMBL106; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 8VZV102JFY; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; alpha-(2,4-Difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; Alflucoz; Cryptal; Dimycon; Oxifugol; Canzol; CHEBI:46081; Forcan; Syscan; Baten; Mutum; Zemyc; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; Fluconazole, 98%; MFCD00274549; difluconazole; NCGC00095089-01; Flunazol; Fluconazol [Spanish]; Fluconazolum [Latin]; Loitin; UK-49,858; DSSTox_CID_627; DSSTox_RID_75701; DSSTox_GSID_20627; FLC; DRG-0005; Diflazon; Fuconal; Triconal; Trican; Diflucan (TN); SMR000471882; CAS-86386-73-4; FLCZ; CCRIS 7211; Fluconazole & hGCSF; DIFLUCAN IN SODIUM CHLORIDE 0.9%; HSDB 7420; SR-01000765440; Fluconazole in sodium chloride 0.9%; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; Flucoral; 2-(2,4-difluorophenyl)-1,3-di(1,2,4-triazolyl)propan-2-ol; Fluconazole & MC-510,011; Fluconazole (f); Fluconazole,(S); Fluconazole in dextrose 5% in plastic container; 2,4-Difluoro-alpha,alpha-1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; Fluzon [Antifungal]; Fluconazole [USAN]; KS-1059; Fluconazole [USAN:USP:INN:BAN:JAN]; Fluconazole in sodium chloride 0.9% in plastic container; Fluconazole in combination with MGCD290; Spectrum_001654; DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Spectrum2_001607; Spectrum3_001912; Spectrum4_000090; Spectrum5_001277; F0677; MGCD290 and Fluconazole; cid_3365; MG-3290 and Fluconazole; SCHEMBL3151; BSPBio_003504; KBioGR_000360; KBioSS_002134; 123631-92-5; MLS001066394; MLS001165780; MLS001195645; MLS001304713; MLS001306492; MLS006011884; BIDD:GT0799; DivK1c_001030; SPECTRUM1503975; SPBio_001613; ZINC4009; Fluconazole (JP17/USP/INN); DTXSID3020627; BDBM25817; HMS503M21; KBio1_001030; KBio2_002134; KBio2_004702; KBio2_007270; KBio3_003009; NINDS_001030; BAYT006267; HMS1922O10; HMS2090I20; HMS2093M21; HMS2230O22; HMS3259H13; HMS3373I19; HMS3654P15; HMS3715F21; HMS3748G19; Pharmakon1600-01503975; AMY23415; BAYT-006267; BCP28522; Fluconazole 2.0 mg/ml in Methanol; HY-B0101; 1,2,4-triazol-1-yl)propan-2-ol; Tox21_111419; Tox21_202240; Tox21_300581; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; ABP001077; AC-428; ANW-42860; BBL005614; CCG-39065; CF0055; DL-407; Fluconazole & Human recombinant granulocyte colony stimulating factor; KM2402; NSC754343; NSC758661; s1331; SBB066063; STK619301; AKOS000280854; Tox21_111419_1; CS-1835; DB00196; Fluconazole, >=98% (HPLC), powder; MCULE-8641424658; NC00650; NSC 758661; NSC-754343; NSC-758661; IDI1_001030; NCGC00095089-02; NCGC00095089-04; NCGC00095089-05; NCGC00095089-06; NCGC00095089-07; NCGC00095089-08; NCGC00095089-09; NCGC00095089-10; NCGC00095089-11; NCGC00254412-01; NCGC00259789-01; 2-(2,4-difluorophenyl)-1,3-di(1H-; Fluconazole 100 microg/mL in Acetonitrile; SBI-0051880.P002; AB0008515; UK-049858; FT-0626437; ST51039043; SW199616-2; EN300-53634; C07002; D00322; J10407; AB00052399-07; AB00052399-08; AB00052399_09; AB00052399_10; 386F734; A841625; Q411478; 3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]propanoicacid; Q-201120; SR-01000765440-2; SR-01000765440-4; SR-01000765440-8; UK-49858;UK 49858;UK49858; BRD-K05977355-001-02-6; BRD-K05977355-001-09-1; F2173-0496; Z235354561; Fluconazole, European Pharmacopoeia (EP) Reference Standard; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)-2-propanol; Fluconazole, United States Pharmacopeia (USP) Reference Standard; 2-[2,4-bis(fluoranyl)phenyl]-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material; Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard; Fluconazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; .alpha.-(2,4-Difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol" Small molecule "1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2" RFHAOTPXVQNOHP-UHFFFAOYSA-N C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O C13H12F2N6O CAS 86386-73-4 CHEBI:46081 . . . DB00196 . DR9913 Edrophonium D0S5LH D0S5LH Approved Myasthenia gravis ICD-11: 8C6Y CID: 3202 Anticancer Treatment "edrophonium; Edrophonum; Tensilon; EDROPHONIUM ION; 312-48-1; Enlon; Reversol; Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-; Edrophone Chloride; UNII-70FP3JLY7N; N-ethyl-3-hydroxy-N,N-dimethylanilinium; (3-hydroxyphenyl)dimethylethylammonium; 70FP3JLY7N; 3-hydroxy-N,N-dimethyl-N-ethylanilinium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; CHEBI:251408; Ammonium, ethyl(m-hydroxyphenyl)dimethyl-(8CI); ENLON-PLUS; NCGC00015409-02; CAS-116-38-1; ethyl-(3-hydroxyphenyl)-dimethylazanium; Edrophonium cation; Spectrum_000442; Edrophonium Chloride, 3; Prestwick0_000083; Prestwick1_000083; Prestwick2_000083; Prestwick3_000083; Spectrum2_001110; Spectrum4_000736; Spectrum5_001531; Lopac-E-3256; cid_8307; CHEMBL1104; Lopac0_000511; SCHEMBL34790; BSPBio_000006; BSPBio_002386; KBioGR_001032; KBioSS_000922; DivK1c_000809; SPBio_001220; SPBio_001945; BPBio1_000008; GTPL9073; ZINC1341; DTXSID4046943; KBio1_000809; KBio2_000922; KBio2_003490; KBio2_006058; NINDS_000809; BDBM120262; CCG-204602; DB01010; MCULE-5963849469; IDI1_000809; NCGC00015409-01; NCGC00015409-03; NCGC00015409-04; NCGC00015409-05; NCGC00015409-06; NCGC00015409-07; NCGC00015409-08; NCGC00015409-15; NCGC00023975-03; AB00053796; C06976; AB00053796_15; Q3177745" Small molecule "1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1" VWLHWLSRQJQWRG-UHFFFAOYSA-O CC[N+](C)(C)C1=CC(=CC=C1)O C10H16NO+ CAS 312-48-1 CHEBI:251408 . . . DB01010 . DR3826 Donepezil D0NS6H D0NS6H Approved Alzheimer disease ICD-11: 8A20 CID: 3152 Anticancer Treatment "donepezil; 120014-06-4; Aricept; 2-((1-Benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; 2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; HSDB 7743; CHEMBL502; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; (S)-E2020 (free base); C24H29NO3; CHEBI:53289; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-; donepezilo; Donepezil [INN:BAN]; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-; 142057-80-5; NSC 737535; NSC 758882; NCGC00167537-01; donepezilum; Domepezil; Donepezil (INN); Donaz (TN); PubChem22271; Spectrum_001664; Spectrum5_001662; SCHEMBL2149; Oprea1_188452; KBioSS_002144; BDBM8960; GTPL6599; SCHEMBL8265876; DTXSID8048317; KBio2_002144; KBio2_004712; KBio2_007280; AMY8939; CHEBI:145499; BCPP000253; HMS3886M11; BCP07590; EBD50998; MFCD00912833; s5073; STK003905; AKOS000277311; AKOS016842349; AC-6969; BCP9000622; CCG-268401; DB00843; MRF-0000323; AK-72906; HY-14566; I903; SBI-0206789.P001; AB0013927; FT-0601545; D07869; S-6065; 32288-EP2269989A1; 32288-EP2269990A1; 32288-EP2275420A1; 32288-EP2278970A1; 32288-EP2280010A2; 32288-EP2281815A1; 32288-EP2283811A1; 32288-EP2289882A1; 32288-EP2289886A1; 32288-EP2295417A1; 32288-EP2298758A1; 32288-EP2298759A1; 32288-EP2298761A1; 32288-EP2298772A1; 32288-EP2298776A1; 32288-EP2301933A1; 32288-EP2305640A2; 32288-EP2305664A1; 32288-EP2305675A1; 32288-EP2308839A1; 32288-EP2311823A1; 32288-EP2311827A1; AB00640013-07; AB00640013-08; AB00640013_09; AB00640013_10; 014D064; Q415081; Q-100098; BRD-A49160188-003-04-4; Z1741977105; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one; (+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-indan-1-one; 2-[(1-benzyl-4-piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1-one; 2,3-dihydro-5,6-dimethoxy-2 [[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 2,3-dihydro-5,6-dimethoxy-2[[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 5,6-dimethoxy-2-[[1-(phenylmethyl)piperidin-4-yl]methyl]-2,3-dihydroinden-1-one" Small molecule "1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3" ADEBPBSSDYVVLD-UHFFFAOYSA-N COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC C24H29NO3 CAS 120014-06-4 CHEBI:53289 . . . DB00843 . DR4175 Domperidone D0AV3G D0AV3G Approved Digestive system disease ICD-11: DE2Z CID: 3151 Anticancer Treatment "domperidone; 57808-66-9; Motilium; Nauzelin; Domperidonum; Domperidona; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; R-33812; R 33,812; NSC299589; Domperidone (Motilium); 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; R33812; UNII-5587267Z69; KW 5338; MLS000069343; CHEMBL219916; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; CHEBI:31515; MFCD00069256; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one; NSC 299589; NSC-299589; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; Motinorm; Costi; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; DSSTox_CID_25116; DSSTox_RID_80682; DSSTox_GSID_45116; 1-(3-(4-(5-chloro-2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one; Domperidonum [INN-Latin]; Domperidona [INN-Spanish]; 5587267Z69; Motillium; Motilium (TN); SMR000326802; CAS-57808-66-9; KW-5338; Lopac-D-122; SR-01000003002; EINECS 260-968-7; BRN 0903774; Nauzelin OD; Domperidone,(S); 5-chloro-1-{1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; Domperidone [USAN:INN:BAN:JAN]; Prestwick_794; NCI299589; HS-0067; PubChem15679; Spectrum_000391; Opera_ID_616; SpecPlus_000825; Prestwick0_000461; Prestwick1_000461; Prestwick2_000461; Prestwick3_000461; Spectrum4_000087; D-122; Biomol-NT_000022; NCIStruc1_001686; NCIStruc2_001819; Lopac0_000427; SCHEMBL43729; BSPBio_002350; GTPL965; KBioGR_000354; KBioSS_000871; 2H-Benzimidazol-2-one, 5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-; 5-24-02-00402 (Beilstein Handbook Reference); MLS000859942; MLS001306482; MLS002222324; DivK1c_006921; SPECTRUM2300212; SPBio_002501; BPBio1_000620; BPBio1_001185; DTXSID1045116; Domperidone (JP17/USAN/INN); KBio1_001865; KBio2_000871; KBio2_003439; KBio2_006007; HMS1922N04; HMS2089C14; HMS2093N22; HMS2096C21; HMS2230N18; HMS3261E16; HMS3269O13; HMS3370L03; HMS3413F15; HMS3656M21; HMS3677F15; HMS3713C21; HMS3884N19; Pharmakon1600-02300212; BCP28265; Domperidone 1.0 mg/ml in Methanol; EBD46624; HY-B0411; ZINC4175569; Tox21_110056; Tox21_500427; ANW-42358; BBL028136; BDBM50241107; CCG-37870; CD0227; NCGC00014670; NSC759575; s2461; STK622843; AKOS005555858; Tox21_110056_1; AC-2037; DB01184; Domperidone, powder, >=98% (HPLC); LP00427; MCULE-4430288884; NSC 759575; NSC-759575; SDCCGSBI-0050412.P004; NCGC00014670-01; NCGC00014670-02; NCGC00014670-03; NCGC00014670-04; NCGC00014670-05; NCGC00014670-06; NCGC00014670-07; NCGC00014670-08; NCGC00014670-09; NCGC00014670-10; NCGC00014670-11; NCGC00014670-12; NCGC00014670-13; NCGC00014670-14; NCGC00014670-16; NCGC00014670-17; NCGC00014670-28; NCGC00015306-01; NCGC00021472-02; NCGC00021472-03; NCGC00021472-04; NCGC00021472-05; NCGC00021472-06; NCGC00021472-07; NCGC00021472-08; NCGC00097773-01; NCGC00261112-01; 2H-Benzimidazol-2-one, 1,3-dihydro-5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; NCI60_002512; SMR000058969; AB0110085; AB00052423; D4125; EU-0100427; FT-0625588; SW196931-3; D01745; AB00052423-06; AB00052423-07; AB00052423_08; AB00052423_09; 808D669; L000230; Q424238; R 33812; SR-01000003002-2; SR-01000003002-4; SR-01000003002-7; W-105440; BRD-K38305202-001-02-6; BRD-K38305202-001-08-3; Domperidone, European Pharmacopoeia (EP) Reference Standard; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolyl)propyl]-4-piperidyl]benzimidazol-2-one; 2H-Benzimidazol-2-one,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo -1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-d ihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1- yl)propyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one;; 5-chloro-1-{1-[3(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-{1-[3-(2-hydroxy-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-2,3-dihydro-1H-benzoimidazol-2-ol; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(domperidone); DOMPERIDONE5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one" Small molecule "1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)" FGXWKSZFVQUSTL-UHFFFAOYSA-N C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O C22H24ClN5O2 CAS 57808-66-9 CHEBI:31515 . . . DB01184 . DR0727 Valproic acid D0Y3KG D0Y3KG Approved Epilepsy/seizure ICD-11: 8A60-8A68 CID: 3121 Anticancer Treatment "VALPROIC ACID; 2-Propylpentanoic acid; 99-66-1; 2-Propylvaleric acid; Dipropylacetic acid; Depakine; Depakene; Ergenyl; Di-n-propylacetic acid; Valproate; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; n-Dipropylacetic acid; Propylvaleric acid; Myproic Acid; n-DPA; Dipropylacetate; Convulex; Depakin; Di-n-propylessigsaure; Avugane; Baceca; Stavzor; Acido valproico; Kyselina 2-propylvalerova; Acide valproique; 2-n-Propyl-n-valeric acid; Acidum valproicum; Acetic acid, dipropyl-; 2,2-di-n-propylacetic acid; Valproinsaeure; Savicol; Depakine chrono; Depakin chrono; Abbott 44090; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; 2-PROPYL-PENTANOIC ACID; Di-n-propylessigsaure [German]; Valeric acid, 2-propyl-; divalproex; Epilim; Kyselina 2-propylvalerova [Czech]; Di-n-propylessigsaeure; VPA;2-Propylpentanoic Acid; UNII-614OI1Z5WI; MFCD00002672; NSC 93819; Delepsine; Sprinkle; Valcote; Valparin; Epilex; PEAC; VPA; Depakene (TN); Vupral; CHEMBL109; (n-C3H7)2CHCOOH; 614OI1Z5WI; CHEBI:39867; NSC-93819; NCGC00091149-01; Deproic; Alti-Valproic; Novo-Valproic; Penta-Valproic; Dom-Valproic; Med Valproic; Nu-Valproic; DSSTox_CID_3733; DSSTox_RID_77171; DSSTox_GSID_23733; Valproic acid USP; PMS-Valproic Acid; 2-Propylpentanoic acid, 99%; Valproic acid (USP); CAS-99-66-1; Depakote (TM); SMR000499581; 362049-65-8; HSDB 3582; 2 PP (base); EINECS 202-777-3; BRN 1750447; Depacane; valproic-acid; Novo-divalproex; Sandoz valproic; Dom-valproate; Gen-divalproex; Apo-valproic; A-44090; AI3-10500; APO-divalproex; DOM-divalproex; Epival er; PHL-valproate; PMS-valproate; PMS-Divalproex; Erganyl; Stavzor; Dom-valproic acid; Apo-valproic syrup; PHL-valproic acid; Epiject I.V.; 2-propyl-Pentanoate; Epical (TM); Epilim (Salt/Mix); Valproic acid [USAN:USP:INN:BAN]; Depacon (Salt/Mix); 345909-03-7; 87745-17-3; Convulex (Salt/Mix); Eurekene (Salt/Mix); G2M-777; Valparin (Salt/Mix); Valproic acid solution; Novo-Valproic - ECC; Spectrum_000521; Divalproex (Salt/Mix); Dom-valproic acid syrup; Ratio-Valproic - ECC; Valdisoval (Salt/Mix); ACMC-209sdq; 2 -propylpentanoic acid; di-n-propyl acetic acid; S(-)-4-En-valproate; Spectrum2_000946; Spectrum3_001733; Spectrum4_000376; DOM-valproic acid E.C.; Heptane-4-carboxylic acid; PHL-valproic acid E.C.; PMS-valproic acid E.C.; Novo-valproic soft gel cap; EC 202-777-3; SCHEMBL2275; S-2-n-Propyl-4-pentenoate; (S)-2-propyl-4-pentanoate; KBioGR_000871; KBioGR_002277; KBioSS_001001; KBioSS_002278; MLS001076682; MLS001335927; MLS001335928; MLS002415770; BIDD:GT0858; DivK1c_000273; SPBio_000912; GTPL7009; DTXSID6023733; WLN: QVY3 & 3; KBio1_000273; KBio2_001001; KBio2_002277; KBio2_003569; KBio2_004845; KBio2_006137; KBio2_007413; KBio3_002626; KBio3_002757; NIJJYAXOARWZEE-UHFFFAOYSA-; Valproic acid [USAN:BAN:INN]; NINDS_000273; HMS2089J06; HMS2231E06; HMS3259C18; HMS3370C21; HMS3715B15; HMS3885G14; ACT05281; ALBB-032973; BCP33204; NSC93819; ZINC3008621; Tox21_111091; Tox21_201963; Tox21_300603; ANW-41052; BDBM50003616; LMFA01020291; s3944; SBB065764; STL445581; AKOS009156895; Tox21_111091_1; Valproic Acid 1.0 mg/ml in Methanol; CCG-221127; CS-1765; DB00313; MCULE-7136317196; NC00584; SDCCGSBI-0050864.P004; NCGC00091149-02; NCGC00091149-03; NCGC00091149-04; NCGC00091149-05; NCGC00091149-06; NCGC00091149-08; NCGC00091149-09; NCGC00162288-07; NCGC00254365-01; NCGC00259512-01; AK128830; AS-11354; HY-10585; SBI-0050864.P003; AB0009719; 791-EP2306789A1; FT-0609289; FT-0675769; P0823; 6400-EP1441224A2; 6400-EP2272537A2; 6400-EP2272827A1; 6400-EP2275420A1; 6400-EP2280008A2; 6400-EP2298764A1; 6400-EP2298765A1; 6400-EP2308867A2; 6400-EP2308870A2; 6400-EP2311494A1; 6400-EP2311840A1; 6400-EP2314585A1; 6400-EP2374790A1; A19450; C07185; D00399; AB00698315-06; 2-(Propyl-3,3,3-d3)pentanoic-5,5,5-d3 Acid; Q240642; Q-200321; Sodium valproate; 2-Propylpentanoic acid sodium salt; SR-01000075242-7; F2191-0115; Z1511532065; Valproic acid, European Pharmacopoeia (EP) Reference Standard; Valproic acid, United States Pharmacopeia (USP) Reference Standard; Valproic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)" NIJJYAXOARWZEE-UHFFFAOYSA-N CCCC(CCC)C(=O)O C8H16O2 CAS 99-66-1 CHEBI:39867 . . . DB00313 . DR0688 Dipyridamole D0F9GE D0F9GE Approved Hypertension ICD-11: BA00-BA04 CID: 3108 Anticancer Treatment "dipyridamole; 58-32-2; Dipyridamol; Dipyridamine; Persantin; Dipyudamine; Persantine; Curantyl; Stimolcardio; Cardoxin; Kurantil; Stenocardil; Cardioflux; Dipiridamol; Dipyridan; Peridamol; Anginal; Apricor; Coribon; Corosan; Coroxin; Stenocardiol; Agilease; Chilcolan; Justpertin; Permiltin; Piroan; Cleridium 150; Coronarine; Gulliostin; Prandiol; Natyl; Prandiol 75; Usaf Ge-12; Dypyridamol; 2,2',2'',2'''-((4,8-Di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol; Dipyridamolum; RA 8; RA-8; Dipyridamole (Persantine); C24H40N8O4; UNII-64ALC7F90C; NSC 515776; NSC-515776; MLS000028420; Cleridium; CHEMBL932; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; Iv Persantine; SMR000058382; 64ALC7F90C; CHEBI:4653; Cardoxil; Pyrimido(5,4-d)pyrimidine, 2,6-bis(bis(2-hydroxyethyl)amino)-4,8-dipiperidino-; MFCD00010555; NSC515776; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)pyrimido[5,4-d][1,3]diazin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol; Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; CAS-58-32-2; NCGC00015385-12; Dypyridamole; Coridil; Protangix; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; DSSTox_CID_20668; DSSTox_RID_79531; DSSTox_GSID_40668; 2,2',2'',2'''-((4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol); 2,2',2'',2'''-{[4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo}tetraethanol; Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-; Ethanol,2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Permole; Persantine (TN); (3E)-3-[[(1S,4aS,8aS)-Decahydro-5,5,8a-trimethyl-2-methylene-1-naphthalenyl]methylene]dihydro-5-methoxy-2(3H)3-[(1E)-2-[(1S,4aS,8aS)-Decahydro-5,5,8a-trimethyl-2-methylene-1-naphthalenyl]ethenyl]furan; (+)-Coronarin E-furanone; Coronarin D methyl ethe; 2,2',2'',2'''-((4,8-Di(piperidin-1-yl)pyrimido[5,4-d]-pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol; SR-01000003065; EINECS 200-374-7; BRN 0068373; Dipridacot; Prestwick_145; Dipyridamole [USAN:USP:INN:BAN:JAN]; Spectrum_001004; Tocris-0691; Opera_ID_494; Prestwick0_000142; Prestwick1_000142; Prestwick2_000142; Prestwick3_000142; Spectrum2_000972; Spectrum3_000402; Spectrum4_000522; Spectrum5_000839; Lopac-D-9766; UPCMLD-DP072; D 9766; cid_3108; 2,2',2'',2'''-((4,8-Dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetraethanol; Lopac0_000464; SCHEMBL16119; BSPBio_000244; BSPBio_001554; BSPBio_001924; KBioGR_001123; KBioSS_001484; 4-26-00-03840 (Beilstein Handbook Reference); MLS001076306; MLS001333724; MLS002548866; DivK1c_000696; SPECTRUM1500259; SPBio_001003; SPBio_002183; BPBio1_000270; GTPL4807; DTXSID6040668; Thymidine,6-dihydro-6-methoxy-; UPCMLD-DP072:001; BDBM23620; Dipyridamole (JP17/USP/INN); HMS502C18; IZEKFCXSFNUWAM-UHFFFAOYSA-; KBio1_000696; KBio2_001484; KBio2_004052; KBio2_006620; KBio3_001144; B01AC07; NINDS_000696; BCPP000256; HMS1568M06; HMS1791N16; HMS1920I10; HMS1989N16; HMS2089N15; HMS2091O18; HMS2095M06; HMS2232E19; HMS3259C03; HMS3261M10; HMS3266J17; HMS3371J03; HMS3402N16; HMS3411B03; HMS3655I20; HMS3675B03; HMS3712M06; HMS3742O03; HMS3867F13; Pharmakon1600-01500259; ZINC643046; AMY40468; BCP26947; EBD20789; HY-B0312; Tox21_110133; Tox21_500464; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; ANW-49242; BBL027781; CCG-40190; NSC756743; s1895; STL377790; AKOS000509426; Tox21_110133_1; BCP9000613; DB00975; Dipyridamole, >=98% (TLC), powder; HS-0041; LP00464; MCULE-3112669573; MP-0582; NC00448; NSC-619103; NSC-756743; SDCCGSBI-0050449.P005; VA10749; IDI1_000696; SMP2_000208; NCGC00015385-01; NCGC00015385-02; NCGC00015385-03; NCGC00015385-04; NCGC00015385-05; NCGC00015385-06; NCGC00015385-07; NCGC00015385-08; NCGC00015385-09; NCGC00015385-10; NCGC00015385-11; NCGC00015385-13; NCGC00015385-14; NCGC00015385-15; NCGC00015385-16; NCGC00015385-18; NCGC00015385-29; NCGC00023914-02; NCGC00023914-04; NCGC00023914-05; NCGC00023914-06; NCGC00023914-07; NCGC00023914-08; NCGC00023914-09; NCGC00023914-10; NCGC00023914-11; NCGC00261149-01; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-bis(1-piperidyl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol; AC-18100; AC-30804; AK-76609; Ethanol, 2,2',2'',2'''-((4,8-dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetra-; H843; NCI60_005689; ST078856; SBI-0050449.P004; 2,8-dipiperidinopyrimido[5,4-d]pyrimidine; AB0013300; AB00051974; B1933; EU-0100464; FT-0603242; SW196456-3; W1467; EN300-70723; BIM-0050449.0001; D00302; J10379; 54290-EP2277865A1; 54290-EP2298773A1; 54290-EP2305653A1; 54290-EP2308562A2; AB00051974-18; AB00051974-19; AB00051974_20; AB00051974_21; A828156; Q419374; SR-01000003065-2; SR-01000003065-4; SR-01000003065-5; SR-01000003065-7; W-105400; BRD-K86301799-001-04-1; BRD-K86301799-001-19-9; BRD-K86301799-001-24-9; Z1259192074; Dipyridamole, British Pharmacopoeia (BP) Reference Standard; Dipyridamole, European Pharmacopoeia (EP) Reference Standard; Dipyridamole, United States Pharmacopeia (USP) Reference Standard; Pyrimido(5, 2,6-bis[bis(2-hydroxyethyl)amino]-4,8-diperidino-; 2,2'',2'''-[4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilotetraethanol; 2,2',2'',2'''-(4,8-Dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilotetraethanol; 2-[[2-(bis(2-hydroxyethyl)amino)-4,8-di(piperidin-1-yl)pyrimido[6,5-e]pyrimidin-; Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard; Ethanol,2',2'',2'''-(4,8-dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetra-; WLN: T66 BN DN GN INJ CCN HCN E- AT6NTJ B2Q F2Q& J- AT6NTJ B2Q F2Q; 2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol; 2,2',2'',2'''-[(4,8-dipiperidin-1-ylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol; 2,2',2'',2'''-[(4,8-Dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol; 2,2',2'',2'''-[(4,8-Dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakisethanol; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-dipiperidylpyrimidino[5,4-d]pyrimidin-2-y l}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-bis(1-piperidinyl)-6-pyrimido[5,4-d]pyrimidinyl]-(2-hydroxyethyl)amino]ethanol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol;; Ethanol, 2,2',2'',2'''-(4,8-dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyldinitrilo)tetra-; Ethanol, 2,2',2',2'''-((4,8-di-1-iperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-; Ethanol,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; Ethanol,2',2'',2'''-[(4,8-dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetra-" Small molecule "1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2" IZEKFCXSFNUWAM-UHFFFAOYSA-N C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO C24H40N8O4 CAS 58-32-2 CHEBI:4653 . . . . . DR1277 Diethylcarbamazine D06RCB D06RCB Approved Filariasis ICD-11: 1F66 CID: 3052 Anticancer Treatment "diethylcarbamazine; 90-89-1; N,N-diethyl-4-methylpiperazine-1-carboxamide; Carbamazine; Diethyl carbamazine; Carbilazine; Ethodryl; Notezine; Bitirazine; Caricide; Cypip; Ditrazine Base; Caracide; Spatonin; 1-Piperazinecarboxamide, N,N-diethyl-4-methyl-; N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-Diethylcarbamazine; UNII-V867Q8X3ZD; RP 3799; 84L; CHEBI:4527; V867Q8X3ZD; Bitirazine; Caracide;Carbamazine; MMV002816; Diaethylcarbamazinum; Dietilcarbamazina; Diethylcarbamazinum; Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; NSC1364; N,N-diethyl(4-methylpiperazinyl)carboxamide; Camin (TN); Diethylcarbamazine (INN); EINECS 202-023-3; 1-Diethylcarbamoyl-4-Methylpiperazine; BRN 0143029; AI3-19612; 1-Diethylcarbamyl-4-methylpiperazine; 1-Methyl-4-diethylcarbamoylpiperazine; Banocide (Salt/Mix); Caritrol (Salt/Mix); Nemacide (Salt/Mix); Spectrum_000938; NN-Diethyl-4-methyl-1-piperazinecarboxamide; Prestwick0_000284; Prestwick1_000284; Prestwick2_000284; Prestwick3_000284; Spectrum2_001022; Spectrum3_000390; Spectrum4_000511; Spectrum5_000877; diethyl carbamazine citrate; CHEMBL684; EC 202-023-3; SCHEMBL67289; BSPBio_000188; BSPBio_002179; KBioGR_001081; KBioSS_001418; 4-23-00-00225 (Beilstein Handbook Reference); DivK1c_000548; SPBio_001203; SPBio_002407; BPBio1_000208; ZINC1288; DTXSID1022928; KBio1_000548; KBio2_001418; KBio2_003986; KBio2_006554; KBio3_001399; NINDS_000548; HMS3604F12; 1-Diethylcarbamoyl-4-methylpiperzine; MFCD00023288; SBB008185; AKOS003268016; DB00711; DS-9360; MCULE-7296820622; NE55264; IDI1_000548; NCGC00178778-01; NCGC00178778-02; NCGC00178778-07; AK158485; ST094965; SBI-0051345.P003; DB-080764; R.P. 3799; 1-(N,N-Diethylcarbamoyl)-4-methylpiperazine; AB00053457; FT-0624832; C07968; D07825; N,N-diethyl-4-methyl-piperazine-1-carboxamide; AB00053457_12; Q409267; BRD-K45542189-048-05-6; BRD-K45542189-048-15-5" Small molecule "1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3" RCKMWOKWVGPNJF-UHFFFAOYSA-N CCN(CC)C(=O)N1CCN(CC1)C C10H21N3O CAS 90-89-1 CHEBI:4527 . . . DB00711 . DR2276 Diazinon . . Investigative Scabies ICD-11: 1G04 CID: 3017 Anticancer Treatment "diazinon; Dimpylate; 333-41-5; Diazinone; Oleodiazinon; Neocidol; Ciazinon; Dassitox; Diazitol; Ektoband; Nedcidol; Spectracide; Antigal; Basudin; Bazuden; Dacutox; Dazzel; Diazide; Diazol; Exodin; Flytrol; Galesan; Nucidol; Sarolex; Dicid; Alfa-tox; Diazajet; Dimpylat; Garden Tox; Neocidol (oil); Bassadinon; Terminator; Compass; Disonex; Dizinon; Drawizon; Kayazinon; Kayazol; Meodinon; Dyzol; Nipsan; Diazinon ag 500; Knox-out; Delzinon; Dimpylatum; Dipofene; Dizictol; Neodinon; Optimizer; Bazudin; Dizinil; Srolex; Basudin 10 G; Geigy 24480; Basudin S; Knox Out 2FM; Diagran; Fezudin; NCI-C08673; AG-500; ENT 19,507; Isopropylmethylpyrimidyl diethyl thiophosphate; G-24480; Diziktol; O,O-Diethyl 2-isopropyl-4-methylpyrimidyl-6-thiophosphate; G 301; O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate; UNII-YUS1M1Q929; 4-Pyrimidinol, 2-isopropyl-6-methyl-, O-ester with O,O-diethyl phosphorothioate; Diethyl 4-(2-isopropyl-6-methylpyrimidinyl)phosphorothionate; O-2-Isopropyl-4-methylpyrimidyl-O,O-diethyl phosphorothioate; O,O-Diethyl O-(2-isopropyl-4-methyl-6-pyrimidyl) thionophosphate; CHEBI:34682; O,O-Diethyl O-6-methyl-2-isopropyl-4-pyrimidinyl phosphorothioate; Phosphorothioate, O,O-diethyl O-6-(2-isopropyl-4-methylpyrimidyl); Thiophosphate de O,O-diethyle et de O-2-isopropyl-4-methyl-6-pyrimidyle; Phosphorothioic acid, O,O-diethyl O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl) ester; YUS1M1Q929; Diethyl 2-isopropyl-4-methyl-6-pyrimidinyl phosphorothionate; NSC8938; O,O-Diethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiofosfaat; Phosphorothioic acid, O,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) ester; Diethyl 2-isopropyl-4-methyl-6-pyrimidyl thionophosphate; NCGC00091073-01; Bazudine; Neotsidol; O,O-Diethyl 2-isopropyl-6-methyl-4-pyrimidinylphosphorothioate; DSSTox_CID_407; O,O-Diethyl O-(2-isopropyl-4-methyl-6-pyrimidinyl) phosphorothioate; O,O-diethyl O-[6-methyl-2-(1-methylethyl)pyrimidin-4-yl] thiophosphate; Kleen-Dok; DSSTox_RID_75567; Phosphorothioic acid, O,O-diethyl O-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl] ester; DSSTox_GSID_20407; Diazinon, analytical standard; KFM Blowfly Dressing; Compass (insecticide); Caswell No. 342; gardentox; Dimpilato; Diaterr-fos; Dimpylatum [INN-Latin]; O,O-Diaethyl-O-(2-isopropyl-4-methyl-pyrinidin-6-yl)-monothiophosphat; O,O-Diethyl O-(2-isopropyl-4-methyl-6-pyrimidyl) phosphorothioate; Cooper's Flystrike Powder; Dimpilato [INN-Spanish]; NSC 8938; Phosphorothioic acid, O,O-diethylO-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl] ester; Diazinon [ANSI:BSI:ISO]; CAS-333-41-5; CCRIS 204; HSDB 303; Knox Out Yellow Jacket Contorl; OMS 469; EINECS 206-373-8; PT 265; EPA Pesticide Chemical Code 057801; BRN 0273790; Spertacide; Bazanon; Antlak; AI3-19507; Root guard; Diethyl dimpylatum; diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidene-?^{5}-phosphane; Dimpylate, INN; Basudin 5G; Dimpylate (INN); Spectracide 25EC; G 24480; Agridin 60; Basudin 10G; Spectrum_001777; Dimpylate [INN:BAN]; New Z Diazinon (TN); SpecPlus_000344; O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl)phosphorothioate; O,O-Diethyl-O-(2-isopropyl-4-methyl-6-pyrimidyl)phosphorothioate; Spectrum2_001226; Spectrum3_000802; Spectrum4_000642; Spectrum5_001929; Thiophosphoric acid 2-isopropyl-4-methyl-6-pyrimidyl diethyl ester; O,O-Diethyl-O-(2-isopropyl-4-methyl-6-pyrimidinyl)-phosphorothioate; Phosphorothioic acid, O,O-diethyl O-(isopropylmethylpyrimidinyl) ester; O,O-Diaethyl-O-(2-isopropyl-4-methyl)-6-pyrimidyl-thionophosphat [German]; O,O-Diaethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiophosphat [German]; O,O-Diethyl O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl)phosphorothioate; O,O-Diethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiofosfaat [Dutch]; O,O-Dietil-O-(2-isopropil-4-metil-pirimidin-6-il)-monotiofosfato [Italian]; Optimizer Insecticide (TN); Thiophosphate de O,O-diethyle et de O-2-isopropyl-4-methyl-6-pyrimidyle [French]; SCHEMBL17453; BSPBio_002263; KBioGR_000983; KBioSS_002258; 5-23-11-00187 (Beilstein Handbook Reference); MLS002207243; BIDD:ER0457; DivK1c_006440; SPBio_001072; CHEMBL388560; ZINC1309; DIAZINON (DIETHYL-D10); DTXSID9020407; FHIVAFMUCKRCQO-UHFFFAOYSA-; KBio1_001384; KBio2_002257; KBio2_004825; KBio2_007393; KBio3_001763; AMY3613; HMS3264I04; Pharmakon1600-00330017; EBD29972; HY-B1113; NSC-8938; O,O-Diaethyl-O-(2-isopropyl-4-methyl)-6-pyrimidyl-thionophosphat; o,o-diethyl o-2-isopropyl-6-methylpyrimidin-4-yl phosphorothioate; Diazinon 100 microg/mL in Acetone; Tox21_111077; Tox21_201409; Tox21_300730; BDBM50005409; CCG-39143; ENT 19507; NSC755893; O,O-Diaethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiophosphat; O,O-Dietil-O-(2-isopropil-4-metil-pirimidin-6-il)-monotiofosfato; Diazinon 10 microg/mL in Cyclohexane; Diazinon 1000 microg/mL in Toluene; AKOS025311513; Diazinon 1000 microg/mL in Methanol; diethoxy-(2-isopropyl-6-methyl-pyrimidin-4-yl)oxy-thioxo-$l^{5}-phosphane; O,O-diethyl O-[6-methyl-2-(propan-2-yl)pyrimidin-4-yl] phosphorothioate; Tox21_111077_1; CS-4712; Diazinon 10 microg/mL in Acetonitrile; Diazinon 100 microg/mL in Cyclohexane; NSC-755893; Diazinon 100 microg/mL in Acetonitrile; NCGC00091073-02; NCGC00091073-03; NCGC00091073-04; NCGC00091073-05; NCGC00091073-06; NCGC00091073-07; NCGC00254636-01; NCGC00258960-01; SMR000777921; SBI-0052498.P002; DB-048387; Diazinon, PESTANAL(R), analytical standard; FT-0603088; FT-0778116; C14324; D07856; AB00053004_04; 333D415; Q411202; SR-01000872734; Q-200952; SR-01000872734-1; BRD-K60567437-001-04-5; Diazinon, certified reference material, TraceCERT(R); 4-Pyrimidinol, O-ester with O,O-diethyl phosphorothioate; WLN: T6N CNJ BY1 & 1 DOPS & O2 & O2 F1; O, O-Diethyl 2-isopropyl-4-methylpyrimidyl-6-thiophosphate; O,O-Diethyl-O-(2-isopropyl-4-methylpyrimidyl)thiophosphate; o,o-Dietil-o-(2-isopropil-4-metil-pirimidin-il)-monotiofosato; Phosphorothioate,O-diethyl O-6-(2-isopropyl-4-methylpyrimidyl); O,O-Diethyl O-(2-isopropyl-6-methyl-4-primidinyl)phosphorothioate; O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) thiophosphate; O,O-Diethyl o-(2-isopropyl-6-methyl-4-pyrimidinyl) thiophosphate #; O,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl)thio-phosphate; O,O-Diethyl-O-(2-isopropyl-4-methyl-6-pyrimidyl) thiophosphate; diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidenephosphorane; o,o-Diethyl-O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl)phosophorothioate; Phosphorothioic acid, O,O-diethyl 2-isopropyl-6-methyl-4-pyrimidinyl ester; Phosphorothioic acid,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) ester; Diazinon solution, 100 mug/mL in acetonitrile, PESTANAL(R), analytical standard; diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidene-$l^{5-phosphane; ethyl 6-methyl-2-(propan-2-yl)pyrimidin-4-yl ethoxy(sulfanylidene)phosphonite; Phosphorothioic acid, O,O-diethyl {O-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl]} ester; PHOSPHOROTHIOIC ACID,O-DIETHYL O-[6-METHYL-2-(1-METHYLETHYL)-4-PYRIMIDINYL] ESTER; O,O-Diethyl O-2-isopropyl-4-methyl-6-pyrimidyl thiophosphate; O,O-Diethyl O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl) phosophorothioate" Small molecule "1S/C12H21N2O3PS/c1-6-15-18(19,16-7-2)17-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3" FHIVAFMUCKRCQO-UHFFFAOYSA-N CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)C(C)C C12H21N2O3PS CAS 333-41-5 CHEBI:34682 . . . . . DR5175 Difluoromethylornithine D0X7JR D0X7JR Approved African trypanosomiasis ICD-11: 1F51 CID: 3009 Anticancer Treatment "EFLORNITHINE; 70052-12-9; Ornidyl; 2-(Difluoromethyl)ornithine; dfmo; Difluoromethylornithine; 2,5-diamino-2-(difluoromethyl)pentanoic acid; Vaniqa; alpha-Difluoromethylornithine; alpha-(Difluoromethyl)-DL-ornithine; 67037-37-0; 2-(Difluoromethyl)-DL-ornithine; Difluromethylornithine; Eflornithine free base; RMI 71782; (RS)-eflornithine; DL-.alpha.-Difluoromethylornithine; CHEMBL830; DFMO HCl; CHEBI:41948; 70052-12-9 (free base); NSC337250; Eflornithinum; Eflornitina; Eflornithinum [Latin]; Eflornitina [Spanish]; 2,5-diamino-2-(difluoromethyl)pentanoic acid.; .alpha.-DFMO HCl; DFMO (growth regulator); Eflornithine [INN:BAN]; L-DFMO;L-RMI71782;L-alpha-difluoromethylornithine; DL-alpha-(Difluoromethyl)ornithine; DL-Ornithine, monohydrochloride; MDL 71782; Eflornithine (INN); CCRIS 3295; Ornithine, 2-(difluoromethyl)-; NSC-337250; 70050-56-5; DL-Ornithine, 2-(difluoromethyl)-; BRN 2250529; alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; D-Ornithine, 2-(difluoromethyl)-; C6H12F2N2O2; HSDB 7923; alpha-DFMO; 66640-93-5; RFI 7178; ACMC-20m6r1; Lopac0_000429; SCHEMBL26327; GTPL5176; 2-(difluoromethyl)-L-ornithine; alpha-difluoromethyl-dl-ornithine; DTXSID3020467; H-DL-(a-Difluoromethyl)Orn-OH; BCP10516; HY-B0744; 2-(difluoromethyl)ornithine (DMFO); BDBM50028197; HSCI1_000267; KM1060; MFCD00221766; AKOS006281180; CCG-204521; DB06243; SDCCGSBI-0050414.P002; NCGC00015316-02; NCGC00015316-03; NCGC00015316-06; NCGC00015316-15; NCGC00162152-01; K100; 2-difluoromethyl-2,5-diaminopentanoic acid; DB-055371; FT-0630795; FT-0720946; FT-0775156; 2-(difluoromethyl)-2,5-diaminopentanoic acid;; C07997; D07883; 020E916; Q424751; (RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid; DFMO;MDL71782;RMI71782;; A-difluoromethylornithine" Small molecule "1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)" VLCYCQAOQCDTCN-UHFFFAOYSA-N C(CC(C(F)F)(C(=O)O)N)CN C6H12F2N2O2 CAS 70052-12-9 CHEBI:41948 . . . . . DR7699 Deferoxamine D06GKR D06GKR Approved Low bone mass disorder ICD-11: FB83 CID: 2973 Anticancer Treatment "deferoxamine; Desferrioxamine B; DESFERRIOXAMINE; 70-51-9; Deferoxamine B; Deferrioxamine B; Deferrioxamine; Deferoxamin; Deferoxaminum; Desferin; DFOM; Desferan; Desferex; Desferral; Desferrin; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; Deferoxamina; NSC-527604; Ferrioxamine B, N-benzoyl-; UNII-J06Y7MXW4D; N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide; Ba-33112; J06Y7MXW4D; CHEBI:4356; NSC527604; 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide; Desferal mesylate; Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid; Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-; Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Desferriferrioxamin B; MLS002702118; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina [INN-Spanish]; N-(5-aminopentyl)-N-hydroxy-N'-[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]butanediamide; Ba 29837; NSC268993; NSC644468; HSDB 3311; SMR000058548; EINECS 200-738-5; Ba 33112; BRN 2514118; Cordaneurin; Desferrioxamin; Perineurin; Desferioxamine B; desferrioxamine-B; C25H48N6O8; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide; N-[5-(3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido)pentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)propionohydroxamic acid; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-; deferoxamine-mesylate; Deferoxamine (USAN); Desferal (Salt/Mix); Spectrum_000892; N-benzoyl-Ferrioxamine B; Prestwick0_000725; Prestwick1_000725; Prestwick2_000725; Prestwick3_000725; Spectrum2_001155; Spectrum3_000376; Spectrum4_000311; Spectrum5_000827; CHEMBL556; EC 200-738-5; SCHEMBL34571; BSPBio_000650; BSPBio_002131; KBioGR_000922; KBioGR_002429; KBioSS_001372; KBioSS_002435; 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane; cid_62881; N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide; DivK1c_000082; Ba 29837 (Salt/Mix); SPBio_001109; SPBio_002589; BPBio1_000716; CGH-749B; ICL-749B; DTXSID7022887; BDBM47715; KBio1_000082; KBio2_001372; KBio2_002429; KBio2_003940; KBio2_004997; KBio2_006508; KBio2_007565; KBio3_001351; KBio3_002908; cMAP_000047; NINDS_000082; HMS3604E17; BCP16524; ZINC3830635; 0917AC; ANW-62156; LMFA08020169; WLN: Z5NQV/2VM5NQV/ 21; DEFEROXAMINE, Deferoxamine Mesylate; AKOS016004824; DB00746; MCULE-3095507442; IDI1_000082; SMP2_000121; NCGC00178802-01; NCGC00178802-02; NCGC00178802-03; NCI60_002181; SMR001550278; SBI-0051332.P003; AB00053447; C06940; D03670; 15182-EP2316832A1; 15182-EP2316833A1; AB00053447_14; 070D519; Q419618; Q-200933; BRD-K09821361-066-05-0; BRD-K09821361-066-06-8; BRD-K09821361-066-08-4; BRD-K09821361-066-13-4; BRD-K09821361-066-15-9; BRD-K09821361-066-16-7; 3,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Butanediamide,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; N''''-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N''''-oxidanyl-butanediamide;methanesulfonic acid; N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-keto-butanoyl]-hydroxy-amino]pentyl]-N''-(5-aminopentyl)-N''-hydroxy-succinamide;mesylic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide; Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)-; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]-" Small molecule "1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)" UBQYURCVBFRUQT-UHFFFAOYSA-N CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O C25H48N6O8 CAS 70-51-9 CHEBI:4356 . . . DB00746 . DR3007 Dapsone D0MA9N D0MA9N Approved Pneumonia ICD-11: CA40 CID: 2955 Anticancer Treatment "dapsone; 80-08-0; 4,4'-Sulfonyldianiline; Diaphenylsulfone; Dapson; 4,4'-Diaminodiphenyl sulfone; 4-Aminophenyl sulfone; 4,4'-Diaminodiphenylsulfone; Diaphenylsulfon; Sulfona; DADPS; Avlosulfone; Diphenasone; Sulfadione; Sulphadione; Disulone; Udolac; p-Aminophenyl sulfone; Bis(4-aminophenyl) sulfone; Avlosulfon; Croysulfone; Dapsonum; Dumitone; Novophone; Aczone; Diphone; Eporal; Diaphenylsulphon; Diaphenylsulphone; Metabolite C; Sulfonyldianiline; Sumicure S; Bis(p-aminophenyl) sulfone; Sulphonyldianiline; p,p-Sulphonylbisbenzamine; Sulfona-MAE; Avlosulphone; Croysulphone; Dubronax; 4,4'-Dapsone; Diaminodiphenyl sulfone; Tarimyl; p,p-Sulphonylbisbenzenamine; Sulfone ucb; 4,4'-Sulfonylbisaniline; p,p'-Diaminodiphenyl sulfone; 4-(4-aminophenyl)sulfonylaniline; Dapsona; Benzenamine, 4,4'-sulfonylbis-; Diaminodiphenylsulfone; Di(p-aminophenyl)sulphone; Bis(4-aminophenyl)sulfone; Di(p-aminophenyl) sulfone; p,p-Sulphonyldianiline; 4,4'-Sulfonylbisbenzamine; Di(4-aminophenyl) sulfone; p,p'-sulfonyldianiline; NSC-6091; 4,4'-Sulfonylbisbenzenamine; p,p-Sulfonylbisbenzamine; Diaminodifenilsulfona; DDS, pharmaceutical; p,p-Sulfonylbisbenzenamine; Araldite HT 976; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl)sulphone; Bis(4-aminophenyl)sulphone; p,p-Diaminodiphenyl sulphone; N,N'-Diphenyl sulfondiamide; 1,1'-Sulfonylbis(4-aminobenzene); 4,4'-Sulphonyldianiline; 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; DDS; 4,4'-Diaminodiphenyl sulphone; WR 448; 4,4-Diaminodifenylsulfon; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; NSC 6091D; NCI-C01718; 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); Aniline, 4,4'-sulfonyldi-; HT 976; 4,4'-diamino diphenyl sulphone; F 1358; 4,4'-Sulfonyldianiline (Dapsone); 1358F; 4-[(4-aminobenzene)sulfonyl]aniline; MFCD00007887; 4,4'-Sulfonylbisbenzeneamine; 4,4'-Sulfonyldianilin; UNII-8W5C518302; 4-[(4-aminophenyl)sulfonyl]aniline; CHEMBL1043; 4-Aminophenyl sulfone, 97%; MLS000069409; CHEBI:4325; DTXSID4020371; Sulfanona-mae; NSC6091; Sulfon-mere; 4,4'-DDS; Di(4-aminophenyl)sulfone; 4-[(4-Aminophenyl)sulfonyl]phenylamine; 4-(4-amino-benzenesulfonyl)-phenylamine; NCGC00016322-08; SMR000059064; Hardener HT 976; DDS (pharmaceutical); Sulphon-mere; DSSTox_CID_371; 8W5C518302; Dapsonum [INN-Latin]; Dapsona [INN-Spanish]; DSSTox_RID_75547; DSSTox_GSID_20371; DSS (VAN); 4-Aminophenylsulfone; DDS, diaphenylsulfone; 4,4'-Diaminodiphenyl suphone; Atrisone; Diaminodifenilsulfona [Spanish]; 4,4-Diaminodifenylsulfon [Czech]; CAS-80-08-0; HY 976; CCRIS 192; Dapsone (USP); Aczone (TN); HSDB 5073; Diaphenylsulfone (JAN); SR-01000002976; NSC 6091; Sulfone, diphenyl, 4,4'-diamino-; EINECS 201-248-4; (4-sulfanilylphenyl)amine; AZT + Dapsone cominbation; BRN 0788055; Servidapson; AI3-08087; diaphenylsulfone;; Diaphenyl sulfone; Dapsone [USAN:USP:INN:BAN]; Dapsone-d8; Dapsone,(S); Prestwick_152; ALBB-005917; Dapsone-[d4]; IN-201; 1632119-29-9; Dapsone-13C12; BIS SULFONE; 4,4''-dapsone; Dapsone-[15N2]; Spectrum_000888; ACMC-209piw; Aniline,4'-sulfonyldi-; Opera_ID_1950; Prestwick0_000035; Prestwick1_000035; Prestwick2_000035; Prestwick3_000035; Spectrum2_001133; Spectrum3_000375; Spectrum4_000310; Spectrum5_000825; WLN: ZR DSWR DZ; 4,4''-sulfonyldianiline; 4,4''-sulfonylbisaniline; 4'-Diaminodiphenyl sulfone; EC 201-248-4; 4,4'-Sulfonyldiphenylamine; Benzenamine,4'-sulfonylbis-; Oprea1_143052; SCHEMBL21428; BSPBio_000129; BSPBio_002129; CBDivE_013582; Dianiline, 4,4'-sulfonyl-; KBioGR_000900; KBioSS_001368; MLS001055349; MLS001076146; 4,4''-Sulfonylbisbenzenamine; 4,4'-Sulfonylbis-benzenamine; 4,4'-Sulfonylbis[benzamine]; BIDD:GT0770; DivK1c_000573; p,p''-diaminodiphenyl sulfone; SPECTRUM1500222; SPBio_001025; SPBio_002050; 4,4''-diaminodiphenyl sulfone; 4,4'-diamino diphenyl sulfone; BPBio1_000143; ZINC6310; GTPL10934; HMS501M15; KBio1_000573; KBio2_001368; KBio2_003936; KBio2_006504; KBio3_001349; NSC-6091D; 4-(4-aminophenylsulfonyl)aniline; J04BA02; NINDS_000573; HMS1568G11; HMS1920C14; HMS2091K04; HMS2095G11; HMS2231G09; HMS3259C13; HMS3369B11; HMS3712G11; Pharmakon1600-01500222; ACT07431; AMY40781; EBD28910; HY-B0688; 1,1''-sulfonylbis(4-aminobenzene); Tox21_110371; Tox21_201347; Tox21_300558; 4-(4-aminophenylsulfonyl)benzenamine; ANW-37350; BBL002412; BDBM50029764; CCG-40260; CD0112; NSC756716; s4612; SBB003168; STK387118; AKOS000119322; Tox21_110371_1; DB00250; HT 9664; KS-1450; LS10738; MCULE-7294380437; NC00488; NSC-756716; IDI1_000573; NCGC00016322-01; NCGC00016322-02; NCGC00016322-03; NCGC00016322-04; NCGC00016322-05; NCGC00016322-06; NCGC00016322-07; NCGC00016322-09; NCGC00016322-10; NCGC00016322-13; NCGC00023946-03; NCGC00023946-04; NCGC00023946-05; NCGC00023946-06; NCGC00254533-01; NCGC00258899-01; AC-10922; AK175100; 4-[(4-Aminophenyl)sulfonyl]phenylamine #; SBI-0051331.P003; DB-056406; AB00051962; D0089; Dapsone, VETRANAL(TM), analytical standard; FT-0624447; FT-0665473; R1186; ST50308134; 4 inverted exclamation marka-Sulfonyldianiline; C07666; D00592; AB00051962_19; A839828; Q422226; 4 inverted exclamation marka-Diaminodiphenyl sulfone; Q-200435; SR-01000002976-2; SR-01000002976-4; BRD-K62363391-001-05-8; BRD-K62363391-001-15-7; 4 4-Diamino Diphenyl Sulfone 99.5%min Cas:80-08-8; Dapsone, British Pharmacopoeia (BP) Reference Standard; Dapsone, European Pharmacopoeia (EP) Reference Standard; F0266-3067; 2-(PIPERAZIN-1-YL)-ACETICACIDN-(2-PHENYLETHYL)-AMIDE; Dapsone, United States Pharmacopeia (USP) Reference Standard; Dapsone, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2" MQJKPEGWNLWLTK-UHFFFAOYSA-N C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N C12H12N2O2S CAS 80-08-0 CHEBI:4325 . . . DB00250 . DR9940 Ciprofloxacin D0O1WX D0O1WX Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 2764 Anticancer Treatment "ciprofloxacin; 85721-33-1; Ciprobay; Ciprofloxacine; Cipro; Ciproxan; Ciprofloxacina; Cipro IV; 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; Ciprofloxacino; Ciprofloxacinum; Ciproflox; Ciproxina; BAY q 3939; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; Cetraxal; Ciloxan; Cipro XR; CPFX; 1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid; Bay-09867; C17H18FN3O3; UNII-5E8K9I0O4U; Ciproxin; Ciflox; BAYQ3939; 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Ciprofloxacin (Cipro); CHEMBL8; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; Bay o 9867; 5E8K9I0O4U; Ciprocinol; Cipromycin; Ciproquinol; Bacquinor; Bernoflox; Cifloxin; Ciprinol; Ciprodar; Septicide; CHEBI:100241; Ciprofloxacin-d8; Velmonit; Ciprofloxacin monohydrochloride; MFCD00185755; Ciprofloxacin, 98%; Ciprecu; Ciprogis; Ciprolin; Ciprolon; Ciprowin; Ciproxine; Citopcin; Corsacin; Fimoflox; Ipiflox; Italnik; Otiprio; Probiox; Proflaxin; Quinolid; Quintor; Roxytal; Spitacin; Superocin; Zumaflox; Baflox; Ciplus; Ciriax; Rancif; Cilab; Cixan; Cycin; Loxan; Unex; Sophixin Ofteno; Ciprobay Uro; Alcon Cilox; Bi-Cipro; Cipro (TN); 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; Proksi 250; Proksi 500; Cyprobay; AuriPro; Eni; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazinylhydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; BAY-o 9867; Ciprofloxacine [INN-French]; Ciprofloxacinum [INN-Latin]; 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid; SMR000471901; Ciprofloxacino [INN-Spanish]; BAY-O-9867; CCRIS 5241; NSC620634; HSDB 6987; SR-05000001863; NCGC00016959-01; CAS-93107-08-5; CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER; BRN 3568352; rubrum; Ciprine; Linhaliq; Bay 09867; CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Ciprofloxacin,(S); Ciprofloxacin [USAN:USP:INN:BAN]; Spectrum_000162; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride; Prestwick0_000113; Prestwick1_000113; Prestwick2_000113; Prestwick3_000113; Spectrum2_001567; Spectrum3_001872; Spectrum4_000874; Spectrum5_001089; Cipro (*Hydrochloride*); CBMicro_048498; Ciloxan (*Hydrochloride*); SCHEMBL2900; Oprea1_008239; Oprea1_313572; BSPBio_000126; BSPBio_003344; KBioGR_001567; KBioSS_000642; ANHYDROUS CIPROFLOXACIN; MLS001336035; MLS006011837; BIDD:GT0205; DivK1c_000095; SPECTRUM1503614; SPBio_001474; SPBio_002065; ARONIS020379; BPBio1_000140; DTXSID8022824; BAY-O9867; BDBM21690; GTPL10902; HMS500E17; KBio1_000095; KBio2_000642; KBio2_003210; KBio2_005778; KBio3_002846; Linhaliq [Liposomal Formulation]; ZINC20220; BAY O 9867 FREE BASE; BAY-O-9867 FREE BASE; Ciprofloxacin (JP17/USP/INN); NINDS_000095; Bay o 9867 (*Hydrochloride*); BAY-Q-3939; HMS1922E18; HMS2090O07; HMS2093I03; Pharmakon1600-01503614; ALBB-015909; BCP28586; HY-B0356; RKL10073; BBL005612; CCG-39345; CIPROFLOXACIN EXTENDED RELEASE; Ciprofloxacin, >=98.0% (HPLC); NSC758467; NSC759028; s2027; SBB012554; STK021082; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid; AKOS000269653; AC-7613; DB00537; KS-5006; MCULE-8631780654; NSC 758467; NSC-758467; NSC-759028; IDI1_000095; SMP1_000125; NCGC00016959-02; NCGC00016959-03; NCGC00016959-04; NCGC00016959-05; NCGC00016959-07; NCGC00095058-01; NCGC00095058-02; NCGC00178128-01; AK163192; ST024751; SBI-0048462.P003; AB0011928; FT-0601635; A-8526; C05349; Ciprofloxacin 100 microg/mL in Methanol:Water; D00186; J10137; 721C331; Ciprofloxacin, VETRANAL(TM), analytical standard; Q256602; Ciprofloxacin, Antibiotic for Culture Media Use Only; SR-05000001863-1; SR-05000001863-3; BRD-K04804440-311-02-3; Z56933707; Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard; Ciprofloxacin, United States Pharmacopeia (USP) Reference Standard; 1-Cyclopropyl-6-fluoro-1,4-dihydro 4-oxo-7-[1-piperazinyl)-quinoline-3-carboxylic Acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl)-3-quinoline-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3- quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline -3-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1piperazinyl)-3quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid; 1-cyclopropyl-6-fluoro-7-(piperazin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid; Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid hydrochloride" Small molecule "1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)" MYSWGUAQZAJSOK-UHFFFAOYSA-N C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O C17H18FN3O3 CAS 85721-33-1 CHEBI:100241 . . . DB00537 . DR1182 Chloroquine D09EGZ D09EGZ Approved Malaria ICD-11: 1F40-1F45 CID: 2719 Anticancer Treatment "chloroquine; 54-05-7; Aralen; Chlorochin; Chloraquine; Artrichin; Chloroquinium; Chloroquina; Reumachlor; Capquin; Chemochin; Chlorquin; Clorochina; Malaquin; Arthrochin; Bemasulph; Benaquin; Bipiquin; Chingamin; Cidanchin; Cocartrit; Dichinalex; Gontochin; Heliopar; Iroquine; Klorokin; Lapaquin; Mesylith; Pfizerquine; Quinachlor; Quinercyl; Quinilon; Quinoscan; Sanoquin; Silbesan; Solprina; Sopaquin; Tresochin; Amokin; Bemaco; Elestol; Imagon; Malaren; Malarex; Neochin; Roquine; Siragan; Trochin; Nivaquine B; Bemaphate; Resoquine; Nivaquine; Chlorochine; Chloroquinum; Cloroquina; Quingamine; Avloclor; Resochin; Ronaquine; Khingamin; N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine; Avlochlor; Nivachine; Quinagamin; Quinagamine; Resochen; Resoquina; Reumaquin; Arechin; Delagil; Tanakan; WIN 244; 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-; RP 3377; W 7618; Chloroin; Miniquine; Rivoquine; Tanakene; Arolen; 7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline; CHEBI:3638; Chloroquine free base; N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine; Gontochin phosphate; CHEMBL76; SN 6718; 54-05-7 (free base); Ipsen 225; Chlorochinum; N(sup 4)-(7-Chloro-4-quinolinyl)-N(sup 1),N(sup 1)-diethyl-1,4-pentanediamine; MFCD00024009; NSC187208; NSC-187208; SN 7618; Chloroquine (VAN); Clorochina [DCIT]; 7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine; Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-; 3377 RP; SN-7618; 1,4-Pentanediamine, N(sup 4)-(7-chloro-4-quinolinyl)-N(sup 1),N(sup 1)-diethyl-; ST 21 (pharmaceutical); Chloroquinum [INN-Latin]; Cloroquina [INN-Spanish]; 3377 RP opalate; Chloroquin; Quinoline, 7-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]-; N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine; ST 21; (+-)-Chloroquine; NSC14050; CCRIS 3439; HSDB 3029; Chloroquine (USP/INN); EINECS 200-191-2; {4-[(7-chloro(4-quinolyl))amino]pentyl}diethylamine; Malaquin (*Diphosphate*); NSC 187208; BRN 0482809; Cloroquine; Chloroquine [USP:INN:BAN]; Chloroquine, 17; Chloroquine-[d4]; 4,7-Dichloroquine; {4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine; Arechin (Salt/Mix); Delagil (Salt/Mix); Tanakan (Salt/Mix); 1246815-14-4; RP-3377; Bemaphate (Salt/Mix); Resoquine (Salt/Mix); Spectrum_000132; Chloroquine + Proveblue; Prestwick0_000548; Prestwick1_000548; Prestwick2_000548; Prestwick3_000548; Spectrum2_000127; Spectrum3_000341; Spectrum4_000279; Spectrum5_000707; (.+/-.)-Chloroquine; 1,4-Pentanediamine, N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-; Epitope ID:131785; MolMap_000009; SCHEMBL8933; Lopac0_000296; BSPBio_000595; BSPBio_002001; KBioGR_000778; KBioSS_000592; DivK1c_000404; CU-01000012392-2; SPBio_000174; SPBio_002516; GNF-Pf-4216; BPBio1_000655; GTPL5535; DTXSID2040446; BDBM22985; KBio1_000404; KBio2_000592; KBio2_003160; KBio2_005728; KBio3_001221; NINDS_000404; HMS2090O03; ALBB-025694; HY-17589A; s6999; SBB072644; AKOS015935106; CCG-204391; CS-W004760; DB00608; KH-0005; MCULE-3610827164; SDCCGSBI-0050284.P005; IDI1_000404; SMP2_000034; NCGC00015256-02; NCGC00015256-03; NCGC00015256-04; NCGC00015256-05; NCGC00015256-06; NCGC00015256-07; NCGC00015256-08; NCGC00015256-09; NCGC00015256-10; NCGC00015256-13; NCGC00015256-17; NCGC00015256-28; NCGC00162120-01; AK116457; NCI60_000894; SY086904; WLN: T66 BNJ EMY1&3N2&2 IG; SBI-0050284.P004; AB00053436; CS-0021871; FT-0623612; ST45028748; C07625; D02366; MLS-0466768.0001; AB00053436-05; AB00053436_06; AB00053436_07; 1, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-; Q422438; BRD-A91699651-065-01-1; BRD-A91699651-316-06-7; n(sup4)-(7-chloro-4-quinolinyl)-n(sup1),4-pentanediamine; N'-(7-chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine; N4-(7-chloro-4-quinolyl)-N1,N1-diethyl-pentane-1,4-diamine; Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-; N(4)-(7-chloroquinolin-4-yl)-N(1),N(1)-diethylpentane-1,4-diamine; 1,4-pentanediamine, N~4~-(7-chloro-4-quinolinyl)-N~1~,N~1~-diethyl-, phosphate (1:2); N(sup4)-(7-chloro-4-quinolinyl)-N(sup1),N(sup1)-diethyl-1,4-pentanediamine; 117399-83-4; Chloroquine; Chloroquine Sulphate; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine" Small molecule "1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)" WHTVZRBIWZFKQO-UHFFFAOYSA-N CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl C18H26ClN3 CAS 54-05-7 CHEBI:3638 . . . DB00608 . DR4093 Chlorambucil D0V8QT D0V8QT Approved Mature B-cell leukaemia ICD-11: 2A82 CID: 2708 Anticancer Treatment "chlorambucil; 305-03-3; Ambochlorin; Chloroambucil; Leukeran; Chloraminophen; Chlorbutin; Chloraminophene; Chlorobutine; Amboclorin; Chlorbutine; Chlorobutin; Linfolizin; Linfolysin; Ecloril; Elcoril; Phenylbutyric acid nitrogen mustard; Chlocambucil; Lympholysin; Leukersan; Leukoran; 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid; Cb l348; NSC-3088; CB 1348; Phenylbuttersaeure-lost; Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-; NSC 3088; Rcra waste number U035; NCI-C03485; 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid; chlorambucilddv; 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid; N,N-Di-2-chloroethyl-gamma-p-aminophenylbutyric acid; 4-(Bis(2-chloroethyl)amino)benzenebutanoic acid; p-(N,N-Di-2-chloroethyl)aminophenyl butyric acid; 4-(p-Bis(beta-chloroethyl)aminophenyl)butyric acid; UNII-18D0SL7309; 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoic acid; CHEBI:28830; NSC3088; 4-[Bis(2-chloroethyl)amino]benzenebutyric acid; 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid; CHEMBL515; gamma-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)-; MLS000028443; Chloorambucol; Chlorbutinum; Elcorin; 4-(Bis(2-chloroethyl)amino)phenylbutyric acid; 4-(p-(Bis(2-chloroethyl)amino)phenyl)butyric acid; gamma-(p-Di(2-chloroethyl)aminophenyl)butyric acid; Butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)-; MFCD00021783; 18D0SL7309; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna; NCGC00015199-08; Chlorambucilum; Clorambucile; Clorambucilo; CAS-305-03-3; SMR000058372; Clorambucile [DCIT]; DSSTox_CID_263; Leukeran tablets; 4-[Bis(2-chloroethyl)amino]phenylbutyric acid; DSSTox_RID_75472; DSSTox_GSID_20263; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid; .gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]-; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; p-N,N-Di-(.beta.-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-.gamma.-p-aminophenylbutyric acid; CB-1348; CCRIS 126; Phenylbuttersaeure-lost [German]; HSDB 3026; SR-01000000062; LEUKERAN (TN); 4-[4-[Bis(2-chloroethyl)amino]phenyl]butyric Acid; EINECS 206-162-0; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric acid; .gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric acid; 4-(p-Bis(.beta.-chloroethyl)aminophenyl)butyric acid; 4-[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; RCRA waste no. U035; Butyric acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-; BRN 0999011; Chlorambucil [USP:INN:BAN]; AI3-26083; p-(N,N-Di-2-chlorethylaminophenyl)butyric acid; para-(Di(2-chloroethyl)aminophenyl)butyric acid; Chlorambucil,(S); gamma-(p-bis(2-chloroethyl)aminophenyl)butyricacid; Butanoic acid, 4-(bis(2-chloroethyl)amino) benzene; gamma-(p-Bis(2-chloroethyl)aminophenyl)butyric acid; phenyl)butanoic acid; p-N,N-Di-(beta-chloroethyl)aminophenyl butyric acid; Butyric acid, 4-(p-(bis(2-chloroethyl)amino)phenyl); para-N,N-Di(beta-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-gamma-para-aminophenyl butyric acid; Opera_ID_51; PubChem21331; Spectrum_000118; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna [Czech]; Prestwick0_001079; Prestwick1_001079; Prestwick2_001079; Prestwick3_001079; Spectrum2_000065; Spectrum3_000336; Spectrum4_000273; Spectrum5_000677; Lopac-C-0253; Epitope ID:139977; SCHEMBL4308; Lopac0_000227; WLN: QV3R DN2G2G; BSPBio_001098; BSPBio_001971; KBioGR_000766; KBioSS_000558; 4-14-00-01715 (Beilstein Handbook Reference); MLS001076130; DivK1c_000688; SPECTRUM1500171; Chlorambucil (JAN/USP/INN); SPBio_000249; SPBio_002999; BPBio1_001208; GTPL7143; ZINC1115; DTXSID7020263; HMS502C10; KBio1_000688; KBio2_000558; KBio2_003126; KBio2_005694; KBio3_001191; NINDS_000688; HMS1571G20; HMS1920M15; HMS2090M19; HMS2091A22; HMS2098G20; HMS2235A04; HMS3259I10; HMS3372O04; HMS3652P08; Pharmakon1600-01500171; 4-(4-(bis(2-chloroethyl)amino); AMY33445; BCP28394; NCI-3088; Tox21_110096; Tox21_201390; Tox21_302996; BDBM50003677; CCG-39872; NSC756674; s4288; AKOS024319346; Tox21_110096_1; Chlorambucil, purum, >=98.0% (T); CS-3118; DB00291; GS-6200; LP00227; MCULE-2575006904; NC00555; NSC-756674; SDCCGSBI-0050215.P005; IDI1_000688; NCGC00015199-01; NCGC00015199-02; NCGC00015199-03; NCGC00015199-04; NCGC00015199-05; NCGC00015199-06; NCGC00015199-07; NCGC00015199-09; NCGC00015199-10; NCGC00015199-11; NCGC00015199-12; NCGC00015199-13; NCGC00015199-14; NCGC00015199-15; NCGC00015199-16; NCGC00015199-17; NCGC00015199-19; NCGC00015199-20; NCGC00023250-00; NCGC00023250-03; NCGC00023250-04; NCGC00023250-05; NCGC00023250-06; NCGC00023250-07; NCGC00023250-08; NCGC00023250-09; NCGC00023250-10; NCGC00256464-01; NCGC00258941-01; AK327627; BP-24028; HY-13593; NCI60_002639; SBI-0050215.P004; AB0093202; DB-047794; AB00051938; EU-0100227; FT-0617365; ST50410766; SW197258-4; A14252; A18607; C 0253; C06900; D00266; AB00051938-14; AB00051938-15; AB00051938_16; 305C033; Q415939; 4[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; Butanoic acid, 4-(bis(2-chloroethyl)amino)benzene-; SR-01000000062-2; SR-01000000062-4; SR-01000000062-7; W-106940; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyricacid; BRD-K29458283-001-04-2; BRD-K29458283-001-05-9; BRD-K29458283-001-17-4; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butanoic acid #; Z1558572529; 4-[4-(N,N-bis(2-chloroethyl)-amino]phenyl)butanoic acid; Chlorambucil, European Pharmacopoeia (EP) Reference Standard; Chlorambucil, United States Pharmacopeia (USP) Reference Standard; Chlorambucil for system suitability, European Pharmacopoeia (EP) Reference Standard" Small molecule "1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)" JCKYGMPEJWAADB-UHFFFAOYSA-N C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl C14H19Cl2NO2 CAS 305-03-3 CHEBI:28830 . . . DB00291 . DR2202 Candesartan cilexetil . . Approved Hypertension ICD-11: BA00 CID: 2540 Anticancer Treatment "Candesartan cilexetil; 145040-37-5; Atacand; TCV-116; Amias; Parapres; Kenzen; candesartancilexetil; CANDESARTAN CILEXTIL; TCV 116; C33H34N6O6; CHEMBL1014; CHEBI:3348; 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; TCY 116; MFCD00871371; 1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; 2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate; 2-ETHOXY-1-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID 1-[[(CYCLOHEXYLOXY)CARBONYL]OXY]ETHYL ESTER; Candesartan cilexetil [USAN]; Racanda; Candesartan hexetil; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; Atacand (TN); candesartan cilexitil; Spectrum_001707; Candesartan (Cilexetil); DSSTox_CID_239; Spectrum2_000485; Spectrum3_000996; Spectrum4_001124; Spectrum5_001462; DSSTox_RID_85567; DSSTox_GSID_20239; SCHEMBL40831; BSPBio_002691; KBioGR_001607; KBioSS_002187; 1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-; Candesartan Cilexetil-[d11]; MLS004774127; Candesartan cilexetil , 97%; SPECTRUM1504261; SPBio_000349; GTPL8352; Candesartan cilexetil (Atacand); DTXSID5020239; KBio2_002187; KBio2_004755; KBio2_007323; KBio3_001911; EBD4212; HMS1922J09; HMS2093E20; HMS3651I08; Pharmakon1600-01504261; Candesartan cilexetil (JP17/USP); BCP22050; Tox21_302202; AC-204; BDBM50318907; CCG-39530; NSC758697; s2037; STL451065; AKOS015894954; AKOS015920180; AB07617; AM90293; BCP9000480; CCG-222334; DB00796; DS-1302; KS-1147; NSC 758697; NSC-758697; VA10473; Candesartan cilexetil, >=98% (HPLC); NCGC00095123-01; NCGC00095123-02; NCGC00095123-03; NCGC00095123-05; NCGC00095123-10; NCGC00095123-16; NCGC00255218-01; (+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester); 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-; AK-75900; HY-17505; SMR003500784; SBI-0206767.P001; AB0012012; C-265; CAS-145040-37-5; FT-0602914; SW220041-1; A-2005; C07709; D00626; J10436; AB01274805-01; AB01274805_02; AB01274805_03; 040C375; H212/91; L006257; SR-05000001976; Camptothecine, Antibiotic for Culture Media Use Only; Q-200786; SR-05000001976-1; BRD-A65671304-001-02-6; BRD-A65671304-001-03-4; Q27075664; Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester; Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard; Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard; Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard; Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard; Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methylbenzimidazole-7-carboxylate; (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7-carboxylate; 1-(Cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate; 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl] methyl]benzimidazole-4-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate.; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester; 2-Ethoxy-1-[2'-(1H-tetrazole-5-yl)-4-biphenylylmethyl]-1H-benzimidazole-7-carboxylic acid 1-(cyclohexyloxycarbonyloxy)ethyl ester; 2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe" Small molecule "1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)" GHOSNRCGJFBJIB-UHFFFAOYSA-N CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6 C33H34N6O6 CAS 145040-37-5 CHEBI:3348 . . . DB00796 . DR0241 Calphostin c D0S6XD D0S6XD Investigative Breast cancer ICD-11: 2C60 CID: 2533 Anticancer Treatment "calphostin C; 121263-19-2; UCN-1028c; CHEMBL261214; MFCD00133155; UCN 1028C; 1-[3,10-dihydroxy-12-(2-{[(4-hydroxyphenoxy)carbonyl]oxy}propyl)-2,6,7,11-tetramethoxy-4,9-dioxo-4,9-dihydroperylen-1-yl]propan-2-yl benzoate; ACMC-20d0wl; Calphostin C, Cladosporium cladosporioides; CBiol_001843; KBioGR_000240; KBioSS_000240; SCHEMBL3469324; SCHEMBL13827621; KBio2_000240; KBio2_002808; KBio2_005376; KBio3_000479; KBio3_000480; DTXSID40923744; Bio1_000129; Bio1_000618; Bio1_001107; Bio2_000240; Bio2_000720; HMS1361L22; BDBM50500850; AKOS024456712; PKF 115584; IDI1_033990; Carbonic acid,(1R)-2-[12-[(2R)-2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethyl4-hydroxyphenyl ester, stereoisomer; Calphostin C from Cladosporium cladosporioides; M04057; J-004473; Calphostin C, Cladosporium cladosporioides - CAS 121263-19-2; Calphostin C from Cladosporium cladosporioides, >=90% (HPLC), powder; (1R)-2-[12-[(2R)-2-(Benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethylcarbonic acid 4-hydroxyphenyl ester; [2-[4,9-dihydroxy-12-[2-(4-hydroxyphenoxy)carbonyloxypropyl]-2,6,7,11-tetramethoxy-3,10-dioxo-perylen-1-yl]-1-methyl-ethyl] benzoate; 1-(4,9-Dihydroxy-12-(2-(((4-hydroxyphenoxy)carbonyl)oxy)propyl)-2,6,7,11-tetramethoxy-3,10-dioxo-3,10-dihydroperylen-1-yl)propan-2-yl benzoate; 1-(4,9-dihydroxy-12-(2-((4-hydroxyphenoxy)carbonyloxy)propyl)-2,6,7,11-tetramethoxy-3,10-dioxo-3,10-dihydroperylen-1-yl)propan-2-yl benzoate; 924657-57-8; Benzoic acid 2-{4,9-dihydroxy-12-[2-(4-hydroxy-phenoxycarbonyloxy)-propyl]-2,6,7,11-tetramethoxy-3,10-dioxo-3,10-dihydro-perylen-1-yl}-1-methyl-ethyl ester; Carbonic acid [2-[[12-[2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxoperylen]-1-yl]-1-methylethyl]4-hydroxyphenyl ester; Carbonic acid,(1R)-2-[12-[(2R)-2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethyl4-hydroxyphenyl ester,stereoisomer; COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1" Small molecule "1S/C44H38O14/c1-20(56-43(50)22-10-8-7-9-11-22)16-25-31-32-26(17-21(2)57-44(51)58-24-14-12-23(45)13-15-24)42(55-6)40(49)34-28(47)19-30(53-4)36(38(32)34)35-29(52-3)18-27(46)33(37(31)35)39(48)41(25)54-5/h7-15,18-21,45,48-49H,16-17H2,1-6H3" LSUTUUOITDQYNO-UHFFFAOYSA-N CC(CC1=C2C3=C(C(=C(C4=C3C(=C5C2=C(C(=O)C=C5OC)C(=C1OC)O)C(=CC4=O)OC)O)OC)CC(C)OC(=O)OC6=CC=C(C=C6)O)OC(=O)C7=CC=CC=C7 C44H38O14 CAS 121263-19-2 . . . . . . DR5795 Verapamil D0R0FE D0R0FE Approved Hypertension ICD-11: BA00-BA04 CID: 2520 Anticancer Treatment "VERAPAMIL; 52-53-9; Iproveratril; Vasolan; Dilacoran; Isoptin; Falicard; Finoptin; Isoptine; Calan; Lekoptin; Verapamilo; Verapamilum; Isotopin; Securon; Verelan; Calcan; Tarka; D-365; Cardibeltin; Izoptin; CP-16533-1; Covera-HS; Verpamil; Verelan PM; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Cardiagutt; Berkatens; Dignover; Geangin; Veramex; Quasar; Univer; 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile; Novo-Veramil; Apo-Verap; Isoptin SR; Nu-Verap; Calan SR; Isoptimo; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; (+/-)-Verapamil hydrochlorid; CHEBI:77733; Cardiabeltin; Cardioprotect; Durasoptin; Hexasoptin; Veratensin; Veroptinstada; Calaptin; Caveril; Civicor; Coraver; Corpamil; Harteze; Hormitol; Ikapress; Inselon; Isoptino; Jenapamil; Lodixal; Magotiron; Praecicor; Robatelan; Vasomil; Vasopten; Verabeta; Veracor; Verahexal; Veraloc; Veramil; Verapin; Verasal; Verasifar; Verdilac; Vetrimil; Akilen; Elthon; Flamon; Ikacor; Univex; Vortac; Anpec; Ormil; Rapam; Civicor Retard; Isoptin Retard; Manidon Retard; Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-; Vera-Sanorania; Verapamil Acis; Verapamil Atid; Verapamil Ebewe; Verapamil Riker; Verapamil Verla; (+/-)-Verapamil;CP-16533-1; Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-; Verapamil Basics; Verapamil Nordic; Verapamil-AbZ; Novapamyl LP; Verapamil AL; Verapamil NM; Verapamil PB; Verapamil SR; Cordilox SR; Dilacoran HTA; Veracaps SR; Verapamil MSD; Verapamilum [INN-Latin]; Arpamyl LP; Hexasoptin Retard; Verapamil Henning; Verelan SR; NCGC00016083-09; Verapamilo [INN-Spanish]; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; Verapamil Injection; CP-16,533-1; Verapamil NM Pharma; Calaptin 240 SR; Verapress 240 SR; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; DSSTox_CID_21152; DSSTox_RID_79636; DSSTox_GSID_41152; (+/-)-VERAPAMIL; Verapamil [USAN:INN:BAN]; dl-Verapamil; r,s-verapamil; CAS-52-53-9; CCRIS 6749; NSC272366; Verapamil (USAN/INN); EINECS 200-145-1; Ansyr; NSC 272306NA; EINECS 260-462-6; Calan (Salt/Mix); Akilen (Salt/Mix); alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Isoptin (Salt/Mix); alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Cordilox (Salt/Mix); delta-365; Covera-HS (Salt/Mix); Prestwick0_000141; Prestwick1_000141; Prestwick2_000141; Prestwick3_000141; Spectrum2_001740; Spectrum4_000906; Spectrum5_001786; CP 16533-1; D 365; CHEMBL6966; Lopac0_001237; SCHEMBL16742; BSPBio_000242; BSPBio_001513; BSPBio_002358; KBioGR_000233; KBioGR_001372; KBioGR_002343; KBioSS_000233; KBioSS_002346; 56949-77-0; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; MLS006011414; DivK1c_000399; SPBio_001820; SPBio_002181; BPBio1_000268; GTPL2406; CP 16533-1 (Verapamil); DTXSID9041152; SCHEMBL13287282; (A+/-)-Verapamil hydrochloride; BDBM81939; HSDB 3928; KBio1_000399; KBio2_000233; KBio2_002343; KBio2_002801; KBio2_004911; KBio2_005369; KBio2_007479; KBio3_000465; KBio3_000466; KBio3_002823; cMAP_000023; NINDS_000399; NSC-272306NA; Bio1_000425; Bio1_000914; Bio1_001403; Bio2_000233; Bio2_000713; HMS1791L15; HMS1989L15; HMS2089H17; HMS3402L15; Tox21_110300; NSC_62969; STK538085; AKOS005468962; Tox21_110300_1; CCG-205311; DB00661; MCULE-3016077278; SDCCGSBI-0051204.P005; CAS_52-53-9; IDI1_000399; IDI1_033983; NCGC00016083-04; NCGC00016083-05; NCGC00016083-06; NCGC00016083-07; NCGC00016083-08; NCGC00016083-10; NCGC00016083-11; NCGC00016083-13; NCGC00016083-14; NCGC00016083-15; NCGC00016083-16; NCGC00016083-17; NCGC00016083-18; NCGC00016083-20; NCGC00016083-25; NCGC00016083-34; NCGC00024710-04; NCGC00024710-05; NCGC00024710-06; NCGC00024710-07; NCGC00024710-08; NCGC00024710-09; NCGC00344584-01; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile; AC-16016; BP-21223; HY-14275; NCI60_020143; SMR001550201; SBI-0051204.P003; CP-165331; AB00053495; CS-0002967; FT-0603225; FT-0675801; ST50826367; 1394-EP2270011A1; 1394-EP2272841A1; 1394-EP2272972A1; 1394-EP2272973A1; 1394-EP2275420A1; 1394-EP2277865A1; 1394-EP2277872A1; 1394-EP2280008A2; 1394-EP2298742A1; 1394-EP2298764A1; 1394-EP2298765A1; 1394-EP2298776A1; 1394-EP2298779A1; 1394-EP2301923A1; 1394-EP2301931A1; 1394-EP2301936A1; 1394-EP2305648A1; 1394-EP2314585A1; 1394-EP2316832A1; 1394-EP2316833A1; 52V114; C07188; D02356; AB00053495-20; AB00053495_21; L001330; Q410291; BRD-A09533288-001-02-7; BRD-A09533288-003-05-6; CP-165331 / CP-16533-1; F2173-0851; VERAPAMIL, Dexverapamil, Verapamyl hydrochloride, VERAPAMIL HYDROCHLORIDE; .alpha.-((N-Methyl-N-homoveratryl)-.gamma.-aminopropyl)-3,4-dimethoxyphenylacetonitrile; (?)-alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl](methyl)amino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; 2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-isopropylpentanenitrile, (+/-)-; 2-(3,4-Dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile #; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}-2-(methy lethyl)pentanenitrile" Small molecule "1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3" SGTNSNPWRIOYBX-UHFFFAOYSA-N CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC C27H38N2O4 CAS 52-53-9 CHEBI:77733 . . . DB00661 . DR9529 Aspirin D0GY5Z D0GY5Z Approved Pain ICD-11: MG30-MG3Z CID: 2244 Anticancer Treatment "aspirin; ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; 2-(Acetyloxy)benzoic acid; O-Acetylsalicylic acid; o-Acetoxybenzoic acid; Acylpyrin; Easprin; Ecotrin; Acenterine; Acetophen; Polopiryna; Acetosal; Acetylsalicylate; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aceticyl; Acetonyl; Acetosalin; Acetylin; Aspergum; Aspirdrops; Benaspir; Micristin; Pharmacin; Premaspin; Salcetogen; Temperal; Ecolen; Empirin; Endydol; Rhodine; Saletin; Rheumintabletten; Solprin acid; Acetisal; Acetylsal; Aspirine; Bialpirina; Bialpirinia; Claradin; Clariprin; Entericin; Enterophen; Enterosarine; Globentyl; Measurin; Neuronika; Salacetin; Solpyron; Acesal; Acisal; Asagran; Asteric; Cemirit; Decaten; Duramax; Extren; Globoid; Helicon; Idragin; Levius; Pirseal; Rhonal; Solfrin; Adiro; Aspec; Aspro; Novid; Yasta; Acetosalic acid; Acidum acetylsalicylicum; Triple-sal; Spira-Dine; ZORprin; Benzoic acid, 2-(acetyloxy)-; Bi-prin; Acetilum acidulatum; Acimetten; Delgesic; Entrophen; Persistin; 2-acetyloxybenzoic acid; 2-Carboxyphenyl acetate; Acetilsalicilico; Dolean pH 8; A.S.A. empirin; XAXA; Acido acetilsalicilico; Contrheuma retard; Acide acetylsalicylique; Endosprin; Kapsazal; Bayer; ASA; Acetylsalicylsaure; aspirin (acetylsalicylic acid); Solprin; Triaminicin; Asatard; Tasprin; Nu-seals aspirin; Salicylic acid, acetate; Acido O-acetil-benzoico; Kyselina acetylsalicylova; 2-Acetoxybenzenecarboxylic acid; St. Joseph Aspirin for Adults; A.S.A.; St. Joseph; Kyselina 2-acetoxybenzoova; acetyl salicylic acid; SP 189; Acetard; AC 5230; Acetylsalicylsaeure; Azetylsalizylsaeure; S-211; UNII-R16CO5Y76E; ECM; CHEBI:15365; 2-(acetyloxy)benzoate; MFCD00002430; o-(Acetyloxy)benzoic acid; Acetylsalicylic acid, 99%; acide 2-(acetyloxy)benzoique; R16CO5Y76E; Aspirin form II; component of Midol; NSC27223; component of Synirin; NSC-27223; 8-hour Bayer; component of Zactirin; NSC-406186; component of Coricidin; component of Persistin; component of Robaxisal; o-Acetoxybenzoate; NCGC00015067-04; o-acetyl-salicylic acid; Acetysal; Istopirin; Magnecyl; Medisyl; Polopirin; Ronal; Bayer Buffered; DSSTox_CID_108; Aspro Clear; component of Ascodeen-30; Bayer Plus; WLN: QVR BOV1; Rheumin tabletten; AcetylsalicylicAcid; DSSTox_RID_75372; DSSTox_GSID_20108; Aspirina 03; 11126-35-5; Acetylsalycilic acid; component of Darvon with A.S.A; Bayer Aspirin 8 Hour; Asaphen; Aspalon; Durlaza; Asprin; Bayer Children's Aspirin; AspirinTest2; Nu-seals; component of St. Joseph Cold Tablets; Aspir-Mox; Durlaza ER; Acetylsalicylsaure [German]; CAS-50-78-2; Acetoxybenzoic acid; Acetysalicylic acid; AIN; SMR000059138; Ascoden-30; Benzoicacid, 2-(acetyloxy)-; Acetylsalicyclic acid; CCRIS 3243; HSDB 652; Acide acetylsalicylique [French]; Acido acetilsalicilico [Italian]; Kyselina acetylsalicylova [Czech]; Acido O-acetil-benzoico [Italian]; SR-01000075668; Kyselina 2-acetoxybenzoova [Czech]; Bayer Extra Strength Aspirin for Migraine Pain; EINECS 200-064-1; NSC 27223; Aspirin [USP:BAN:JAN]; Bayer Enteric 325 mg Regular Strength; BRN 0779271; Bay E4465; Aspropharm; Bayer Enteric 81 mg Adult Low Strength; Cardioaspirin; Cardioaspirina; Acetyonyl; Asacard; Ascolong; Bayer Enteric 500 mg Arthritis Strength; Colsprin; Miniasal; Salospir; Acesan; Toldex; AI3-02956; 1oxr; 2-Acetoxybenzoate; 99512-66-0; Aspirin,(S); Aspalon (JAN); Durlaza (TN); Easprin (TN); acetyl-salicylic acid; Aspirin USP-26; acetyl salicyclic acid; o-(Acetyloxy)benzoate; 1173022-25-7; Percodan (Salt/Mix); Ascriptin (Salt/Mix); Micrainin (Salt/Mix); 2-acetoxy benzoic acid; PubChem20190; Spectrum_001245; 2-Acetylsalicyclic acid; ACMC-209kpz; Salicylic acid, acetyl-; CHEMBL25; Spectrum2_001899; Spectrum3_001295; Spectrum4_000099; Spectrum5_000740; Aspirin (JP17/USP); Lopac-A-5376; Salycylacetylsalicylic acid; benzoic acid, 2-acetoxy-; Epitope ID:114151; Percodan Demi (Salt/Mix); Soma Compound (Salt/Mix); ZINC53; EC 200-064-1; Aspirin USP (3080); cid_2244; Pravigard PAC (Salt/Mix); SCHEMBL1353; 2-(Acetyloxy)-benzoic acid; Aspirin USP (2080B); Bay-e-4465; Acetylsalicylic acid-[13C]; Lopac0_000038; KBioGR_000398; KBioGR_002271; KBioSS_001725; KBioSS_002272; 4-10-00-00138 (Beilstein Handbook Reference); MLS001055329; MLS001066332; MLS001336045; MLS001336046; BIDD:GT0118; DivK1c_000555; SPECTRUM1500130; SPBio_001838; Acetylsalicylic acid, >=99%; GTPL4139; (non-d)Acetylsalicylic Acid-d3; O-Acetylsalicylic acid; Aspirin; DTXSID5020108; Acetylsalicylic acid-carboxy-14c; BDBM22360; HMS501L17; KBio1_000555; KBio2_001725; KBio2_002271; KBio2_004293; KBio2_004839; KBio2_006861; KBio2_007407; KBio3_002149; KBio3_002751; Empirin with Codeine (Salt/Mix); Acetylsalicylic acid, >=99.0%; cMAP_000006; component of Zactirin (Salt/Mix); NINDS_000555; HMS1920E13; HMS2090G03; HMS2091K13; HMS2233L18; HMS3260G17; HMS3372N15; HMS3656N14; HMS3715P19; HMS3866L03; HMS3885G03; Pharmakon1600-01500130; BCP21790; STR01551; ACETYLSALICYLIC ACID; ASPIRIN; Tox21_110076; Tox21_202117; Tox21_300146; Tox21_500038; ANW-31125; BBL005469; CCG-39490; NSC406186; NSC755899; s3017; SBB015069; STL137674; 2-Acetoxybenzoic-3,4,5,6-d4 Acid; AKOS000118884; component of Ascodeen-30 (Salt/Mix); Tox21_110076_1; BAY1019036; CS-2001; DB00945; LP00038; MCULE-3199019536; NSC-755899; PL-2200; SDCCGSBI-0050027.P005; BAY-1019036; IDI1_000555; Acetylsalicylic acid, analytical standard; NCGC00015067-01; NCGC00015067-02; NCGC00015067-03; NCGC00015067-05; NCGC00015067-06; NCGC00015067-07; NCGC00015067-08; NCGC00015067-09; NCGC00015067-10; NCGC00015067-11; NCGC00015067-12; NCGC00015067-13; NCGC00015067-14; NCGC00015067-26; NCGC00090977-01; NCGC00090977-02; NCGC00090977-03; NCGC00090977-04; NCGC00090977-05; NCGC00090977-06; NCGC00090977-07; NCGC00254034-01; NCGC00259666-01; NCGC00260723-01; Aspirin, meets USP testing specifications; H740; HY-14654; NCI60_002222; ST075414; SBI-0050027.P004; DS-017139; UNM-0000306102; component of Darvon with A.S.A (Salt/Mix); EU-0100038; FT-0655181; FT-0661360; SW199665-2; 1777-EP2269989A1; 1777-EP2269990A1; 1777-EP2272825A2; 1777-EP2275420A1; 1777-EP2277865A1; 1777-EP2280008A2; 1777-EP2281563A1; 1777-EP2281815A1; 1777-EP2281818A1; 1777-EP2292227A2; 1777-EP2295055A2; 1777-EP2298764A1; 1777-EP2298765A1; 1777-EP2298768A1; 1777-EP2298776A1; 1777-EP2305219A1; 1777-EP2305260A1; 1777-EP2305640A2; 1777-EP2305652A2; 1777-EP2308510A1; 1777-EP2311453A1; 1777-EP2314590A1; 1777-EP2314593A1; 1777-EP2316459A1; 1777-EP2371811A2; 6474-EP1441224A2; 6474-EP2272832A1; 6474-EP2275420A1; 6474-EP2277861A1; 6474-EP2277875A2; 6474-EP2298757A2; 6474-EP2298764A1; 6474-EP2298765A1; 6474-EP2314585A1; A 5376; Acetylsalicylic Acid 1.0 mg/ml in Acetonitrile; C01405; D00109; Q18216; 24189-EP2295409A1; 24189-EP2314590A1; AB00051918-08; AB00051918_09; AB00051918_10; 170197-EP2275413A1; 170197-EP2287156A1; 186947-EP2270113A1; 186947-EP2272935A1; Arthritis Pain Formula Maximum Strength (Salt/Mix); SR-01000075668-1; SR-01000075668-4; SR-01000075668-6; Acetylsalicylic acid, Vetec(TM) reagent grade, >=99%; Aspirin, British Pharmacopoeia (BP) Reference Standard; F2191-0068; Z234893989; Aspirin, United States Pharmacopeia (USP) Reference Standard; D41527A7-A9EB-472D-A7FC-312821130549; Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard; Acetylsalicylic acid, BioReagent, plant cell culture tested, >=99.0%; Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard; Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)" BSYNRYMUTXBXSQ-UHFFFAOYSA-N CC(=O)OC1=CC=CC=C1C(=O)O C9H8O4 CAS 50-78-2 CHEBI:15365 . . . DB00945 . DR0775 Amlodipine D08JIV D08JIV Approved Hypertension ICD-11: BA00-BA04 CID: 2162 Anticancer Treatment "amlodipine; 88150-42-9; Norvasc; AMLODIPINE BASE; Amlodipino; Amlodipinum; Caduet; Istin; Amlodipine Free Base; Amlodipine besilate; Amvaz; Amlodis; CHEBI:2668; 3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; Norvasc (TN); Amlocard; Coroval; Lipinox; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; UK-4834011; Amlor; Amlodipinum [Latin]; Amlodipino [Spanish]; 88150-42-9 (free base); Amdepin; Amdipin; Amlodin; Pelmec; MFCD00864687; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; Amlodipine [INN:BAN]; Racemic Amlodipine; (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; C20H25ClN2O5; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-ethyl 5-O-methyl 4-(2-chlorophenyl)-1-deuterio-2-[2-(dideuterioamino)ethoxymethyl]-6-methyl-4H-pyridine-3,5-dicarboxylate; O3-ethyl O5-methyl 2-(2-azanylethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; SR-05000001461; NCGC00165957-04; r-amlodipine; Amlodipine/; Amlodipine D4; HSDB 7079; 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 2-[2-aminoethoxymethyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; amlodipine (NORVASC); Amlodipine (USP/INN); (R)-Amlodipine-[d4]; 2-[(2-Aminoethoxy)-methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester benzene sulfonate; Spectrum2_000486; Spectrum3_001004; Spectrum4_001132; Spectrum5_001550; EC 425-820-1; CHEMBL1491; SCHEMBL26478; BSPBio_002727; KBioGR_001643; MLS001401409; BIDD:GT0810; SPBio_000351; GTPL6981; CHEMBL3211346; CHEMBL3304444; DTXSID7022596; KBio3_001947; Copalia (amlodipine + valsartan); HGP0904; BCPP000403; HMS2052N03; HMS2089H07; HMS2231K08; HMS3370G17; HMS3394N03; HMS3651I04; HMS3713C10; ALBB-027270; BCP02420; HGP-0904; HY-B0317; ABP000734; BBL023710; BDBM50088383; CA0134; s1905; STL356053; CKD-330 COMPONENT AMLODIPINE; AKOS015843475; AC-4535; BCP9000295; CCG-101157; CCG-220414; DB00381; MCULE-8264151664; NC00407; NCGC00165957-01; NCGC00165957-02; NCGC00165957-03; NCGC00165957-05; NCGC00165957-07; 3-Ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; AK163198; Amlodipine 100 microg/mL in Acetonitrile; AS-13747; CPD000469198; K577; O3-ethyl O5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; SMR000469198; SY104813; AB0008128; UK-48,340; FT-0602653; FT-0657130; FT-0662111; FT-0662112; R3932; SW220228-1; 50A429; C06825; D07450; J10237; W-3152; AB01209618-01; AB01274726-01; AB01274726-02; AB01274726_03; AB01274726_04; AB01274726_05; A800681; Q411347; Katerzia® (amlodipine oral suspension, 1 mg/mL); SR-05000001461-3; SR-05000001461-4; SR-05000001461-5; BRD-A22032524-074-02-4; BRD-A22032524-074-03-2; BRD-A22032524-074-04-0; 2-(2-aminoethoxy)methyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid O3-ethyl ester O5-methyl ester; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methylester; 2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 3,5-pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, benzene sulfonate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzene sulfonate; 3-Ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorphenyl)-6-methyl-1,4-dihydropyridin-3,5-dicarboxylat; 3-Ethyl 5-methylester, (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate" Small molecule "1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3" HTIQEAQVCYTUBX-UHFFFAOYSA-N CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN C20H25ClN2O5 CAS 88150-42-9 CHEBI:2668 . . . DB00381 . DR6126 Amifostine D06CIE D06CIE Approved Nasopharyngitis ICD-11: CA00 CID: 2141 Anticancer Treatment "amifostine; 20537-88-6; Ethiofos; Gammaphos; Ethyol; Sapep; Apaetp; Aminopropylaminoethyl thiophosphate; WR 2721; NSC-296961; YM-08310; 2-(3-Aminopropylamino)ethyl thiophosphate; AU-95722; UNII-ILA426L95O; NSC296961; Amifostine (Hydrate); WR2721; NSC 296961; WR-2721; S-(2-(3-Aminopropylamino)ethyl) phosphorothioate; CHEBI:2636; ILA426L95O; WR 2721C; Amifostina; NCGC00015073-02; S-(2-((3-Aminopropyl)amino)ethyl) dihydrogen phosphorothioate; Ethanethiol, 2-[(3-aminopropyl)amino]-, 1-(dihydrogen phosphate); 2-((3-Aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9CI); DSSTox_CID_2585; Ethiofos Anhydrous; DSSTox_RID_76644; DSSTox_GSID_22585; C5H15N2O3PS; ({2-[(3-aminopropyl)amino]ethyl}sulfanyl)phosphonic acid; S-{2-[(3-aminopropyl)amino]ethyl} dihydrogen thiophosphate; Amifostine Ethiofos; Amifostine Anhydrous; Amifostine [USAN:INN:BAN]; CAS-20537-88-6; S-[2-(3-Aminopropylamino)ethyl] phosphorothioate; SR-01000075680; BRN 2088122; YM 08310; S-[2-[(3-Aminopropyl)amino]ethyl] dihydrogen phosphorothioate; CCRIS 9316; HSDB 7560; Amifostine,(S); 2-(3-aminopropylamino)ethylsulfanylphosphonic acid; Amifostine disulfide; S,2-(3-Aminopropylamino)ethyl-phosphorothioic acid; S-2-(3-Aminopropylamino)ethyl phosphorothioic acid; Ethyol;WR2721; Spectrum_000332; S-omega-(3-Aminopropylamino)ethyl dihydrogen phosphorothioate; SpecPlus_000647; 2-(3-Aminopropyl)aminoethylphosphorothioate; Acide ((amino-3 propylamino)-2 ethyl)-S-phosphorothioique [French]; Spectrum5_001920; Lopac-A-5922; Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester); NCIMech_000622; S 8744; CHEMBL1006; Lopac0_000029; SCHEMBL18464; KBioSS_000812; cc-307; MLS000028473; S-2-(3-aminopropylamino)-ethylphosphorothioic acid; BIDD:GT0059; DivK1c_006743; WR-2721 TRIHYDRATE; DTXSID8022585; KBio1_001687; KBio2_000812; KBio2_003380; KBio2_005948; Acide ((amino-3 propylamino)-2 ethyl)-S-phosphorothioique; HMS2090I03; HMS3260E19; HMS3713C06; Pharmakon1600-01503081; Phosphorothioic acid, S-(2-(3-aminopropylamino)ethyl) ester; BCP08957; HY-B0639; Phosphorothioic acid, S-[2-[(3-aminopropyl)amino]ethyl] ester; Tox21_110077; Tox21_500029; CCG-35734; MFCD00233058; NSC758236; ZINC21992285; AKOS015895196; Tox21_110077_1; AC-1126; DB01143; LP00029; NSC-758236; SDCCGSBI-0050018.P005; SMP2_000335; NCGC00015073-01; NCGC00015073-03; NCGC00015073-04; NCGC00015073-05; NCGC00015073-15; NCGC00093549-01; NCGC00093549-02; NCGC00260714-01; AS-13020; Ethanethiol, dihydrogen phosphate (ester); NCI60_002485; SMR000058413; Ethanethiol, dihydrogen phosphate- (ester); SBI-0050018.P003; AB0012846; EU-0100029; FT-0622272; 37A886; A 5922; C06819; [2-(3-aminopropylamino)ethylthio]phosphonic acid; 33870-EP2275420A1; 33870-EP2295055A2; 33870-EP2295416A2; 33870-EP2295426A1; 33870-EP2295427A1; 33870-EP2298748A2; 33870-EP2298764A1; 33870-EP2298765A1; 33870-EP2305642A2; 33870-EP2311453A1; 33870-EP2311808A1; 33870-EP2311829A1; AB00053311-04; AB00053311-05; AB00053311_06; A814662; Q251698; {S-[2-(3-Aminopropylamino)ethyl]} phosphorothioate; 2-(3-azanylpropylamino)ethylsulfanylphosphonic acid; J-013390; J-519582; SR-01000075680-1; SR-01000075680-3; SR-01000075680-5; 2-(3-Aminopropyl)aminoethyl phosphorothioate; WR2721; BRD-K73947551-001-01-0; 2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate; 2-(3-aminopropylamino)ethylsulfanylphosphonic acid,trihydrate; Phosphorothioic acid, S-[2-[(3-aminopropyl)amino]ethyl]ester; S-2-(3-aminopropylamino)ethyl O,O-dihydrogen phosphorothioate; {S-[2-[(3-Aminopropyl)amino]ethyl]} dihydrogen phosphorothioate; Ethanethiol, {S-[(3-aminopropyl)amino]-,} dihydrogen phosphate- (ester)" Small molecule "1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)" JKOQGQFVAUAYPM-UHFFFAOYSA-N C(CN)CNCCSP(=O)(O)O C5H15N2O3PS CAS 20537-88-6 CHEBI:2636 . . . DB01143 . DR9473 Amantadine D02KRS D02KRS Approved Influenza ICD-11: 1E30 CID: 2130 Anticancer Treatment "amantadine; 1-Adamantanamine; 768-94-5; adamantan-1-amine; 1-Adamantylamine; 1-Aminoadamantane; Adamantanamine; Adamantylamine; Aminoadamantane; Symmetrel; Amantidine; Symadine; Pk-merz; Adamantamine; 1-Adamantamine; Amantadina; Amantadinum; adamantan-1-ylamine; Gocovri; TCMDC-125869; 1-adamantaneamine; UNII-BF4C9Z1J53; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; NSC 341865; Tricyclo(3.3.1.13,7)decan-1-amine; tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; MFCD00074732; CHEMBL660; adamantanylamine; (3s,5s,7s)-Tricyclo[3.3.1.1~3,7~]decan-1-Amine; BF4C9Z1J53; CHEBI:2618; NSC341865; NSC-341865; 768-94-5 (FREE BASE); NCGC00015036-03; Tricyclo[3.3.1.13,7]decan-1-amine; Tricyclo[3.3.1.13,7]decane-1-amine; Amantadine Base; 1-Adamantanamine, 96%; DSSTox_CID_2117; Amantadine [INN:BAN]; DSSTox_RID_76493; Amantadinum [INN-Latin]; DSSTox_GSID_22117; Amantadina [INN-Spanish]; Amant; Amantadine (INN); CAS-768-94-5; NSC83653; 40933-03-7; HSDB 3202; Tricyclo(3.3.1.1(3,7))-decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; EINECS 212-201-2; 1-Adamantanamine (8CI); ADAMANTANE,1-AMINO; adamantaneamine; BRN 2204333; adamantyl amine; AmantadineHCl; 1-admantaneamine; 1-Amantadine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; 1-adamantanylamine; 1-adamantyl amine; Adamant-1-ylamine; 1-amino-adamantane; adamantane-1-amine; PubChem8733; Mantadine (Salt/Mix); Symmetrel (Salt/Mix); PubChem13903; Spectrum_000030; Tricyclo[3.3.1.1^3,7]decan-1-amine; Prestwick0_000407; Prestwick1_000407; Prestwick2_000407; Prestwick3_000407; Spectrum2_000081; Spectrum3_000291; Spectrum4_000134; Spectrum5_000772; tricyclo[3.3.1.1(3,7)]decan-1-ylamine; tricyclo[3.3.1.1(3,7)]decane-1-amine; 1-Adamantylamine, 97%; Lopac-A-1260; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; EC 212-201-2; SCHEMBL4098; NCIOpen2_001059; Lopac0_000004; Oprea1_248648; BSPBio_000334; BSPBio_001570; BSPBio_001822; KBioGR_000548; KBioSS_000390; BIDD:GT0757; DivK1c_000815; Exp-105-1 (Salt/Mix); SPBio_000002; SPBio_002273; BPBio1_000368; GTPL4128; SCHEMBL2619248; DTXSID8022117; SCHEMBL15672299; SCHEMBL20409394; SCHEMBL21309814; SCHEMBL21310017; KBio1_000815; KBio2_000390; KBio2_002958; KBio2_005526; KBio3_001322; NINDS_000815; (3R,5S,7s)-Adamantan-1-amine; 1-Adamantamine(1-Aminoadamantane); HMS1791O12; HMS1989O12; HMS3604O07; HMS3887I19; ZINC968256; ACT02873; ALBB-013871; BCP09869; STR04703; Tox21_110068; ANW-43040; BBL004977; BDBM50033369; HTS001826; s5499; SBB071506; STK298781; AKOS000113994; AKOS000119324; AKOS007930692; AKOS015935124; Tox21_110068_1; CCG-204100; CS-W008656; DB00915; MCULE-9686682307; SDCCGSBI-0049993.P005; IDI1_000815; NCGC00015036-01; NCGC00015036-02; NCGC00015036-04; NCGC00015036-05; NCGC00015036-06; NCGC00015036-07; NCGC00015036-08; NCGC00015036-09; NCGC00015036-11; NCGC00015036-13; NCGC00015036-24; NCGC00162039-01; NCGC00162039-02; NCGC00162039-03; NCGC00162039-04; NCGC00179597-01; AC-25879; ADS-5102, EXP 105-1; AK-77141; AS-14215; BP-13040; K333; ST097860; SBI-0049993.P004; AB0014168; WLN: L66 B6 A B- C 1B ITJ BZ; AB00514655; FT-0607338; C06818; D07441; M-4039; AB00053414-14; AB00053414-16; AB00053414_17; AB00053414_18; AB01275427-01; 768A945; A838887; AE-641/01634060; L000868; Q409761; J-650234; W-104338; BRD-K70330367-003-01-2; BRD-K70330367-003-03-8; Q27453436; F0001-1962" Small molecule "1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2" DKNWSYNQZKUICI-UHFFFAOYSA-N C1C2CC3CC1CC(C2)(C3)N C10H17N CAS 768-94-5 CHEBI:2618 . . . DB00915 . DR4185 Albendazole D00KVO D00KVO Approved Parasitic worm infestation ICD-11: 1F90 CID: 2082 Anticancer Treatment "albendazole; 54965-21-8; Albenza; Eskazole; Valbazen; Zentel; Proftril; Albendazolum; SK&F 62979; SKF 62979; Methyl 5-(propylthio)-2-benzimidazolecarbamate; SK&F-62979; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole; methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; MFCD00083232; NSC 220008; UNII-F4216019LN; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Albendazol; Bilutac; CHEMBL1483; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; CHEBI:16664; Zental; Albendazole-D3; F4216019LN; NSC-220008; methyl 5-(propylthio)-1H-benzo[d]imidazol-2-ylcarbamate; methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; NCGC00016876-01; CAS-54965-21-8; DSSTox_CID_2563; Methyl 5-n-propylthio-2-benzimidazolecarbamate; DSSTox_RID_76632; DSSTox_GSID_22563; Albendazol [INN-Spanish]; Albendazolum [INN-Latin]; methoxy-N-(5-propylthiobenzimidazol-2-yl)carboxamide; methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; methyl N-(5-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; SKF-62979; Andazol; Albenza (TN); Albendazole(Albenza); HSDB 7444; EINECS 259-414-7; Albendazole (JAN/USP/INN); Zenteltrade mark; Albenzatrade mark; Andazoltrade mark; Eskazoletrade mark; Albendazole,(S); ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; Prestwick_675; Albendazole (Albenza); Albendazole [USAN:USP:INN:BAN:JAN]; Spectrum_001532; CPD000036735; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; Prestwick0_000247; Prestwick1_000247; Prestwick2_000247; Prestwick3_000247; Spectrum4_000201; Spectrum5_001567; ChemDivAM_000003; ChemDiv1_000190; Oprea1_429292; Oprea1_585016; Oprea1_640007; SCHEMBL44682; BSPBio_000034; BSPBio_002548; KBioGR_000801; KBioSS_002012; MLS000069722; BIDD:GT0615; DivK1c_000704; SPECTRUM1503903; SPBio_002253; BPBio1_000038; DTXSID0022563; HMS502D06; HMS587I14; HXHWSAZORRCQMX-UHFFFAOYSA-; KBio1_000704; KBio2_002012; KBio2_004580; KBio2_007148; NINDS_000704; HMS1568B16; HMS1922K04; HMS2090G19; HMS2093K13; HMS2095B16; HMS2231O03; HMS3259B05; HMS3369C03; HMS3651C15; HMS3712B16; Pharmakon1600-01503903; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; BCP12108; HY-B0223; Tox21_110659; Tox21_302300; AC-015; ANW-42170; BBL005883; BDBM50241293; CCG-39620; MFCD01220143; N-[6-(propylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; NSC220008; NSC758644; s1640; SBB056658; STK387550; STL046130; ZINC17146904; AKOS000540882; AKOS005431684; AKOS005699352; Tox21_110659_1; CCG-220247; DB00518; KS-5159; MCULE-5872469561; NC00615; NE41026; NSC-758644; IDI1_000704; methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; NCGC00016876-02; NCGC00016876-03; NCGC00016876-04; NCGC00016876-05; NCGC00016876-06; NCGC00016876-07; NCGC00016876-08; NCGC00016876-09; NCGC00016876-10; NCGC00016876-12; NCGC00022896-03; NCGC00022896-04; NCGC00022896-05; NCGC00022896-06; NCGC00022896-07; NCGC00022896-08; NCGC00255250-01; AK405353; Albendazole, analytical standard, >=98%; H152; SMR000036735; ST012016; Albendazole 100 microg/mL in Acetonitrile; SBI-0051849.P002; AB0012898; DB-052669; AB00052377; FT-0621945; SW196830-3; T9034; EN300-49850; methyl 5-propylthio-2-benzimidazole carbamate; VU0239747-6; BIM-0051849.0001; C01779; D00134; J10424; AB00052377-13; AB00052377-14; AB00052377_15; AB00052377_16; A830429; Albendazole, Antibiotic for Culture Media Use Only; Q411629; SR-01000000171; SR-05000001875; methyl 5-(propylthio)-1H-benzimidazol-2-ylcarbamate; Q-200603; Q-200604; SR-01000000171-2; SR-05000001875-1; BRD-K79131256-001-04-7; BRD-K79131256-001-08-8; methyl 6-(propylthio)-1H-benzo[d]imidazol-2-ylcarbamate; Z1245635850; 2-[(Methoxycarbonyl)amino]-5-propylthio-1H-benzimidazole; Albendazole, European Pharmacopoeia (EP) Reference Standard; Methyl (6-(propylthio)-1H-benzo[d]imidazol-2-yl)carbamate; Methyl 5-(propylsulfanyl)-1H-benzimidazol-2-ylcarbamate #; Albendazole, United States Pharmacopeia (USP) Reference Standard; Albendazole, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)" HXHWSAZORRCQMX-UHFFFAOYSA-N CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC C12H15N3O2S CAS 54965-21-8 CHEBI:16664 . . . DB00518 . DR4368 Acetazolamide D0E1SW D0E1SW Approved Glaucoma ICD-11: 9C61 CID: 1986 Anticancer Treatment "acetazolamide; 59-66-5; Diamox; N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide; Acetazolamid; Acetamox; Diacarb; Glaupax; Defiltran; Nephramide; Cidamex; Diluran; Edemox; Dehydratin; Diuramid; Diutazol; Duiramid; Eumicton; Natrionex; Nephramid; Phonurit; Diakarb; Donmox; Fonurit; Glupax; Vetamox; Didoc; SK-acetazolamide; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide; Diuriwas; Acetazoleamide; Acetozalamide; Diureticum-holzinger; Acetamidothiadiazolesulfonamide; Acetazolamida; Acetazolamidum; 4-Diamox; Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-; Carbonic Anhydrase Inhibitor No. 6063; 2-Acetylamino-1,3,4-thiadiazole-5-sulfonamide; N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide; C4H6N4O3S2; 2-Acetamido-5-sulfonamido-1,3,4-thiadiazole; Carbonic anhydrase inhibitor 6063; UNII-O3FX965V0I; MFCD00003105; NSC 145177; 1,3,4-Thiadiazole-2-sulfonamide, 5-acetamido-; 5-Acetamide-1,3,4-thiadiazole-2-sulfonamide; CHEMBL20; Diamox (TN); N-(5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl)acetamide; MLS000028435; O3FX965V0I; CHEBI:27690; Acetamide, N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-; NSC-145177; CAS-59-66-5; N-[5-(Aminosulfonyl)-1,3,4-thiadiozol-2-yl]-Acetamide; NCGC00015074-10; Acetazolamine; Acetamide, N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)-; Atenezol; Glaumox; SMR000058394; Diamox Sequels; DSSTox_CID_2544; 5-acetylamino-1,3,4-thiadiazole-2-sulfonamide; DSSTox_RID_76621; DSSTox_GSID_22544; Acetazolamidum [INN-Latin]; Acetazolamida [INN-Spanish]; N-(5-[Aminosulfonyl]-1,3,4-thiadiazol-2-yl)acetamide; N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide; CCRIS 5811; Acetazolamide (AAZ); HSDB 3002; SR-01000000065; EINECS 200-440-5; AI3-52458; Prestwick_4; 1azm; 1yda; 1ydb; 1ydd; 1zsb; 2xtk; 3czv; 3ucj; Acetazolamide, 5; Acetazolamide [USP:INN:BAN:JAN]; Acerazolamide, AAZ; Acetazolamide, AAZ; Acetazolamide, AZA; Acetazolamide, AZM; ACMC-20gwkd; PubChem12858; Spectrum_000018; 1jd0; 2h4n; 2uy4; 3dc3; 3hs4; 3ml5; 4g0c; Opera_ID_288; AZA2; Prestwick0_000003; Prestwick1_000003; Prestwick2_000003; Prestwick3_000003; Spectrum2_000082; Spectrum3_000284; Spectrum4_000139; Spectrum5_000738; Lopac-A-6011; A 6011; Lopac0_000039; SCHEMBL23219; BSPBio_000005; BSPBio_001788; KBioGR_000558; KBioSS_000358; MLS001148438; BIDD:GT0643; DivK1c_000017; SPECTRUM1500102; N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-acetamide; SPBio_000004; SPBio_001926; BPBio1_000007; GTPL6792; (non-d)Acetazolamide-13C2-d3; Acetazolamide, >=99%, powder; DTXSID7022544; SCHEMBL11049053; BDBM10880; BZKPWHYZMXOIDC-UHFFFAOYSA-; HMS500A19; KBio1_000017; KBio2_000358; KBio2_002926; KBio2_005494; KBio3_001288; Acetazolamide (JP17/USP/INN); AMY3289; Acetazolamide, analytical standard; NINDS_000017; HMS1568A07; HMS1920A05; HMS2091G05; HMS2095A07; HMS2232G23; HMS3259I13; HMS3260G19; HMS3370P01; HMS3712A07; HMS3744A21; Pharmakon1600-01500102; WLN: T5NN DSJ CSZW EMV1; ALBB-023617; BCP29616; EBD55026; HY-B0782; ZINC3813042; Tox21_110078; Tox21_201559; Tox21_302773; Tox21_500039; CCG-38900; NSC145177; NSC755854; s4506; SBB056640; AKOS000715163; Tox21_110078_1; CS-3568; DB00819; LP00039; MCULE-4029778803; NC00491; NSC-755854; SDCCGSBI-0050028.P005; Acetazolamide Related Compound (5-acetamido-1,3,4-thiadiazole-2-sulfonic acid); IDI1_000017; NCGC00015074-01; NCGC00015074-02; NCGC00015074-03; NCGC00015074-04; NCGC00015074-05; NCGC00015074-06; NCGC00015074-07; NCGC00015074-08; NCGC00015074-09; NCGC00015074-11; NCGC00015074-12; NCGC00015074-14; NCGC00015074-15; NCGC00015074-22; NCGC00023455-03; NCGC00023455-04; NCGC00023455-05; NCGC00023455-06; NCGC00023455-07; NCGC00256374-01; NCGC00259108-01; NCGC00260724-01; AC-12779; AK324920; AS-13169; H501; SBI-0050028.P004; 2-Acetamido-5-sulfonamido-1,4-thiadiazole; 5-Acetamide-1,4-thiadiazole-2-sulfonamide; DB-053437; 5-Acetamido-1,3,4-thiadiazol-2-sulfonamide; AB00051906; EU-0100039; R1055; ST45022057; 1,4-Thiadiazole-2-sulfonamide, 5-acetamido-; C06805; D00218; J10059; 20506-EP2269989A1; 20506-EP2275420A1; 20506-EP2280008A2; 20506-EP2295406A1; 20506-EP2298772A1; 20506-EP2308562A2; 20506-EP2308839A1; 20506-EP2314585A1; AB00051906_15; 003A105; A832415; N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)ethanamide; Q413690; L 579486; Q-200579; Q-200580; SR-01000000065-2; SR-01000000065-4; SR-01000000065-6; BRD-K43457670-001-22-9; BRD-K43457670-001-26-0; Z277559108; Acetazolamide, European Pharmacopoeia (EP) Reference Standard; 2,2,2-trideuterio-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide; Acetazolamide, United States Pharmacopeia (USP) Reference Standard; N - (5 - Sulfamoyl - 1,3, 4 - thiadiazol - 2 - yl) acetamide; Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Acetazolamide, Pharmaceutical Secondary Standard; Certified Reference Material; 124442-28-0; 2-Acetamido-5-sulfamoyl-1,3,4-thiadiazole; 2-Acetylamino-1,3,4-thiadiazole-5-sulfonamide; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide" Small molecule "1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)" BZKPWHYZMXOIDC-UHFFFAOYSA-N CC(=O)NC1=NN=C(S1)S(=O)(=O)N C4H6N4O3S2 CAS 59-66-5 CHEBI:27690 . . . DB00819 . DR0990 Paracetamol D0U5QK D0U5QK Approved Pain ICD-11: MG30-MG3Z CID: 1983 Anticancer Treatment "acetaminophen; Paracetamol; 4-Acetamidophenol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Panadol; Acetaminofen; Datril; N-Acetyl-p-aminophenol; p-Hydroxyacetanilide; 4'-Hydroxyacetanilide; p-Acetamidophenol; Algotropyl; Lonarid; Naprinol; p-Acetaminophenol; Acamol; Acenol; Anelix; Multin; Abensanil; Acetagesic; Acetalgin; Clixodyne; Gelocatil; Injectapap; Liquagesic; Pyrinazine; Servigesic; Alvedon; Anaflon; Apamide; Dymadon; Febridol; Febrilix; Febrolin; Finimal; Homoolan; Lestemp; Paracet; Tabalgin; Tralgon; Tussapap; Valadol; Valgesic; Alpiny; Amadil; Anhiba; Calpol; Dirox; Eneril; Fendon; Hedex; Lyteca; Pacemo; Panets; Parmol; Tapar; Tempra; Acetamide, N-(4-hydroxyphenyl)-; Paracetamolo; Doliprane; Dolprone; Momentum; Ortensan; Paldesic; Banesin; Captin; Disprol; Enelfa; Neopap; Salzone; Exdol; p-Acetylaminophenol; Febro-Gesic; NEBS; Biocetamol; Dafalgan; Dolgesic; Elixodyne; Febrectal; Tempanal; Vermidon; Abenol; Apacet; Apadon; Cetadol; Fensum; Janupap; Minoset; Napafen; Neodol; Nobedon; Pacemol; Panodil; Parapan; Pedric; Phendon; Rounox; Suppap; Korum; Pinex; Temlo; 4-(Acetylamino)phenol; Ben-u-ron; Dial-A-Gesic; Anacin-3; Calmanticold; Codoliprane; Demogripal; Dolegrippin; Doloreduct; Dristancito; Duracetamol; Eu-Med; Grippostad; Gynospasmine; Medocodene; Paedialgon; Paracetamolum; Paracetanol; Parakapton; Pediapirin; Phenipirin; Phogoglandin; Predualito; Sanicopyrine; Scentalgyl; Sunetheton; Tachiprina; Termalgine; Treuphadol; Abrolet; Acertol; Acetamol; Acetofen; Afebrin; Afebryl; Aferadol; Algesidal; Algomol; Alpinyl; Analter; Antidol; Apitrelal; Atralidon; Babikan; Bacetamol; Cadafen; Calapol; Causalon; Cefalex; Codabrol; Codalgin; Codapane; Codicet; Codisal; Cofamol; Cosutone; Cuponol; Curadon; Custodial; Darocet; Daygrip; Deminofen; Democyl; Desfebre; Dimindol; Dolefin; Dolofugin; Dolorfug; Dolorstop; Dolotec; Dorocoff; Dularin; Durapan; Ecosetol; Excipain; Fanalgic; Farmadol; Febranine; Febrectol; Febricet; Febrinol; Fepanil; Finiweh; Fluparmol; Geluprane; Ildamol; Inalgex; Infadrops; Kataprin; Labamol; Lekadol; Lemgrip; Lupocet; Magnidol; Malidens; Maxadol; Mexalen; Minafen; Miralgin; Nealgyl; Neodolito; Neotrend; Neuridon; Nodolex; Oralgan; Oxycocet; Pacimol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorbe; Panofen; Pantalgin; Paracemol; Paracenol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parasedol; Parasin; Paraspen; Parcetol; Parogal; Pediatrix; Piramin; Pirinasol; Polmofen; Predimol; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Remedol; Rivalgyl; Rubophen; Rupemol; Sanicet; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Sifenol; Sinaspril; Sinedol; Stanback; Stopain; Supofen; Tazamol; Termacet; Termalgin; Termofren; Titralgan; Tricoton; Upsanol; Utragin; Veralgina; Viruflu; Vivimed; Zatinol; Abrol; Algina; Anapap; Andox; Arfen; Asetam; Asomal; Aspac; Asplin; Benmyo; Curpol; Dhamol; Dolcor; Dolko; Dresan; Dypap; Febrex; Febrin; Lemsip; Malgis; Noral; Oltyl; Paceco; Pacet; Paedol; Painex; Pamol; Panex; Parake; Paroma; Plicet; Prodol; Reliv; Scanol; Setol; Sinmol; Tiffy; Tylex; Tylol; Tymol; Verpol; Volpan; Zolben; NeoCitran; NilnOcen; Nina; RubieMol; Vips; Supadol mono; Treupel mon; Bickie-mol; Fortalidon P; Gattaphen T; Gripin Bebe; Influbene N; Lonarid Mono; Lyteca Syrup; Panadeine Co; Dymadon Co; Toximer P; Treupel N; Accu-Tap; 4-Acetaminophenol; Helon N; Malex N; Spalt N; Tylex CD; N-Acetyl-4-aminophenol; SK-Apap; Paracetamole; Conacetol; Darvocet; Empracet; Panasorb; Perfalgan; A-Per; Apamid; Ofirmev; Parelan; Prompt; Vicodin; Fevor; Freka-cetamol; Codisal Forte; Croix Blanche; Dolorol Forte; Dymadon Forte; Junior Disprol; Kinder Finimal; Liquigesic Co; Mono Praecimed; Percocet-Demi; Perdolan Mono; Rockamol Plus; Viclor Richet; Actifed Plus; Kratofin simplex; Neo-Fepramol; Paracetamol AL; Paracetamol BC; Paracetamol PB; Acetanilide, 4'-hydroxy-; Claradol Codeine; Geralgine-P; Melabon Infantil; Migraleve Yellow; Paracetamol Saar; Pyregesic-C; Anti-Algos; Para-Suppo; Pasolind N; Supramol-M; No-Febril; Panado-Co; Para-Tabs; Paracetamol Hexal; Paracetamol Raffo; Paracetamol Rosch; Paracetamol Stada; Dol-Stop; Anadin dla dzieci; p-Hydroxyphenolacetamide; Percocet-5; Cod-Acamol Forte; Contra-Schmerz P; Hy-Phen; Medinol Paediatric; Paracetamol Basics; Panado-Co Caplets; Paracetamol von ct; Pe-Tam; Paracetamol Fecofar; Paracetamol Harkley; Paracetamol Heumann; Paracetamol Nycomed; Codral Pain Relief; Paracetamol Hanseler; Paracetamol Winthrop; 4-Hydroxyacetanilide; Phenaphen W/Codeine; Spalt fur die nacht; A.F. Anacin; Capital with Codeine; Paracetamol Genericon; Anexsia; Demilets; Endecon; Intensin; Naldegesic; Propacet; Resfenol; Theraflu; Wygesic; Paracetamol Ratiopharm; Coricidin Sinus; Paracetamol Italfarmaco; Sudafed Sinus; Coricidin D; Paracetamol DC; Quiet World; Paracetamol Antipanin P; St Joseph Aspirin-Free; New Cortal for Children; INFANTS' FEVERALL; St. Joseph Fever Reducer; Midol Teen Formula; Paracetamol Dr. Schmidgall; Acetamide, N-(p-hydroxyphenyl)-; Aspirin-Free Anacin; Children's Tylenol Chewable; NCI-C55801; PCM Paracetamol Lichtenstein; Tylenol Allergy Sinus; p-(Acetylamino)phenol; Rhinex D-Lay Tablets; acetaminophene; Midol Regular Strength; Paracetamol SmithKline Beecham; Scherzatabletten Rezeptur 534; Percogesic with Codeine; 4-Hydroxyanilid kyseliny octove; Bayer Select Head Cold; n-acetyl-4-hydroxyaniline; Bayer Select Allergy-Sinus; Bayer Select Headache Pain; Dristan Cold No Drowsiness; Prestwick_13; St Joseph Aspirin-Free for Children; UNII-362O9ITL9D; 4-acetylaminophenol; Children's Acetaminophen Elixir Drops; MFCD00002328; Children's Acetaminophen Oral Solution; Midol PM Night Time Formula; Triaminic Sore Throat Formula; N-(4-hydroxyphenyl)ethanamide; Bayer Select Sinus Pain Relief; Phenol, p-acetamido-; Sine-Off Sinus Medicine Caplets; CHEBI:46195; Roxicet 5/500; Tocris-1706; N-acetyl-para-aminophenol; 4-(N-Acetylamino)phenol; Acetaminophen (4-hydroxyacetanilide); Bayer Select Menstrual Multi-Symptom; Acetaco; 4-Acetamidophenol, 98%; St. Joseph Cold Tablets for Children; CHEMBL112; N-(4-Hydroxyphenyl)acetamide (Tylenol); N-(4-hydroxyphenyl)-acetamide; 362O9ITL9D; Aminofen; DTXSID2020006; Atasol; Duaneo; Duorol; component of Dialog; component of Dilone; Fever All; NSC-3991; component of Endecon; component of Percocet; NSC-109028; component of Phenaphen; TYL; component of Percogesic; DSSTox_CID_6; NCGC00016361-07; Acetominophen; Actamin; CAS-103-90-2; Pasolind; Redutemp; Robigesic; Valorin; Aceta Elixir; Dafalgan Codeine; Jin Gang; WLN: QR DMV1; DSSTox_RID_75318; DSSTox_GSID_20006; component of Hycomine Compound; Acetavance; Paracetamolo [Italian]; Calonal; Flexsure; Acenol (pharmaceutical); N-(4-Hydroxyphenyl)acetanilide; Drixoral Sinus; Aceta Tablets; Paracetamol [INN:BAN]; Valorin Extra; CCRIS 3; Snaplets-FR; Oraphen-PD; Phenaphen Caplets; Paracetamolum [INN-Latin]; Tylenol (caplet); Tylenol (geltab); Tylenol 8-Hour; SMR000112065; Tavist Allergy/Sinus/Headache; Dapa X-S; Drixoral Cold & Flu; HSDB 3001; SR-01000597517; EINECS 203-157-5; 222 AF; Acetaminophen [USP:JAN]; paracetamol (acetaminophen); NSC 109028; acetominophene; 4-Hydroxyanilid kyseliny octove [Czech]; Children's Acetaminophen Elixir Solution; Claratal; Daphalgan; Resprin; Daga; Apacet Capsules; Atasol Caplets; Atasol Tablets; Tempra Caplets; Tylenol Caplets; Tylenol Elixir; Tylenol Gelcaps; Tylenol Tablets; Actamin Extra; Actamin Super; Aminofen Max; ANEXSIA 10/660; Apacet Elixir; Atasol Drops; Exdol Strong; p-Acetoaminophen; Tempra Drops; Tempra Syrup; Tylenol Drops; alpha-Per; Citramon P; Excedrin Caplets; Dial-alpha-gesic; Apo-Acetaminophen; 4-acetominophenol; Genebs X-Tra; Paracetamol;Tylenol; 4-acetamido phenol; 4-acetamido-phenol; Tempra D.S; APAP, Paracetamol; p-hydroxy-acetanilid; p-hydroxyacetoanilide; Paracetamol (INN); Tylenol (TN); Supac (Salt/Mix); Tylox (Salt/Mix); Acetaminophen (d4); Zydone (Salt/Mix); Atasol Forte Caplets; Atasol Forte Tablets; Atasol Oral Solution; para-acetylaminophenol; Anexsia (Salt/Mix); Endecon (Salt/Mix); Sinubid (Salt/Mix); Talacen (Salt/Mix); Vicodin (Salt/Mix); Wygesic (Salt/Mix); Acetaminophen Uniserts; Datril Extra-Strength; Tylenol Infants Drops; Demilets (Salt/Mix); Empracet (Salt/Mix); Intensin (Salt/Mix); Propacet (Salt/Mix); Suppap-120; Suppap-325; Suppap-650; Panadol Extra Strength; TheraFlu (Salt/Mix); Coricidin (Salt/Mix); Liquiprin (Salt/Mix); Hy-Phen (Salt/Mix); IV-APAP; phenol derivative, 11; PubChem17726; Spectrum_000016; Tempra Chewable Tablets; Naldegesic (Salt/Mix); Actimol Chewable Tablets; Feverall Junior Strength; Darvocet-N (Salt/Mix); Anacin-3 Extra Strength; Liquiprin Infants' Drops; N-acetyl para aminophenol; Prestwick0_000868; Prestwick1_000868; Prestwick2_000868; Prestwick3_000868; Spectrum2_000085; Spectrum3_000283; Spectrum4_000140; Spectrum5_000736; Coricidin D (Salt/Mix); Quiet World (Salt/Mix); Genapap Children's Elixir; Tylenol Children's Elixir; Actifed Plus (Salt/Mix); Epitope ID:117710; Genapap Children's Tablets; Sudafed Sinus (Salt/Mix); EC 203-157-5; Actimol Infants' Suspension; Drixoral Sinus (Salt/Mix); Liquiprin Children's Elixir; N-acetyl-4-hydroxyaniline;; SCHEMBL3480; Acetaminophen (JP17/USP); Coricidin Sinus (Salt/Mix); N-(4-hydroxyfenyl)ethanamid; BSPBio_000915; BSPBio_001786; DDS-06A; KBioGR_000560; KBioSS_000356; 4-13-00-01091 (Beilstein Handbook Reference); Actimol Children's Suspension; Apacet Extra Strength Caplets; Apacet Extra Strength Tablets; Aspirin-Free Excedrin Caplets; Genebs Extra Strength Caplets; MLS001146925; MLS001331684; MLS002154041; BIDD:GT0005; DivK1c_000660; SPECTRUM1500101; Genapap Extra Strength Caplets; Genapap Extra Strength Tablets; SPBio_000010; SPBio_002836; Tapanol Extra Strength Caplets; Tapanol Extra Strength Tablets; Tylenol Extra Strength Caplets; Tylenol Extra Strength Gelcaps; Tylenol Extra Strength Tablets; ACMC-20989w; Actimol Junior Strength Caplets; Apacet Regular Strength Tablets; BPBio1_001007; Excedrin Extra Strength Caplets; Genebs Regular Strength Tablets; GTPL5239; Panadol Junior Strength Caplets; SGCUT00014; Tylenol Junior Strength Caplets; Midol Teen Formula (Salt/Mix); Genapap Regular Strength Tablets; Panadol Maximum Strength Caplets; Panadol Maximum Strength Tablets; SCHEMBL19474893; Tylenol Regular Strength Caplets; Tylenol Regular Strength Tablets; Aspirin-Free Anacin (Salt/Mix); BDBM26197; HMS502A22; KBio1_000660; KBio2_000356; KBio2_002924; KBio2_005492; KBio3_001286; EBD5728; NSC3991; Tylenol Arthritis Extended Relief; Acetaminophen, analytical standard; NINDS_000660; Tylenol Infants' Suspension Drops; BCPP000441; Drixoral Cold & Fl" Small molecule "1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)" RZVAJINKPMORJF-UHFFFAOYSA-N CC(=O)NC1=CC=C(C=C1)O C8H9NO2 CAS 103-90-2 CHEBI:46195 . . . DB00316 . DR6918 Tacrine D0E6YQ D0E6YQ Approved Alzheimer disease ICD-11: 8A20 CID: 1935 Anticancer Treatment "Tacrine; 1,2,3,4-tetrahydroacridin-9-amine; 321-64-2; Tetrahydroaminacrine; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; Tetrahydroaminoacridine; Cognex; Tetrahydroaminocrin; Tetrahydroaminocrine; 9-amino-1,2,3,4-tetrahydroacridine; 9-Acridinamine, 1,2,3,4-tetrahydro-; CS 12602; UNII-4VX7YNB537; 1,2,3,4-Tetrahydro-9-aminoacridine; Acridine, 1,2,3,4-tetrahydro-9-amino-; CHEMBL95; 5-Amino-6,7,8,9-tetrahydroacridine; 4VX7YNB537; CHEBI:45980; 5,6,7,8-tetrahydroacridin-9-amine; tacrine.HCl; NCGC00015054-06; Tacrina; Tacrinum; Tacrine [INN:BAN]; Tacrinum [INN-Latin]; Tacrina [INN-Spanish]; DSSTox_CID_17272; DSSTox_RID_79318; DSSTox_GSID_37272; 5,6,7,8-tetrahydroacridine-9-ylamine; Tacrinal (TN); CAS-321-64-2; Tacrine (INN); EINECS 206-291-2; 5-Amino-6,7,8,9-tetrahydroacridine (European); BRN 0147610; 1,2,3,4-Tetrahydro-acridin-9-ylamine; Tracine; 1acj; 2aow; 2aox; BBL001044; 1,2,3,4-Tetrahydro-9-acridineamine; Romotal (Salt/Mix); 9-Acridinamine,1,2,3,4-tetrahydro-; Spectrum_000416; Tocris-0965; 1mx1; Prestwick0_000329; Prestwick1_000329; Prestwick2_000329; Prestwick3_000329; Spectrum2_001812; Spectrum3_001709; Spectrum4_000819; Spectrum5_001402; Lopac-A-3773; cid_1935; SCHEMBL2828; 9-THA; NCIOpen2_003667; Lopac0_000036; Oprea1_008681; Acridine, 9-aminotetrahydro-; BSPBio_000337; BSPBio_003298; KBioGR_001337; KBioSS_000896; BIDD:GT0090; DivK1c_000936; SPBio_001823; SPBio_002258; BDBM8961; BPBio1_000371; GTPL6687; DTXSID1037272; KBio1_000936; KBio2_000896; KBio2_003464; KBio2_006032; KBio3_002518; NINDS_000936; HMS2089F19; HMS3743C11; BCP03564; Tox21_110073; Tox21_302277; ANW-46208; MFCD00046923; PDSP1_000330; PDSP2_000328; SBB003560; STK101308; ZINC19014866; AKOS000277493; Tox21_110073_1; BCP9000019; CCG-204132; DB00382; MCULE-3628803328; NE25597; SDCCGSBI-0050025.P004; VZ20338; 1,2,3,4-tetra -hydro-9-acridinamine; IDI1_000936; NCGC00015054-01; NCGC00015054-02; NCGC00015054-03; NCGC00015054-04; NCGC00015054-05; NCGC00015054-07; NCGC00015054-08; NCGC00015054-09; NCGC00015054-10; NCGC00015054-12; NCGC00024908-01; NCGC00024908-03; NCGC00024908-04; NCGC00024908-05; NCGC00255540-01; 1,2,3,4-tetrahydro-acridin-9-yl-amine; ST083243; Acridine, 9-amino-1,2,3,4-tetrahydro-; SBI-0050025.P003; AB0126098; DB-000650; 9-amino-1,2,3,4-tetrahydroacridine (THA); AB00053524; C-110; EU-0010966; FT-0631953; R9947; 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI); A18628; C01453; D08555; AB00053524-17; AB00053524_18; AB00053524_19; AE-641/00604043; Q421076; 1,2,3,4-tetrahydroacridin-9-amine dihydrochloride; BRD-K81473089-003-03-0; BRD-K81473089-003-04-8; BRD-K81473089-003-15-4; SR-01000075593-13; Z56790573" Small molecule "1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)" YLJREFDVOIBQDA-UHFFFAOYSA-N C1CCC2=NC3=CC=CC=C3C(=C2C1)N C13H14N2 CAS 321-64-2 CHEBI:45980 . . . DB00382 . DR9235 PD173074 D0VF6E D0VF6E Investigative Nasopharyngeal cancer ICD-11: 2B6B CID: 1401 Anticancer Treatment "219580-11-7; PD173074; PD 173074; PD-173074; 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; UNII-A4TLL8634Y; A4TLL8634Y; CHEMBL189584; PD-0173074; CHEBI:63448; C28H41N7O3; MFCD08705327; 1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea; 3-tert-butyl-1-(2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 2fgi; N-[2-[[4-(Diethylamino)butyl]amino] -6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-y l]-N'-(1,1-dimethylethyl)urea; SMR000568412; FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074; PubChem22593; cc-523; MLS001074892; MLS006011101; SCHEMBL177946; Pyrido[2,3-d]pyrimidine 12; BDBM6190; GTPL5037; AOB2517; DTXSID30176363; EX-A197; SYN1176; BCPP000121; HMS2233G17; HMS3265E09; HMS3265E10; HMS3265F09; HMS3265F10; HMS3371E08; HMS3648A10; HMS3654L09; BCP02368; ZINC3870533; ABP000888; ANW-73236; NSC766908; s1264; AKOS016008595; BCP9001065; CCG-264881; CS-0182; NSC-766908; QC-7737; SB19382; NCGC00165863-01; NCGC00165863-02; NCGC00165863-17; 1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea; AC-24850; AK105355; AS-16310; HY-10321; AB0033759; FT-0673540; P2474; SW218104-2; X7486; PD 173074, >=96% (HPLC), powder; A25450; W-5382; PD173074/PD-173074/; SR-01000837541; J-014372; J-523314; SR-01000837541-2; Q27088276; FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7; 1-(tert-Butyl)-3-[7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-2-yl]urea; 1-tert-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)pyrido(2,3-d)pyrimidin-7-yl)urea; N-(tert-Butyl)-N -[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; N-[2-[[4-(Dethylamno)butyl]amno]-6-(3,5-dmethoxyphenyl)pyrdo[2,3-d ]pyrmdn-7-yl]-n'-(1,1-dmethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5- dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1- dimethylethyl)urea; N-[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; PD 173074;n-[2-[[4-(diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-n'-(1,1-dimethylethyl)urea" Small molecule "1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)" DXCUKNQANPLTEJ-UHFFFAOYSA-N CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C C28H41N7O3 CAS 219580-11-7 CHEBI:63448 . . . . . DR8195 Selenite . . Phase 3 Arsenical melanosis ICD-11: ED6Y CID: 1090 Anticancer Treatment selenite; Selenite ion; 14124-67-5; UNII-KXO0259XJ1; selenite(2-); KXO0259XJ1; Selenit; trioxoselenate(IV); trioxoselenate(2-); trioxidoselenate(2-); Selenium (IV) trioxide; Monohydrated selenuim dioxide; DTXSID9074517; SeO3(2-); CHEBI:18212; [SeO3](2-); C05684; Q27102911 Small molecule "1S/H2O3Se/c1-4(2)3/h(H2,1,2,3)/p-2" MCAHWIHFGHIESP-UHFFFAOYSA-L [O-][Se](=O)[O-] O3Se-2 CAS 14124-67-5 CHEBI:18212 . . . DB11127 . DR5963 Pyrroloquinoline quinone . . Investigative Osteoporosis ICD-11: FB83 CID: 1024 Anticancer Treatment "methoxatin; pyrroloquinoline quinone; 72909-34-3; 4,5-dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; Coenzyme pqq; Pyrrolo-quinoline quinone; UNII-47819QGH5L; Pyrroloquinoline-quinone; PQQ;Methoxatin; 4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; PQQ; CHEBI:18315; 47819QGH5L; pyrroloquinolinedione tricarboxylic acid; 2,7,9-Tricarboxy-1H-pyrrolo(2,3-f)quinoline-4,5-dione; Pqq coenzyme; Pqq cofactor; 4,5-dioxo-1H,4H,5H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; 4,5-Dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; 4,5-Dihydro-4,5-dioxo-1H-pyrrolo(2,3-f)quinoline-2,7,9-tricarboxylic acid; 1H-Pyrrolo(2,3-f)quinoline-2,7,9-tricarboxylic acid, 4,5-dihydro-4,5-dioxo-; Pyrroloquinolinequinone; 4,5-Dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylate; Methoxantin; Methoxatine; 2,7,9-Tricarboxypyrroloquinoline quinone; 1H-Pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid, 4,5-dihydro-4,5-dioxo-; 2,4,6-tricarboxylic-pyrrolo[2,3-5,6]quinoline 8,9-quinone; Pyrroloquinoline dione; 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-5,6]quinoline-2,7,9-tricarboxylic acid; Pyrroloquinoline quinone/PQQ; SCHEMBL37975; Pyrroloquinoline quinone(PQQ); Pyrroloquinoline Quinone (PQQ); CHEMBL1235421; DTXSID3041162; SCHEMBL21049248; BCP06301; ZINC1532545; ANW-49082; MFCD00043125; AKOS015920260; CS-W009276; DB03205; GS-6613; QC-4272; VA11282; Pyrroloquinoline dione tricarboxylic acid; AK-76674; AB0026456; DB-055694; HY-100196; A9450; FT-0617182; Pyrroloquinoline quinone, >=95.0% (HPLC); Pyrroloquinoline quinone, >=97.0% (HPLC); W8127; C00113; S-7393; 909M343; Q414583; C(=O)(O)C1=CC=2C(C=3C(=CC(=NC=3C(C=2O)=O)C(=O)O)C(=O)O)=N1; 4,5-Dioxo-4,5-dihydro-1H-pyrrolo-[2,3-f]quinoline-2,7,9-tricarboxylic acid" Small molecule "1S/C14H6N2O8/c17-10-4-2-6(14(23)24)15-8(4)7-3(12(19)20)1-5(13(21)22)16-9(7)11(10)18/h1-2,15H,(H,19,20)(H,21,22)(H,23,24)" MMXZSJMASHPLLR-UHFFFAOYSA-N C1=C(C2=C(C(=O)C(=O)C3=C2NC(=C3)C(=O)O)N=C1C(=O)O)C(=O)O C14H6N2O8 CAS 72909-34-3 CHEBI:18315 . . . DB03205 . DR7446 Hydroquinone D03UOT D03UOT Approved Acquired hypermelanosis ICD-11: ED60 CID: 785 Anticancer Treatment "hydroquinone; 1,4-benzenediol; Benzene-1,4-diol; 123-31-9; Quinol; 1,4-Dihydroxybenzene; p-Benzenediol; p-Hydroquinone; p-Hydroxyphenol; p-Dihydroxybenzene; 4-Hydroxyphenol; Benzoquinol; Eldoquin; hydroquinol; Eldopaque; Phiaquin; p-Dioxybenzene; Benzohydroquinone; Dihydroquinone; Hydroquinole; Idrochinone; Tecquinol; Dihydroxybenzene; Solaquin forte; Arctuvin; Hidroquinone; Tequinol; Derma-Blanch; Tenox HQ; Hydrochinon; Hydrochinone; Artra; Eldopaque Forte; Eldoquin Forte; Diak 5; Benzene, p-dihydroxy-; 1,4-Dihydroxy-benzol; Usaf ek-356; 1,4-Diidrobenzene; p-Dioxobenzene; 1,4-Dihydroxybenzen; para-Dioxybenzene; para-Hydroquinone; Pyrogentistic acid; 1,4-Dihydroxy-benzeen; NCI-C55834; HE 5; para-Dihydroxybenzene; Black and White Bleaching Cream; Melanex; Idrochinone [Italian]; Hydrochinon [Czech, Polish]; 1,4-Dihydroxybenzen [Czech]; 1,4-Diidrobenzene [Italian]; Benzosemiquinone; 1,4-Dihydroxy-benzeen [Dutch]; 1,4-Dihydroxy-benzol [German]; UNII-XV74C1N1AE; NSC 9247; MFCD00002339; UN2662; Hydroquinone [USP]; CHEBI:17594; AI3-00072; 4-DIHYDROXYBENZENE; HQ; CHEMBL537; XV74C1N1AE; DTXSID7020716; NSC-9247; Hydroquinone [UN2662] [Poison]; Hydroquinone (USP); Hydroquinone, 99%; NCGC00015523-02; beta-quinol; Hydroquinone, 99.5%; DSSTox_CID_716; DSSTox_RID_75754; DSSTox_GSID_20716; Eldopacque; Hydroquinone (Benzene-1,4-diol); Epiquin; Sunvanish; p Benzendiol; p-Dihydroquinone; alpha-hydroquinone; para-Hydroxyphenol; CAS-123-31-9; SMR000059154; CCRIS 714; 1,4-Hydroxybenzene; HSDB 577; SR-01000075920; EINECS 204-617-8; hydroquinon; Hydroquinoue; hydroq uinone; hydroquinone gr; a-Hydroquinone; Black & White Bleaching Cream; p-Hydroxybenzene; b-Quinol; 4-Benzenediol; Hydroquinone, HQ; .beta.-Quinol; 1,4 benzenediol; Hydroquinone,(S); p-dihydroxy benzene; HQE; Hydroquinone polymer; PLQ; Artra (Salt/Mix); 1, 4-Benzenediol; HYDROP; .alpha.-Hydroquinone; phenol derivative, 4; PubChem9139; 4-hydroxyphenyl alcohol; Spectrum_001757; 4e3h; ACMC-209aok; SpecPlus_000769; 1,4-Dihydrobenzoquinone; ELDOQUIN (TN); hydroquinone for synthesis; Spectrum2_001672; Spectrum3_000656; Spectrum4_000633; Spectrum5_001430; Lopac-H-9003; 1,2 BENZOLDIOL; WLN: QR DQ; bmse000293; Epitope ID:116206; EC 204-617-8; Lopac0_000577; SCHEMBL15516; BSPBio_002291; KBioGR_001246; KBioSS_002237; 1,4-Dihydroxybenzene, XIII; Hydroquinone-1,4-Benzenediol; MLS000069815; MLS001074911; BIDD:ER0340; DivK1c_006865; Hydroquinone, LR, >=99%; SPECTRUM1504237; Hydrochinon(CZECH, POLISH); SPBio_001883; BDBM26190; Hydroquinone, puriss., 99.0%; KBio1_001809; KBio2_002237; KBio2_004805; KBio2_007373; KBio3_001511; NSC9247; Benzene-1,4-diol (Hydroquinone); HMS1922H15; HMS2093E08; HMS3261D16; LABOTEST-BB LTBB001931; Pharmakon1600-01504237; HY-B0951; ZINC5133378; Tox21_110169; Tox21_202345; Tox21_300015; Tox21_500577; ANW-18114; BBL011606; CCG-39082; NSC758707; s4580; SBB060421; STK397446; AKOS000119003; Tox21_110169_1; AM10548; AS00174; DB09526; LP00577; MCULE-3953269041; NE10177; NSC-758707; SDCCGSBI-0050559.P003; UN 2662; Hydroquinone, ReagentPlus(R), >=99%; Hydroquinone, USP, 99.0-100.5%; NCGC00015523-01; NCGC00015523-03; NCGC00015523-04; NCGC00015523-05; NCGC00015523-06; NCGC00015523-07; NCGC00015523-08; NCGC00015523-09; NCGC00015523-10; NCGC00015523-11; NCGC00015523-12; NCGC00015523-13; NCGC00015523-19; NCGC00090880-01; NCGC00090880-02; NCGC00090880-03; NCGC00090880-04; NCGC00090880-05; NCGC00254037-01; NCGC00259894-01; NCGC00261262-01; BP-21160; DA-33570; Hydroquinone, ReagentPlus(R), >=99.5%; SBI-0050559.P002; Hydroquinone, SAJ first grade, >=99.0%; EU-0100577; FT-0606877; Hydroquinone, SAJ special grade, >=99.0%; ST50214344; Hydroquinone, meets USP testing specifications; C00530; D00073; H 9003; 19538-EP2272837A1; 19538-EP2284165A1; 19538-EP2302015A1; 19538-EP2305825A1; 19538-EP2309584A1; 19538-EP2311804A2; 19538-EP2314576A1; 19538-EP2314579A1; 19538-EP2314584A1; 19538-EP2315303A1; 19538-EP2371803A1; 19538-EP2377843A1; 97871-EP2305685A1; AB00053361_08; 122680-EP2295053A1; Q419164; J-004910; J-521469; SR-01000075920-1; SR-01000075920-4; Q27102742; Z57127551; 094CADDB-59BF-4EDF-B278-59791B203EA2; F1908-0167; Hydroquinone, certified reference material, TraceCERT(R); Hydroquinone, United States Pharmacopeia (USP) Reference Standard; Hydroquinone, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H" QIGBRXMKCJKVMJ-UHFFFAOYSA-N C1=CC(=CC=C1O)O C6H6O2 CAS 123-31-9 CHEBI:17594 . . . DB09526 . DR6027 Bupropion D0X4ZR D0X4ZR Approved Nicotine use disorder ICD-11: 6C4A CID: 444 Anticancer Treatment "bupropion; Amfebutamone; 34911-55-2; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; Amfebutamon; Wellbutrin; amfebutamonum; Amfebutamona; (+-)-Bupropion; 34841-39-9; Elontril; Wellbatrin; Zyban; AMFEBUTAMONE HCl; Bupropion SR; Bupropion hydrocloride; CHEMBL894; alpha-(tert-butylamino)-m-chloropropiophenone; CHEBI:3219; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; Bupropion [INN:BAN]; Amfebutamonum [INN-Latin]; Amfebutamona [INN-Spanish]; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; UNII-01ZG3TPX31; Bupropion (INN); Bupropion (USAN); BW-323; NSC315851; bupropion (amfebutamone); BRN 2101062; 01ZG3TPX31; Bupropion-[d9]; Zyban (Salt/Mix); 150988-80-0; Budeprion (Salt/Mix); Spectrum_001663; Wellbutrin (Salt/Mix); SpecPlus_000954; (.+/-.)-Bupropion; 2-(Tert-Butylamino)-3'-chloropropiophenone; Prestwick0_000249; Prestwick1_000249; Prestwick2_000249; Prestwick3_000249; Spectrum2_001659; Spectrum3_000644; Spectrum4_000614; Spectrum5_001406; (+-)-2-(tert-Butylamino)-3'-chlorpropiophenon; Lopac0_000166; SCHEMBL38777; BSPBio_000038; BSPBio_002247; KBioGR_001168; KBioSS_002143; (+-)-2-(tert-Butylamino)-3'-chloropropiophenone; MLS001424015; DivK1c_007050; SPBio_001817; SPBio_002257; BPBio1_000042; GTPL7135; DTXSID7022706; HSDB 6988; KBio1_001994; KBio2_002143; KBio2_004711; KBio2_007279; KBio3_001467; HMS2051G10; HMS2089G14; HMS2232P04; HMS3369P11; HMS3393G10; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-; AMY32517; BCP24193; 8068AH; AC-197; BBL029065; BDBM50048392; STL373006; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, (+-)-; AKOS015961770; CCG-100858; CCG-204261; DB01156; NC00108; NSC 758686; SDCCGSBI-0050154.P004; MRF-0000143; NCGC00015122-03; NCGC00015122-04; NCGC00015122-06; NCGC00015122-07; NCGC00015122-09; NCGC00015122-14; NCGC00015122-20; NCGC00089751-02; AM807634; NCI60_002714; SMR000472526; SBI-0050154.P003; DB-048697; AB00053756; .alpha.-(tert-Butylamino)-m-chloropropiophenone; 3'-Chloro-alpha-(tert-butylamino)propiophenone; C-6222; C06860; D07591; Propiophenone, 2-(tert-butylamino)-3'-chloro-; AB00053756-16; AB00053756-18; AB00053756-19; AB00053756_20; AB00053756_21; 2-tert-Butylamino-1-(3-chlorophenyl)propan-1-one; L000725; Q834280; (.+/-.)-2-(tert-Butylamino)-3'-chloropropiophenone; BRD-A05186015-003-05-7; BRD-A05186015-003-09-9; 2-(tert-Butylamino)-1-(3-chlorophenyl)-1-propanone #; 1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; 1-Propanone, 1-(3-chlorophenyl)-2-[(1, 1-dimethylethyl)amino]-; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, (.+/-.)-" Small molecule "1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3" SNPPWIUOZRMYNY-UHFFFAOYSA-N CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C C13H18ClNO CAS 34911-55-2 CHEBI:3219 . . . DB01156 . DR5078 Cephalosporin D07JVS D07JVS Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 25058126 Anticancer Treatment "CEPHALOSPORIN; CHEMBL1235646; Q27465008; (2R)-2-[(R)-{[(6R)-6-amino-6-carboxyhexanoyl]amino}(carboxy)methyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; REC" Small molecule "1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1" JGKXEMYIHDYWCZ-JFUSQASVSA-N C=C1CSC(N=C1C(=O)O)C(C(=O)O)NC(=O)CCCCC(C(=O)O)N C15H21N3O7S . . . . . . . DR3924 Bis(7)-tacrine . . Investigative Glaucoma ICD-11: 9C61 CID: 9959612 Anticancer Treatment "bis(7)-Tacrine; 224445-12-9; 9-Amino-1,2,3,4-tetrahydroacridine bis 1,7-heptylene dihydrochloride; Tacrine-Based Inhibitor 2f; N,N/'-bis(1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine;dihydrochloride; C33H40N4.2HCl; CHEMBL3752685; DTXSID80433317; 1640AH; SR-01000946720; SR-01000946720-1; Bis(heptyl)-cognitin dihydrochloride, >=98% (HPLC); 9-Amino-1,2,3,4-tetrahydroacridine bis 1,7-heptylene dihydrochloride, >97%, solid" Small molecule "1S/C33H40N4.2ClH/c1(2-12-22-34-32-24-14-4-8-18-28(24)36-29-19-9-5-15-25(29)32)3-13-23-35-33-26-16-6-10-20-30(26)37-31-21-11-7-17-27(31)33;;/h4,6,8,10,14,16,18,20H,1-3,5,7,9,11-13,15,17,19,21-23H2,(H,34,36)(H,35,37);2*1H" RHKXINFBJWDTSK-UHFFFAOYSA-N C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCNC4=C5CCCCC5=NC6=CC=CC=C64.Cl.Cl C33H42Cl2N4 CAS 224445-12-9 . . . . . . DR7740 BIBR1532 . . Investigative Lung cancer ICD-11: 2C25 CID: 9927531 Anticancer Treatment BIBR 1532; 321674-73-1; BIBR1532; (E)-2-(3-(naphthalen-2-yl)but-2-enamido)benzoic acid; BIBR-1532; CHEMBL27323; 2-{[(2e)-3-(Naphthalen-2-Yl)but-2-Enoyl]amino}benzoic Acid; 2-[[(E)-3-naphthalen-2-ylbut-2-enoyl]amino]benzoic Acid; 2-(3-Naphthalen-2-yl-but-2-enoylamino)-benzoic acid; MLS006011127; SCHEMBL16964998; CHEBI:94985; DTXSID70432975; EX-A381; BIBR-1532/BIBR1532; IBR 1532; ABP000274; BDBM50126186; MFCD11112195; s1186; ZINC13488964; AKOS024457366; CCG-264852; CS-0902; SB19493; NCGC00242492-01; NCGC00242492-09; AC-26865; AS-56088; HY-17353; SMR004702907; SW219803-1; X7524; EC-000.2388; W-5477; 2-(3-(Naphthalen-2-yl)but-2-enamido)benzoic acid; BRD-K04623885-001-01-8; Q27455481; 2-[(e)-3-naphthalen-2-yl-but-2-enoylamino]-benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl]amino]benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoicacid; 2197129-84-1; 55C Small molecule "1S/C21H17NO3/c1-14(16-11-10-15-6-2-3-7-17(15)13-16)12-20(23)22-19-9-5-4-8-18(19)21(24)25/h2-13H,1H3,(H,22,23)(H,24,25)/b14-12+" PGFQXGLPJUCTOI-WYMLVPIESA-N CC(=CC(=O)NC1=CC=CC=C1C(=O)O)C2=CC3=CC=CC=C3C=C2 C21H17NO3 CAS 321674-73-1 CHEBI:94985 . . . . . DR1629 Avibactam . . Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 9835049 Anticancer Treatment "Avibactam; NXL104; Avibactam free acid; Avibactam (free acid); 1192500-31-4; NXL 104; UNII-7352665165; CHEMBL1689063; CHEBI:85984; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; Avibactam [USAN:INN]; SCHEMBL1666807; GTPL10761; AMY24028; AVI; ZINC9302239; BDBM50339145; CS-0593; DB09060; HY-14879; Q15410251; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; trans-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octan-2-carboxamide; (1R,2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate; SULFURIC ACID, MONO[(1R,2S,5R)-2-(AMINOCARBONYL)-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCT-6-YL] ESTER" Small molecule "1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1" NDCUAPJVLWFHHB-UHNVWZDZSA-N C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N C7H11N3O6S CAS 1192500-31-4 CHEBI:85984 . . . DB09060 . DR6887 Cefepime D0A1CB D0A1CB Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 5479537 Anticancer Treatment "cefepime; Maxipime; Cefepima; Cefepimum [Latin]; Cefepima [Spanish]; Cefepimum; 88040-23-7; Axepim; BMY-28142; E-Cefepime; CFPM; UNII-807PW4VQE3; 807PW4VQE3; CHEBI:478164; BMY 28142; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Cefepime (USAN/INN); Cefepime [USAN:INN:BAN]; J01DE01; Cefepime(Maxipime)/; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); Cefepime, Antibiotic for Culture Media Use Only; CHEMBL186; SCHEMBL65720; VNRX-5022; DTXSID70873208; BCPP000292; HMS2089M18; ABP000468; BDBM50350470; AKOS015850865; AKOS016014147; BCP9000504; DB01413; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate; C08111; D02376; AB01275446-01; A842445; Q27294816; (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-[(1-methyl-1-pyrrolidin-1-iumyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-azanyl-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium" Small molecule "1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1" HVFLCNVBZFFHBT-ZKDACBOMSA-N C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-] C19H24N6O5S2 CAS 88040-23-7 CHEBI:478164 . . . DB01413 . DR8350 Cyclosporin D0O3YF D0O3YF Approved Psoriasis vulgaris ICD-11: EA90 CID: 5284373 Anticancer Treatment "cyclosporin A; cyclosporine; Ciclosporin; 59865-13-3; Cyclosporine A; Sandimmune; Sandimmun; Neoral; Cyclosporin; Ciclosporine; Gengraf; Ramihyphin A; Sandimmun Neoral; Sang-35; Ciclosporina; Ciclosporinum; Consupren; Equoral; Neoplanta; UNII-83HN0GTJ6D; Antibiotic S 7481F1; SangCyA; MFCD00274558; 83HN0GTJ6D; MLS001333756; CHEBI:4031; CSA; S-Neoral; Cipol N; Sigmasporin Microoral; Cyclosporin A solution; DSSTox_CID_365; Ciclosporin (Ciclosporin A); DSSTox_RID_75541; DSSTox_GSID_20365; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; SDZ-OXL 400; Ciclosporin A; OL 27-400; Abrammune; Imusporin; Optimmune; Seciera; Vekacia; Papilock Mini; Arpimune ME; Zinograf ME; Sandimmune Neoral; Ciclosporina Germed; (R-(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); CYA; SMR000058578; Cicloral (antibiotic); Debio088; Sang 35; Cyclosporine [USAN:USP]; Ciclosporine [INN-French]; Ciclosporinum [INN-Latin]; Ciclosporina [INN-Spanish]; Cyclospori; Sigmasporin; Cyclokat; Mitogard; Papilock; Pulminiq; Zyclorin; CicloMulsion; Ciclosporin;; CCRIS 1590; Ciclosporin DT; Consupren S; NSC290193; Modusik-A; HSDB 6881; NeuroSTAT; 1cyn; 2wfj; 4jjm; NSC-290193; Cipol-N; NCGC00016890-01; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,2; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19; (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); Cyclo(((E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl); Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]; DRG-0275; Prestwick_731; Ciclosporin [INN]; CAS-59865-13-3; NSC 290193; CsA & IFN.alpha.; 1c5f; 2z6w; S 7481F1; Cyclosporine manufacturer; Prestwick2_000435; Prestwick3_000435; CHEMBL160; Sang-2000; SCHEMBL3491; SCHEMBL4442; Nova-22007; Ikervis (opthalmic solution); BSPBio_000450; Cyclosporin A & IFN.alpha.; MLS000028376; MLS002153454; MLS002207033; Verkazia (opthalmic solution); SDZ-OXL-400; BPBio1_000496; GTPL1024; ANTIBIOTIC S-7481F1; DTXSID0020365; CHEBI:92233; AOB2581; ATH-002; OLO-400; CB-01-09 MMX; HMS1569G12; HMS2089A09; HMS2096G12; HMS2230M14; HMS3713G12; 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]; 30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); Cyclosporin A, Ready Made Solution; EX-A4110; HY-B0579; Tox21_110667; Tox21_301849; BDBM50022815; DE-076; ST-603; Cyclosporin A, >=98.5% (TLC); AKOS015969287; Tox21_110667_1; CCG-208184; DB00091; EBD2126862; KS-1257; SDCCGSBI-0050230.P004; NCGC00093704-12; NCGC00164258-01; NCGC00164258-02; NCGC00164258-03; NCGC00255232-01; AT-12519; C042; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); OL-27400; SBI-0050230.P003; AB0090560; OL-27-400; 5946-EP0930075A1; 5946-EP2289877A1; 5946-EP2292601A1; 5946-EP2292602A1; 5946-EP2292603A1; 5946-EP2292604A2; 5946-EP2292618A1; 5946-EP2293650A1; 5946-EP2298737A1; 5946-EP2298739A1; 5946-EP2298740A1; 5946-EP2298741A1; 5946-EP2298771A2; 5946-EP2301920A1; 5946-EP2301940A1; 5946-EP2308843A1; 5946-EP2308861A1; J10181; J90049; 865C133; Cyclosporin A, VETRANAL(TM), analytical standard; Q367700; SR-01000780563; Q-200913; SR-01000780563-3; BRD-K03222093-001-01-8; BRD-K13533483-001-03-0; Ciclosporin, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, >=95% (HPLC), solid; Cyclosporine, United States Pharmacopeia (USP) Reference Standard; Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, >=95%; Cyclosporine, Pharmaceutical Secondary Standard; Certified Reference Material; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17; 104250-72-8; 30-Ethyl-33-((E)-1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone" Small molecule "1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1" PMATZTZNYRCHOR-CGLBZJNRSA-N CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C C62H111N11O12 CAS 59865-13-3 CHEBI:4031 . . . DB00091 . DR6730 10058F4 . . Investigative Acute myeloid leukemia ICD-11: 2A60 CID: 1271002 Anticancer Treatment "10058-F4; 403811-55-2; (5E)-5-(4-ethylbenzylidene)-2-mercapto-1,3-thiazol-4(5H)-one; 5-[(4-Ethylphenyl)methylene]-2-thioxo-4-thiazolidinone; 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; 10058F4; (E)-5-(4-Ethylbenzylidene)-2-mercaptothiazol-4(5H)-one; c-Myc Inhibitor; 10058-F4 compound; 5-(4-ethylbenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one; CHEMBL1568415; SCHEMBL10042186; (Z,E)-5-(4-Ethylbenzylidine)-2-thioxothiazolidin-4-one; EX-A660; CHEBI:149696; HMS3260I13; ALBB-009118; Tox21_500046; MFCD00758517; MFCD04969046; NSC764582; s7153; ZINC12406714; (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one; AKOS000307369; AKOS003017633; CCG-221350; CS-3965; LP00046; NSC-764582; SB19479; SDCCGSBI-0633678.P001; NCGC00185994-01; NCGC00185994-10; NCGC00260731-01; AC-32727; AS-55984; HY-12702; c-Myc Inhibitor - CAS 403811-55-2; BB 0259511; SW219661-1; 10058-F4, >=98% (HPLC), solid; A13725; Y-1489; AB00084200-01; SR-01000208026; SR-01000208026-1; 5-(4-ethylbenzylidene)-2-mercapto-1,3-thiazol-4(5H)-one; 5-[(4-ethylphenyl)methylidene]-2-sulfanyl-4,5-dihydro-1,3-thiazol-4-one" Small molecule "1S/C12H11NOS2/c1-2-8-3-5-9(6-4-8)7-10-11(14)13-12(15)16-10/h3-7H,2H2,1H3,(H,13,14,15)/b10-7+" SVXDHPADAXBMFB-JXMROGBWSA-N CCC1=CC=C(C=C1)C=C2C(=O)NC(=S)S2 C12H11NOS2 CAS 403811-55-2 CHEBI:149696 . . . . . DR8562 Pirarubicin D0T8EH D0T8EH Approved Breast cancer ICD-11: 2C60-2C65 CID: 636397 Anticancer Treatment "pirarubicin; 72496-41-4; Theprubicin; MFCD00869742; Therarubicin (TN); (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2S)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-6-methyl-5-(((S)-tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; THP-doxorubicin; C32H37NO12; NCGC00167982-01; Pirarubicin (JP17/INN); CHEMBL1398373; SCHEMBL15472856; CHEBI:32011; AOB5649; EX-A494; AMY10325; ZINC3913909; AKOS015895621; NCGC00167982-02; NCGC00167982-04; K234; D01885; 15207-EP2272827A1; 15207-EP2275420A1; 15207-EP2295055A2; 15207-EP2295416A2; 15207-EP2295426A1; 15207-EP2295427A1; 15207-EP2298748A2; 15207-EP2298764A1; 15207-EP2298765A1; 15207-EP2298768A1; 15207-EP2298778A1; 15207-EP2305642A2; 15207-EP2311453A1; 15207-EP2311808A1; 15207-EP2311829A1; 15207-EP2316832A1; 15207-EP2316833A1; 496P414; Pirarubicin, Antibiotic for Culture Media Use Only; Q-201589; (8S)-10-((2R,4S,5S,6S)-4-amino-6-methyl-5-((S)-tetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione" Small molecule "1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1" KMSKQZKKOZQFFG-HSUXVGOQSA-N CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6 C32H37NO12 CAS 72496-41-4 CHEBI:32011 . . . DB11616 . DR1499 Laninamivir . . Phase 2 Influenza ICD-11: 1E30 CID: 502272 Anticancer Treatment "Laninamivir; 203120-17-6; UNII-B408IW3GL5; R-125489; Laninamivir (CS-8958); B408IW3GL5; (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 5-(Acetylamino)-2,6-Anhydro-4-Carbamimidamido-3,4,5-Trideoxy-7-O-Methyl-D-Glycero-D-Galacto-Non-2-Enonic Acid; Laninamivir [INN:JAN]; Laninamivir (INN); LANI; R 125489; CHEMBL466246; SCHEMBL12284832; DTXSID60942457; BCPP000190; C13H22N4O7; BCP27633; EX-A4019; ZINC3985629; BDBM50009296; AKOS015850995; AKOS032947260; BCP9000836; DB12791; (2R,3R,4S)-3-acetamido-2-[(1R,2R)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid; HY-14818; CS-0003575; Y0284; C21557; D09410; S-7726; 120L176; A814430; Q6487096; (2R,3R,4S)-3-acetamido-4-[bis(azanyl)methylideneamino]-2-[(1R,2R)-1-methoxy-2,3-bis(oxidanyl)propyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; (4S,5R,6R)-5-acetamido-4-carbamimidamido-6-((1R,2R)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid; 2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-5-[(1-hydroxyethylidene)amino]-7-O-methylnon-2-enonic acid; 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid; 5-Acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid" Small molecule "1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1" QNRRHYPPQFELSF-CNYIRLTGSA-N CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N C13H22N4O7 CAS 203120-17-6 . . . . DB12791 . DR5808 MG262 . . Investigative Ovarian cancer ICD-11: 2C73 CID: 490002 Anticancer Treatment "MG-262; PS-III; MG262; UNII-549V4DP94W; 179324-22-2; CHEMBL114388; 549V4DP94W; boro-LLL; ((5S,8S,11R)-5,8-diisobutyl-13-methyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazatetradecan-11-yl)boronic acid; Z-Leu-Leu-Leu-B(OH)2 (MG262); [(1R)-1-[[(2S)-2-[[(2S)-2-(benzyloxycarbonylamino)-4-methyl-pentanoyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-butyl]boronic acid; MG 262; SCHEMBL12384366; DTXSID80170795; BDBM50069984; ZINC169998630; [(1R)-3-methyl-1-[[(2S)-4-methyl-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]butyl]boronic acid; A8179; Q27261199; L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N1-[(1R)-1-borono-3-methylbutyl]-; (R)-1-((S)-2-((S)-2-(benzyloxycarbonyl)-4-methylpentanamido)-4-methylpentanamido)-3-methylbutylboronic acid" Small molecule "1S/C25H42BN3O6/c1-16(2)12-20(24(31)29-22(26(33)34)14-18(5)6)27-23(30)21(13-17(3)4)28-25(32)35-15-19-10-8-7-9-11-19/h7-11,16-18,20-22,33-34H,12-15H2,1-6H3,(H,27,30)(H,28,32)(H,29,31)/t20-,21-,22-/m0/s1" MWKOOGAFELWOCD-FKBYEOEOSA-N B(C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1)(O)O C25H42BN3O6 CAS 179324-22-2 . . . . . . DR1860 Rosuvastatin D0JE2E D0JE2E Approved Hyper-lipoproteinaemia ICD-11: 5C80 CID: 446157 Anticancer Treatment "Rosuvastatin; 287714-41-4; ZD4522; UNII-413KH5ZJ73; CHEMBL1496; CHEBI:38545; 413KH5ZJ73; ZD-4522; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid; 7-[4-(4-fluorophenyl)-6E-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3R,5S-dihydroxy-6-heptenoic acid; Creston (TN); Rosuvastatin (INN); Rosuvastatin [INN:BAN]; C22H28FN3O6S; HSDB 7317; Spectrum5_001695; SCHEMBL2520; BSPBio_003429; SCHEMBL154400; SPECTRUM1505213; GTPL2954; DTXSID8048492; BDBM18372; CHEBI:93454; HMS1922N09; ZINC1535101; CCG-40119; HY-17504A; MFCD18783208; AKOS000280777; AM84890; DB01098; NCGC00178070-01; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); AC-30585; AS-12247; SBI-0206727.P001; S5072; A11122; A24862; D08492; 28050-EP2269990A1; 28050-EP2272841A1; 28050-EP2272842A1; 28050-EP2280006A1; 28050-EP2281813A1; 28050-EP2284158A1; 28050-EP2287165A2; 28050-EP2287166A2; 28050-EP2292620A2; 28050-EP2295406A1; 28050-EP2298731A1; 28050-EP2298742A1; 28050-EP2298745A1; 28050-EP2298772A1; 28050-EP2298776A1; 28050-EP2298779A1; 28050-EP2301923A1; 28050-EP2301931A1; 28050-EP2301936A1; 28050-EP2308839A1; 28050-EP2314588A1; Q415159; BRD-K82941592-001-01-3; BRD-K82941592-238-02-9; (3R,5S)-7-[4-(4-fluorophenyl)-2-(methyl-methylsulfonylamino)-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-trans-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6enoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-; 7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid;Rosuvastatin;Rosuvastatin Acid; E-(7-{2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl}-(3R,5S)-3,5-dihydroxy-hept-6-enoic acid]; E-7-[2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; FBI" Small molecule "1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1" BPRHUIZQVSMCRT-VEUZHWNKSA-N CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C C22H28FN3O6S CAS 287714-41-4 CHEBI:38545 . . . DB01098 . DR7530 Fluvastatin D08GHB D08GHB Approved Hyper-lipoproteinaemia ICD-11: 5C80 CID: 446155 Anticancer Treatment "fluvastatin; 93957-54-1; (3R,5S)-fluvastatin; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (+)-(3R,5S)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEBI:38565; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL1078; Fluvastatin & Primycin; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; PubChem10727; DSSTox_CID_636; Prestwick2_000859; SCHEMBL2846; DSSTox_RID_75707; DSSTox_GSID_20636; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXSID2020636; BDBM86704; CHEBI:93160; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; ACT03305; ZINC1886617; Tox21_302765; DL-108; HY-14664B; NSC758896; CCG-213323; NC00659; NSC-758896; NCGC00256490-01; CAS-93957-54-1; CAS_93957-54-1; CS-0019897; EN300-51915; W-5176; 957F541; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; UNII-4L066368AS component FJLGEFLZQAZZCD-MCBHFWOFSA-N; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; Fluvastatin sodium L1483" Small molecule "1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1" FJLGEFLZQAZZCD-MCBHFWOFSA-N CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F C24H26FNO4 CAS 93957-54-1 CHEBI:38565 . . . DB01095 . DR7903 SLC-0111 . . Phase 1 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 310360 Anticancer Treatment "178606-66-1; U-104; 4-(3-(4-fluorophenyl)ureido)benzenesulfonamide; 1-(4-fluorophenyl)-3-(4-sulfamoylphenyl)urea; SLC-0111; mst-104; 4-{[(4-Fluorophenyl)carbamoyl]amino}benzenesulfonamide; NSC213841; CHEMBL1615281; Carbonic Anhydrase IX/XII Inhibitor II(U-104); 4-{[(4'-Fluorophenyl)Carbamoyl]Amino}Benzenesulfonamide; 4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzenesulfonamide; 4-[3-(4-Fluorophenyl)ureido]benzenesulfonamide; WWZ; NSC 213841; 3n4b; SCHEMBL672955; GTPL10149; AOB5732; EX-A904; SLC0111; HMS3651H21; HMS3872E13; BCP14895; ZINC1752601; BDBM50334354; MFCD00159265; s2866; 4-fluorophenylureido-benzenesulfonamide; AKOS001123930; CCG-267573; compound 7 [PMID: 21361354]; CS-4495; MCULE-4710078413; NSC-213841; SB19580; NCGC00379154-03; AC-32932; AK341046; AS-66547; HY-13513; FT-0699833; SW220124-1; U 104; U-104, >=98% (HPLC); U-104;NSC213841;MST104; X5935; A14959; J-690246; (3?,5?)-3,14,17-Trihydroxycard-20(22)-enolide; 3-(4-FLUOROPHENYL)-1-(4-SULFAMOYLPHENYL)UREA; Q27467365; 4-(((4-Fluoroanilino)carbonyl)amino)benzenesulfonamide; 4-{[(4''-Fluorophenyl)carbamoyl]amino}benzenesulfonamide; 4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzesulfonamide" Small molecule "1S/C13H12FN3O3S/c14-9-1-3-10(4-2-9)16-13(18)17-11-5-7-12(8-6-11)21(15,19)20/h1-8H,(H2,15,19,20)(H2,16,17,18)" YJQZNWPYLCNRLP-UHFFFAOYSA-N C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)S(=O)(=O)N)F C13H12FN3O3S . . . . . . . DR9688 S3I-201 D0TU0X D0TU0X Investigative Lupus nephritis ICD-11: 4A40 CID: 252682 Anticancer Treatment "501919-59-1; Nsc 74859; S3I-201; S31-201; 2-hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid; NSC-74859; NSC74859; UNII-JG1E8503OI; MLS002701911; JG1E8503OI; NSC 74859 (S3I-201); 2-Hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]benzoic acid; Benzoic acid, 2-hydroxy-4-((2-(((4-methylphenyl)sulfonyl)oxy)acetyl)amino)-; SMR001565495; Benzoic acid, 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-; Salicylic acid, 4-p-toluenesulfonate; S3I201; STAT3-inhibitor-VI; S3I 201; NCIOpen2_008987; cc-515; MLS006011065; CHEMBL477936; cid_252682; SCHEMBL4456216; BDBM20283; CHEBI:91224; AOB4162; DTXSID00198234; EX-A342; GLG-302; BCPP000083; HMS3654C12; BCP01761; ZINC1621282; 2-hydroxy-4-[[2-(4-methylphenyl)sulfonyloxyacetyl]amino]benzoic acid; ABP000942; s1155; AKOS016366328; AM81245; CCG-268227; CS-0512; QC-8386; SB17268; NCGC00262641-02; NSC 74859,S3I-201; AC-32045; AK175837; AS-55944; HY-15146; AB0007928; FT-0704713; S31-201,NSC74859/; S3I-201 (NSC-74859); S3I-201 - NSC 74859; SW219398-1; X7562; S3I-201, >=97% (HPLC); A25494; S-7755; J-509627; Q27163139; 2-hydroxy-4-((((4-methylphenyl)sulfonyloxy)acetyl)amino)-benzoic acid; 2-hydroxy-4-(2-{[(4-methylbenzene)sulfonyl]oxy}acetamido)benzoic acid; 2-Hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid; 2-hydroxy-4-{2-[(4-methylbenzene-1-sulfonyl)oxy]acetamido}benzoic acid; S3I-201; ; ; 2-Hydroxy-4-[[2-(4-methylphenyl)sulfonyloxyacetyl]amino]benzoic acid" Small molecule "1S/C16H15NO7S/c1-10-2-5-12(6-3-10)25(22,23)24-9-15(19)17-11-4-7-13(16(20)21)14(18)8-11/h2-8,18H,9H2,1H3,(H,17,19)(H,20,21)" HWNUSGNZBAISFM-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O C16H15NO7S CAS 501919-59-1 CHEBI:91224 . . . . . DR8131 Peramivir D0P2IW D0P2IW Approved Influenza ICD-11: 1E30-1E32 CID: 154234 Anticancer Treatment "Peramivir; 330600-85-6; Rapiacta; BCX-1812; 229614-55-5; RWJ-270201; UNII-9ZS94HQO3B; RAPIVAB; CHEBI:85202; Peramivir hydrate; BCX1812; BCX 1812; RWJ270201; 229614-56-6; RWJ 270201; 9ZS94HQO3B; (1S,2S,3R,4R)-3-((S)-1-Acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid; 330600-85-6 (free); (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID; 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid; BCZ; Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)-; (+/-)-Peramivir; Peramivir [USAN:INN]; PeramiFlu; Peramivir anhydrous; (1S,2R,3R,4R)-3-(1-acetamido-2-ethyl-butyl)-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid; Cyclopentanecarboxylic acid, 3-((1S)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1S,2S,3R,4R)-; Peramivir, (+/-)-; cc-227; SCHEMBL744373; BDBM5024; CHEMBL139367; SCHEMBL12795462; DTXSID10904727; BCPP000117; ZINC3981610; ABP000969; BDBM50181441; CP0131; HY-17015A; MFCD09837902; AKOS016007760; CS-0638; DB06614; DT-0029; NCGC00346433-07; (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane; (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid; 3(R)-[1(S)-Acetamido-2-ethylbutyl]-4(R)-guanidino-2(S)-hydroxycyclopentane-1(S)-carboxylic acid; AC-22715; Cyclopentanecarboxylic acid, 3-((1R)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1R,2R,3S,4S)-rel-; A11124; AB01566838_01; 600P856; Q412734; S-021812; (-)-(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic Acid; (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic acid; (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid; (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid; (1S,2S,3S,4R)-4-[(DIAMINOMETHYLIDENE)AMINO]-3-[(1S)-1-ACETAMIDO-2-ETHYLBUTYL]-2-HYDROXYCYCLOPENTANE-1-CARBOXYLIC ACID" Small molecule "1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1" XRQDFNLINLXZLB-CKIKVBCHSA-N CCC(CC)C(C1C(CC(C1O)C(=O)O)N=C(N)N)NC(=O)C C15H28N4O4 CAS 330600-85-6 CHEBI:85202 . . . DB06614 . DR5764 Desloratadine D01GBY D01GBY Approved Vasomotor/allergic rhinitis ICD-11: CA08 CID: 124087 Anticancer Treatment "Desloratadine; 100643-71-8; Clarinex; Descarboethoxyloratadine; Desloratidine; Neoclarityn; Sch-34117; Aerius; Azomyr; Denosin; Sch 34117; Descarboethoxyoratidine; 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; MFCD00871949; UNII-FVF865388R; CHEMBL1172; Loratadine related compound a; C19H19ClN2; 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; MLS000559042; CHEBI:291342; FVF865388R; NCGC00159325-02; SMR000149358; Opulis; Allex; Clarinex RediTabs; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; DSSTox_CID_24196; DSSTox_RID_80112; DSSTox_GSID_44196; Desalex; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-; 8-chloro-11-piperidin-4-ylidene-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine; 8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Clarinex (TN); CAS-100643-71-8; SR-01000668962; Neoclaritin; Desloratadine [USAN:INN:BAN]; Clarinex(R); 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine; 4-{8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}-piperidine; 4-{8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}piperidine; Desloratadine-[d7]; MK-4117; CPD000149358; Opera_ID_1891; SCHEMBL4425; MLS000759406; MLS001201801; MLS001424247; BEN691; Desloratadine (JAN/USP/INN); GTPL7157; ZINC1261; DTXSID1044196; Loratadine related compound a rs; HMS2052H05; HMS2090C06; HMS2093F19; HMS3394H05; HMS3652O15; HMS3715J15; HMS3885C18; Pharmakon1600-01505393; ALBB-027276; BCP02340; HY-B0539; Tox21_111574; ANW-42359; BBL010777; BDBM50073179; CD0143; NSC675447; NSC759824; s4012; STK586537; AKOS000280921; Tox21_111574_1; AC-1279; CCG-101162; DB00967; KS-1048; MCULE-2975958622; NC00412; NSC 759824; NSC-675447; NSC-759824; SB17503; Desloratadine, powder, >=98% (HPLC); NCGC00159325-03; NCGC00159325-04; NCGC00159325-05; 13-chloro-2-(2,2,6,6-tetradeuteriopiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene; AK163520; Loratadine EP Impurity D (Desloratadine); SBI-0206828.P001; AB0012600; D3787; FT-0602522; FT-0666048; R3930; SW197792-3; A19515; D03693; J10309; AB00456701-11; AB00456701-13; AB00456701_14; AB00456701_15; 643D718; L001025; Q418060; Q-200936; SR-01000668962-4; SR-01000668962-5; SR-01000668962-8; BRD-K82357231-001-13-4; Desloratadine, European Pharmacopoeia (EP) Reference Standard; Desloratadine, United States Pharmacopeia (USP) Reference Standard; 4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta [1,2-b]pyridin-11-ylidene) piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene) piperidine; 8-chloro-11-(4-piperidinylidene)-6,11-dihydro-5H- benzo[4,5]cyclohepta[2,1-b]pyridine; 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridine; 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-11-(4-piperidylidene)-6,11-dihydro-5h-benzo[5.6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H- benzo[5,6]cyclohepta[1,2,b]pyridine; 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Desloratadine for system suitability, European Pharmacopoeia (EP) Reference Standard; Desloratidine, Pharmaceutical Secondary Standard; Certified Reference Material; Loratadine Related Compound A, United States Pharmacopeia (USP) Reference Standard; 13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene; 8-CHLORO-11-(4-PIPERIDYLIDENE)-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE; 8-Chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (Descarboethoxyloratadine; Desloratadine)" Small molecule "1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2" JAUOIFJMECXRGI-UHFFFAOYSA-N C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4 C19H19ClN2 CAS 100643-71-8 CHEBI:291342 . . . DB00967 . DR5849 Tazobactam D0QQ7D D0QQ7D Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 123630 Anticancer Treatment "Tazobactam; 89786-04-9; Tazobactam acid; Tazobactamum; YTR-830H; YTR 830H; UNII-SE10G96M8W; CHEMBL404; CL-298741; YTR 830; CHEBI:9421; SE10G96M8W; (2S,3S,5R)-3-((1H-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; CL 298,741; YTR 830 H; 89786-04-9 (free acid); (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; SR-01000872598; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-; Tazobactamum [INN-Latin]; YTR830H; CCRIS 2203; YTR830; Tazobactam,(S); Tazobactam [USAN:USP:INN:BAN]; (2S,3S,5R)-3-METHYL-4,4,7-TRIOXO-3-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC ACID; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4?^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Cl 298741; BRN 4787943; CL298741; Tazobactum (Free acid); Tazobactam;Tazobactan acid; EC 618-303-7; BIDD:GT0212; SCHEMBL122302; CXA201; Tazobactam (JP17/USP/INN); DTXSID8023634; GTPL10789; HMS3714G17; (2S,3S,5S)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; BCP09757; EX-A1377; HY-B1418; ZINC3787060; BDBM50053173; MFCD00867002; s3077; AKOS015960801; AC-7620; CCG-207890; CS-4914; DB01606; DS-8301; NSC 759887; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide; A-8312; C07771; D00660; T-1445; 786T049; A843310; Q423376; Tazobactam, Antibiotic for Culture Media Use Only; SR-01000872598-1; SR-01000872598-2; 89786-04-9, 89785-84-2 (sodium salt); BRD-K14312455-001-01-6; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1-triazolylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[(1H-1,2,3-triazol-1-yl)methyl]-4lambda(6)-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda 6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-tris(oxidanylidene)-3-(1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S-(2alpha,3beta,5alpha))-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7- oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, [2S- (2alpha,3beta,5alpha)]-" Small molecule "1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1" LPQZKKCYTLCDGQ-WEDXCCLWSA-N CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3 C10H12N4O5S CAS 89786-04-9 CHEBI:9421 . . . DB01606 . DR0221 2-deoxy-D-glucose D0H3KI D0H3KI Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 108223 Anticancer Treatment "154-17-6; Deoxyglucose; 2-Desoxy-D-glucose; 2-DG; 2-Deoxy-D-arabinohexose; 2-Deoxy-D-mannose; D-2-Deoxyglucose; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; arabino-Hexose, 2-deoxy-; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; D-Glucose, 2-deoxy-; 9G2MP84A8W; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; 2-Desoxy-D-glucose [French]; CCRIS 9094; MFCD00151328; d-2-glucodesose; EINECS 205-823-0; D-2dGlc; BRN 1723331; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; SCHEMBL7670; 4-01-00-04282 (Beilstein Handbook Reference); CHEMBL2074932; DTXSID1037648; ALBB-022735; AMY10934; ZINC2512351; ANW-21488; CD0012; AKOS015919409; AKOS015924825; DB08831; LS30109; 2-Deoxy-D-glucose, BioXtra, >=98%; AS-12502; AB0012037; DB-024740; D0051; 54D176; D-arabino-Hexose, 2-deoxy- (6CI,8CI,9CI); S-1013; 2-Deoxy-D-glucose, >=98% (GC), crystalline; 2-Deoxy-D-glucose, >=99% (GC), crystalline; Q3266534; 5CFA0332-FB70-485D-A064-6C4C39E7CBA1; 2-Deoxy-D-glucose, United States Pharmacopeia (USP) Reference Standard" Small molecule "1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1" C(C=O)C(C(C(CO)O)O)O C6H12O5 CAS 154-17-6 . . . . DB08831 . DR2521 Mevastatin D0J9GD D0J9GD Investigative Diabetic foot ulcer ICD-11: BD54 CID: 64715 Anticancer Treatment "Mevastatin; compactin; 73573-88-3; ML-236B; Mevastatina; Mevastatine; Mevastatinum; Mevastatinum [INN-Latin]; Antibiotic ML 236B; CS 500; UNII-1UQM1K0W9X; ML 236 B; 1UQM1K0W9X; CHEMBL54440; [(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; CHEBI:34848; MFCD05662341; Mevastatin (Compactin); Mevastatin [INN]; Compactin (penicillium); Mevastatine [INN-French]; Mevastatina [INN-Spanish]; (1S,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate; (S)-((1S,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; Butanoic acid, 2-methyl-, (1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-; SMR000336944; CCRIS 4505; kompaktin; NCGC00095942-01; EC 700-442-0; SCHEMBL1116; DSSTox_CID_20684; DSSTox_RID_79540; DSSTox_GSID_40684; Lopac0_000754; MLS000721804; MLS000759452; MLS001424284; MLS002207227; GTPL3031; DTXSID4040684; Mevastatin, >=96% (HPLC); HMS2052P07; HMS2089D10; HMS2232N09; HMS3262G10; HMS3268A19; HMS3412H15; HMS3676H15; HMS3713B06; ZINC3833876; Tox21_111540; Tox21_500754; ANW-41687; BDBM50011036; CS-500; NSC779705; s4223; AKOS015994712; Mevastatin, >=95% (HPLC), powder; CCG-101174; CS-1234; DB06693; KS-1085; LP00754; NC00424; NSC 759322; NSC-779705; SDCCGSBI-0050732.P002; 7-(1,2,6,7,8,8a-Hexahydro-2-methyl-8-(2-methylbutyryloxy)naphthyl)-3-hydroxyheptan-5-olide; SMP1_000077; NCGC00025202-04; NCGC00261439-01; (1S,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl(2S)-2-methylbutanoate; Butanoic acid, 2-methyl-, (1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-7-methyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1-alpha(R*),7-beta,8-beta(2S*,4S*),8a-beta))-; HY-17408; I518; Mevastatin 100 microg/mL in Acetonitrile; AB0013739; CAS-73573-88-3; B1788; EU-0100754; M2275; C13963; M 2537; W-5323; AB00588266-06; AB00588266-08; AB00588266_09; 573M883; Q414407; SR-01000729493; L-637312; SR-01000729493-4; BRD-K94441233-001-03-1; BRD-K94441233-001-17-1; (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; (S)-((1S,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; (S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester; 2-Methyl-butyric acid 8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester; 2-Methyl-butyric acid 8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester((+)-compactin); 2-Methyl-butyric acid 8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester(compactin)" Small molecule "1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1" AJLFOPYRIVGYMJ-INTXDZFKSA-N CCC(C)C(=O)OC1CCC=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O C23H34O5 CAS 73573-88-3 CHEBI:34848 . . . DB06693 . DR5601 Lovastatin D06WTZ D06WTZ Approved Hyper-lipoproteinaemia ICD-11: 5C80 CID: 53232 Anticancer Treatment "lovastatin; 75330-75-5; mevinolin; Mevacor; MK-803; Altoprev; Lovalord; Nergadan; Artein; 6alpha-Methylcompactin; Lovalip; Monacolin K; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatine; Mevinacor; Altocor; Hipovastin; Lovasterol; Cholestra; Closterol; Colevix; Hipolip; Lestatin; Lipivas; Lipofren; Lovastin; Lozutin; Paschol; Rodatin; Rovacor; Tecnolip; Teroltrat; Belvas; Lipdip; Mevlor; Sivlor; Taucor; UNII-9LHU78OQFD; MLS000069585; MSD 803; MFCD00072164; 9LHU78OQFD; MK 803; 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; SMR000058779; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; CHEBI:40303; L-154803; Lovastatin, 98%; Lovastatin (Mevacor); (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate; HSDB 6534; NCGC00023509-03; Lovastatina; Lovastatinum; C24H36O5; DSSTox_CID_784; butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-; DSSTox_RID_75788; DSSTox_GSID_20784; Liposcler; 6 alpha-Methylcompactin; Rextat; Monakolin K; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate; (S)-(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoate; Mevacor (TN); CHEMBL503; Lovastatin & Primycin; Lovastatin (USP/INN); SR-05000001880; (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-2-Methylbutanoic acid 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; 1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone; BRN 3631989; Mevinolin from Aspergillus sp.; CCRIS 8092; 1cqp; Lovastatin,(S); ML-530B; Lovastatin [USAN:USP:INN:BAN]; (+)-mevinolin; (S)-((1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; Prestwick_819; CAS-75330-75-5; Lovastatin [USAN]; Mevinolin (lovastatin); Opera_ID_1578; Prestwick0_000516; Prestwick1_000516; Prestwick2_000516; Prestwick3_000516; Spectrum3_001873; Spectrum5_001294; Lovastatin (MK-803); EC 616-212-7; SCHEMBL3136; US9115116, lovastatin; BIDD:PXR0113; BSPBio_000471; BSPBio_001265; BSPBio_003346; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-; cid_53232; MLS001055358; MLS006011867; US9353061, Lovastatina; ARONIS24208; BIDD:GT0749; DivK1c_001032; SPECTRUM1503977; SPBio_002392; BPBio1_000519; GTPL2739; MEGxm0_000398; DTXSID5020784; SCHEMBL14227102; ACon0_000534; ACon1_000390; BDBM34168; HMS503O05; KBio1_001032; KBio3_002848; AOB5269; C10AA02; Simvastatin impurity, lovastatin-; NINDS_001032; HMS1569H13; HMS1792O07; HMS1923O13; HMS1990O07; HMS2089M06; HMS2093O03; HMS2096H13; HMS2236F07; HMS3039N16; HMS3259F10; HMS3268C03; HMS3403O07; HMS3412H19; HMS3676H19; HMS3713H13; HMS3884B03; Pharmakon1600-01503977; (S)-((1S,3R,7S,8S,8AR)-8-(2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-2H-PYRAN-2-YL)ETHYL)-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL) 2-METHYLBUTANOATE; 2-Methyl-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester butanoic acid; ACT02620; ALBB-027272; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; HY-N0504; MK-803; LOVALIP; MEVACOR; ZINC3812841; Tox21_110888; Tox21_201475; Tox21_300268; ANW-41686; BBL024473; CCG-39627; NSC633781; NSC758662; NSC779704; s2061; SBB080686; STK801953; AKOS005267139; Tox21_110888_1; CS-1990; DB00227; EBD2126857; KS-1082; MCULE-4740518260; MCULE-7087866108; Mevinolin from Aspergillus sp., powder; NC00713; NSC 758662; NSC-633781; NSC-758662; NSC-779704; IDI1_001032; NCGC00023509-04; NCGC00023509-05; NCGC00023509-06; NCGC00023509-07; NCGC00023509-08; NCGC00023509-09; NCGC00023509-10; NCGC00023509-11; NCGC00023509-13; NCGC00023509-14; NCGC00023509-16; NCGC00254157-01; NCGC00259026-01; 74133-25-8; AC-13961; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; G226; SMR000673570; SBI-0051881.P002; AB0108514; L0214; N1632; EN300-52515; C07074; D00359; J10136; S-7779; 28048-EP2269989A1; 28048-EP2270011A1; 28048-EP2272825A2; 28048-EP2272841A1; 28048-EP2277507A1; 28048-EP2277865A1; 28048-EP2280006A1; 28048-EP2281813A1; 28048-EP2284158A1; 28048-EP2286795A1; 28048-EP2287165A2; 28048-EP2287166A2; 28048-EP2289892A1; 28048-EP2292620A2; 28048-EP2295406A1; 28048-EP2295409A1; 28048-EP2298742A1; 28048-EP2298745A1; 28048-EP2298772A1; 28048-EP2298776A1; 28048-EP2298779A1; 28048-EP2301923A1; 28048-EP2301931A1; 28048-EP2301936A1; 28048-EP2305648A1; 28048-EP2308839A1; 28048-EP2311808A1; 28048-EP2311829A1; 28048-EP2314588A1; 96638-EP2287163A1; 96638-EP2305678A1; AB00052400-17; AB00052400_18; AB00052400_19; Mevinolin from Aspergillus sp., >=98% (HPLC); 117141-EP2272825A2; 117141-EP2298776A1; 330L755; A838030; Q417740; SR-01000000123; SR-01000000123-3; SR-05000001880-1; SR-05000001880-2; BRD-K09416995-001-06-8; BRD-K09416995-001-21-7; Z1258578375; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-8-(2-((4R,6R)-4-hydroxy-2-oxo-2H-pyran-6-yl)ethyl)-3,7-dimethylnaphtyl(S)-2-methylbutyrat; (2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl-2-methyl butanoate; (2S)-2-Methylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; (2S)-2-methylbutanoic acid [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-2-oxanyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] ester; (S)-2-Methyl-butyric acid (1S,3R,7S,8S,8aR)-8-[2-((3R,5R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl ester; [(1S,3R,7S,8S,8aR)-3,7-dimethyl-8-[2-[(2R,4R)-4-oxidanyl-6-oxidanylidene-oxan-2-yl]ethyl]-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; 1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; 8-[2-((2R,4R)-4-hydroxy-6-oxo(2H-3,4,5-trihydropyran-2-yl))ethyl](1S,7S,8S,3R, 8aR)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthyl (2S)-2-methylbutanoate; 8-[2-(4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydro-1-naphthale; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-- oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-" Small molecule "1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1" PCZOHLXUXFIOCF-BXMDZJJMSA-N CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C C24H36O5 CAS 75330-75-5 CHEBI:40303 . . . DB00227 . DR7850 Piperacillin D04ZAH D04ZAH Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 43672 Anticancer Treatment "piperacillin; 61477-96-1; Pipracil; Piperacillin anhydrous; Piperacilline; PIPC; Piperacillina; PIPERACILLIN SODIUM; Piperacillin hydrate; Piperacillin (INN); Piperacillin [INN]; CHEBI:8232; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; UNII-9I628532GX; CHEMBL702; (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 66258-76-2; Cl-227193; 9I628532GX; C23H27N5O7S; (2S,5R,6R)-6-((R)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; Peperacillin; Piperacilina; Piperacillinum; Pipracil, Piper; Peracin (TN); CCRIS 7362; EINECS 262-811-8; Piperacilina [INN-Spanish]; Piperacilline [INN-French]; Piperacillinum [INN-Latin]; 1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-; Pipracil,(S); PIPERACILLIN NA; Prestwick0_000755; Prestwick1_000755; Prestwick2_000755; Prestwick3_000755; Epitope ID:116652; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid; SCHEMBL33894; BSPBio_000770; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; BIDD:GT0167; SPBio_002709; BPBio1_000848; DTXSID2023482; GTPL10921; HMS2090H19; ZINC3913937; Tazocin (piperacillin + tazobactam); BDBM50240426; KM0517; MFCD00865043; AKOS016007827; DB00319; (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxo-piperazine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-, (2S-(2-alpha,5-alpha,6-beta(S*)))-; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; AS-13671; C14034; D08380; J10085; AB01275515-01; 127490-EP2272832A1; 127490-EP2292612A2; 127490-EP2295402A2; 477P961; Q423787; Piperacillin, Antibiotic for Culture Media Use Only; W-105153; BRD-K86873305-236-03-0; (2S,5R,6R)-6-((R)-2-(4-ethyl-2,3-dioxopiperazine-; (2S,5R,6R)-6-[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; WPP" Small molecule "1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1" IVBHGBMCVLDMKU-GXNBUGAJSA-N CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O C23H27N5O7S CAS 61477-96-1 CHEBI:8232 . . . DB00319 . DR3755 Biphenyl dimethyl dicarboxylate . . Phase 3 Cholecystitis ICD-11: DC12 CID: 13099 Anticancer Treatment "792-74-5; Dimethyl biphenyl-4,4'-dicarboxylate; dimethyl [1,1'-biphenyl]-4,4'-dicarboxylate; Biphenyl dimethyl dicarboxylate; DIMETHYL 4,4'-BIPHENYLDICARBOXYLATE; [1,1'-Biphenyl]-4,4'-dicarboxylic acid, dimethyl ester; methyl 4-(4-methoxycarbonylphenyl)benzoate; Nissel; UNII-K61BXA0U9C; 4,4'-Biphenyldicarboxylic acid, dimethyl ester; K61BXA0U9C; 4,4'-Bibenzoic Acid Dimethyl Ester; MFCD00017201; methyl 4-[4-(methoxycarbonyl)phenyl]benzoate; Dimethyl (1,1'-biphenyl)-4,4'-dicarboxylate; (1,1'-Biphenyl)-4,4'-dicarboxylic acid, dimethyl ester; (1,1'-Biphenyl)-4,4'-dicarboxylic acid, 4,4'-dimethyl ester; 1219803-50-5; [1,1'-Biphenyl]-4,4'-dicarboxylic acid, 4,4'-dimethyl ester; HSDB 5754; EINECS 212-341-4; PubChem8961; ACMC-209pgt; Maybridge1_001712; 4,4-Dicarboxymethylbiphenyl; 4,4'-Dicarbomethoxybiphenyl; SCHEMBL68521; MLS000720058; CHEMBL4297409; DTXSID2061143; HMS546F18; ZINC132343; 4,4'-Bis(methoxycarbonyl)biphenyl; 4,4'-bis (methoxycarbonyl)biphenyl; ANW-37275; CCG-45472; SBB005981; AKOS001588888; DB12475; Dimethyl biphenyl-4,4''-dicarboxylate; LS10548; MCULE-5377004782; AK121980; O731; SMR000304587; ST023391; SY057043; TS-00900; HY-128854; 4,4-Biphenyldicarboxylic acid dimethyl ester; B1309; CS-0100928; Dimethyl biphenyl-4,4'-dicarboxylate, 99%; FT-0625049; 4,4'-Biphenyldicarboxylic Acid Dimethyl Ester; 92D745; Biphenyl 4,4'-dicarboxylic acid, dimethyl ester; A839634; SR-01000397421; 4-(4-methoxycarbonylphenyl)benzoic acid methyl ester; SR-01000397421-1; SR-01000397421-2; W-111708; 4,4'-dimethyl [1,1'-biphenyl]-4,4'-dicarboxylate; BRD-K33126632-001-02-1; Q27281994; Dimethyl 4,4 inverted exclamation mark -Biphenyldicarboxylate; Dimethyl biphenyl-4,4 inverted exclamation marka-dicarboxylate; Dimethyl 4,4 inverted exclamation marka-Biphenyl-d8-dicarboxylate; Biphenyl-4'4-dicarboxylic acid dimethyl ester C16H14O4 270.29 212-216 degrees 792-74-5 212-341-4 MFCD00017201 Y" Small molecule "1S/C16H14O4/c1-19-15(17)13-7-3-11(4-8-13)12-5-9-14(10-6-12)16(18)20-2/h3-10H,1-2H3" BKRIRZXWWALTPU-UHFFFAOYSA-N COC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)OC C16H14O4 CAS 792-74-5 . . . . DB12475 . DR9957 Ampicillin D0YA9Z D0YA9Z Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 6249 Anticancer Treatment "69-53-4; Ampicillin; Aminobenzylpenicillin; Ampicillin acid; Amcill; Polycillin; Principen; Omnipen; Ampicilline; Penbritin; Pentrexyl; Synpenin; Tokiocillin; Totacillin; Novo-ampicillin; D-Ampicillin; Ampicillin Anhydrous; D-(-)-Ampicillin; Adobacillin; Amblosin; Ampichel; Ampicilina; Ampicillinum; Ampifarm; Ampipenin; Ampiscel; Amplacilina; Amplipenyl; Amplisom; Amplital; Bonapicillin; Britacil; Campicillin; Copharcilin; Delcillin; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Lifeampil; Norobrittin; Orbicilina; Penbristol; Penbrock; Penicline; Pentrexl; Princillin; Racenacillin; Rosampline; Roscillin; Semicillin; Servicillin; Sumipanto; Texcillin; Totalciclina; Trifacilina; Ultrabion; Ultrabron; Viccillin; Acillin; Amfipen; Ampicil; Ampikel; Ampimed; Ampisyn; Ampivax; Ampivet; Amplin; Binotal; Morepen; Nuvapen; Penimic; Pensyn; Pentrex; Ponecil; Tolomol; Totapen; Vampen; Cimex; Supen; anhydrous ampicillin; Ampicillin anhydrate; Pfizerpen A; Amipenix S; Ampi-bol; SK-Ampicillin; Amfipen V; Pen Ampil; QIDamp; Ampi-Tab; D-Cillin; Olin Kid; Ro-Ampen; Ampi-Co; Austrapen; Pen A; Ampicillina [DCIT]; Bayer 5427; D-(-)-alpha-Aminobenzylpenicillin; ABPC; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampicin; D-(-)-alpha-Aminopenicillin; Deripen; Wypicil; Alpen; Ampicillin A; Polycillin-N; Totacillin-N; Penbritin-S; AY-6108; Omnipen-N; BRL 1341; Penbritin syrup; Semicillin R; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; P-50; KS-R1; Penbritin paediatric; NSC-528986; AB-PC; BRL-1341; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; Guicitrine; Ampen; NSC 528986; AB-PC Sol; Ampicillin, anhydrous; UNII-7C782967RD; C16H19N3O4S; CHEBI:28971; MFCD00005175; Alpha-Aminobenzylpenicillin; 6-(D-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; MLS000028405; (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ampicillina; HI 63; Ukapen; Pfizerpen-A; WY-5103; AMPI; 7C782967RD; (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; P 50; SQ 17382; Penicillin, (aminophenylmethyl)-; SMR000058352; Ampicillin Base; DSSTox_CID_2602; AY 6108; DSSTox_RID_76654; DSSTox_GSID_22602; (2S,5R,6R)-6-((R)-2-Amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[(R)-2-Amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Polyflex (Veterinary); ampicillanyl; Ampicillin [USAN:BAN:INN:JAN]; CAS-69-53-4; (2S,5R,6R)-6-{[(2R)-2-AMINO-2-PHENYLETHANOYL]AMINO}-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC ACID; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,6-[[(2R)-aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, trihydrate,(2S,5R,6R)-; Omnipen (TN); Totacillin (sodium); BA 7305; HSDB 3009; AMPICILLIN/AMPICILLIN TRIHYDRATE; Ampicillin (USP/INN); EINECS 200-709-7; vidopen; Vidocillin; Marcillin; Pentritin; NSC528986; D-(-)-.alpha.-Aminobenzylpenicillin; Ampicillin,(S); NCGC00018160-02; (2s,5r,6r)-6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-phenyl-acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; Ampicillin [USAN:USP:INN:BAN:JAN]; Ampicillin (anhydrous); Spectrum_000050; 1h8s; AY 6108; D-a-Aminobenzylpenicillin; Opera_ID_1630; Prestwick0_000114; Prestwick1_000114; Prestwick2_000114; Prestwick3_000114; Spectrum2_000769; Spectrum3_000301; Spectrum4_000149; Spectrum5_000814; CHEMBL174; Epitope ID:115008; Epitope ID:116057; EC 200-709-7; SCHEMBL3526; BSPBio_000128; BSPBio_001862; KBioGR_000598; KBioSS_000430; Anhydrous ampicillin (JP17); MLS001074168; BIDD:GT0184; DivK1c_000466; SPBio_000818; SPBio_002067; Ampicillin, analytical standard; BPBio1_000142; DTXSID4022602; CHEBI:53713; GTPL10896; KBio1_000466; KBio2_000430; KBio2_002998; KBio2_005566; KBio3_001362; NINDS_000466; HMS2090I11; HMS2233H23; Ampicillin acid; Principen; Amcill; HY-B0522; ZINC3830218; Tox21_113049; Tox21_301416; BDBM50350465; SBB063111; AKOS015888156; Tox21_113049_1; AC-8805; DB00415; VA10275; WY 5103; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; IDI1_000466; SMP1_000211; NCGC00023282-05; NCGC00023282-06; NCGC00023282-21; NCGC00178944-03; NCGC00248937-01; NCGC00255127-01; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-, D-(-)-; ST077148; SBI-0051283.P003; 6-(a-Aminophenylacetamido)penicillanic acid; C06574; D00204; AMPICILLIN ANHYDROUS, PHARMACEUTICAL GRADE; Q244150; 6-D(-)-alpha-Aminophenylacetamido-penicillanic acid; BRD-K68432770-001-08-0; Ampicillin, anhydrous, 96.0-100.5% (anhydrous basis); Ampicillin, United States Pharmacopeia (USP) Reference Standard; Anhydrous ampicillin, British Pharmacopoeia (BP) Reference Standard; Ampicillin, anhydrous, European Pharmacopoeia (EP) Reference Standard; (2S,5R,6R)-6-[(2R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-AMINO-2-PHENYLETHANOYL]AMINO}-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 6-((2R)-2-amino-2-phenylacetylamino)(2S,5R,6R)-3,3-dimethyl-7-oxo-4-thia-1-aza bicyclo[3.2.0]heptane-2-carboxylic acid; 6-((2R)-2-amino-2-phenylacetylamino)(2S,5R,6R)-3,3-dimethyl-7-oxo-4-thia-1-aza bicyclo[3.2.0]heptane-2-carboxylic acid, oxamethane, oxamethane, oxamethane; 6-[(Aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI; AMPICILLIN; D(-)-ALPHA-AMINOBENZYLPENICILLIN; 6-[D(-)-ALPHA-AMINOPHENYLLACETAMIDO]PENICILLANIC ACID" Small molecule "1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1" AVKUERGKIZMTKX-NJBDSQKTSA-N CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)C C16H19N3O4S CAS 69-53-4 CHEBI:28971 . . . DB00415 . DR2919 Rabeprazole D0KL4J D0KL4J Approved Bacterial infection ICD-11: 1A00-1C4Z CID: 5029 Anticancer Treatment "rabeprazole; 117976-89-3; Aciphex; Habeprazole; Pariets; 2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; CHEBI:8768; LY307640; Sodium rabeprazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; Rabeprazole [INN:BAN]; 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; rabeprazol; Rabeloc; 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-; Rabeprazole (INN); Eraloc (TN); HSDB 7321; 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole; 2-{[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1H-benzimidazole; 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2--1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; LY 307640; CHEMBL1219; SCHEMBL23336; MLS001401446; BIDD:GT0019; GTPL7290; DTXSID3044122; HMS2052P03; HMS3394P03; AMY10338; BCP06638; HY-B0656; ANW-57672; BDBM50070209; E-3810 (PPI); MFCD00868879; s4845; STL186112; AKOS015895259; CCG-101158; DB01129; MCULE-7848941080; NC00408; PB21725; 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; NCGC00388029-07; NCGC00388029-09; AK-55871; AS-34993; SMR000469174; SBI-0206867.P001; AB0107093; DB-020298; DS-002860; FT-0602569; FT-0674301; FT-0674302; Q3515; C07864; D08463; Q-1236; AB00698237-06; 976R893; A803856; SR-01000763041; J-003691; SR-01000763041-3; BRD-A39390670-236-04-0; (R)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; (S)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 1H-benzimidazole,2-[(r)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methylsulfinyl]-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-{[(3-Methyl-4-(3-methoxypropoxy)-2-pyridinyl)methyl]sulphinyl}1H-benzimidazole; 2-{4-(3-Methoxypropoxy)-3-methylpyridine-2-yl}methylsulfinyl-1H-benzimidazole" Small molecule "1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)" YREYEVIYCVEVJK-UHFFFAOYSA-N CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC C18H21N3O3S CAS 117976-89-3 CHEBI:8768 . . . DB01129 . DR1093 Omeprazole D01XNB D01XNB Approved Gastro-oesophageal reflux disease ICD-11: DA22 CID: 4594 Anticancer Treatment "omeprazole; 73590-58-6; Prilosec; Losec; Antra; Esomeprazole; Omeprazon; Audazol; Omapren; Omepral; Parizac; Zegerid; Mopral; Miol; Belmazol; Ceprandal; Dizprazol; Dudencer; Emeproton; Epirazole; Gastrimut; Gastroloc; Gibancer; Indurgan; Inhibitron; Inhipump; Logastric; Pepticum; Peptilcer; Prazidec; Sanamidol; Secrepina; Ulcometion; Mepral; Miracid; Omeprol; Omezol; Omisec; Omizac; Ompanyt; Ozoken; Prysma; Ramezol; Ulceral; Ulcesep; Ulcozol; Zefxon; Zoltum; Desec; Elgam; Lomac; Ulsen; Ultop; Zimor; Ocid; Omed; Omid; OMEP; Demeprazol; Nopramin; Omeprazol; Omezolan; Paprazol; Pepticus; Prazentol; Prazolit; Procelac; Regulacid; Danlox; Erbolin; Lensor; Morecon; Nilsec; Olexin; Omegast; Omesek; Ortanol; Osiren; Proclor; Result; Ulcsep; Victrix; Zepral; Exter; Gasec; Ulzol; Omebeta 20; Tedec Ulceral; AULCER; Antra MUPS; Omerprazole; Omez; Omepradex; Omeprazolum; Prilosec OTC; Nexium IV; H 168/68; Gastrogard; Nuclosina; 119141-88-7; Esomperazole; MFCD00083192; Prestwick_808; OMZ; C17H19N3O3S; CHEBI:77260; Esomeprazole sodium salt; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; Aisi'aomeilazuona Esomeprazole Sodium; H-168/68; CHEMBL1503; Nexiam; 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; MLS000069373; 73590-58-6 (free form); 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; Omeprazole, 98+%; Omeprazol [INN-Spanish]; Omeprazolum [INN-Latin]; NCGC00016925-06; SMR000058847; Emilok; CAS-73590-58-6; DSSTox_CID_1080; (s)-omeprazole sodium; 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole; 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; DSSTox_RID_75929; DSSTox_GSID_21080; ( -)-Omeprazole; Omeprazone; Omeprazen; Omesec; Omeprazole delayed-release; Omeprazole Pellets; 1H-Benzimidazole,5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole; Prilosec (TN); (+-)-Omeprazole; CCRIS 7099; HSDB 3575; (S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; SR-01000003003; Omperazole; Omeprazole-d6; 161796-78-7; Omeprazole, solid; 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; AGI-010; Omeprazole,(S); Omeprazole solution; Omeprazole-[d3]; Omeprazole S-Isomer; 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole; DM-3458; Omeprazole [USAN:USP:INN:BAN:JAN]; Omeprazole-13C,D3; Omeprazole (Prilosec); ACMC-20p1du; Maybridge4_002645; Opera_ID_1863; Prestwick0_000493; Prestwick1_000493; Prestwick2_000493; Prestwick3_000493; (.+/-.)-Omeprazole; O0359; UPCMLD-DP075; 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; cid_4594; SCHEMBL1191; BSPBio_000385; MLS001076112; MLS001424148; MLS006010400; MLS006011759; BIDD:GT0189; SPBio_002306; BPBio1_000425; GTPL4279; Omeprazole (JP17/USP/INN); Esomeprazole sodium salt hydrate; DTXSID6021080; SCHEMBL11995456; UPCMLD-DP075:001; CHEBI:91766; HMS1528I05; HMS1569D07; HMS2052G17; HMS2090E16; HMS2090F11; HMS2096D07; HMS2232B21; HMS3269D17; HMS3394G17; HMS3413J07; HMS3651A11; HMS3677J07; HMS3713D07; Pharmakon1600-01505693; (S)-Omeprazole sodium salt hydrate; AMY30573; BCP05852; BCP13592; BCP21299; HY-B0113; 2,3,5-Trimethylpyridine/Omeprazole; Tox21_110686; Tox21_200509; AC-401; BBL028172; BDBM50103597; BDBM50241343; CO0037; DL-462; NSC751450; NSC759192; s1389; STK623746; 119141-88-7 (base); AKOS005066653; AKOS015895343; Tox21_110686_1; AC-4676; CCG-101130; CCG-213517; CS-1868; DB00338; HS-0055; MCULE-3224208952; NC00380; NE55490; NSC 751450; NSC 759192; NSC-751450; NSC-759192; IDI1_032523; NCGC00016925-01; NCGC00016925-02; NCGC00016925-03; NCGC00016925-04; NCGC00016925-05; NCGC00016925-07; NCGC00016925-08; NCGC00016925-10; NCGC00016925-11; NCGC00021522-03; NCGC00021522-04; NCGC00021522-05; NCGC00258063-01; Omeprazole, analytical reference material; AK162396; K253; SY077145; SBI-0206896.P001; AB0014122; FT-0601585; FT-0652860; FT-0653294; FT-0673283; FT-0689771; H 199; SW196942-4; A19447; C07324; D00455; J10125; 668985-31-7 (Mg); 141O887; A837865; Q422210; SR-01000003003-4; SR-01000003003-7; SR-01000003003-8; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl); BRD-A55962179-001-04-9; BRD-A55962179-001-08-0; BRD-A55962179-001-20-5; BRD-A88691025-001-07-4; F0001-2386; Z1672902589; Omeprazole, British Pharmacopoeia (BP) Reference Standard; Omeprazole, European Pharmacopoeia (EP) Reference Standard; Omeprazole, United States Pharmacopeia (USP) Reference Standard; 2-(3-methoxy-2,4-dimethylbenzylsulfinyl)-6-methoxy-1H-benzo[d]imidazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-; Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material; (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (RS)-5-Methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl)benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyrdinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-(2-(4-methoxy-3,5-dimethylpyridin-2-yl)ethylsulfinyl)-1H-benzo[d]imidazole; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl- 1H-benzimidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3H-benzoimidazole; 5-Methoxy-2-[(RS)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphinyl]1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole; 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4methoxy-3,5-dimethyl2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; Omeprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; Omeprazole solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (omeprazole)5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; (RS)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) methylsulfinyl)-1H-benzo[d]imidazole; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole (omeprazole); 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole(Omeprazole); 6-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt; 934293-91-1" Small molecule "1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)" SUBDBMMJDZJVOS-UHFFFAOYSA-N CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC C17H19N3O3S CAS 73590-58-6 CHEBI:77260 . . . DB00338 . DR4912 Memantine D01JEU D01JEU Approved Alzheimer disease ICD-11: 8A20 CID: 4054 Anticancer Treatment "memantine; 19982-08-2; 3,5-dimethyladamantan-1-amine; Namenda; 1-Amino-3,5-dimethyladamantane; Ebixa; 3,5-Dimethyl-1-adamantanamine; Memantina; Memantinum [INN-Latin]; Memantina [INN-Spanish]; Memantinum; 1,3-Dimethyl-5-adamantanamine; Memantine [INN]; 3,5-Dimethyl-1-aminoadamantane; UNII-W8O17SJF3T; 3,5-Dimethyl-1-adamantylamine; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine; Tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl-; CHEMBL807; 3,5-dimethyladamantanylamine; W8O17SJF3T; D-145; CHEBI:64312; Memantine (INN); alzantin; NCGC00015705-04; DSSTox_CID_25174; DSSTox_RID_80723; DSSTox_GSID_45174; D 145; Memantine [INN:BAN]; CAS-19982-08-2; HSDB 7327; 3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine; DMAA [Antiparkinson Agent]; Retyliumtosylate; 1,3-Dimethyl-5-aminoadamantane; DRG 0267; DRG-0267; Exiba (TN); Spectrum_000607; Prestwick0_000978; Prestwick1_000978; Prestwick2_000978; Prestwick3_000978; Spectrum2_001408; Spectrum3_000923; Spectrum4_001022; Spectrum5_001355; CBMicro_020348; Biomol-NT_000209; SCHEMBL2688; Lopac0_000861; Oprea1_480562; BSPBio_001015; KBioGR_001543; KBioSS_001087; DivK1c_000068; SPBio_001456; SPBio_002926; 1-amino-3,5-dimethyladamantan; BPBio1_001117; BPBio1_001270; GTPL4253; DTXSID5045174; SCHEMBL13213676; HMS500D10; KBio1_000068; KBio2_001087; KBio2_003655; KBio2_006223; KBio3_001926; 1-amino-3,5-dimethyl adamantane; 1-amino-3,5-dimethyl-adamantane; Tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-; NINDS_000068; (3,5-Dimethyl-1-adamantyl)amine; 3,5-Dimethyl-adamantan-1-ylamine; ALBB-013872; BCP29702; Tox21_110199; 3,5-Dimethyl-1-aminoadamantane HCl; ANW-56451; BBL000737; BDBM50062599; SBB002574; STK520682; AKOS000113995; AKOS015953276; AKOS016340748; Tox21_110199_1; CCG-204092; DB01043; DS-3152; MCULE-3726352671; NSC 757843; SDCCGSBI-0020417.P005; IDI1_000068; NCGC00015705-03; NCGC00015705-05; NCGC00015705-07; NCGC00015705-09; NCGC00015705-16; NCGC00024782-02; NCGC00024782-03; D145 pound>>D 145 pound>>D-145; ST057652; SBI-0020417.P004; AB0212255; AB00053600; BB 0216388; EU-0053634; FT-0649142; AZ0001-0553; C13736; D08174; S-1686; AB00053600-13; AB00053600_14; AB00053600_15; Q412189" Small molecule "1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3" BUGYDGFZZOZRHP-UHFFFAOYSA-N CC12CC3CC(C1)(CC(C3)(C2)N)C C12H21N CAS 19982-08-2 CHEBI:64312 . . . DB01043 . DR9316 Lansoprazole . . Unknown Gastro-oesophageal reflux disease ICD-11: DA22 CID: 3883 Anticancer Treatment "lansoprazole; 103577-45-3; Prevacid; Bamalite; Monolitum; Ogastro; Lansoprazol; Agopton; Limpidex; Lanzor; Opiren; Prevacid SoluTab; Lanzopral; Takepron; Zoton; Lanproton; Lansopep; Lasoprol; Mesactol; Aprazol; Blason; Ketian; Lancid; Lanston; Lanz; AG-1749; Lansoprazolum; Prevacid Iv; AG 1749; Lansox; Lanzo; A-65006; Prevacid 24HR; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:6375; Prezal; Pro Ulco; Compraz; Ilsatec; Prosogan; Suprecid; Dakar; Promp; Zoprol; TAK-390MR; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; MLS000069705; Lanzol-30; Ogast; MFCD00866873; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; C16H14F3N3O2S; NCGC00015615-02; SMR000058469; Lansoprazol [INN-Spanish]; Lansoprazolum [INN-Latin]; CAS-103577-45-3; DSSTox_CID_3200; MLS-0003247.0001; Prevacid NapraPAC; 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; DSSTox_RID_76922; DSSTox_GSID_23200; Prevacid I.V.; TAK 390MR; Lansophed; Lanzol; Lanzul; PrevOnco; 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; 2-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Prevacid (TN); 2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole;2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole; (r)-(+)-lansoprazole; 1261394-42-6; HSDB 7204; SR-01000000169; A 65006; BRN 4333393; Lanfast; Lapraz; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl}-1H-benzimidazole; ABT-006; Lansoprazole,(S); Lansoprazole [USAN:USP:INN:BAN]; CG-4801; PubChem16834; Spectrum_001580; CPD000058469; Prevacid Delayed Release; Opera_ID_1676; Prestwick0_001072; Prestwick1_001072; Prestwick2_001072; Prestwick3_001072; Spectrum2_000444; Spectrum3_000295; Spectrum4_000856; Spectrum5_001521; Dexlansoprazole-[13C6]; Lopac-L-8533; CHEMBL480; L 8533; cid_3883; Lopac0_000709; SCHEMBL22365; BSPBio_001084; BSPBio_001830; KBioGR_001491; KBioSS_002060; MLS000759405; MLS001074170; MLS001424235; BIDD:GT0006; DivK1c_000920; SPECTRUM1503926; SPBio_000488; SPBio_002992; BPBio1_001194; GTPL7208; DTXSID4023200; BDBM47032; HMS502N22; KBio1_000920; KBio2_002060; KBio2_004628; KBio2_007196; KBio3_001330; Lansoprazole (JP17/USP/INN); 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-[(S)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Levolansoprazole;(-)-Lansoprazole; NINDS_000920; HMS1571G06; HMS1922M04; HMS2052F05; HMS2093M07; HMS2098G06; HMS2234B10; HMS3262M19; HMS3264E12; HMS3269D15; HMS3371E21; HMS3394F05; HMS3413J05; HMS3654J17; HMS3677J05; HMS3715G06; Pharmakon1600-01503926; Pharmakon1600-01504282; ACT03358; BCP22331; BCP34129; EBD14854; Tox21_110184; Tox21_301023; Tox21_500709; BBL029072; BDBM50070208; CCG-39952; CL0035; NSC758638; NSC758710; s1354; STK621169; AKOS005554811; Tox21_110184_1; AC-1233; CS-1847; DB00448; KS-1075; Lansoprazole, >=98% (TLC), powder; LP00709; MCULE-8446262134; NC00411; NSC 758638; NSC-758638; NSC-758710; SB19127; SDCCGSBI-0050687.P004; 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; IDI1_000920; NCGC00015615-01; NCGC00015615-03; NCGC00015615-04; NCGC00015615-05; NCGC00015615-06; NCGC00015615-07; NCGC00015615-08; NCGC00015615-09; NCGC00015615-10; NCGC00015615-11; NCGC00015615-12; NCGC00015615-14; NCGC00015615-15; NCGC00023826-03; NCGC00023826-04; NCGC00023826-05; NCGC00023826-06; NCGC00023826-07; NCGC00254925-01; NCGC00261394-01; NCGC00381720-13; AK308448; HY-13662; SBI-0050687.P003; AB0005100; AB00052388; EU-0100709; FT-0610894; FT-0670721; FT-0670722; L0233; ST51015040; SW197226-4; D00355; AB00052388-17; AB00052388_18; AB00052388_19; 577L453; A800764; Q254296; J-007154; SR-01000000169-2; SR-01000000169-6; SR-01000000169-9; BRD-A49172652-001-05-7; BRD-A49172652-001-13-1; F2173-0222; Lansoprazole, British Pharmacopoeia (BP) Reference Standard; Lansoprazole, European Pharmacopoeia (EP) Reference Standard; Lansoprazole, United States Pharmacopeia (USP) Reference Standard; (+)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl}sulfinyl)benzimidazol e; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; 2-[[ [3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]-sulfinyl]1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]-methyl]sulfinyl]benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzoimidazole; 2-[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl-methanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; 1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-" Small molecule "1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)" MJIHNNLFOKEZEW-UHFFFAOYSA-N CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F C16H14F3N3O2S CAS 103577-45-3 CHEBI:6375 . . . DB00448 . DR8680 TNF-related apoptosis inducing ligand . . Phase 3 Lung cancer ICD-11: 2C25 . Anticancer Treatment . . . . . . . . . . . . TRAIL DR6300 Trastuzumab D04WFL D04WFL Approved Breast cancer ICD-11: 2C60 . Anticancer Treatment Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor) Antibody . . . . . . . . . DB00072 . DR9921 Tumor necrosis factor alpha . . Phase 2 Colorectal cancer ICD-11: 2B91 . Anticancer Treatment . Protein . . . . . . . . . . . DR4154 Thymidine kinase/ganciclovir . . Approved Cytomegaloviral disease ICD-11: 1D82 . Anticancer Treatment . . . . . . . . . . . DB01004 . DR5958 SMC3 . . Investigative Breast cancer ICD-11: 2C60 . Anticancer Treatment Smac mimetic compound 3 . . . . . . . . . . . . DR8070 S-1 . . Phase 3 Gastrointestinal stromal tumor ICD-11: 2B5B . Anticancer Treatment Fluoropyrimidine anticancer agent . . . . . . . . . . . . DR2830 Rev-caspase-3 . . Investigative Ovarian cancer ICD-11: 2C73 . Anticancer Treatment . . . . . . . . . . . . . DR4274 Recombinant vaccinia Neu vaccine . . Investigative Breast cancer ICD-11: 2C60 . Anticancer Treatment . Vaccine . . . . . . . . . . . DR3141 N-(4-hydroxyphenyl) retinamide . . Phase 3 Cervical cancer ICD-11: 2C77 . Anticancer Treatment . Small molecule . . . . . . . . . . . DR4889 Interferon alpha-2b . . Approved Acute lymphoblastic leukemia ICD-11: 2B33 . Anticancer Treatment . Protein . . . . . . . . . DB00105 . DR7601 IL-24 . . Investigative Colon cancer ICD-11: 2B90 . Anticancer Treatment . Protein . . . . . . . . . . . DR0813 hu14.18-IL2 immunicytokine . . Phase 2 Melanoma ICD-11: 2C30 . Anticancer Treatment . . . . . . . . . . . . . DR9830 HSV-TK/GCV . . Phase 2 Ovarian cancer ICD-11: 2C73 . Anticancer Treatment . . . . . . . . . . . . . DR4869 Endostar D05YAG D05YAG Approved Solid tumour/cancer ICD-11: 2A00-2F9Z . Anticancer Treatment "Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn" Protein . . . . . . . . . DB11727 . DR5221 Cetuximab D0N5OV D0N5OV Approved Colorectal cancer ICD-11: 2B91 . Anticancer Treatment Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors Antibody . . . . . . . . . DB00002 Cetuximab DR8144 CD55-TRAIL . . Investigative Lung cancer ICD-11: 2C25 . Anticancer Treatment . . . . . . . . . . . . . DR3731 Bevacizumab D04KBL D04KBL Approved Colorectal cancer ICD-11: 2B91 . Anticancer Treatment Bevacizumab (ophthalmic slow-release tissue tablet) Antibody . . . . . . . . . DB00112 . DR4267 TRAIL/Apo2L . . Phase 3 Lung cancer ICD-11: 2C25 . Anticancer Treatment . . . . . . . . . . . . . DR0951 Anti-PD-1 antibody . . Approved Melanoma ICD-11: 2C30 . Anticancer Treatment Anti-programmed cell death-1 (anti-PD-1) . . . . . . . . . . . . DR4698 Anti-CD25 monoclonal antibody . . Approved Acute lymphoblastic leukemia ICD-11: 2B33 . Anticancer Treatment Humanized anti-Tac antibody (HAT) Antibody . . . . . . . . . . . DR9274 6-OH-11-O-Hydroxyphenanthrene . . Investigative Breast cancer ICD-11: 2C60 . Anticancer Treatment . Small molecule . . . . . . . . . . . DR7137 "25-methoxyl-dammarane-3beta, 12beta, 20-triol" . . Investigative Breast cancer ICD-11: 2C60 . Anticancer Treatment . Small molecule . . . . . . . . . . . DR9900 Sildenafil D05ULR D05ULR Approved Erectile dysfunction ICD-11: HA01 CID: 135398744 Anticancer Treatment "VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; BNRNXUUZRGQAQC-UHFFFAOYSA-N" Small molecule "1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)" BNRNXUUZRGQAQC-UHFFFAOYSA-N CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C C22H30N6O4S CAS 139755-83-2 . . . . DB00203 . DR0371 Dacarbazine D0Y7ZU D0Y7ZU Approved Melanoma ICD-11: 2C30 CID: 135398738 Anticancer Treatment "Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide" Small molecule "1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+" FDKXTQMXEQVLRF-ZHACJKMWSA-N CN(C)N=NC1=C(NC=N1)C(=O)N C6H10N6O CAS 4342-03-4 CHEBI:4305 . . . DB00851 . DR9477 IPI-549 D0I3LO D0I3LO Phase 1 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 91933883 Anticancer Treatment "XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((" Small molecule "1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1" XUMALORDVCFWKV-IBGZPJMESA-N CC(C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N C30H24N8O2 CAS 1693758-51-8 CHEMBL3984425 . . . DB16296 . DR2915 Abivertinib D0FV3K D0FV3K Phase 1 Lung cancer ICD-11: 2C25 CID: 72734520 Anticancer Treatment "Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-" Small molecule "1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)" UOFYSRZSLXWIQB-UHFFFAOYSA-N CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F C26H26FN7O2 CAS 1557267-42-1 . . . . DB15327 . DR6823 Osimertinib D0O8GK D0O8GK Approved Lung cancer ICD-11: 2C25 CID: 71496458 Anticancer Treatment Tagrisso Small molecule "1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)" DUYJMQONPNNFPI-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC C28H33N7O2 CAS 1421373-65-0 . . . . DB09330 Osimertinib DR9185 "Pyrrolo-1,5-benzoxazepine" . . Investigative Colorectal cancer ICD-11: 2B91 CID: 69345756 Anticancer Treatment "SCHEMBL5185374; 2H-pyrrolo[2,3-i][1,5]benzoxazepine" Small molecule "1S/C11H8N2O/c1-5-12-10-3-2-9-8(4-6-13-9)11(10)14-7-1/h1-6H,7H2" UNHWZPWLXOALOM-UHFFFAOYSA-N C1C=CN=C2C=CC3=NC=CC3=C2O1 C11H8N2O . . . . . . . DR2728 17-beta estradiol . . Investigative Hepatocellular carcinoma ICD-11: 2C12 CID: 66795326 Anticancer Treatment Ostradiol.Ostradiol; Beta Estradiol Anhydrate; SCHEMBL772341 Small molecule "1S/2C18H24O2/c2*1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2*3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t2*14-,15-,16+,17+,18+/m11/s1" DWMXQLDCXDJLRZ-ZFOCPYFBSA-N CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O.CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O C36H48O4 . . . . . . . DR5956 Dimethylaminoparthenolide . . Investigative Lung cancer ICD-11: 2C25 CID: 52945794 Anticancer Treatment CHEMBL1270635 Small molecule "1S/C17H27NO3/c1-11-6-5-9-17(2)15(21-17)14-12(8-7-11)13(10-18(3)4)16(19)20-14/h6,12-15H,5,7-10H2,1-4H3/t12-,13?,14-,15+,17+/m0/s1" UJNSFDHVIBGEJZ-CALVTZMJSA-N CC1=CCCC2(C(O2)C3C(CC1)C(C(=O)O3)CN(C)C)C C17H27NO3 . . . . . . . DR2639 Venetoclax D00PBX D0X1KN Approved Chronic lymphocytic leukaemia ICD-11: 2A82 CID: 49846579 Anticancer Treatment Venclexta Small molecule "1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)" LQBVNQSMGBZMKD-UHFFFAOYSA-N CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C C45H50ClN7O7S CAS 1257044-40-8 . . . . DB11581 Venetoclax DR1969 ABT-888 D0Q7UD D0Q7UD Phase 3 Malignant mesenchymal neoplasm ICD-11: 2B5D CID: 45480520 Anticancer Treatment Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride Small molecule "1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1" DSBSVDCHFMEYBX-FFXKMJQXSA-N CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl C13H18Cl2N4O CAS 912445-05-7 . . . . DB07232 ABT-888 DR7304 ABT-263 D06ETI D06ETI Phase 2 Chronic lymphocytic leukaemia ICD-11: 2A82 CID: 24978538 Anticancer Treatment "Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide" Small molecule "1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1" JLYAXFNOILIKPP-KXQOOQHDSA-N CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C C47H55ClF3N5O6S3 CAS 923564-51-6 . . . . DB12340 ABT-263 DR8026 Ponatinib D0H0EQ D0H0EQ Approved Mantle cell lymphoma ICD-11: 2A85 CID: 24826799 Anticancer Treatment Iclusig (TN) Small molecule "1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)" PHXJVRSECIGDHY-UHFFFAOYSA-N CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5 C29H27F3N6O CAS 943319-70-8 . . . . DB08901 Ponatinib DR7812 Dactolisib D0VG0D D0VG0D Phase 2 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 11977753 Anticancer Treatment "BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile" Small molecule "1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3" JOGKUKXHTYWRGZ-UHFFFAOYSA-N CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5 C30H23N5O CAS 915019-65-7 . . . . DB11651 Dactolisib DR0618 Carfilzomib D00UVA D00UVA Approved Multiple myeloma ICD-11: 2A83 CID: 11556711 Anticancer Treatment Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide; 868540-17-4 Small molecule "1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1" BLMPQMFVWMYDKT-NZTKNTHTSA-N CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4 C40H57N5O7 CAS 868540-17-4 CHEBI:65347 . . . DB08889 . DR3439 Apatinib D0SZ6E D0SZ6E Approved Breast cancer ICD-11: 2C60 CID: 11315474 Anticancer Treatment "Apatinib mesylate; VEGF receptor inhibitor (cancer), Advenchen; VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang" Small molecule "1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)" WPEWQEMJFLWMLV-UHFFFAOYSA-N C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4 C24H23N5O CAS 811803-05-1 . . . . DB14765 Apatinib DR6631 ABT-737 D0L8WH D0L8WH Phase 1 Ovarian cancer ICD-11: 2C73 CID: 11228183 Anticancer Treatment "ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide" Small molecule "1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1" HPLNQCPCUACXLM-PGUFJCEWSA-N CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-] C42H45ClN6O5S2 CAS 852808-04-9 . . . . . . DR6166 Regorafenib D09GDD D09GDD Approved Colorectal cancer ICD-11: 2B91 CID: 11167602 Anticancer Treatment BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]; 755037-03-7 Small molecule "1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)" FNHKPVJBJVTLMP-UHFFFAOYSA-N CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F C21H15ClF4N4O3 CAS 755037-03-7 CHEBI:68647 . . . DB08896 . DR7572 PHA665752 D00TBD D00TBD Investigative Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 10461815 Anticancer Treatment "PHA-665752; 477575-56-7; PHA 665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate" Small molecule "1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35H,3-4,6-7,12-14,17-18H2,1-2H3,(H,36,39)/b24-16-/t21-/m1/s1" OYONTEXKYJZFHA-SSHUPFPWSA-N CC1=C(NC(=C1C(=O)N2CCCC2CN3CCCC3)C)C=C4C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O C32H34Cl2N4O4S CAS 477575-56-7 . . . . . PHA665752 DR6422 MST312 . . Investigative Lung cancer ICD-11: 2C25 CID: 10385095 Anticancer Treatment "Telomerase Inhibitor IX; 368449-04-1; CHEMBL2170856; N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]-2,3-dihydroxybenzamide; N-[3-[[(2,3-dihydroxyphenyl)-oxomethyl]amino]phenyl]-2,3-dihydroxybenzamide; Benzamide, N,N'-1,3-phenylenebis[2,3-dihydroxy-; MST312; SCHEMBL17005794; CHEBI:95003; DTXSID90439103; ZINC3937611; BDBM50396097; MST-312, >=98% (HPLC); BRD-K19894101-001-01-6; Q27166764" Small molecule "1S/C20H16N2O6/c23-15-8-2-6-13(17(15)25)19(27)21-11-4-1-5-12(10-11)22-20(28)14-7-3-9-16(24)18(14)26/h1-10,23-26H,(H,21,27)(H,22,28)" MIQUEZGHEJGPJB-UHFFFAOYSA-N C1=CC(=CC(=C1)NC(=O)C2=C(C(=CC=C2)O)O)NC(=O)C3=C(C(=CC=C3)O)O C20H16N2O6 CAS 368449-04-1 . . . . . MST312 DR0141 Oxaliplatin D0Y3ME D0Y3ME Approved Colorectal cancer ICD-11: 2B91 CID: 9887053 Anticancer Treatment Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN) Small molecule "1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1" DRMCATBEKSVAPL-BNTLRKBRSA-N C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2] C8H14N2O4Pt CAS 61825-94-3 CHEBI:31941 . . . DB00526 Oxaliplatin DR1078 Cabazitaxel D02HSB D02HSB Approved Breast cancer ICD-11: 2C60 CID: 9854073 Anticancer Treatment Jevtana; Taxoid XRP6258; Jevtana (TN) Small molecule "1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1" BMQGVNUXMIRLCK-OAGWZNDDSA-N CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC C45H57NO14 CAS 183133-96-2 . . . . DB06772 . DR1957 Tapentadol D0K4MH D0K4MH Approved Acute pain ICD-11: MG31 CID: 9838022 Anticancer Treatment "Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL; 175591-23-8" Small molecule "1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1" KWTWDQCKEHXFFR-SMDDNHRTSA-N CCC(C1=CC(=CC=C1)O)C(C)CN(C)C C14H23NO CAS 175591-23-8 . . . . DB06204 . DR7558 ONO-8711 D0X2OV D0X2OV Terminated Pain ICD-11: MG30-MG3Z CID: 9824507 Anticancer Treatment "6-[(2R,3S)-3-(4-Chloro-2-methylphenylsulfonamidomethyl)bicyclo[2.2.2]oct-2-yl]-5(Z)-hexenoic acid" Small molecule "1S/C22H30ClNO4S/c1-15-13-18(23)11-12-21(15)29(27,28)24-14-20-17-9-7-16(8-10-17)19(20)5-3-2-4-6-22(25)26/h3,5,11-13,16-17,19-20,24H,2,4,6-10,14H2,1H3,(H,25,26)/b5-3-/t16?,17?,19-,20-/m0/s1" VVEXPDRCGCQELD-CFDZEDGGSA-N CC1=C(C=CC(=C1)Cl)S(=O)(=O)NCC2C3CCC(C2C=CCCCC(=O)O)CC3 C22H30ClNO4S CAS 216158-34-8 . . . . . . DR1590 Leptomycin B . . Investigative Lung cancer ICD-11: 2C25 CID: 6917907 Anticancer Treatment "Elactocin; Mantuamycin; Antibiotic CI 940; 87081-35-4; Antibiotic CL 1957A; leptomycin; UNII-Y031I2N1EO; CI-940; CHEBI:52646; PD 114720; C33H48O6; antibiotic ATS 1287B; Antibiotic PD 114720; Y031I2N1EO; ATS 1287B; MFCD06795848; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2S,3S)-3-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]-8-oxononadeca-2,10,12,16,18-pentaenoic acid; CI 940; LMB; NSC-364372; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-((2S,3S)-3-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2S,3S)-3-methyl-6-oxo-2,3-dihydropyran-2-yl]-8-oxo-nonadeca-2,10,12,16,18-pentaenoic acid; CL 1957A; NSC 364372; CHEMBL486133; SCHEMBL12361304; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-19-[(2S,3S)-3,6-Dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-2,10,12,16,18-nonadecapentaenoic acid; CL-1957A; EX-A4641; KOS-1688; 1816AH; 2514AH; BDBM50245464; ZINC17654252; 2,10,12,16,18-Nonadecapentaenoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-; HY-16909; Leptomycin B, Streptomyces sp. ATS1287; PD-114720; B6907; CS-0012947; Q6528191; (2E,10E,12E,16E,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxo-nonadeca-2,10,12,16,18-pentaenoic acid; 2,10,12,16,18-Nonadecapentaenoic acid, 19-[(2S,3S)-3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-,(2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-; 2,10,12,16,18-Nonadecapentanoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-; Leptomycin B solution from Streptomyces sp., >=95% (HPLC), Supplied in methanol: water (7:3)" Small molecule "1S/C33H48O6/c1-9-28(14-15-29-24(5)13-16-31(36)39-29)19-22(3)12-10-11-21(2)17-25(6)32(37)27(8)33(38)26(7)18-23(4)20-30(34)35/h10-11,13-17,19-20,22,24-27,29,33,38H,9,12,18H2,1-8H3,(H,34,35)/b11-10+,15-14+,21-17+,23-20+,28-19-/t22-,24+,25-,26+,27-,29+,33-/m1/s1" YACHGFWEQXFSBS-XYERBDPFSA-N CCC(=CC(C)CC=CC(=CC(C)C(=O)C(C)C(C(C)CC(=CC(=O)O)C)O)C)C=CC1C(C=CC(=O)O1)C C33H48O6 CAS 87081-35-4 . . . . . . DR1669 Cisplatin D0U5HU D0U5HU Approved Bladder cancer ICD-11: 2A00-2F9Z CID: 5702198 Anticancer Treatment Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy) Small molecule 1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2 LXZZYRPGZAFOLE-UHFFFAOYSA-L N.N.Cl[Pt]Cl Cl2H6N2Pt CAS 15663-27-1 CHEBI:27899 . . . DB00515 Cisplatin DR5996 Sulindac sulfone D0M9VE D0M9VE Phase 3 Colorectal cancer ICD-11: 2B91 CID: 5472495 Anticancer Treatment Aposulind; Aptosyn; FGN-1; Prevatac (former Brand Name); Exisulind; (Z)-5-Fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-indene-3-acetic acid Small molecule "1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-" MVGSNCBCUWPVDA-MFOYZWKCSA-N CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O C20H17FO4S CAS 59973-80-7 . . . . DB06246 . DR3681 Depsipeptide D0L7LC D0L7LC Approved Mycosis fungoides ICD-11: 2B01 CID: 5352062 Anticancer Treatment "Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone" Small molecule "1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1" OHRURASPPZQGQM-GCCNXGTGSA-N CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C C24H36N4O6S2 CAS 128517-07-7 . . . . . . DR0749 Sunitinib D0R0MW D0R0MW Approved Malignant digestive organ neoplasm ICD-11: 2C11 CID: 5329102 Anticancer Treatment "Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)" Small molecule "1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-" WINHZLLDWRZWRT-ATVHPVEESA-N CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C C22H27FN4O2 CAS 557795-19-4 CHEBI:38940 . . . DB01268 Sunitinib DR4256 SU5416 D01PZD D01PZD Approved Thrombocytopenia ICD-11: 3B64 CID: 5329098 Anticancer Treatment "Semaxanib; Semaxinib; SU 5416; 204005-46-9; Semoxind; Semaxanib (SU5416); SU-5416; 194413-58-6; TSU 16; Z-Semaxanib; UNII-71IA9S35AJ; VEGF Receptor 2 Kinase Inhibitor III; (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; NSC-696819; (Z)-SU 5416; 71IA9S35AJ; CHEMBL276711; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole; 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone; Semaxnib; Sugen 5416; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; (3Z)-3-[(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE]-2,3-DIHYDRO-1H-INDOL-2-ONE; 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one; SMR000568416; TSU-16; SR-01000076044; Semaxanib (USAN/INN); Semaxanib [USAN:INN]; methylene]-2H-indol-2-one; VEGFR2 Kinase Inhibitor III; 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-; NCGC00094381-03; 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one; NSC 696819; 2x2m; Semaxanib; SU5416; 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one; H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-; S 8442; SCHEMBL8190; Lopac0_001110; SCHEMBL19571; 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl); MLS001074896; MLS001332519; MLS001332520; BDBM4810; GTPL5056; QCR-86; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one; CHEBI:91083; cid_5329098; AOB6828; HMS2234L12; HMS3229O13; HMS3263M22; HMS3268J13; HMS3413H10; HMS3648O12; HMS3677H10; AMY10847; BCP06068; EX-A2158; Tox21 111271; Tox21_501110; 2033AH; 2712AH; HSCI1_000303; MFCD01940922; NSC696819; s2845; SU5146; ZINC12410091; 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one; AKOS015994557; CCG-205186; CS-1225; DB06436; ES-0010; LP01110; SDCCGSBI-0051079.P003; NCGC00094381-01; NCGC00094381-02; NCGC00094381-04; NCGC00094381-05; NCGC00094381-19; NCGC00261795-01; HY-10374; QC-11357; SU005416; AB0094985; EU-0101110; SW219791-1; A12437; D05819; W-5403; 2H-Indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-; J-013281; Q7449140; SR-01000076044-2; SR-01000076044-8; BRD-K63504947-001-05-5; 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinon; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one; Semaxanib, Semoxind, TSU-16, NSC-696819, SU-5416; 3-[(3,5-Dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-indol-2-ol; 3-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- 2H-indol-2-one; 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-; 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)-; 2H-Indol-2-one, 3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene)- 1,3-dihydro-, (Z)-; 3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole" Small molecule "1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-" WUWDLXZGHZSWQZ-WQLSENKSSA-N CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C C15H14N2O CAS 194413-58-6 . . . . DB06436 . DR2609 Fenretinide D08JAC D08JAC Phase 3 Retinopathy ICD-11: 9B78 CID: 5288209 Anticancer Treatment "RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR" Small molecule "1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+" AKJHMTWEGVYYSE-FXILSDISSA-N CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C C26H33NO2 CAS 65646-68-6 . . . . DB05076 . DR4137 Rapamycin D0T6DK D0T6DK Approved Multiple myeloma ICD-11: 2A83 CID: 5284616 Anticancer Treatment "(-)-Rapamycin; 53123-88-9; AY 22989; AY-22989; I 2190A; I-2190A; I2190A; NSC 226080; RAPA; Rapammune; Rapamune; Rapamycin; SIIA 9268A; Sirolimus; Wy 090217; Rapamycin (Sirolimus); Antibiotic AY 22989; UNII-W36ZG6FT64; CHEBI:9168; W36ZG6FT64; WY-090217; DE-109; MFCD00867594; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; SILA 9268A; Supralimus; CAS-53123-88-9; sirolimusum; Perceiva; Cypher; CCRIS 9024; NSC226080; HSDB 7284; 1fkb; 1pbk; NSC-226080; NCGC00181146-01; LCP-Siro; RAP; S1039; PubChem16645; BiomolKI2_000084; Rapamycin C-7, analog 4; SCHEMBL3463; Rapamycin,Sirolimus,Rapamune; BIDD:PXR0165; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; MLS006010168; Sirolimus [USAN:INN:BAN]; GTPL6031; DTXSID5023582; BDBM36609; L04AA10; MS-R001; SYN1185; SM-88 COMPONENT SIROLIMUS; HMS2089A21; HMS3403F11; HMS3884C03; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; EX-A1044; Tox21_110870; Tox21_112750; AC-722; BDBM50064359; STL570275; AKOS015850976; AKOS015961618; ZINC169289388; ACN-035837; CCG-100684; CS-0063; DB00877; NCGC00021305-06; NCGC00021305-07; Rapamycin from Streptomyces hygroscopicus; AS-11687; HY-10219; SMR004701276; UNM-0000358684; A-275; R0097; Rapamycin, RAPA, Rapamune, Sirolimus, RPM; Rapamycin, VETRANAL(TM), analytical standard; EC 610-965-5; Q32089; S-7759; 123R889; Q-201659; " Small molecule "1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1" QFJCIRLUMZQUOT-HPLJOQBZSA-N CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC C51H79NO13 CAS 53123-88-9 CHEBI:9168 . . . DB00877 Rapamycin DR3078 "1,25-dihydroxyvitamin D3" D0T2PL D0T2PL Approved Congenital alopecia ICD-11: LC30 CID: 5280453 Anticancer Treatment "calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)" Small molecule "1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1" GMRQFYUYWCNGIN-NKMMMXOESA-N CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C C27H44O3 CAS 32222-06-3 . . . . DB15557 . DR9093 Sodium butyrate D0I7IB D0I7IB Phase 2 Acute myeloid leukemia ICD-11: 2A60 CID: 5222465 Anticancer Treatment "Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)" Small molecule "1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1" MFBOGIVSZKQAPD-UHFFFAOYSA-M CCCC(=O)[O-].[Na+] C4H7NaO2 CAS 156-54-7 . . . . DB03568 . DR5851 Dasatinib D0E6XR D0E6XR Approved Chronic myelogenous leukaemia ICD-11: 2A20 CID: 3062316 Anticancer Treatment "Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel" Small molecule "1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)" ZBNZXTGUTAYRHI-UHFFFAOYSA-N CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO C22H26ClN7O2S CAS 302962-49-8 CHEBI:49375 . . . DB01254 Dasatinib DR1563 Tamoxifen D07KSG D07KSG Approved Breast cancer ICD-11: 2C60 CID: 2733526 Anticancer Treatment "tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno; Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen" Small molecule "1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-" NKANXQFJJICGDU-QPLCGJKRSA-N CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3 C26H29NO CAS 10540-29-1 CHEBI:41774 . . . DB00675 Tamoxifen DR8341 Sulindac D0Z5IU D0Z5IU Approved Rheumatoid arthritis ICD-11: FA20 CID: 1548887 Anticancer Treatment Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid Small molecule "1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-" MLKXDPUZXIRXEP-MFOYZWKCSA-N CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O C20H17FO3S CAS 38194-50-2 CHEBI:9352 . . . DB00605 . DR2889 Tolfenamic acid . . Investigative Pancreatic cancer ICD-11: 2C10 CID: 610479 Anticancer Treatment "Clotam; Tolfedine; 2-[(3-Chloro-2-methylphenyl)amino]benzoic Acid; N-(3-Chloro-2-methylphenyl)anthranilic acid; GEA 6414; Acido tolfenamico; Acide tolfenamique; Acidum tolfenamicum; 2-((3-Chloro-2-methylphenyl)amino)benzoic acid; 2-(3-Chloro-2-methylanilino)benzoic acid; N-(2-Methyl-3-chlorophenyl)anthranilic acid; UNII-3G943U18KM; N-(3-Chloro-o-tolyl)-anthranilic acid; Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]-; Anthranilic acid, N-(3-chloro-o-tolyl)-; N-(3-Chloro-ortho-tolyl) anthranilic acid; CHEBI:32243; 3G943U18KM; NCGC00016705-05; Bifenac; CAS-13710-19-5; DSSTox_CID_25409; DSSTox_RID_80860; DSSTox_GSID_45409; Tolfine; tolfenamic-acid; 2-([3-Chloro-2-methylphenyl]amino)benzoic acid; SR-01000000102; N-(3-Chloro-o-tolyl)anthranilic acid; Tolfenamic; Acide tolfenamique [INN-French]; Acido tolfenamico [INN-Spanish]; Acidum tolfenamicum [INN-Latin]; Tolfenamic acid [INN:BAN:JAN]; Prestwick_579; EINECS 237-264-3; Clotam (TN); TOLFENAMICACID; BRN 0657821; Spectrum_001263; ACMC-209cat; Tolfenamic Acid-13C6; Tolfenamic acid, NSAID; Prestwick0_000205; Prestwick1_000205; Prestwick2_000205; Prestwick3_000205; Spectrum2_001446; Spectrum3_001762; Spectrum4_000238; Spectrum5_001143; Oprea1_692996; SCHEMBL25190; Tolfenamic acid (JAN/INN); BSPBio_000189; BSPBio_003223; KBioGR_000935; KBioSS_001743; flufenamic acid analogue, 32; MLS000028531; BIDD:GT0343; SPECTRUM1501198; SPBio_001311; SPBio_002110; BPBio1_000209; CHEMBL121626; cid_610479; GTPL8769; ZINC2188; DTXSID1045409; BDBM35905; KBio2_001743; KBio2_004311; KBio2_006879; KBio3_002723; YEZNLOUZAIOMLT-UHFFFAOYSA-; HMS1568J11; HMS1921P13; HMS2090D04; HMS2095J11; HMS2230J13; HMS3370A02; HMS3651E06; HMS3712J11; HMS3884M16; Pharmakon1600-01501198; HY-B0335; Tox21_110570; ANW-20211; CCG-39189; MFCD00133865; NSC757873; s1959; SBB058187; AKOS012836098; Tox21_110570_1; 2-(3-Chloro-o-toluidino)benzoic Acid; DB09216; MCULE-9901889833; NSC-757873; 2(3-Chloro-2-methylanilino)benzoic acid; NCGC00016705-01; NCGC00016705-02; NCGC00016705-03; NCGC00016705-04; NCGC00016705-06; NCGC00016705-07; NCGC00016705-10; NCGC00022587-03; NCGC00022587-04; NCGC00022587-05; AK305709; AS-13748; DA-11289; n-(3-chloro-ortho-tolyl)anthranilic acid; SMR000058289; SBI-0051687.P002; AB0032595; 2-(3-Chloro-2-methylanilino)benzoic acid #; AB00052244; FT-0652603; ST51015128; SW196753-3; UNM000001237003; X5948; 2-(3-chloro-2-methylphenylamino)benzoic acid; D01183; J10240; Q59412; AB00052244-15; AB00052244_16; AB00052244_17; A807198; Benzoic acid, 2-(3-chloro-2-methylphenylamino)-; 2-[(3-chloranyl-2-methyl-phenyl)amino]benzoic acid; J-006962; SR-01000000102-2; SR-01000000102-3; Tolfenamic acid, VETRANAL(TM), analytical standard; BRD-K50133271-001-05-4; BRD-K50133271-001-10-4; Benzoic acid, 2-((3-chloro-2-methylphenyl)amino)- (9CI); Tolfenamic acid, European Pharmacopoeia (EP) Reference Standard; Tolfenamic Acid, Pharmaceutical Secondary Standard; Certified Reference Material" Small molecule "1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)" YEZNLOUZAIOMLT-UHFFFAOYSA-N CC1=C(C=CC=C1Cl)NC2=CC=CC=C2C(=O)O C14H12ClNO2 CAS 13710-19-5 . . . . DB09216 . DR8776 Melphalan D06XES D06XES Approved Ovarian cancer ICD-11: 2C73 CID: 460612 Anticancer Treatment melphalan; 148-82-3; Alkeran; Melfalan; L-PAM; Phenylalanine mustard; L-Sarcolysine; L-Sarcolysin; L-Phenylalanine mustard; p-L-Sarcolysin; Levofalan; Melphalanum; Levopholan; Melfalano; Levofolan; L-Sarkolysin; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; Phenylalanine nitrogen mustard; p-Di-(2-chloroethyl)amino-L-phenylalanine; p-Bis(beta-chloroethyl)aminophenylalanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; Melphalanum [INN-Latin]; p-N-Bis(2-chloroethyl)amino-L-phenylalanine; Melfalano [INN-Spanish]; 4-(Bis(2-chloroet Small molecule "1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1" SGDBTWWWUNNDEQ-LBPRGKRZSA-N C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl C13H18Cl2N2O2 CAS 148-82-3 . . . . DB01042 . DR8551 Decitabine D0X5XU D0X5XU Approved Myelodysplastic syndrome ICD-11: 2A37 CID: 451668 Anticancer Treatment "AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′ 5-Azadeoxycytidine; 5-Deoxy-2′ 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc" Small molecule "1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1" XAUDJQYHKZQPEU-KVQBGUIXSA-N C1C(C(OC1N2C=NC(=NC2=O)N)CO)O C8H12N4O4 CAS 2353-33-5 CHEBI:50131 . . . DB01262 . DR8164 Eicosapentaenoic acid D0G2MW D0G2MW Approved Inherited coagulation factor deficiency ICD-11: 3B14 CID: 446284 Anticancer Treatment "Icosapent; Timnodonic acid; 10417-94-4; Icosapentaenoic acid; cis-5,8,11,14,17-Eicosapentaenoic acid; EPA; 5,8,11,14,17-EICOSAPENTAENOIC ACID; Icosapento; Icosapentum; (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid; UNII-AAN7QOV9EA; Icosapent [INN]; (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid; 5,8,11,14,17-Icosapentaenoic acid; CCRIS 3279; AAN7QOV9EA; (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid; CHEMBL460026; (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate; CHEBI:28364; all-cis-icosa-5,8,11,14,17-pentaenoic acid; Icosapent (INN); cis-Delta(5,8,11,14,17)-eicosapentaenoic acid; 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)-; Icosapentaenoate; (all-Z)-delta5,8,11,14,17-Eicosapentaenoic acid; C20:5n-3,6,9,12,15; MFCD00065716; eicosapentaenoate; cis-5,8,11,14,17-EPA; NCGC00161344-03; EICOSAPENTAENOIC ACID (20:5 n-3); all-cis-5,8,11,14,17-icosapentaenoic acid; all-cis-5,8,11,14,17-eicosapentaenoic acid; Miraxion; Eicosapentanoic acid; Eye Q; Eye-Q; 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-; EPA [drug]; Icosapentum [INN-Latin]; C20:5 omega-3; Icosapento [INN-Spanish]; (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Timnodonate; 3gwx; FA 20:5; all-cis-icosapentaenoate; all-cis-icosapentaenoic acid; DSSTox_CID_21023; DSSTox_RID_79612; DSSTox_GSID_41023; SCHEMBL20469; BSPBio_001328; EPA 45G; Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3); BML3-B01; GTPL3362; DTXSID9041023; HMS1361C10; HMS1791C10; HMS1989C10; HMS3402C10; HMS3649D19; HY-B0660; ZINC4474603; 5,8,11,14,17-Icosapentaenoate; Tox21_111991; 1755AH; 5,8,11,14,17-Eicosapentaenoate; BDBM50242349; LMFA01030759; s6476; AKOS027470327; CCG-207957; CCG-208136; DB00159; cis-5,8,11,14,17-eicosapentaenoate; IDI1_033798; NCGC00161344-01; NCGC00161344-02; NCGC00161344-04; NCGC00161344-07; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoate; AC-31072; AS-53730; CAS-10417-94-4; E0441; 5,8,11,14,17-Eicosapentaenoic acid (6CI); all cis-5,8,11,14,17-Eicosapentaenoic Acid; all cis-5,8,11,14,17-Icosapentaenoic Acid; C06428; D08061; (all-cis)-5,8,11,14,17-Eicosapentaenoic acid; L001256; Q409990; SR-01000946647; J-001125; SR-01000946647-1; z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoic acid; (Z,Z,Z,Z,Z)-5,8,11,14,17-eicosapentaenoic acid; BRD-K47192521-001-02-1; cis-5,8,11,14,17-Eicosapentaenoic acid, >=99%; 7F8BF016-B146-4F72-A52E-B9298BA3A9AB; C20H30O2 (cis-5,8,11,14,17-eicosapentaenoic acid); Eicosapentaenoic acid, 5,8,11,14,17-(Z,Z,Z,Z,Z)-; 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)- (8CI); cis-5,8,11,14,17-Eicosapentaenoic acid, >=85%, liquid; UNII-317SQ4W8IJ component JAZBEHYOTPTENJ-JLNKQSITSA-N; UNII-71M78END5S component JAZBEHYOTPTENJ-JLNKQSITSA-N; UNII-9B22238JYI component JAZBEHYOTPTENJ-JLNKQSITSA-N; UNII-F85N2YHE4E component JAZBEHYOTPTENJ-JLNKQSITSA-N; cis-5,8,11,14,17-Eicosapentaenoic acid, analytical standard; (5Z,8Z,11 Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid; cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid; 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI); cis-5,8,11,14,17-Eicosapentaenoic acid, 500 mug/mL in ethanol, certified reference material" Small molecule "1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-" JAZBEHYOTPTENJ-JLNKQSITSA-N CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O C20H30O2 CAS 10417-94-4 CHEBI:28364 . . . DB00159 . DR7217 Trichostatin A D0NF6F D0NF6F Investigative Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 444732 Anticancer Treatment "trichostatin A; 58880-19-6; Trichostatin A (TSA); TSA; Trichostatin; Tricostatin A; UNII-3X2S926L3Z; CHEBI:46024; (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide; GNF-PF-1011; RTKIYFITIVXBLE-QEQCGCAPSA-N; 3X2S926L3Z; 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-; 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE" Small molecule "1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1" RTKIYFITIVXBLE-QEQCGCAPSA-N CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C C17H22N2O3 CAS 58880-19-6 CHEBI:46024 . . . DB04297 Trichostatin+A DR3943 Carboplatin D0X7HM D0X7HM Approved Ovarian cancer ICD-11: 2C73 CID: 426756 Anticancer Treatment "Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)" Small molecule "1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2" VSRXQHXAPYXROS-UHFFFAOYSA-N C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2] C6H12N2O4Pt CAS 41575-94-4 CHEBI:31355 . . . DB00958 . DR6052 Halofuginone . . Phase 1 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 400772 Anticancer Treatment "7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one; empostatin; 7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one.; Halofuginone (INN); Halocur [veterinary] (TN); SCHEMBL25596; CHEMBL1199539; DTXSID0048260; BCBcMAP01_000063; BCBcMAP01_000107; AMY39119; HY-N1584; ZINC1849659; AKOS026669540; CS-5485; SB19686; 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one; NCI60_039464; D08034; 837H202; A830836; Q-201182; UNII-L31MM1385E component LVASCWIMLIKXLA-LSDHHAIUSA-N; 7-Bromo-6-chloro-3-[3-(3alpha-hydroxypiperidin-2beta-yl)-2-oxopropyl]quinazolin-4(3H)-one; 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4-quinazolinone; 7-bromanyl-6-chloranyl-3-[2-oxidanylidene-3-[(2S,3R)-3-oxidanylpiperidin-2-yl]propyl]quinazolin-4-one; 7695-84-3" Small molecule "1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2/t14-,15+/m0/s1" LVASCWIMLIKXLA-LSDHHAIUSA-N C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O C16H17BrClN3O3 CAS 55837-20-2 . . . . DB04866 . DR8611 Bortezomib D03AJX D03AJX Approved Mantle cell lymphoma ICD-11: 2A85 CID: 387447 Anticancer Treatment "[(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; PS 341 (pharmaceutical); MG 341; NSC 681239; NCGC00168751-01; (1S,2R)-Bortezomib; Bortezomib [USAN:INN]; SCHEMBL3676; AC1L3R1E; CHEMBL1530; Bortezomib Impurity (S,S-Isomer); Bortezomib Impurity (R,R-Isomer); Bortezomib Impurity (R,S-Isomer); N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide; 1132709-16-0" Small molecule "1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1" GXJABQQUPOEUTA-RDJZCZTQSA-N B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O C19H25BN4O4 CAS 179324-69-7 CHEBI:52717 . . . DB00188 Bortezomib DR2073 Sorafenib D0W5HK D0W5HK Approved Renal cell carcinoma ICD-11: 2C90 CID: 216239 Anticancer Treatment Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor) Small molecule "1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)" MLDQJTXFUGDVEO-UHFFFAOYSA-N CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F C21H16ClF3N4O3 CAS 284461-73-0 CHEBI:50924 . . . DB00398 Sorafenib DR6077 Lapatinib D08CDI D08CDI Approved Breast cancer ICD-11: 2C60 CID: 208908 Anticancer Treatment "FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)" Small molecule "1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)" BCFGMOOMADDAQU-UHFFFAOYSA-N CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl C29H26ClFN4O4S CAS 231277-92-2 . . . . DB01259 Lapatinib DR8028 Erlotinib D07POC D07POC Approved Lung cancer ICD-11: 2C25 CID: 176870 Anticancer Treatment "Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline" Small molecule "1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)" AAKJLRGGTJKAMG-UHFFFAOYSA-N COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC C22H23N3O4 CAS 183321-74-6 . . . . DB00530 Erlotinib DR4854 Roscovitine D05ADP D05ADP Phase 2 Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 160355 Anticancer Treatment "Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine" Small molecule "1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1" BTIHMVBBUGXLCJ-OAHLLOKOSA-N CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3 C19H26N6O CAS 186692-46-6 . . . . . Roscovitine DR5916 Centchroman D0ER8I D0ER8I Phase 3 Bacterial infection ICD-11: 1A00-1C4Z CID: 154413 Anticancer Treatment "Cellulose sulfate gel, Polydex" Small molecule "1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m0/s1" XZEUAXYWNKYKPL-URLMMPGGSA-N CC1(C(C(C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C C30H35NO3 CAS 31477-60-8 . . . . . . DR7626 Docetaxel D0O5WP D05ZOT Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 148124 Anticancer Treatment "Taxotere; 114977-28-5; Docetaxel anhydrous; Docetaxol; RP-56976; EmDOC; RP 56976; NSC 628503; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; UNII-699121PHCA; TXL; Taxotere (TN); MFCD00800737; N-debenzoyl-N-Boc-10-deacetyl taxol; Docetaxolum; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; CHEBI:4672; 699121PHCA; Docetaxel, 98%; NSC628503; NSC-628503; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; DSSTox_CID_20464; DSSTox_RID_79497; DSSTox_GSID_40464; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; Docetaxel, Trihydrate; Taxoel; Taxotere(R); Docetaxel Winthrop; Docetaxel [INN]; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; CAS-114977-28-5; Docetaxolum [INN-Latin]; Docecad; Docefrez; docetaxel 114977-28-5; HSDB 6965; XRP-6976L; ANX-514; SDP-014; SID 530; Docetaxel (TN); NCGC00181306-01; NCGC00181306-02; 5?,20-Epoxy-1,7?,10?-trihydroxy-9-oxotax-11-ene-2?,4,13?-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate]; Taxotere (Aventis); CID148124; Docetaxel - Taxotere; bind-014; Docetaxel (JAN/INN); CHEMBL92; SCHEMBL4419; docetaxel anhydrous derivatives; GTPL6809; DTXSID0040464; BDBM36351; SYP-0704A; ZDZOTLJHXYCWBA-VCVYQWHSSA-; AMY4356; 114977-28-5, Docetaxel; HMS2089K08; EX-A1206; HY-B0011; Tox21_112781; Tox21_113088; AC-383; CD0182; ZINC85537053; AKOS015960718; AKOS024457953; Tox21_112781_1; CS-1144; DB01248; KS-1452; MCULE-1930158681; ISOCYANATOETHYLMETHACRYLATEPOLYMER; Docetaxel, purum, >=97.0% (HPLC); NCGC00181306-04; NCGC00242509-01; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; AB0072965; D4102; C11231; D07866; W-1428; AB01273941-01; AB01273941-02; Q420436; SR-01000003023; W-60384; Q-100074; SR-01000003023-5; BRD-K30577245-001-04-3; BRD-K30577245-341-01-9; Z1551429742; Anhydrous Docetaxel, European Pharmacopoeia (EP) Reference Standard; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate; (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; [2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxy-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid; [acetoxy-[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate; 114915-20-7; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)" Small molecule "1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1" ZDZOTLJHXYCWBA-VCVYQWHSSA-N CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O C43H53NO14 CAS 114977-28-5 . . . . DB01248 Docetaxel DR7799 Sulfinosine . . Investigative Lung cancer ICD-11: 2C25 CID: 130209 Anticancer Treatment "2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide; 2-Amino-9-beta-ribofuranosylpurine-6-sulfinamide; SCHEMBL6907463; 9H-Purine-6-sulfinamide, 2-amino-9-beta-D-ribofuranosyl-; DTXSID70924860; 2-amino-9-beta-d-ribofuranosylpurine-6-sulfinamide; 2-Amino-9-beta-D-ribofuranosyl-9H-purine-6-sulfinamide; 2-Imino-9-pentofuranosyl-3,9-dihydro-2H-purine-6-sulfinamide" Small molecule "1S/C10H14N6O5S/c11-10-14-7-4(8(15-10)22(12)20)13-2-16(7)9-6(19)5(18)3(1-17)21-9/h2-3,5-6,9,17-19H,1,12H2,(H2,11,14,15)/t3-,5-,6-,9-,22?/m1/s1" NIXVOFULDIFBLB-QVRNUERCSA-N C1=NC2=C(N1C3C(C(C(O3)CO)O)O)N=C(N=C2S(=O)N)N C10H14N6O5S CAS 124508-99-2 . . . . . . DR1258 Methotrexate D0SV8E D04VCW Approved Leukaemia ICD-11: 2A60-2B33 CID: 126941 Anticancer Treatment diazinon; Dimpylate; 333-41-5; Diazinone; Oleodiazinon; Neocidol; Spectracide; Diazitol; Nedcidol; Dassitox; Ciazinon; Ektoband; Nucidol; Flytrol; Exodin; Galesan; Bazuden; Diazol; Diazide; Sarolex; Dazzel; Dacutox; Basudin; Antigal; Dicid; Alfa-tox; Diazajet; Dimpylat; Garden Tox; Neocidol (oil); Bassadinon; Terminator; Kayazol; Dizinon; Disonex; Compass; Meodinon; Kayazinon; Drawizon; Nipsan; Dyzol; Diazinon ag 500; Knox-out; Neodinon; Optimizer; Dimpylatum; Delzinon; Dizictol; Dipofene; Dizinil; Bazudin; Srolex; Basudin 10 G; Geigy 24480; Basudin S; Knox Small molecule "1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1" FBOZXECLQNJBKD-ZDUSSCGKSA-N CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O C20H22N8O5 CAS 59-05-2 . . . . DB00563 Methotrexate DR9742 Gefitinib D09XZB D01RYO Approved Lung cancer ICD-11: 2A00-2F9Z CID: 123631 Anticancer Treatment Iressa; ZD1839; Irressat; gefitinib (zd1839); N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; ZD 1839; ZD-1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; UNII-S65743JHBS; CCRIS 9011; CHEMBL939; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4; 184475-35-2 Small molecule "1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)" XGALLCVXEZPNRQ-UHFFFAOYSA-N COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 C22H24ClFN4O3 CAS 184475-35-2 . . . . DB00317 Gefitinib DR3243 Clofarabine D0R5RR D0R5RR Approved Myelodysplastic syndrome ICD-11: 2A37 CID: 119182 Anticancer Treatment "CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048" Small molecule "1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1" WDDPHFBMKLOVOX-AYQXTPAHSA-N C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N C10H11ClFN5O3 CAS 123318-82-1 . . . . DB00631 . DR4180 Nimustine hydrochloride . . Phase 2 Brain cancer ICD-11: 2A00 CID: 91657 Anticancer Treatment "Nimustine HCl; ACNU; Nidran hydrochloride; Nimustine (hydrochloride); Nimustina clorhidrato; CS 439 HCl; UNII-DFR965WKBU; NSC-245,382; DFR965WKBU; Nimustine hydrochloride [JAN]; CHEBI:7576; 52208-23-8; Nidran; MFCD01676942; 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-((4-Amino-2-methylpyrimidin-5-yl)methyl)-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride; Urea, N'-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(2-chloroethyl)-N-nitroso-, monohydrochloride (9CI); Nimustine hydrochloride (JAN); 1-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)-3-nitrosourea Hydrochloride; Nimustina clorhidrato [Spanish]; CS-439; 3-[(4-azanyl-2-methyl-pyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitroso-urea hydrochloride; Nidran (TN); Nimustine HCl(ACNU); nimustine monohydrochloride; 1-(2-Cloroetil)-1-nitroso-3-((2-metil-4-aminopirimidin-5-il)metil)urea clorhidrato [Spanish]; 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; 1-(4-Amino-2-methylpyrimidine-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; N'-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(2-chloroethyl)-N-nitrosourea HCl; N'-((4-Amino-2-metil-5-pirimidinil)metil)-N-(2-cloroetil)-N-nitrosourea clorhidrato [Spanish]; SCHEMBL98303; C9H14Cl2N6O2; MLS002153238; Nimustine hydrochloride, solid; CHEMBL1256616; DTXSID80204185; AMY23419; BCP11668; ANW-42405; HY-13703A; NSC245382; s5293; AKOS015895226; CCG-267570; MCULE-2422791904; NSC-245382; 1-(2-Cloroetil)-1-nitroso-3-((2-metil-4-aminopirimidin-5-il)metil)urea clorhidrato; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea;hydrochloride; N'-((4-Amino-2-metil-5-pirimidinil)metil)-N-(2-cloroetil)-N-nitrosourea clorhidrato; AC-15840; AK683740; SMR001230702; Urea, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-1-(2-chloroethyl)-1-nitroso-, monohydrochloride; WLN: T6N CNJ B1 DZ E1MVNNO&2G; CS-0007733; FT-0630684; N0821; C11276; D01059; 208N238; A825909; A828980; A830740; Q27107532; Nimustine HCl; NSC-245,382; NSC245,382; NSC 245,382; 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-(2-chloroethyl)-3-nitrosourea; 1-[(4-amino-2-methylpyrimidin-5-yl)methyl]-3-(2-chloroethyl)-3-nitrosourea hydrochloride; N'-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea hydrochloride; Urea, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitroso-" Small molecule "1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H" KPMKNHGAPDCYLP-UHFFFAOYSA-N CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O.Cl C9H14Cl2N6O2 CAS 55661-38-6 . . . . DB13069 . DR8032 Rosiglitazone . . Phase 3 Prostate cancer ICD-11: 2C82 CID: 77999 Anticancer Treatment "Avandia; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; Brl-49653; Rosiglizole; Brl 49653; rosiglitazone (Avandia); BRL49653; Avandaryl; TDZ 01; Avandamet; C18H19N3O3S; CHEBI:50122; MFCD00871760; Rosigilitazone; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-; 2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-; NCGC00095124-01; BRL 49653C; 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; DSSTox_CID_17131; DSSTox_RID_79303; DSSTox_GSID_37131; Rosiglitazone [INN:BAN]; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; CAS-122320-73-4; SR-01000763023; rosiglitazona; rosiglitazonum; Rezult; Rosi; HSDB 7555; Rosiglitazone base; 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; Gaudil (TN); Rosiglitazone (INN); 1132641-22-5; Spectrum_001703; 1217260-35-9; Spectrum2_001241; Spectrum3_000997; Spectrum4_001125; Spectrum5_001464; SCHEMBL5169; Dioxopromethazinehydrochloride; BSPBio_002693; KBioGR_001609; KBioSS_002183; SPECTRUM1504263; SPBio_001142; GTPL1056; TDZ-01; DTXSID7037131; SCHEMBL14383595; KBio2_002183; KBio2_004751; KBio2_007319; KBio3_001913; Rosiglitazone, >=98% (HPLC); HMS1922J11; HMS2094O13; HMS3649G08; HMS3656K16; HMS3744M11; HMS3871L03; HMS3884N08; Pharmakon1600-01504263; ACT04332; BCP03047; Tox21_111434; ANW-44906; BBL029079; BDBM50030474; CCG-39102; NSC758698; STL350047; AKOS015894872; Tox21_111434_1; AC-3459; BCP9000017; CS-1088; DB00412; MCULE-8293284864; MP-0331; NSC-758698; SB17326; VA11695; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]-phenyl]methyl]-2,4-thiazolidine-dione; NCGC00095124-02; NCGC00095124-03; NCGC00095124-04; NCGC00095124-05; NCGC00095124-06; NCGC00095124-08; AK-72839; HY-17386; SY031184; BCP0726000232; AB0011992; FT-0602578; R0106; S2556; SW197573-6; 20R734; 6P-065; D08491; J10213; S00306; AB00698473-15; AB00698473-17; AB00698473-18; AB00698473-19; AB00698473_20; AB00698473_21; AB00698473_22; AB00698473_23; Q424771; Q-201681; SR-01000763023-5; SR-01000763023-6; BRD-A97437073-001-02-3; BRD-A97437073-001-03-1; BRD-A97437073-001-04-9; SR-01000763023-12; (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)-benzyl)thiazolidine-2,4-dione; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione; IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin); (+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI); 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(Methyl-2-pyridinylamino)e thoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione" Small molecule "1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)" YASAKCUCGLMORW-UHFFFAOYSA-N CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3 C18H19N3O3S CAS 122320-73-4 . . . . DB00412 . DR8472 2-methoxyestradiol D06NYA D06NYA Phase 2 Pulmonary hypertension ICD-11: BB01 CID: 66414 Anticancer Treatment "ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene" Small molecule "1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1" CQOQDQWUFQDJMK-SSTWWWIQSA-N CC12CCC3C(C1CCC2O)CCC4=CC(=C(C=C34)OC)O C19H26O3 CAS 362-07-2 CHEBI:28955 . . . DB02342 . DR8297 Capecitabine D00HCQ D00HCQ Approved Colorectal cancer ICD-11: 2B91 CID: 60953 Anticancer Treatment "Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340; R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)" Small molecule "1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1" GAGWJHPBXLXJQN-UORFTKCHSA-N CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O C15H22FN3O6 CAS 154361-50-9 CHEBI:31348 . . . DB01101 . DR3489 Irinotecan D07HOB D07HOB Approved Colorectal cancer ICD-11: 2B91 CID: 60838 Anticancer Treatment "Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde" Small molecule "1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1" UWKQSNNFCGGAFS-XIFFEERXSA-N CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7 C33H38N4O6 CAS 97682-44-5 . . . . DB00762 Irinotecan DR2391 Gemcitabine D03UVS D03UVS Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 60750 Anticancer Treatment Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN) Small molecule "1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1" SDUQYLNIPVEERB-QPPQHZFASA-N C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F C9H11F2N3O4 CAS 95058-81-4 . . . . DB00441 Gemcitabine DR2080 Topotecan D02PMO D02PMO Approved Ovarian cancer ICD-11: 2C73 CID: 60700 Anticancer Treatment "Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin" Small molecule "1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1" UCFGDBYHRUNTLO-QHCPKHFHSA-N CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O C23H23N3O5 CAS 123948-87-8 . . . . DB01030 Topotecan DR0490 Etoposide D06GMG D06GMG Approved Testicular carcinoma ICD-11: 2C80 CID: 36462 Anticancer Treatment etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposido; Etoposidum; Etoposidum [INN-Latin]; VP-16; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Vepesid J; Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP 16; VP-16-213; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC-141540; NSC 141540; CCRIS 2392; HSDB 6517; EINECS 251-509-1; Epipodophyllotoxin VP-162 Small molecule "1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1" VJJPUSNTGOMMGY-MRVIYFEKSA-N CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O C29H32O13 CAS 33419-42-0 . . . . DB00773 Etoposide DR4469 Doxorubicin D07VLY D0F4KU Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 31703 Anticancer Treatment "Adriacin; 25316-40-9; Doxorubicin HCl; ADRIAMYCIN HYDROCHLORIDE; Hydroxydaunorubicin hydrochloride; Doxorubicin (Adriamycin) HCl; UNII-82F2G7BL4E; ADRIAMYCIN, HYDROCHLORIDE; KW-125; Lipodox; MLS001401460; 82F2G7BL4E; SMR000058570; CPD000058570; DSSTox_RID_78854; DSSTox_RID_80678; DSSTox_CID_10636; DSSTox_GSID_30636; DSSTox_GSID_45111; CCRIS 740; CAS-NOCAS_45111" Small molecule "1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1" AOJJSUZBOXZQNB-TZSSRYMLSA-N CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O C27H29NO11 CAS 23214-92-8 CHEBI:28748 . . . DB00997 Doxorubicin DR2724 Sodium selenite . . Phase 2 Breast cancer ICD-11: 2C60 CID: 24934 Anticancer Treatment "Disodium selenite; 10102-18-8; Natriumselenit; disodium;selenite; UNII-HIW548RQ3W; MFCD00003489; Selenious acid, sodium salt (1:2); Sodium selenite, anhydrous; HIW548RQ3W; CHEBI:48843; 10102-18-8(disodiumsalt)7782-82-3(monosodiumsalt); Natriumselenit [German]; Selenite sodium; Selenious Acid Disodium Salt; Sodium selenite, 44-46% Se, anhydrous; CCRIS 1260; HSDB 768; EINECS 233-267-9; NA2630; Sodium-selenite; H2-O3-Se.1/2Na; Aselend (TN); Selenious acid, sodium salt (2:1); Sodium Selenite,(S); Sodium selenite (JAN); Sodium selenite anhydrous; EC 233-267-9; DSSTox_CID_12077; DSSTox_RID_78904; DSSTox_GSID_32077; CHEMBL112302; DTXSID0032077; Tox21_202977; AKOS015912461; Sodium selenite [NA2630] [Poison]; NCGC00260523-01; 14013-56-0; CAS-10102-18-8; D10530; SODIUM SELENITE HIGH PURITY GRADE 100G; Q414626" Small molecule "1S/2Na.H2O3Se/c;;1-4(2)3/h;;(H2,1,2,3)/q2*+1;/p-2" BVTBRVFYZUCAKH-UHFFFAOYSA-L [O-][Se](=O)[O-].[Na+].[Na+] Na2O3Se CAS 10102-18-8 . . . . DB11127 . DR6969 Platinum D0E5FF D0E5FF Investigative Diabetes mellitus ICD-11: 5A10 CID: 23939 Anticancer Treatment "Precision tolerogens (autoimmune disease), NaniRx" Small molecule 1S/Pt BASFCYQUMIYNBI-UHFFFAOYSA-N [Pt] Pt CAS 7440-06-4 . . . . DB12257 Platinum DR2370 Azacitidine D09FAZ D09FAZ Approved Myelodysplastic syndrome ICD-11: 2A37 CID: 9444 Anticancer Treatment "Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine; A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC" Small molecule "1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1" NMUSYJAQQFHJEW-KVTDHHQDSA-N C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N C8H12N4O5 CAS 320-67-2 CHEBI:2038 . . . DB00928 . DR7876 Cytarabine D07XSN D07XSN Approved Mantle cell lymphoma ICD-11: 2A85 CID: 6253 Anticancer Treatment "Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one" Small molecule "1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1" UHDGCWIWMRVCDJ-CCXZUQQUSA-N C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O C9H13N3O5 CAS 147-94-4 CHEBI:28680 . . . DB00987 Cytarabine DR8841 Mitomycin C D0Y0GH D0Y0GH Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 5746 Anticancer Treatment "Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free" Small molecule "1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1" NWIBSHFKIJFRCO-WUDYKRTCSA-N CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N C15H18N4O5 CAS 50-07-7 CHEBI:27504 . . . DB00305 . DR6763 Dexamethasone D0IT2G D0DV8K Approved Rheumatoid arthritis ICD-11: FA20 CID: 5743 Anticancer Treatment Decadron; Dexamethazone; Maxidex; Prednisolone F; Decaspray; Desametasone; Hexadecadrol; Hexadrol; Dexasone; Oradexon; Dexacort; Deltafluorene; Superprednol; Visumetazone; Mediamethasone; Desamethasone; Dergramin; Mymethasone; Dinormon; Dexapolcort; Dexalona; Desameton; Desadrene; Cortisumman; Aphtasolon; Turbinaire; Dextelan; Dexameth; Decaderm; Millicorten; Gammacorten; Fortecortin; Dexadeltone; Dekacort; Dectancyl; Decasone; Dexason; Mexidex; Dexone; Calonat; Corsone; Auxiron; Fluormethylprednisolone; Azium; Dexa-Cortisyl Small molecule "1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1" UREBDLICKHMUKA-CXSFZGCWSA-N CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C C22H29FO5 CAS 50-02-2 . . . . DB01234 . DR0683 Thioridazine D0U1OE D0U1OE Approved Schizophrenia ICD-11: 6A20 CID: 5452 Anticancer Treatment "Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine" Small molecule "1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3" KLBQZWRITKRQQV-UHFFFAOYSA-N CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC C21H26N2S2 CAS 50-52-2 CHEBI:9566 . . . DB00679 . DR6736 Thalidomide D0U7GK D0U7GK Approved Multiple myeloma ICD-11: 2A83 CID: 5426 Anticancer Treatment "Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide" Small molecule "1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)" UEJJHQNACJXSKW-UHFFFAOYSA-N C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O C13H10N2O4 CAS 50-35-1 . . . . DB01041 . DR6516 Temozolomide D0C8EU D0C8EU Approved Brain cancer ICD-11: 2A00 CID: 5394 Anticancer Treatment "Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ" Small molecule "1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)" BPEGJWRSRHCHSN-UHFFFAOYSA-N CN1C(=O)N2C=NC(=C2N=N1)C(=O)N C6H6N6O2 CAS 85622-93-1 . . . . DB00853 Temozolomide DR2632 Vorinostat D0E7PQ D0E7PQ Approved Mycosis fungoides ICD-11: 2B01 CID: 5311 Anticancer Treatment "NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)" Small molecule "1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)" WAEXFXRVDQXREF-UHFFFAOYSA-N C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO C14H20N2O3 CAS 149647-78-9 . . . . DB02546 Vorinostat DR8244 Imatinib D0R6RU D0R6RU Approved Mantle cell lymphoma ICD-11: 2A85 CID: 5291 Anticancer Treatment Imatinib-d8; Imatinib D8; [d8]-Imatinib; 1092942-82-9; DTXSID70649425; J-002260 Small molecule "1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)" KTUFNOKKBVMGRW-UHFFFAOYSA-N CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 C29H31N7O CAS 152459-95-5 . . . . . Imatinib DR4213 Raloxifene D01XBA D01XBA Approved Osteoporosis ICD-11: FB83 CID: 5035 Anticancer Treatment "raloxifene; 84449-90-1; Keoxifene; Evista; Raloxifenum [Latin]; Raloxifeno [Spanish]; Raloxifenum; Raloxifeno; LY 139481; LY-139481; UNII-YX9162EO3I; Optruma; CHEMBL81; Keoxifene; LY 139481;; CHEBI:8772; YX9162EO3I; RAL; LY139481; CCRIS 7129; HSDB 7460; NCGC00015889-05; CAS-82640-04-8; Pharoxifene; Raloxifene D4; Raloxifene, 6; Raloxifene (INN); Eviden (TN); Raxeto (TN); Lopac-R-1402; DSSTox_CID_3550; SCHEMBL6144; DSSTox_RID_77076; DSSTox_GSID_23550; Lopac0_001051; BSPBio_000903; KBioGR_002361; KBioSS_002364; BIDD:ER0216; BIDD:GT0795; SPBio_002824; BPBio1_000995; GTPL2820; DTXSID3023550; BDBM19441; KBio2_002361; KBio2_004929; KBio2_007497; KBio3_002840; cid_11071264; cMAP_000032; HMS2089F06; HMS3742O11; ZINC538275; BCP09772; Tox21_202603; MFCD00866415; NSC747974; NSC761389; s5781; AKOS015896267; AC-8399; CCG-205128; DB00481; MCULE-4598311006; NSC-747974; NSC-761389; SDCCGSBI-0051021.P003; MRF-0000684; SMP2_000095; AS-35086; HY-13738; J22.982B; SBI-0051021.P002; AB0073011; CAS-84449-90-1; CS-0007764; FT-0674305; VU0155042-3; C07228; D08465; 449R901; Q425223; BRD-K63828191-003-11-5; " Small molecule "1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2" GZUITABIAKMVPG-UHFFFAOYSA-N C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O C28H27NO4S CAS 84449-90-1 . . . . DB00481 . DR4666 PD98059 . . Investigative Gastrointestinal stromal tumor ICD-11: 2B5B CID: 4713 Anticancer Treatment "PD98059; PD 98059; 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one; PD-98059; PD 98,059; 2-(2-amino-3-methoxyphenyl)chromen-4-one; 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 2'-AMINO-3'-METHOXYFLAVONE; PD-098059; 4H-1-Benzopyran-4-one, 2-(2-Amino-3-methoxyphenyl)-; UNII-SJE1IO5E3I; SJE1IO5E3I; CHEMBL35482; C16H13NO3; CHEBI:77954; MFCD00671789; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one; SR-01000076097; PD 098059; 2-(2-Amino-3-methoxyphenyl)-chromen-4-one; Tocris-1213; PD098059; Lopac-P-215; BiomolKI_000001; 2-(2-amino-3-methoxy-phenyl)chromen-4-one; BiomolKI2_000011; PD 98,059, solid; Lopac0_001028; BMK1-B1; BSPBio_000996; KBioGR_000336; KBioSS_000336; 2-(2'-amino-3'-methoxyphenyl)oxanaphthalen-4-one; cc-461; MLS006010134; SCHEMBL157826; 4H-1-Benzopyran-4-one,2-(2-amino-3-methoxyphenyl)-; GTPL5241; QCR-14; 2''-amino-3''-methoxyflavone; BCBcMAP01_000049; KBio2_000336; KBio2_002904; KBio2_005472; KBio3_000671; KBio3_000672; AOB2598; DTXSID40168416; BCPP000123; Bio1_000475; Bio1_000964; Bio1_001453; Bio2_000338; Bio2_000818; HMS1362B17; HMS1792B17; HMS1990B17; HMS3229M08; HMS3263M17; HMS3267D03; HMS3403B17; HMS3412O09; HMS3649N14; HMS3654I16; HMS3676O09; BCP02423; EX-A2127; ZINC1420826; Tox21_501028; ABP000927; BDBM50108771; NSC679828; s1177; AKOS015995212; BCP9001060; CCG-100605; CS-0169; LP01028; NSC 679828; NSC-679828; SB16629; SDCCGSBI-0051000.P003; IDI1_002093; SMP2_000052; NCGC00015790-01; NCGC00015790-02; NCGC00015790-03; NCGC00015790-04; NCGC00015790-05; NCGC00015790-06; NCGC00015790-07; NCGC00015790-08; NCGC00025045-01; NCGC00025045-02; NCGC00025045-03; NCGC00025045-04; NCGC00025045-05; NCGC00179347-01; NCGC00261713-01; AC-28412; AK-60664; AS-19374; HY-12028; NCI60_028554; SMR001456459; AB0033706; EU-0101028; FT-0716482; P-215; PD-98059/PD98059/; SW218254-2; X7398; EC-000.2425; A25454; P-4313; PD 98059 & Z-100; InSolution PD 98059 - CAS 167869-21-8; J-505513; SR-01000076097-1; SR-01000076097-3; SR-01000076097-6; 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran; BRD-K62810658-001-05-6; BRD-K62810658-001-06-4; Q27088281; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one(PD98059); PD 98059 - CAS 167869-21-8; 4H-1-Benzopyran-4-one, 2-(2-amino-3-methoxyphenyl)- & Z-100" Small molecule "1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3" QFWCYNPOPKQOKV-UHFFFAOYSA-N COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2 C16H13NO3 CAS 167869-21-8 . . . . . . DR8320 Mitoxantrone D0R3JB D0R3JB Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 4212 Anticancer Treatment "DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)" Small molecule "1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2" KKZJGLLVHKMTCM-UHFFFAOYSA-N C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO C22H28N4O6 CAS 65271-80-9 CHEBI:50729 . . . DB01204 Mitoxantrone DR1575 Letrozole D0C1WH D0C1WH Approved Breast cancer ICD-11: 2C60 CID: 3902 Anticancer Treatment "Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile" Small molecule "1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H" HPJKCIUCZWXJDR-UHFFFAOYSA-N C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3 C17H11N5 CAS 112809-51-5 CHEBI:6413 . . . DB01006 . DR6637 Indole-3-carbinol . . Phase 1 Breast cancer ICD-11: 2C60 CID: 3712 Anticancer Treatment "3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; I3C; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; 1~{H}-indol-3-ylmethanol; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; 00I061; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165; FXK" Small molecule "1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2" IVYPNXXAYMYVSP-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)CO C9H9NO CAS 700-06-1 . . . . DB12881 . DR5670 Ibuprofen D0R1QE D0R1QE Approved Pain ICD-11: MG30-MG3Z CID: 3672 Anticancer Treatment "ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid; Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol; Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid; Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN" Small molecule "1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)" HEFNNWSXXWATRW-UHFFFAOYSA-N CC(C)CC1=CC=C(C=C1)C(C)C(=O)O C13H18O2 CAS 15687-27-1 CHEBI:5855 . . . DB01050 . DR9868 HA14-1 . . Investigative Colon cancer ICD-11: 2B90 CID: 3549 Anticancer Treatment "Ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; HA 14-1; Ethyl [2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)]-4H-chromene-3-carboxylate; MFCD00218213; HA-14-1; Ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylate; 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylic acid ethyl ester; 927635-64-1; SR-01000511000; C17H17BrN2O5; Maybridge1_000786; 2-oxo-2-(2-(tritylamino)thiazol-5-yl)acetic acid; BSPBio_001583; KBioGR_000303; KBioSS_000303; cc-453; SCHEMBL1427458; CHEBI:94328; HMS543L16; KBio2_000303; KBio2_002871; KBio2_005439; KBio3_000605; KBio3_000606; AOB6777; DTXSID20274403; EX-A148; Bio2_000303; Bio2_000783; HMS1361P05; HMS1791P05; HMS1989P05; HMS3268C09; HMS3414M05; HMS3678M05; BCP01804; ABP000246; BTB 02933; HA 141; HA14-1/HA141; HSCI1_000186; NSC720569; AKOS007930839; BCP9000758; CCG-233971; NSC-720569; QC-8196; 2-Amino-6-bromo-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester; IDI1_034053; SMP2_000039; NCGC00025207-02; NCGC00025207-03; NCGC00025207-04; NCGC00025207-05; NCGC00025207-06; NCGC00025207-12; NCGC00025207-15; NCGC00025207-16; AC-32822; AK687960; NCI60_041312; PS-10256; AB0008001; DB-011974; FT-0761318; Y9750; HA 14-1, >=95% (CHN/NMR), powder; S-7766; J-520710; SR-01000511000-1; SR-01000511000-2; BRD-A13807286-001-03-9; Q27166151; 2-Amino-6-bromo-?-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester; (; inverted exclamation markR,4R)-rel-2-amino-6-bromo-; A-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid, ethyl ester; (alphaR,4R)-rel-2-amino-6-bromo-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-aceticacid,ethylester" Small molecule "1S/C17H17BrN2O5/c1-3-23-16(21)11(8-19)13-10-7-9(18)5-6-12(10)25-15(20)14(13)17(22)24-4-2/h5-7,11,13H,3-4,20H2,1-2H3" SXJDCULZDFWMJC-UHFFFAOYSA-N CCOC(=O)C1=C(OC2=C(C1C(C#N)C(=O)OCC)C=C(C=C2)Br)N C17H17BrN2O5 CAS 65673-63-4 . . . . . . DR0258 Flutamide D0Y0SW D0Y0SW Approved Prostate cancer ICD-11: 2C82 CID: 3397 Anticancer Treatment "Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)" Small molecule "1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)" MKXKFYHWDHIYRV-UHFFFAOYSA-N CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F C11H11F3N2O3 CAS 13311-84-7 CHEBI:5132 . . . DB00499 . DR9021 5-fluorouracil D05LEO D05LEO Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 3385 Anticancer Treatment "fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 51-21-8; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU" Small molecule "1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)" GHASVSINZRGABV-UHFFFAOYSA-N C1=C(C(=O)NC(=O)N1)F C4H3FN2O2 CAS 51-21-8 CHEBI:46345 . . . DB00544 5-Fluorouracil DR6122 Enoxacin D0R8ER D0R8ER Approved Urinary tract infection ICD-11: GC08 CID: 3229 Anticancer Treatment "Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid" Small molecule "1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)" IDYZIJYBMGIQMJ-UHFFFAOYSA-N CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O C15H17FN4O3 CAS 74011-58-8 . . . . DB00467 . DR3720 "3,3'-diindolylmethane" . . Phase 2 Breast cancer ICD-11: 2C60 CID: 3071 Anticancer Treatment "diindolylmethane; di(1H-indol-3-yl)methane; 3,3'-Methylenebis-1H-indole; 3,3'-Methylenediindole; DIM; ARUNDINE; 1H-Indole, 3,3'-methylenebis-; Di(3-indolyl)methane; 3,3'-Di-indolylmethane; 3-(1H-indol-3-ylmethyl)-1H-indole; 3,3'-methylenebis(1H-indole); 3,3,-diindolylmethane; UNII-SSZ9HQT61Z; MFCD00195766; SSZ9HQT61Z; bis-1H-indol-3-ylmethane; CHEBI:50182; 3,3'-methanediylbis(1H-indole); 3-Diindolyl methane; 33'-Diindolylmethane; 3,3'-Diindolymethane; Diidolylmethane; Infemin; CCRIS 5806; Plant Indole; Di-3-indolylmethane; HB 236; NSC708486; PubChem8119; Spectrum2_001711; Spectrum3_001989; Spectrum5_001955; CBiol_001839; Oprea1_472633; Oprea1_740951; BSPBio_001290; BSPBio_003589; CBDivE_010856; KBioGR_000010; KBioSS_000010; MLS006011847; SCHEMBL325162; SPECTRUM1505331; SPBio_001722; ACMC-20976o; 3,3'-di(indol-3-yl)methane; BML3-F11; CHEMBL446452; 3,3'-Diindolylmethane (DIM); DTXSID8037047; GTPL11208; KBio2_000010; KBio2_002578; KBio2_005146; KBio3_000019; KBio3_000020; KBio3_003002; Bio1_000125; Bio1_000614; Bio1_001103; Bio2_000010; Bio2_000490; HMS1361A12; HMS1791A12; HMS1989A12; HMS3402A12; ZINC187911; 3,3'-diindolylmethane, AldrichCPR; ACT06989; ALBB-016048; BCP00470; ANW-13582; BBL015828; CCG-39861; GR-207; HSCI1_000069; s4728; STK263696; AKOS003627372; AM84671; CS-1652; DB11875; KS-5266; MCULE-3718375492; NSC-708486; SB16901; IDI1_033760; NCGC00095348-01; NCGC00095348-02; NCGC00095348-03; NCGC00095348-04; NCGC00095348-05; NCGC00095348-06; NCGC00095348-07; AC-11611; AK-45887; HY-15758; NCI60_038418; SMR001828114; SY038972; 3,3'-Diindolylmethane, >=98% (HPLC); 3,3'-Diindolylmethane, analytical standard; DB-011102; FT-0614061; M1399; A16321; D-3720; M-1632; 968D054; Q4634053; BRD-K37846922-001-05-2; BRD-K37846922-001-06-0; BRD-K37846922-001-09-4; C444299000" Small molecule "1S/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2" VFTRKSBEFQDZKX-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43 C17H14N2 CAS 1968-05-4 . . . . DB11875 . DR2176 Cyclophosphamide D0CT9C D0CT9C Approved Solid tumour/cancer ICD-11: 2A00-2F9Z CID: 2907 Anticancer Treatment "ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide" Small molecule "1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)" CMSMOCZEIVJLDB-UHFFFAOYSA-N C1CNP(=O)(OC1)N(CCCl)CCCl C7H15Cl2N2O2P CAS 50-18-0 . . . . DB00531 Cyclophosphamide DR2742 Celecoxib D03RTS D03RTS Approved Rheumatoid arthritis ICD-11: FA20 CID: 2662 Anticancer Treatment "CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide" Small molecule "1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)" RZEKVGVHFLEQIL-UHFFFAOYSA-N CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F C17H14F3N3O2S CAS 169590-42-5 CHEBI:41423 . . . DB00482 . DR9249 "1,3-bis(2-chloroethyl)-1-nitrosourea" D01OXI D01OXI Approved Hepatocellular carcinoma ICD-11: 2C12 CID: 2578 Anticancer Treatment "Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics" Small molecule "1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)" DLGOEMSEDOSKAD-UHFFFAOYSA-N C(CCl)NC(=O)N(CCCl)N=O C5H9Cl2N3O2 CAS 154-93-8 . . . . . . DR3231 Busulfan D07SUG D07SUG Approved Myelofibrosis ICD-11: 2A22 CID: 2478 Anticancer Treatment "Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate" Small molecule "1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3" COVZYZSDYWQREU-UHFFFAOYSA-N CS(=O)(=O)OCCCCOS(=O)(=O)C C6H14O6S2 CAS 55-98-1 CHEBI:28901 . . . DB01008 . DR0904 Bicalutamide D0V9BD D0V9BD Approved Prostate cancer ICD-11: 2C82 CID: 2375 Anticancer Treatment "Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide" Small molecule "1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)" LKJPYSCBVHEWIU-UHFFFAOYSA-N CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O C18H14F4N2O4S CAS 90357-06-5 CHEBI:3090 . . . DB01128 Bicalutamide DR0401 Atosiban D0D8XY . . . . CID: 5311010 Anticancer Treatment "Atosiban 90779-69-4 Tractocile Antocin Antocin II" . "InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1" VWXRQYYUEIYXCZ-OBIMUBPZSA-N CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O C43H67N11O12S2 90779-69-4 CHEBI:135899 . . . DB09059 . DR0402 Poly lactic-co-glycolic acid . . Anticancer Treatment . . . . . . . . . . . . . DR0403 Abiraterone D02STN . Approved Prostate cancer ICD-11: 2C82.0 CID: 132971 Anticancer Treatment "Abiraterone 154229-19-3 CB 7598 CB-7598 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol" Small molecule "InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1" GZOSMCIZMLWJML-VJLLXTKPSA-N C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O C24H31NO 154229-19-3 CHEBI:68642 . . . DB05812 . DR0404 Domiphen . . CID: 3149 Anticancer Treatment "Domiphen Phenododecinium Domiphen cation Domiphen ion 13900-14-6" Small molecule "InChI=1S/C22H40NO/c1-4-5-6-7-8-9-10-11-12-16-19-23(2,3)20-21-24-22-17-14-13-15-18-22/h13-15,17-18H,4-12,16,19-21H2,1-3H3/q+1" YXUPZGKORWTXID-UHFFFAOYSA-N CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 C22H40NO+ 13900-14-6 CHEBI:135978 . . . DB11594 . DR0405 Trifluridine D05RHI . Approved Virus infection ICD-11: 1A24-1D9Z CID: 6256 Anticancer Treatment "Trifluridine TRIFLUOROTHYMIDINE 70-00-8 5-Trifluorothymidine Trifluoromethyldeoxyuridine" Small molecule "InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1" VSQQQLOSPVPRAZ-RRKCRQDMSA-N C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O C10H11F3N2O5 70-00-8 CHEBI:75179 . . . DB00432 . DR0406 Antinociceptive . . Anticancer Treatment . . . . . . . . . . . . . DR0408 Autophagy/mitophagy inhibitors . . Anticancer Treatment . . . . . . . . . . . . . DR0409 DNMT Inhibitor . . CID: 135564655 Anticancer Treatment "Guadecitabine 929901-49-5 SGI-110 SGI-110 free acid 2KT4YN1DP7" Small molecule "InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1" GUWXKKAWLCENJA-WGWHJZDNSA-N C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC(=NC5=O)N)O C18H24N9O10P 929901-49-5 CHEBI:231603 . . . DB11918 . DR0410 Minoxidil D0Y2CJ . Approved Hypertension ICD-11: BA00-BA04 CID: 4201 Anticancer Treatment "minoxidil 38304-91-5 Minoximen Regaine Alopexil" Small molecule "InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2" ZIMGGGWCDYVHOY-UHFFFAOYSA-N C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O C9H15N5O 38304-91-5 CHEBI:6942 . . . DB00350 . DR0411 Fibroblast growth factor 1 (FGF1) . . Anticancer Treatment . Small molecule . . . . . . . . . . . DR0412 SN38 prodrug . . Anticancer Treatment . Small molecule . . . . . . . . . . . DR0413 Single-chain variable fragment (scFv) HS72 . . Anticancer Treatment . Small molecule . . . . . . . . . . . DR0414 Salinomycin . . CID: 3085092 Anticancer Treatment "salinomycin 53003-10-4 Procoxacin Coxistac Salinomicina" Small molecule "InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1" KQXDHUJYNAXLNZ-XQSDOZFQSA-N CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O C42H70O11 53003-10-4 CHEBI:80025 . . . DB11544 . DR0416 Berberine D0W8WB . CID: 2353 Anticancer Treatment "berberine 2086-83-1 Umbellatine Berberin Berbericine" Small molecule "InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1" YBHILYKTIRIUTE-UHFFFAOYSA-N COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC C20H18NO4+ 2086-83-1 CHEBI:16118 HBIN000108 SMCC000055 MOL001576 DB04115 . DR0417 Metformin D0D7LA . Approved Type-2 diabetes ICD-11: 5A11 CID: 4091 Anticancer Treatment "metformin 657-24-9 1,1-Dimethylbiguanide N,N-dimethylimidodicarbonimidic diamide Imidodicarbonimidic diamide, N,N-dimethyl-" Small molecule "InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)" XZWYZXLIPXDOLR-UHFFFAOYSA-N CN(C)C(=N)N=C(N)N C4H11N5 657-24-9;1115-70-4 CHEBI:6801 . . . DB00331 . DR0419 Vancomycin D0B1IV . Approved Methicillin-resistant staphylococci infection ICD-11: 1A00-1A09 CID: 14969 Anticancer Treatment "VANCOMYCIN 1404-90-6 Vancomicina Vancomycine Vancomycinum" Small molecule "InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1" MYPYJXKWCTUITO-LYRMYLQWSA-N C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O C66H75Cl2N9O24 1404-90-6 CHEBI:28001 . . . DB00512 . DR0420 Capsaicin D0U5CE . Approved Neuropathic pain ICD-11: 8E43.0 CID: 1548943 Anticancer Treatment "Capsaicin 404-86-4 CAPSAICINE Qutenza trans-Capsaicin" Small molecule "InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+" YKPUWZUDDOIDPM-SOFGYWHQSA-N CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC C18H27NO3 404-86-4 CHEBI:3374 . . . DB06774 . DR0421 Paclitaxel . . CID: 36314 Anticancer Treatment "paclitaxel TAXOL 33069-62-4 Taxol A Yewtaxan" Small molecule "InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1" RCINICONZNJXQF-MZXODVADSA-N CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C C47H51NO14 33069-62-4;92950-39-5 CHEBI:45863 . . . DB01229 . DR0422 Colistin D0K7NQ . Approved Pseudomonas infection ICD-11: 1B92 Anticancer Treatment "colistin Colomycin Colisticina Colistinum Colistina" Small molecule "InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36-,37+,38-,39-,41?,42+/m1/s1" YKQOSKADJPQZHB-RGYSVOEGSA-N CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O C52H98N16O13 1066-17-7 . . . . DB00803 . DR0423 thiamine dilauryl sulphate . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0424 photodynamic therapy . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0425 antibiotics . . . . . 46874763 Anticancer Treatment . . "InChI=1S/C28H44IN4O24P3/c1-10(23(41)31-12(3)58(46,47)9-13(26(43)44)4-5-17(36)37)53-22-18(30-11(2)35)27(55-15(7-34)20(22)39)56-60(50,51)57-59(48,49)52-8-16-19(38)21(40)25(54-16)33-6-14(29)24(42)32-28(33)45/h6,10,12-13,15-16,18-22,25,27,34,38-40H,4-5,7-9H2,1-3H3,(H,30,35)(H,31,41)(H,36,37)(H,43,44)(H,46,47)(H,48,49)(H,50,51)(H,32,42,45)/t10-,12-,13?,15?,16-,18?,19-,20?,21-,22?,25?,27?/m1/s1" LRJAGMBMPSXEFP-UDPUMDPQSA-N C[C@H](C(=O)N[C@@H](C)P(=O)(CC(CCC(=O)O)C(=O)O)O)OC1C(C(OC(C1O)CO)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H](C(O2)N3C=C(C(=O)NC3=O)I)O)O)NC(=O)C C28H44IN4O24P3 . . . . . . . DR0426 levothyroxine sodium . . . . . 23666112 Anticancer Treatment . . "InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m0./s1" YDTFRJLNMPSCFM-YDALLXLXSA-M C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+] C15H10I4NNaO4 "55-03-8,25416-65-3" CHEBI:6446 . . . . . DR0427 sacubitril valsartan . . . . . 24755620 Anticancer Treatment . . "InChI=1S/C24H29N5O3.C24H29NO5/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t22-;17-,21+/m01/s1" XTKIDERFOUYBDE-QEPKIHTBSA-N CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O C48H58N6O8 1360873-85-3 . . . . . . DR0429 ticagrelor . . . . . 9871419 Anticancer Treatment . . "InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1" OEKWJQXRCDYSHL-FNOIDJSQSA-N CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F C23H28F2N6O4S 274693-27-5 CHEBI:68558 . . . DB08816 . DR0430 carbapenems . . . . . 134085 Anticancer Treatment . . "InChI=1S/C7H7NO3/c9-6-3-4-1-2-5(7(10)11)8(4)6/h2,4H,1,3H2,(H,10,11)" BSIMZHVOQZIAOY-UHFFFAOYSA-N C1C=C(N2C1CC2=O)C(=O)O C7H7NO3 "83200-96-8,82768-37-4" . . . . . . DR0431 Quinine D03DDR . . . . 3034034 Anticancer Treatment . . "InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1" LOUPRKONTZGTKE-WZBLMQSHSA-N COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O C20H24N2O2 "130-95-0,72402-53-0" CHEBI:15854 . . . DB00468 . DR0432 Phosphatidylinositol 3-Kinase Inhibitor (LY294002) . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0433 R-1-R Peptide . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0434 alpha-Tocopherol . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0435 sodium propionate . . . . . 2723816 Anticancer Treatment . . "InChI=1S/C3H6O2.Na/c1-2-3(4)5;/h2H2,1H3,(H,4,5);/q;+1/p-1" JXKPEJDQGNYQSM-UHFFFAOYSA-M CCC(=O)[O-].[Na+] "C3H5O2Na,CH3CH2COONa,C3H5NaO2,C3H5NaO2" "137-40-6,63785-15-9" CHEBI:132106 . . . . . DR0436 pantoprazole D0T6XX . . . . 4679 Anticancer Treatment . . "InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)" IQPSEEYGBUAQFF-UHFFFAOYSA-N COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC C16H15F2N3O4S "102625-70-7,164579-32-2" CHEBI:7915 . . . DB00213 . DR0437 Chidamide . . . . . 9800555 Anticancer Treatment . . "InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+" WXHHICFWKXDFOW-BJMVGYQFSA-N C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=CC(=C3)F)N C22H19FN4O2 1883690-47-8 . . . . . . DR0438 beta-lactam . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0439 aminoglycoside antibiotics . . . . . 16220018 Anticancer Treatment . . "InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1" NLVFBUXFDBBNBW-SNGYORCQSA-N C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N C18H37N5O9 . . . . . . . DR0440 omega-3 fish oil . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0441 5-ASA . . . . . 4075 Anticancer Treatment . . "InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)" KBOPZPXVLCULAV-UHFFFAOYSA-N C1=CC(=C(C=C1N)C(=O)O)O C7H7NO3 89-57-6 CHEBI:6775 . . . DB00244 . DR0442 Kojic Acid D0F3CO . . . . 3840 Anticancer Treatment . . "InChI=1S/C6H6O4/c7-2-4-1-5(8)6(9)3-10-4/h1,3,7,9H,2H2" BEJNERDRQOWKJM-UHFFFAOYSA-N C1=C(OC=C(C1=O)O)CO C6H6O4 501-30-4 CHEBI:43572 . . . DB01759 . DR0443 triclosan D00CSQ . . . . 5564 Anticancer Treatment . . "InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H" XEFQLINVKFYRCS-UHFFFAOYSA-N C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl C12H7Cl3O2 3380-34-5 CHEBI:164200 . . . DB08604 . DR0444 oxacillin sodium . . . . . 23694213 Anticancer Treatment . . "InChI=1S/C19H19N3O5S.Na.H2O/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22;;/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26);;1H2/q;+1;/p-1/t13-,14+,17-;;/m1../s1" ZVIYWUUZWWBNMB-VICXVTCVSA-M CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[Na+] C19H20N3NaO6S "1173-88-2,7240-38-2" CHEBI:7810 . . . . . DR0445 CPT-11 . . . . . 74990 Anticancer Treatment . . "InChI=1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1" GURKHSYORGJETM-WAQYZQTGSA-N CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl C33H39ClN4O6 "100286-90-6,136572-09-3" CHEBI:5971 . . . . . DR0446 camrelizumab . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0447 notopterol . . . . . 5320227 Anticancer Treatment . . "InChI=1S/C21H22O5/c1-13(2)10-15(22)11-14(3)6-8-25-21-16-4-5-20(23)26-19(16)12-18-17(21)7-9-24-18/h4-7,9-10,12,15,22H,8,11H2,1-3H3/b14-6+" BKIACVAZUKISOR-MKMNVTDBSA-N CC(=CC(C/C(=C/COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)/C)O)C C21H22O5 88206-46-6 CHEBI:81136 . . . . . DR0448 Leptin D0C6TL . . . . 157010069 Anticancer Treatment . . "InChI=1S/C87H138N22O28S2/c1-41(2)27-48(88)72(121)97-50(18-21-65(89)112)73(122)93-36-68(115)95-61(38-110)84(133)104-54(28-42(3)4)77(126)98-52(20-23-67(91)114)75(124)106-59(33-70(117)118)82(131)100-53(24-26-139-11)76(125)102-55(29-43(5)6)78(127)105-58(32-46-35-92-49-16-13-12-15-47(46)49)81(130)99-51(19-22-66(90)113)74(123)101-56(30-44(7)8)79(128)107-60(34-71(119)120)83(132)103-57(31-45(9)10)80(129)108-62(39-111)86(135)109-25-14-17-64(109)85(134)94-37-69(116)96-63(40-138)87(136)137/h12-13,15-16,35,41-45,48,50-64,92,110-111,138H,14,17-34,36-40,88H2,1-11H3,(H2,89,112)(H2,90,113)(H2,91,114)(H,93,122)(H,94,134)(H,95,115)(H,96,116)(H,97,121)(H,98,126)(H,99,130)(H,100,131)(H,101,123)(H,102,125)(H,103,132)(H,104,133)(H,105,127)(H,106,124)(H,107,128)(H,108,129)(H,117,118)(H,119,120)(H,136,137)/t48-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1" NRYBAZVQPHGZNS-ZSOCWYAHSA-N CC(C)C[C@@H](C(=N[C@@H](CCC(=N)O)C(=NCC(=N[C@@H](CO)C(=N[C@@H](CC(C)C)C(=N[C@@H](CCC(=N)O)C(=N[C@@H](CC(=O)O)C(=N[C@@H](CCSC)C(=N[C@@H](CC(C)C)C(=N[C@@H](CC1=CNC2=CC=CC=C21)C(=N[C@@H](CCC(=N)O)C(=N[C@@H](CC(C)C)C(=N[C@@H](CC(=O)O)C(=N[C@@H](CC(C)C)C(=N[C@@H](CO)C(=O)N3CCC[C@H]3C(=NCC(=N[C@@H](CS)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N C87H138N22O28S2 169494-85-3 DB05098 . . . . . DR0449 Probiotics . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0451 antibiotics . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0452 Tagetes lucida Ethyl Acetate Extract . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0453 GoldenBifid . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0454 oxytocin D0M3FJ . . . . 439302 Anticancer Treatment . . "InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1" XNOPRXBHLZRZKH-DSZYJQQASA-N CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N C43H66N12O12S2 50-56-6 CHEBI:7872 . . . DB00107 . DR0455 beta-Cypermethrin . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0456 shanzhiside methyl ester . . . . . 13892722 Anticancer Treatment . . "InChI=1S/C17H26O11/c1-17(24)3-7(19)9-6(14(23)25-2)5-26-15(10(9)17)28-16-13(22)12(21)11(20)8(4-18)27-16/h5,7-13,15-16,18-22,24H,3-4H2,1-2H3/t7-,8-,9+,10-,11-,12+,13-,15+,16+,17+/m1/s1" KKSYAZCUYVRKML-IRDZEPHTSA-N C[C@@]1(C[C@H]([C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O C17H26O11 . CHEBI:193584 . . . . . DR0457 Huafengdan . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0458 carabrone . . . . . 164879 Anticancer Treatment . . "InChI=1S/C15H20O3/c1-8(16)4-5-11-12-6-10-9(2)14(17)18-13(10)7-15(11,12)3/h10-13H,2,4-7H2,1,3H3/t10-,11+,12+,13-,15-/m1/s1" AGIQIKMGJVLKMA-NLRWUALESA-N CC(=O)CC[C@H]1[C@H]2[C@@]1(C[C@@H]3[C@H](C2)C(=C)C(=O)O3)C C15H20O3 1748-81-8 . . . . . . DR0459 total ginsenosides from Panax ginseng? . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0461 miconazole nitrate . . . . . 68553 Anticancer Treatment . . "InChI=1S/C18H14Cl4N2O.HNO3/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22;2-1(3)4/h1-8,11,18H,9-10H2;(H,2,3,4)" MCCACAIVAXEFAL-UHFFFAOYSA-N C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-] C18H15Cl4N3O4 22832-87-7 . . . . . . DR0462 almonertinib DDH8L6 . . . . 121280087 Anticancer Treatment . . "InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)" DOEOECWDNSEFDN-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC C30H35N7O2 1899921-05-1 . . . . DB16640 . DR0463 Nisin D01RBK . . . . 16129667 Anticancer Treatment . . "InChI=1S/C143H230N42O37S7/c1-24-69(11)105(148)135(213)162-82(27-4)118(196)174-94-58-225-59-95(175-123(201)89(48-67(7)8)169-115(193)74(16)158-138(216)107(70(12)25-2)180-132(94)210)133(211)184-112-79(21)229-61-96(160-104(190)56-152-134(212)100-38-34-44-185(100)142(112)220)128(206)164-84(36-29-32-42-145)120(198)182-109-76(18)226-60-97(161-103(189)55-151-117(195)85(39-45-223-22)165-122(200)88(47-66(5)6)168-113(191)72(14)156-102(188)54-153-136(109)214)129(207)171-92(51-101(147)187)125(203)166-86(40-46-224-23)119(197)163-83(35-28-31-41-144)121(199)183-110-77(19)228-63-99-130(208)170-90(49-80-52-149-64-154-80)124(202)176-98(62-227-78(20)111(141(219)177-99)181-116(194)75(17)159-140(110)218)131(209)173-93(57-186)127(205)179-108(71(13)26-3)139(217)172-91(50-81-53-150-65-155-81)126(204)178-106(68(9)10)137(215)157-73(15)114(192)167-87(143(221)222)37-30-33-43-146/h27,52-53,64-72,75-79,83-100,105-112,186H,15-16,24-26,28-51,54-63,144-146,148H2,1-14,17-23H3,(H2,147,187)(H,149,154)(H,150,155)(H,151,195)(H,152,212)(H,153,214)(H,156,188)(H,157,215)(H,158,216)(H,159,218)(H,160,190)(H,161,189)(H,162,213)(H,163,197)(H,164,206)(H,165,200)(H,166,203)(H,167,192)(H,168,191)(H,169,193)(H,170,208)(H,171,207)(H,172,217)(H,173,209)(H,174,196)(H,175,201)(H,176,202)(H,177,219)(H,178,204)(H,179,205)(H,180,210)(H,181,194)(H,182,198)(H,183,199)(H,184,211)(H,221,222)/b82-27-" NVNLLIYOARQCIX-GSJOZIGCSA-N CCC(C)C1C(=O)NC(=C)C(=O)NC(C(=O)NC(CSCC(C(=O)N1)NC(=O)/C(=C/C)/NC(=O)C(C(C)CC)N)C(=O)NC2C(SCC(NC(=O)CNC(=O)C3CCCN3C2=O)C(=O)NC(CCCCN)C(=O)NC4C(SCC(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC4=O)C)CC(C)C)CCSC)C(=O)NC(CC(=O)N)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC5C(SCC6C(=O)NC(C(=O)NC(CSC(C(C(=O)N6)NC(=O)C(NC5=O)C)C)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(CC7=CN=CN7)C(=O)NC(C(C)C)C(=O)NC(=C)C(=O)NC(CCCCN)C(=O)O)CC8=CN=CN8)C)C)C)CC(C)C C143H230N42O37S7 1414-45-5 . . . . . . DR0465 chitosan nanoparticles . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0466 Azithromycin D06VYK . . . . 447043 Anticancer Treatment . . "InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1" MQTOSJVFKKJCRP-BICOPXKESA-N CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O C38H72N2O12 83905-01-5 CHEBI:2955 . . . DB00207 . DR0467 Honey . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0468 Chloramphenicol D0X6IU . . . . 5959 Anticancer Treatment . . "InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1" WIIZWVCIJKGZOK-RKDXNWHRSA-N C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-] C11H12Cl2N2O5 "56-75-7,2787-09-9" CHEBI:17698 . . . DB00446 . DR0469 beta-lactam and fluoroquinolones drugs . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0470 isochlorogenic acid A? . . . . . 6474310 Anticancer Treatment . . "InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(30)36-19-11-25(35,24(33)34)12-20(23(19)32)37-22(31)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-29,32,35H,11-12H2,(H,33,34)/b7-3+,8-4+/t19-,20-,23?,25?/m1/s1" KRZBCHWVBQOTNZ-RDJMKVHDSA-N C1C(C[C@H](C([C@@H]1OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)(O)C(=O)O C25H24O12 "89919-62-0,2450-53-5" CHEBI:65751 . . . . . DR0471 glucantime . . . . . 64953 Anticancer Treatment . . "InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1" XOGYVDXPYVPAAQ-SESJOKTNSA-M CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.O[Sb](=O)=O C7H18NO8Sb 133-51-7 . . . . DB13732 . DR0472 Citrullus colocynthis (L.) Schrad . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0473 metoprolol D0I2MK . . . . 4171 Anticancer Treatment . . "InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3" IUBSYMUCCVWXPE-UHFFFAOYSA-N CC(C)NCC(COC1=CC=C(C=C1)CCOC)O C15H25NO3 "51384-51-1,37350-58-6" CHEBI:6904 . . . DB00264 . DR0474 Rhynchosia nulubilis . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0475 Ampicillin D0YA9Z . . . . 6249 Anticancer Treatment . . "InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1" AVKUERGKIZMTKX-NJBDSQKTSA-N CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C C16H19N3O4S "69-53-4,69-52-3; 69-53-4; 7177-48-2" CHEBI:28971 . . . DB00415 . DR0476 antibiotics . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0477 calcium hydroxide . . . . . 6093208 Anticancer Treatment . . InChI=1S/Ca.2H2O/h;2*1H2/q+2;;/p-2 AXCZMVOFGPJBDE-UHFFFAOYSA-L [OH-].[OH-].[Ca+2] "CaH2O2,Ca(OH)2," "1305-62-0,7719-01-9" CHEBI:31341 . . . . . DR0478 ampicillin . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0479 mometasone furoate cream . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0480 topoisomerase poisons . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0481 cefquinoxime sulfate . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0482 chemoembolization-immune therapy . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0483 BET inhibitor . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0484 ferroptosis inducer . . . . . 76853263 Anticancer Treatment . . "InChI=1S/C11H11NOS/c1-3-11-12-9(6-14-11)8-4-5-10(13)7(8)2/h1,6,10,13H,4-5H2,2H3/t10-/m0/s1" UBTALUNCVHPQQK-JTQLQIEISA-N CC1=C(CC[C@@H]1O)C2=CSC(=N2)C#C C11H11NOS . . . . . . . DR0485 puerarin D0I7MT . . . . 5281807 Anticancer Treatment . . "InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1" HKEAFJYKMMKDOR-VPRICQMDSA-N C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O C21H20O9 3681-99-0 CHEBI:8633 . . . DB12290 . DR0486 pelubiprofen D0X4JN . . . . 5282203 Anticancer Treatment . . "InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+" AUZUGWXLBGZUPP-GXDHUFHOSA-N CC(C1=CC=C(C=C1)/C=C/2\CCCCC2=O)C(=O)O C16H18O3 69956-77-0 . . . . DB12150 . DR0487 berberine hydrochloride . . . . . 12456 Anticancer Treatment . . "InChI=1S/C20H18NO4.ClH/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2;/h3-4,7-10H,5-6,11H2,1-2H3;1H/q+1;/p-1" VKJGBAJNNALVAV-UHFFFAOYSA-M COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-] "C20H18NO4.Cl,C20H18ClNO4" 633-65-8 CHEBI:31271 . . . . . DR0488 spirodiclofen . . . . . 177863 Anticancer Treatment . . "InChI=1S/C21H24Cl2O4/c1-4-20(2,3)19(25)26-17-16(14-9-8-13(22)12-15(14)23)18(24)27-21(17)10-6-5-7-11-21/h8-9,12H,4-7,10-11H2,1-3H3" DTDSAWVUFPGDMX-UHFFFAOYSA-N CCC(C)(C)C(=O)OC1=C(C(=O)OC12CCCCC2)C3=C(C=C(C=C3)Cl)Cl C21H24Cl2O4 148477-71-8 CHEBI:38639 . . . . . DR0489 Repaglinide D0N5YA . . . . 65981 Anticancer Treatment . . "InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1" FAEKWTJYAYMJKF-QHCPKHFHSA-N CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O C27H36N2O4 135062-02-1 CHEBI:8805 . . . DB00912 . DR0490 Autocrine Motility Factor Peptide . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0491 chemoradiation . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0492 dihydroartemisinin hetero-polymeric prodrug NPs . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0493 glucosamine sulfate capsules . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0494 vitamin A acid . . . . . 444795 Anticancer Treatment . . "InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+" SHGAZHPCJJPHSC-YCNIQYBTSA-N CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C C20H28O2 "302-79-4,4759-48-2" CHEBI:15367 . . . DB00755 . DR0495 Synthetically Improved Analogue Toward Antimycobacterial Agents . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0496 enzalutamide D0QK5X . . . . 15951529 Anticancer Treatment . . "InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)" WXCXUHSOUPDCQV-UHFFFAOYSA-N CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C C21H16F4N4O2S 915087-33-1 CHEBI:68534 . . . DB08899 . DR0497 anti-CD19 CAR-T . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0498 Oct4/sonic hedgehog . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0499 IFNgamma . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0500 arsenic (As) . . . . . 5359596 Anticancer Treatment . . InChI=1S/As RQNWIZPPADIBDY-UHFFFAOYSA-N [As] As "7440-38-2,7784-42-1" CHEBI:27563 . . . . . DR0501 Lenvatinib D0R0FO . . . . 9823820 Anticancer Treatment . . "InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)" WOSKHXYHFSIKNG-UHFFFAOYSA-N COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl C21H19ClN4O4 417716-92-8 CHEBI:85994 . . . DB09078 . DR0502 anlotinib . . . . . 25017411 Anticancer Treatment . . "InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3" KSMZEXLVHXZPEF-UHFFFAOYSA-N CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC C23H22FN3O3 1058156-90-3 . . . . DB11885 . DR0503 adriamycin . . . . . 31703 Anticancer Treatment . . "InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1" AOJJSUZBOXZQNB-TZSSRYMLSA-N C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O C27H29NO11 "23214-92-8,25316-40-9" CHEBI:28748 . . . DB00997 . DR0504 BRAF inhibitors . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0505 MEK inhibitors . . . . . . Anticancer Treatment . . . . . . . . . . . . . DR0505 Adriamycin . . . . . . Anticancer Treatment . . . . . . . . . . . . .